<SEC-DOCUMENT>0001396814-18-000009.txt : 20180228
<SEC-HEADER>0001396814-18-000009.hdr.sgml : 20180228
<ACCEPTANCE-DATETIME>20180228150534
ACCESSION NUMBER:		0001396814-18-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180228
DATE AS OF CHANGE:		20180228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510619477
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		18650442

	BUSINESS ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054
		BUSINESS PHONE:		973-254-3560

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pcrx-12312017x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2CB4D2ED67125F1E94789EEB01349B10"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Use these links to rapidly review the document:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:11pt;">TABLE OF CONTENTS</font></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="#s1B204D49DE545C63B9294739270CFC6E"><font style="font-family:inherit;font-size:11pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></a></div><div><br></div><hr style="page-break-after:always"><div><a name="sF4020C66B1F7579D8E2874F249CAA4B2"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:6pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.157088122605366%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.157088122605366%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Mark One)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Fiscal Year Ended: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Or</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160; to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 001-35060</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="paciralogoa05.jpg" alt="paciralogoa05.jpg" style="height:93px;width:241px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">PACIRA PHARMACEUTICALS,&#160;INC.</font></div><div style="line-height:120%;text-align:center;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.37547892720306%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">51-0619477</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 Sylvan Way, Suite&#160;300</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Parsippany, New Jersey 07054</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address and Zip Code of Principal Executive Offices)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(973)&#160;254-3560</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.06896551724138%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name of each exchange</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">on which registered</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock, $0.001 par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NASDAQ</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section&#160;12(g) of the Act: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (&#167;229.405) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate market value of the registrant&#8217;s voting stock held by non-affiliates of the registrant, based upon the closing sale price of the common stock as reported on the NASDAQ on June&#160;30, 2017, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, of $47.70 per share was approximately $1.9 billion. Shares of common stock held by each director and executive officer (and their respective affiliates) and by each person who owns 10&#160;percent or more of the outstanding common stock or who is otherwise believed by the registrant to be in a control position have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February&#160;20, 2018, 40,711,707 shares of the registrant&#8217;s common stock, $0.001 par value per share, were outstanding.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Part&#160;III of this Annual Report on Form&#160;10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual meeting of stockholders to be filed no later than 120&#160;days after the end of the registrant&#8217;s fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="sF317C49ACF63518DBE54395C43B5F267"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page No.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72E566DDC6B3518F9962BB29F31B1F85"><font style="font-family:inherit;font-size:10pt;">PART I</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72E566DDC6B3518F9962BB29F31B1F85">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3BE3C8497D62526F92130E779BAC477E"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3BE3C8497D62526F92130E779BAC477E"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3BE3C8497D62526F92130E779BAC477E">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8F38AC202A965944AB7BF9AD3A439AE0"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8F38AC202A965944AB7BF9AD3A439AE0"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8F38AC202A965944AB7BF9AD3A439AE0">22</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB4B294C4D015ECF995ED57323D0A1CF"><font style="font-family:inherit;font-size:10pt;">Item&#160;1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB4B294C4D015ECF995ED57323D0A1CF"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB4B294C4D015ECF995ED57323D0A1CF">45</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s25A22F165391572F9F127A02A36096D7"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s25A22F165391572F9F127A02A36096D7"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s25A22F165391572F9F127A02A36096D7">45</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE6925573338577892080306337A4DD2"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE6925573338577892080306337A4DD2"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEE6925573338577892080306337A4DD2">45</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD498527C1A715D3392FAC88F57A913A6"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD498527C1A715D3392FAC88F57A913A6"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD498527C1A715D3392FAC88F57A913A6">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s30140912E72D53079D6448A5BBB23D39"><font style="font-family:inherit;font-size:10pt;">PART II</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s30140912E72D53079D6448A5BBB23D39">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDEE883146F245586B9B86A63EAA37638"><font style="font-family:inherit;font-size:10pt;">Item&#160;5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDEE883146F245586B9B86A63EAA37638"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDEE883146F245586B9B86A63EAA37638">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s692A07CDDCF35153993ECDCDDA80E0E0"><font style="font-family:inherit;font-size:10pt;">Item&#160;6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s692A07CDDCF35153993ECDCDDA80E0E0"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s692A07CDDCF35153993ECDCDDA80E0E0">47</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s84FB334BF2065D2FB2A23B8A40F7263E"><font style="font-family:inherit;font-size:10pt;">Item&#160;7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s84FB334BF2065D2FB2A23B8A40F7263E"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s84FB334BF2065D2FB2A23B8A40F7263E">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC2A6A7CB83F568AAA332193BD411A3F"><font style="font-family:inherit;font-size:10pt;">Item&#160;7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC2A6A7CB83F568AAA332193BD411A3F"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC2A6A7CB83F568AAA332193BD411A3F">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s88F9921AF8CA5A84B6C652DEC1CB978C"><font style="font-family:inherit;font-size:10pt;">Item&#160;8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s88F9921AF8CA5A84B6C652DEC1CB978C"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s88F9921AF8CA5A84B6C652DEC1CB978C">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BBE7F359A15DE6912893990A59681C"><font style="font-family:inherit;font-size:10pt;">Item&#160;9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BBE7F359A15DE6912893990A59681C"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BBE7F359A15DE6912893990A59681C">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s45379360AB455B82A7C6E0A17017B774"><font style="font-family:inherit;font-size:10pt;">Item&#160;9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s45379360AB455B82A7C6E0A17017B774"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s45379360AB455B82A7C6E0A17017B774">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE18872E4F0465FD1AF47EC13DCFD6AE0"><font style="font-family:inherit;font-size:10pt;">Item&#160;9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE18872E4F0465FD1AF47EC13DCFD6AE0"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE18872E4F0465FD1AF47EC13DCFD6AE0">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2B3B913FC3445756A140728472392C01"><font style="font-family:inherit;font-size:10pt;">PART III</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2B3B913FC3445756A140728472392C01">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5584B9AF3C1454828171FE751B245668"><font style="font-family:inherit;font-size:10pt;">Item&#160;10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5584B9AF3C1454828171FE751B245668"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5584B9AF3C1454828171FE751B245668">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC72C2B850F15733AD2325CD3F444D3F"><font style="font-family:inherit;font-size:10pt;">Item&#160;11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC72C2B850F15733AD2325CD3F444D3F"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDC72C2B850F15733AD2325CD3F444D3F">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEB9820891C8F558680B7DAFD4F5C60C7"><font style="font-family:inherit;font-size:10pt;">Item&#160;12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEB9820891C8F558680B7DAFD4F5C60C7"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEB9820891C8F558680B7DAFD4F5C60C7">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1193ACF7F85A593A9D465281A853345C"><font style="font-family:inherit;font-size:10pt;">Item&#160;13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1193ACF7F85A593A9D465281A853345C"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1193ACF7F85A593A9D465281A853345C">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCBA4FD9F9425BE8886CECFAF469F8AD"><font style="font-family:inherit;font-size:10pt;">Item&#160;14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCBA4FD9F9425BE8886CECFAF469F8AD"><font style="font-family:inherit;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCBA4FD9F9425BE8886CECFAF469F8AD">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4E0EB603C5335E1EB7E1F9F833369863"><font style="font-family:inherit;font-size:10pt;">PART IV</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4E0EB603C5335E1EB7E1F9F833369863">65</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50C90BCA561453AEAF4B481D93DD3995"><font style="font-family:inherit;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50C90BCA561453AEAF4B481D93DD3995"><font style="font-family:inherit;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50C90BCA561453AEAF4B481D93DD3995">65</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06508C2E878856C79FD2F24001D0AC7D"><font style="font-family:inherit;font-size:10pt;">Item 16.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06508C2E878856C79FD2F24001D0AC7D"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06508C2E878856C79FD2F24001D0AC7D">65</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Annual Report on Form&#160;10-K and certain other communications made by us contain forward-looking statements within the meaning of Section&#160;21E of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), including statements about our growth and future operating results, discovery and development of products, strategic alliances and intellectual property. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We often use the words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may&#8221; and similar expressions to help identify forward-looking statements. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. These forward-looking statements include, among others, statements about: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL&#174; (bupivacaine liposome injectable suspension) and our other products; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; the Company&#8217;s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of a U.S. Department of Justice inquiry; our plans to evaluate, develop and pursue additional DepoFoam&#174;-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; our commercialization and marketing capabilities and the Company&#8217;s and Patheon UK Limited&#8217;s ability to successfully and timely construct EXPAREL manufacturing suites. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, including those discussed below in Part&#160;I-Item&#160;1A. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:inherit;font-size:10pt;">. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on the forward-looking statements as representing our views as of any date subsequent to the date of the filing of this Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in Part&#160;I-Item&#160;1A. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s72E566DDC6B3518F9962BB29F31B1F85"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div><a name="s3BE3C8497D62526F92130E779BAC477E"></a></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">References</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals,&#160;Inc., a Delaware corporation, is the holding company for our California operating subsidiary of the same name, or Pacira California. In March 2007, we acquired Pacira California from SkyePharma Holdings,&#160;Inc., or Skyepharma (referred to in this Annual Report on Form&#160;10-K as the &#8220;Acquisition&#8221;). Unless the context requires otherwise, references to &#8220;Pacira,&#8221; &#8220;we,&#8221; the &#8220;Company,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this Annual Report on Form&#160;10-K refers to Pacira Pharmaceuticals,&#160;Inc., a Delaware corporation, and its subsidiaries. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed our name to Pacira,&#160;Inc. in June 2007. In October 2010, we changed our name to Pacira Pharmaceuticals,&#160;Inc. Our principal executive offices are in Parsippany, New Jersey.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, EXPAREL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, DepoFoam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(United States (U.S.) registration), DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(European Union (E.U.) registration), the Pacira logo and other trademarks or service marks of Pacira appearing in this Annual Report on Form&#160;10-K are the property of Pacira. In addition, references in this Annual Report on Form&#160;10-K to DepoCyt(e) mean DepoCyt when discussed in the context of the U.S. and Canada and DepoCyte when discussed in the context of the E.U.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;This Annual Report on Form&#160;10-K contains additional trade names, trademarks and service marks of other companies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a specialty pharmaceutical company focused on driving improved patient outcomes with opioid-reducing strategies. Our marketed product, EXPAREL (bupivacaine liposome injectable suspension) was approved by the U.S. Food and Drug Administration, or FDA, in October 2011 and was commercially launched in April 2012. EXPAREL is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, our proprietary technology that delivers bupivacaine over time for extended analgesia. We believe that EXPAREL addresses a significant medical need for a long-acting non-opioid postsurgical analgesic and plays a significant role in opioid minimization strategies. EXPAREL is designed for recovery with minimal opioid use by (i) delivering targeted local analgesia at the surgical site; (ii) reliably releasing bupivacaine over time for prolonged analgesia; (iii) eliminating the need for catheters and pumps that may hinder recovery; and (iv) providing long-lasting pain control while reducing the need for opioids. Our internal sales force is entirely dedicated to commercializing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL. Our net product sales for EXPAREL in 2017 were </font><font style="font-family:inherit;font-size:10pt;">$282.9 million</font><font style="font-family:inherit;font-size:10pt;">. For the years ended December 31, 2017, 2016 and 2015, net product sales of EXPAREL accounted for </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">96%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">96%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our total revenues, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to EXPAREL, DepoFoam is also the basis for our product candidates and our other FDA-approved commercial product, DepoCyt(e), which we discontinued production of in June 2017 due to persistent technical issues specific to the DepoCyt(e) manufacturing process.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current product portfolio and product candidate pipeline, along with anticipated milestones over the next 12 to 18 months, are summarized in the table below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:14%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Proprietary Pipeline:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product / Product Candidates</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Status</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Next Expected Milestone</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL </font><font style="font-family:inherit;font-size:8pt;">(bupivacaine liposome injectable suspension)</font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Surgical Infiltration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Approved (U.S.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series of Phase 4 data readouts</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Nerve Block</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">sNDA (U.S.)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Completion of FDA review</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;C-Section</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report top-line results</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Hip fracture</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiate study</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Spine</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiate study</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Colorectal</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiate study</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Breast reconstruction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiate study</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;E.U. Surgical Infiltration/Nerve Block</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">MAA (E.U.)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File E.U. Marketing Authorization Application</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Pediatrics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Phase 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finalize clinical strategy with FDA and E.U. regulators</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoMeloxicam</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">IND</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiate Phase 1 study</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Partnered Products:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoCyt(e) </font><font style="font-family:inherit;font-size:8pt;">(cytarabine liposome injection)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Lymphomatous meningitis</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Approved</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leadiant Biosciences Ltd. (U.S.) and MundiPharma (E.U.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:8pt;">(bupivacaine liposome injectable suspension)</font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Surgical infiltration in dogs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Approved (U.S.)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aratana Therapeutics</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1 - Production discontinued in June 2017 due to persistent technical issues specific to the DepoCyt(e) manufacturing process.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NOCITA</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">&#32;is a registered trademark of Aratana Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to be a leading specialty pharmaceutical company focused on postsurgical innovation to address unmet medical needs and improve clinical results. We plan to achieve this by:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercializing EXPAREL in the U.S. for postsurgical analgesia by infiltration;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintaining a streamlined commercial organization concentrating on major hospitals and ambulatory surgery centers in the U.S. and targeting surgeons, anesthesiologists, pharmacists and nurses;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">utilizing strategic commercial partnerships to broaden the use of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrating the economic benefits of EXPAREL, working directly with managed care payers, quality improvement organizations, Key Opinion Leaders, or KOLs, in the field of postsurgical pain management and leading influential hospitals in conducting Phase&#160;4 retrospective and prospective trials and drug utilization evaluations;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">educating strategic commercial audiences for local infiltration procedures, including soft tissue, orthopedic, anesthesia (such as infiltration into the transversus abdominis plane, or TAP block) and oral and maxillofacial surgeries, to ensure appropriate use of the product;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining FDA approval for additional indications for EXPAREL, including expanding the label to include the pediatric population, as well as administration via nerve block for regional analgesia;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing our DepoFoam-based products, including EXPAREL, in facilities compliant with the FDA&#8217;s current Good Manufacturing Practices, or cGMP, and expanding such manufacturing capacity to meet demand;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continuing to expand our marketed product portfolio through development of additional DepoFoam-based hospital products utilizing a Section 505(b)(2) strategy, which permits the reliance upon previous findings of safety and effectiveness for an approved product; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continuing research and development partnerships to provide DepoFoam-based products to enhance the duration of action and patient compliance for partner products.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPAREL</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Opioid addiction in the U.S. has reached epidemic proportions, with the Centers for Disease Control and Prevention (CDC) estimating that 91 people die every day from an opioid overdose. Overreliance on opioids in the postsurgical setting has caused a rapid deluge of opioid misuse, abuse and addiction. In 2017, the QuintilesIMS Institute published new research showing that an overwhelming majority of surgery patients (nine in 10) are exposed to opioids to manage postsurgical pain, and those given prescriptions received an average of 85 pills each. In addition, nearly 3 million individuals who had surgery in 2016 became persistent opioid users, continuing to take opioids three to six months after their procedure. Further, the overprescribing of opioids has resulted in 3.3 billion unused pills annually, making them available for potential diversion or misuse. This report, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The United States for Non-Dependence</font><font style="font-family:inherit;font-size:10pt;">, represents the most current analysis of national trends in opioid prescribing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on our clinical data, EXPAREL provides continuous and extended postsurgical analgesia and reduces the consumption of opioid medications. We believe EXPAREL simplifies postsurgical pain management, minimizes breakthrough episodes of pain and has the potential to result in improved patient care and outcomes, as well as enhanced hospital economics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are advancing a three-part growth strategy to expand the use of EXPAREL to fulfill our mission to provide an opioid alternative to as many appropriate patients as possible:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First, we are advancing the understanding among our customers and patients that the operating room, in the absence of EXPAREL as part of non-narcotic multimodal pain management, has served as a gateway to the opioid epidemic. In 2016, we launched </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Choices Matter</font><font style="font-family:inherit;font-size:10pt;">, our national educational campaign aimed at empowering patients to proactively discuss postsurgical pain management, including non-opioid options, with their doctors. We are building a coalition of like-minded individuals and organizations to generate widespread public awareness of the role that postsurgical opioids play in this public health crisis in the U.S., while highlighting the opportunity to alleviate the risks associated with opioid dependence and/or addiction through the utilization of non-opioid pain management approaches.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second, we are investing in clinical trials in key surgical procedures to expand the EXPAREL label to include nerve block for regional analgesia and to demonstrate procedure-specific pain reduction, opioid reduction and best-practice surgical infiltration techniques within the currently approved indication. We have submitted a supplemental New Drug Application, or sNDA, with the FDA. The sNDA filing is based on positive data from a Phase 3 study of EXPAREL in femoral nerve block for total knee arthroplasty, or TKA, (lower extremity) and a Phase 3 study of EXPAREL in brachial plexus block for shoulder surgeries (upper extremity). It includes data from eight company-sponsored studies with safety and pharmacokinetic data through 120 hours. In addition, the sNDA includes data from two investigator-initiated studies that provide additional experience in smaller, peripheral nerve block settings. Our sNDA for EXPAREL as a nerve block for regional analgesia was discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, on February 14-15, 2018. The AADPAC committee members voted six to four against approval of the EXPAREL sNDA. The committee&#8217;s feedback will be considered by the FDA in its review of the sNDA. The FDA&#8217;s Prescription Drug User Fee Act (PDUFA) goal date for completion of its review is April 6, 2018. For our currently approved infiltration indication, we have published positive results from our completed Phase 4 multicenter, randomized, double-blind trial in TKA and we are currently enrolling a C-Section study. We also expect to initiate additional Phase 4 studies in key procedures, such as hip fracture, spine, colorectal and breast reconstruction surgeries. We believe positive data from our Phase 4 studies will lead to improved patient outcomes and customer satisfaction.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third, we are forming strategic collaborations to expand education on the importance of non-opioid multimodal alternatives for post-surgical pain management and broaden our commercial reach. These include agreements with industry partners, as well as healthcare providers and hospital systems to support their implementation of opioid-sparing enhanced recovery protocols. In January 2017, we formed a partnership with DePuy Synthes Sales Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies, to support the promotion, education and training </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">of EXPAREL in orthopedics. Our growing coalition of collaborators also includes Trinity Health, Aetna, the American Association of Oral and Maxillofacial Surgeons, or AAOMS, the American College of Surgeons, the American Society for Enhanced Recovery, Cancer Treatment Centers of America, the Illinois Surgical Quality Improvement Collaborative, the WellStar Health System and Shatterproof.org. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXPAREL Clinical Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe EXPAREL can replace the use of bupivacaine via elastomeric pumps as the foundation of a multimodal regimen for long-acting postsurgical pain management. Based on our clinical data, EXPAREL:&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provides long-lasting postsurgical analgesia;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is a ready-to-use formulation;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expands easily with saline or lactated Ringer&#8217;s to reach a desired volume;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">leverages existing postsurgical infiltration administration techniques; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">facilitates treatment of both small and large surgical sites.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe EXPAREL can become the foundation of a long-acting postsurgical pain management regimen to reduce the need for opioids. Based on the clinical data from our Phase&#160;3 hemorrhoidectomy trial, our Phase 4 TKA trial, as well as our retrospective health outcomes studies data, EXPAREL significantly delays and reduces opioid usage while improving postsurgical pain management.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Phase&#160;3 hemorrhoidectomy trial, EXPAREL:</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delayed the median time to rescue analgesic use (opioids) to 15&#160;hours for patients treated with EXPAREL and one hour for patients treated with placebo;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significantly increased the percentage of patients requiring no opioid rescue medication through 72 hours post-surgery to 28%, compared to 10% for placebo;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">resulted in 45% less opioid usage through 72 hours post-surgery compared to placebo; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased the percentage of patients who were pain free at 24&#160;hours post-surgery compared to placebo.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Phase&#160;4 trial of EXPAREL versus bupivacaine HCl in TKA, EXPAREL:</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased total opioid consumption by 78 percent (18.7 mg versus 84.9 mg in the bupivacaine group; p=0.0048) expressed as morphine equivalents from zero to 48 hours after surgery; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced pain scores (180.8 versus 209.3 in the bupivacaine group; p=0.0381), using the area under the curve of the pain intensity scores measured on a visual analog scale from 12 to 48 hours after surgery, which required 78 percent fewer opioids through 72 hours than those in the bupivacaine arm (20.9 mg versus 93.6 mg, respectively; p=0.0108), with 10 percent remaining opioid-free through 48 and 72 hours (compared to zero patients in the bupivacaine arm; p&lt;0.01). </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL can improve patient satisfaction and outcomes. We believe EXPAREL:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provides effective pain control without the need for expensive and difficult-to-use delivery technologies that extend the duration of action for bupivacaine, such as elastomeric bags, or opioids administered through patient-controlled analgesia, or PCA, when used as part of a multimodal postsurgical pain regimen;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduces the need for patients to be constrained by elastomeric bags and PCA systems, which are barriers to earlier ambulation and may introduce catheter-related issues, including infection; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">promotes maintenance of early postsurgical pain management, which may reduce the time spent in the intensive care unit.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXPAREL Health Economic Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to being efficacious and safe, we believe that EXPAREL provides health economic benefits that play an important role in formulary decision-making and that these health economic benefits are often overlooked. Several members of our management team have extensive experience applying health economic outcomes research to support commercial success. Our strategy is to work directly with the senior leadership of our hospital customers, integrated health networks, quality improvement organizations, KOLs in the field of postsurgical pain management and leading influencer hospitals to provide them with retrospective and prospective studies to demonstrate the economic benefits of EXPAREL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our national, regional and local analyses assessing retrospective health outcomes, conducted in conjunction with hospital customer groups utilizing their own hospital databases, revealed that the use of opioids for postsurgical pain control is a significant driver of hospital resource consumption, including higher hospitalization costs, longer length of stay and the potential for opioid-related adverse events.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPAREL Label Expansion</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nerve Block</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are pursuing additional indications to expand the label for EXPAREL. The FDA is currently reviewing our sNDA seeking expansion of the EXPAREL label to include administration as a nerve block to produce regional analgesia. Nerve block is a general term used to refer to the injection of local anesthetic onto a nerve or bundle of nerves for regional pain control. Traditionally, nerve blocks are single injections of short-acting anesthetics and as a result, have a limited duration of action. When extended pain management is required, a catheter is used to deliver bupivacaine continuously using an external pump. EXPAREL is designed to provide extended pain management using a single injection.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that this new indication would (i) present an alternative long-term method of pain control with a single injection, replacing the costly and cumbersome standard of care requiring a perineural catheter, drug reservoir and pump needed to continuously deliver bupivacaine and (ii) allow us to further leverage our manufacturing and commercial infrastructure. Our sNDA for EXPAREL as a nerve block for regional analgesia was discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, on February 14-15, 2018. The AADPAC committee members voted six to four against approval of the EXPAREL sNDA. The committee&#8217;s feedback will be considered by the FDA in its review of the sNDA. The expected action date by the FDA is April 6, 2018.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sNDA filing is based on the positive data from a Phase 3 study of EXPAREL in femoral nerve block for TKA (lower extremity) and a Phase 3 study of EXPAREL in brachial plexus block for shoulder surgeries (upper extremity). It includes safety and pharmacokinetic data through 120 hours from eight company-sponsored studies. In addition, the sNDA includes data from two investigator-initiated studies that provide additional experience in smaller, peripheral nerve block settings.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A nerve block indication has the potential to expand EXPAREL use. We believe there is an opportunity for EXPAREL to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">eliminate catheters and pumps by turning off pain at the surgical site;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engage the anesthesiologist audience;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increase adoption in key procedures, such as shoulder, wrist/hand and foot/ankle; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shift inpatient procedures to ambulatory surgery centers.</font></div></td></tr></table><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pediatrics</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA, as a condition of EXPAREL approval, has required us to study EXPAREL in pediatric patients. We were granted a deferral for the required pediatric trials in all age groups for EXPAREL in the setting of wound infiltration and plan to conduct these pediatric trials as a post-marketing requirement, which was stated in the New Drug Application, or NDA, approval letter for EXPAREL. We have assembled an extensive package of real-world evidence on the use of EXPAREL from The Cleveland Clinic and the Premier Database from patients under the age of 18 for several surgical procedures. We are currently working with the FDA to define a regulatory pathway using these data as the core of our submission. Pediatric patients currently have no approved alternatives to opioids for the management of severe postsurgical pain, and we believe they are in desperate need of additional pain control options. As a result, we are aggressively moving forward to make EXPAREL available to this particularly vulnerable patient population.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXPAREL Phase 4 Clinical Trials</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are investing in a series of blinded, randomized, bupivacaine-comparator Phase 4 trials in key surgical procedures. Our positive Phase 4 study of EXPAREL in patients undergoing TKA was published in July 2017 (Local Infiltration Analgesia with Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. Mont, Michael A. et al. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Arthroplasty</font><font style="font-family:inherit;font-size:10pt;">, Volume 33, Issue 1, 90 - 96). We are currently enrolling a Phase 4 study in C-Section and we also expect to launch additional Phase 4 studies in hip fracture, spine, colorectal and breast reconstruction surgeries. These trials are designed to assess the differences in postsurgical pain and opioid use between patients receiving EXPAREL as the foundation of a multimodal analgesic regimen versus a bupivacaine-based multimodal analgesic regimen. Our Phase 4 trials are also designed to support clinician education on procedure-specific best-practice care.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each of our Phase 4 trials we are taking the following approach: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">publishing procedure-specific technique and best-practice protocol to demonstrate (i) volume expansion to ensure proper coverage of the surgical field, (ii) admixing with bupivacaine to ensure pain relief that spans both the acute and later postsurgical periods and (iii) proper infiltration technique;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">creating KOL educational videos of proper technique; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">publishing trial results.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Molar Procedures</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, we announced a collaboration with Aetna, one of the nation&#8217;s leading diversified health care benefits companies, with the support of AAOMS. This national program aims to reduce the number of opioid tablets dispensed to patients undergoing impacted third molar (wisdom tooth) extractions by at least 50 percent through the utilization of EXPAREL to provide prolonged non-opioid postsurgical pain control. Aetna will include the cost of EXPAREL as a covered expense for impacted third molar extractions performed by surgeons who have completed training on use of the product.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to a Journal of the American Medical Association (JAMA) study, more than two-thirds of patients who underwent surgical tooth extractions reported unused prescription opioids, with the majority also indicating that these medications are neither safely stored nor disposed of. These facts suggest that there is a dangerous accumulation of opioids in the home, which are available for potential diversion or misuse.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EXPAREL Dosing, Volume Expansion and Admixing with Bupivacaine HCl</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL is available as a 266 mg/20 mL single-use vial and a 133 mg/10 mL single-use vial. The recommended dose of EXPAREL is based on (i) the size of the surgical site, (ii) the volume needed to cover the width and depth of the surgical site and (iii) patient-specific factors that could impact safety of an amide-type local anesthetic. The maximum dose should not exceed 266 mg.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL can be expanded in volume to optimize results. Physicians consider the size of the surgical site and neuroanatomy to determine dosing and volume expansion. The 266 mg (20 mL) EXPAREL vial can be expanded with up to 280 mL of normal (0.9%) saline or lactated Ringer&#8217;s solution for a total volume of 300 mL (a 1:14 ratio). For smaller surgical sites where 20 mL is too much volume, the 133 mg (10 mL) vial should be considered.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To ensure early analgesic activity, EXPAREL can be admixed with bupivacaine HCl so long as the ratio does not exceed 1:2. For example, the 266 mg/20mL vial may be administered with up to 30 mL of 0.5% bupivacaine HCl or up to 60 mL of 0.25% bupivacaine HCl. Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Products</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DepoCyt(e)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing our DepoFoam technology. DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Lymphomatous meningitis can be controlled with conventional </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cytarabine, but because of the drug&#8217;s short half-life, a spinal injection is required twice per week, whereas DepoCyt(e) is dosed once every two weeks in an outpatient setting. DepoCyt(e) was granted accelerated approval by the FDA in 1999 and full approval in 2007. In June 2017 we discontinued production of DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(U.S. and Canada) and DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DepoFoam&#8212;Our Proprietary Drug Delivery Technology</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current product development activities utilize our proprietary DepoFoam drug delivery technology. DepoFoam consists of microscopic spherical particles composed of a honeycomb-like structure of numerous internal aqueous chambers containing an active drug ingredient. Each chamber is separated from adjacent chambers by lipid membranes. Following injection, the DepoFoam particles release drug over an extended period by erosion and/or reorganization of the particles&#8217; lipid membranes. Release rates are determined by the choice and relative amounts of lipids in the formulation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the DepoFoam formulation provides several technical, regulatory and commercial advantages over competitive technologies, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convenience. </font><font style="font-family:inherit;font-size:10pt;">Our DepoFoam products are ready to use, do not require reconstitution or mixing with another solution, and can be used with patient-friendly narrow gauge needles and pen systems;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple regulatory precedents. </font><font style="font-family:inherit;font-size:10pt;">Our current and past DepoFoam products have been approved in the U.S. and Europe, making regulatory authorities familiar with our DepoFoam technology;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Extensive safety history. </font><font style="font-family:inherit;font-size:10pt;">Our DepoFoam products have nearly 20 years of safety data;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Proven manufacturing capabilities. </font><font style="font-family:inherit;font-size:10pt;">We make EXPAREL, a DepoFoam-based product, in our cGMP facilities;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Flexible time release. </font><font style="font-family:inherit;font-size:10pt;">Encapsulated drug releases over a desired period, from 1 to 30&#160;days;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Favorable pharmacokinetics. </font><font style="font-family:inherit;font-size:10pt;">Decrease in adverse events associated with high peak blood levels, thereby improving the utility of the product;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shortened development timeline. </font><font style="font-family:inherit;font-size:10pt;">Does not alter the native molecule, potentially enabling the filing of a          505(b)(2) application; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aseptic manufacturing and filling. </font><font style="font-family:inherit;font-size:10pt;">Enables use with proteins, peptides, nucleic acids, vaccines and small molecules.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DepoMeloxicam</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our preclinical product candidate, DepoMeloxicam, or DepoMLX, is a long-acting non-steroidal anti-inflammatory drug, or NSAID, designed to treat moderate to severe pain as part of a non-opioid multimodal regimen. A product designed for single-dose local administration such as DepoMLX could provide a longer duration of pain relief at a significantly lower concentration of systemic NSAIDs, which are known to cause dose-dependent gastrointestinal side effects. Meloxicam, which is currently available as an oral formulation, is a commonly used NSAID on the market today.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We opened an Investigational New Drug, or IND, application for DepoMLX in December 2017 and expect to initiate a Phase 1 clinical trial in 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we spent </font><font style="font-family:inherit;font-size:10pt;">$57.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$45.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$28.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, on research and development activities. For additional information, see Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Research and Development Expenses.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales and Marketing</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have built our marketing and sales organization to commercialize EXPAREL and potential future commercial products in the U.S. We intend to out-license commercialization rights for other territories. Our goal is to retain significant control over the development process and commercial execution for our product candidates, while participating in a meaningful </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">way in the economics of all products that we bring to the market. The primary target audience for EXPAREL is healthcare practitioners who influence pain management decisions including surgeons, anesthesiologists, pharmacists and nurses.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our field team, consisting of both sales representatives and scientific and medical affairs professionals, executes on a full range of activities for EXPAREL, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">providing publications and abstracts showing the EXPAREL clinical program efficacy and safety, health outcomes program and review articles on pain management;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">working in tandem with hospital staff, such as registered nurses, surgeons, heads of quality, pharmacists and executives, to provide access and resources for drug utilization or medication use evaluations and health outcomes studies, which provide retrospective and prospective analyses for our hospital customers using their own hospital data to demonstrate the true cost of opioid-based postsurgical pain control;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">working with KOLs and advisory boards to address topics of best practice techniques as well as guidelines and protocols for the use of EXPAREL, meeting the educational and training needs of our physician, surgeon, anesthesiologist, pharmacist and registered nurse customers;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">undertaking education initiatives such as center of excellence programs; preceptorship programs; pain protocols and predictive models for enhanced patient care; interactive discussion forums; patient education platforms leveraging public relations, advocacy partnerships and public affairs efforts where appropriate; web-based training and virtual launch programs; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborating with surgeons towards improving the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives and engaging our field-based medical teams in system-wide partnerships to address the national opioid epidemic, with a goal of studying alternative postsurgical pain management options that focus on optimization and opioid alternative strategies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DePuy Synthes Sales Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, we entered into a co-promotion agreement with DePuy Synthes to market and promote the use of EXPAREL for orthopedic procedures in the U.S. market. Through this collaboration, we believe we can accelerate the EXPAREL growth strategy by quickly leveraging the broad reach of DePuy Synthes and their established relationships and scale within hospitals and ambulatory surgery centers.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine and trauma, collaborate with, and supplement, our field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings. DePuy Synthes is also including EXPAREL in their Orthopedic Episode of Care Approach for health systems and surgeons. In addition to supporting orthopedic specialties, we are focusing on soft tissue surgeons in key specialties and anesthesiologists and we continue to act as the overall EXPAREL account manager. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will also work with DePuy Synthes to develop enhanced recovery after surgery (ERAS) protocols to improve procedure-specific patient care and to then rapidly communicate opportunities to utilize EXPAREL-based multimodal pain strategies to minimize opioids and improve patient satisfaction and hospital economics. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DePuy Synthes receives commissions on sales of EXPAREL under the agreement, subject to conditions, limitations and adjustments. The initial term of the agreement began on January 24, 2017 and ends on December 31, 2021, with the option to extend the agreement in 12-month increments upon the parties&#8217; mutual agreement, subject to certain conditions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and DePuy Synthes have mutual termination rights under the agreement, subject to certain terms, conditions, and notice; provided that neither party may terminate the agreement, without cause, within three years of the effective date of the agreement. We also have additional unilateral termination rights under certain circumstances. The agreement contains customary representations, warranties, covenants and confidentiality provisions, and mutual indemnification obligations. DePuy Synthes is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and our policies, in connection with fulfilling their obligations under the agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Agreements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TELA Bio, Inc.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we made an investment of&#160;$15.0 million&#160;in TELA Bio, Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;portfolio of products for ventral hernia repair and abdominal wall reconstruction. OviTex Reinforced BioScaffolds (RBSs) are intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. We may be required to invest up to an additional&#160;$10.0 million&#160;in TELA Bio under certain performance scenarios or upon our own election.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SkyePharma Holdings, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the stock purchase agreement related to the Acquisition, we agreed to certain earn-out payments based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL, and certain other yet-to-be-developed products as well as milestone payments for DepoBupivacaine products, including EXPAREL as follows:</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">$10.0 million upon first commercial sale in the U.S. (met April 2012);</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">$4.0 million upon first commercial sale in a major E.U. country (United Kingdom, France, Germany,&#160;Italy and Spain);</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:10pt;">$8.0 million when annual net sales collected reach $100.0 million (met September 2014);</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:10pt;">$8.0 million when annual net sales collected reach $250.0 million (met June 2016); and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(v)</font><font style="font-family:inherit;font-size:10pt;">$32.0 million when annual net sales collected reach $500.0 million.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of meeting future potential milestone payments, with certain exceptions, annual net sales are measured on a rolling quarterly basis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we agreed to pay to Skyepharma a certain percentage of net sales of DepoBupivacaine products, including EXPAREL, collected in the U.S., Japan, the United Kingdom, France, Germany, Italy and Spain. Such obligations to make percentage payments will continue for the term in which such sales related to EXPAREL are covered by a valid claim in certain patent rights related to EXPAREL and other biologics products. Cumulatively through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Skyepharma has earned </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of percentage payments on net sales of EXPAREL and other DepoBupivacaine products collected. We have the right to cease paying the percentage payments if Skyepharma breaches certain non-compete covenants contained in the stock purchase agreement or the last valid patent claim expires.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;">Note 6</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font><font style="font-family:inherit;font-size:10pt;">, to our consolidated financial statements included herein for further information related to the Skyepharma agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Development Foundation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to an agreement with one of our stockholders, the Research Development Foundation, or RDF, we are required to pay RDF a low single-digit royalty on the collection of revenues from our DepoFoam-based products for as long as certain patents assigned to us under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by us, in connection with our bankruptcy or insolvency or if we directly or indirectly oppose or dispute the validity of the assigned patent rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leadiant Biosciences Limited (Formerly Sigma-Tau Rare Disease Limited)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2002, we entered into a supply and distribution agreement with Enzon Pharmaceuticals&#160;Inc., or Enzon, regarding the promotion and distribution of DepoCyt. Pursuant to the agreement, Enzon was appointed the exclusive distributor of DepoCyt in the U.S. and Canada for a ten-year term, with successive two year renewal periods. In January 2010, Sigma-Tau Rare Disease,&#160;Ltd., or Sigma-Tau, acquired the rights to sell DepoCyt from Enzon for the U.S. and Canada. In December 2016, Sigma-Tau changed their name to Leadiant Biosciences, Ltd., or Leadiant. We and Leadiant are currently operating under the terms of the agreement. Under the supply and distribution agreement, we supply unlabeled DepoCyt vials to Leadiant. Under these agreements, we receive a fixed payment for the sale of DepoCyt vials, as well as a royalty on their sales in the thirty percent range.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Leadiant have the right to terminate the agreement for an uncured material breach by the other party or in the event that a generic pharmaceutical product that is therapeutically equivalent to DepoCyt is commercialized. We may terminate the agreement if certain minimum sales targets are not met by Leadiant. Leadiant may terminate the agreement if, as a result of a settlement or a final court or regulatory action, the manufacture, use or sale of DepoCyt in the U.S. is prohibited.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017 we discontinued production of DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(U.S. and Canada) and DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process, and thus, we do not have the ability to supply DepoCyt to Leadiant in the future.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mundipharma International Holdings Limited</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2003, we entered into an agreement granting Mundipharma International Holdings Limited, or Mundipharma, exclusive marketing and distribution rights to DepoCyte in the E.U. and certain other European countries. In April 2014, we amended the agreements to extend the term of the agreements by an additional 15 years to June 2033 and we expanded Mundipharma&#8217;s exclusive territory to include all countries other than the U.S., Canada and Japan. In connection with the amendments, in May 2014, we received a non-refundable upfront payment of $8.0 million. Under the agreement, as amended, and a separate supply agreement, we receive a fixed payment for the sale of DepoCyte vials, as well as a royalty in the thirty percent range. If annual sales exceed a certain amount, we receive an additional mid single-digit royalty. We are also entitled to receive up to &#8364;10.0&#160;million in milestone payments from Mundipharma upon the achievement by Mundipharma of certain milestone events, of which we have already received &#8364;2.5&#160;million and do not expect to receive the remaining &#8364;7.5&#160;million. We and Mundipharma have the right to terminate the agreement for an uncured material breach by the other party, in connection with the other party&#8217;s bankruptcy or insolvency or the repossession of all or any material part of the other party&#8217;s business or assets. Mundipharma has the right to terminate the agreement if its marketing authorization is cancelled or withdrawn for a certain period, or if it is prevented from selling DepoCyte in any three countries in the territory covered in the agreement by a final non-appealable judgment in respect of infringement by DepoCyte of any third-party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017 we discontinued production of DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(U.S. and Canada) and DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process, and thus, we do not have the ability to supply DepoCyte to Mundipharma in the future.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Aratana Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, we entered into an Exclusive License, Development and Commercialization Agreement and related Supply Agreement with Aratana Therapeutics,&#160;Inc., or Aratana. Under the agreements, we granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of our bupivacaine liposome injectable suspension product for animal health indications. In August 2016, the FDA&#8217;s Center for Veterinary Medicine approved NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana began purchasing bupivacaine liposome injectable suspension product in 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with its entry into the license agreement, we received a one-time payment of $1.0 million. In December 2013, we received a $0.5 million milestone payment under the agreement. In June 2016, we recorded $1.0 million in milestone revenue for Aratana&#8217;s filing of an FDA Administrative New Animal Drug Application, or ANADA, and in August 2016 recorded $1.0 million related to the FDA&#8217;s approval of the ANADA. We are eligible to receive up to an additional aggregate $40.0 million upon the achievement of commercial milestones. Aratana is required to pay us a tiered double-digit royalty on net sales made in the U.S. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay us a tiered double-digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into a jurisdiction or if Aratana must pay royalties to third parties under certain circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Either party has the right to terminate the license agreement in connection with (i)&#160;an insolvency event involving the other party that is not discharged in a specified period of time; (ii)&#160;a material breach of the agreement by the other party that remains uncured for a specified cure period or (iii)&#160;the failure to achieve a minimum annual revenue as set forth in the agreement, all on specified notice. We may terminate the agreement in connection with (i)&#160;Aratana&#8217;s failure to pay any amounts due under the agreement; (ii)&#160;Aratana&#8217;s failure to achieve regulatory approval in a particular jurisdiction with respect to such jurisdiction or (iii)&#160;Aratana&#8217;s failure to achieve its first commercial sale within a certain amount of time on a country by country basis after receiving regulatory approval, all on specified notice. Aratana may terminate the license agreement (i)&#160;upon the entry of a generic competitor for animal health indications on a country by country basis or (ii)&#160;at any time on a country by country basis except with respect to the U.S. and any country in the E.U., all on specified notice. The parties may also terminate the license agreement by mutual consent. The license agreement will terminate automatically if we terminate the supply agreement. In the event that the license agreement is terminated, all rights to the product (on a jurisdiction by jurisdiction basis) will be terminated and returned to us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless terminated earlier pursuant to its terms, the license agreement is effective until December&#160;5, 2027, after which Aratana has the option to extend the agreement for an additional five&#160;(5)&#160;year term, subject to certain requirements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;is a registered trademark of Aratana Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had three wholesalers each comprising 10% or more of our total revenue for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">: Cardinal Health, Inc., McKesson Drug Company and AmerisourceBergen Health Corporation, which accounted for </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our revenues, respectively. These wholesalers process orders for EXPAREL under a drop-ship program. EXPAREL is delivered directly to end-users without the wholesalers ever taking physical possession of the product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing and Research Facilities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Internal Facilities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manufacture EXPAREL at our manufacturing facility San Diego, California. This facility is designated as Building 1. We also have a research and development facility, Building 2, which sits adjacent to Building 1, and a warehouse, Building 7, located within five miles of our manufacturing facilities. Our DepoCyt(e) manufacturing facility, designated as Building 6, is located within two miles of Building 1. We refer to these four buildings as the Science Center Campus, and together these four buildings consist of approximately 172,000 square feet. Our manufacturing facilities are inspected regularly and approved for pharmaceutical manufacturing by the FDA, the European Medicines Agency, or EMA, the Medicines and Healthcare Products Regulatory Agency, or MHRA, and the Environmental Protection Agency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We purchase raw materials and components from third-party suppliers to manufacture EXPAREL. In most instances, alternative sources of supply are available, although switching to an alternative source would, in some instances, take time and could lead to delays in manufacturing our drug candidates. While we have not experienced shortages of our raw materials in the past, such suppliers may not sell these raw materials to us at the times that we need them or on commercially reasonable terms and we do not have direct control over the availability of these raw materials from our suppliers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All manufacturing of products, initial product release and stability testing are conducted by us in accordance with cGMP.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building 1 is an approximately 84,000 square foot concrete structure located on a five acre site. It was custom built as a pharmaceutical research and development and manufacturing facility in 1995. Activities in this facility include the manufacture of EXPAREL bulk product on dedicated production lines and its fill/finish into vials, microbiological and quality control testing, product storage, development of analytical methods and manufacturing of development products. Prior to 2014, the bulk manufacturing of all EXPAREL product sold to the marketplace had occurred in a manufacturing line housed in what we refer to as Suite A. In 2014, the FDA approved our manufacturing lines, referred to as Suite&#160;C. Suite C significantly increased our manufacturing capacity and ability to meet the growing demand for EXPAREL. In 2018, we expect Suite A to be used for producing clinical material for development products. We are expanding our EXPAREL manufacturing capacity directly and through agreements with a third-party, Patheon U.K. Limited, or Patheon, as demand for EXPAREL increases, as explained below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building 2 is an approximately 45,000 square foot steel and concrete structure located adjacent to Building 1, originally built as a pharmaceutical research and development lab and office building in 2003. We moved most of our Science Center related general and administrative functions to this building in 2015 when it was renovated, as roughly half of the building is office space. The other half of the building is being used for research and development activities as it includes both laboratories and the building infrastructure necessary to support the formulation, analytical testing, clinical and process development activities for additional commercial product indications and new pipeline products. Our pilot plant suite for early-stage clinical product production is also located at Building 2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building 6, located in a 17-acre pharmaceutical industrial park, is a two-story concrete masonry structure built in 1977 that we and our predecessors have leased since August 1993. We occupy approximately 22,000 square feet of the first floor. Building 6 houses idle manufacturing equipment that was previously used for DepoCyt(e) production.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building 7 is an approximately 21,000 square foot concrete panel structure built in 1988 that serves as the main cGMP warehouse for our San Diego operations. It was renovated in 2014 to support the expansion of EXPAREL. The warehouse is primarily used for the storage of materials used in the production of our products. It contains ambient as well as cold temperature cGMP warehouse storage for materials used in our manufacturing operations.&#160;It also features a quality control clean room for sampling incoming materials. &#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution of our DepoFoam products, including EXPAREL, requires cold-chain distribution, whereby a product must be maintained between specified temperatures. We have validated processes for continuous monitoring of temperature from manufacturing through delivery to the end-user.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Co-Production Facilities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In April 2014, we and Patheon entered into a Strategic Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement (the &#8220;Patheon Agreements&#8221;) to collaborate in the manufacture of EXPAREL. Patheon has agreed to undertake certain technical transfer activities and construction services needed to prepare Patheon&#8217;s Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. We will provide Patheon with the equipment necessary to manufacture EXPAREL and will pay fees to Patheon based on Patheon&#8217;s achievement of certain technical transfer and construction milestones. We will also reimburse Patheon for certain nominal expenses and additional services. We also currently expect, subject to receipt of regulatory approvals, the first commercial manufacturing suite at Patheon&#8217;s facility to commence commercial production in the second half of 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Technical Transfer and Service Agreement expires upon receipt of FDA approval of the manufacturing suites. We may terminate the Technical Transfer and Service Agreement if Patheon does not meet certain construction and manufacturing milestones, or at any time for convenience upon 30 days notice. Either party may terminate the Technical Transfer and Service Agreement in the event of a breach by or bankruptcy of the other party. If the Technical Transfer and Service Agreement is terminated before the completion of the first manufacturing suite, the Manufacturing and Supply Agreement and Strategic Co-Production Agreement will concurrently and automatically terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial term of the Manufacturing and Supply Agreement is 10 years from the date of FDA approval of the initial manufacturing suite. We will pay fees to Patheon for their operation of the manufacturing suites and the amount of EXPAREL produced by Patheon. We will also reimburse Patheon for purchases made on our behalf, certain nominal expenses and additional services. We may terminate this agreement upon one month&#8217;s notice if a regulatory authority causes the withdrawal of EXPAREL from the U.S. or any other market that represents 80% of our overall sales, or at any time for convenience by providing between 18 and 36 months notice (depending on the number of years after the FDA approval date). Either party may terminate the Manufacturing and Supply Agreement in the event of the breach or bankruptcy of the other party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon termination of the Technical Transfer and Service Agreement (other than termination by us for a breach by Patheon), we will pay for the make good costs occasioned by the removal of our manufacturing equipment, for Patheon&#8217;s termination costs up to a maximum amount of $2.7 million. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property and Exclusivity</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek to protect our product candidates and our technology through a combination of patents, trade secrets, proprietary know-how, regulatory exclusivity and contractual restrictions on disclosure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patents and Patent Applications</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek to protect the proprietary position of our product candidates by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are over nine families of patents and patent applications relating to various aspects of the DepoFoam delivery technology. Patents have been issued in numerous countries, with an emphasis on the North American, European and Japanese markets. These patents generally have a term of 20&#160;years from the date of the non-provisional filing unless referring to an earlier filed application. Some of our expired U.S. patents have a term from 17&#160;years from the grant date. Our issued patents expire at various dates in the future, as discussed below, with the last currently issued patent expiring in 2033.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received an issue notification from the United States Patent and Trademark Office, or USPTO, stating that a patent relating to product-by-process and process claims in connection with the production of multivesicular liposomes was issued on March 7, 2017. This patent is listed on the Orange Book for EXPAREL, and includes patent term adjustment that equates to an expiration date of December 24, 2021.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued patents for EXPAREL in the U.S. relating to methods for modifying the rate of drug release of the product candidate and the composition of the product candidate expired in January 2017 and will expire in September 2018, respectively. Pursuant to 35 U.S.C. &#167; 156, an application for patent term extension was filed with the USPTO in October 2016 in connection with the regulatory approval of Aratana Therapeutics, Inc.&#8217;s NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. That application was subsequently </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawn after the product-by-process patent, referenced above, was issued on March 7, 2017. A patent relating to the composition of the product was issued in September 2014 and will expire in September 2018. A patent relating to the method of treatment using EXPAREL was issued in December 2015 and will expire in September 2018. In Europe, granted patent(s) related to the composition of the product candidate expire in September 2018. In Europe, a patent relating to methods of modifying the rate of drug release of the product candidate expired in January 2018. In addition, a granted European patent relating to the process for making the product candidate will expire in November 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, a provisional patent was filed relating to a new process to manufacture EXPAREL and other DepoFoam-based products. The process offers many advantages to the current process, including larger scale production and lower manufacturing costs. In April 2011, we filed an international patent application providing the basis for several non-provisional patent applications, for example in the U.S., Europe, China and Japan which, if granted, could potentially prevent others from using this process until at least 2031. In the U.S., six of the applications were issued as patents in 2017. Patents that claim the process and apparatus will expire at the latest in June 2033. One of the patents claims a product made by the process and expires in April 2031. In 2016, one such application was granted as a patent in Japan. In China, applications have been granted as patents in 2015, 2017 and 2018. They claim the methods of using the apparatus and the apparatus itself. Furthermore, a non-exclusively licensed patent of ours relating to EXPAREL was allowed in Europe with an expiration date in October 2021 and was extended in the U.S. until October 2023.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also taken steps to protect our product candidate DepoMLX. Currently, we have one patent application allowed in the U.S. for methods of treatment using DepoMLX. Pending patent applications for compositions and methods of treatment using DepoMLX, if granted, would expire in October 2031 and November 2037.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Secrets and Proprietary Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade secrets play an important role in protecting DepoFoam-based products and provide protection beyond patents and regulatory exclusivity. The scale-up and commercial manufacture of DepoFoam products involves processes, custom equipment and in-process and release analytical techniques that we believe are unique to us. The expertise and knowledge required to understand the critical aspects of DepoFoam manufacturing steps requires knowledge of both traditional and non-traditional emulsion processing and traditional pharmaceutical production, overlaid with all of the challenges presented by aseptic manufacturing. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute proprietary information and confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention obligations. Further, we require confidentiality agreements from third parties that receive our confidential data or materials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological change. Our competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our competitors have greater financial and other resources than we have, such as more commercial resources, larger research and development staffs and more extensive marketing and manufacturing organizations. As a result, these companies may obtain marketing approval more rapidly than we are able and may be more effective in developing, selling and marketing their products. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our competitors may succeed in developing, acquiring or licensing on an exclusive basis technologies and drug products that are more effective or less costly than EXPAREL or any other products that we are currently selling through partners or developing or that we may develop, which could render our products obsolete and noncompetitive. We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price and the availability of reimbursement from government and other third-party payers. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL competes with well-established products with similar indications. Competing products available for postsurgical pain management include opioids such as morphine, fentanyl, meperidine and hydromorphone, each of which is available generically from several manufacturers, and several of which are available as proprietary products using novel </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delivery systems. Ketorolac, an NSAID, is also available generically in the U.S. from several manufacturers, and Caldolor (ibuprofen for injection), an NSAID, has been approved by the FDA for pain management and fever in adults. EXPAREL also competes with currently-marketed non-opioid products such as bupivacaine, marcaine, ropivacaine and other anesthetics/analgesics, all of which are also used in the treatment of postsurgical pain and are available as either oral tablets, injectable dosage forms or administered using novel delivery systems. Additional products may be developed for the treatment of acute pain, including new injectable NSAIDs, novel opioids, new formulations of currently available opioids and NSAIDs, long-acting local anesthetics and new chemical entities as well as alternative delivery forms of various opioids and NSAIDs. Currently EXPAREL also competes with elastomeric pump/catheter devices intended to provide bupivacaine over several days. I-FLOW Corporation (acquired by Kimberly-Clark Corporation in 2009 and spun off into Halyard Health, Inc. in 2014) has marketed these medical devices in the U.S. since 2004.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the U.S., prescription drug products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the research, development, testing, manufacturing, distribution, safety, efficacy, approval, labeling, storage, record keeping, reporting, advertising and promotion of such products under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. Outside the U.S., prescription drug products are regulated by comparable agencies, laws and regulations. Failure to comply with applicable regulatory requirements in the U.S. or elsewhere may result in, among other things, refusal to approve pending applications, withdrawal of an approval, warning letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, debarment, partial or total suspension of production or withdrawal of the product from the market. Any agency or judicial enforcement action could have a material adverse effect on the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">United States Regulatory Environment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, the FDA must approve any new drug, including a new use of a previously approved drug, before marketing of the drug occurs in the U.S.. This process generally involves:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completion of preclinical laboratory and animal testing and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice regulations (21 CFR 58);</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin for unapproved use in the U.S.;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approval by an independent Institutional Review Board, or IRB, at each clinical trial site before each trial may be initiated;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed drug product for each intended use;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completion of process validation, quality product release and stability;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission of an NDA to the FDA;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA pre-approval inspection of the product&#8217;s manufacturing facility or facilities to assess compliance with cGMP requirements and to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, quality and purity;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA advisory committee review, if applicable; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and approval by the FDA of the NDA.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that the FDA will grant approvals for any of our product candidates on a timely basis, if at all. Preclinical tests include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals. The results of preclinical tests, together with manufacturing information, analytical data and a proposed clinical trial protocol and other information, are submitted as part of an IND application to the FDA. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA places the trial on a clinical hold because of, among other things, concerns about the conduct of the clinical trial or about exposure of human research subjects to unreasonable health risks. In such a case, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Thus, submission of an IND does not by itself automatically result in FDA authorization to commence a clinical trial. In addition, the FDA requires us to amend an existing IND for each successive clinical trial conducted during product development. Further, an IRB covering each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial along with informed consent information for subjects before the clinical trial commences at that center. The IRB also must monitor the clinical trial until it is completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time, on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Sponsors of clinical trials generally must register at the NIH-maintained website www.clinicaltrials.gov and report key findings and parameters. For purposes of an NDA submission and approval, typically, the conduct of human clinical trials occurs in the following three pre-market sequential phases, which may overlap or be combined:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase&#160;1: </font><font style="font-family:inherit;font-size:10pt;">Sponsors initially conduct clinical trials in a limited population, either patients or healthy volunteers, to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution, excretion and clinical pharmacology, and, if possible, to gain early evidence of effectiveness. In the cases of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing often is conducted only on patients having the specific disease. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase&#160;2: </font><font style="font-family:inherit;font-size:10pt;">Sponsors conduct clinical trials generally in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dose tolerance, optimal dosage and dosing schedule. Sponsors may conduct multiple Phase&#160;2 clinical trials to obtain information prior to beginning larger and more extensive Phase&#160;3 clinical trials.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase&#160;3: </font><font style="font-family:inherit;font-size:10pt;">These include expanded controlled and uncontrolled trials, including pivotal clinical trials. When Phase&#160;2 evaluations suggest the effectiveness of a dose range of the product and acceptability of such product&#8217;s safety profile, sponsors undertake Phase&#160;3 clinical trials in larger patient populations to obtain additional information needed to evaluate the overall benefit and risk balance of the drug and to provide an adequate basis to develop labeling.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some clinical trials may be overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. The process of completing clinical testing and obtaining FDA approval for a new drug is likely to take a number of years and requires the expenditure of substantial resources. If an application is submitted, there can be no assurance that the FDA will review and approve the NDA. In addition, sponsors may elect to conduct, or be required by the FDA to conduct, post-approval clinical trials to further assess the drug&#8217;s safety or effectiveness after NDA approval. Such post approval trials are typically referred to as Phase&#160;4 clinical trials.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Review and Approval Process</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, sponsors submit the results of product development, preclinical studies and clinical trials to the FDA as part of an NDA requesting approval to market the product for one or more indications. NDAs must also contain extensive information relating to the product&#8217;s pharmacology, chemistry, manufacture, controls and proposed labeling, among other things. In addition, 505(b)(2) applications must contain a patent certification for each patent listed in FDA&#8217;s &#8220;Orange Book&#8221; that covers the drug referenced in the application and upon which the third-party studies were conducted. For some drugs, the FDA may require risk evaluation and mitigation strategies, or REMS, which could include medication guides, physician communication plans or restrictions on distribution and use, such as limitations on who may prescribe the drug or where it may be dispensed or administered. Upon receipt of an NDA, the FDA has 60&#160;days to determine whether it is sufficiently complete to initiate a substantive review. If the FDA identifies deficiencies that would preclude substantive review, the FDA will refuse to accept the NDA (&#8220;refuse to file&#8221;) and will inform the sponsor of the deficiencies that must be corrected prior to resubmission. The resubmitted application is also subject to review before the FDA accepts it for filing. If the FDA accepts the submission for substantive review, the FDA typically reviews the NDA in accordance with established timeframes. Under the Prescription Drug User Fee Act, or PDUFA, the FDA establishes goals for NDA review time through a two-tiered classification system: Priority Review and Standard Review. A Priority Review designation is given to drugs that address and unmet medical need by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">offering major advances in treatment or providing a treatment where no adequate therapy currently exists. Standard Review applies to all applications that are not eligible for Priority Review. The FDA aims to complete Standard Reviews of NDAs within ten months of submission and Priority Reviews within 6 months. Review processes may sometimes extend beyond these target completion dates due to FDA requests for additional information or clarification, difficulties scheduling an advisory committee meeting, negotiations regarding REMS or FDA workload issues, but in general under PDUFA the FDA is supposed to complete its reviews within the target timeframes despite these factors. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to the application&#8217;s approval. The recommendations of an advisory committee do not bind the FDA, but the FDA generally follows such recommendations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under PDUFA, NDA applicants must pay significant NDA user fees upon submission. In addition, manufacturers of approved prescription drug products must pay annual establishment and product user fees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to ensure consistent production of the product within required specifications. Additionally, the FDA will typically inspect one or more clinical sites to ensure compliance with GCP before approving an NDA.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the FDA evaluates the NDA and the manufacturing facilities, it may issue an approval letter or a Complete Response Letter, or CRL, to indicate that the review cycle for an application is complete and that the application is not ready for approval. CRLs generally outline the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we do. The FDA could also require a REMS plan to mitigate risks, which could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may approve an NDA contingent on, among other things, changes to proposed labeling, a commitment to conduct one or more post-market studies or clinical trials and the correction of identified manufacturing deficiencies, including the development of adequate controls and specifications. If and when the deficiencies have been addressed to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Section&#160;505(b)(2) New Drug Applications</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an alternate path to FDA approval, particularly for modifications to drug products previously approved by the FDA, an applicant may submit an NDA under Section&#160;505(b)(2) of the FDCA. Section&#160;505(b)(2) was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, and permits the submission of an NDA where at least some of the information required for approval comes from preclinical and/or clinical trials not conducted by or for the applicant. The FDA interprets Section&#160;505(b)(2) of the FDCA to permit the applicant to rely upon the FDA&#8217;s previous findings of safety and effectiveness for an approved product. The FDA may also require companies to perform additional clinical trials or measurements to support any change from the previously approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b)(2) applicant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applications under Section&#160;505(b)(2) are subject to any non-patent exclusivity period applicable to the referenced product, which may delay approval of the 505(b)(2) application even if FDA has completed its substantive review and determined the drug should be approved. In addition, 505(b)(2) applications must include patent certifications to any patents listed in the FDA&#8217;s Orange Book as covering the referenced product. If the 505(b)(2) applicant seeks to obtain approval before the expiration of an applicable listed patent, the 505(b)(2) applicant must provide notice to the patent owner and NDA holder of the referenced product. If the patent owner or NDA holder brings a patent infringement lawsuit within 45&#160;days of such notice, the 505(b)(2) application cannot be approved for 30&#160;months or until the 505(b)(2) applicant prevails, whichever is sooner. If the 505(b)(2) applicant loses the patent infringement suit, FDA may not approve the 505(b)(2) application until the patent expires, plus any period of pediatric exclusivity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the NDA submissions for our product candidates, we intend to follow the development and approval pathway permitted under the FDCA that we believe will maximize the commercial opportunities for these product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Post-Approval Requirements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After approval, the NDA sponsor must comply with comprehensive requirements governing, among other things, drug listing, recordkeeping, manufacturing, marketing activities, product sampling and distribution, annual reporting and adverse event reporting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If new safety issues are identified following approval, the FDA can require the NDA sponsor to revise the approved labeling to reflect the new safety information; conduct post-market studies or clinical trials to assess the new safety information and implement a REMS program to mitigate newly-identified risks. The FDA may also require post-approval testing, including Phase&#160;4 trials, and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the authority to prevent or limit further marketing of a product based on the results of these post-marketing programs. Drugs may be marketed only for approved indications and in accordance with the provisions of the FDA-approved label. Further, if we modify a drug, including any changes in indications, labeling or manufacturing processes or facilities, the FDA may require us to submit and obtain FDA approval of a new or supplemental NDA, which may require us to develop additional data or conduct additional preclinical studies and clinical trials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If after approval the FDA determines that the product does not meet applicable regulatory requirements or poses unacceptable safety risks, the FDA may take other regulatory actions, including initiating suspension or withdrawal of the NDA approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines, warning letters or holds on post-approval clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. While physicians may prescribe for off-label uses, manufacturers may only promote for the approved indications and in accordance with the provisions of the approved label. The FDA has very broad enforcement authority under the FDCA, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing entities to correct deviations from FDA standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA, and state and federal civil and criminal investigations and prosecutions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution, including a drug pedigree which tracks the distribution of prescription drugs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015 we announced that we achieved an amicable resolution with the U.S. in our lawsuit filed in September 2015 against the FDA and other governmental defendants. The resolution confirms that EXPAREL is, and has been since 2011, broadly indicated for administration into the surgical site to provide postsurgical analgesia.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Regulation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulations in the U.S., we are subject to a variety of foreign regulations governing clinical trials and the commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, in Europe, there are several tracks for marketing approval, for product approval and post-approval regulatory processes, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing application is similar to the NDA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use, or CHMP, the expert scientific committee of the EMA. If the CHMP determines that the marketing application fulfills the requirements for quality, safety and efficacy, it will submit a favorable opinion to the European Commission, or EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all member states. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the centralized procedure, Europe also has (i) a nationalized procedure, which requires a separate application to and approval determination by each country; (ii) a decentralized procedure whereby applicants submit identical applications to several countries and receive simultaneous approval and (iii) a mutual recognition procedure, where applicants submit an application to one country for review and the other countries may accept or reject the initial decision. Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection and evaluation of adverse events post-approval, including national authorities, the EMA, the EC and the marketing authorization holder. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As with FDA approval, we may not be able to secure regulatory approvals in Europe in a timely manner, if at all. Additionally, as in the U.S., post-approval regulatory requirements, such as those regarding product manufacture, marketing or distribution would apply to any product that is approved in Europe, and failure to comply with such obligations could have a material adverse effect on our ability to successfully commercialize any product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulations in Europe and the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of any future products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-Party Payer Coverage and Reimbursement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of our products and product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payers at the federal, state and private levels. Government payer programs, including Medicare and Medicaid, private health care insurance companies and managed care plans may deny coverage or reimbursement for a product or therapy in whole or in part if they determine that the product or therapy is not medically appropriate or necessary. Also, third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular procedures or drug treatments. The United States Congress and state legislatures from time to time propose and adopt initiatives aimed at cost containment that could impact our ability to sell our products at a price level high enough to realize an appropriate return on our investment, which would materially impact our results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, which we refer to collectively as the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates owed to states by pharmaceutical manufacturers for covered outpatient drugs. The Affordable Care Act also established a new Medicare Part&#160;D coverage gap discount program, in which drug manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand name drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Further, the new law imposed a significant annual, nondeductible fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may require us to modify our business practices with healthcare practitioners. There have been proposed in Congress a number of legislative initiatives regarding healthcare, including possible repeal of the Affordable Care Act. At this time, it remains unclear whether there will be any changes made to the Affordable Care Act. The full impact that the Affordable Care and other new laws will have on our business is uncertain. However, such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">laws appear likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Moreover, in the coming years, additional changes could be made to governmental healthcare programs that could significantly impact the success of our products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The marketability of our products may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the U.S. has increased, and we expect will continue to increase, the pressure on pharmaceutical pricing. Some third-party payers require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers that use such therapies, or place limits on the amount of reimbursement. Coverage policies and third-party payer reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for our products, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. There can be no assurance that our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payers or that an adequate level or reimbursement will be available so that the third-party payers&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketing/Data Exclusivity</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may grant three or five years of marketing exclusivity in the U.S. for the approval of new or supplemental NDAs, including Section&#160;505(b)(2) NDAs, for, among other things, new indications, dosages or dosage forms of an existing drug, if new clinical investigations that were conducted or sponsored by the applicant are essential to the approval of the application. Additionally, six months of marketing exclusivity in the U.S. is available under Section&#160;505A of the FDCA if, in response to a written request from the FDA, a sponsor submits and the agency accepts requested information relating to the use of the approved drug in the pediatric population. This six month pediatric exclusivity period is not a standalone exclusivity period, but rather is added to any existing patent or non-patent exclusivity period for which the drug product is eligible. Based on our clinical trial program for EXPAREL, the FDA granted three years of marketing exclusivity to EXPAREL, which expired on October&#160;28, 2014. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing Requirements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must comply with the FDA&#8217;s cGMP requirements and comparable regulations in other countries. The cGMP provisions include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our products must meet cGMP requirements to the satisfaction of the FDA and other authorities pursuant to a pre-approval inspection before we can use them to manufacture our products. We and any third-party manufacturers we engage or with which we partner are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations. Failure to comply with these and other statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Adverse experiences with the product or product complaints must be reported and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulations Pertaining to Sales and Marketing</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under the anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payers (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and civil monetary penalties and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include the federal Physician Payment Sunshine Act, or &#8220;sunshine&#8221; provisions, enacted in 2010 as part of the Affordable Care Act. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. We are cooperating with the government&#8217;s inquiry.&#160;We can make no assurances as to the time or resources that will need to be devoted to this inquiry or its final outcome, or the impact, if any, of this inquiry or any proceedings on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Privacy and Security Laws</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be subject to, or our marketing activities may be limited by the Health Insurance Portability and Accountability Act, or HIPAA and its implementing regulations, which established uniform standards for certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information. The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included sweeping expansion of HIPAA&#8217;s privacy and security standards called the Health Information Technology for Economic and Clinical Health Act, or HITECH, which became effective on February&#160;17, 2010. Among other things, the new law makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates&#8221;&#8212;independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development processes and our manufacturing processes involve the controlled use of hazardous materials and chemicals and produce waste products. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and waste products. We do not expect the cost of complying with these laws and regulations to be material. While we believe we are in compliance with applicable environmental regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">489</font><font style="font-family:inherit;font-size:10pt;">&#32;employees. All of our employees are located in the U.S. except for seven located in England. None of our employees are represented by a labor union, and we consider our current employee relations to be good.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file reports and other information with the SEC as required by the Exchange Act. We make available free of charge through our website (http://www.pacira.com) our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Sections&#160;13(a) and 15(d) of the Exchange Act. We </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors&#160;&amp; Media,&#8221; as a source of information about us. The foregoing references to our website are not intended to, nor shall they be deemed to, incorporate information on our website into this Annual Report on Form&#160;10-K by reference.</font></div><div><a name="s8F38AC202A965944AB7BF9AD3A439AE0"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the other information in this Annual Report on Form&#160;10-K, any of the factors set forth below could significantly and negatively affect our business, financial condition, results of operations or prospects. The trading price of our common stock may decline due to these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page&#160;1.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Development and Commercialization of Our Product Candidates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our success depends on our ability to successfully commercialize EXPAREL.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have invested a significant portion of our efforts and financial resources in the development and commercialization of our lead product, EXPAREL, which was approved by the FDA on October&#160;28, 2011 and commercially launched in April 2012. During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, sales of EXPAREL constituted the vast majority of our total revenue, and we expect it will do so for the foreseeable future. Our success depends on our ability to continue to effectively commercialize EXPAREL. Our ability to effectively generate revenues from EXPAREL will depend on our ability to, among other things:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">create market demand for EXPAREL through our marketing and sales activities and other arrangements established for the promotion of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">train, deploy and support a qualified sales force;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">secure formulary approvals for EXPAREL at a substantial number of targeted hospitals;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacture EXPAREL in sufficient quantities in compliance with requirements of the FDA and similar foreign regulatory agencies and at acceptable quality and pricing levels in order to meet commercial demand;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">implement and maintain agreements with wholesalers and distributors on commercially reasonable terms;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">receive adequate levels of coverage and reimbursement for EXPAREL from commercial health plans and governmental health programs;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain compliance with regulatory requirements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain regulatory approvals for additional indications for the use of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ensure that our entire supply chain efficiently and consistently delivers EXPAREL to our customers; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain and defend our patent protection and regulatory exclusivity for EXPAREL.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any disruption in our ability to generate revenues from the sale of EXPAREL will have a material and adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our efforts to successfully commercialize EXPAREL are subject to many internal and external challenges and if we cannot overcome these challenges in a timely manner, our future revenues and profits could be materially and adversely impacted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL has been a commercialized drug for less than five years. As a result, we continue to expend significant time and resources to train our sales force to be credible and persuasive in convincing physicians and hospitals to use EXPAREL. In addition, we also must train our sales force to ensure that a consistent and appropriate message about EXPAREL is delivered to our potential customers. If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of EXPAREL and its proper administration, our efforts to successfully commercialize EXPAREL could be put in jeopardy, which could have a material adverse effect on our future revenues and profits.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our extensive internal efforts, the successful commercialization of EXPAREL will require many third parties, over whom we have no control, to choose to utilize EXPAREL. These third parties include physicians and hospital pharmacy and therapeutics committees, which we refer to as P&amp;T committees. Generally, before we can attempt to sell </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL in a hospital, EXPAREL must be approved for addition to that hospital&#8217;s list of approved drugs, or formulary list, by the hospital&#8217;s P&amp;T committee. A hospital&#8217;s P&amp;T committee typically governs all matters pertaining to the use of medications within the institution, including the review of medication formulary data and recommendations for the appropriate use of drugs within the institution to the medical staff. The frequency of P&amp;T committee meetings at hospitals varies considerably, and P&amp;T committees often require additional information to aid in their decision-making process. Therefore, we may experience substantial delays in obtaining formulary approvals. Additionally, hospital pharmacists may be concerned that the cost of acquiring EXPAREL for use in their institutions will adversely impact their overall pharmacy budgets, which could cause pharmacists to resist efforts to add EXPAREL to the formulary, or to implement restrictions on the usage of EXPAREL or to encourage use of a lower cost dose than a surgeon would otherwise choose in order to control costs. We cannot guarantee that we will be successful in obtaining the approvals we need from enough P&amp;T committees quickly enough to optimize hospital sales of EXPAREL.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if we obtain hospital formulary approval for EXPAREL, physicians must still prescribe EXPAREL for its commercialization to be successful. Because EXPAREL is a relatively new drug with a limited track record of sales in the U.S., any inability to timely supply EXPAREL to our customers, or any unexpected side effects that develop from use of the drug, particularly early in product launch, may lead physicians to not accept EXPAREL as a viable treatment alternative.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If EXPAREL does not achieve broad market acceptance, the revenues that we generate from its sales will be limited. The degree of market acceptance of EXPAREL also depends on a number of other factors, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care for the targeted indications for EXPAREL, which could reduce the marketing impact of any claims that we can make;&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the relative efficacy, convenience and ease of administration of EXPAREL;&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of adverse events associated with EXPAREL;&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost of treatment versus economic and clinical benefit, both in absolute terms and in relation to alternative treatments;&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payers, and by government healthcare programs, including Medicare and Medicaid;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent and strength of our marketing and distribution of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the safety, efficacy and other potential advantages over, and availability of, alternative treatments, including, in the case of EXPAREL, a number of products already used to treat pain in the hospital setting; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory risk evaluation and mitigation strategy or voluntary risk management plan.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to effectively promote and sell EXPAREL and any product candidates that we may develop, license or acquire in the hospital marketplace will also depend on pricing and cost effectiveness, including our ability to produce a product at a competitive price and therefore achieve acceptance of the product onto hospital formularies, and our ability to obtain sufficient third-party coverage or reimbursement. We will also need to demonstrate acceptable evidence of safety and efficacy, as well as relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and severity of any expected or unexpected adverse side effects associated with our product candidates.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the labeling approved by the FDA does not contain claims that EXPAREL is safer or more effective than competitive products and does not permit us to promote EXPAREL as being superior to competing products. Further, the availability of inexpensive generic forms of postsurgical pain management products may also limit acceptance of EXPAREL among physicians, patients and third-party payers. If EXPAREL does not achieve an adequate level of acceptance among physicians, patients and third-party payers, we may not generate meaningful revenues from EXPAREL and we may not become profitable.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face significant competition from other pharmaceutical and biotechnology companies. Our operating results will suffer if we fail to compete effectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological change. Our major competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies and specialty pharmaceutical and generic drug companies. Many of our competitors have greater financial and other resources than we have, such as larger research and development staff, more extensive marketing, distribution, sales and manufacturing organizations and experience, more extensive clinical trial and regulatory experience, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expertise in prosecution of intellectual property rights and access to development resources like personnel and technology. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis technologies and drug products that are more effective or less costly than EXPAREL or any product candidate that we are currently developing or that we may develop, which could render our products obsolete and noncompetitive or significantly harm the commercial opportunity for EXPAREL or our product candidates.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of these factors, our competitors may obtain patent protection or other intellectual property rights that may limit our ability to develop other indications for, or commercialize, EXPAREL. Our competitors may also develop drugs that are safer, more effective, useful or less costly than ours and may be more successful than us in manufacturing and marketing their products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL competes with well-established products with similar indications. Competing products available for postsurgical pain management include opioids such as morphine, fentanyl, meperidine and hydromorphone, each of which is available generically from several manufacturers, and several of which are available as proprietary products using novel delivery systems. Ketorolac, an NSAID is also available generically in the U.S. from several manufacturers, and Caldolor (ibuprofen for injection), an NSAID, has been approved by the FDA for pain management and fever in adults. In addition, EXPAREL competes with non-opioid products such as bupivacaine, marcaine, ropivacaine and other anesthetics/analgesics, all of which are also used in the treatment of postsurgical pain and are available as either oral tablets, injectable dosage forms or administered using novel delivery systems. Additional products may be developed for the treatment of acute pain, including new injectable NSAIDs, novel opioids, new formulations of currently available opioids and NSAIDs, long-acting local anesthetics and new chemical entities as well as alternative delivery forms of various opioids and NSAIDs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL also competes with elastomeric bag/catheter devices intended to provide bupivacaine over several days.          I-FLOW Corporation (acquired by Kimberly-Clark Corporation in 2009 and spun off into Halyard Health, Inc. in 2014) has marketed these medical devices in the U.S. since 2004.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and allegations of our failure to comply with such approved indications could limit our sales efforts and have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. For example, the FDA-approved label for EXPAREL does not include an indication in obstetrical paracervical block anesthesia. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While physicians in the U.S. may choose, and are generally permitted to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is narrowly limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. Although recent court decisions suggest that certain off-label promotional activities may be protected under the First Amendment, the scope of any such protection is unclear. If our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall or institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, we received a warning letter from the FDA&#8217;s Office of Prescription Drug Promotion, or OPDP, pertaining to certain promotional aspects of EXPAREL, and in February 2015, agreement was reached with the OPDP on the content and mechanisms for distribution of corrective action, which consisted of a Dear Healthcare Provider Letter and a corrective journal advertisement. Although the warning letter was subsequently withdrawn we expect that it had a negative impact on our customers&#8217; perception of us. We can make no assurances that we will not receive FDA warning letters in the future or be subject to other regulatory action. As noted above, any regulatory violation or allegations of a violation may have a material adverse effect on our reputation and business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell EXPAREL, we may be unable to generate product revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are continuing to build our commercial infrastructure for the marketing, sale and distribution of pharmaceutical products. In order to continue commercializing EXPAREL effectively, we must continue to build our marketing, sales and distribution capabilities. We entered into an agreement with Quintiles for the outsourcing of our specialty sales force, which we then hired as direct employees in January 2013. The establishment, development and training of our sales force and related compliance plans to market EXPAREL is expensive and time consuming. In the event we are not successful in developing our marketing and sales infrastructure, we may not be able to successfully commercialize EXPAREL, which would limit our ability to generate product revenues.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our internal marketing and sales efforts, we have entered into agreements with third-party distributors to promote and sell EXPAREL in certain territories. For example, in January 2017, we entered into a co-promotion agreement with DePuy Synthes to market and promote the use of EXPAREL for orthopedic procedures in the U.S. market. The initial term of the agreement commenced on January 24, 2017 and ends on December 31, 2021, with the option to extend the agreement in 12 month increments upon mutual agreement of the parties, subject to certain conditions. We may seek additional distribution arrangements in the future, including arrangements with third-party distributors to commercialize and sell EXPAREL in certain foreign countries. The use of distributors involves certain risks, including risks that such distributors will:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not effectively distribute or support our products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not provide us with accurate or timely information regarding their inventories, the number of accounts using our products or complaints about our products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fail to comply with their obligations to us;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fail to comply with laws and regulations to which they are subject, whether in the U.S. or in foreign jurisdictions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce or discontinue their efforts to sell or promote our products; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cease operations.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any such failure may result in decreased sales, which would have an adverse effect on our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to perform many essential services for EXPAREL and any other products that we commercialize, including services related to customer service support, warehousing and inventory program services, distribution services, contract administration and chargeback processing services, accounts receivable management and cash application services, and financial management and information technology services. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize EXPAREL will be significantly impacted and we may be subject to regulatory sanctions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into agreements with third-party service providers to perform a variety of functions related to the sale and distribution of EXPAREL, key aspects of which are out of our direct control. These service providers provide key services related to customer service support, warehousing and inventory program services, distribution services, contract administration and chargeback processing services, accounts receivable management and cash application services, financial management and information technology services. In addition, our inventory is stored at two warehouses maintained by two service providers. We substantially rely on these providers as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired. In addition, we may engage third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, we could be subject to regulatory sanctions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution of our DepoFoam-based products, including EXPAREL, requires cold-chain distribution provided by third parties, whereby the product must be maintained between specified temperatures. We and our partners have utilized similar cold-chain processes for DepoCyt(e) and, when it was produced, DepoDur. If a problem occurs in our cold-chain distribution processes, whether through our failure to maintain our products or product candidates between specified temperatures or because of a failure of one of our distributors or partners to maintain the temperature of the products or product candidates, the product or product candidate could be adulterated and rendered unusable. We have obtained limited inventory and cargo insurance coverage for our products. However, our insurance coverage may not reimburse us or may not be sufficient to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reimburse us for any expenses or losses we may suffer. This could have a material adverse effect on our business, financial condition, results of operations and reputation.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need to increase the size of our organization and effectively manage our sales force, and we may experience difficulties in managing growth.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">489</font><font style="font-family:inherit;font-size:10pt;">&#32;employees. We may need to expand our personnel resources in order to manage our operations and sales of EXPAREL. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. In addition, we may not be able to recruit and retain qualified personnel in the future, particularly marketing positions, due to competition for personnel among pharmaceutical businesses, and the failure to do so could have a significant negative impact on our future product revenues and business results. Our need to effectively manage our operations, growth and various projects requires that we:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the hiring and training of an effective commercial organization for the commercialization of EXPAREL, and establish appropriate systems, policies and infrastructure to support that organization;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to establish and maintain effective relationships with distributors and commercial partners for the promotion and sale of our products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ensure that our distributors, partners, suppliers, consultants and other service providers successfully carry out their contractual obligations, provide high quality results and meet expected deadlines;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manage our development efforts and clinical trials effectively;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expand our manufacturing capabilities and effectively manage our co-production arrangement with Patheon;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to carry out our own contractual obligations to our licensors and other third parties; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to improve our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our development and commercialization goals. Additionally, these tasks may impose a strain on our administrative and operational infrastructure. If we are unable to effectively manage our growth, our product sales and resulting revenues will be negatively impacted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to attract or retain qualified management and commercial, scientific and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, as well as universities, non-profit research organizations and government entities, particularly in the San Diego, California and northern New Jersey areas. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development and manufacturing expertise for our DepoFoam delivery technology and the commercialization expertise of certain members of our senior management. In particular, we are highly dependent on the skills and leadership of our senior management team. If we lose one or more of these key employees, our ability to successfully implement our business strategy could be seriously harmed. Replacing key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate additional key personnel.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for EXPAREL, DepoCyt(e) or product candidates that we may develop and may have to limit their commercialization.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of EXPAREL, DepoCyt(e) and any product candidates that we may develop, license or acquire in clinical trials and the sale of any products for which we obtain regulatory approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. We have been a party of these suits in the past and may be again in the future. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenue from decreased demand for our products and/or product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment of our business reputation or financial stability;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of related litigation;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or other claimants;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management attention;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenues;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained limited product liability insurance coverage for our products and our clinical trials with a $10.0&#160;million annual aggregate coverage limit. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer, including our indemnification obligations to other parties. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage on acceptable terms, at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of additional commercial products upon FDA approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to manufacture EXPAREL in sufficient quantities and at acceptable quality and pricing levels, or to fully comply with cGMP regulations, we may face delays in the commercialization of this product or be unable to meet market demand, and may lose potential revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture of EXPAREL requires significant expertise and capital investment, including the development of advanced manufacturing techniques, process controls and the use of specialized processing equipment. We must comply with federal, state and foreign regulations, including the FDA&#8217;s regulations governing cGMP, enforced by the FDA through its facilities inspection program and by similar regulatory authorities in other jurisdictions where we do business. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory authorities at any time may implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of our products. Any failure by us or our manufacturing partner to comply with applicable regulations may result in fines and civil penalties, suspension of production, product seizure or recall, operating restrictions, imposition of a consent decree, modification or withdrawal of product approval or criminal prosecution and would limit the availability of our product. Any manufacturing defect or error discovered after products have been produced and distributed also could result in significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to produce the required commercial quantities of EXPAREL to meet market demand for EXPAREL on a timely basis or at all, or if we fail to comply with applicable laws for the manufacturing of EXPAREL, we will suffer damage to our reputation and commercial prospects and we will lose potential revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to expand our manufacturing operations or outsource such operations to third parties.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To successfully meet future customer demand for EXPAREL, we will need to expand our existing commercial manufacturing facilities or establish large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. As a result, we must continue to improve our manufacturing processes to allow us to reduce our production costs. We may not be able to manufacture our drugs at a cost or in quantities necessary to be commercially successful.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The build-up or other expansion of our internal manufacturing capabilities for EXPAREL production in San Diego, California exposes us to significant up-front fixed costs. If market demand for EXPAREL does not align with our expanded manufacturing capacity, we may be unable to offset these costs and to achieve economies of scale, and our operating results may be adversely affected as a result of high operating expenses. Alternatively, if we experience demand for EXPAREL in excess of our estimates, our facilities may be insufficient to support higher production volumes, which could harm our customer </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relationships and overall reputation. Our ability to meet such excess demand could also depend on our ability to raise additional capital and effectively scale our manufacturing operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the procurement time for the equipment that we use to manufacture EXPAREL requires long lead times. Therefore, we may experience delays, additional or unexpected costs and other adverse events in connection with our capacity expansion projects, including those associated with potential delays in the procurement of manufacturing equipment required to manufacture EXPAREL, including the equipment for the construction of manufacturing suites at Patheon.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to expanding our internal manufacturing facilities, we may enter into arrangements with third parties to supply, manufacture, package, test and/or store EXPAREL or our other products, such as our manufacturing arrangement with Patheon. Entering into such arrangements requires testing and compliance inspections, FDA approvals and development of the processes and facilities necessary for the production of our products. Such arrangements also involve additional risks, many of which would be outside of our control. Such risks include disruptions or delays in production, manufactured products that do not meet our required specifications, the failure of such third-party manufacturers to comply with cGMP regulations or other regulatory requirements, protection of our intellectual property and manufacturing process, loss of control of our complex manufacturing process, inabilities to fulfill our commercial needs and financial risks in connection with our investment in setting up a third-party manufacturing process, such as substantial capital outlays required by us to assist in setting up our manufacturing process at Patheon&#8217;s facilities.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to timely achieve and maintain satisfactory production yields and quality, whether through our internal manufacturing capabilities or arrangements with contract manufacturers, our relationships with potential customers and overall reputation may be harmed and our revenues could decrease.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are currently the sole manufacturer of EXPAREL. Our inability to continue manufacturing adequate supplies of the product could result in a disruption in the supply to our customers and partners, which could have a material adverse impact on our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently the sole manufacturer of EXPAREL, and we expect to be the sole manufacturer until, if and when manufacturing operations commence at Patheon&#8217;s facility, which we currently expect, subject to receipt of regulatory approvals, to commence during the second half of 2018. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we currently develop and manufacture EXPAREL at our facilities in San Diego, California, which are the only currently-FDA approved sites for manufacturing EXPAREL in the world. We may experience temporary or prolonged suspensions in production of our products due to issues in our manufacturing process that must be remediated or in response to inspections conducted by the FDA or similar foreign regulatory authorities, which could have a material adverse effect on our business, financial position and results of operations. For example, in June 2017 we discontinued production of DepoCyt(e) due to persistent technical issues specific to the DepoCyt(e) manufacturing process.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our San Diego facilities are also subject to the risks of a natural or man-made disaster, including earthquakes and fires, or other business disruptions. In addition, we have obtained limited property and business interruption insurance coverage for our facilities in San Diego. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. There can be no assurance that we would be able to meet our requirements for EXPAREL if there were a catastrophic event or failure of our current manufacturing system. If we are required to change or add a new manufacturer or supplier, the process would likely require prior FDA and/or equivalent foreign regulatory authority approval, and would be very time consuming. An inability to continue manufacturing adequate supplies of EXPAREL at our facilities in San Diego, California could result in a disruption in the supply of EXPAREL to our customers and partners and a breach of our contractual obligations to such counterparties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our co-production and other agreements with Patheon may involve unanticipated expenses and delays, including the need for the Patheon facilities to receive regulatory approvals required for manufacturing to commence at the Patheon suites.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Patheon have entered into a Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement. Under these agreements, Patheon will undertake certain technical transfer activities and construction services to prepare Patheon&#8217;s Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. We have agreed with Patheon, among other things, to provide them with the process equipment necessary to manufacture EXPAREL in these suites. We have anticipated and budgeted for capital expenditures associated with the two Patheon suites, including the equipment purchase and construction of the suites as well as payments to be made to Patheon. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Patheon facilities must be approved by the FDA prior to any production and manufacturing of EXPAREL. We currently expect, subject to receipt of regulatory approvals, that the first commercial manufacturing suite at Patheon&#8217;s facility will commence commercial production in the second half of 2018. If the construction of the Patheon suites is delayed, if Patheon experiences unanticipated cost overruns, or if the Patheon suites do not receive or maintain regulatory approvals in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">timeframe anticipated (if at all), this could have a material adverse effect on our business, financial position and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, if and when the Patheon facilities are constructed and have received the required FDA approvals, the production under these agreements involve additional risks, many of which would be outside of our control, such as disruptions or delays in production, manufactured products that do not meet our required specifications, the failure of Patheon to comply with cGMP regulations or other regulatory requirements, protection of our intellectual property and manufacturing process, loss of control of our complex manufacturing process and inabilities to fulfill our commercial needs. &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties for the timely supply of specified raw materials and equipment for the manufacture of EXPAREL. Although we actively manage these third-party relationships to provide continuity and quality, some events which are beyond our control could result in the complete or partial failure of these goods and services. Any such failure could have a material adverse effect on our financial condition and operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We purchase certain raw materials and equipment from various suppliers in order to manufacture our products. The acquisition of certain of these materials may require considerable lead times, and our ability to source such materials is also dependent on logistics providers. If we are unable to source the required raw materials and equipment from our suppliers on a timely basis and in accordance with our specifications, we may experience delays in manufacturing and may not be able to meet our customers&#8217; or partners&#8217; demands for our products. In addition, we and our third-party suppliers must comply with federal, state and foreign regulations, including cGMP regulations, and any failure to comply with applicable regulations, or failure of government agencies to provide necessary authorizations, may harm our ability to manufacture and commercialize our products on a timely and competitive basis, which could result in decreased product sales and lower revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future growth depends on our ability to identify, develop, acquire or in-license products and if we do not successfully identify, develop, acquire or in-license related product candidates or integrate them into our operations, we may have limited growth opportunities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An important part of our business strategy is to continue to develop a pipeline of product candidates by developing, acquiring or in-licensing products, businesses or technologies that we believe are a strategic fit with our focus on the hospital marketplace, including our current product candidate DepoMLX. However, these business activities may entail numerous operational and financial risks, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant capital expenditures;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty or inability to secure financing to fund development activities for such development, acquisition or in-licensed products or technologies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incurrence of substantial debt or dilutive issuances of securities to pay for development, acquisition or in-licensing of new products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disruption of our business and diversion of our management&#8217;s time and attention;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">higher than expected development, acquisition or in-license and integration costs;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exposure to unknown liabilities;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to retain key employees of any acquired businesses;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty entering markets in which we have limited or no direct experience;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty in managing multiple product development programs; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to successfully develop new products or clinical failure.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have limited resources to identify and execute the development, acquisition or in-licensing of products, businesses and technologies and integrate them into our current infrastructure. We may compete with larger pharmaceutical companies and other competitors, including public and private research organizations, academic institutions and government agencies, in our efforts to establish new collaborations and in-licensing opportunities. These competitors may have access to greater financial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">resources, research and development staffs and facilities than us and may have greater expertise in identifying and evaluating new opportunities. We may not be successful in locating and acquiring or in-licensing additional desirable product candidates on acceptable terms or at all. We may also not be successful in developing or commercializing our current product candidate DepoMLX. Such efforts may require the dedication of significant financial and personnel resources, and any diversion of resources may also disrupt our management from expanding on EXPAREL sales. Moreover, we may devote resources to potential development, acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our manufacturing activities involve the controlled storage, use and disposal of hazardous materials, including the components of our products, product candidates and other hazardous compounds. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. Violation of these laws and regulations could lead to substantial fines and penalties. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials or unintended failure to comply with these laws and regulations. In the event of an accident or failure to comply with these laws and regulations, state or federal authorities may curtail our use of these materials and interrupt our business operations. In addition, we could become subject to potentially material liabilities relating to the investigation and cleanup of any contamination, whether currently unknown or caused by future releases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of system failures.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems are vulnerable to damage from computer viruses, human error, unauthorized access, natural disasters, intentional acts of vandalism, terrorism, war and telecommunication and electrical failures. Any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed clinical trials for EXPAREL could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, reputation damage and harm to our business operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business model is to commercialize our product candidates in the U.S. and generally to seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our product candidates in the rest of the world. Accordingly, we may enter into collaboration arrangements in the future on a selective basis. Any future collaboration arrangements that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaboration arrangements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision making authority.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials may fail to demonstrate the safety and efficacy of our drug products, which could prevent or significantly delay obtaining regulatory approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to receiving approval to commercialize any of our drug products, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, other regulatory authorities in the U.S., and other countries, that each of the products is both safe and effective. For each drug product, we will need to demonstrate its efficacy and monitor its safety throughout the process. If such development is unsuccessful, our business and reputation would be harmed and our stock price would be adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our drug products are prone to the risks of failure inherent in drug development. Clinical trials of new drug products sufficient to obtain regulatory marketing approval are expensive and take years to complete. We may not be able to successfully complete clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a result of, the clinical trial process which could delay or prevent us from receiving regulatory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approval or commercializing our drug products. In addition, the results of pre-clinical studies and early-stage clinical trials of our drug products do not necessarily predict the results of later-stage clinical trials. Later-stage clinical trials may fail to demonstrate that a drug product is safe and effective despite having progressed through initial clinical testing. Even if we believe the data collected from clinical trials of our drug products is promising, such data may not be sufficient to support approval by the FDA or any other U.S. or foreign regulatory approval authority. Pre-clinical and clinical data can be interpreted in different ways.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, FDA officials could interpret such data in different ways than we or our partners do which could delay, limit or prevent regulatory approval. The FDA, other regulatory authorities, our institutional review boards, our contract research organizations or we ourselves may suspend or terminate our clinical trials for our drug products. Any failure or significant delay in completing clinical trials for our drug products, or in receiving regulatory approval for the sale of any drugs resulting from our drug products, may severely harm our business and reputation. Even if we receive FDA and other regulatory approvals, our drug products may later exhibit adverse effects that may limit or prevent their widespread use, may cause the FDA to revoke, suspend or limit their approval, or may force us to withdraw products derived from those drug products from the market.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our dependence on contract research organizations could result in delays in and additional costs for our drug development efforts.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may rely on contract research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates that we choose to develop without a collaborator. If the CROs that we hire to perform our preclinical testing and clinical trials or our collaborators or licensees do not meet deadlines, do not follow proper procedures or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may be delayed or may be terminated. If we were forced to find a replacement CRO to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable replacement on favorable terms, if at all. Even if we were able to find another CRO to perform a preclinical test or clinical trial, any material delay in a test or clinical trial may result in significant additional expenditures that could adversely affect our operating results. Events such as these may also delay regulatory approval for our drug candidates or our ability to commercialize our products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on clinical investigators and clinical sites to enroll patients in our clinical trials and sometimes other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays outside of our control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on clinical investigators and clinical sites to enroll patients and sometimes third parties to manage our trials and to perform related data collection and analysis. However, we may be unable to control the amount and timing of resources that the clinical sites which conduct the clinical testing may devote to our clinical trials. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trials may be delayed or terminated due to the inability of our clinical investigators to enroll enough patients. Patient enrollment depends on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites and the eligibility criteria for the trial. If our clinical investigators and clinical sites fail to enroll a sufficient number of patients in our clinical trials or fail to enroll them on our planned schedule, we may face increased costs, delays or termination of the trials, which could delay or prevent us from obtaining regulatory approvals for our product candidates. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our agreements with clinical investigators and clinical sites for clinical testing and for trial management services place substantial responsibilities on these parties, which could result in delays in, or termination of, our clinical trials if these parties fail to perform as expected. For example, if any of our clinical trial sites fail to comply with FDA-approved GCPs, we may be unable to use the data gathered at those sites. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for, or successfully commercialize, our product candidates.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to periodic litigation, which could result in losses or unexpected expense of time and resources. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we are called upon to defend ourselves against lawsuits relating to our business. Due to the inherent uncertainties of litigation, we cannot accurately predict the ultimate outcome of any such proceedings. See Item 3 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings</font><font style="font-family:inherit;font-size:10pt;">&#32;in Part I of this Form 10-K. An unfavorable outcome in either of these or other proceedings could have an adverse impact on our business, financial condition and results of operations. In addition, any significant litigation in the future, regardless of its merits, could divert management&#8217;s attention from our operations and result in substantial legal fees. In addition, if our stock price is volatile, we may become involved in additional securities class action lawsuits in the future. Any litigation could result in substantial costs and a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><br><br>        We are involved in an ongoing inquiry by the United States Department of Justice, the results of which could result in significant liability and have a material adverse effect on our sales, financial condition, results of operations and cash flows.<br>        <br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. We are cooperating with the government&#8217;s inquiry. We cannot estimate what impact this inquiry and any results from this inquiry or any proceedings could have on our business, financial condition, results of operations or cash flows. Cooperation with this inquiry may divert the attention of management and require the devotion of a substantial amount of time and resources. The existence of the inquiry could also adversely impact our sales activity or our customers&#8217; perception of us or EXPAREL. Any of these impacts could have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If, as a result of this inquiry, proceedings are initiated and we are found to have violated one or more applicable laws, we may be subject to significant liability, including without limitation, civil fines, criminal fines and penalties, civil damages and exclusion from federal funded healthcare programs such as Medicare and Medicaid, as well as potential liability under the federal False Claims Act and state false claims acts, and/or be required to enter into a corporate integrity or other settlement with the government, any of which could materially affect our reputation, business, financial condition, results of operations and cash flows. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payors or other persons allegedly harmed by such conduct. In addition, if some of our existing business practices are challenged as unlawful, we may have to change those practices, including changes and impacts on the practices of our sales force, which could also have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business could be materially adversely affected if the FDA determines that we are promoting or have in the past promoted the &#8220;Off-label&#8221; use of drugs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. According to these regulations, companies may not promote drugs for &#8220;Off-label&#8221; uses&#8212;that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. For example, the FDA-approved label for EXPAREL does not include an indication in obstetrical paracervical block anesthesia. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While physicians in the U.S. may choose, and are generally permitted to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, under the FDA&#8217;s regulations our ability to promote the products is narrowly limited to those indications that are approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. Although recent court decisions suggest that certain off-label promotional activities may be protected under the First Amendment, the scope of such protection is unclear. Moreover, while we promote our products consistent with what we believe to be the approved indication for our drugs, the FDA may disagree. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall or institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.<br>        <br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, we received a warning letter from the OPDP pertaining to certain promotional aspects of EXPAREL. We took actions to immediately address the FDA&#8217;s concerns and minimize further disruption to our business. Ultimately, however, in September 2015, we, along with two independent physicians, filed a lawsuit in federal court against the FDA and other governmental defendants seeking to exercise our lawful rights to communicate truthful and non-misleading information about EXPAREL. The complaint outlined our belief that the FDA&#8217;s warning letter received in September 2014 and regulations restricting our truthful and non-misleading speech about EXPAREL violate the Administrative Procedure Act and the First and Fifth Amendments of the U.S. Constitution. The lawsuit sought a declaration and injunctive relief to permit us to promote </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL consistent with its approved indication and pivotal trials that supported FDA approval. On December 15, 2015, we announced that the FDA had formally withdrawn the September 2014 Warning Letter via a &#8220;Rescission Letter,&#8221; and that the FDA and Pacira had reached an amicable resolution of the lawsuit. As part of the resolution of this matter, the FDA confirmed that EXPAREL was broadly approved for &#8220;administration into the surgical site to product postsurgical analgesia&#8221; in a variety of surgeries not limited to those studied in its pivotal trials. The FDA also approved a labeling supplement for EXPAREL that further clarified that EXPAREL was not limited to any specific surgery type or site, that the proper dosage and administration of EXPAREL is based on various patient and procedure-specific factors, that there was a significant treatment effect for EXPAREL compared to placebo over the first 72 hours in the pivotal hemorrhoidectomy trial and that EXPAREL may be admixed with bupivacaine, provided certain medication ratios are observed. We and the FDA have agreed that, in future interactions, the parties will deal with each other in an open, forthright and fair manner.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are unable to predict whether any future regulatory actions will have an effect on EXPAREL sales, and even if such actions are ultimately resolved favorably, our sales may suffer due to reputational or other concerns. We can make no assurances that we will not receive FDA warning letters in the future or be subject to other regulatory action. As noted above, any regulatory violation or allegations of a violation may have a material adverse effect on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not receive regulatory approval for any of our product candidates, or the approval may be delayed for various reasons, including successful challenges to the FDA&#8217;s interpretation of Section&#160;505(b)(2), which would have a material adverse effect on our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may experience delays in our efforts to obtain regulatory approval from the FDA for any of our product candidates, and there can be no assurance that such approval will not be delayed, or that the FDA will ultimately approve these product candidates. Although the FDA&#8217;s longstanding position has been that the Agency may rely upon prior findings of safety or effectiveness to support approval of a 505(b)(2) application, this policy has been controversial and subject to challenge in the past. If the FDA&#8217;s policy is successfully challenged administratively or in court, we may be required to seek approval of our products via full NDAs that contain a complete data package demonstrating the safety and effectiveness of our product candidates, which would be time-consuming, expensive and would have a material adverse effect on our business and financial condition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA, as a condition of the EXPAREL NDA approval on October&#160;28, 2011, has required us to study EXPAREL in pediatric patients. We have agreed to a trial timeline where, over several years, we will study pediatric patient populations in descending order starting with 12-18&#160;year olds and ending with children under two years of age. These trials will be expensive and time consuming and we are required to meet the timelines for submission of protocols and data and for completion as agreed with the FDA, and we may be delayed in meeting such timelines. We are required to conduct these trials even if we believe that the costs and potential benefits of conducting the trials are not warranted from a scientific or financial perspective. The failure to conduct these pediatric trials or to meet applicable deadlines could result in the imposition of sanctions, including, among other things, issuance of warnings letters or imposition of seizures or injunctions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The FDA may determine that EXPAREL or any of our product candidates have undesirable side effects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If concerns are raised regarding the safety of a new product candidate as a result of undesirable side effects identified during clinical testing, the FDA may decline to approve the drug at the end of the NDA review period or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the drug. The number of such requests for additional data or information issued by the FDA in recent years has increased, and resulted in substantial delays in the approval of several new drugs. Undesirable side effects caused by EXPAREL or any product candidate could also result in the inclusion of unfavorable information in our product labeling, imposition of distribution or use restrictions, a requirement to conduct post-market studies or to implement a risk evaluation and mitigation strategy, denial, suspension or withdrawal of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing and generating revenues from the sale of EXPAREL or any product candidate.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, the side effects observed in the EXPAREL clinical trials completed to date include nausea and vomiting. In addition, the class of drugs that EXPAREL belongs to has been associated with nervous system and cardiovascular toxicities at high doses. We cannot be certain that these side effects and others will not be observed in the future, or that the FDA will not require additional trials or impose more severe labeling restrictions due to these side effects or other concerns. The active component of EXPAREL is bupivacaine and bupivacaine infusions have been associated with the destruction of articular cartilage, or chondrolysis. Chondrolysis has not been observed in clinical trials of EXPAREL, but we cannot be certain that this side effect will not be observed in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following approval of EXPAREL or any of our product candidates, if we or others later identify previously unknown undesirable side effects caused by such products, if known side effects are more frequent or severe than in the past, or if we or others detect unexpected safety signals for such products or any products perceived to be similar to such products:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of unfavorable labeling statements, specific warnings or contraindications (including boxed warnings);</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may suspend or withdraw their approval of the product, or require it to be removed from the market;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may impose restrictions on the distribution or use of the product;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to change the way the product is administered, conduct additional clinical trials, reformulate the product, change the labeling of the product or change or obtain re-approvals of manufacturing facilities;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of the product may be significantly decreased from projected sales;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to government investigations, product liability claims and litigation; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of EXPAREL or any of our product candidates and could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from its sale.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. For example, the FDA-approved label for EXPAREL does not include an indication in obstetrical paracervical block anesthesia. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. Although recent court decisions suggest that certain off-label promotional activities may be protected under the First Amendment, the scope of any such protection is unclear. If our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, suspend or withdraw an approved product from the market, require a recall or institute fines or civil fines or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not comply with federal, state and foreign laws and regulations relating to the health care business, we could face substantial penalties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and our customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which we may conduct our business. In the U.S., the laws that directly or indirectly affect our ability to operate our business include the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Federal Anti-Kickback Law, which prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual or furnishing or arranging for a good or service for which payment may be made under federal health care programs such as Medicare and Medicaid;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other Medicare laws and regulations that prescribe the requirements for coverage and payment for services performed by our customers, including the amount of such payment;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Federal False Statements Act, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with delivery of or payment for health care benefits, items or services; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various state laws that impose similar requirements and liability with respect to state healthcare reimbursement and other programs.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our operations are found to be in violation of any of the laws and regulations described above or any other law or governmental regulation to which we or our customers are or will be subject, we may be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment or restructuring of our operations. Similarly, if our customers are found to be non-compliant with applicable laws, they may be subject to sanctions, which could also have a negative impact on us. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of our business and damage our reputation.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The design, development, manufacture, supply and distribution of EXPAREL are highly regulated and technically complex.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The design, development, manufacture, supply and distribution of EXPAREL are all highly regulated. We, along with our third-party providers, must comply with all applicable regulatory requirements of the FDA and foreign authorities. In addition, the facilities used to manufacture, store and distribute EXPAREL are subject to inspection by regulatory authorities at any time to determine compliance with applicable regulations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacturing techniques and facilities used for the manufacture and supply of our products must be operated in conformity with cGMP and other FDA and MHRA regulations, including potentially prior regulatory approval. In addition, any expansion of our existing manufacturing facilities or the introduction of any new manufacturing facilities, including the manufacturing suites to be constructed at Patheon&#8217;s facility, also require conformity with cGMP and other FDA and MHRA regulations. In complying with these requirements, we, along with our co-production partners and suppliers, must continually expend time, money and effort in production, record keeping and quality assurance and control to ensure that our products meet applicable specifications and other requirements for safety, efficacy and quality. In addition, we, along with our co-production partners and suppliers, are subject to unannounced inspections by the FDA, MHRA and other regulatory authorities.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any failure to comply with regulatory and other legal requirements applicable to the manufacture, supply and distribution of our products could lead to remedial action (such as recalls), civil and criminal penalties and delays in manufacture, supply and distribution of our products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The design, development, manufacture, supply and distribution of EXPAREL are all highly complex. As part of our routine stability monitoring that occurred in October 2016, it came to our attention that one of two test batches of EXPAREL made in early 2016 had fallen slightly out of specification for one of the 21 acceptance criteria measured during testing. This test result was unexpected and suggestive of some deviation from a consistency of manufacturing output. As a result, we have been in discussions with the FDA about both a modification of that specification as well as the potential development of a new analytical test for this attribute. Until that process is completed, we agreed with the FDA that all EXPAREL manufactured beginning in October 2016 will include 12 month expiration dating. In connection with this issue, in 2016, we recorded a $20.7 million charge to cost of goods sold. An internal investigation tied this unexpected result to a modification in the manufacturing process that existed when this product was made, which has subsequently been corrected. If we are unable to manufacture EXPAREL in compliance with our specifications, we may be subject to product exchanges or other corrective measures.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with the extensive regulatory requirements to which we and our products are subject, such products could be subject to restrictions or withdrawal from the market and we could be subject to penalties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The testing, manufacturing, quality control, labeling, safety, effectiveness, advertising, promotion, storage, sales, distribution, import, export and marketing, among other things, of EXPAREL and our product candidates are subject to extensive regulation by governmental authorities in the U.S. and elsewhere throughout the world. Quality control and manufacturing procedures regarding EXPAREL and our product candidates must conform to cGMP. Regulatory authorities, including the FDA and the MHRA, periodically inspect manufacturing facilities to assess compliance with cGMP. Our failure, or the failure of any contract manufacturers with whom we may work in the future, to comply with the laws administered by the FDA, the MHRA or other governmental authorities could result in, among other things, any of the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product recall or seizure;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of an approved product from the market;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interruption of production;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reputational concerns of our customers or the medical community;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to permit import or export of an approved product;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">denial of permission to file an application or supplement in a jurisdiction;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consent decrees;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or termination of ongoing clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines and other monetary penalties;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecutions; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated expenditures.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the government or third-party payers fail to provide coverage and adequate coverage and payment rates for EXPAREL or any future products, or if hospitals choose to use therapies that are less expensive, our revenue and prospects for profitability will be limited.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In both domestic and foreign markets, sales of our existing products and any future products will depend in part upon the availability of coverage and reimbursement from third-party payers. Such third-party payers include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Assuming coverage is approved, the resulting reimbursement payment rates might not be adequate. In particular, many U.S. hospitals receive a fixed reimbursement amount per procedure for certain surgeries and other treatment therapies they perform. Because this amount may not be based on the actual expenses the hospital incurs, hospitals may choose to use therapies which are less expensive when compared to our product candidates. Although hospitals may receive separate reimbursement for EXPAREL used in the hospital outpatient setting, EXPAREL or any product candidates that we may develop, in-license or acquire, if approved, will face competition from other therapies and drugs for these limited hospital financial resources. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals, other target customers and their third-party payers. Such studies might require us to commit a significant amount of management time, financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. For example, third-party payers may limit the indications for which our products will be reimbursed to a smaller set of indications than we believe is appropriate or limit the circumstances under which our products will be reimbursed to a smaller set of circumstances than we believe is appropriate. In addition, in the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party payers. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the U.S. and in international markets, as federal, state and foreign governments continue to propose and pass new legislation designed to reduce or contain the cost of healthcare. Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the U.S. or international markets, which could have a negative effect on our business, results of operations, financial condition and prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public concern regarding the safety of drug products such as EXPAREL could result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of widely publicized events concerning the safety risk of certain drug products, the FDA, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the establishment of risk management programs that may, for example, restrict distribution of drug products after approval. The Food and Drug Administration Amendments Act of 2007, or FDAAA, grants significant expanded authority to the FDA, much of which is aimed at improving the safety of drug products before and after approval. In particular, the FDAAA authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to drug labeling to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs, including certain currently approved drugs. The FDAAA also significantly expands the federal government&#8217;s clinical trial registry and results databank, which we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate these and other provisions of the new law are subject to substantial civil monetary penalties, among other regulatory, civil and criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials. If the FDA requires us to provide additional clinical or preclinical data for EXPAREL, the indications for which this product candidate was approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize EXPAREL may be otherwise adversely impacted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The patents and the patent applications that we have covering our products are limited to specific injectable formulations, processes and uses of drugs encapsulated in our DepoFoam drug delivery technology and our market opportunity for our product candidates may be limited by the lack of patent protection for the active ingredient itself and other formulations and delivery technology and systems that may be developed by competitors.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active ingredient in EXPAREL is bupivacaine. Patent protection for the bupivacaine molecules themselves has expired and generic immediate-release products are available. As a result, competitors who obtain the requisite regulatory approval can offer products with the same active ingredient as EXPAREL so long as the competitors do not infringe any process, use or formulation patents that we have developed for drugs encapsulated in our DepoFoam drug delivery technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, we are aware of at least one long-acting injectable bupivacaine product in development which utilizes an alternative delivery system to EXPAREL. Such a product is similar to EXPAREL in that it also extends the duration of effect of bupivacaine, but achieves this clinical outcome using a completely different drug delivery system as compared to our DepoFoam drug delivery technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of patents and patent applications covering products in the same field as EXPAREL indicates that competitors have sought to develop and may seek to market competing formulations that may not be covered by our patents and patent applications. The commercial opportunity for EXPAREL could be significantly harmed if competitors are able to develop and commercialize alternative formulations of bupivacaine that are long-acting but outside the scope of our patents.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because EXPAREL has been approved by the FDA, one or more third parties may challenge the patents covering this product, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. For example, if a third-party files an Abbreviated New Drug Application, or ANDA, for a generic drug product containing bupivacaine and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (i)&#160;there is no patent information listed in the FDA&#8217;s Orange Book with respect to our NDA for EXPAREL; (ii)&#160;the patents listed in the Orange Book have expired; (iii)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic drug product. A certification that the new product will not infringe the Orange Book-listed patents for EXPAREL, or that such patents are invalid, is called a paragraph&#160;IV certification. If the third-party submits a paragraph&#160;IV certification to the FDA, a notice of the paragraph&#160;IV certification must also be sent to us once the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30&#160;months or the date on which the patent expires, the lawsuit is settled or the court reaches a decision in the infringement lawsuit in favor of the third-party. If we do not file&#160;a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the 30-month stay. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our products.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection and all patents will eventually expire.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for EXPAREL, DepoFoam and for any product candidates that we may develop, license or acquire and the methods we use to manufacture them, as well as successfully defending these patents and trade secrets against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the U.S.. Patent positions and policies outside the U.S. are even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not have been the first to file patent applications for these inventions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may independently develop similar or alternative technologies or duplicate any of our product candidates or technologies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">it is possible that none of the pending patent applications will result in issued patents;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issued patents covering our product candidates may not provide a basis for commercially viable active products, may not provide us with any competitive advantages, may not have sufficient scope or strength to protect the technologies they were intended to protect or may be challenged by third parties;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may design around our patent claims to produce competitive products that fall outside the scope of our patents;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not develop or in-license additional proprietary technologies that are patentable;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patents of others may have an adverse effect on our business; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitors may infringe our patents and we may not have adequate resources to enforce our patents.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent applications in the U.S. are maintained in confidence for at least 18&#160;months after their earliest effective filing date. Consequently, we cannot be certain we were the first to invent or the first to file patent applications on EXPAREL, our DepoFoam drug delivery technology or any product candidates that we may develop, license or acquire. In the event that a third-party has also filed a U.S. patent application relating to our product candidates or a similar invention, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the U.S.. The costs of these proceedings could be substantial and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. Furthermore, we may not have identified all U.S. and foreign patents or published applications that affect our business either by blocking our ability to commercialize our drugs or by covering similar technologies that affect our drug market.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, some countries, including many in Europe, do not grant patent claims directed to methods of treating humans, and in these countries patent protection may not be available at all to protect our product candidates. Even if patents are issued, we cannot guarantee that the claims of those patents will be valid and enforceable or provide us with any significant protection against competitive products, or otherwise be commercially valuable to us. Furthermore, while we generally apply for patents in those countries where we intend to make, have made, use or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file&#160;a patent application in any such country, we may be precluded from doing so at a later date. We also cannot assure you that the patents issuing as a result of our foreign patent applications will have the same scope of coverage as our U.S. patents.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of our older patents have already expired. In the case of DepoCyt(e), key patents providing protection in Europe have expired. In the case of EXPAREL, our European and U.S. patent applications have been granted and provide protection through November 2018 and September 2018, respectively. An existing formulation patent for EXPAREL expired in November 2013. An existing formulation patent for EXPAREL expired in the U.S. in 2013 and its equivalents in Canada, Germany, France, Spain, Italy and the United Kingdom expired in 2014. Once our patents covering EXPAREL have expired, we will be more reliant on trade secrets to protect against generic competition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secrets to protect our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets through confidentiality and non-disclosure agreements, our licensors, employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Policing unauthorized use of our trade secrets or enforcing a claim that a third-party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, trade secret laws in other countries may not be as protective as they are in the U.S.. Thus, courts outside the U.S. are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to protect the goodwill associated with our company and product names, we rely on trademark protection for our marks. We have registered the &#8220;Pacira&#8221;, &#8220;EXPAREL&#8221;, &#8220;DepoCyt&#8221;, and &#8220;DepoCyte&#8221; marks with the USPTO. A third-party may assert a claim that one of our marks is confusingly similar to its mark, and such claims or the failure to timely register a mark or objections by the FDA could force us to select a new name for one of our product candidates, which could cause us to incur additional expense or delay the commercialization of such product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we fail to obtain or maintain patent protection or trade secret protection for EXPAREL, DepoCyt(e), DepoFoam or any product candidate that we may develop, license or acquire, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to develop, manufacture, market and sell EXPAREL, our DepoFoam drug delivery technology or any product candidates that we may develop, license or acquire depends upon our ability to avoid infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the general fields of pain management and cancer treatment and cover the use of numerous compounds and formulations in our targeted markets. Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual property claims by third parties, which could have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management. In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that EXPAREL or DepoCyt(e) may infringe. There could also be existing patents of which we are not aware that EXPAREL or DepoCyt(e) may inadvertently infringe.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries in general. If a third-party claims that we infringe on their products or technology, we could face a number of issues, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">infringement and other intellectual property claims which, with or without merit, can be expensive and time consuming to litigate and can divert management&#8217;s attention from our core business;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial damages for past infringement which we may have to pay if a court decides that our product infringes on a competitor&#8217;s patent;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">redesigning our processes so they do not infringe, which may not be possible or could require substantial funds and time.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cumulatively, we have incurred significant losses since our inception and may incur additional losses in the future.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a specialty pharmaceutical company with a limited operating history. We have focused primarily on developing and commercializing EXPAREL. Up until 2015, we had incurred losses in each year since our inception in December 2006. We had a net loss of </font><font style="font-family:inherit;font-size:10pt;">$42.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a net loss of </font><font style="font-family:inherit;font-size:10pt;">$37.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2016 and net income of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, 2015. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$389.1 million</font><font style="font-family:inherit;font-size:10pt;">. These losses, among other things, have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. We incurred significant pre-commercialization expenses as we prepared for the commercial launch of EXPAREL, and we incur significant sales, marketing and manufacturing expenses, as well as continued development expenses related to the commercialization of EXPAREL. As a result, we had not been profitable prior to 2015 and were not profitable in 2016 or 2017. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not return to profitability.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to return to profitability depends upon our ability to generate revenue from EXPAREL. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacture commercial quantities of EXPAREL at acceptable cost levels; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to develop a commercial organization and the supporting infrastructure required to successfully market and sell EXPAREL.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate incurring significant additional costs associated with the commercialization of EXPAREL and are unsure as to whether we will be able to return to profitability. If we are unable to generate additional revenues, we will not be able to do so and may be unable to continue operations without continued funding.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developing and commercializing products for use in the hospital setting, conducting clinical trials, establishing outsourced manufacturing relationships and successfully manufacturing and marketing drugs that we may develop is expensive. We may need to raise additional capital to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to fund our operations;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue our efforts to hire additional personnel and build a commercial infrastructure to commercialize EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">qualify, outsource or build additional commercial-scale manufacturing of our products under cGMP;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in-license and develop additional product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refinance our current 2.375% convertible senior notes, due April 2022.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not have sufficient financial resources to continue our operations or meet all of our objectives, which could require us to postpone, scale back or eliminate some, or all, of these objectives. Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of maintaining a commercial organization to sell, market and distribute EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of the commercialization of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of manufacturing sufficient supplies of EXPAREL to meet customer demand, including the cost of expanding our manufacturing facilities to produce EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rate of progress and costs of our efforts to prepare for the submission of an NDA for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our product candidates, including any such costs we may be required to expend if our licensors are unwilling or unable to do so;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing technological and market developments;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential that we may be required to file&#160;a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of extended-release liposome injection of bupivacaine.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until we can generate a sufficient amount of product revenue, if ever, we expect to finance or supplement future cash needs through public or private equity offerings, debt financings, product supply revenue and royalties, collaboration and licensing arrangements, as well as through interest income earned on cash and investment balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our development programs or our commercialization efforts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our operating results to be subject to quarterly fluctuations. Our operating results will be affected by numerous factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the level of underlying hospital demand for EXPAREL and end-user buying patterns;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintaining our existing manufacturing facilities and expanding our manufacturing capacity and constructing facilities for the manufacture of EXPAREL with our co-production partner, Patheon, including installing specialized processing equipment for the manufacturing of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our execution of other collaborative, licensing, distribution, manufacturing or similar arrangements and the timing of payments we may make or receive under these arrangements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">variations in the level of expenses related to our future development programs;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any product liability or intellectual property infringement lawsuit in which we may become involved; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory developments, lawsuits and investigations affecting EXPAREL or the product candidates of our competitors;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership will be diluted. If we raise additional funds through licensing arrangements, it may be necessary to relinquish potentially valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable to us. Any debt financing we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The use of our net operating loss carryforwards and research tax credits will be limited.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have significant federal and state net operating loss, or NOL, carryforwards and federal and state research and development tax credit carryforwards. Our NOL carryforwards and research and development tax credits may expire and not be used. Our NOL carryforwards will begin expiring in 2025 for federal purposes and in 2024 for state purposes if we have not used them prior to that time. For any federal NOLs generated after December 31, 2017, the NOLs will have an indefinite life and utilization will be subject to a limitation of 80% of taxable income. The non-U.S. NOLs do not expire. Additionally, our ability to use certain NOLs and credit carryforwards to offset taxable income or tax, respectively, in the future will be limited under Internal Revenue Code Sections&#160;382 and 383 because we experienced cumulative changes in ownership of more than 50% within a three-year period. Such ownership changes were triggered by the cumulative ownership changes arising as a result of the initial acquisition of the Company&#8217;s stock in 2007 and the completion of our initial public offering and our other financing transactions. Because of the ownership changes, we will be limited regarding the amount of NOL carryforwards and research tax credits that we can utilize annually in the future to offset taxable income or tax, respectively. Such an annual limitation will significantly reduce the utilization of the NOLs and research tax credits before they expire. In addition, California and certain states have suspended use of NOL carryforwards for certain taxable years, and other states are considering similar measures. As a result, we may incur higher state income tax expense in the future. Depending on our future tax position, continued suspension of our ability to use NOL carryforwards in states in which we are subject to income tax could have an adverse impact on our results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related Our Indebtedness and our Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our common stock price may be subject to significant fluctuations and volatility.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stock price is volatile, and from February&#160;3, 2011, the first day of trading of our common stock, to February&#160;27, 2018, the trading prices of our stock have ranged from $6.16 to $121.95 per share.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stock could be subject to wide fluctuations in price in response to various factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercial success of EXPAREL;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">results of clinical trials of our product candidates or those of our competitors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes or developments in laws or regulations applicable to our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">introduction of competitive products or technologies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed financial projections we provide to the public;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated variations in quarterly operating results;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed the estimates and projections of the investment community;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory concerns or government actions</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic and market conditions and overall fluctuations in U.S. equity markets;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments concerning our sources of manufacturing supply;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to patents or other proprietary rights;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key scientific or management personnel;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issuances of debt, equity or convertible securities;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the market valuations of similar companies; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the stock market in general, and the market for small pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Fluctuations in our stock price could, among other things, adversely impact the trading price of our shares.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial indebtedness.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to make payments of the principal of, to pay interest on or to refinance our indebtedness, including the 2.375% convertible senior notes due 2022, or 2022 Notes, issued in our private offering completed on March 13, 2017, as described below, or to make cash payments in connection with any conversion of the 2022 Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2017, the Company completed a private placement of $345.0 million in aggregate principal amount of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture agreement, or 2022 Indenture, with</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per year, payable semiannually in arrears on</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 1 and October 1 of each year. The 2022 Notes mature on April 1, 2022.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our total consolidated gross indebtedness was $345.3 million, all of which was unsecured indebtedness, and our subsidiaries had no indebtedness (in each case, excluding trade payables, intercompany liabilities and income tax-related liabilities). The total consists of $345.0 million of principal outstanding on the 2022 Notes and $0.3 million of principal outstanding on our 3.25% convertible senior notes due 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Despite our current indebtedness levels, we may still incur substantially more indebtedness or take other actions which would intensify the risks discussed above.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Despite our current consolidated indebtedness levels, we and our subsidiaries may be able to incur substantial additional indebtedness in the future, subject to any restrictions contained in our then-existing debt instruments, some of which may be secured indebtedness. We are not restricted under the terms of the indenture governing the 2022 Notes from incurring additional indebtedness, securing existing or future indebtedness, recapitalizing our indebtedness or taking a number of other actions that could have the effect of diminishing our ability to make payments on the 2022 Notes or any future indebtedness.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not have the ability to raise the funds necessary to settle conversions of the 2022 Notes in cash to the extent elected or to repurchase the 2022 Notes upon a fundamental change, and our future indebtedness may contain limitations on our ability to pay cash upon conversion of the 2022 Notes or limitations on our ability to repurchase the 2022 Notes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the 2022 Notes will have the right to require us to repurchase their 2022 Notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any. In addition, upon conversion of the 2022 Notes, (if we choose to settle the principal amount in cash at our option) we will be required to make cash payments for each $1,000 in principal amount of 2022 Notes converted of at least the lesser of $1,000 and the sum of the daily conversion values. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of 2022 Notes surrendered therefor or 2022 Notes being converted. Any credit facility or other agreement that we may enter into may limit our ability to make cash payments at the time of a fundamental change or upon conversion of the 2022 Notes. Further, our ability to repurchase the 2022 Notes or to pay cash upon conversions of the 2022 Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase 2022 Notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the 2022 Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the 2022 Notes or make cash payments upon conversions thereof.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The conditional conversion feature of the 2022 Notes, if triggered and elected, may adversely affect our financial condition and operating results.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain circumstances, holders of the 2022 Notes are entitled to convert their 2022 Notes to common stock at any time during specified periods at their option. If one or more holders elect to convert their 2022 Notes, we would be required to settle any converted principal through the payment of cash, shares of our common stock or a combination of cash and shares of our common stock, at our option, which could adversely affect our liquidity to the extent cash is paid. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion of the 2022 Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2022 Notes, or may otherwise depress the price of our common stock.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The conversion of the 2022 Notes into shares of our common stock, to the extent that we choose not to deliver all cash for the conversion value in excess of the principal amount (or if we elect to settle the principal amount in shares of our common stock at our option), will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon conversion of the 2022 Notes could adversely affect prevailing market prices of our common stock. In addition, the existence of the 2022 Notes may encourage short selling by market participants due to this dilution or may facilitate trading strategies involving the 2022 Notes and our common stock.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future sales in the public market or issuances of our common stock could lower the market price for our common stock.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the future, we may sell additional shares of our common stock to raise capital. Except under limited circumstances, we are not restricted from issuing additional common stock, including securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The issuance of additional shares of our common stock or convertible securities, including upon exercise of our outstanding options or otherwise, will dilute the ownership interest of our common stockholders. In addition, our greater than 5% stockholders may sell a substantial number of their shares in the public market, which could also affect the market price for our common stock. We cannot predict the size of future sales or issuances of our common stock or the effect, if any, that they may have on the market price for our common stock. The liquidity and trading volume of our common stock is limited. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the average per day trading volume of our common stock was 764,778 shares. The issuance and/or sale of substantial amounts of common stock, or the perception that such issuances and/or sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or debts securities.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The accounting method for convertible debt securities that may be settled in cash, such as the 2022 Notes, could have a material effect on our reported financial results.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. APB&#160;14-1, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)</font><font style="font-family:inherit;font-size:10pt;">, which has subsequently been codified as Accounting Standards Codification 470-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options</font><font style="font-family:inherit;font-size:10pt;">, or ASC 470-20. Under ASC 470-20, an entity must separately account for the liability and equity components of the convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The effect of ASC 470-20 on the accounting for the 2022 Notes is that the equity component is required to be included in the additional paid-in capital section of stockholders&#8217; equity on our consolidated balance sheet at the issuance date and the value of the equity component would be treated as debt discount for purposes of accounting for the debt component of the 2022 Notes. As a result, we are required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted carrying value of the 2022 Notes to their face amount over the term of the 2022 Notes. We will report larger net losses in our financial results because ASC 470-20 will require interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results, the trading price of our common stock and the trading price of the 2022 Notes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under certain circumstances, convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the 2022 Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the 2022 Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. If we are unable to use the treasury stock method in accounting for the shares issuable upon conversion of the 2022 Notes, then our net losses per share would be increased.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions in our restated certificate of incorporation and our bylaws, as well as provisions of the Delaware General Corporation Law, or DGCL, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">eliminating the ability of stockholders to call a special meeting of stockholders; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&#160;203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends on our common stock for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements, restrictions contained in future financing instruments and such other factors as our board of directors deems relevant.</font></div><div><a name="sCB4B294C4D015ECF995ED57323D0A1CF"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s25A22F165391572F9F127A02A36096D7"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Properties</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We occupy four facilities totaling approximately 172,000 square feet at our Science Center Campus in San Diego, California. We use these facilities for research and development, manufacturing, general and administrative purposes and the storage of inventory and raw materials. Our research and development, warehouse and DepoCyt(e) manufacturing properties in San Diego are under leases which expire in August 2020 and our EXPAREL manufacturing facility in San Diego is under a lease which expires in December 2025. In addition, we maintain our executive offices and our commercial and business development facility in Parsippany, New Jersey, where we occupy approximately 42,000 square feet under a lease expiring in March 2028.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our research and development and manufacturing facilities at our Science Center Campus and those being developed in conjunction with Patheon (as discussed in Item 1&#8212;Business above) will be sufficient for our commercial and pipeline development needs. We also may add new facilities or expand existing facilities as we add employees, expand our geographic markets and if demand for EXPAREL increases and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</font></div><div><a name="sEE6925573338577892080306337A4DD2"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of our business. Except as described below, we are not presently a party to any litigation that we believe to be material and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition or cash flows.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. We are cooperating with the government&#8217;s inquiry.&#160;We can make no assurances as to the time or resources that will need to be devoted to this inquiry or its final outcome, or the impact, if any, of this inquiry or any proceedings on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD498527C1A715D3392FAC88F57A913A6"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="s30140912E72D53079D6448A5BBB23D39"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div><a name="sDEE883146F245586B9B86A63EAA37638"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;5.    Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed under the ticker symbol &#8220;PCRX&#8221; on the NASDAQ Global Select Market. The following table sets forth, for the periods indicated, the high and low intraday sales prices of our common stock as reported by the NASDAQ:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 20, 2018, the closing price of our common stock as reported on The NASDAQ Global Select Market was $31.25 per share and we had approximately 13 holders of record of our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graph shows the value of an investment of $100 on December 31, 2012, in each of our common stock (PCRX), the NASDAQ Composite index (^IXIC) and the NASDAQ Biotechnology index (^NBI). The indices are included for comparative purposes only and do not necessarily reflect management&#8217;s opinion that such indices are an appropriate measure of the relative performance of our common stock. All results assume the reinvestment of dividends, if any, and are calculated as of December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of each year. The historical stock price performance of our common stock shown in the performance graph is not necessarily indicative of future stock price performance.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of Cumulative Total Returns</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><img src="item5colorcharta02.jpg" alt="item5colorcharta02.jpg" style="height:365px;width:665px;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cumulative Total Return as of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc. (PCRX)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ Composite (^IXIC)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ Biotechnology (^NBI)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain earnings, if any, to finance the growth and development of our business, and as such we do not expect to pay any cash dividends on our common stock in the foreseeable future. The payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in future financing instruments, provisions of applicable law and any other factors the board of directors deems relevant.</font></div><div><a name="s692A07CDDCF35153993ECDCDDA80E0E0"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Selected Financial Data</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables provide selected consolidated financial data. We have prepared this information using our audited consolidated financial statements as of and for the years ended December 31, 2017, 2016, 2015, 2014 and 2013. The following consolidated financial data should be read in conjunction with our consolidated financial statements and related notes and Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Consolidated Statements of Operations Data</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Net product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Collaborative licensing and milestone revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,855</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286,630</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">3</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Product discontinuation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,024</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (expense) income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,732</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Royalty interest obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,471</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Basic net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1 - Relates to a $5.4 million charge related to to the discontinuation of our DepoCyt(e) manufacturing activities, including&#160;$0.5 million&#160;for DepoCyt(e) related inventory, which is recorded in cost of goods sold, and&#160;$4.9 million&#160;for the remaining lease costs less an estimate of potential sublease income for the facility where DepoCyt(e) was manufactured, the write-off of property, plant and equipment, employee severance, asset retirement obligations and other estimated exit costs. For further discussion of this charge, see </font><font style="font-family:inherit;font-size:8pt;">Note 15</font><font style="font-family:inherit;font-size:8pt;">, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Commercial Partners and Other Agreements</font><font style="font-family:inherit;font-size:8pt;">, to our consolidated financial statements included herein.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2 - Includes a $20.7 million charge for inventory and related reserves for the cost of EXPAREL batches impacted by a routine stability test that did not meet required specifications. For further discussion of this charge, see </font><font style="font-family:inherit;font-size:8pt;">Note 4</font><font style="font-family:inherit;font-size:8pt;">, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Inventories</font><font style="font-family:inherit;font-size:8pt;">, to our consolidated financial statements included herein.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3 - Includes a $7.1 million contract termination charge due to CrossLink Bioscience, LLC. For further discussion of this charge, see </font><font style="font-family:inherit;font-size:8pt;">Note 15</font><font style="font-family:inherit;font-size:8pt;">, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Commercial Partners and Other Agreements</font><font style="font-family:inherit;font-size:8pt;">, to our consolidated financial statements included herein.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Consolidated Balance Sheet Data</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, restricted cash,<br>short-term and long-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,794</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">628,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,671</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,628</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(389,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(308,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(296,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,976</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s84FB334BF2065D2FB2A23B8A40F7263E"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Annual Report on Form&#160;10-K. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth under &#8220;Risk Factors&#8221; in Part I, Item&#160;1A of this Annual Report on Form&#160;10-K, our actual results may differ materially from those anticipated in these forward-looking statements.</font></div><div><a name="s22BC054504625663A7167556CA75D315"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a specialty pharmaceutical company committed to driving innovation in postsurgical pain management with opioid-sparing strategies. Our product pipeline is based on our proprietary DepoFoam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. We are currently commercializing EXPAREL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(bupivacaine liposome injectable suspension), an amide-type local anesthetic indicated for single-dose administration into the surgical site to produce postsurgical analgesia. EXPAREL was approved by the United States Food and Drug Administration, or FDA, in October 2011 and commercially launched in April 2012.&#160;We drop-ship EXPAREL directly to the end-user based on orders placed to wholesalers or directly to us, and we have no product held by wholesalers. Our pipeline includes the DepoFoam-based product candidate, DepoMeloxicam.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to incur significant expenses as we pursue the expanded use of EXPAREL in additional indications and opportunities; advance our earlier-stage pipeline; seek FDA approvals for our product candidates; develop our sales and marketing capabilities to prepare for their commercial launch; expand and enhance our manufacturing capacity for EXPAREL and support regulatory and legal matters.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Highlights and Recent Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we announced that the FDA accepted the resubmission of our supplemental New Drug Application, or sNDA, seeking expansion of the EXPAREL label to include administration via nerve block for prolonged regional analgesia. Our sNDA for EXPAREL as a nerve block for regional analgesia was discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, on February 14-15, 2018. The AADPAC committee members voted six to four against approval of the EXPAREL sNDA. The committee&#8217;s feedback will be considered by the FDA in its review of the sNDA. The FDA&#8217;s Prescription Drug User Fee Act (PDUFA) goal date for completion of its review is April 6, 2018. The sNDA is based on the positive data from a Phase 3 study of EXPAREL in femoral nerve block for total knee arthroplasty, or TKA, (lower extremity) and a Phase 3 study of EXPAREL in brachial plexus block for shoulder surgeries (upper extremity). It also includes safety and pharmacokinetic data through 120 hours.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we made a cash investment of&#160;$15.0 million&#160;in convertible preferred B shares of TELA Bio Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;portfolio of products for ventral hernia repair and abdominal wall reconstruction. OviTex Reinforced BioScaffolds (RBSs) are intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. In conjunction with the investment in TELA Bio, we acquired an option to purchase an additional $10.0 million of convertible preferred B shares of TELA Bio under the same terms and conditions as existed on the initial purchase date. The purchase option expires on September 15, 2018. If we do not exercise our purchase option, we may be required to invest up to $10.0 million in TELA Bio convertible preferred B shares under certain conditions. This contingent purchase obligation expires on October 31, 2018.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, we announced a collaboration with Aetna, one of the nation&#8217;s leading diversified health care benefits companies, with the support of the American Association of Oral and Maxillofacial Surgeons. This national program aims to reduce the number of opioid tablets dispensed to patients undergoing impacted third molar (wisdom tooth) extractions by at least 50 percent through the utilization of EXPAREL to provide prolonged non-opioid postsurgical pain control. Aetna will include the cost of EXPAREL as a covered expense for impacted third molar extractions performed by surgeons who have completed training on use of the product.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, we received an issue notification from the U.S. Patent and Trademark Office stating that a patent relating to product-by-process and process claims in connection with the production of multivesicular liposomes was issued on March 7, 2017. This patent is listed on the Orange Book for EXPAREL, and includes a patent term adjustment that equates to an expiration date of December 24, 2021. For further discussion, see &#8220;Intellectual Property and Exclusivity&#8221; in Item 1. &#8220;Business&#8221; included in this report.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, we announced the initiation of an agreement with&#160;DePuy Synthes Sales, Inc., or DePuy Synthes,&#160;to market and promote the use of EXPAREL for orthopedic procedures in&#160;the U.S.&#160;market. DePuy Synthes&#160;field representatives, specializing in joint reconstruction, spine, sports medicine and trauma, will collaborate with, and supplement our field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings. We believe our collaboration with&#160;DePuy Synthes will accelerate and enhance our education and training efforts with orthopedic customers as we aim to broaden and strengthen the adoption and use of EXPAREL. In addition to supporting&#160;orthopedic specialties, we will focus on soft tissue surgeons in key specialties and anesthesiologists, and continue to act as the overall EXPAREL account manager.</font></div></td></tr></table><div><a name="s84166CAF0CEA513B82070747BBA292E2"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPAREL</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expanded Indication</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA is currently reviewing our sNDA seeking an expansion of the EXPAREL label to include administration via nerve block for prolonged regional analgesia. The AADPAC committee members voted six to four against approval of the EXPAREL sNDA. The committee&#8217;s feedback will be considered by the FDA in its review of the sNDA. We believe that this new indication would (i) present an alternative long-term method of pain control with a single injection, replacing the costly and cumbersome standard of care requiring a perineural catheter, drug reservoir and pump needed to continuously deliver bupivacaine and (ii) allow us to further leverage our manufacturing and commercial infrastructure. The expected action date by the FDA is April 6, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sNDA is based on positive data from a Phase 3 study of EXPAREL in femoral nerve block for TKA (lower extremity) and a Phase 3 study of EXPAREL in brachial plexus block for shoulder surgeries (upper extremity). It includes data from eight company sponsored studies with safety and pharmacokinetic data through 120 hours. In addition, the sNDA includes data from two investigator-initiated studies that provide additional experience in smaller, peripheral nerve block settings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 4 Trials</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are investing in a series of blinded, randomized, bupivacaine comparator Phase 4 trials in key surgical procedures with EXPAREL as the foundation of a multimodal analgesic regimen, such as C-Section, hip fracture, spine, colorectal and breast reconstruction surgeries. Our Phase 4 trials are also designed to support clinician education on procedure-specific best-practice care. We believe positive data from our Phase 4 studies will lead to improved patient outcomes and customer satisfaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, results from our Phase 4 study of EXPAREL in patients undergoing total knee replacement were published in&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Arthroplasty</font><font style="font-family:inherit;font-size:10pt;">. The study compared EXPAREL admixed with bupivacaine HCl versus bupivacaine HCl alone. EXPAREL achieved statistical significance for its co-primary endpoints of opioid reduction and postsurgical pain. The EXPAREL group demonstrated a 78 percent reduction in opioid consumption from zero to 48 hours after surgery and a reduction in pain scores from 12 to 48 hours after surgery. EXPAREL also achieved statistical significance for the study&#8217;s key secondary endpoints related to opioid reduction. Patients in the EXPAREL arm required 77.6 percent fewer opioids through 72 hours than those in the bupivacaine arm with 10 percent remaining opioid-free through 48 and 72 hours (compared to zero patients in the bupivacaine arm; P&lt;0.01). Time to first opioid rescue was analyzed using logistic regression and Kaplan-Meier methods, with a significant difference between the EXPAREL group versus the bupivacaine group; P=0.0230.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pediatrics</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA, as a condition of EXPAREL approval, has required us to study EXPAREL in pediatric patients. We were granted a deferral for the required pediatric trials in all age groups for EXPAREL in the setting of wound infiltration and plan to conduct these pediatric trials as a post-marketing requirement, which was stated in the NDA approval letter for EXPAREL. We have assembled an extensive package of real-world evidence on the use of EXPAREL from The Cleveland Clinic and the Premier Database from patients under the age of 18 for several surgical procedures. We are currently working with the FDA to define a regulatory pathway using these data as the core of our submission. Pediatric patients currently have no approved alternatives to opioids for the management of severe postsurgical pain, and we believe they are in desperate need of additional pain control options. As a result, we are aggressively moving forward to make EXPAREL available to this particularly vulnerable patient population.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Pipeline</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoFoam is used to extend the release of active drug substances. With this technology, we are currently developing DepoMeloxicam, or DepoMLX, a non-steroidal anti-inflammatory drug, or NSAID. Completion of clinical trials may take several years or more. The length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. We are also evaluating other potential DepoFoam compounds, and formulation work is underway for a number of pipeline candidates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoMLX is a long-acting NSAID, designed to treat moderate to severe pain as part of a non-opioid multimodal regimen. A product designed for single-dose local administration such as DepoMLX could provide a longer duration of pain relief at a significantly lower concentration of systemic NSAIDs, which are known to cause dose-dependent gastrointestinal side effects. Meloxicam, which is currently available as an oral formulation, is a commonly used NSAID on the market today. We expect our customer audience for this drug to be similar to the target for EXPAREL infiltration.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We opened an Investigational New Drug (IND) application for DepoMLX in December 2017 and expect to initiate a Phase 1 clinical trial in 2018.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1A1CBC8921F95B3DA33715B1AB554D31"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Years Ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our net product sales primarily include sales of EXPAREL in the U.S. and DepoCyt(e) in the U.S. and Europe. We also earn royalties based on sales by commercial partners of DepoCyt(e) and license fees and milestone payments from third parties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product sales:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,802</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,851</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoCyt(e) and other product sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net product sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,342</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,073</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,487</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative licensing and milestone revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL revenue grew </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, primarily due to increased sales volumes of 7% and 10%. The difference between annual volume growth and the related revenue increase is generally due to modest changes in revenue related allowances. The demand for EXPAREL has continued as a result of new accounts and growth within existing accounts, which has been driven by continued adoption of EXPAREL use in soft tissue and orthopedic procedures.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DepoCyt(e) and other product sales decreased </font><font style="font-family:inherit;font-size:10pt;">66%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;versus 2016, primarily due to fewer DepoCyt(e) lots sold to our commercial partners as a result of persistent technical issues specifically related to the DepoCyt(e) manufacturing process and the discontinuation of our DepoCyt(e) manufacturing activities in June 2017. DepoCyt(e) and other product sales decreased </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily due to a decrease in domestic DepoCyt(e) sales volume.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative licensing and milestone revenue decreased </font><font style="font-family:inherit;font-size:10pt;">89%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;versus 2016, primarily due to $2.0 million in milestones earned in 2016 under our agreement with Aratana Therapeutics, Inc., or Aratana, for the development and commercialization of our products in animal health indications and the cessation of recognizing deferred revenue from a development and licensing agreement with Amylin Pharmaceuticals, Inc. which expired in January 2017. The increase in collaborative licensing and milestone revenue of </font><font style="font-family:inherit;font-size:10pt;">140%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;versus 2015 was primarily due to the Aratana milestones earned in 2016.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue primarily reflects royalties earned on collections of end-user sales of DepoCyt(e) by our commercial partners. Royalty revenue decreased </font><font style="font-family:inherit;font-size:10pt;">34%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017 versus 2016 due to the discontinuation of our DepoCyt(e) manufacturing activities in June 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Goods Sold</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, royalty payments, quality control and engineering.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding cost of goods sold and gross margin during the periods indicated, including percent changes (dollar amounts in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 9 percentage point increase in our gross margins in 2017 versus 2016 is largely due to a $20.7 million charge for inventory and related reserves in second half of 2016 related to a single stability batch for EXPAREL that was outside of specification for one of 21 acceptance criteria, improving 2017 gross margins by 7 percentage points. The manufacturing issue that existed when this batch was made was subsequently corrected. We also had $5.9 million of unplanned manufacturing shutdown charges in 2016 related to this event improving gross margins in 2017 by 2 percentage points.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 11 percentage point decrease in our gross margins in 2016 versus 2015 primarily reflects $20.7 million for inventory and related reserves discussed above.&#160;We also had a higher EXPAREL manufacturing cost per vial due to lower planned production, partially offset by a shift to utilizing a portion of our manufacturing lines in support of new pipeline product development opportunities at our Science Center Campus in San Diego starting mid-year 2015. In addition, gross margins decreased due to higher costs of $3.0 million related to the expansion of our manufacturing capacity in Swindon, England, in partnership with Patheon U.K. Limited, or Patheon, and increases of $2.9 million for unplanned manufacturing shutdown charges in 2016 versus 2015.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses primarily consist of costs related to clinical trials and related outside services, product development and other research and development costs, including Phase 4 trials that are required as a condition of FDA approval or are conducted to generate new data such as dosing and administration techniques and stock-based compensation expenses. Clinical development expenses include costs for clinical personnel, clinical trials performed by third-party contract research organizations, materials and supplies, database management and other third-party fees. Product development and other research and development expenses include development costs for our products and medical information expenses, which include personnel, equipment, materials and contractor costs for process development and product candidates, toxicology studies, development costs related to significant scale-ups of our manufacturing capacity and facility costs for our research space. Stock-based compensation expense relates to the costs of stock option grants to employees and non-employees, awards of restricted stock units, or RSUs, and our employee stock purchase plan, or ESPP.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a breakout of our research and development expenses during the periods indicated, including percent changes (dollar amounts in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product development and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,815</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,678</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,662</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses increased </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017 versus 2016 largely due to a $9.6 million increase in clinical development expenses driven by the completion of our two Phase 3 trials evaluating EXPAREL as a single-dose nerve block for prolonged regional analgesia. Enrollment in these studies began in the second quarter of 2016 and concluded in June 2017. The increase in clinical development expense was partially offset by a decrease in research grants. Product development and other expense increased $2.0 million which reflects higher research and development facility costs at our Science Center Campus in San Diego, increased support from commercial manufacturing and quality organizations to support research and development functions and expenditures to develop a 200-liter manufacturing skid as part of a scale-up of our manufacturing capacity in Swindon, England. These increases were partially offset by reduced expenditures investigating the 2016 stability issue and fewer preclinical toxicology studies. Stock-based compensation increased </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses increased </font><font style="font-family:inherit;font-size:10pt;">59%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015 largely due to an $11.0 million increase in clinical development expenses driven by the enrollment of the Phase 4 infiltration trial in TKA and two Phase 3 nerve block trials. We also incurred start-up expenses for a spine trial and costs for planning pediatric trials. Increased costs also reflect a larger clinical workforce to manage our increased investment in research and development. The increase in clinical development expense was partially offset by a decrease in research grants. Product development and other expenses increased $7.9 million which reflects our investments in the development of a new EXPAREL DepoFoam spray manufacturing process and our pipeline products, along with increased depreciation on our new research and development facility placed into service in August 2015. Expenses for investigational runs and development of a new analytical tool for stability testing are also included in costs for product development and other. Stock-based compensation decreased 36%, which was largely attributable to the requirement to revalue non-employee grants.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses primarily consist of compensation and benefits for our sales force and personnel that support our sales, marketing, medical and scientific affairs operations, commission payments to our marketing partners for the promotion and sale of EXPAREL, expenses related to communicating health outcome benefits of EXPAREL and educational programs for our customers. General and administrative expenses consist of compensation and benefits for legal, finance, regulatory, compliance, information technology, human resources, business development, executive management and other supporting personnel. It also includes professional fees for legal, audit, tax and consulting services. Stock-based compensation expense relates to the costs of stock option grants, RSU awards and our ESPP.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding selling, general and administrative expenses during the periods indicated, including percent changes (dollar amounts in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,088</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,793</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,613</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,043</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expenses increased </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017 versus 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses increased by </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017 versus 2016. The year over year increase of $5.6 million was driven by an $12.7 million increase in spending for EXPAREL marketing, educational initiatives and programs to create product awareness within key surgical markets. Included in this increase are salaries and related personnel costs for field-based medical and sales professionals to better support and educate our customers, initiatives related to our co-promotion agreement with DePuy Synthes and a new EXPAREL website that includes a surgeon selector tool. We also supported multiple educational programs related to the impact of opioids and postsurgical pain management along with our &#8220;Choices Matter&#8221; campaign, which is raising awareness about non-opioid treatment options. The increase was partially offset by a $7.1 million contract termination charge due to CrossLink BioScience, LLC, or CrossLink, which was recognized in 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses increased&#160;</font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#160;in 2017 versus 2016. The increase in general and administrative expenses was largely attributable to a $1.1 million increase in regulatory expenses, primarily in preparation for a European Medicines Agency Marketing Authorization Application for EXPAREL in the E.U. Other increased expenditures included support related to our expanded manufacturing facility in England and the development and launch of new corporate and EXPAREL websites.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation increased </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017 versus 2016, primarily due to new awards granted in mid-to-late 2016 and 2017.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expenses increased </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses increased by </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015 primarily due to a $7.1 million contract termination charge due to CrossLink which was recognized in June 2016, and is payable quarterly over two years beginning in the fourth quarter of 2016. In addition, we increased the number of our field-based hospital sales specialists and commercial personnel to better support and educate our customers, resulting in a $2.1 million increase in salaries, benefits and other personnel-related costs. We also had a $3.9 million increase in spending for EXPAREL, which included educational initiatives and programs to create product awareness among key orthopedic and soft tissue surgical markets, along with other selling initiatives and promotional activities to support the growth of EXPAREL. Included in the increased spending for EXPAREL was our &#8220;Choices Matter&#8221; campaign, a national patient education campaign launched in August 2016, focused on educating the patient population about postsurgical non-opioid options for pain relief. We also unveiled a virtual reality educational program to focus on the proper EXPAREL infiltration technique for TKA procedures. In the third quarter of 2016, we launched EXPAREL to the oral and maxillofacial market by introducing a 10mL vial for use in patients undergoing third molar (wisdom teeth) extractions. The increases were partially offset by a decrease in commission-based payments to CrossLink as a result of the mid-year contract termination.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses increased </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015 largely due to increases of $1.6 million in business development and $1.5 million in regulatory activities. Business development costs increased commensurate with added personnel to support our strategic initiatives, including our co-promotion agreement with DePuy Synthes executed in January 2017. Regulatory spending increased in support of our EXPAREL sNDA for nerve block, as well as activities for other product pipeline candidates. Expenditures also increased for the expansion of our New Jersey headquarters and in our finance and human resource functions. Legal costs decreased by $2.6 million, driven by a decrease of $4.1 million in legal expenses related to the amicable resolution in December 2015 of a lawsuit with the FDA, which stemmed from a warning letter issued by the FDA&#8217;s Office of Prescription Drug Promotion and legal costs related to an April 2015 subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey. These decreases were partially offset by a $1.1 million increase in intellectual property matters and pipeline protection and $0.4 million in other legal matters.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation decreased </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015, mostly as a result of lower grant-date fair values of equity awards.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Discontinuation Expenses</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we discontinued production of DepoCyt(e) due to persistent technical issues specific to the DepoCyt(e) manufacturing process. In the year ended&#160;December 31, 2017, we recorded a charge of $5.4 million, of which $0.5 million was for related inventory recorded in cost of goods sold, $2.0 million for lease costs less an estimate of potential sub-lease income, $1.9 million for the write-off of fixed assets and $1.0 million relating to employee severance, asset retirement obligations and other product discontinuation costs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense)</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding other income (expense) during the periods indicated, including percent changes (dollar amounts in thousands):</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,047</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,725</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty interest obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net&#160;increased by&#160;</font><font style="font-family:inherit;font-size:10pt;">201%</font><font style="font-family:inherit;font-size:10pt;">&#160;in 2017, versus 2016 almost entirely due to the March 2017 issuance of $345.0 million of 2.375% convertible senior notes due 2022, or 2022 Notes, and the repurchase of $118.2 million of our 3.25% convertible senior notes due 2019, or 2019 Notes, which resulted in an&#160;increase&#160;in interest expense of&#160;$11.0 million and a&#160;$3.7 million&#160;loss on early extinguishment of debt in&#160;2017&#160;versus 2016. Partially offsetting this was an increase in interest income of&#160;$2.8 million&#160;as a result of additional investments from the net proceeds of the 2022 Notes and $0.2 million of favorable foreign currency gains.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net decreased by&#160;</font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2016 versus 2015 largely due to a decrease in interest expense arising from a $0.6 million increase in capitalized interest, primarily on construction of our new manufacturing suites and an increase in interest income as a result of higher average investment returns. We had no expenses for our DepoCyt(e) royalty obligation and loss on early extinguishment of debt in 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information regarding our income tax expense during the periods indicated, including percent changes (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 versus<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 versus<br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% Increase / (Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We recorded tax</font><font style="font-family:inherit;font-size:10pt;">&#32;provisions of $0.1 million, $0.1 milli</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">on and $0.3 million for the years end</font><font style="font-family:inherit;font-size:10pt;">ed December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2015, respectively. Since our deferred tax assets are fully offset by a valuation allowance, our total income tax expense includes only current tax expense. The 2017 and 2016 tax provisions consist principally of minimum state taxes and the 2015 tax provision reflects federal alternative minimum tax as well as state taxes. The decrease in 2016 versus 2015 was primarily attributable to the federal alternative minimum tax not being applicable in 2016.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation (the &#8220;Tax Act&#8221;), which significantly revises the U.S. corporate income tax law by, among other things, lowering the U.S. federal corporate income tax rate from 35% to 21%, implementing a territorial tax system, imposing a one-time transition tax on foreign unremitted earnings, setting limitations on the deductibility of certain costs (e.g., interest expense) and utilization of net operating losses, or NOLs. Any federal NOLs generated after December 31, 2017 will have an indefinite life. The lower U.S. corporate income tax rate is effective January 1, 2018, however the U.S. deferred tax assets and liabilities were adjusted in 2017 when the new tax law was enacted. The estimated impact of the re-measurement of U.S. deferred tax assets and liabilities resulting from the Tax Act was a charge of $55.7 million which was offset by a change in the year-end valuation allowance.&#160;The Company had no foreign subsidiary earnings as a result of the historical losses of its foreign subsidiaries.</font></div><div><a name="sF7EC492C246459CEB49A8A3B0DE598AC"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in 2006, we have devoted most of our cash resources to manufacturing, research and development and selling, general and administrative activities related to the development and commercialization of EXPAREL. We are highly dependent on the commercial success of EXPAREL. We have financed our operations primarily with the proceeds from the sale of convertible senior notes, convertible preferred stock, common stock, secured and unsecured notes, borrowings under debt facilities, product sales and collaborative licensing and milestone revenue. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$389.1 million</font><font style="font-family:inherit;font-size:10pt;">, cash and cash equivalents, short-term investments and long-term investments of </font><font style="font-family:inherit;font-size:10pt;">$371.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and working capital of </font><font style="font-family:inherit;font-size:10pt;">$334.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Cash Flows</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows from operating, investing and financing activities for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Consolidated Statement of Cash Flows Data:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,785</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,699</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,464</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, our net cash provided by operating activities was </font><font style="font-family:inherit;font-size:10pt;">$17.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$33.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2016. The decrease of $15.6 million was largely driven by increased expenditures for clinical trials including our two Phase 3 EXPAREL nerve block trials and our Phase 4 EXPAREL infiltration trials and payments to terminate a distribution agreement with CrossLink.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, our net cash provided by operating activities was </font><font style="font-family:inherit;font-size:10pt;">$33.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2015. Positive cash flows from a $26.0 million increase in EXPAREL net product sales, $2.0 million in milestones earned under our agreement with Aratana and a significantly reduced inventory investment in 2016 versus 2015 was partially offset by increases in our operating expenses. The net result was an increase of $5.4 million in cash from operating activities.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;">$223.8 million</font><font style="font-family:inherit;font-size:10pt;">. This included purchases of fixed assets of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;">, including continued expenditures for expanding our EXPAREL manufacturing capacity in Swindon, England in partnership with Patheon and facility upgrades at our Science Center Campus in San Diego. We also purchased $181.0 million of short-term and long-term investments (net of maturities) primarily funded from the net proceeds of the 2022 Notes, made $8.5 million of contingent consideration payments to SkyePharma Holding, Inc., or Skyepharma, on collections of net sales of EXPAREL and made an equity investment in TELA Bio of $15.0 million as previously discussed in &#8220;Highlights and Developments&#8221; above.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, net cash used in investing activities was $61.8 million, which included purchases of fixed assets of $24.7 million. Major capital projects included the continued expansion of our manufacturing capacity in Swindon, England. We also purchased $21.2 million of short-term investments (net of maturities) and made $15.9 million of contingent consideration payments to Skyepharma, including an $8.0 million milestone payment in connection with achieving $250.0 million of EXPAREL net sales collected on an annual basis and $7.9 million of contingent consideration payments.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, net cash used in investing activities was $19.3 million. This included purchases of fixed assets of $40.3 million. Major capital projects included investing in a new research and development facility at our Science Center Campus and continued expenditures for expanding our manufacturing capacity in Swindon, England. We also made contingent consideration payments to Skyepharma of $7.1 million. These expenditures were partially offset by $28.2 million of short-term investment maturities (net of purchases).</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$224.2 million</font><font style="font-family:inherit;font-size:10pt;">, which consisted of proceeds from the issuance of the 2022 Notes of $345.0 million, partially offset by $11.0 million of debt issuance and financing costs. In addition, a portion of the net proceeds from the 2022 Notes was used to retire $118.2 million in principal of the 2019 Notes and for $0.3 million in related costs. Proceeds from the exercise of stock options were $6.8 million and proceeds from the issuance of shares under our ESPP were $1.9 million.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, net cash provided by financing activities was $7.3 million, which reflected proceeds from the exercise of stock options of $5.8 million and proceeds from the issuance of shares under our ESPP of $1.5 million.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, net cash provided by financing activities was $10.7 million, which reflected proceeds from the exercise of stock options of $10.1 million and proceeds from the issuance of shares under our ESPP of $2.1 million. The increase was offset by the cash settlement of $1.5 million in principal on a conversion of our 2019 Notes.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Financings</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From inception through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have raised $344.5&#160;million of net proceeds from the sale of common stock and other equity securities via public offerings.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2022 Convertible Senior Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2017, we completed a private placement of $345.0 million in aggregate principal amount of our 2022 Notes, and entered into an indenture agreement, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per annum, payable semiannually in arrears on April&#160;1 and October&#160;1 of each year. The 2022 Notes mature on April 1, 2022. At&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the outstanding principal on the 2022 Notes was $345.0 million.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding April 1, 2022, holders may convert their 2022 Notes at any time. Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value. For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. The initial conversion rate for the 2022 Notes is 14.9491 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $66.89 per share of our common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the close of business on the business day immediately preceding October 1, 2021, holders may convert the 2022 Notes under certain circumstances&#8212;including, but not limited to&#8212;if during any given calendar quarter, our stock price closes at or above 130% of the conversion price then applicable during a period of at least 20 out of the last 30 consecutive trading days of the previous quarter.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the 2022 Notes are currently classified on our consolidated balance sheet at&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;as long-term debt, the future convertibility and resulting balance sheet classification of this liability will be monitored at each quarterly reporting date and will be analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that the holders of the 2022 Notes have the election to convert the 2022 Notes at any time during the prescribed measurement period, the 2022 Notes would then be considered a current obligation and classified as such.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to April 1, 2020, we may not redeem the 2022 Notes. On or after April 1, 2020, we may redeem for cash, shares of our common stock or a combination of cash and shares of our common stock, at our option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 out of 30 consecutive trading-day period ending within five trading days prior to the date on which we provide notice of redemption.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 8,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">, to our consolidated financial statements included herein for further discussion of the 2022 Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Convertible Senior Notes</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January&#160;23, 2013, we completed a private offering of $120.0 million in aggregate principal of our 2019 Notes. The 2019 Notes accrue interest at a rate of 3.25% per annum, payable semiannually in arrears on February&#160;1 and August&#160;1 of each year, and mature on February&#160;1, 2019. In March 2017, we used part of the net proceeds from the issuance of the 2022 Notes discussed above to repurchase </font><font style="font-family:inherit;font-size:10pt;">$117.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal of the 2019 Notes in privately-negotiated transactions for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$118.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The partial repurchase of the 2019 Notes resulted in a </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loss on early extinguishment of debt. In May 2017, we repurchased </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal of the 2019 Notes in a privately-negotiated transaction for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">10 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the outstanding principal on the 2019 Notes was approximately&#160;$0.3 million.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">, to our consolidated financial statements included herein for further discussion of the 2019 Notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future Capital Requirements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our existing cash and cash equivalents, short-term investments, long-term investments and cash received from product sales will be sufficient to enable us to fund our operating expenses, capital expenditure requirements, payment of the principal on any conversions of the 2022 Notes and to service our indebtedness through at least </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2019</font><font style="font-family:inherit;font-size:10pt;">. Our future use of operating cash and capital requirements will depend on many forward-looking factors, including, but not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully continue to expand the commercialization of EXPAREL;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of expanding our manufacturing facilities for EXPAREL and our other product candidates, including costs associated with certain technical transfer activities and the construction of manufacturing suites at Patheon&#8217;s facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of and extent to which the holders of our 2022 Notes elect to convert their notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of potential milestone payments to Skyepharma, which could be up to an aggregate of $36.0 million if certain milestones pertaining to net sales of DepoBupivacaine products, including EXPAREL, are met;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to legal and regulatory issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of performing additional clinical trials for EXPAREL, including the pediatric trials required by the FDA as a condition of approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs for the development and commercialization of other product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in products, businesses and technologies.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may require additional debt or equity financing to meet our future operating and capital requirements. We have no committed external sources of funds, and additional equity or debt financing may not be available on acceptable terms, if at all.</font></div><div><a name="s68D6B0BBC006552C9CA2E848106A76B4"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below presents a summary of our contractual obligations as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contractual Obligations (1)</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less Than One Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1-3 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3-5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">More Than<br>5 Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Senior convertible notes - principal (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Senior convertible notes - interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,291</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lease obligations (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,659</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchase obligations (4)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">436,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">367,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;"><hr></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(1) This table does not include potential future milestone payments to Skyepharma which could be up to an aggregate of $36.0 million if certain milestones pertaining to net sales of DepoBupivacaine products, including EXPAREL are met, including $32.0 million when annual net sales of DepoBupivacaine products, including EXPAREL collected reach $500.0 million (measured on a rolling quarterly basis) and $4.0 million upon the first commercial sale in a major E.U. country. This contingency is described further in </font><font style="font-family:inherit;font-size:8pt;">Note 6</font><font style="font-family:inherit;font-size:8.5pt;">, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Goodwill</font><font style="font-family:inherit;font-size:8.5pt;">, to our consolidated financial statements included herein. In addition, this table does not include various agreements that we have entered into for services with third-party vendors, including agreements to conduct clinical trials, and for consulting and other contracted services due to the cancelable nature of the services.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(2) The amounts displayed in the table above represent the February 2019 maturity of our 2019 Notes and April 2022 maturity of our 2022 Notes. See </font><font style="font-family:inherit;font-size:8pt;">Note 8</font><font style="font-family:inherit;font-size:8.5pt;">, </font><font style="font-family:inherit;font-size:8pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:8.5pt;">, to our consolidated financial statements included herein for further discussion. Additionally, it excludes any conversion premium on the 2019 Notes and/or 2022 Notes, which may be settled in cash or stock at the Company&#8217;s discretion. If the 2019 Notes were converted at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;">, it would result in an approximate premium of less than ten thousand shares, $0.3 million of cash, or a combination thereof, at the Company&#8217;s option. The 2022 Notes were not convertible as of </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(3) The amounts consist of operating leases for our corporate headquarters in Parsippany, New Jersey and manufacturing, research and development and warehouse space in San Diego, California.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(4) The amounts consist of minimum non-cancelable contractual commitments for the purchase of certain raw materials.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2016, we provided notice to CrossLink electing to terminate our Master Distributor Agreement (as amended) effective as of September&#160;30, 2016. In connection with the termination of the Agreement, a termination fee based on a percentage of earned performance-based fees is due to CrossLink.&#160;This fee of&#160;$7.1 million is payable to CrossLink quarterly over&#160;two&#160;years and was recorded in selling, general and administrative expense in the consolidated statements of operations. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is classified in accrued expenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, we and Patheon entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the Technical Transfer and Service Agreement, Patheon has agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. Under these agreements, we will make monthly base fee payments for services rendered. The agreements will remain in full effect unless and until they expire or are terminated. Upon termination of the Technical Transfer and Services Agreement (other than termination by us in the event that Patheon does not meet the construction and manufacturing milestones or for a breach by Patheon), we will pay for the make good costs occasioned by the removal of our manufacturing equipment and for Patheon&#8217;s termination costs up to a maximum amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Manufacturing and Supply Agreement, following the FDA approval date of the suites, we have agreed to purchase EXPAREL product from Patheon. Unless earlier terminated by giving notice of up to three years (other than termination by us in the event of a material breach by Patheon), this agreement will expire on the&#160;</font><font style="font-family:inherit;font-size:10pt;">10th</font><font style="font-family:inherit;font-size:10pt;">&#32;anniversary of the FDA approval date for the initial manufacturing suite.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s219014B98FFC51B29B2329B701A4CD6A"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have based our management&#8217;s discussion and analysis of our financial condition and results of operations on our financial statements that have been prepared in accordance with generally accepted accounting principles, or GAAP, in the U.S.. The preparation of these financial statements require us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, inventory costs, liabilities and accruals, clinical trial expenses, stock-based compensation and the valuation of deferred tax assets. We base our estimates on historical experience, contract terms and on other factors we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are more fully discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 2</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:10pt;">, to our audited consolidated financial statements included in this filing. The following accounting policies, which may include significant judgments and estimates, were used in the preparation of our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our sources of revenue include (i) sales of EXPAREL in the U.S.; (ii) sales of DepoCyt(e) to our commercial partners within the U.S. and E.U.; (iii) sales of our bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of our bupivacaine liposome injectable suspension product for use in animal health indications and (v) license fees and milestone payments. We recognize revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. We record revenue at the time the product is delivered to the end-user. We also recognize revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and our bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, we conduct initial product release and stability testing in accordance with the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contracts, inventory data and other related information that may become known in the future. We review the adequacy of our provisions on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Returns Allowances</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allow customers to return product that is damaged or received in error. In addition, we allow EXPAREL to be returned beginning six months prior to, and twelve months following product expiration. We estimate our sales returns reserve based on our historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment terms. We accrue discounts to wholesalers based on contractual terms of agreements and historical experience. We account for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wholesaler Service Fees</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our customers include major and regional wholesalers with whom we have contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volume Rebates and Chargebacks</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers we provide to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to our sales related allowances and accruals for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Returns Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prompt Payment Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wholesaler Service Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Volume Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,482</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total reductions of gross product sales from sales-related allowances and accruals were $15.6 million, $12.9 million and $10.7 million, or 5.2%, 4.6% and 4.2% of gross product sales, for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The overall increase in sales-related allowances and accruals was directly related to the increase in product sales. The increase in the percentage of sales-related allowances and accruals for the years ended December 31, 2017 and 2016 was primarily related to an increase in volume related rebates and chargebacks.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from royalties based on our commercial partners&#8217; net sales of DepoCyt(e) and sales of our bupivacaine liposome injectable suspension product to serve animal health indications. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Licensing and Milestone Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the collaboration agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, we will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of the termination of a collaboration agreement, any remaining non-refundable license fees received by us, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in our consolidated statements of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, we have no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, we recognize milestone payments ratably over the remaining period of our performance obligations under the applicable collaboration agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for an equity investment in a minority interest of a company over which we do not exercise significant</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is evidence that</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investments are reviewed on a regular basis for possible impairment. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern and (v) any other information that we may be aware of related to the investment.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Debt Transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We separately account for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. We recognize the amortization of the resulting discount as part of interest expense in our consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon settlement of the convertible senior notes, the liability component is measured at fair value. We allocate a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Tax Expense (Benefit)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management&#8217;s assessment of estimated future taxes to be paid. Significant judgments and estimates are required in determining the realization of our deferred tax assets. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have significant federal and state income tax NOLs and credit carry forwards, the use of which may be limited by historic and future ownership changes within the meaning of Section 382 of the Internal Revenue Code. There is significant doubt regarding our ability to utilize our net deferred tax assets and, therefore, we have recorded a full valuation allowance reducing our net deferred tax assets to zero at both </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sFB623D5CED325096826BEBB7429665CB"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;">Note 3</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">, to the Notes to Consolidated Financial Statements in Item&#160;15 below for further discussion of recent accounting pronouncements.</font></div><div><a name="sC6E7B637CAA85AB8843F6EBAE5E8AF61"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any material off-balance sheet arrangements as of&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, except for operating leases, nor do we have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="sDC2A6A7CB83F568AAA332193BD411A3F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of our cash equivalent and investment activities is to preserve principal while at the same time maximizing the income that we receive from our investments without significantly increasing risk. We invest in corporate bonds, commercial paper and asset-backed securities, which are reported at fair value. These securities are subject to interest rate risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline. A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;by $1.5 million.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we issued $345.0 million in aggregate principal amount of 2.375% convertible senior notes, which mature</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in April 2022. Holders may convert their 2022 Notes prior to maturity under certain circumstances. Upon conversion, holders</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">will receive the principal amount of the 2022 Notes and any excess conversion value in cash, shares of our common stock or a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">combination of cash and shares, at our option. The fair value of the 2022 Notes is impacted by both the fair value of our</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common stock and interest rate fluctuations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the 2022 Notes was $1,048 per $1,000 principal amount. See </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">, to the Notes to Consolidated Financial Statements in Item 15 below for additional information on the 2022 Notes. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, $345.0 million of principal remains outstanding on the 2022 Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, our accounts receivable are concentrated with three large regional wholesalers of pharmaceutical products. In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.</font></div><div><a name="s88F9921AF8CA5A84B6C652DEC1CB978C"></a></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-bottom:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements required by this item, together with the reports of our independent registered public accounting firms, appear on pages&#160;F-1 through F-35 of this Annual Report on Form&#160;10-K.</font></div><div><a name="s37BBE7F359A15DE6912893990A59681C"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-bottom:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s45379360AB455B82A7C6E0A17017B774"></a></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures, as such term is defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, which are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chairman and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on their evaluation as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our Chief Executive Officer and Chairman and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chairman and Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based upon the results of the evaluation, our management concluded that our internal control over financial reporting was effective as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was audited by KPMG&#160;LLP, our independent registered public accounting firm, as stated in their report appearing below, which expressed an unqualified opinion on the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting that occurred during the quarter ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Opinion on Internal Control Over Financial Reporting </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited Pacira Pharmaceuticals, Inc.&#8217;s and subsidiaries&#8217; (the Company) internal control over financial reporting as of December&#160;31, 2017, based on criteria established in</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Internal Control - Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2017, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2017 and 2016, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for the years ended December&#160;31, 2017 and 2016, and the related notes (collectively, the consolidated financial statements), and our report dated February 28, 2018 expressed an unqualified opinion on those consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Opinion </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Definition and Limitations of Internal Control Over Financial Reporting </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short Hills, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="sE18872E4F0465FD1AF47EC13DCFD6AE0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s2B3B913FC3445756A140728472392C01"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div><a name="s5584B9AF3C1454828171FE751B245668"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information required by this item will be included in the proxy statement for our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual stockholders&#8217; meeting and is incorporated by reference into this report.</font></div><div><a name="sDC72C2B850F15733AD2325CD3F444D3F"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11.&#160;&#160;&#160;&#160;Executive Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information required by this item will be included in the proxy statement for our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual stockholders&#8217; meeting and is incorporated by reference into this report.</font></div><div><a name="sEB9820891C8F558680B7DAFD4F5C60C7"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Authorized For Issuance Under Equity Compensation Plans</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth certain information, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, concerning shares of our common stock authorized for issuance under our equity compensation plans. We have two equity compensation plans under which shares are currently authorized for issuance, our Amended and Restated 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;) and our 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;). We also maintain our 2007 Stock Incentive Plan (&#8220;2007 Plan&#8221;), however, no additional awards may be issued under the 2007 Plan. The 2007 Plan, the 2011 Plan and the 2014 ESPP were approved by stockholders. In April 2014, our board of directors adopted (without stockholder approval) the 2014 Inducement Plan, which authorized&#160;175,000&#160;shares of common stock to be granted as equity awards to new employees.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:35%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(c)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1) (2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price of Outstanding Options and Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans approved by stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans not approved by stockholders </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity compensation plans</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,016,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:8.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">Awards issuable under our 2011 Plan include common stock, stock options, restricted stock, restricted stock units, stock appreciation rights, dividend equivalents, Operating Partnership units and other incentive awards.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:8.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">Does not include 499,546 unvested shares outstanding as of </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;">&#32;in the form of restricted stock units under our 2011 Plan, which do not require the payment of any consideration by the recipients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:8.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">See Note 11, </font><font style="font-family:inherit;font-size:8.5pt;font-style:italic;">Stock Plans</font><font style="font-family:inherit;font-size:8.5pt;">, to our consolidated financial statements included herein for further descriptions of our equity compensation plans.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other information required by this item will be included in the proxy statement for our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual stockholders&#8217; meeting and is incorporated by reference into this report.</font></div><div><a name="s1193ACF7F85A593A9D465281A853345C"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information required by this item will be included in the proxy statement for our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual stockholders&#8217; meeting and is incorporated by reference into this report.</font></div><div><a name="sFCBA4FD9F9425BE8886CECFAF469F8AD"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information required by this item will be included in the proxy statement for our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual stockholders&#8217; meeting and is incorporated by reference into this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s4E0EB603C5335E1EB7E1F9F833369863"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div><a name="s50C90BCA561453AEAF4B481D93DD3995"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Documents filed as part of Form&#160;10-K.</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.90643274853801%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:33%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report of KPMG LLP, Independent Registered Public Accounting Firm</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report of CohnReznick LLP, Independent Registered Public Accounting Firm</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedules</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All financial statement schedules have been omitted because they are not required, are not applicable or the information is included in the consolidated financial statements or related notes thereto.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Exhibits listed in the Exhibit Index are filed with, or incorporated by reference in this Form&#160;10-K.</font></div><div><a name="s06508C2E878856C79FD2F24001D0AC7D"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><a name="sE2FB67FC96A65CD785D7000AA8580A16"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:5%;"></td><td style="width:50%;"></td><td style="width:5%;"></td><td style="width:4%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS,&#160;INC.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID STACK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stack</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Chairman</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID STACK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director, Chief Executive Officer and Chairman</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stack</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;CHARLES A. REINHART, III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles A. Reinhart, III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;LAUREN RIKER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Riker</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;LAURA BREGE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laura Brege</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ MARK FROIMSON</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Froimson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ YVONNE GREENSTREET</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yvonne Greenstreet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ MARK KRONENFELD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Kronenfeld</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;JOHN LONGENECKER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John Longenecker</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;GARY PACE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gary Pace</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;ANDREAS WICKI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andreas Wicki</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;DENNIS WINGER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dennis Winger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;PAUL HASTINGS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lead Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Hastings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="s1B204D49DE545C63B9294739270CFC6E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE YEAR ENDED DECEMBER 31, 2017</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:624px;"></td><td style="width:58px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A0933CB842A5F9695E75A23DE7E9687"><font style="font-family:inherit;font-size:10pt;">Report of KPMG LLP, Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#s5A0933CB842A5F9695E75A23DE7E9687">F-2</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60DE5077034A57AB8DD0EC0ECE7B35C5"><font style="font-family:inherit;font-size:10pt;">Report of CohnReznick LLP, Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#s60DE5077034A57AB8DD0EC0ECE7B35C5">F-3</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFDF139BD0CD7575089D603A7ABE4D9A8"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of December&#160;31, 2017 and 2016</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#sFDF139BD0CD7575089D603A7ABE4D9A8">F-4</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD8899725438A593B9218BA5F8CED053C"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations for the years ended December&#160;31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#sD8899725438A593B9218BA5F8CED053C">F-5</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0566DB01E3A25F5A8BBE50D29E331523"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss) for the years ended December&#160;31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#s0566DB01E3A25F5A8BBE50D29E331523">F-6</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s668FF397715E5539AAE91928EAAC86C5"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#s668FF397715E5539AAE91928EAAC86C5">F-7</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF38D5D320A6581D83DC1DF830B4FE37"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#sBF38D5D320A6581D83DC1DF830B4FE37">F-8</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6372863579395481B929A5621F332CE2"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0540ff;" href="#s6372863579395481B929A5621F332CE2">F-9</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s5A0933CB842A5F9695E75A23DE7E9687"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Opinion on the Consolidated</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Statements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Pacira Pharmaceuticals, Inc. and&#160;subsidiaries (the Company) as of December&#160;31, 2017 and 2016, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for the years ended December&#160;31, 2017 and 2016, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2017 and 2016, and the results of its operations and its cash flows the years ended December&#160;31, 2017 and 2016, in conformity with U.S.&#160;generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2017, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 28, 2018 expressed</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2015.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short Hills, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:40px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s60DE5077034A57AB8DD0EC0ECE7B35C5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated statements of operations, comprehensive income, stockholders&#8217; equity and cash flows of Pacira Pharmaceuticals, Inc. and Subsidiaries for the year ended December 31, 2015. Pacira Pharmaceuticals, Inc.&#8217;s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:2px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:2px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the results of operations and cash flows of Pacira Pharmaceuticals, Inc. and Subsidiaries for the year ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ CohnReznick, LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roseland, New Jersey</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 25, 2016</font></div><div style="line-height:120%;text-align:left;padding-left:221px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="sFDF139BD0CD7575089D603A7ABE4D9A8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,653</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,110</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,089</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">628,371</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,466</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,658</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,511</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,738</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,888</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,490</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 17)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December&#160;31, 2017 and 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, par value $0.001; 250,000,000 shares authorized; 40,668,877 shares issued and outstanding at December&#160;31, 2017; 37,480,952 shares issued and outstanding at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(389,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346,238</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,483</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,976</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">628,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,466</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sD8899725438A593B9218BA5F8CED053C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative licensing and milestone revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product discontinuation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,937</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,455</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (expense) income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,732</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty interest obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,471</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s0566DB01E3A25F5A8BBE50D29E331523"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss):</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net unrealized gain (loss) on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,927</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s668FF397715E5539AAE91928EAAC86C5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE YEARS ENDED DECEMBER&#160;31, 2017, 2016 AND 2015</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:35%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common <br>Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Paid-In</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,072</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Shares issued under employee<br>     stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Issuance of common stock upon<br>     conversion of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Retirement of equity component<br>     of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net unrealized gain on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(308,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Shares issued under employee<br>     stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Retirement of equity component<br>     of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net unrealized gain on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Cumulative effect adjustment of the adoption<br>     of Accounting Standards Update 2016-09<br>     (Note 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(287</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Vested restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Shares issued under employee stock<br>     purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Issuance of common stock upon<br>     conversion of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Retirement of equity component<br>     of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126,328</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126,328</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Equity component of 2022 convertible<br>     senior notes issued, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669,032</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(389,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><a name="sBF38D5D320A6581D83DC1DF830B4FE37"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of fixed assets and amortization of intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization&#160;of&#160;unfavorable&#160;lease&#160;obligation&#160;and&#160;debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,088</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on disposal of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,732</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,721</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,082</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,476</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,377</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,007</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses and income taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty interest obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,785</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,453</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,021</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(502,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,713</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,627</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from shares issued under employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from 2022 convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of 2019 convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of debt issuance and financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs for conversion of convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,182</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,040</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,464</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,126</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,944</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,984</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest, including royalty interest obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for income taxes, net of refunds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Issuance of common stock from conversion of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of equity component of 2019 convertible senior notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126,328</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in accrued fixed assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><a name="s6372863579395481B929A5621F332CE2"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="s88A7221D547859BFB0681EFD5F000229"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 1&#8212;DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals,&#160;Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its proprietary DepoFoam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Pacira is committed to driving innovation in postsurgical pain management with opioid-sparing strategies.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s lead product, EXPAREL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, was approved by the United States Food and Drug Administration, or FDA, on October&#160;28, 2011 and launched commercially in April 2012. DepoFoam is also the basis for the Company&#8217;s other FDA-approved product, DepoCyt(e), which the Company had manufactured for its commercial partners before discontinuing production in June 2017. The Company also sells its bupivacaine liposome injectable suspension product to a commercial partner to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira is subject to risks common to companies in similar industries and stages of development, including, but not limited to, competition from larger companies, reliance on revenue from one product, reliance on a single manufacturing site, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology and compliance with government regulations.</font></div><div><a name="sEB55EDF4F6845EA488FEEFD2948A2F67"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, inventory costs, impairments of goodwill and long-lived assets, liabilities and accruals and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management believes that the Company&#8217;s existing cash and cash equivalents, short-term and long-term investments and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses, capital expenditure requirements, payment of the principal on any conversions of the Company&#8217;s convertible senior notes and to service its indebtedness at least through </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2019</font><font style="font-family:inherit;font-size:10pt;">. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. See </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">,</font><font style="font-family:inherit;font-size:10pt;">&#32;for further discussion of the Company&#8217;s convertible senior notes and conversion elections. The Company expects to continue to incur substantial additional expenditures as it continues to commercialize EXPAREL, develops and seeks regulatory approval for its product candidates and expands its manufacturing facilities for EXPAREL and its other product candidates, including costs associated with certain technical transfer activities and the construction of two dedicated manufacturing suites in England.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the United States, or U.S.; (ii) sales of DepoCyt(e) to its commercial partners within the U.S. and the European Union, or E.U.; (iii) sales of its bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product for use in animal health indications and (v) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">license fees and milestone payments. The Company recognizes revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company records revenue at the time the product is delivered to the end-user. The Company also recognizes revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and its bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contract terms, inventory data and other related information which may become known in the future. The Company reviews the adequacy of its provisions on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Returns Allowances</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows customers to return product that is damaged or received in error. In addition, the Company allows EXPAREL to be returned beginning </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months</font><font style="font-family:inherit;font-size:10pt;">&#32;prior to, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">twelve months</font><font style="font-family:inherit;font-size:10pt;">&#32;following product expiration. The Company estimates its sales return reserve based on its historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terms. The Company accrues discounts to wholesalers based on contractual terms of agreements and historical experience. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wholesaler Service Fees</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers include major and regional wholesalers with whom the Company has contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volume Rebates and Chargebacks</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers the Company provides to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Returns Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prompt Payment Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wholesaler Service Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Volume Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,482</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from royalties based on sales of its commercial partners&#8217; net sales of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Licensing and Milestone Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of a termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in the Company&#8217;s consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company&#8217;s performance obligations under the applicable agreements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Major Customers</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers are national and regional wholesalers of pharmaceutical products as well as commercial, collaborative and licensing partners. The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The table below includes the percentage of revenue comprised by the Company&#8217;s three largest wholesalers in each year presented:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:71%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest wholesaler</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from customers outside the U.S. accounted for less than </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s total revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs associated with products and processes being developed, and include related personnel expenses, laboratory supplies, active pharmaceutical ingredients, manufacturing supplies, facilities costs, preclinical and clinical trial costs, development costs related to significant scale-ups of manufacturing capacity and other outside service fees. The Company expenses research and development costs as incurred. A significant portion of the development activities are outsourced to third parties, including contract research organizations. In such cases, the Company may be required to estimate related service fees to be accrued.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, all deferred tax assets were fully offset by a valuation allowance because there is significant doubt regarding the Company&#8217;s ability to utilize such net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s stock-based compensation program includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation of stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable stock options. Accordingly, the Company uses an option pricing model to derive an estimated fair value. In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected term of the option</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected dividends</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes its available historic volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option exercises. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. The Company records forfeitures as they occur rather than estimating forfeitures during each period.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments with maturities of 90 days or less when purchased are considered cash equivalents.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term and Long-Term Investments</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with initial maturities of greater than three months at the date of purchase, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with initial maturities greater than one year at the date of purchase. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from net loss and are reported as a separate component of accumulated other comprehensive loss until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 to 3&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 to 10&#160;years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Retirement Obligations</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records interest expense to accrete the ARO to full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over fair value acquired in a business combination and is not amortized, but subject to impairment at least annually or when a triggering event occurs that could indicate a potential impairment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Investments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its equity investment in a minority interest of a company over which it does not exercise significant influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evidence that changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investments are reviewed on a regular basis for possible impairment. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern and (v) any other information that the Company may be aware of related to the investment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reviews long-lived assets, including fixed assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Debt Transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon settlement of the convertible senior notes, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Per Share Data</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and warrants, the vesting of RSUs and the purchase of shares from the Company&#8217;s employee stock purchase plan (using the treasury stock method), as well as the conversion of the excess conversion value on the Company&#8217;s convertible senior notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;reportable segment and, accordingly, no segment disclosures have been presented.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><a name="sA1E242D3524C5E1A843290B37307C087"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 3&#8212;RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">. This update includes multiple provisions intended to simplify various aspects of accounting for share-based payment transactions including accounting for excess tax benefits and tax deficiencies, classification of excess tax benefits and tax deficiencies in the statement of cash flows and accounting for award forfeitures. The update also removes the requirement to delay recognition of an excess tax benefit until it reduces current taxes payable, instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This update became effective for the Company beginning January 1, 2017. The Company elected an accounting policy change to record forfeitures as they occur rather than estimating forfeitures during each period and recorded a charge of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to retained earnings as of January 1, 2017 related to the reversal of cumulative forfeiture estimates. The adoption of this standard also resulted in the recognition of </font><font style="font-family:inherit;font-size:10pt;">$29.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. The changes have been applied prospectively in accordance with the update, and prior periods have not been adjusted. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based awards, will be classified as cash flows from operating activities in the Company&#8217;s consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. The standard requires entities to measure most inventory &#8220;at the lower of cost and net realizable value&#8221;, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of which is net realizable value). Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The standard became effective for the Company prospectively beginning January 1, 2017. The adoption of ASU 2015-11 did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not Adopted as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2017</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, and has subsequently issued a number of amendments to this update. The new standard, as amended, provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The standard&#8217;s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 provides a five-step model that includes (1) identifying the contract with a customer, (2) identifying the performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations and (5) recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard will become effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective&#160;method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt this standard using the modified retrospective method.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with the current revenue accounting standards. Based on its review of its current customer contracts, the implementation of ASU 2014-09 will not have a material quantitative impact on the Company&#8217;s consolidated financial statements, as the timing of revenue recognition for EXPAREL product sales is not expected to significantly change. The Company will recognize existing collaborative licensing, milestone and royalty revenue earlier, subject to the variable consideration constraints, than it would have under the current standard, however, such changes are not expected to be material to the Company&#8217;s consolidated financial statements. Adoption of the new standard will result in additional revenue-related disclosures in the footnotes to the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-01 changes accounting for equity investments and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income (loss). Entities have the option to measure equity investments without readily determinable fair values either at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The standard also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. ASU 2016-01 will become effective for the Company beginning January 1, 2018. The Company has elected to measure equity investments without readily determinable fair values at cost adjusted for changes in observable prices. The guidance related to equity investments without readily determinable fair values will be applied prospectively to equity investments that exist as of the date of adoption. The adoption of ASU 2016-01 may increase volatility in the Company&#8217;s net income as changes in observable prices of equity investments without readily determinable fair values will be recorded in net income (loss). The Company does not expect the implementation of this standard to have a material impact on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">.&#160;This update requires lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment for items such as initial direct costs. For income statement purposes, the new standard retains a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while financing leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). This update also introduces new disclosure requirements for leasing arrangements. The standard will become effective for the Company beginning January 1, 2019. Early adoption is permitted, although the Company does not expect to do so. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. For operating leases it will result in the recognition of lease liabilities and corresponding right-of-use assets upon adoption, which will have a material impact on the Company&#8217;s consolidated balance sheet. The Company does not believe the adoption of this ASU will have a significant impact on its consolidated statements of operations, stockholders&#8217; equity or cash flows. At adoption, this update will be applied using a modified retrospective approach. Refer to Note&#160;17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on the Company&#8217;s leases.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity&#8217;s portfolio. This ASU will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued&#160;ASU&#160;2016-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic&#160;230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a&#160;business combination.&#160;ASU&#160;2016-15&#160;will become effective for the Company in the first quarter of fiscal year 2018. The Company does not expect any changes to its consolidated statement of cash flows upon the adoption of this standard.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><a name="sD7650949A7E65EE88A7DDD3A20A09573"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 4&#8212;INVENTORIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of inventories are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to perform ongoing stability testing on select lots of EXPAREL at various time intervals. In October 2016, as part of its ongoing stability testing, the Company identified that a single batch of EXPAREL, which was manufactured in early 2016, did not meet the required specification. An internal investigation tied this unexpected result to a modification in the manufacturing process that existed when this product was made, which has subsequently been corrected. The Company reserved all impacted inventory on hand and recorded a </font><font style="font-family:inherit;font-size:10pt;">$20.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;charge to cost of goods sold in 2016 related to this matter.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB1EE803BA7C0595CB4CC8A6EBFA26310"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 5&#8212;FIXED ASSETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net summarized by major category, consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,933</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,787</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,256</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,526</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$13.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company capitalized interest of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located in England in the amount of </font><font style="font-family:inherit;font-size:10pt;">$59.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$33.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had an ARO of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, included in other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements. The increase in 2017 relates to a </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;revision in estimated future cash flows related to the AROs, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of liabilities incurred in the current period and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of accretion expense.</font></div><div><a name="sD445D9F3FD2D5CDFBC1D3432C1BB7BB1"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 6&#8212;GOODWILL AND INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2007, the Company acquired from SkyePharma Holding, Inc., or Skyepharma, its California operating subsidiary (Pacira California), referred to herein as the Acquisition. The Company&#8217;s goodwill arose in April 2012 from a contingent milestone payment to Skyepharma in connection with the Acquisition. The Acquisition was accounted for under Statement of Financial Accounting Standards 141, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Business Combinations</font><font style="font-family:inherit;font-size:10pt;">, which was the effective GAAP standard at the Acquisition date. In connection with the Acquisition, the Company agreed to certain earn-out payments based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL and certain other yet-to-be-developed products, as well as milestone payments for DepoBupivacaine products, including EXPAREL, as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 6&#8212;GOODWILL AND INTANGIBLE ASSETS (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the first commercial sale in the U.S. (met April 2012);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the first commercial sale in a major E.U. country (United Kingdom, France, Germany, Italy and Spain);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(met September 2014);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(met June 2016); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$500.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first milestone was met in April 2012 resulting in a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment to Skyepharma. The Company recorded this payment net of a </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;contingent consideration liability recognized at the time of the Acquisition, resulting in </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded as goodwill. In September 2014, the Company recorded an </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone in connection with achieving </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of annual EXPAREL net sales collected, and in June 2016, the Company recorded another </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone for achieving </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of annual EXPAREL net sales collected. For purposes of meeting future potential milestone payments, with certain exceptions, annual net sales are measured on a rolling quarterly basis. Cumulatively through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as goodwill for earn-out payments which are based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL. Any remaining earn-out payments will also be treated as additional costs of the Acquisition and, therefore, recorded as goodwill if and when each contingency is resolved. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Acquisition was treated as a stock acquisition for tax purposes and, therefore, the acquired intangibles for book purposes are not deductible for income tax purposes. The Company also recorded goodwill related to contingent payments due under the Acquisition during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, which are not deductible for income tax purposes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the carrying value of goodwill is summarized as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Milestone payment triggered by collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,737</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets acquired in the Acquisition consisted of core technology, developed technology, trademarks and trade names. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;amortization expense for intangibles for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. For the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, amortization expense for intangibles was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s2E4EEFA632E351558E1B8FCFB3D1771B"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 7&#8212;ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalties</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product returns, rebates and other fees </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><a name="s5B8CEA6B31AD5CA7A8447889DB22D1EE"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 8&#8212;DEBT</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes Due 2022</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2017, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$345.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.375%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible senior notes due 2022, or 2022 Notes, and entered into an indenture agreement, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">2.375%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year, payable semiannually in arrears on April 1 and October 1 of each year. The 2022 Notes mature on April 1, 2022.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2022 Notes is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net proceeds from the issuance of the 2022 Notes were </font><font style="font-family:inherit;font-size:10pt;">$334.0 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2022 Notes were used by the Company to repurchase the majority of its then-outstanding convertible senior notes due 2019 in privately-negotiated transactions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders may convert the 2022 Notes at any time prior to the close of business on the business day immediately preceding October 1, 2021, only under the following circumstances:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) during any calendar quarter commencing after the calendar quarter ended June 30, 2017 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;trading days (whether or not consecutive) during a period of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the conversion price on each applicable trading day;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;business-day period immediately after any </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading-day period (the &#8216;&#8216;measurement period&#8217;&#8217;) in which the trading price (as defined in the 2022 Indenture) per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount of the 2022 Notes for each trading day of the measurement period was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&#8217;s assets; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv) if the Company calls the 2022 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding April 1, 2022, holders may convert their 2022 Notes at any time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2022 Notes is </font><font style="font-family:inherit;font-size:10pt;">14.9491</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount, which is equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$66.89</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately </font><font style="font-family:inherit;font-size:10pt;">37.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;to the closing sale price of </font><font style="font-family:inherit;font-size:10pt;">$48.65</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of the Company&#8217;s common stock on the NASDAQ Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 8&#8212;DEBT (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the 2022 Notes had a market price of </font><font style="font-family:inherit;font-size:10pt;">$1,048</font><font style="font-family:inherit;font-size:10pt;">&#32;per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are converted, the Company would be required to repay the </font><font style="font-family:inherit;font-size:10pt;">$345.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to April 1, 2020, the Company may not redeem the 2022 Notes. On or after April 1, 2020, the Company may redeem for cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&#8217;s common stock has been at least </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the conversion price then in effect for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;trading days (whether or not consecutive) during any </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading-day period ending within </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;trading days prior to the date on which the Company provides notice of redemption. The redemption price will equal the sum of (i) </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &#8220;make whole fundamental change&#8221; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2022 Indenture) occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2022 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the 2022 Notes are currently classified on the Company&#8217;s consolidated balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as long-term debt, the future convertibility and resulting balance sheet classification of this liability will be monitored at each quarterly reporting date and will be analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2022 Notes have the election to convert the 2022 Notes at any time during the prescribed measurement period, the 2022 Notes would then be considered a current obligation and classified as such.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under ASC 470-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options</font><font style="font-family:inherit;font-size:10pt;">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of </font><font style="font-family:inherit;font-size:10pt;">$274.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was calculated using a </font><font style="font-family:inherit;font-size:10pt;">7.45%</font><font style="font-family:inherit;font-size:10pt;">&#32;assumed borrowing rate. The equity component of </font><font style="font-family:inherit;font-size:10pt;">$70.9 million</font><font style="font-family:inherit;font-size:10pt;">, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the five year term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allocated the total transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 8&#8212;DEBT (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes Due 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 23, 2013, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate principal amount of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible senior notes due 2019, or 2019 Notes. The 2019 Notes accrue interest at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year, payable semiannually in arrears on February 1 and August 1 of each year. The 2019 Notes mature on February 1, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2019 Notes is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company used part of the net proceeds from the issuance of the 2022 Notes discussed above to repurchase </font><font style="font-family:inherit;font-size:10pt;">$117.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal of the 2019 Notes in privately-negotiated transactions for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$118.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The partial repurchase of the 2019 Notes resulted in a </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loss on early debt extinguishment. In May 2017, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal of the 2019 Notes in a privately-negotiated transaction for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">10 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal remains outstanding on the 2019 Notes.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders may convert their 2019 Notes prior to August 1, 2018 only if certain circumstances are met, including if during the previous calendar quarter, the sales price of the Company&#8217;s common stock was greater than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the conversion price then applicable for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;out of the last </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days of the quarter. During the quarter ended December&#160;31, 2017, this condition for conversion was met. As a result, the 2019 Notes are classified as a current obligation and will be convertible until March&#160;31, 2018. As of December&#160;31, 2017, the 2019 Notes had a market price of </font><font style="font-family:inherit;font-size:10pt;">$1,905</font><font style="font-family:inherit;font-size:10pt;">&#32;per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount, compared to an estimated conversion value of </font><font style="font-family:inherit;font-size:10pt;">$1,839</font><font style="font-family:inherit;font-size:10pt;">&#32;per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount. In the event that the remaining 2019 Notes are converted, the Company would be required to repay the </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal value in cash and settle approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the conversion premium in cash, common stock or a combination of cash and shares of its common stock at the Company&#8217;s option as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the total interest expense recognized in the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized interest and other (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,725</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective interest rate on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><a name="s3D01107F0E905C6693BDE81414007D38"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 9&#8212;FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1: </font><font style="font-family:inherit;font-size:10pt;">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2: </font><font style="font-family:inherit;font-size:10pt;">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3: </font><font style="font-family:inherit;font-size:10pt;">Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div></td></tr></table><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&#8217;s convertible senior notes at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The carrying amount and fair value of the Company&#8217;s convertible senior notes are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Liabilities Carried at Historical Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying<br>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(1) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;">&#32;per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;">&#32;compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$66.89</font><font style="font-family:inherit;font-size:8.5pt;">&#32;per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">5.2 million</font><font style="font-family:inherit;font-size:8.5pt;">&#32;shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(2) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;">&#32;per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;">&#32;compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$24.82</font><font style="font-family:inherit;font-size:8.5pt;">&#32;per share which, if converted, would result in a conversion premium of less than </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;">&#32;shares of the Company&#8217;s common stock or </font><font style="font-family:inherit;font-size:8.5pt;">$0.3 million</font><font style="font-family:inherit;font-size:8.5pt;">&#32;of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;">&#32;shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with maturities greater than three months, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with maturities greater than one year. Net unrealized gains or losses from the Company&#8217;s short-term and long-term investments are reported in other comprehensive income (loss). At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s short-term investments are classified as available for sale investments and are determined to be Level&#160;2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, all short-term and long-term investments were rated A or better by Standard &amp; Poor&#8217;s.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the Company&#8217;s investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 9&#8212;FINANCIAL INSTRUMENTS (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br>Unrealized<br>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Long-term:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,430</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br>Unrealized<br>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,010</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain assets and liabilities are measured at fair value on a nonrecurring basis, including assets and liabilities acquired in a business combination, and long-lived assets, which would be recognized at fair value if deemed to be impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level&#160;3 inputs. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">TELA Bio, Inc.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company made a cash investment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in convertible preferred B shares of TELA Bio Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;portfolio of products for ventral hernia repair and abdominal wall reconstruction. In conjunction with the investment in TELA Bio, the Company acquired an option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of convertible preferred B shares of TELA Bio under the same terms and conditions as existed on the initial purchase date. The purchase option expires on September 15, 2018. If the Company does not exercise its purchase option, the Company may be required to invest up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in TELA Bio convertible preferred B shares under certain conditions. This contingent purchase obligation expires on October 31, 2018.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in TELA Bio, the purchase option and the contingent purchase obligation were recorded at fair value based on integrated valuation pricing models. These models included both unobservable and observable market inputs including projected revenues, option purchase price, volatility and projected liquidity date. The equity investment in the TELA Bio preferred B shares was recorded at </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the purchase option was recorded in prepaid expenses and other current assets at </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the contingent purchase obligation was determined to be de minimis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;wholesalers accounted for over </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s accounts receivable: </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;">, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;wholesalers accounted for over </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s accounts receivable: </font><font style="font-family:inherit;font-size:10pt;">36%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">29%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">, respectively. Revenues are primarily derived from major wholesalers and pharmaceutical companies which generally have significant cash resources. Allowances for doubtful accounts receivable are maintained based </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 9&#8212;FINANCIAL INSTRUMENTS (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on historical payment patterns, aging of accounts receivable and actual write-off history. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, no allowances for doubtful accounts were deemed necessary by the Company on its accounts receivable.</font></div><div><a name="sBC4AE5AFB6EC5968AEDA3BFC239E1473"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 10&#8212;STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">250,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, of which </font><font style="font-family:inherit;font-size:10pt;">40,668,877</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">37,480,952</font><font style="font-family:inherit;font-size:10pt;">&#32;were outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,000,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;shares of preferred stock. No preferred stock was outstanding at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;or </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2016</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Unrealized Gains</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Losses) From Available</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For Sale Investments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div><a name="s1FECAE000BF4570F833D115BC89F422A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11&#8212;STOCK PLANS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Incentive Plans</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s amended and restated 2011 stock incentive plan, or 2011 Plan, was adopted by its board of directors and approved by its stockholders in June 2014. The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. Since the adoption of the 2011 Plan, any remaining shares available for issuance under a 2007 stock incentive plan, or 2007 Plan, are reallocated to the 2011 Plan. In April 2014, the Company&#8217;s board of directors adopted the 2014 Inducement Plan which authorized </font><font style="font-family:inherit;font-size:10pt;">175,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to be granted as equity awards to new employees.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company&#8217;s board of directors adopted an amendment to the 2011 Plan. Under the amendment, an additional&#160;</font><font style="font-family:inherit;font-size:10pt;">4,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were authorized for issuance as equity awards under the 2011 Plan. The amendment to the 2011 Plan was subsequently approved by the Company&#8217;s stockholders and became effective in June 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s stock option grants have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (generally over four years from the date of grant although the Company may occasionally grant options with different vesting terms). Since 2015, the Company has granted RSUs to employees and its board of directors. The Company uses authorized and unissued shares to satisfy its obligations under these plans.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company&#8217;s board of directors adopted the 2014 Employee Stock Purchase Plan, or ESPP, which was subsequently approved by the Company&#8217;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&#8217;s common stock at a discounted price and to help retain and motivate </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11&#8212;STOCK PLANS (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">current employees as well as attract new talent. Under the ESPP, up to </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Internal Revenue Code. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $</font><font style="font-family:inherit;font-size:10pt;">25,000</font><font style="font-family:inherit;font-size:10pt;">. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&#8217;s common stock on the purchase dates of June 30 and December 31 or the last trading day of an offering period. The per share purchase price will be equal to the lesser of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fair market value of the Company&#8217;s common stock on either the offering date or the purchase date.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table contains information about the Company&#8217;s plans at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Reserved for Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards<br>Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Available for Grant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2007 Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2011 Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,931,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,037,947</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893,753</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014 Inducement plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,129,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,113,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,016,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Reserved<br>for Purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares<br>Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Available<br>for Purchase</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014 ESPP</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation expense for stock options and RSUs granted to employees and directors is based on the estimated grant date fair value of options recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for options and RSUs granted to non-employees is based on the fair value of options, which are revalued each reporting period until vested and are recognized as expense over the requisite service period. Compensation expense for ESPP options is based on the grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized stock-based compensation expense (net of forfeitures) in its consolidated statements of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation from:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (employee awards)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (consultant awards)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,367</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">785</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock option activity and related information for the period from January&#160;1, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11&#8212;STOCK PLANS (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of<br>Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted<br>Average<br>Exercise Price (Per Share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average<br>Remaining<br>Contractual<br>Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate<br>Intrinsic Value<br>(in Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,677,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">906,706</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,880</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,645,722</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,340</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,656,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518,226</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175,303</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,072,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(232,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,882,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$41.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of total unrecognized compensation cost related to non-vested stock options is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.7 years</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s stock options have a maximum expiration date of ten years from the date of grant. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average fair value of stock options granted for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$20.78</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$19.13</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$37.82</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68% - 2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03% - 2.48%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40% - 2.28%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.9%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.31 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76 years</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11&#8212;STOCK PLANS (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s RSU activity and related information for the period from January&#160;1, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number<br>of Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted<br>Average Grant<br>Date Fair Value (Per Share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate<br>Intrinsic Value<br>(in Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(101,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested and expected to vest at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of total unrecognized compensation cost related to non-vested RSUs is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.9 years</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s RSUs have a maximum vest date of four years from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&#8217;s common stock on the date of grant.</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the ESPP share options granted are estimated using the Black-Scholes model with the following weighted average assumptions:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:56%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP option fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.80 - $13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.57 - $25.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21.93 - $25.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62% - 1.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37% - 0.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11% - 0.13%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of ESPP share options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td></tr></table></div></div><div><a name="sB79C1C5C496C583CABD510E7DC6F75AC"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 12&#8212;NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, no potentially dilutive securities have been included in the computation of diluted net loss per share for those periods. As discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">, the Company has either the obligation or the option to pay cash for the aggregate principal amount due upon the conversion of its convertible senior notes. Since it is the Company&#8217;s intent to settle the principal amount of its convertible senior notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands, except per share amounts):</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 12&#8212;NET INCOME (LOSS) PER SHARE (Continued)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computation of diluted securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of RSUs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of conversion premium on the 2019 Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,113</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ESPP purchase options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding stock options, RSUs, conversion premiums on the Company&#8217;s convertible senior notes, warrants and ESPP purchase options are antidilutive in the periods presented (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of RSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion premium on the 2019 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average ESPP purchase options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sF2BD2E90CFF751AEADCBACEDD4E1E613"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 13&#8212;INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes and the related tax expense is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,898</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax provision of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;is principally the result of minimum state taxes. The tax provision of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2015 is the result of the federal alternative minimum tax and state taxes.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 13&#8212;INCOME TAXES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. federal statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes refinancing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of the adoption of ASU 2016-09</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s effective tax rates of </font><font style="font-family:inherit;font-size:10pt;">(0.33)%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">(0.28)%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, differed from the expected U.S. statutory tax rate of </font><font style="font-family:inherit;font-size:10pt;">35.0%</font><font style="font-family:inherit;font-size:10pt;">. This difference was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance. The Company&#8217;s effective tax rate of </font><font style="font-family:inherit;font-size:10pt;">12.45%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2015 was favorably impacted by the utilization of domestic net operating loss, or NOL, carryforwards for which there was a full valuation allowance.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,067</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,841</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,939</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,230</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,753</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s federal NOLs and federal tax credit carryforwards totaled </font><font style="font-family:inherit;font-size:10pt;">$380.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$10.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company also had state NOLs and state tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$232.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.0 </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 13&#8212;INCOME TAXES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which are subject to change on an annual basis due to variations in the Company&#8217;s annual state apportionment factors. The Company had non-U.S. tax NOLs of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The existing federal NOLs will begin expiring in 2025 while the existing state NOLs begin expiring in 2024, if the Company has not used them prior to that time. The non-U.S. NOLs do not expire. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the Company had cumulative changes in ownership of more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;within a three-year period, under Internal Revenue Code sections 382 and 383, the Company&#8217;s ability to use certain net operating loss and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&#8217;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&#8217;s initial public offering and other financing transactions. As a result of these ownership changes, the Company estimates that approximately </font><font style="font-family:inherit;font-size:10pt;">$192.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of federal net operating losses are subject to annual limitations. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$134.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of these federal net operating losses were available. The Company estimates that an additional </font><font style="font-family:inherit;font-size:10pt;">$10.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will become available from 2018 through 2022, and the remaining </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through 2025. In addition, California and certain states have previously suspended or limited the use of net operating loss carryforwards for certain taxable years, and certain states are considering similar future measures. As a result, the Company may incur higher state income tax expense in the future. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance is appropriate. The Company had a net reduction in its valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$28.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and a net increase in its valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. There is significant doubt regarding the Company&#8217;s ability to utilize its net deferred tax assets and, therefore, the Company has recorded a full valuation allowance reducing its net deferred tax assets to zero at both </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, new legislation was signed into law reducing the corporate U.S. tax rate from 35% to 21% for tax years beginning after December 31, 2017, fully repealing the corporate alternative minimum tax and making the NOL carryforward period indefinite for NOLs generated after 2017. In accordance with ASC Topic 740, deferred tax assets and liabilities are required to be measured at the enacted tax rate expected to apply when temporary differences are to be realized or settled. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company re-measured its deferred tax balances based upon the new 21% tax rate. This resulted in a reduction of </font><font style="font-family:inherit;font-size:10pt;">$55.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the Company&#8217;s deferred tax assets, which was offset by a change in its year-end valuation allowance.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company established a deferred tax liability with an offset to additional paid-in capital resulting from the conversion feature of the 2022 Notes. The initial difference between the book value of the convertible debt, issued with a beneficial conversion feature, and its tax basis was </font><font style="font-family:inherit;font-size:10pt;">$70.9 million</font><font style="font-family:inherit;font-size:10pt;">, a temporary difference. The net effect of the deferred tax liability recorded to additional paid-in capital was zero because the Company has a full valuation allowance against its net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Company recorded a reserve of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to unrecognized tax benefits, or UTBs, of which </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;relates to tax positions taken in 2017 and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;relates to tax positions taken in 2016. The Company did not have any such liability at December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&#8217;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&#8217;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Due to the Company&#8217;s full valuation allowance against deferred tax assets, none of the UTBs, if recognized, would affect the effective income tax rate. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates that it is not reasonably possible that within the next twelve months, any of the unrecognized tax benefits will significantly increase or decrease. The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2014 through 2017, and state tax jurisdictions for the years 2013 through 2017. However, the IRS or states may still examine and adjust a net operating loss arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&#8217;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-30</font></div></div><hr style="page-break-after:always"><div><a name="s5DF096291CDE5CB381DEA99894DC989D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 14&#8212;OTHER EMPLOYEE BENEFITS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a discretionary percentage match as defined in the plan and determined by the board of directors. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of related compensation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s4D418DD85A8157B697C676C1F4CED0B4"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 15&#8212;COMMERCIAL PARTNERS AND OTHER AGREEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DepoCyt(e) Discontinuation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, the Company&#8217;s board of directors approved a decision to discontinue production of DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(U.S. and Canada) and DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process. DepoCyt(e) accounted for </font><font style="font-family:inherit;font-size:10pt;">2.6%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s 2016 total full-year revenues of </font><font style="font-family:inherit;font-size:10pt;">$276.4 million</font><font style="font-family:inherit;font-size:10pt;">. As of June 30, 2017, the Company had ceased all production of DepoCyt(e).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the discontinuation, the Company received a fixed payment for the supply of DepoCyt(e) and double-digit royalties, net of supply price, on the sales of DepoCyt by Leadiant Bioscience, Ltd. in the U.S. and Canada, and on the sales of DepoCyte by Mundipharma International Corporation Limited, or Mundipharma, in the E.U. and other European countries. In addition, the Company also received a non-refundable upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with a </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">&#32;year extension and concurrent expansion of the territories where Mundipharma can market and distribute DepoCyte.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Company recorded a non-recurring charge of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the discontinuation of its DepoCyt(e) manufacturing activities, including </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for DepoCyt(e) related inventory, which is recorded in cost of goods sold, and </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the remaining lease costs less an estimate of potential sublease income for the facility where DepoCyt(e) was manufactured, the write-off of property, plant and equipment, employee severance, asset retirement obligations and other estimated exit costs. Cash payments related to the lease on the DepoCyt(e) manufacturing facility are expected to continue through the end of the lease term in August 2020.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a summary of the Company&#8217;s costs and reserves related to the DepoCyt(e) discontinuation are as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:209px;"></td><td style="width:9px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Severance and Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Write-Off of Property, Plant &amp; Equipment and Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Retirement Obligations and Other Discontinuation Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges incurred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments made</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposal of property, plant &amp;<br>   equipment and inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may be required to make additional payments or incur additional costs relating to the DepoCyt(e) discontinuation which could be material to the Company&#8217;s results of operations and/or cash flows in a given period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial Partners</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patheon UK Limited</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company and Patheon UK Limited, or Patheon, entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the Technical Transfer and Service Agreement, Patheon has agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. Under these agreements, the Company will make monthly base fee payments for services rendered. The agreements will remain in full effect unless and until they expire or are terminated. Upon termination of the Technical Transfer and Services Agreement (other than termination by the Company in the event that Patheon does not </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 15&#8212;COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Continued)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">meet the construction and manufacturing milestones or for a breach by Patheon), the Company will pay for the make good costs occasioned by the removal of its manufacturing equipment and for Patheon&#8217;s termination costs up to a maximum amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Manufacturing and Supply Agreement, following the FDA approval date of the suites, the Company has agreed to purchase EXPAREL product from Patheon. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Patheon), this agreement will expire on the&#160;</font><font style="font-family:inherit;font-size:10pt;">10th</font><font style="font-family:inherit;font-size:10pt;">&#32;anniversary of the FDA approval date for the initial manufacturing suite.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DePuy Synthes Sales, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company announced the initiation of a Co-Promotion Agreement, or the Agreement, with DePuy</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies, to market and promote the use of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL for orthopedic procedures in the U.S.. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine and trauma, collaborates with and supplements the Company&#8217;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the five-year arrangement, DePuy Synthes is the exclusive third-party distributor during the term of the Agreement to promote and sell EXPAREL for operating room use for orthopedic and spine surgeries (including knee, hip, shoulder, sports and trauma surgeries) in the U.S.. DePuy Synthes receives a tiered commission ranging from low single-digits to double-digits on sales of EXPAREL under the Agreement, subject to conditions, limitations and adjustments. The initial term of the Agreement commenced on January 24, 2017 and ends on December 31, 2021, with the option to extend the Agreement in additional 12-month increments upon mutual agreement of the parties, subject to certain conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and DePuy Synthes have mutual termination rights under the Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or DePuy Synthes generally may not terminate the Agreement, without cause, within three years of the effective date of the Agreement. The Company also has additional unilateral termination rights under certain circumstances. The Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. DePuy Synthes is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&#8217;s policies, in connection with fulfilling their obligations under the Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aratana Therapeutics,&#160;Inc. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;5, 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&#160;Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&#8217;s bupivacaine liposome injectable suspension product for animal health indications. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. In connection with its entry into the license agreement, the Company received a one-time payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. In December 2013, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment under the agreement. In June 2016, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in milestone revenue for Aratana&#8217;s filing of an FDA Administrative New Animal Drug Application, or ANADA, and in August 2016 recorded </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the FDA&#8217;s approval of the ANADA. The Company is eligible to receive up to an additional aggregate </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double digit royalty on net sales made in the U.S.. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into a jurisdiction or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until December 2027, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;is a registered trademark of Aratana Therapeutics, Inc.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 15&#8212;COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Continued)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CrossLink BioScience,&#160;LLC</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company and CrossLink BioScience, LLC, or CrossLink, commenced a five-year arrangement for the promotion and sale of EXPAREL, pursuant to the terms of a Master Distributor Agreement (as amended, the &#8220;CrossLink Agreement&#8221;). On June&#160;30, 2016, the Company provided notice to CrossLink electing to terminate the CrossLink Agreement effective as of September&#160;30, 2016. In connection with the termination of the CrossLink Agreement, a termination fee based on a percentage of earned performance-based fees is due to CrossLink.&#160;This fee of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is payable to CrossLink quarterly over two years beginning in the fourth quarter of 2016, and was recorded in selling, general and administrative expense in the consolidated statements of operations. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is classified in accrued expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCC5A0296662F52A5879EB664B71EDC01"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 16&#8212;RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s former Chief Medical Officer, Dr. Gary Patou, is a partner of MPM Asset Management LLC, or MPM, an investor in the Company. The Company incurred </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;consulting expenses with MPM or Dr. Patou in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31,</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;there was </font><font style="font-family:inherit;font-size:10pt;">nothing</font><font style="font-family:inherit;font-size:10pt;">&#32;payable to MPM. The Company&#8217;s agreement with MPM expired on December 31, 2015. The Company contracted with Dr. Patou directly for his services for the first six months of 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana as discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 15</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Partners and Other Agreements</font><font style="font-family:inherit;font-size:10pt;">. MPM and its affiliates are holders of capital stock of Aratana. David Stack, the Company&#8217;s Chief Executive Officer and Chairman, was a managing director at MPM from 2005 through March 2017.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;expenses under the consulting arrangement in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and expenses of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. In connection with the consulting arrangement, Dr. Pace received an option to purchase </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$11.02</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and an option to purchase </font><font style="font-family:inherit;font-size:10pt;">70,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.67</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">nothing</font><font style="font-family:inherit;font-size:10pt;">&#32;payable to Dr. Pace for consulting services.</font></div><div><a name="s1151D4F229AE5B6ABD02BE91756E1A62"></a></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 17&#8212;COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s leases for its research and development, warehouse and DepoCyt(e) manufacturing facility in San Diego, California all expire in August 2020, and its lease for its EXPAREL manufacturing facility in San Diego, California expires in December 2025. The Company&#8217;s lease for its corporate headquarters in Parsippany, New Jersey expires in March 2028.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, aggregate annual minimum payments due under the Company&#8217;s lease obligations are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Minimum Payments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023 through 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total rent expense, net of amortization of unfavorable lease obligations and tenant improvements, under all operating leases for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Deferred rent at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company&#8217;s research and development facility in San Diego, California included a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the payment of leasehold </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 17&#8212;COMMITMENTS AND CONTINGENCIES (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">improvements, which the Company utilized completely in 2015 and 2016. The leasehold improvements were capitalized into fixed assets, net on the consolidated balance sheets and are depreciated over the lease term.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any litigation which it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. The Company is cooperating with the government&#8217;s inquiry. The Company can make no assurances as to the time or resources that will need to be devoted to this inquiry or the impact, if any, of this inquiry or any proceedings on its business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Obligations </font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients. The Company was granted a deferral for the required pediatric trials in all age groups for EXPAREL in the setting of wound infiltration and plans to conduct these pediatric trials as a post-marketing requirement, which was stated in the New Drug Application approval letter for EXPAREL. The Company recently secured feedback from the FDA on a pediatric trial design in all age groups and is in the process of finalizing its clinical strategy.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the initial </font><font style="font-family:inherit;font-size:10pt;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;purchase price for the Acquisition, the Company entered into an earn-out agreement with Skyepharma which was based on the Company reaching certain revenue milestones following the Acquisition. Pursuant to this agreement, the Company is required to pay Skyepharma milestone payments up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$62.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;are for milestones not yet met. Additionally, the Company agreed to pay to Skyepharma a low single-digit percentage payment on collections of EXPAREL sales in the U.S., Japan, United Kingdom, France, Germany, Italy and Spain. Such obligations to make percentage payments will continue for the term in which such sales related to EXPAREL are covered by a valid claim in certain patent rights related to EXPAREL and other biologics products. The Company has the right to cease paying the low single-digit percentage payments in the event that Skyepharma breaches certain covenants not to compete contained in the stock purchase agreement or the last valid patent claim expires. Refer to </font><font style="font-family:inherit;font-size:10pt;">Note 6</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font><font style="font-family:inherit;font-size:10pt;">, for further discussion.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to an agreement with Research Development Foundation, or RDF, the Company is required to pay RDF a low single-digit royalty on the collection of revenues from its DepoFoam-based products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-34</font></div></div><hr style="page-break-after:always"><div><a name="sF37505ABA2FA503C91AEC7DFB457A646"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 18&#8212;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present selected quarterly financial data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,228</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,866</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,743</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,597</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,152</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,973</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods where the Company reported a net loss, no potentially dilutive securities were included in the computation of diluted net loss per share.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-35</font></div></div><hr style="page-break-after:always"><div><a name="sC6D7B50B139657B08DC75DD8B5561BAF"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:89%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exhibit</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511032911/dex31.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation of the Registrant.</font></a><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511032911/dex32.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of the Registrant.</font></a><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511006874/dex41.htm"><font style="font-family:inherit;font-size:10pt;">Specimen Certificate evidencing shares of common stock.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465913004136/a13-3455_1ex4d1.htm"><font style="font-family:inherit;font-size:10pt;">Indenture (including form of 2019 Notes), dated January 23, 2013, between the Registrant and Wells Fargo Bank, National Association, as trustee.</font></a><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465917016145/a17-8213_1ex4d1.htm"><font style="font-family:inherit;font-size:10pt;">Indenture (including form of 2022 Notes), dated March 13, 2017, between the Registrant and Wells Fargo Bank, National Association, as trustee.</font></a><font style="font-family:inherit;font-size:10pt;">(19)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510242595/dex101.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated 2007 Stock Option/Stock Issuance Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(2)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510242595/dex102.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement under the Second Amended and Restated 2007 Stock Option/Stock Issuance Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(2)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510242595/dex103.htm"><font style="font-family:inherit;font-size:10pt;">Investors&#8217; Rights Agreement, dated March&#160;23, 2007, among the Registrant and the parties named therein.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex104.htm"><font style="font-family:inherit;font-size:10pt;">Assignment Agreement, dated February&#160;9, 1994, amended April&#160;15, 2004, between the Registrant and Research Development Foundation.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex105.htm"><font style="font-family:inherit;font-size:10pt;">Stock Purchase Agreement, dated January 8, 2007, between SkyePharma, Inc. and the Registrant.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex108.htm"><font style="font-family:inherit;font-size:10pt;">Supply Agreement, dated June&#160;30, 2003, between SkyePharma,&#160;Inc. and Mundipharma Medical Company.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex109.htm"><font style="font-family:inherit;font-size:10pt;">Distribution Agreement, dated June&#160;30, 2003, between SkyePharma,&#160;Inc. and Mundipharma International Holdings Limited.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex1010.htm"><font style="font-family:inherit;font-size:10pt;">Distribution Agreement, dated July&#160;27, 2005, between SkyePharma,&#160;Inc. and Mundipharma International Holdings Limited.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex1012.htm"><font style="font-family:inherit;font-size:10pt;">DepoCyt Supply and Distribution Agreement, dated December 31, 2002, between SkyePharma, Inc. and Enzon Pharmaceuticals, Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510242595/dex1019.htm"><font style="font-family:inherit;font-size:10pt;">Industrial Real Estate Triple Net Lease, dated August&#160;17, 1993, between the Registrant and HCP TPSP,&#160;LLC.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465913021811/a13-7707_1ex99d2.htm"><font style="font-family:inherit;font-size:10pt;">Fifth Amendment, dated March 13, 2013, to the Industrial Real Estate Triple Net Lease, dated August 17, 1993, between the Registrant and HCP TPSP, LLC (and successor-in-interest to Equitable Life Assurance Society of the United States).</font></a><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510242595/dex1020.htm"><font style="font-family:inherit;font-size:10pt;">Industrial Real Estate Lease, dated December&#160;8, 1994, amended July&#160;2, 2009, between the Registrant and LASDK Limited Partnership.</font></a><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465913021811/a13-7707_1ex99d1.htm"><font style="font-family:inherit;font-size:10pt;">Third Amendment, dated March 13, 2013, to the Industrial Real Estate Lease, dated December 8, 1994, between the Registrant and LASDK Limited Partnership.</font></a><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex1014.htm"><font style="font-family:inherit;font-size:10pt;">Fourth Amendment, dated December 28, 2017, to the Industrial Real Estate Lease, dated December 8, 1994, between the Registrant and LASDK Limited Partnership.</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex1021.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Registrant and David Stack.</font></a><font style="font-family:inherit;font-size:10pt;">(2)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465913021811/a13-7707_1ex99d3.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1 to Executive Employment Agreement, dated March 13, 2013, between the Registrant and David Stack.</font></a><font style="font-family:inherit;font-size:10pt;">(4)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit102.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2 to Executive Employment Agreement, dated June 30, 2015, between the Registrant and David Stack.</font></a><font style="font-family:inherit;font-size:10pt;">(14)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000006/pcrx-33115xex102.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated November 29, 2012, between the Registrant and Kristen Williams.</font></a><font style="font-family:inherit;font-size:10pt;">(13)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000006/pcrx-33115xex103.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1 to Employment Agreement, dated March 13, 2013, between the Registrant and Kristen Williams.</font></a><font style="font-family:inherit;font-size:10pt;">(13)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit105.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2 to Employment Agreement, dated June 30, 2015, between the Registrant and Kristen Williams.</font></a><font style="font-family:inherit;font-size:10pt;">(14)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681416000023/pcrx-63016xex101.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 2, 2016, between the Registrant and Charles A. Reinhart, III.</font></a><font style="font-family:inherit;font-size:10pt;">(17)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000162828016015255/pcrx-33116xex101.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated June 11, 2015, between the Registrant and Scott Braunstein.</font></a><font style="font-family:inherit;font-size:10pt;">(16)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511006874/dex1032.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement between the Registrant and its directors and officers.</font></a><font style="font-family:inherit;font-size:10pt;">(2)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465911059158/a11-26671_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">Commercial Outsourcing Services Agreement entered into as of August&#160;25, 2011 by the Registrant and Integrated Commercialization Solutions,&#160;Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000144530513002604/pcrx-9302013xex101.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment to Commercial Outsourcing Services Agreement, dated August 1, 2013, between the Registrant and Integrated Commercialization Solutions, Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000013/pcrx-93014xex101.htm"><font style="font-family:inherit;font-size:10pt;">Second Amendment to Commercial Outsourcing Services Agreement, dated August 25, 2014, between the Registrant and Integrated Commercialization Solutions, Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(12)</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit101.htm"><font style="font-family:inherit;font-size:10pt;">Third Amendment to Commercial Outsourcing Services Agreement, dated April 29, 2015, between the Registrant and Integrated Commercialization Solutions, Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(14)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465914044018/a14-14761_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated 2011 Stock Incentive Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(8)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465914044018/a14-14761_1ex10d3.htm"><font style="font-family:inherit;font-size:10pt;">Form&#160;of Nonstatutory Stock Option Agreement under the Amended and Restated 2011 Stock Incentive Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(8)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit106.htm"><font style="font-family:inherit;font-size:10pt;">Form&#160;of Restricted Stock Unit Award Agreement (Employees) under the Amended and Restated 2011 Stock Incentive Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(14)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit107.htm"><font style="font-family:inherit;font-size:10pt;">Form&#160;of Restricted Stock Unit Award Agreement (Non-Employee Directors) under the Amended and Restated 2011 Stock Incentive Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(14)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000104746913002336/a2213236zex-10_47.htm"><font style="font-family:inherit;font-size:10pt;">License, Development and Commercialization Agreement, dated December&#160;5, 2012 between the Registrant and Aratana Therapeutics,&#160;Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000104746913002336/a2213236zex-10_48.htm"><font style="font-family:inherit;font-size:10pt;">Supply Agreement, dated December&#160;5, 2012 between the Registrant and Aratana Therapeutics,&#160;Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000006/pcrx-33114xex101.htm"><font style="font-family:inherit;font-size:10pt;">2014 Inducement Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(10)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465914044018/a14-14761_1ex10d2.htm"><font style="font-family:inherit;font-size:10pt;">2014 Employee Stock Purchase Plan.</font></a><font style="font-family:inherit;font-size:10pt;">(8)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.36&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex101.htm"><font style="font-family:inherit;font-size:10pt;">Strategic Co-Production Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.</font></a><font style="font-family:inherit;font-size:10pt;">(11)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.37&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex102.htm"><font style="font-family:inherit;font-size:10pt;">Manufacturing and Supply Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.</font></a><font style="font-family:inherit;font-size:10pt;">(11)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex103.htm"><font style="font-family:inherit;font-size:10pt;">Technical Transfer and Service Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.</font></a><font style="font-family:inherit;font-size:10pt;">(11)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465912034943/a12-8876_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Consulting Agreement, dated April&#160;3, 2012, between the Registrant and Gary Pace.</font></a></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465912073140/a12-20102_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Consulting Agreement, dated August&#160;17, 2012, between the Registrant and Gary Pace.</font></a><font style="font-family:inherit;font-size:10pt;">(15)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000144530513002604/pcrx-9302013xex103.htm"><font style="font-family:inherit;font-size:10pt;">Third Amendment to Consulting Agreement, dated September 11, 2013, between the Registrant and Gary Pace.</font></a><font style="font-family:inherit;font-size:10pt;">(7)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000162828016011728/pcrx-12312015xex1057.htm"><font style="font-family:inherit;font-size:10pt;">Fourth Amendment to Consulting Agreement, dated November 25, 2015, between the Registrant and Gary Pace.</font></a><font style="font-family:inherit;font-size:10pt;">(18)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43&#8224;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681417000015/pcrx-33117xex101.htm"><font style="font-family:inherit;font-size:10pt;">Co-Promotion Agreement, dated January 24, 2017, between the Registrant and DePuy Synthes Sales, Inc.</font></a><font style="font-family:inherit;font-size:10pt;">(20)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681417000015/pcrx-33117xex102.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated April 11, 2016, between the Registrant and Robert Weiland.</font></a><font style="font-family:inherit;font-size:10pt;">(20)***</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex211.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of the Registrant.</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex231.htm"><font style="font-family:inherit;font-size:10pt;">Consent of KPMG LLP.</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex232.htm"><font style="font-family:inherit;font-size:10pt;">Consent of CohnReznick&#160;LLP.</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex311.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer and Chairman pursuant to Exchange Act Rule&#160;13a-14(a).</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex312.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer pursuant to Exchange Act Rule&#160;13a-14(a).</font></a><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex321.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer and Chairman pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pcrx-12312017xex322.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Schema Document.*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Calculation Linkbase Document.*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Label Linkbase Document.*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Presentation Linkbase Document.*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.*</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">_______________________________________________________________________________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on February&#160;11, 2011.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (SEC File&#160;333-170245).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 23, 2013.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Current Report on Form 8-K, filed on March 18, 2013.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q, filed on October&#160;31, 2011.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q, filed on May&#160;9, 2012.</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF317C49ACF63518DBE54395C43B5F267"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on October 31, 2013.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on June&#160;4, 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 7, 2013.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 1, 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on July 31, 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on October 30, 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on April 30, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(14)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on July 30, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(15)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 1, 2012.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(16)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 2, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(17)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 4, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(18)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 10.57 to the Registrant&#8217;s Annual Report on Form 10-K, filed on February 25, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(19)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on March 13, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(20)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the exhibits to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 4, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">* </font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furnished herewith.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">***</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denotes management contract or compensatory plan or arrangement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been granted as to certain portions, which portions were omitted and filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>pcrx-12312017xex1014.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s27bf3e29017048b39e846ab2ad303169"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.14</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">FOURTH AMENDMENT TO INDUSTRIAL REAL ESTATE LEASE</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This FOURTH AMENDMENT TO INDUSTRIAL REAL ESTATE LEASE ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Fourth Amendment</font><font style="font-family:inherit;font-size:11pt;">") is made and entered into as of the 28</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;day of December, 2017, by and between LASDK LIMITED PARTNERSHIP, a Delaware limited partnership ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Landlord</font><font style="font-family:inherit;font-size:11pt;">"), and PACIRA PHARMACEUTICALS, INC., a California corporation ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tenant</font><font style="font-family:inherit;font-size:11pt;">").</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">R</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">E</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">C</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">I</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">T</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">A</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">L</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">S</font><font style="font-family:inherit;font-size:11pt;">&#32;:</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:11pt;">Landlord (as successor-in-interest to Lankford &amp; Associates, Inc., a Colorado corporation) and Tenant (as successor-in-interest to Depotech Corporation, a California corporation) are parties to that certain Industrial Real Estate Lease dated December&#160;8, 1994 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Original</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Lease</font><font style="font-family:inherit;font-size:11pt;">"), as amended by that certain Amendment No. 1 to Industrial Real Estate Lease dated October&#160;26, 1995 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:11pt;">"), that Second Amendment to Industrial Real Estate Lease dated July 2, 2009 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Second Amendment</font><font style="font-family:inherit;font-size:11pt;">"), and that Third Amendment to Industrial Real Estate Lease dated March 13, 2013 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Third Amendment</font><font style="font-family:inherit;font-size:11pt;">"), whereby Landlord leases to Tenant and Tenant leases from Landlord the "Premises," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;1.5</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Original Lease, which Premises includes, without limitation, the entirety of that certain building (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Building</font><font style="font-family:inherit;font-size:11pt;">") located at 10450 Science Center Drive, San Diego, California  92121.  The Original Lease, First Amendment, Second Amendment and Third Amendment shall hereafter be referred to, collectively, as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Lease</font><font style="font-family:inherit;font-size:11pt;">."</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:11pt;">The parties desire to amend the Lease on the terms and conditions set forth in this Fourth Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">A</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">G</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">R</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">E</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">E</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">M</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">E</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">N</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">T</font><font style="font-family:inherit;font-size:11pt;">&#32;:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Terms</font><font style="font-family:inherit;font-size:11pt;">.  All capitalized terms when used herein shall have the same respective meanings as are given such terms in the Lease unless expressly provided otherwise in this Fourth</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Amendment.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Condition of the Premises</font><font style="font-family:inherit;font-size:11pt;">.  Landlord and Tenant acknowledge that Tenant has been occupying the Premises pursuant to the Lease, and therefore Tenant continues to accept the Premises in its presently existing, "as is" condition.  Except to the extent expressly set forth herein or in the Work Letter (as defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:11pt;">&#32;below), and without waiving the Landlord's obligations pursuant to the Lease with respect to maintenance, repairs, replacements, alterations, and services as set forth in the Lease, including, without limitation, Landlord's obligations pursuant to the terms and conditions of Section 6.2.2 of the Original Lease, Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Extended Lease Term; Option Term</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Extended Lease Term</font><font style="font-family:inherit;font-size:11pt;">.  Pursuant to the Lease, the Lease Term is scheduled to expire on August 31, 2020.  Landlord and Tenant hereby agree to extend the Lease Term for a period of five (5) years and four (4) months, from August 31, 2020, until December 31, 2025, on the terms and conditions set forth in the Lease, as hereby amended by this Fourth</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Amendment, unless sooner terminated as provided in the Lease or this Fourth Amendment.  Notwithstanding the fact that the extension of the Lease Term does not commence until September 1, 2020, for purposes of this Fourth Amendment, the period of time commencing on January 1, 2018, and ending on December 31, 2025, shall be referred to herein as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Second</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Extended Term</font><font style="font-family:inherit;font-size:11pt;">."</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Option Term</font><font style="font-family:inherit;font-size:11pt;">.  Tenant's option to extend the Extended Term for a period of five&#160;(5) years pursuant to Section 3.2 of the Third Amendment shall remain in full force and effect, provided that all references in Section 3.2 of the Third Amendment to the "Third Amendment" shall be deemed to mean this Fourth Amendment, and all references in Section 3.2 of the Third Amendment to the "Extended Term" shall be deemed to mean the "Second Extended Term."</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Basic Monthly Rent</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding anything set forth in the Lease to the contrary, effective as of the date of this Fourth Amendment, during the Second Extended Term, Tenant shall pay monthly installments of Basic Monthly Rent for the Premises as follows: </font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.1875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:40%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Period During                   </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Second Extended Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Annual Basic Monthly Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Monthly Installment of</font><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Basic Monthly Rent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2018 -                           December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$3,694,880.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$307,906.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2019 -                   December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$3,805,726.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$317,143.90</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2020 -                  December 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$3,919,898.64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$326,658.22</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2021 -                   December 31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$4,037,495.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$336,457.96</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2022 -                December 31, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$4,158,620.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$346,551.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2023 -                 December 31, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$4,283,379.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$356,948.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2024 -                 December 31, 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$4,411,880.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$367,656.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 1, 2025 -                 December 31, 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$4,544,236.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$378,686.40</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Additional Rent</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall continue to be obligated to pay Additional Rent during the Second Extended Term.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Improvements</font><font style="font-family:inherit;font-size:11pt;">.  Tenant hereby acknowledges that Tenant is currently in possession of the Premises, and that neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises, the Building or the Project, or with respect to the suitability of any of the foregoing for the conduct of Tenant's business.  Tenant shall continue to accept the Premises in its "as is" condition as of the date of this Fourth Amendment.  Except as specifically set forth in this Fourth Amendment and the Work Letter attached hereto as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:11pt;">&#32;(the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Work Letter</font><font style="font-family:inherit;font-size:11pt;">"), and without waiving the Landlord's obligations pursuant to the Lease with respect to maintenance, repairs, replacements, alterations, and services as set forth in the Lease, including, without limitation, Landlord's obligations pursuant to the terms and conditions of Section 6.2.2 of the Original Lease, Landlord shall not be required to construct or pay for any improvements, alterations or refurbishment work for the Premises.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Termination Right</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exercise of Termination Right</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Tenant shall have the one-time right to terminate and cancel this Lease effective as of December 31, 2023 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Termination Date</font><font style="font-family:inherit;font-size:11pt;">"), provided that, not later than October 1, 2022, Landlord receives (i)&#160;written notice from Tenant (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Termination Notice</font><font style="font-family:inherit;font-size:11pt;">") that Tenant intends to terminate this Lease pursuant to the terms of this Section&#160;6, and (ii)&#160;cash in the amount of Three Million Two Hundred Seventy Thousand and No/100 Dollars ($3,270,000.00) (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Termination Fee</font><font style="font-family:inherit;font-size:11pt;">").  Upon Tenant's delivery of the Termination Notice to Landlord, all of Tenant's rights under Section&#160;3.2 of the Third Amendment, as amended by Section 3.2 of this Fourth Amendment (with respect to the Option Term), shall automatically terminate and be of no further force and effect regardless of whether this Lease thereafter shall be terminated in accordance with the terms of this Section&#160;6.  </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Termination of Lease</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Provided that Tenant timely elects to terminate the Lease in accordance with Section&#160;6.1, above, the Lease, as amended, shall automatically terminate and be of no further force or effect, and Landlord and Tenant shall be relieved of their respective obligations under the Lease, as amended, as of the Termination Date, except with respect to those obligations set forth in the Lease, as amended, which specifically survive the expiration or earlier termination of the Lease, including, without limitation, the payment by Tenant of all amounts owed by Tenant under the Lease, as amended, which accrue through and including the Termination Date.  The termination right contained in this Section&#160;6 shall be personal to the Original Tenant, as that term is defined in Section 3.2.1 of the Third Amendment, any "10.1.1 Transferee," as that term is defined in Section 8 of this Fourth Amendment, and any "Related Entity," as that term is defined in Section 10.1.1 of the Original Lease, and may only be exercised by Original Tenant, a 10.1.1 Transferee, or a Related Entity (and not by any other assignee, sublessee or other transferee).  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">No Tenant Default</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Notwithstanding anything to the contrary contained in this Section&#160;6, Tenant shall have no right to exercise the termination right set forth in this Section&#160;6 if Tenant is in material default under the Lease, as amended, beyond any applicable notice and cure period expressly set forth in Section 11.2 of the Original Lease, as of the date of Tenant's delivery to Landlord of the Termination Notice.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Broker</font><font style="font-family:inherit;font-size:11pt;">.  Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Fourth Amendment other than Kidder Mathews, representing Tenant, and CBRE, representing Landlord (collectively, the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Brokers</font><font style="font-family:inherit;font-size:11pt;">"), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Fourth Amendment.  Landlord shall pay the Brokers pursuant to a separate written agreement.  Each party agrees to indemnify and defend the other party for, from and against and hold the other party harmless for, from and against any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys' fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party.  The terms of this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;7</font><font style="font-family:inherit;font-size:11pt;">&#32;shall survive the expiration or earlier termination of the term of the Lease, as hereby amended.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Assignment and Subletting</font><font style="font-family:inherit;font-size:11pt;">.  Section 10.1.1(i) of the Original Lease is hereby amended and restated in its entirety as follows:  "to any corporation or other entity which is a successor to Tenant either by merger, consolidation or reincorporation (i.e., the incorporation of Tenant in a state other than California),".  The last two sentences of Section 10.1 of the Original Lease are hereby deleted.  Any person or entity that Tenant may assign the Lease, as amended, or sublease all or a portion of the Premises without Landlord's consent pursuant to the terms of Section 10.1.1 of the Original Lease, as amended, is referred to herein as a "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.1.1 Transferee</font><font style="font-family:inherit;font-size:11pt;">."  Section 10.3 of the Original Lease is hereby amended by inserting before the words "financial details" in the fifth line of said Section the following:  "except in connection with the sale of all or a portion of Tenant's business,".  Section 10.5 of the Original Lease is hereby amended by inserting after the word "assigned" in the first line of said Section the following:  "other than in connection with the sale of all or a portion of Tenant's business".</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Restoration</font><font style="font-family:inherit;font-size:11pt;">.  Landlord and Tenant hereby agree that, notwithstanding anything set forth in the Lease to the contrary, (a)&#160;Tenant shall not be required to remove any alterations or improvements or assets which are permanently affixed to the Premises as of the date of this Fourth Amendment, with the exception of the alterations and/or improvements and/or assets set forth on </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">, attached hereto (collectively, the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Removable Assets</font><font style="font-family:inherit;font-size:11pt;">"), and (b)&#160;Tenant shall, at Tenant's expense, remove, and shall have the right to remove, the Removable Assets and, in connection with such removal, Tenant shall restore the Premises to the extent set forth on </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:11pt;">&#32;attached hereto, as well as repair any physical damage to other areas of the Premises or the Building that occurs as a result of such removal (provided Tenant shall not be required to repair the floor coverings).    With respect to any additional alteration or improvement installed by Tenant after the date of this Fourth Amendment (collectively, "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Alterations</font><font style="font-family:inherit;font-size:11pt;">") other than the "Base Building Improvements" (as defined in Section 2.2 of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:11pt;">&#32;hereto), Landlord may, by written notice delivered to Tenant at least six (6) months prior to the expiration of the Lease, or given following any earlier termination of this Lease, require Tenant, at Tenant's expense, to remove same if, but only if, they are "Specialty Alterations", as that term is defined below, and to repair any damage to the Premises and Building caused by such removal and return the affected portion of the Premises to their condition existing prior to the installation of such Specialty Alterations as reasonably determined by Landlord; provided, however, that notwithstanding the foregoing, upon request by Tenant </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">at the time of Tenant's request for approval of any Alterations, Landlord shall notify Tenant whether or not the applicable Alteration constitutes a Specialty Alteration, as reasonably determined by Landlord, that will be required to be removed and if Landlord does not notify Tenant that removal will be required or if the item is not a Specialty Alteration, notwithstanding anything to the contrary, removal shall not be required.  If Tenant fails to complete any required removal and/or to repair any damage caused by the removal of any Specialty Alterations in the Premises and return the affected portion of the Premises to their condition existing prior to the installation of such Specialty Alterations, as reasonably determined by Landlord, prior to the expiration or earlier termination of this Lease, then Landlord shall have the right, but not the obligation, to perform such work and to charge the cost thereof to Tenant.  As used herein, "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Specialty Alterations</font><font style="font-family:inherit;font-size:11pt;">" shall mean any Alteration that (a) is not a normal and customary general office improvement and would reasonably be anticipated to cost materially more to demolish than normal and customary general office improvements, or (b) includes any of the following: (i) any improvement that perforates (other than by virtue of being bolted or similarly attached), penetrates (other than by virtue of being bolted or similarly attached) or requires reinforcement of a floor slab (including, without limitation, interior stairwells or high-density filing or racking systems), (ii) any improvement that consists of the installation of a raised flooring system, (iii) any improvement that consists of the installation of a vault or other similar device or system intended to secure the Premises or a portion thereof in a manner that exceeds the level of security necessary for ordinary office space, (iv) any improvement that involves material plumbing connections (such as, for example but not by way of limitation, kitchens (other than customary break-rooms with a refrigerator, sink and dishwasher), cafeteria, saunas, showers, and executive bathrooms outside of the Building core and/or special fire safety systems), or (v) any improvement that can be seen from outside the Premises; provided, however, in no event shall any Alteration that is materially consistent with any alterations or improvements or assets which are permanently affixed to the Premises as of the date of this Fourth Amendment, but which are not deemed Removable Assets pursuant to the terms of this Section 9, be deemed a Specialty Alteration.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Work Letter</font><font style="font-family:inherit;font-size:11pt;">.  Landlord and Tenant hereby agree to the terms of the Work Letter attached hereto as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">, the terms of which are hereby incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:11pt;">.  Paragraph 1 of the First Amendment (amending Section 6.4.2 of the Original Lease) is hereby deleted in its entirety and the terms of Section 6.4.2 of the Original Lease are restored in its entirety.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Estoppels</font><font style="font-family:inherit;font-size:11pt;">.  The following is hereby added as Section 12.4.3 of the Original Lease:  "Upon Tenant's written request, Landlord shall execute, acknowledge and deliver to Tenant a written statement certifying if true (or if not, stating why):  (i) that none of the terms or provisions of this Lease have been changed (or if they have been changed, stating how they have been changed); (ii) that this Lease has not been cancelled or terminated; (iii) the last date of payment of the Basic Monthly Rent and other charges and the time period covered by such payment; and (iv) that to Landlord's knowledge Tenant is not in default under this Lease (or, if Tenant is claimed to be in default, stating why).  Landlord shall deliver such statement to Tenant within ten (10) business days after Tenant's request.  Any such statement by Landlord shall be addressed to Tenant, or at Tenant's request, to its lender, a purchaser of Tenant, an assignee of this Lease or subtenant of Tenant, or if such certification is required by Tenant's auditor or to an underwriter in connection with a public offering of stock or otherwise if required by the Securities and Exchange Commission; provided such third-party entity is named in the certification, and such third party may rely conclusively upon such statement as true and correct.  If Landlord does not deliver such statement to Tenant within such ten (10) business day period, any such named third party may conclusively presume and rely upon the following facts:  (i) that the terms and provisions of the Lease have not been changed except as otherwise represented by Tenant; (ii) that this Lease has not been cancelled or terminated except as otherwise represented by Tenant; (iii) that not more than one month's Basic Monthly Rent or other charges have been paid in advance; and (iv)&#160;that Tenant is not in default under the Lease.  Landlord shall, within ten (10) business days following Tenant's written request, certify to Tenant and any transferee or lender of Tenant, if true, that to Landlord's knowledge there are no uncured defaults in Tenant's performance under this Lease."</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">No Default</font><font style="font-family:inherit;font-size:11pt;">.  To Tenant's knowledge, as of the date of this Fourth Amendment, Landlord is not in default (nor does a situation exist which, with the passage of time, the giving of notice, or both, would constitute a default) under any of the terms or provisions of the Lease.  To Landlord's knowledge, as of the date of this Fourth Amendment, Tenant is not in default (nor does a situation exist which, with the passage of time, the giving of notice, </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">or both, would constitute a default) and there are no Monetary Defaults under any of the terms or provisions of the Lease, as hereby amended.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:11pt;">. This Lease may be executed in counterparts with the same effect as if both parties hereto had executed the same document.  Both counterparts shall be construed together and shall constitute a single lease.  In addition, the parties hereto consent and agree that this document may be signed and/or transmitted by facsimile or e-mail of a .pdf document, and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party's handwritten signature.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">No Further Modification</font><font style="font-family:inherit;font-size:11pt;">.  Except as specifically set forth in this Fourth</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Amendment, all of the terms and provisions of the Lease shall remain unmodified and in full force and effect.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[signature page to follow]</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, this Fourth Amendment has been executed as of the day and year first above written.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:46%;"></td><td style="width:54%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LANDLORD</font><font style="font-family:inherit;font-size:11pt;">"</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">LASDK LIMITED PARTNERSHIP,</font></div><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a Delaware limited partnership</font></div><div style="padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: HCP-Torrey Pines I, Inc.,</font></div><div style="text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a Delaware corporation,</font></div><div style="text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">its Managing General Partner</font></div><div style="text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Michael Dorris</font></div><div style="text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Michael Dorris</font></div><div style="padding-left:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Its:  Vice President</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TENANT</font><font style="font-family:inherit;font-size:11pt;">"</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PACIRA PHARMACEUTICALS, INC.,</font></div><div style="padding-top:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a California corporation </font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Kristen Williams</font></div><div style="padding-left:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Kristen Williams</font></div><div style="padding-left:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Its:  CAO, General Counsel and Secretary</font></div><div style="padding-top:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Daina Borteck</font></div><div style="padding-left:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Daina Borteck</font></div><div style="padding-left:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Its:  Associate General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">WORK LETTER</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Work Letter shall set forth the terms and conditions relating to the construction of the tenant improvements in the Premises.  This Work Letter is essentially organized chronologically and addresses the issues of the construction of the Premises, in sequence, as such issues will arise during the actual construction of the Premises.  All references in this Work Letter to Articles or Sections of "this Fourth Amendment" shall mean the relevant portion of the Fourth Amendment to which this Work Letter is attached as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:11pt;">&#32;and of which this Work Letter forms a part, and all references in this Work Letter to Sections of "this Work Letter" shall mean the relevant portion of </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sections&#160;1</font><font style="font-family:inherit;font-size:11pt;">&#32;through </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">5</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter.  All references in this Work Letter to the "Lease" shall mean the relevant portions of the Lease as defined in the Fourth Amendment.  All references herein to "Premises" shall mean the "Premises," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;1.5</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Original Lease.  Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Fourth Amendment.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SECTION&#160;1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">PREMISES AND BASE BUILDING; LANDLORD WORK</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Premises and Base Building</font><font style="font-family:inherit;font-size:11pt;">.  Except as expressly set forth in this Work Letter or in the Fourth Amendment, and without waiving the Landlord's obligations pursuant to the Lease with respect to maintenance, repairs, replacements, alterations, and services as set forth in the Lease, including, without limitation, Landlord's obligations pursuant to the terms and conditions of Section 6.2.2 of the Original Lease, Tenant shall continue to accept the Premises from Landlord in its presently existing, "as-is" condition.  Notwithstanding anything set forth in the Lease to the contrary, but subject to the terms of Section 1.2, below, if and when Tenant commences work on an element of the "Base Building Improvements," as that term is defined in Section 2, below, Tenant shall be required to complete such work in a commercially expeditious manner in accordance with applicable building codes and other governmental laws, ordinances and regulations, including without limitation any work related to handicap access that arises in connection with Tenant's construction of the Base Building Improvements or in connection with Tenant's receipt of the "permits," as that term is defined in Section 3.4, below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Landlord Work</font><font style="font-family:inherit;font-size:11pt;">.  Landlord and Tenant acknowledge and agree that Tenant currently has permits issued by the City of San Diego that remain open as of the date of this Fourth Amendment (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Existing Permits</font><font style="font-family:inherit;font-size:11pt;">").  In order to close the Existing Permits, Landlord shall, at Landlord's sole cost and expense, as soon as is commercially reasonably practical, complete the Building parking and entry handicap accessibility work set forth on Schedule 1, attached hereto.  Tenant shall complete any work that is not set forth on Schedule 1 to the extent required to close the Existing Permits.  From and after the date the Existing Permits have been closed, Landlord shall, to the extent required in order to allow Tenant to obtain a certificate of occupancy, or its legal equivalent, for the Premises for general office use assuming a normal and customary office occupancy density, or to the extent required in order for Tenant to obtain the "Permits," as that term is defined in Section 3.4, below, cause the exterior of the Building and the areas of the Project located outside of the Building, to comply with applicable building codes and other governmental laws, ordinances and regulations related to handicap access, which were enacted and enforced as of the date of this Fourth Amendment. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SECTION&#160;2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">TENANT IMPROVEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.1&#160;&#160;&#160;&#160;[Intentionally Omitted.]</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Base Building Allowance</font><font style="font-family:inherit;font-size:11pt;">.  Tenant may elect to construct all or a portion of the "Base Building Improvements," as that term is defined below.  If Tenant elects to construct all or a portion of the Base Building Improvements, then, subject to the terms and conditions set forth in this Section 2.2, Tenant shall be entitled to an improvement allowance in an amount not to exceed Two Million Five Hundred Thirty Thousand Seven Hundred Forty </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and No/100 Dollars ($2,530,740.00.00) (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Base Building Allowance</font><font style="font-family:inherit;font-size:11pt;">") solely for the work to the "Building Systems," as that term is defined below (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Base Building Improvements</font><font style="font-family:inherit;font-size:11pt;">" or the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tenant Improvements</font><font style="font-family:inherit;font-size:11pt;">"), set forth on Schedule 2, attached hereto.  As used herein, the term "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Building Systems</font><font style="font-family:inherit;font-size:11pt;">" shall mean the mechanical, electrical, life safety, plumbing, sprinkler and HVAC systems of the Building.  Tenant shall have no obligation to complete all of the Base Building Improvements and may elect to apply the Base Building Allowance to one or a combination of the Base Building Improvements as Tenant deems appropriate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Disbursement of the Base Building Allowance</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Base Building Allowance Items</font><font style="font-family:inherit;font-size:11pt;">.  Except as otherwise set forth in this Work Letter, the Base Building Allowance shall be disbursed by Landlord only for the following items and costs (collectively the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Base Building Allowance Items</font><font style="font-family:inherit;font-size:11pt;">"):  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.1&#160;&#160;&#160;&#160;Payment of the fees of the "Architect," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;3.1</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter, which fees shall, notwithstanding anything to the contrary contained in this Work Letter, not exceed an aggregate amount equal to $5.00 per rentable square foot of the Building, and payment of the fees incurred by, and the cost of documents and materials supplied by, Landlord and Landlord's consultants in connection with the preparation and review of the "Construction Drawings," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;3.1</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.2&#160;&#160;&#160;&#160;The payment of plan check, permit and license fees relating to construction of the Base Building Improvements;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.3&#160;&#160;&#160;&#160;The cost of the purchasing, construction, and installation of the Base Building Improvements, including, without limitation, testing and inspection costs, freight elevator usage, hoisting and trash removal costs, and contractors' fees and general conditions;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.4&#160;&#160;&#160;&#160;The cost of any changes in the Base Building when such changes are required by the Base Building Improvements (including if such changes are due to the fact that such work is prepared on an unoccupied basis), such cost to include all direct architectural and/or engineering fees and expenses incurred in connection therewith;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.5&#160;&#160;&#160;&#160;The cost of any changes to the Base Building Improvements required by all applicable building codes (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Code</font><font style="font-family:inherit;font-size:11pt;">");</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.6&#160;&#160;&#160;&#160;The cost of the "Coordination Fee," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;4.2.2</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.7&#160;&#160;&#160;&#160;Sales and use taxes and Title 24 fees; and</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.1.8&#160;&#160;&#160;&#160;All other actual and reasonable out-of-pocket costs expended by Landlord in connection with the construction of the Base Building Improvements.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Disbursement of Base Building Allowance</font><font style="font-family:inherit;font-size:11pt;">.  During the construction of the Base Building Improvements, Landlord shall make monthly disbursements of the Base Building Allowance for Base Building Allowance Items for the benefit of Tenant and shall authorize the release of monies for the benefit of Tenant as follows.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.2.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Monthly Disbursements</font><font style="font-family:inherit;font-size:11pt;">.  On or before the fifth (5</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) day of each calendar month, during the construction and installation of the Base Building Improvements, Tenant shall deliver to Landlord (a "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Payment Request</font><font style="font-family:inherit;font-size:11pt;">"):  (i)&#160;a request for payment of the "Contractor," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;4.1</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter, approved by Tenant, in a form to be provided by Landlord, showing the schedule, by trade, of percentage of completion of the Base Building Improvements in the Premises, detailing the portion of the work completed and the portion not completed; (ii)&#160;invoices from all of "Tenant's Agents," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;4.1.2</font><font style="font-family:inherit;font-size:11pt;">&#32;of this Work Letter, for labor rendered and materials delivered to the Premises; (iii)&#160;executed mechanic's lien releases, if applicable, from all of Tenant's Agents which shall comply with the appropriate provisions, as reasonably determined by Landlord, of California Civil Code Sections&#160;8132, 8134, 8136 and 8138; and (iv)&#160;all other information reasonably requested by </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Landlord.  Payment requests must be submitted electronically to hcpinvoices_SD@pmainc.com, and must contain the project name and PMA project number.  Within forty-five (45) days after Landlord's receipt of a Payment Request, Landlord shall deliver a check payable to Tenant in payment of the lesser of:  (A)&#160;the amounts so requested by Tenant, as set forth in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;2.2.2.1</font><font style="font-family:inherit;font-size:11pt;">, above, less a ten percent (10%)&#160;retention on the cost of the work being performed under the "Contract," as that term is defined in Section 4.2.1, below (the aggregate amount of such retentions to be known as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Final Retention</font><font style="font-family:inherit;font-size:11pt;">"); provided, however, if the amount requested by Tenant is already reduced by a ten percent (10%) retention, then Landlord shall pay one hundred percent (100%) of the amount requested by Tenant and shall then internally allocate ten percent (10%) of the amount due to the Contractor but not requested to the Final Retention, and (B)&#160;the balance of any remaining available portion of the Base Building Allowance (not including the Final Retention), provided that Landlord does not dispute any request for payment based on non-compliance of any work with the "Approved Working Drawings," as that term is defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;3.4</font><font style="font-family:inherit;font-size:11pt;">&#32;below, or due to any substandard work, or for any other reason.  Landlord's payment of such amounts shall not be deemed Landlord's approval or acceptance of the work furnished or materials supplied as set forth in Tenant's payment request.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.2.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Final Retention</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the provisions of this Work Letter, a check for the Final Retention payable to Tenant shall be delivered by Landlord to Tenant following the completion of construction of the Base Building Improvements, provided that (i)&#160;Tenant delivers to Landlord properly executed mechanics lien releases in compliance with California Civil Code Section&#160;8138, (ii)&#160;Landlord has determined that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building, the curtain wall of the Building, the structure or exterior appearance of the Building, or any other tenant's use of such other tenant's leased premises in the Building and (iii)&#160;Architect delivers to Landlord a certificate, in a form reasonably acceptable to Landlord, certifying that the construction of the Base Building Improvements in the Premises has been substantially completed.  To the extent the Base Building Improvements are completed in different phases, with each such phase being subject to a separate "Contract," as that term is defined in Section 4.2.1, below, then Landlord shall disburse the Final Retention to Tenant separately as to each such Contract once the terms and conditions set forth in this Section 2.3.2.2 have been satisfied with respect to such Contract.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.3.2.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Other Terms</font><font style="font-family:inherit;font-size:11pt;">.  Landlord shall only be obligated to make disbursements from the Base Building Allowance to the extent costs are incurred by Tenant for Base Building Allowance Items.  All Base Building Improvements shall be deemed Landlord's property under the terms of the Lease and, notwithstanding anything set forth in the Lease to the contrary, Tenant shall not have the right nor shall Tenant be required to remove same.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECTION&#160;3</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">CONSTRUCTION DRAWINGS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Selection of Architect/Construction Drawings</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall retain one or more architects/space planners and/or engineers designated by Tenant and reasonably approved by Landlord (collectively and individually, the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Architect</font><font style="font-family:inherit;font-size:11pt;">") to prepare the "Construction Drawings," as that term is defined in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;3.1</font><font style="font-family:inherit;font-size:11pt;">.  The plans and drawings to be prepared by the Architect hereunder shall be known collectively as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Construction Drawings</font><font style="font-family:inherit;font-size:11pt;">."  All Construction Drawings shall comply with the drawing format and specifications reasonably determined by Landlord, and shall be subject to Landlord's approval, which shall not be unreasonably withheld, delayed or conditioned.  Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the base building plans, and Tenant and Architect shall be solely responsible for the same, and Landlord shall have no responsibility in connection therewith.  Landlord's review of the Construction Drawings as set forth in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;3</font><font style="font-family:inherit;font-size:11pt;">, shall be for its sole purpose and shall not imply Landlord's review of the same, or obligate Landlord to review the same, for quality, design, Code compliance or other like matters.  Accordingly, notwithstanding that any Construction Drawings are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance which may be rendered to Tenant by Landlord or Landlord's space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith and shall not be responsible for any omissions or errors contained in the Construction Drawings, and Tenant's waiver and indemnity set forth in the Lease shall specifically apply to the Construction Drawings.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.2&#160;&#160;&#160;&#160;[Intentionally Omitted.]</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Final Working Drawings</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall supply the Architect with a complete listing of standard and non-standard equipment and specifications, including, without limitation, B.T.U. calculations, electrical requirements and special electrical receptacle requirements for the Premises, to enable the Architect to complete the "Final Working Drawings" (as that term is defined below) in the manner as set forth below.  If applicable, Tenant shall promptly cause the Architect to complete the architectural and engineering drawings for the Premises, and Architect shall compile a fully coordinated set of architectural, structural, mechanical, electrical and plumbing working drawings in a form which is complete to allow subcontractors to bid on the work and to obtain all applicable permits (collectively, the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Final Working Drawings</font><font style="font-family:inherit;font-size:11pt;">") and shall submit the same to Landlord for Landlord's approval.  Tenant shall supply Landlord with electronic (both CADD (computer-aided design and drafting) files) and .pdf) copies of such Final Working Drawings.  Landlord shall advise Tenant within five (5) business days after Landlord's receipt of the Final Working Drawings for the Premises if the same is unsatisfactory or incomplete in any respect.  If Tenant is so advised, Tenant shall promptly revise the Final Working Drawings in accordance with such review and any disapproval of Landlord in connection therewith.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Approved Working Drawings</font><font style="font-family:inherit;font-size:11pt;">.  The Final Working Drawings shall be approved by Landlord (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Approved Working Drawings</font><font style="font-family:inherit;font-size:11pt;">") prior to the commencement of construction by Tenant.  After approval by Landlord of the Final Working Drawings, Tenant may submit the same to the appropriate municipal authorities for all applicable building permits (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Permits</font><font style="font-family:inherit;font-size:11pt;">").  Tenant hereby agrees that neither Landlord nor Landlord's consultants shall be responsible for obtaining any building permit or certificate of occupancy for the Premises and that obtaining the same shall be Tenant's responsibility; provided, however, that Landlord shall cooperate with Tenant in executing permit applications and performing other ministerial acts reasonably necessary to enable Tenant to obtain any such permit or certificate of occupancy.  No changes, modifications or alterations in the Approved Working Drawings may be made without the prior written consent of Landlord, which consent may not be unreasonably withheld, delayed or conditioned.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SECTION&#160;4</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">CONSTRUCTION OF THE TENANT IMPROVEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Tenant's Selection of Contractors</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">The Contractor</font><font style="font-family:inherit;font-size:11pt;">.  One or more contractors shall be retained by Tenant to construct the Tenant Improvements.  Such contractors (collectively and individually, "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contractor</font><font style="font-family:inherit;font-size:11pt;">") shall be selected by Tenant and approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.  Subject to such contractors complying with the terms of Section 4.1.3, below, the following contractors are hereby preapproved by Landlord as a Contractor:  AO&#160;Reed, Pacrim, AMC, University Mechanical and Siemens.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tenant's Agents</font><font style="font-family:inherit;font-size:11pt;">.  All subcontractors, laborers, materialmen, and suppliers used by Tenant (such subcontractors, laborers, materialmen, and suppliers, and the Contractor to be known collectively as "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tenant's Agents</font><font style="font-family:inherit;font-size:11pt;">") shall be subject to Landlord's approval, which approval shall not be unreasonably withheld, conditioned or delayed.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Union Labor</font><font style="font-family:inherit;font-size:11pt;">.  Tenant covenants and agrees that all contractors and subcontractors at any tier performing any construction, repair, refurbishment or restoration, including, without limitation, tenant improvements, build-out, alterations, additions, improvements, renovations, repairs, remodeling, painting and installations of fixtures, mechanical, electrical, plumbing, data, security, telecommunication, low voltage or elevator equipment or systems or other equipment, or with respect to any other construction work in, on, or to the Premises (including any such work performed by any person who contracts to provide services to any portion of  the Premises, such as cable, DSL, communications, telecommunications or similar services) shall: (i) be bound by and signatory to a collective bargaining agreement with a labor organization (a) whose jurisdiction covers the type of work to be performed on the Premises, and (b) who is an Approved Building Trades Department Contractor or Subcontractor (as hereinafter defined); and (ii) observe area standards for wages and other terms and conditions of employment, including fringe benefits.  For purposes hereof, an "</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Approved Building Trades Department Contractor or Subcontractor</font><font style="font-family:inherit;font-size:11pt;">" is a contractor or subcontractor who is currently affiliated with the Building and Construction Trades Department of the AFL-CIO (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">BCTD</font><font style="font-family:inherit;font-size:11pt;">") or, if no such BCTD-affiliated contractor or subcontractor is available for a particular trade (e.g., carpentry work), a contractor </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">or subcontractor which is affiliated with a national trade union which was formerly affiliated with the BCTD and which recognizes (and will recognize and respect, for its work on the Premises), the jurisdictional limitations established by the local BCTD.  The foregoing requirements shall be referred to as the &#8220;Labor Requirements.&#8221; Notwithstanding the foregoing, the Labor Requirements shall not be applicable with respect to (i) the installation, repair and maintenance of equipment and systems where the manufacturer or vendor thereof requires or recommends that such work be performed by its own personnel or approved subcontractors in order to comply with warranty, quality control or similar requirements of the manufacturer or vendor, (ii) specialized work required as a result of the regulated and quality controlled nature of Tenant&#8217;s manufacturing activities where no reasonably acceptable and qualified Approved Building Trades Department Contractor or Subcontractor is available to perform such work on a reasonable and practicable basis, (iii) where a qualified Approved Building Trades Department Contractor or Subcontractors for the trade in question is not generally available on a reasonable and practicable basis in the locale where the Building is located, and (iv) the Electrical Exception Work (as defined below), provided that (A) with respect to the exception noted in subclause (i), above, such exception is only available to the extent necessary to meet the requirements or recommendations of the corresponding manufacturer or vendor, and all other work related thereto (e.g., without limitation, the pulling of cables, &#8220;behind the wall&#8221; work, etc&#8230;) shall otherwise be performed in accordance with the Labor Requirements; (B) with respect to each of the exceptions provided for in subclauses (ii) and (iii), such exceptions shall not apply to electrical related work, including, without limitation, low voltage, communications, telecommunications, DSL, cable and other related services and work other than Electrical Exception Work; and (C) with respect to each of the exceptions provided for in subclauses (i) - (iii), above , the work in question shall be performed in such a manner as to maintain, to the greatest extent practicable, labor peace and harmony. &#8220;Electrical Exception Work&#8221; shall be defined as low voltage, signal wiring and teledata work that is to be performed as a part of an integrated system, installation or service where the requirement to use an Approved Building Trades Department Contractor or Subcontractor could reasonably be expected to (X) result in material delay, (Y) result in a material risk of adding expense, delay or uncertainty in Tenant&#8217;s ability to determine and/or impose responsibility on a manufacturer, vendor, contractor or subcontractor for inadequate, deficient or non-conforming work, or (Z) which would require that the electrical contractor or subcontractor be granted access to information/content on Tenant&#8217;s servers, provided, that if Tenant seeks to assert the Electrical Exception Work, (i) Tenant shall promptly notify Landlord in writing and enter into good faith discussions with Landlord regarding Tenant&#8217;s concerns; (ii) Landlord shall be given a reasonable opportunity in the context of the given issue to address the Tenant&#8217;s concerns such that an Approved Building Trades Contractor or Subcontractor can be engaged for such scope of work; and (iii) Landlord and Tenant will act reasonably and in good faith in such matter, recognizing the Landlord&#8217;s interest in maximizing the use of contractors and subcontractors that are Approved Building Trades Contractors or Subcontractors. In connection with the application of this provision, Landlord shall respond promptly to any request by Tenant for confirmation that a particular scope of proposed work is or is not subject to the use of an Approved Building Trades Contractor or Subcontractor.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Construction of Tenant Improvements by Tenant's Agents</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Construction Contract; Cost Budget</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall deliver a copy of each construction contract and general conditions that Tenant executes with a Contractor (each, a "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contract</font><font style="font-family:inherit;font-size:11pt;">").  Prior to the commencement of the construction of the Tenant Improvements, and after Tenant has accepted all bids for the Tenant Improvements, Tenant shall provide Landlord with a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred, in connection with the design and construction of the Tenant Improvements to be performed by or at the direction of Tenant or the Contractor, which costs form a basis for the amount of the Contract (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Final Costs</font><font style="font-family:inherit;font-size:11pt;">").  Notwithstanding anything set forth in this Work Letter to the contrary, on-site construction of the Tenant Improvements shall not commence until (a)&#160;Landlord has received a copy of the Contract, and (b) Tenant has submitted the Approved Working Drawings to the appropriate municipal authorities for all applicable Permits (provided that Tenant shall procure and deliver to Landlord a copy of all Permits prior to the first inspection in connection with the Tenant Improvements).  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tenant's Agents</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Landlord's General Conditions for Tenant's Agents and Tenant Improvement Work</font><font style="font-family:inherit;font-size:11pt;">.  Tenant's and Tenant's Agent's construction of the Tenant Improvements shall comply with the following:  (i)&#160;the Tenant Improvements shall be constructed in strict accordance with the Approved Working Drawings; and (ii)&#160;Landlord's rules and regulations reasonably established by Landlord for the construction of improvements in the Building, a copy of </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">which is attached to the Fourth Amendment as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall pay a logistical coordination fee (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Coordination Fee</font><font style="font-family:inherit;font-size:11pt;">") to Landlord in an amount equal to the actual and reasonably out-of-pocket costs incurred by Landlord for the services of Landlord's representative, as set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.2</font><font style="font-family:inherit;font-size:11pt;">, below, not to exceed an amount equal to one and one-half percent (1&#189;%) of the Base Building Allowance and any other amounts expended by Tenant in connection with the design and construction of the Tenant Improvements (collectively, the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Total TI Cost</font><font style="font-family:inherit;font-size:11pt;">"), which Coordination Fee shall be for services relating to the coordination of the construction of the Tenant Improvements.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Indemnity</font><font style="font-family:inherit;font-size:11pt;">.  Tenant's indemnity of Landlord as set forth in the Lease shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to any negligent act or omission of Tenant or Tenant's Agents, or anyone directly or indirectly employed by any of them, or in connection with Tenant's non-payment of any amount arising out of the Tenant Improvements and/or Tenant's disapproval of all or any portion of any request for payment.  Such indemnity by Tenant, as set forth in the Lease, shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to Landlord's performance of  any ministerial acts reasonably necessary (i)&#160;to permit Tenant to complete the Tenant Improvements, and (ii)&#160;to enable Tenant to obtain any building permit or certificate of occupancy for the Premises.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Requirements of Tenant's Agents</font><font style="font-family:inherit;font-size:11pt;">.  Each of Tenant's Agents shall guarantee to Tenant and for the benefit of Landlord that the portion of the Tenant Improvements for which it is responsible shall be free from any defects in workmanship and materials for a period of not less than one (1) year from the date of completion thereof.  Each of Tenant's Agents shall be responsible for the replacement or repair, without additional charge, of all work done or furnished in accordance with its contract that shall become defective within one (1) year after the completion of the work performed by such contractor or subcontractors.  The correction of such work shall include, without additional charge, all additional expenses and damages incurred in connection with such removal or replacement of all or any part of the Tenant Improvements, and/or the Building and/or common areas that may be damaged or disturbed thereby.  All such warranties or guarantees as to materials or workmanship of or with respect to the Tenant Improvements shall be contained in the Contract or subcontract and shall be written such that such guarantees or warranties shall inure to the benefit of both Landlord and Tenant, as their respective interests may appear, and can be directly enforced by either.  Tenant covenants to give to Landlord any assignment or other assurances which may be necessary to effect such right of direct enforcement.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Insurance Requirements</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:208px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.4.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General Coverages</font><font style="font-family:inherit;font-size:11pt;">.  All of Tenant's Agents that are on site shall, at a minimum, carry the insurance set forth on the last page of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">&#32;to the Fourth Amendment.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:208px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.4.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Special Coverages</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall carry, or cause to be carried by its contractors, "Builder's All Risk" insurance in an amount approved by Landlord covering the construction of the Tenant Improvements, it being understood and agreed that the Tenant Improvements shall be insured by Tenant's commercial property insurance pursuant to the Lease immediately upon completion thereof.  Tenant shall also maintain Products and Completed Operation Coverage insurance in an amount of not less than $5,000,000 per incident, $5,000,000 in aggregate, and in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:208px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.2.4.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General Terms</font><font style="font-family:inherit;font-size:11pt;">.  Certificates, evidencing required coverage under Exhibit C for contractors, along with copies of additional insured endorsement (providing additional insured status for ongoing and completed operations coverage) on the general liability policy are required.  Waiver of subrogation by form of endorsement on the builders risk and workers compensation policies shall also be required in favor of Landlord.  All insurance carried pursuant to this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;4.2.2.4</font><font style="font-family:inherit;font-size:11pt;">&#32;shall be confirmed via certificate of insurance and applicable endorsements to Landlord before the commencement of on-site construction of the Tenant Improvements and before the Contractor's equipment is moved onto the site.  Tenant or Tenant's Agents will give Landlord thirty (30) days prior written notice of any cancellation or lapse of the effective date or any reduction in the amounts of such insurance that falls below the minimum insurance requirements within this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 4.2.2.4</font><font style="font-family:inherit;font-size:11pt;">.  In the event that the Tenant Improvements are damaged by any cause during the course of the construction thereof, Tenant shall immediately repair the same at Tenant's sole cost and expense.  Tenant's Agents shall maintain all of the insurance coverage required under this </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">&#32;and </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">&#32;in force until the Tenant Improvements are fully completed and accepted by Landlord, except, </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">notwithstanding anything to the contrary on </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">, for Tenant's Agents' Products and Completed Operation Coverage insurance required by Landlord, which is to be maintained for a period equal to or greater than the applicable statute of repose for completed operations.  General liability policies required under this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 4.2.2.4</font><font style="font-family:inherit;font-size:11pt;">&#32;by Tenant and Tenant's Agents shall name Landlord and Tenant, as their interests may appear, as additional insureds.  All insurance maintained by Tenant's Agents shall preclude subrogation claims by the insurer against anyone insured thereunder.  Such waiver of subrogation shall apply to the extent of any deductibles, self-insured retentions or self-insurance maintained by Tenant, Tenant&#8217;s Agents and contractors.  Such insurance required of Tenant's Agents shall provide that it is primary insurance as respects the owner and that any other insurance maintained by owner is excess and noncontributing with the insurance required hereunder.  The general liability insurance required within this provision will include contractual liability coverage. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governmental Compliance</font><font style="font-family:inherit;font-size:11pt;">.  The Tenant Improvements shall comply in all respects with the following to the extent applicable:  (i)&#160;the Code and other state, federal, city or quasi-governmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person; (ii)&#160;applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code; and (iii)&#160;building material manufacturer's specifications.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Inspection by Landlord</font><font style="font-family:inherit;font-size:11pt;">.  Tenant shall provide Landlord with reasonable prior notice of any inspection to be performed by a governmental entity in connection with the construction of the Tenant Improvements (provided that Tenant has prior notice of such inspection) in order to allow Landlord to be present during such inspection.  Landlord shall have the right to inspect the Tenant Improvements at all times, provided however, that Landlord's failure to inspect the Tenant Improvements shall in no event constitute a waiver of any of Landlord's rights hereunder nor shall Landlord's inspection of the Tenant Improvements constitute Landlord's approval of the same.  Should Landlord disapprove any portion of the Tenant Improvements for failure to comply with the requirements hereof or with the Approved Working Drawings, Landlord shall notify Tenant in writing of such disapproval and shall specify the items disapproved.  Any defects or deviations in, and/or disapproval by Landlord for failure to comply with the requirements hereof or with the Approved Working Drawings of, the Tenant Improvements shall be rectified by Tenant at no expense to Landlord, provided however, that in the event Landlord reasonably determines that a defect or deviation exists or disapproves of any matter in connection with any portion of the Tenant Improvements and such defect, deviation or matter might adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life-safety systems of the Building, the structure or exterior appearance of the Building, Landlord may, take such action as Landlord deems necessary, at Tenant's expense and without incurring any liability on Landlord's part, to correct any such defect, deviation and/or matter, including, without limitation, causing the cessation of performance of the construction of the Tenant Improvements until such time as the defect, deviation and/or matter is corrected to Landlord's satisfaction.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2.5&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:11pt;">.  Once any on-site work commences, Tenant shall hold monthly meetings at a reasonable time with Landlord, which meetings may include Landlord's  agents, the Architect and/or the Contractor, for the purpose of reviewing any request by Tenant for a disbursement of the Base Building Allowance (and any documentation required in connection therewith).  In addition, once any on-site work commences, minutes shall be taken by Tenant at all meetings between Tenant and the Architect and/or the Contractor to the extent that such meetings update the major objectives, schedule and activities in connection with the design and construction of the Base Building Improvements or Tenant Improvements (not including on-site inspections of the work being performed by such Contractor), a copy of which minutes shall be promptly delivered to Landlord.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notice of Completion; Copy of Record Set of Plans</font><font style="font-family:inherit;font-size:11pt;">.  Within ten (10) days after completion of construction of the Tenant Improvements, Tenant shall cause a Notice of Completion to be recorded in the office of the Recorder of the county in which the Building is located in accordance with Section&#160;3093 of the Civil Code of the State of California or any successor statute, and shall furnish a copy thereof to Landlord upon such recordation.  If Tenant fails to do so, Landlord may execute and file the same on behalf of Tenant as Tenant's agent for such purpose, at Tenant's sole cost and expense.  At the conclusion of construction, (i)&#160;Tenant shall cause the Architect and Contractor (A)&#160;to update the Approved Working Drawings as necessary to reflect all changes made to the Approved Working Drawings during the course of construction, (B)&#160;to certify to the best of their knowledge that the "record-set" of as-built drawings are true and correct, which certification shall survive the expiration or termination of the Lease, and </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(C)&#160;to deliver to Landlord copies of such record set of drawings in electronic form (in CADD and .pdf format) within ninety (90) days following issuance of a certificate of occupancy for the Premises, and (ii)&#160;Tenant shall deliver to Landlord a copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems in the Premises.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SECTION&#160;5</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tenant's Representative</font><font style="font-family:inherit;font-size:11pt;">.  Tenant has designated Ryan Shore  as its representative with respect to the matters set forth in this Work Letter, who shall have full authority and responsibility to act on behalf of the Tenant as required in this Work Letter.  Tenant shall have the right to designate one or more additional or substitute representatives upon notice to Landlord, each whom, once so designated by Tenant, shall have full authority and responsibility to act on behalf of the Tenant as required in this Work Letter.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Landlord's Representative</font><font style="font-family:inherit;font-size:11pt;">.  Landlord has designated Project Management Advisors, Inc. ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PMA</font><font style="font-family:inherit;font-size:11pt;">") as a third party project manager for construction oversight of the Tenant Improvements on behalf of Landlord, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Work Letter.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Time of the Essence in This Work Letter</font><font style="font-family:inherit;font-size:11pt;">.  Unless otherwise indicated, all references herein to a "number of days" shall mean and refer to calendar days.  If any item requiring approval is timely disapproved by Landlord, the procedure for preparation of the document and approval thereof shall be repeated until the document is approved by Landlord.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tenant's Lease Default</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding any provision to the contrary contained in the Lease, if an event of default as described in the Lease or this Work Letter has occurred at any time and continues beyond applicable notice or cure periods and before the Substantial Completion of the Premises, then (i)&#160;in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to withhold payment of all or any portion of the Base Building Allowance and/or Landlord may cause Contractor to cease the construction of the Premises (in which case, Tenant shall be responsible for any delay in the substantial completion of the Premises caused by such work stoppage), and (ii)&#160;all other obligations of Landlord under the terms of this Work Letter shall be forgiven until such time as such default is cured pursuant to the terms of the Lease (in which case, Tenant shall be responsible for any delay in the substantial completion of the Premises caused by such inaction by Landlord).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SCHEDULE 1 TO EXHIBIT A</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">LANDLORD WORK</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The work set forth on those certain Building 1 Refresh Project cGMP Areas Upgrade, prepared by Ferguson Pape Baldwin Architects, Construction Change dated June 21, 2017, consisting of the following sheets:</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;Title Sheet - T1.1-P3</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;Site Plan - A1.1-Ps</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;Enlarged Site Plan - A1.2-P3</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;Civil Title Sheet - C1.0</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.&#160;&#160;&#160;&#160;Demolition &amp; Improvement Plan - C2.0</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.&#160;&#160;&#160;&#160;Erosion Control &amp; Minor Water Pollution Control Plan - C3.0</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SCHEDULE 2 TO EXHIBIT A</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">BASE BUILDING IMPROVEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;Replace the HVAC air handling system serving the second (2</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">nd</sup></font><font style="font-family:inherit;font-size:11pt;">) floor of the Building, comprised of three (3) units:  AC-9, AC-10 and AC-11, to modern standards.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;Replace the three (3) HVAC chillers, cooling towers, accompanying pumps(s), and necessary piping to modern standards.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;Upgrade the HVAC system controls (RH coils, VAVs, Interface) for offices and labs to bring up to modern standard and connect with the existing Siemens Building management systems technology.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;Upgrade the Building heating hot water generation system to modern standard.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[SEE ATTACHED]</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="itemsremoved.jpg" alt="itemsremoved.jpg" style="font-size:11pt;height:883px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="premises.jpg" alt="premises.jpg" style="font-size:11pt;height:871px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">CONSTRUCTION RULES AND REGULATIONS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">GENERAL CONSTRUCTION RULES</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor shall comply with all Federal, State and local laws, ordinances and regulations which may be applicable to the performance of services hereunder which are in effect at the time the services are performed. </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">This includes but is not limited to the handling, storage, notification, transportation, clean-up and disposal of surplus and hazardous materials.</font><font style="font-family:inherit;font-size:11pt;">&#32;Contractor shall remove all such materials from the site at job completion. Contractor will perform all work in a safe, workmanlike, and lawful manner consistent with the standards practiced by firms providing similar services. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Contractor assumes full responsibility for existing doors, frames and hardware, for operation and finish and for the protection of such doors as necessary.  It is the Contractor's responsibility to review these items and notify Tenant of existing damage prior to work starting.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor will be liable for any damage while performing the work (i.e., water damage, fire, carelessness, damaged ceiling tile, wall and floor covering, etc.).  While Contractor is working, they will be responsible for keeping debris to a minimum.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tenant shall neutralize smoke detectors after a 24-hour (48 hour for weekends) notice during construction, as required to prevent false alarms. Any requisitions affecting Fire/Life/Safety systems, device lock out or testing or service shall be processed by Tenant.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exposed no-rated telephone or computer cables shall not be permitted in return air plenums.  Such cabling shall be enclosed only in steel conduit with steel connectors or plenum-rated wire approved by the Fire Marshall.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The contractor shall be responsible for replacing ceiling tiles removed to facilitate their operations, to the satisfaction of Tenant.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">CONTRACTOR REQUIREMENTS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any Contractor performing work in the premises must be licensed by the State of California and furnish proof of same prior to the commencement of work. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Insurance Requirements: See below. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b)&#160;&#160;&#160;&#160;Tenant/Landlordrequires satisfactory lien waivers from General Contractors and Sub-Contractors prior to the performance payment of work.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All Plans and Specifications must be submitted to Tenant/Landlord, in advance for review and approval.  Written approval must be obtained from the tenant and landlord prior to commencement of work.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">GENERAL PROCEDURES</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Building Permit shall be properly posted in the area of construction prior to commencement of work.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The contractor shall request authorization from Tenant at least 24 hours in advance of any interruption of building services.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The landlord and property management assume no responsibility whatsoever for loss of, or damage to, Contractors' materials or tools on the site.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Maintain cleanliness throughout</font><font style="font-family:inherit;font-size:11pt;">; do not clutter or block hallways, exits, elevator lobby, electrical or telephone closets.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor shall provide a means for cleaning tools, brushes and discarding waste drywall mud, paints and other liquids and solids off site. REST-ROOM FACILITIES, JANITORIAL SINKS, FLOOR AND LOADING DOCK DRAINS ARE NOT TO BE USED FOR THIS PURPOSE. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Restricted parking zones at or around the building must be adhered to.  Violators will be towed at their expense.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SUBMITTALS TO LANDLORD</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Two (2) weeks before the commencement of any work, Landlord requires the following information to be available for review:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certificates of Insurance as required including Workman's Compensation Coverage.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor is responsible for furnishing a copy of the Certificate of Occupancy to Tenant/Landlord.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor&#8217;s employees and subcontractors shall limit their activities to the construction site.  Trespassing in other areas of the building or project shall not be permitted</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A professional atmosphere must be maintained at all times.  As such, the Contractor, their employees and subcontractors shall be dressed appropriately.  Tank tops, shorts, sandals, T-shirts with objectionable printing, etc., shall not be permitted.  Anyone dressed in such a manner will be asked to leave the premises.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">There is no smoking permissible anywhere in the building</font><font style="font-family:inherit;font-size:11pt;">.   </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CONTRACTOR INSURANCE REQUIREMENTS:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(see next page)</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="hcpvendorinsurance.jpg" alt="hcpvendorinsurance.jpg" style="background-color:#ffffff;font-size:11pt;height:790px;width:682px;"></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>pcrx-12312017xex211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7BEE915217205728BE99CC0552F8A7B5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;21.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSIDIARIES OF THE REGISTRANT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals,&#160;Inc., a California corporation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals International, Inc., a Delaware corporation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Ltd., a company organized under the laws of the United Kingdom</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>pcrx-12312017xex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8AECA9AF73765AAEB240786ADF3554EE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;23.1 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;padding-bottom:20px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We consent to the incorporation by reference in the registration statements (Nos.&#160;333-175101, 333-181986, 333-196542 and 333-212098) on Form&#160;S-8 and the registration statement (No. 333-195099) on Form&#160;S-3 of Pacira Pharmaceuticals, Inc. of our reports dated February 28, 2018, with respect to the consolidated balance sheets of Pacira Pharmaceuticals, Inc. as of December 31, 2017 and 2016, and the related consolidated statements of operations,  comprehensive income (loss), stockholders&#8217; equity and cash flows for the years ended December 31, 2017 and 2016, and the related notes (collectively, the consolidated financial statements), and effectiveness of internal control over financial reporting as of December 31, 2017, which reports appear in the December 31, 2017 annual report on Form 10-K of Pacira Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-bottom:20px;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short Hills, NJ</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>pcrx-12312017xex232.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1C6833DBE17B52819CC1509A683CD737"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;23.2</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in Registration Statement Nos.&#160;333-175101, 333-181986, 333-196542, and 333-212098 on Form&#160;S-8 and Registration Statement No.&#160;333-195099 on Form&#160;S-3 filed by Pacira Pharmaceuticals, Inc. of our report dated February 25, 2016, on our audit of the consolidated statements of operations, comprehensive income, stockholders&#8217; equity and cash flows of Pacira Pharmaceuticals,&#160;Inc. and Subsidiaries for the year ended December&#160;31, 2015, included in this Annual Report on Form&#160;10-K of Pacira Pharmaceuticals,&#160;Inc. for the year ended December&#160;31, 2017.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ CohnReznick LLP</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roseland, NJ</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>pcrx-12312017xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC356AFDAA27251159D8427439575E46B"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David Stack, certify that:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Pacira Pharmaceuticals,&#160;Inc. (the &#8220;Registrant&#8221;);</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:59%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID STACK</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stack<br>Chief Executive Officer and Chairman<br>(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>pcrx-12312017xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s38BEB4DCF9E6537D81D52AEFC7E083F3"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Charles A. Reinhart, III, certify that:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Pacira Pharmaceuticals,&#160;Inc. (the &#8220;Registrant&#8221;);</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:59%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;CHARLES A. REINHART, III</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles A. Reinhart, III</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>pcrx-12312017xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s623F1228BD0B5DED89C33A6F1851667C"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT PURSUANT TO 18 U.S.C. &#167;1350</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. &#167;1350, the undersigned certifies that this Annual Report on Form&#160;10-K of Pacira Pharmaceuticals,&#160;Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira Pharmaceuticals,&#160;Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:59%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID STACK</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stack</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer and Chairman</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>pcrx-12312017xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE52C563A66A15D66ADF2CF594980C843"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT PURSUANT TO 18 U.S.C. &#167;1350</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. &#167;1350, the undersigned certifies that this Annual Report on Form&#160;10-K of Pacira Pharmaceuticals,&#160;Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira Pharmaceuticals,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:59%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;CHARLES A. REINHART, III</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles A. Reinhart, III<br>Chief Financial Officer<br>(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>pcrx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:F263C04AA8305869ABE660028F7B22EF,x:baad85227ec845de866635c73160f916-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pcrx="http://www.pacira.com/20171231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="pcrx-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForPromotionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1SDJAN1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponFirstCommercialSaleInUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponFirstCommercialSaleInUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar100.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q2Apr01toApr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar250.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar250.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar100.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar100.0MillionThresholdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponFirstCommercialSaleInMajorEUCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponFirstCommercialSaleInMajorEUCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-13</xbrli:startDate>
			<xbrli:endDate>2017-03-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-13</xbrli:startDate>
			<xbrli:endDate>2017-03-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtRedemptionTermsonorafterApril12020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-13</xbrli:startDate>
			<xbrli:endDate>2017-03-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-13</xbrli:startDate>
			<xbrli:endDate>2017-03-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1Jan23_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-01-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar07_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q1Jan22toJan23_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-22</xbrli:startDate>
			<xbrli:endDate>2013-01-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2May02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TwoThousandNineteenSeniorConvertibleNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-13</xbrli:startDate>
			<xbrli:endDate>2017-03-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Apr30_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_pcrx_TwoThousandSevenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:TwoThousandSevenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_StockIncentivePlan2011Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_pcrx_StockIncentivePlan2011Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_TwoThousandSevenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:TwoThousandSevenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_pcrx_ProductAxis_pcrx_DepoCyteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:ProductAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Dec01-Dec31_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-12-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2SD_us-gaap_LeaseArrangementTypeAxis_pcrx_MundipharmaLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">pcrx:MundipharmaLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2SD_us-gaap_LeaseArrangementTypeAxis_pcrx_PatheonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">pcrx:PatheonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_pcrx_ProductAxis_pcrx_DepoCyteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:ProductAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q4Dec05_pcrx_AchievementOfMilestoneAxis_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4Dec04toDec05_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-12-04</xbrli:startDate>
			<xbrli:endDate>2012-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_LeaseArrangementTypeAxis_pcrx_PatheonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">pcrx:PatheonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_pcrx_ProductAxis_pcrx_DepoCyteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pcrx:ProductAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcrx:MPMAssetManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q2Apr01toApr30_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcrx:MPMAssetManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcrx:MPMAssetManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q3Aug01toAug31_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-08-01</xbrli:startDate>
			<xbrli:endDate>2012-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcrx:MPMAssetManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_pcrx_SkyePharmaHoldingIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pcrx:SkyePharmaHoldingIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_pcrx_SkyePharmaHoldingIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pcrx:SkyePharmaHoldingIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2007Q1March20-March21_us-gaap_BusinessAcquisitionAxis_pcrx_CaliforniaOperatingSubsidiaryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:CaliforniaOperatingSubsidiaryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2007-03-20</xbrli:startDate>
			<xbrli:endDate>2007-03-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="d">
		<xbrli:measure>utreg:D</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="customer">
		<xbrli:measure>pcrx:customer</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>pcrx:segment</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-04AF2AB8162E230D3D909CCE5558FE60">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-C98211020F78946136A49CCE5558DBDD">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-44C507C3EA66DA6D809F9CCE5558C77C">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-F0796DB601333B86FA199CCE5558E37D">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-FDA91489BD74C720C3CA9CCE5558CD4A">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-AC0667B59BF640DDCCFE9CCE555810B2">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-EC28B33DD3BF79FEC4CC9CCE5558C2E2">0001396814</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1SharesOutstanding" decimals="INF" id="Fact-9173AF9688845320DA7E9CCE555868B4" unitRef="shares">40711707</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-631C957817921987D9CE9CCE55586801">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-01F4CEF76DC363FB4D849CCE55589CF2">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="-8" id="Fact-59E9FD7E0F85405D434A9CCE5558F998" unitRef="usd">1900000000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-B39C6AECB030FC6358739CCE5558CFA5">Pacira Pharmaceuticals, Inc.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-8AC19E6C7BBFFD6E20B19CCE55584EDD">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-1996DC5F05352CF772F69CCE5558679E">Yes</dei:EntityWellKnownSeasonedIssuer>
	<pcrx:AccruedEndOfTermFeeCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7055258103368D91ECEE9CCE55294188" unitRef="usd">1605000</pcrx:AccruedEndOfTermFeeCurrent>
	<pcrx:AccruedEndOfTermFeeCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3B5EC71DF015E9A9DE319CCE5529F3C8" unitRef="usd">2053000</pcrx:AccruedEndOfTermFeeCurrent>
	<pcrx:AccruedOperatingExpensesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-307250BC2B653E71EA9B9CCE5529359C" unitRef="usd">16538000</pcrx:AccruedOperatingExpensesCurrent>
	<pcrx:AccruedOperatingExpensesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-54E41824E82971B0A5E39CCE55292330" unitRef="usd">20646000</pcrx:AccruedOperatingExpensesCurrent>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" decimals="-5" id="Fact-26CDA18624D8655D9D369CCE555885FA" unitRef="usd">8000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" decimals="-5" id="Fact-F928837270935F902D729CCE5558B96B" unitRef="usd">8000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" decimals="-5" id="Fact-C85CB801D78097A64A6E9CCE5549A0D1" unitRef="usd">32000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" decimals="-5" id="Fact-24101BBA9D4581E921CD9CCE5558EC23" unitRef="usd">4000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponFirstCommercialSaleInUnitedStatesMember" decimals="-5" id="Fact-FEB7DE05E02A9F1DA5AC9CCE5558FB63" unitRef="usd">10000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_pcrx_SkyePharmaHoldingIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-5" id="Fact-FC4CDBEC2B79B90FCC7C9CCE55499012" unitRef="usd">62000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
	<pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A9F34566B5042A6FCF509CCE55496911" unitRef="usd">481000</pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation>
	<pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A2D56D43E523BD69D88E9CCE55492D70" unitRef="usd">479000</pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation>
	<pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2297B227E6D9962F93E39CCE55496C87" unitRef="usd">1248000</pcrx:AmortizationOfOtherAssetsAndUnfavorableLeaseObligation>
	<pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" decimals="INF" id="Fact-9E03E2466F2123A7AC489CCE55581C10" unitRef="usd">100000000</pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition>
	<pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" decimals="INF" id="Fact-DB191F724B79CC3A7CD99CCE55589244" unitRef="usd">250000000</pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition>
	<pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition contextRef="FI2017Q4_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" decimals="INF" id="Fact-457CF16CE38D46C4C0029CCE5549DEFD" unitRef="usd">500000000</pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition>
	<pcrx:AvailableNetOperatingLossSubjecttoLimitation contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-3316B887B429FACA02749CCE55498C76" unitRef="usd">134800000</pcrx:AvailableNetOperatingLossSubjecttoLimitation>
	<pcrx:BeginningPeriodPriorToProductExpirationAllowedForReturningProduct contextRef="FD2017Q4YTD" id="Fact-E2627EB8B8012D294D0E9CCE55683669">P6M</pcrx:BeginningPeriodPriorToProductExpirationAllowedForReturningProduct>
	<pcrx:CollaborativeArrangementMilestonePaymentsReceived contextRef="D2013Q4Dec01-Dec31_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember" decimals="-5" id="Fact-2EFAB5BAD2C25288D7F89CCE5549E10B" unitRef="usd">500000</pcrx:CollaborativeArrangementMilestonePaymentsReceived>
	<pcrx:CollaborativeArrangementMilestonePaymentsReceived contextRef="D2016Q2_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember" decimals="-5" id="Fact-22F49566482F632E24869CCE5549DC50" unitRef="usd">1000000</pcrx:CollaborativeArrangementMilestonePaymentsReceived>
	<pcrx:CollaborativeArrangementMilestonePaymentsReceived contextRef="D2016Q3_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember" decimals="-5" id="Fact-4A9EEAC5E1DDA3B2EFB59CCE5549A5E6" unitRef="usd">1000000</pcrx:CollaborativeArrangementMilestonePaymentsReceived>
	<pcrx:CollaborativeArrangementMilestonePaymentsToBeReceived contextRef="I2012Q4Dec05_pcrx_AchievementOfMilestoneAxis_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember" decimals="-5" id="Fact-4D745825F5388ED421809CCE55295D4E" unitRef="usd">40000000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceived>
	<pcrx:CollaborativeArrangementUpfrontPaymentReceived contextRef="D2012Q4Dec04toDec05_us-gaap_TypeOfArrangementAxis_pcrx_AratanaTherapeuticsIncMember" decimals="-5" id="Fact-B3976CBE29545FFD79D69CCE5529D224" unitRef="usd">1000000</pcrx:CollaborativeArrangementUpfrontPaymentReceived>
	<pcrx:CollaborativeLicensingAndDevelopmentRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2FFEB53100CFFA63D0FD9CCE5558DBB4" unitRef="usd">1426000</pcrx:CollaborativeLicensingAndDevelopmentRevenue>
	<pcrx:CollaborativeLicensingAndDevelopmentRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A4C53EDA594E35F65619CCE5558A07A" unitRef="usd">3426000</pcrx:CollaborativeLicensingAndDevelopmentRevenue>
	<pcrx:CollaborativeLicensingAndDevelopmentRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5B8A3C2AABC59D2BC6CB9CCE55588448" unitRef="usd">387000</pcrx:CollaborativeLicensingAndDevelopmentRevenue>
	<pcrx:Compensationexpensefromemployeestockpurchaseplan contextRef="FD2015Q4YTD" decimals="-3" id="Fact-995618BF0C351BF6D3429CCE5549878F" unitRef="usd">852000</pcrx:Compensationexpensefromemployeestockpurchaseplan>
	<pcrx:Compensationexpensefromemployeestockpurchaseplan contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2C15E5A3FE81B1CF7C1F9CCE5568D934" unitRef="usd">785000</pcrx:Compensationexpensefromemployeestockpurchaseplan>
	<pcrx:Compensationexpensefromemployeestockpurchaseplan contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4F3BB3119006403C94E09CCE5558C1C6" unitRef="usd">680000</pcrx:Compensationexpensefromemployeestockpurchaseplan>
	<pcrx:Compensationexpensefromstockoptionsemployees contextRef="FD2015Q4YTD" decimals="-3" id="Fact-05D9EFA08955EDB6A81A9CCE553947B1" unitRef="usd">27262000</pcrx:Compensationexpensefromstockoptionsemployees>
	<pcrx:Compensationexpensefromstockoptionsemployees contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2DC50A6B159377B9157D9CCE5558CFFC" unitRef="usd">24505000</pcrx:Compensationexpensefromstockoptionsemployees>
	<pcrx:Compensationexpensefromstockoptionsemployees contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E2C7008F14CB7CF519469CCE5529042D" unitRef="usd">24056000</pcrx:Compensationexpensefromstockoptionsemployees>
	<pcrx:Compensationexpensefromstockoptionsnonemployeeawards contextRef="FD2015Q4YTD" decimals="-3" id="Fact-40AEACF7377F4ACB8E6A9CCE5568DC5D" unitRef="usd">2367000</pcrx:Compensationexpensefromstockoptionsnonemployeeawards>
	<pcrx:Compensationexpensefromstockoptionsnonemployeeawards contextRef="FD2016Q4YTD" decimals="-3" id="Fact-722B3C5BCE647619B4369CCE5568D2C6" unitRef="usd">841000</pcrx:Compensationexpensefromstockoptionsnonemployeeawards>
	<pcrx:Compensationexpensefromstockoptionsnonemployeeawards contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A34208C2F75175603B079CCE555821D5" unitRef="usd">167000</pcrx:Compensationexpensefromstockoptionsnonemployeeawards>
	<pcrx:ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition contextRef="I2012Q2Apr30" decimals="-5" id="Fact-E06532DED8815958C6D19CCE554967D7" unitRef="usd">2000000</pcrx:ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition>
	<pcrx:ContractTerminationFee contextRef="FI2017Q4" decimals="-5" id="Fact-A8696F8702F121AD05CA9CCE5549E1ED" unitRef="usd">7100000</pcrx:ContractTerminationFee>
	<pcrx:ContractTerminationFee contextRef="FI2017Q4_us-gaap_LeaseArrangementTypeAxis_pcrx_PatheonMember" decimals="INF" id="Fact-A28926779EEAA588291C9CCE5529B4B6" unitRef="usd">2700000.0</pcrx:ContractTerminationFee>
	<pcrx:ContractTerminationFeeCurrentPortion contextRef="FI2017Q4" decimals="-5" id="Fact-C41CEB731188A87399619CCE55495E56" unitRef="usd">2400000</pcrx:ContractTerminationFeeCurrentPortion>
	<pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-09CFD8909C3977CF69D2A51B7865537B" unitRef="usd">0</pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes>
	<pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6C1FA0FDFAB6CC248312A51B7403069E" unitRef="usd">0</pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes>
	<pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3507038432CA849BF50CA51AECF35347" unitRef="usd">285000</pcrx:Conversionofprincipalandequitycomponentofconvertibleseniornotes>
	<pcrx:DebtConversionConvertedInstrumentSharesIssuedValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3525FDF01F355322FE9FB9BFEE0EA9CF" unitRef="usd">3929000</pcrx:DebtConversionConvertedInstrumentSharesIssuedValue>
	<pcrx:DebtConversionConvertedInstrumentSharesIssuedValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-27A79B395B9F7CEA5BFFB9BFEE1302D8" unitRef="usd">0</pcrx:DebtConversionConvertedInstrumentSharesIssuedValue>
	<pcrx:DebtConversionConvertedInstrumentSharesIssuedValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-67392D4A844DB513EAA9B9BFEE15EB14" unitRef="usd">120960000</pcrx:DebtConversionConvertedInstrumentSharesIssuedValue>
	<pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-7B2FC20ECA18CF596E83B6DD9A0DC294" unitRef="number">1.3</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice>
	<pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-E74D7AC75F98F708C1A9B6E0CAED7886" unitRef="number">1.3</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice>
	<pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-75A29CD7CAF58DD4558DB6DD441EED61">P20D</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays>
	<pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-667C087A14E887156795B6E1020401F2">P20D</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays>
	<pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-486AAF33C78587AE871EBAE7D267539D">P5D</pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod>
	<pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-17E667D5E26EAAD93AE9B6DD748016B4">P30D</pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays>
	<pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-433E27B67060925C16DCB6E13F758AD4">P30D</pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays>
	<pcrx:DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-53C63AFF2AA5A4EC8766BAF1B5849373">P5D</pcrx:DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption>
	<pcrx:DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption contextRef="FD2017Q3YTD" id="Fact-9F07B8EC6E34C1A7B41CB712BC35B14D">P30D</pcrx:DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption>
	<pcrx:DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-3B8C0958B60AFB062500BAE91C879192">P5D</pcrx:DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays>
	<pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock contextRef="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="3" id="Fact-9A8F181632069C0A2A43B6DFBB3A0297" unitRef="number">0.375</pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock>
	<pcrx:DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-F517EF171080F8F9BF87B6DE6E669E1C" unitRef="number">0.98</pcrx:DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum>
	<pcrx:DebtInstrumentConvertibleAssumedBorrowingRate contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-4DA4D0BD5EBCC7AED3AAB6E2315BD094" unitRef="number">0.0745</pcrx:DebtInstrumentConvertibleAssumedBorrowingRate>
	<pcrx:DebtInstrumentConvertibleConversionPremiumShares contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-5" id="Fact-EBA0F8BB68AECF7A0E8D2AE0B89F0367" unitRef="shares">5200000</pcrx:DebtInstrumentConvertibleConversionPremiumShares>
	<pcrx:DebtInstrumentConvertibleConversionPremiumShares contextRef="FD2017Q4YTD" decimals="INF" id="Fact-8A57639C19E87B76E8CF9CCE555819FC" unitRef="shares">10000</pcrx:DebtInstrumentConvertibleConversionPremiumShares>
	<pcrx:DebtInstrumentConvertibleConversionPremiumShares contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-F8B729022219DD8F40229CCE55587998" unitRef="shares">10000</pcrx:DebtInstrumentConvertibleConversionPremiumShares>
	<pcrx:DebtInstrumentConvertibleConversionValue contextRef="FI2017Q4" decimals="-5" id="Fact-B943127895A89BC4453DB71415A4293F" unitRef="usd">300000</pcrx:DebtInstrumentConvertibleConversionValue>
	<pcrx:DebtInstrumentConvertibleConversionValue contextRef="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="0" id="Fact-594AFD1C29DE76A49AC3B71394DCBC4D" unitRef="usd">1839</pcrx:DebtInstrumentConvertibleConversionValue>
	<pcrx:DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-9001D59B923257DE5AF8B6E2D39A4E40" unitRef="number">1</pcrx:DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault>
	<pcrx:DebtInstrumentMarketPrice contextRef="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="0" id="Fact-8BE29E9D23F648CBD477B712F79B134B" unitRef="usd">1905</pcrx:DebtInstrumentMarketPrice>
	<pcrx:DebtInstrumentMarketPrice contextRef="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="0" id="Fact-1A3C7420C059457881FAB6E02758612E" unitRef="usd">1048</pcrx:DebtInstrumentMarketPrice>
	<pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice contextRef="D2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtRedemptionTermsonorafterApril12020Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-28EF0099E17BED2A185BB6E191030E38" unitRef="number">1</pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice>
	<pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="INF" id="Fact-5DD04E765A0BCEE6D5B4B6DF4EE49CF3" unitRef="usd">1000</pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock>
	<pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock contextRef="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="INF" id="Fact-62CE644A583A0A17B4F0B713BDD12D22" unitRef="usd">1000</pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock>
	<pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock contextRef="FI2017Q4_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-31F344128D9F678356D1B6E049AE8036" unitRef="usd">1000</pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock>
	<pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock contextRef="I2017Q1Mar13_pcrx_DebtConversionAndRedemptionTermsAxis_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-5C8F90132B9D95D939EDB6DE418526CB" unitRef="usd">1000</pcrx:DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock>
	<pcrx:DebtIssuanceCostsAmortizationperiod contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" id="Fact-61C5C57E1DBA302EFD6CBAF6B88EA65D">P5Y</pcrx:DebtIssuanceCostsAmortizationperiod>
	<pcrx:DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-10159D62501BCAA0FAD9B6E1C6F19298" unitRef="number">1</pcrx:DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
	<pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-0E5014AD3D6280454F249CCE55581E7B" unitRef="usd">148753000</pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance>
	<pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-1885446B283EA4F6F37D9CCE55391E1B" unitRef="usd">120230000</pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance>
	<pcrx:DeferredTaxAssetsStockBasedCompensation contextRef="FI2016Q4" decimals="-3" id="Fact-5FD384E6A623921BA7B59CCE55396AFA" unitRef="usd">21890000</pcrx:DeferredTaxAssetsStockBasedCompensation>
	<pcrx:DeferredTaxAssetsStockBasedCompensation contextRef="FI2017Q4" decimals="-3" id="Fact-46F5632CD5F1BD8D468F9CCE55394459" unitRef="usd">16925000</pcrx:DeferredTaxAssetsStockBasedCompensation>
	<pcrx:DiscontinuedOperationsAssetsremovedfromService contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5F4B36DE7B4575E9A5C8D1CA8F358FAF" unitRef="usd">2470000</pcrx:DiscontinuedOperationsAssetsremovedfromService>
	<pcrx:DiscontinuedOperationsFixedAssetandInventoryWritedown contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8EC8D49B5E116F762A77D1CA81EDA351" unitRef="usd">2470000</pcrx:DiscontinuedOperationsFixedAssetandInventoryWritedown>
	<pcrx:DiscontinuedOperationsPaymentsForLeaseCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6A406A0F101E516A3602A53832E0545E" unitRef="usd">744000</pcrx:DiscontinuedOperationsPaymentsForLeaseCosts>
	<pcrx:DiscontinuedOperationsRemainingLeaseCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A521FAC90B817D081D44D1CA80498467" unitRef="usd">2018000</pcrx:DiscontinuedOperationsRemainingLeaseCosts>
	<pcrx:DiscontinuedOperationsResidualLeaseCosts contextRef="FI2016Q4" decimals="-3" id="Fact-EDBDD8ACCE2EB935E03DD1C700DBB52D" unitRef="usd">0</pcrx:DiscontinuedOperationsResidualLeaseCosts>
	<pcrx:DiscontinuedOperationsResidualLeaseCosts contextRef="FI2017Q4" decimals="-3" id="Fact-F9561D5E931047312901D1C712C95745" unitRef="usd">1274000</pcrx:DiscontinuedOperationsResidualLeaseCosts>
	<pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing contextRef="FD2015Q4YTD" decimals="4" id="Fact-45132712681D90D07324BA72D590FCEA" unitRef="number">0.0000</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
	<pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing contextRef="FD2016Q4YTD" decimals="4" id="Fact-C8AF22C4EF58DAA28D05BA72D58AD5C1" unitRef="number">0.0000</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
	<pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing contextRef="FD2017Q4YTD" decimals="4" id="Fact-5B022613693D502310B4BA72D58DF356" unitRef="number">0.0655</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
	<pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements contextRef="FD2015Q4YTD" decimals="4" id="Fact-A0757ABD3121E89B4B38BA738C2ECDAB" unitRef="number">0.0000</pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements>
	<pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements contextRef="FD2016Q4YTD" decimals="4" id="Fact-8F8387315265DBB3FE4BBA738C301735" unitRef="number">0.0000</pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements>
	<pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements contextRef="FD2017Q4YTD" decimals="4" id="Fact-1662E929AC8B7CA44636BA738C332AB8" unitRef="number">0.6889</pcrx:EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements>
	<pcrx:EffectiveIncomeTaxRateReconciliationForeign contextRef="FD2015Q4YTD" decimals="4" id="Fact-221FE7F655C5D8963EDD9CCE552942C1" unitRef="number">0.1203</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
	<pcrx:EffectiveIncomeTaxRateReconciliationForeign contextRef="FD2016Q4YTD" decimals="4" id="Fact-F2CA2E96569E913FDC429CCE552975BD" unitRef="number">-0.0081</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
	<pcrx:EffectiveIncomeTaxRateReconciliationForeign contextRef="FD2017Q4YTD" decimals="4" id="Fact-95942A07713A745D868B9CCE55293F88" unitRef="number">-0.0128</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
	<pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent contextRef="FD2015Q4YTD" decimals="4" id="Fact-28EF2DEFCA0B394FFCDC9CCE5529A445" unitRef="number">-0.3757</pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent>
	<pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent contextRef="FD2016Q4YTD" decimals="4" id="Fact-A0DCB24EBB8C95D1CFDF9CCE5539322F" unitRef="number">0.0575</pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent>
	<pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent contextRef="FD2017Q4YTD" decimals="4" id="Fact-778736024AE3A1792E0F9CCE5529101C" unitRef="number">0.0290</pcrx:EffectiveIncomeTaxRateReconciliationInterestExpensePercent>
	<pcrx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax contextRef="D2017Q1SDJAN1" decimals="-5" id="Fact-8FFAD2ACD4E0B3872C073E9FDE00E832" unitRef="usd">29300000</pcrx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax>
	<pcrx:Effectofstateblendedtaxratechanges contextRef="FD2015Q4YTD" decimals="4" id="Fact-FF1AA098893A955FD7AF9CCE55298F6A" unitRef="number">0.0000</pcrx:Effectofstateblendedtaxratechanges>
	<pcrx:Effectofstateblendedtaxratechanges contextRef="FD2016Q4YTD" decimals="4" id="Fact-AB9614D2D4189E731BE29CCE554939E9" unitRef="number">-0.0465</pcrx:Effectofstateblendedtaxratechanges>
	<pcrx:Effectofstateblendedtaxratechanges contextRef="FD2017Q4YTD" decimals="4" id="Fact-E8F7FAE7EBE05D497ACA9CCE5539C294" unitRef="number">-1.3088</pcrx:Effectofstateblendedtaxratechanges>
	<pcrx:EmployeeStockPurchasePlanESPPSharesinESPP contextRef="FI2017Q4" decimals="INF" id="Fact-0A4BE5D357C9D4E2E7E29CCE554928C3" unitRef="shares">500000</pcrx:EmployeeStockPurchasePlanESPPSharesinESPP>
	<pcrx:EmployeeStockPurchasePlanNumberofSharesAuthorized contextRef="FD2017Q4YTD" decimals="INF" id="Fact-FB4C10C12B33DE0E25609CCE5529CBB8" unitRef="shares">500000</pcrx:EmployeeStockPurchasePlanNumberofSharesAuthorized>
	<pcrx:EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase contextRef="FD2017Q4YTD" decimals="INF" id="Fact-4D17F8A438DE9E488CF89CCE55293DD5" unitRef="shares">339853</pcrx:EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase>
	<pcrx:EmployeeStockPurchasePlanfairvalue contextRef="FI2017Q4" decimals="INF" id="Fact-D3DD2EA1EE8DEB290A549CCE5549C43D" unitRef="number">0.85</pcrx:EmployeeStockPurchasePlanfairvalue>
	<pcrx:EuropeanRightsExpansionNewDistributionPayment contextRef="D2014Q2SD_us-gaap_LeaseArrangementTypeAxis_pcrx_MundipharmaLtdMember" decimals="-5" id="Fact-26ADE6FF51CAE3ACD0F737FD0154942B" unitRef="usd">8000000</pcrx:EuropeanRightsExpansionNewDistributionPayment>
	<pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5CAFB45142425A666A0A9CCE55492BF0" unitRef="usd">0</pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium>
	<pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AC8FF425CE68CF3E86FC9CCE55495B05" unitRef="usd">0</pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium>
	<pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium contextRef="FD2017Q4YTD" decimals="-3" id="Fact-604B02419A142C5C3A269CCE5549BC7C" unitRef="usd">126328000</pcrx:FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium>
	<pcrx:ForeignPropertyPlantandEquipmentNet contextRef="FI2016Q4" decimals="-5" id="Fact-94792E593691A1AD94E69CCE5549234E" unitRef="usd">33700000</pcrx:ForeignPropertyPlantandEquipmentNet>
	<pcrx:ForeignPropertyPlantandEquipmentNet contextRef="FI2017Q4" decimals="-5" id="Fact-3AF81FD150ACDD0C5CEC9CCE5549EBE1" unitRef="usd">59800000</pcrx:ForeignPropertyPlantandEquipmentNet>
	<pcrx:FutureNOLsWhichWillBecomeAvailable2015Onward contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-89AF131D26DFBA8B62C59CCE5549C079" unitRef="usd">6000000</pcrx:FutureNOLsWhichWillBecomeAvailable2015Onward>
	<pcrx:FutureNOLsWhichWillBecomeAvailable20182022 contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-19327D525586ABE052999CCE55493CAD" unitRef="usd">10300000</pcrx:FutureNOLsWhichWillBecomeAvailable20182022>
	<pcrx:GoodwillRecordedforEarnOutPayments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-09FF1B294CF169F5818F9CCE55293F16" unitRef="usd">7857000</pcrx:GoodwillRecordedforEarnOutPayments>
	<pcrx:GoodwillRecordedforEarnOutPayments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-105E82E3DBDB50BB3C8E9CCE552990C3" unitRef="usd">8460000</pcrx:GoodwillRecordedforEarnOutPayments>
	<pcrx:GoodwillRecordedonMilestonePayments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F5C14200F52B30071DAEB6C5261EF56D" unitRef="usd">8000000</pcrx:GoodwillRecordedonMilestonePayments>
	<pcrx:GrossProceedsFromIssuanceofDebt contextRef="D2013Q1Jan22toJan23_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-9E04D685490CC3A7AA22B6F81E753CE3" unitRef="usd">120000000</pcrx:GrossProceedsFromIssuanceofDebt>
	<pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A7D86BDE3FCFD72608549CCE5529E660" unitRef="usd">2120000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
	<pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal contextRef="FD2016Q4YTD" decimals="-3" id="Fact-73AD4FC42F50C175A6A69CCE5529D38A" unitRef="usd">-37844000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
	<pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CCD1AAA0F3407662C17F9CCE5539A9A0" unitRef="usd">-42471000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
	<pcrx:IncomeTaxProvision contextRef="FD2015Q4YTD" decimals="-5" id="Fact-648A1C141644583469D89CCE55497DA5" unitRef="usd">300000</pcrx:IncomeTaxProvision>
	<pcrx:IncomeTaxProvision contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EDBCF6E655A40A7FF3673D9E33C354BA" unitRef="usd">100000</pcrx:IncomeTaxProvision>
	<pcrx:IncomeTaxProvision contextRef="FD2017Q4YTD" decimals="-5" id="Fact-62C77E9890013B5F9BDE9CCE5549FED2" unitRef="usd">100000</pcrx:IncomeTaxProvision>
	<pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-253153EA45D6759123729CCE55294900" unitRef="usd">1393000</pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid>
	<pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-741F6E2957A765AF2CC49CCE5549709B" unitRef="usd">-789000</pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid>
	<pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-92AA55F290AD7C8C80189CCE5558A1C7" unitRef="usd">2189000</pcrx:IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid>
	<pcrx:IncreaseDecreaseInRoyaltyInterestObligation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5AFD30D32691C8FD5BC69CCE5549FC77" unitRef="usd">276000</pcrx:IncreaseDecreaseInRoyaltyInterestObligation>
	<pcrx:IncreaseDecreaseInRoyaltyInterestObligation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-543B8A1283316614E7009CCE5549EE12" unitRef="usd">0</pcrx:IncreaseDecreaseInRoyaltyInterestObligation>
	<pcrx:IncreaseDecreaseInRoyaltyInterestObligation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2E76062ADE76FBB4A4F59CCE55490B90" unitRef="usd">0</pcrx:IncreaseDecreaseInRoyaltyInterestObligation>
	<pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8353397973465772CDF79CCE5558EE17" unitRef="shares">3000</pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits>
	<pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3D92C9B7E2B4CAB293659CCE5568BA22" unitRef="shares">0</pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits>
	<pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1E33C995572523BC65C49CCE5568A62D" unitRef="shares">0</pcrx:IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits>
	<pcrx:InitialTermofManufacturingSupplyAgreement contextRef="D2014Q2SD_us-gaap_LeaseArrangementTypeAxis_pcrx_PatheonMember" id="Fact-F9D09852A1BB433B2E849CCE5529C60E">10th</pcrx:InitialTermofManufacturingSupplyAgreement>
	<pcrx:InvestmentsContingentPurchaseObligation contextRef="FI2017Q4" decimals="-5" id="Fact-D3E1894DD72E5DC70E73BA0C8BAE8EB4" unitRef="usd">900000</pcrx:InvestmentsContingentPurchaseObligation>
	<pcrx:MaximumFairMarketValuePurchaseofESPPShares contextRef="FI2017Q4" decimals="INF" id="Fact-9A98BBD127AA6C226D809CCE5549F68A" unitRef="usd">25000</pcrx:MaximumFairMarketValuePurchaseofESPPShares>
	<pcrx:MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax contextRef="FD2017Q4YTD" decimals="INF" id="Fact-31FC0A8298785B785D179CCE5549836A" unitRef="number">0.5</pcrx:MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax>
	<pcrx:NetOperatingLossSubjecttoLimitation contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-6A362BFC2C71DB18D6959CCE554939CF" unitRef="usd">192400000</pcrx:NetOperatingLossSubjecttoLimitation>
	<pcrx:NetSalesCollectedThresholdWhichTriggersaPaymentObligation contextRef="FI2014Q3_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" decimals="-5" id="Fact-36886EAD4EBD0EE522569CCE5558998D" unitRef="usd">100000000</pcrx:NetSalesCollectedThresholdWhichTriggersaPaymentObligation>
	<pcrx:NetSalesCollectedThresholdWhichTriggersaPaymentObligation contextRef="FI2016Q2_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" decimals="-5" id="Fact-A7E41D09E08C483A0AF39CCE5558C6BA" unitRef="usd">250000000</pcrx:NetSalesCollectedThresholdWhichTriggersaPaymentObligation>
	<pcrx:NonUSNetOperatingLoss contextRef="FI2017Q4" decimals="-5" id="Fact-8096F9C94E4931AA972A9CCE5549282A" unitRef="usd">5900000</pcrx:NonUSNetOperatingLoss>
	<pcrx:NumberOfMajorCustomers contextRef="FD2016Q4YTD" decimals="INF" id="Fact-F46CED7D853D8147AD309CCE55581F94" unitRef="customer">3</pcrx:NumberOfMajorCustomers>
	<pcrx:NumberOfMajorCustomers contextRef="FD2017Q4YTD" decimals="INF" id="Fact-626F293B9C459551E5449CCE555879AF" unitRef="customer">3</pcrx:NumberOfMajorCustomers>
	<pcrx:PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition contextRef="I2012Q2Apr30" decimals="-5" id="Fact-EC29C60B5C04E056B5F89CCE55585F80" unitRef="usd">10000000</pcrx:PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition>
	<pcrx:PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million contextRef="FI2014Q3_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" decimals="-5" id="Fact-87B7FE7AEE237BA872E29CCE5558B401" unitRef="usd">8000000</pcrx:PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million>
	<pcrx:PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million contextRef="FI2016Q2_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" decimals="-5" id="Fact-0B3355461C4C255CD0579CCE55586B06" unitRef="usd">8000000</pcrx:PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million>
	<pcrx:PaymentOfContingentConsideration contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5D402123134945E9535D9CCE5529ABA2" unitRef="usd">7119000</pcrx:PaymentOfContingentConsideration>
	<pcrx:PaymentOfContingentConsideration contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D5A875123E4701306A979CCE55491282" unitRef="usd">15857000</pcrx:PaymentOfContingentConsideration>
	<pcrx:PaymentOfContingentConsideration contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4276D2216943650AAD959CCE5558B518" unitRef="usd">8460000</pcrx:PaymentOfContingentConsideration>
	<pcrx:Percentageoftotalrevenue contextRef="FD2016Q4YTD_pcrx_ProductAxis_pcrx_DepoCyteMember" decimals="3" id="Fact-81892E2314718419EFCE8A21316A8A01" unitRef="number">0.026</pcrx:Percentageoftotalrevenue>
	<pcrx:PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned contextRef="FD2017Q4YTD" id="Fact-0097EC99325351C9FB859CCE55397BE1">P12M</pcrx:PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned>
	<pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D77BEE411FFF53C1B26D9CCE554965E9" unitRef="usd">2093000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
	<pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6AAEA48E23A9D8B747469CCE55496ACC" unitRef="usd">1495000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
	<pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan contextRef="FD2017Q4YTD" decimals="-3" id="Fact-18304F5821E6DD1F076F9CCE5558EF19" unitRef="usd">1862000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
	<pcrx:ProceedsfromConvertibleDebtNet contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-5" id="Fact-CA111F960E3C3D6F6021B6DCD983DA07" unitRef="usd">334000000</pcrx:ProceedsfromConvertibleDebtNet>
	<pcrx:ProductReturnsRebatesandOtherFees contextRef="FI2016Q4" decimals="-3" id="Fact-FA18FE3A1D37645BA6DB9CCE55295D03" unitRef="usd">3473000</pcrx:ProductReturnsRebatesandOtherFees>
	<pcrx:ProductReturnsRebatesandOtherFees contextRef="FI2017Q4" decimals="-3" id="Fact-2FE014492D966FF029709CCE55298841" unitRef="usd">1972000</pcrx:ProductReturnsRebatesandOtherFees>
	<pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice contextRef="D2012Q2Apr01toApr30_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-EF92AB8018A4651E02E79CCE55498D58" unitRef="usdPerShare">11.02</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice>
	<pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice contextRef="D2012Q3Aug01toAug31_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-E53C0648D5EB1E0923809CCE55498A2A" unitRef="usdPerShare">16.67</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice>
	<pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares contextRef="D2012Q2Apr01toApr30_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-CDF0A9AA3F89F2DA80159CCE5549CFA2" unitRef="shares">20000</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares>
	<pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares contextRef="D2012Q3Aug01toAug31_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-F63C029D027F683CA16B9CCE5549BEDB" unitRef="shares">70000</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares>
	<pcrx:SettlementPeriodConvertibleDebtConversionRequest contextRef="FD2017Q3YTD" id="Fact-4046C7C030D71A953113B6DEF262362D">P40D</pcrx:SettlementPeriodConvertibleDebtConversionRequest>
	<pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-71A1417300EE1B58822223BC3E2D421B" unitRef="shares">499546000</pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest>
	<pcrx:SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue contextRef="FI2017Q4" decimals="2" id="Fact-C68821071C25ECA7BCAE23BC406AD487" unitRef="usdPerShare">47.32</pcrx:SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue>
	<pcrx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue contextRef="FI2017Q4" decimals="-3" id="Fact-0371E21C6B67D818F4B023BC42510868" unitRef="usd">22804000</pcrx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue>
	<pcrx:TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FFA3186DC19E868A9ACEBA796470CE97" unitRef="usd">55700000</pcrx:TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit>
	<pcrx:TermExtensionof2003Agreements contextRef="D2014Q2SD_us-gaap_LeaseArrangementTypeAxis_pcrx_MundipharmaLtdMember" id="Fact-A69B044F6512260D56CB37FD48ED7DAB">15</pcrx:TermExtensionof2003Agreements>
	<pcrx:TotalChangeinDiscontinuedOperationsBalance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D1C3341E289258D53332D1CA91DD8AB2" unitRef="usd">2470000</pcrx:TotalChangeinDiscontinuedOperationsBalance>
	<pcrx:TotalGoodwillRecordedforEarnOutPayments contextRef="FI2017Q4" decimals="-5" id="Fact-A898404D718D5AD47A889CCE55582E0A" unitRef="usd">31200000</pcrx:TotalGoodwillRecordedforEarnOutPayments>
	<pcrx:TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_pcrx_SkyePharmaHoldingIncMember" decimals="-5" id="Fact-84403D81ECC1BE952C799CCE5558EA25" unitRef="usd">36000000</pcrx:TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition>
	<pcrx:UnitedStatesStatutoryTaxRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-044CFF6513D2DB685A919CCE5549B011" unitRef="number">0.35</pcrx:UnitedStatesStatutoryTaxRate>
	<pcrx:UnitedStatesStatutoryTaxRate contextRef="FD2016Q4YTD" decimals="2" id="Fact-14CC9FFACA7DE3C7D31E9CCE5549061D" unitRef="number">0.35</pcrx:UnitedStatesStatutoryTaxRate>
	<pcrx:UnitedStatesStatutoryTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-CA40E232FCDD14B5BB729CCE55491208" unitRef="number">0.35</pcrx:UnitedStatesStatutoryTaxRate>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-A7A8A41A60D44329C9DC9CCE5529FEC5" unitRef="usd">7511000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3FE6B33629A8DCE2D9149CCE55298BD3" unitRef="usd">14658000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E38E1F86BF8D7719D5329CCE55394ABE" unitRef="usd">29937000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D892127FEFA4B06199B59CCE5549E799" unitRef="usd">31658000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-EB06DF18FCEF768F2B399CCE5529A697" unitRef="usd">36666000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DBE2EA7541886F6125819CCE55398F80" unitRef="usd">41057000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2D10D11AAA0F4F660B549CCE55298B2E" unitRef="usd">3822000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7A0655DEF7CD989893499CCE5529E822" unitRef="usd">4091000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-A3B3F17F97214B4102179CCE5539B9EE" unitRef="usd">37510000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-A162C923DCA47B1424E09CCE55396D03" unitRef="usd">49210000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-C14F61C92F445819ED2B9CCE555890C9" unitRef="usd">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-30F0092E13819B125AC99CCE55292FBF" unitRef="usd">-30000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-97C9C8C2D7777B9FD87B9CCE55580C43" unitRef="usd">-30000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-46FAE8C34280F71EBB829CCE5539DE54" unitRef="usd">-454000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-336C4E780AA1DFDBFFDD9CCE55586F69" unitRef="usd">-454000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-29FEA26C1A62CC231DE19CCE5529C49B" unitRef="usd">565207000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-2B125593E513F13E8AA19CCE5529E47C" unitRef="usd">669032000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DC153A8A2ECFA52A504A9CCE5568EA09" unitRef="usd">-4100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E1412AB1537C3FEA44799CCE5558DD4C" unitRef="usd">-4100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A8B63496911B619B6929CCE5529BDEA" unitRef="usd">-2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1A36510B03BE9E0194079CCE55580DF5" unitRef="usd">-2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="-3" id="Fact-2241DDD462A27482A7AAA4FCCB86AC0E" unitRef="usd">68669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2096F8709514E3332A31A4FCBD7AC293" unitRef="usd">68669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-3811371E249D5EAE3EB3A4FCB40EE5B6" unitRef="usd">-126328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D76BB3011E43D3643931A4FCA2589FA2" unitRef="usd">-126328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C189F301E78363191CAA9CCE5529C12E" unitRef="usd">33368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C521C5173301BC53B82F9CCE5529F886" unitRef="usd">33368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F5A925FB2E77C8DD3C419CCE556806F1" unitRef="usd">31248000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7CA5F7667616375B52509CCE55298590" unitRef="usd">31248000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E0138E4D5A82FD1D2854A4FC88EEC065" unitRef="usd">31601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7A4BD0CF61E1693E660EA4FC83A08AEE" unitRef="usd">31601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CA1E451EEDBE69F6987E9CCE55586D7A" unitRef="usd">33368000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-86BF4DF7B6341ED76B339CCE5529B80D" unitRef="usd">6012000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-66C946618B5519CAB30A9CCE5558057F" unitRef="usd">5134000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-960116A54B3CD036905D9CCE5558BD9C" unitRef="usd">22222000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6C14C4600C4949B90B0D9CCE5558C81F" unitRef="usd">31248000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-6464CEA041CD14B7178A9CCE5539B930" unitRef="usd">6438000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-A437DA54CB2BAE16C4A59CCE5568E365" unitRef="usd">3297000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-E14B8B1B88102A27D7069CCE55497BFC" unitRef="usd">21513000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-83057D339A710C6736C69CCE55585372" unitRef="usd">31601000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-E8070820B7251BAD169C9CCE553982AF" unitRef="usd">5467000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-5F5E4176CE53CBCA53909CCE55396F4C" unitRef="usd">3341000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-B45246DBA317C98EF1A69CCE55581A72" unitRef="usd">22793000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2015Q4YTD" decimals="-3" id="Fact-443B6CCA7F18CEFDA90F9CCE5558B2E6" unitRef="usd">4102000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-887259EDC8BD830C10579CCE5549537B" unitRef="usd">4102000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CAD9EF8AFCE7DDFB0E839CCE5529AF53" unitRef="usd">4088000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-523EA37A8A39DA63AA8B9CCE55494C67" unitRef="usd">4088000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5DBF722C3E6E2B16FC209CCE554924CC" unitRef="usd">10423000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-4BDF97161A0D7D05CE229CCE5549CB2E" unitRef="usd">10423000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-9C1CA2CCF8E254207C3E9CCE55497E25" unitRef="usd">615000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-DD45AC56C17722B6195B9CCE554944C7" unitRef="usd">612000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-273F814E99746ED7325F9CCE554939C9" unitRef="usd">1381000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9623A530122927503F379CCE55493019" unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C3369FFD8046C165E9D89CCE5558942D" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-395AF5A761563655DE9B9CCE55584D85" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3D61B8FC855501E8A6129CCE55391D0C" unitRef="shares">1998000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-08481053FFDCC503C07A9CCE553967DE" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" decimals="-3" id="Fact-AA9A5011D5EC8452E90D9CCE55495DA2" unitRef="shares">8000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5455E7D6846F5AD9EB229CCE55396A36" unitRef="shares">1891000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-235BEA6F919B26ECD2D09CCE5539490B" unitRef="shares">99000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-F83586688D46C160511A9CCE55398C39" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4FA89EF3FD653F464A299CCE55391910" unitRef="shares">6816000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-FA9F7666C42B56D36D229CCE5539E0DD" unitRef="shares">2022000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" decimals="-3" id="Fact-71F3D2538D32FD97E4369CCE55398E1A" unitRef="shares">21000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-82C176D8726C035219779CCE55396091" unitRef="shares">4482000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-844C1583E15917A32B4E9CCE5539D75B" unitRef="shares">290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-7B97C8A7B929B1889E079CCE553928ED" unitRef="shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A6BEBF5B434D512EBCA69CCE553951A8" unitRef="shares">6060000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-5E1D53074F2551064E429CCE5539496A" unitRef="shares">411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" decimals="-3" id="Fact-2274C73DF55CE74717D69CCE5549F75B" unitRef="shares">29000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-FB2E0476B6C5B56933609CCE5539F82B" unitRef="shares">5171000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-8109951ED380D626213E9CCE5539D167" unitRef="shares">449000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-022BDECF92A695A494159CCE5549E07D" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AssetRetirementObligation contextRef="FI2016Q4" decimals="-5" id="Fact-39769312228F9FC546D09CCE554993E5" unitRef="usd">500000</us-gaap:AssetRetirementObligation>
	<us-gaap:AssetRetirementObligation contextRef="FI2017Q4" decimals="-5" id="Fact-BDEB2732FAFD61C5FAF19CCE55492497" unitRef="usd">1500000</us-gaap:AssetRetirementObligation>
	<us-gaap:AssetRetirementObligationAccretionExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-28BFE802E2B363E3B2009FD8AFB5D5AE" unitRef="usd">100000</us-gaap:AssetRetirementObligationAccretionExpense>
	<us-gaap:AssetRetirementObligationCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-65BED1497A5C8E297ABAD1C70379EBDD" unitRef="usd">0</us-gaap:AssetRetirementObligationCurrent>
	<us-gaap:AssetRetirementObligationCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D1504EF898DEC17D9A47D1C713AFD570" unitRef="usd">236000</us-gaap:AssetRetirementObligationCurrent>
	<us-gaap:AssetRetirementObligationLiabilitiesIncurred contextRef="FD2017Q4YTD" decimals="-5" id="Fact-49E7582E72230FABCBD39FD83FF4E6EA" unitRef="usd">400000</us-gaap:AssetRetirementObligationLiabilitiesIncurred>
	<us-gaap:AssetRetirementObligationLiabilitiesSettled contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0DBF18FD08A0F6CD6F61A53837171ECF" unitRef="usd">420000</us-gaap:AssetRetirementObligationLiabilitiesSettled>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-96A683CE97DF7894D9429CCE554999D4" unitRef="usd">391466000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-3A6EC0ACF2E1EBE9DD4B9CCE553944F6" unitRef="usd">628371000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1D1B7CD188F28160E8E19CCE55490FB3" unitRef="usd">243089000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BEEB57F956E0500048C39CCE55292074" unitRef="usd">391110000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-3" id="Fact-191B8F181193B296395B9CCE5539C243" unitRef="usd">136683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-49B4E4588DB3856E44539CCE5539C89D" unitRef="usd">9012000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2A13D365BEABB734C3469CCE5558BA89" unitRef="usd">39530000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-AB941B8AF258C1D883689CCE55392D2B" unitRef="usd">88141000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-066C940E89BB3AF8D1A99CCE55398B8A" unitRef="usd">317722000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember" decimals="-3" id="Fact-E442D115566DB446B10BA4CAAC8695E5" unitRef="usd">60266000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-62F076FBFC6E898EBFBAA4CA726A63DB" unitRef="usd">23836000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-0363AD41AD765FE07BB69CCE5539C4BD" unitRef="usd">36430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-396D959BDC897470233F9CCE5539489C" unitRef="usd">257456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-3ACB3D9A1981DB10DCEC9CCE55584CBB" unitRef="usd">28338000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B7B9AE2736B994CAE0AB9CCE55399AC4" unitRef="usd">48999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-856D3825980B1F374FB09CCE5558214C" unitRef="usd">180119000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-D61635E36A2B2DA5409E9CCE55392AA9" unitRef="usd">136653000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-FE52A7E44AFB0E97B5479CCE55396B7A" unitRef="usd">9010000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-CCBCFEE73652FF79AB449CCE5539AE57" unitRef="usd">39523000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-79F2560CE2C7621CC97A9CCE55391F3F" unitRef="usd">88120000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-9E67F4FF1061BFA3BF2A9CCE5539875C" unitRef="usd">317268000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember" decimals="-3" id="Fact-70F55FA94C7F81864AC0A4CAB8C7516B" unitRef="usd">60047000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-8CD3E60257A9CBA6C736A4CA82A87E7E" unitRef="usd">23757000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-BB24C24414DDFDB742F39CCE5539888E" unitRef="usd">36290000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-74CBD0D799FAC3A74A379CCE5539FF8C" unitRef="usd">257221000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-89B356934E6E9CE440699CCE55396606" unitRef="usd">28301000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-8A1A9BDA63FC1F0277169CCE5539A14D" unitRef="usd">48976000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-4DBF2521DA567E71C6049CCE5539111D" unitRef="usd">179944000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-682D863B3032896DA8F69CCE5539FEAF" unitRef="usd">19000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-1B37A0650A27BD099EDE9CCE5539BD1B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-85F84D6226B52E158D8F9CCE5539B178" unitRef="usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-9B9E5993D4804E5B5DBD9CCE553907A7" unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-515DE991492C234B09259CCE55394D1A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember" decimals="-3" id="Fact-8A27B83DEF689184F18EA4CAB17064A0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-62A44344E576FF6FD71CA4CA75A3DBF5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-72013544F51662E5DC369CCE5529CF8E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-D30A6543C9253E7673AD9CCE5529607C" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-91418199314E529361E49CCE55399E7E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-CB66E1C2B7FD31B4C00B9CCE55582B1A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E2E4CA00FE3542C74E539CCE5558393B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-AAA8885FCC6F301521889CCE5539B2E9" unitRef="usd">49000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-190DFE81E5C106E6F8169CCE5539FEB4" unitRef="usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-4E4B77BCADBD8DC9F75D9CCE55391FFF" unitRef="usd">15000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-D25D6387C9D7B9457BDE9CCE5539B7C2" unitRef="usd">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-8A7D9730481BE3B411289CCE555855D8" unitRef="usd">454000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember" decimals="-3" id="Fact-19A5DC63046C000F1A71A4CAB5536950" unitRef="usd">219000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-0F3508B765764DD1D79AA4CA7C4EC594" unitRef="usd">79000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_pcrx_LongTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-25EDEBC13CA6508EAB3F9CCE55398A36" unitRef="usd">140000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-10481EF86AA30C85FC749CCE5539A46D" unitRef="usd">235000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-96F341D358F8557E73C59CCE553922DB" unitRef="usd">37000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-76DD57F7B56F228B31729CCE5539C763" unitRef="usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-5BCAD5E34267A3BAC3559CCE555814E8" unitRef="usd">175000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2007Q1March20-March21_us-gaap_BusinessAcquisitionAxis_pcrx_CaliforniaOperatingSubsidiaryMember" decimals="-5" id="Fact-267BC2EF60D5F7FEEF969CCE5549BD98" unitRef="usd">19600000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q3" decimals="-5" id="Fact-4239AB10DFA7FB90C35753FDF8C6817E" unitRef="usd">10000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-5D11710B97F1212678029CCE5549D774" unitRef="usd">37520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-ED5A56F9875D105DF5C19CCE5549E8BA" unitRef="usd">56984000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-B2716C5AFEC29DCCC4459CCE55394A93" unitRef="usd">35944000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-612BF24C7B5C6B82006C9CCE552930ED" unitRef="usd">54126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2012Q2May02" decimals="INF" id="Fact-9FFC51AA0935E0B2DE499CCE5539D830" unitRef="shares">162885</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-6562D650F6DA2796CA349CCE5529EAFF" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-635ECFC4658F9E130C729CCE553984B3" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-FCF4935079EDD383DBD69CCE5539CAD3" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-AC0A5C08267E3CBBA3B19CCE5549D20E" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-79C88A2A03EFB42375819CCE5539FA5D" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-5B97762293DE5217C9FC9CCE5539ADE7" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-11E9721AAA87DBD79A1A9CCE5539DC0F" unitRef="shares">37480952</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-99704E12A9884A5659C29CCE55493B69" unitRef="shares">40668877</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-E89FB443C81E43B79DFC9CCE554911D7" unitRef="shares">37480952</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-091C2F63525F8C38ABE49CCE5539D922" unitRef="shares">40668877</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-AE0AAFB5E686781457FE9CCE5529B19C" unitRef="usd">37000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-10620AB0266D9880A87A9CCE552987F3" unitRef="usd">41000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-685C85F98C89CA9BFB409CCE55682FA4" unitRef="usd">1884000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-619B57AC0B9E42ECB8029CCE5558B9DC" unitRef="usd">-37927000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8FCEFF11FAC7DC00380D9CCE55586731" unitRef="usd">-43035000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-A6C1E4D81B7F30DD002D9CCE55589E05" unitRef="number">0.90</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember" decimals="2" id="Fact-22C914E6C9609FFEFC839CCE553929FE" unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember" decimals="2" id="Fact-E61E7CE79ECDEE8222589CCE5558DF59" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember" decimals="2" id="Fact-6F57F58E22ADD9C1E83D9CCE55587A1A" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember" decimals="2" id="Fact-FA8E6748AF3CFD6C4A729CCE5558C1E7" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerOneMember" decimals="2" id="Fact-44C9908FC98AF9DAE73F9CCE55588BDB" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerThreeMember" decimals="2" id="Fact-F09DE5EBE11FD164D8DC9CCE5558CE93" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerTwoMember" decimals="2" id="Fact-640D1F7A903395544B529CCE55587717" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-BCF8E7BBC2BF8885479D9CCE555891FF" unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember" decimals="2" id="Fact-63B310F73531C82DB7049CCE55298158" unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember" decimals="2" id="Fact-8C172B9845DA433784079CCE555854C2" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember" decimals="2" id="Fact-9A14E101350A975700889CCE5558CBF8" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember" decimals="2" id="Fact-0EC94746A78CB144A7249CCE55588192" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerOneMember" decimals="2" id="Fact-976A5F96C0F1F1EC755B9CCE5558D9B1" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerThreeMember" decimals="2" id="Fact-C1E41319E62DB69EC8E59CCE55586C26" unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_MajorCustomerTwoMember" decimals="2" id="Fact-838B7B35ACD9A1CD62049CCE555874F5" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-E63ACD816235699290D7158E585C5D40" unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_CustomersOutsideUSMember" decimals="2" id="Fact-11D17314F9506977A8ED9CCE5529BA69" unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_LargestCustomerMember" decimals="2" id="Fact-85E9BBC5DD13E94E109A158E531E1856" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_SecondLargestCustomerMember" decimals="2" id="Fact-F709B1C9EB732E6DFE46158E54E35CC4" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_pcrx_ThirdLargestCustomerMember" decimals="2" id="Fact-1192D7116C51866172B3158E56B7C09E" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConvertibleDebt contextRef="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="-5" id="Fact-6BE486E12FD6EB3D7D7DB6E207E0D5E7" unitRef="usd">274100000</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-00F3D0CA71D7EDB624B29CCE55396026" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-63C08B720B3B446E680B9CCE5529E891" unitRef="usd">324000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8CB866AD06242C500F389CCE55297F80" unitRef="usd">108738000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-5EC711AE2586218770EE9CCE55297460" unitRef="usd">276173000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:CostOfRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-66817477278D63B9372F9CCE55497403" unitRef="usd">71837000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q1QTD" decimals="-3" id="Fact-66B596C28F25F894F12A9CCE554980C9" unitRef="usd">20278000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q2QTD" decimals="-3" id="Fact-EA41AA3FBDB5744E6D679CCE5549C4B5" unitRef="usd">23053000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-177029DF4C5DA6823EB99CCE554934EA" unitRef="usd">43152000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q4QTD" decimals="-3" id="Fact-81B622D54369B94BF5E19CCE55494996" unitRef="usd">23621000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F606C137998923CA4E999CCE555835DB" unitRef="usd">110104000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B7EED0C3B95F25EC835C9CCE55589409" unitRef="usd">24581000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-8A12D1DDE0262456C26C9CCE5558F497" unitRef="usd">23811000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5394E0C5E8A22D94F2AF9CCE5558647A" unitRef="usd">18228000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2017Q4QTD" decimals="-3" id="Fact-067E17C600E93A9AE8809CCE55585072" unitRef="usd">21295000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4D7DCB15C44F239F928D9CCE5558556A" unitRef="usd">87915000</us-gaap:CostOfRevenue>
	<us-gaap:CostsIncurredAssetRetirementObligationIncurred contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BF64A4D170FDAC6FD5C8D1CA83873307" unitRef="usd">656000</us-gaap:CostsIncurredAssetRetirementObligationIncurred>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-27BA5506158E3A1A85ABA4FC40D317B8" unitRef="usd">287000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0A521806F90507ECD09CA4FC45EF4810" unitRef="usd">-287000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 contextRef="D2017Q1SDJAN1" decimals="-5" id="Fact-05F557E00108472546443EA0062706E9" unitRef="usd">300000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6D9F7CE1FDFC5CD78BD99CCE5568A85B" unitRef="usd">92000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-32EEEDC31EE7017B0D2C9CCE5529E6BE" unitRef="usd">11000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-71352F9704EE14468EF49CCE55490933" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-14BC20048F8CDACCD2E29CCE5568A7CE" unitRef="usd">172000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FAEBC682BB5EBDF7AFD69CCE55682B35" unitRef="usd">94000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2A778C879ADC686BE1519CCE5539EA82" unitRef="usd">140000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1Mar" decimals="-5" id="Fact-B746A783656AF109DE88B7107531C3FB" unitRef="shares">2500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1SD" decimals="-3" id="Fact-D2E35699A6F9AC1DB702B7112CD5837E" unitRef="shares">10000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-BE86594471552DF07D1FB7044FB624B4" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-2A80E049BAB9C542A3BD9CCE55494EFC" unitRef="usd">118531000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-7E0D8B030D6145761623B7044BF17181" unitRef="usd">345000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-B2C759E0BC25815810759CCE55495325" unitRef="usd">338000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="-5" id="Fact-6EA0D71B4DC510BFBBDFB6E254E3BF60" unitRef="usd">70900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="2" id="Fact-77EC2E64764E4165CB7E9CCE5558D075" unitRef="usdPerShare">24.82</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="INF" id="Fact-A76607D043C5416BBDC1B6DF7D9B4983" unitRef="usdPerShare">66.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="4" id="Fact-A24E74DAA70D97310A4CB6DF26EDBFBC" unitRef="number">14.9491</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="FD2017Q3YTD" decimals="INF" id="Fact-343C5EBB877D5DD59BE3B71274F55AC5" unitRef="number">1.3</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
	<us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="FD2017Q3YTD" decimals="INF" id="Fact-91FDE64CA923C51417B3B71298483606" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-C5795D8981D2A059632DBA0215F8F66B" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-000592DAF7C2322DCF19BA0217EF1C08" unitRef="usd">361526000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-3063725544F5DB7A05E2BA0219E152DE" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-FAD6D09C34E711293990BA02138F6249" unitRef="usd">276173000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-49121028CAD6B7820DA49CCE5539AA52" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-259DDEF5054DD27395EF9CCE5549CD94" unitRef="usd">644000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-F4A7D696D7D0145E281A9CCE5539B3D4" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-274B579C8B72328A77EE9CCE55394D5F" unitRef="usd">324000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="4" id="Fact-AF7749679BE6F577F2D19CCE5549A06B" unitRef="number">0.0721</us-gaap:DebtInstrumentInterestRateDuringPeriod>
	<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="4" id="Fact-FC12D0A0427BDF2A75509CCE554992D1" unitRef="number">0.0722</us-gaap:DebtInstrumentInterestRateDuringPeriod>
	<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="4" id="Fact-2D8E480DEE374793645E9CCE55497FD6" unitRef="number">0.0777</us-gaap:DebtInstrumentInterestRateDuringPeriod>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="INF" id="Fact-4BB9B79B8B94B84C6543B6F85D17F425" unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q1Jan23_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="INF" id="Fact-2F444D07E2B980BE8BF1B6F83588ED0C" unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="INF" id="Fact-CB045680D713709FEB76B6DC763E1A92" unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRepurchaseAmount contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-208C5177AB8F636CE996B7104D23D22B" unitRef="usd">118200000</us-gaap:DebtInstrumentRepurchaseAmount>
	<us-gaap:DebtInstrumentRepurchaseAmount contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-60A0513DFA69372A57FAB7110436BA70" unitRef="usd">500000</us-gaap:DebtInstrumentRepurchaseAmount>
	<us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-BE3365AB47A563B8111BB7102444A101" unitRef="usd">117700000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
	<us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-FE8C1A5DF401D4C73BBEB710DA409C5D" unitRef="usd">500000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-A187D69270C721EE6971B7045C15FF40" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-345092D5818E71FB02A59CCE5549FE49" unitRef="usd">8517000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-569DAD8AA4385573FC18B70457FF8E6C" unitRef="usd">61345000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-F6F335EF1B97BA9CAF109CCE5549C217" unitRef="usd">12000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="-5" id="Fact-544228217CDFE3076C2FB6E28147EE56" unitRef="usd">11000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-B2EE51382A50CD9BE76FB70455F1EEE5" unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-80F8A8CC471A7DF9D43F9CCE55496E99" unitRef="usd">1276000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-BFEFD5BCB4E376648066B704520D48DE" unitRef="usd">7482000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-B6925C2D8BDFC0769AA79CCE5549B6C5" unitRef="usd">2000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-E27C77AD719F98B744E89CCE55293051" unitRef="usd">8600000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-BC7C15B88A7BD68857079CCE55492FFB" unitRef="usd">6800000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BA6AD1792DC0EBB589C99CCE55494203" unitRef="usd">595000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-361AFEB0878C08A812979CCE55394616" unitRef="usd">102000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2016Q4" decimals="-3" id="Fact-800823A414B0D1D7B90D9CCE55588626" unitRef="usd">3023000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2017Q4" decimals="-3" id="Fact-1E5D435CFD40850E9BB09CCE5539846B" unitRef="usd">1841000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-3D99EF9034795A956D959CCE55396F73" unitRef="usd">151939000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-476468A3D73EA02BE2E59CCE55583EA9" unitRef="usd">134908000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2016Q4" decimals="-3" id="Fact-14DE6CCE306DC88CE506779A2E1A8D1D" unitRef="usd">9811000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2017Q4" decimals="-3" id="Fact-9C2978148B33331E9428779A2C9C975C" unitRef="usd">552000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-2DA4649831648D390F4C9CCE55394FA9" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-A951E14D1CA043BD6E219CCE5539A619" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-B008F2E200ED48ECBEF99CCE55396E87" unitRef="usd">96163000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-349B22F4752407ECB8A79CCE55397283" unitRef="usd">95067000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-3" id="Fact-087EB73B87B26A0AA01B9CCE5539230A" unitRef="usd">52000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-3" id="Fact-5D65778E8478584226079CCE55399EF4" unitRef="usd">139000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-E24E260E76FB5DB9FD899CCE55393FFA" unitRef="usd">2604000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-6A18720AF239C95061BD9CCE553910F2" unitRef="usd">2593000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4" decimals="-3" id="Fact-2BD42ACE1C9E4CA1AD649CCE55587F45" unitRef="usd">13724000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-8BF34EC3B2BFFD8732089CCE55394D7F" unitRef="usd">15048000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="FI2016Q4" decimals="-3" id="Fact-0D518F3587441D68B62C9CCE55391414" unitRef="usd">4672000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="FI2017Q4" decimals="-3" id="Fact-E8523135B78D332FD2349CCE5558DD1E" unitRef="usd">2743000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-558FB31AFFF56DD836C69CCE55582107" unitRef="usd">148753000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-48A8EA48462A9BDB0F629CCE5539F102" unitRef="usd">120230000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="FI2016Q4" decimals="-3" id="Fact-329BC2A06B1A5188222B9CCE555862BC" unitRef="usd">3186000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
	<us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="FI2017Q4" decimals="-3" id="Fact-53C0D035DD5C35433CF59CCE553916C6" unitRef="usd">14678000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FDFF7DACED640504548B9CCE55588AB7" unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0DCDDE52DAD33FBDCC389CCE55589016" unitRef="usd">1500000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3A6CAA3CA6F0539FD5569CCE55580A8D" unitRef="usd">1300000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E4D35A8156771A6393699CCE554948C5" unitRef="usd">11200000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F7EDB72B7B557158BBAF9CCE5549670B" unitRef="usd">12800000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E9CFA4829C81B28EDE499CCE5549EB82" unitRef="usd">13800000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-319C702BC76554F1E7E89CCE554957E1" unitRef="usd">11475000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EB3F95F43628873FDC9E9CCE5529B9F3" unitRef="usd">12919000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-789493C4219FDF1A2BEF9CCE55393579" unitRef="usd">13833000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining contextRef="FI2016Q4" decimals="-3" id="Fact-C9DAE53291520588B162D1C7042DF905" unitRef="usd">0</us-gaap:DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining>
	<us-gaap:DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining contextRef="FI2017Q4" decimals="-3" id="Fact-152CB1CD9D2EC7D77A0DD1C71427592C" unitRef="usd">1510000</us-gaap:DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining>
	<us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0E694A1DC806193B65DEA51F5895F167" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0A5AF2B10E3EA3DD87E5A51F5671E6B1" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="FD2017Q2QTD_pcrx_ProductAxis_pcrx_DepoCyteMember" decimals="-5" id="Fact-EC4E2CF4C0809CD4C568D1B4A088512F" unitRef="usd">-4900000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B137926CC295273484C0A51F238EE1F5" unitRef="usd">-4868000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="FD2017Q4YTD_pcrx_ProductAxis_pcrx_DepoCyteMember" decimals="-3" id="Fact-606E14C7E2FBB0C6AE66D1CA852BD1B6" unitRef="usd">5447000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D3266B65A411EF0D6A28D1B41DF264B7" unitRef="usd">5400000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-73AA0D83CABA80DA244DA5383923A6A8" unitRef="usd">1467000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2016Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-5" id="Fact-539640477FBB282EE2311F0FE37B319D" unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember" decimals="0" id="Fact-725B177B37861D37A1009CCE5549C730" unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="0" id="Fact-33BAA0384E205A5AE74C9CCE554961C1" unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4YTD" decimals="2" id="Fact-9FEE4AF08C4C6478D6AB9CCE5558BEC6" unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4YTD" decimals="2" id="Fact-040489847F521BA0A3739CCE55490C3E" unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-0A479C17A4FC87D8B4D89CCE5558547B" unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-D91DCE48B9CE2BD1A8A09CCE5549BC66" unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-D28DE49CF0F9C17075D79CCE5549EBD4" unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-A9848D1C98AA19769B1D9CCE55493110" unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-6BDC6F7D446CBBD808209CCE55290470" unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-A59A7346E78ADC25EB3C9CCE55582D05" unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-338B784CD5B7FDB1F7679CCE55587838" unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-BF60A9AF15EA0420BD799CCE55588D00" unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-2A3887A46A69816E09279CCE55589A55" unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-8ECACDCA6BA65B8F5E529CCE55586DE3" unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-F3A6430182E3FB79D5BF9CCE55588881" unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-6DCD6F7CE7E8B8B8B4F29CCE55497174" unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="4" id="Fact-E928AE3933CCFC4C32BB9CCE5549303F" unitRef="number">0.1245</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="4" id="Fact-D6DAC693280571ACB4FB9CCE5529477B" unitRef="number">-0.0028</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="4" id="Fact-237096FC7F203D7DBBAE9CCE55291650" unitRef="number">-0.0033</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-425673C1F3EAC26D9DE19CCE5549AC92" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-B6C56CFA23EF75B0A7959CCE55299091" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-44CFBE005B05BF5232999CCE5549398E" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="4" id="Fact-53E3DA00AD89A3102D8B9CCE55293F26" unitRef="number">0.1032</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="4" id="Fact-688A70FD8C6DA69397819CCE5529B702" unitRef="number">-0.4396</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="4" id="Fact-50F3A255078E0BCA75379CCE55396D79" unitRef="number">0.0458</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2015Q4YTD" decimals="4" id="Fact-A44226B852A37C89BF709CCE5549EF9A" unitRef="number">0.0726</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2016Q4YTD" decimals="4" id="Fact-697769A358CCA28475C09CCE55299C12" unitRef="number">-0.0054</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2017Q4YTD" decimals="4" id="Fact-6488F3E004A13EEDD0499CCE5529B0E4" unitRef="number">-0.0121</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="4" id="Fact-BF7710848C53689D4BB69CCE55292FEA" unitRef="number">0.1533</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="4" id="Fact-CAAA9F8F75B1D0CA181B9CCE5529EACA" unitRef="number">-0.0204</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="4" id="Fact-BC4CC79E5C97A676BDB69CCE55294904" unitRef="number">0.0790</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="4" id="Fact-226E495B6EBF9A264E5A9CCE55394870" unitRef="number">0.0071</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="4" id="Fact-18A0B35D58FCD90457259CCE5549C856" unitRef="number">0.0220</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="4" id="Fact-EF8956547E15CC9A17B69CCE55294FE0" unitRef="number">0.0226</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="4" id="Fact-24BFF1531B6A096CB1119CCE5549D1AC" unitRef="number">0.3063</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="4" id="Fact-516BFFCBA519EAF2AABD9CCE5549F3C7" unitRef="number">-0.0877</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="4" id="Fact-02C151D9D9824F5E374A9CCE55494354" unitRef="number">-0.0496</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5B8B9037553722BD41DD9CCE5529AEDE" unitRef="usd">11228000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3D1B49405D61B6FF41A69CCE55290171" unitRef="usd">12295000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-017C62103159A02EDBE99CCE55498A31" unitRef="usd">19100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-2F80A28EC054B0C077049CCE5549162B">P2Y7M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-61064EFCAA64C4BC58099CCE5549214D">P2Y10M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-54297EC964106BD52AAE9CCE5549B913" unitRef="usd">41600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A12DD53B2B33DDB9D8BF9CCE55299D6E" unitRef="usd">-6000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-787FFC5E8E1E9FC222DD9CCE5549695C" unitRef="usd">-389000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C099950DE1251F7BA4669CCE5558882E" unitRef="usd">-2133000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q1Mar" decimals="-5" id="Fact-D96637A45BE52DF31FFEB710A945CEC5" unitRef="usd">-3700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D7BFDC61BA8825100B019CCE5549DD2B" unitRef="usd">-52000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-861B486E11281723C9B99CCE5568477E" unitRef="usd">-3732000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-45E43128C837985B86A89CCE5529EFFE" unitRef="usd">30880000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-3" id="Fact-04207CF131B360EA5EAD9CCE5529D873" unitRef="usd">46737000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-EFD5A84007143C6D78DF9CCE554956D9" unitRef="usd">55197000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="D2012Q2Apr01toApr30" decimals="-5" id="Fact-9A2D9C602B32D8870A269CCE5558FEA8" unitRef="usd">8000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:IncentiveFromLessor contextRef="FI2017Q4" decimals="-5" id="Fact-A1DDDEC0D8815EC2E9AC9CCE55490523" unitRef="usd">5600000</us-gaap:IncentiveFromLessor>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3D312C140342AB9F25D19CCE554993C5" unitRef="usd">3760000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2ABD9C5B2CCC1427BBBE9CCE55298C3A" unitRef="usd">-36339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-591F2DEFDD3DDFCCA7489CCE55299CE2" unitRef="usd">-39898000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7AE4662867089DA6FC159CCE5558F605" unitRef="usd">2120000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5F809DF5E8B15A737AC39CCE555857F7" unitRef="usd">-37844000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-98179DFA650825F21D419CCE5558AB28" unitRef="usd">-42471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B334ABBEE6BC18F0805D9CCE5558DE1A" unitRef="usd">-1640000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2016Q4YTD" decimals="-3" id="Fact-05232DBC787777CAB2279CCE55498782" unitRef="usd">-1505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9D552095C54A244BC2719CCE5529FF82" unitRef="usd">-2573000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6DE1B9C79CB0777954729CCE5549A39D" unitRef="usd">264000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-01650B3122C93A8DD1E99CCE5549EF56" unitRef="usd">105000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9CDCDC6198FA403DC19C9CCE55589D0C" unitRef="usd">140000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3903B169611DC9DA04AB9CCE55494DA2" unitRef="usd">195000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9D3790DB366E1362432A9CCE5549F582" unitRef="usd">247000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6F359BF4C1C3AC77F1169CCE55392ACA" unitRef="usd">129000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D02FB27A042642BB9D309CCE554993BC" unitRef="usd">8966000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6D4EA07C1E9FB88B41A39CCE55398920" unitRef="usd">710000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C68C7EB1380F4D0E8BFD9CCE5549BB65" unitRef="usd">9359000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3C47E92C5DDD1F8BD3B89CCE5539DF15" unitRef="usd">3489000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6A07F41684909B0A24FC9CCE55491E2C" unitRef="usd">4082000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C056BE2D7116221CB90E9CCE55292C25" unitRef="usd">1721000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAssetRetirementObligations contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DCD810325F0B32F58D839FD7C2A368DD" unitRef="usd">500000</us-gaap:IncreaseDecreaseInAssetRetirementObligations>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-3" id="Fact-75F617014243E7474F2A9CCE55491164" unitRef="usd">32382000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-3" id="Fact-562A0481C4A8445BEFE79CCE55393173" unitRef="usd">-30367000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-3" id="Fact-587017D9497E9A6CEB6F9CCE554995E5" unitRef="usd">10133000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BB2F4302E18CBDC88A5A9CCE5558C7BE" unitRef="usd">4360000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F5562F31DFF30457C96B9CCE5539211A" unitRef="usd">-1339000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-86A069C5ACD1D0BA87979CCE55395896" unitRef="usd">-3555000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5D96AFD727E41E0E138F9CCE5549AEEC" unitRef="usd">2007000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B3CDCDFE2E238AE3FB449CCE552939E0" unitRef="usd">3377000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BA6B28974164E4899B8C9CCE5549DDFF" unitRef="usd">-3476000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5460FC2F97A8E81AC8E89CCE5539942A" unitRef="usd">-1509000</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D9F7B682CDA322ED4D9D9CCE55582340" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CED9224E4EB4F79D89389CCE5549EDB1" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-11CE02772E49D7933EBA9CCE55686D74" unitRef="shares">6000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DB2F435A14F045641CCF9CCE5568E137" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-161FD1045A590592F8389CCE5568DBD4" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9B4F24542C873198AE519CCE5568FCC1" unitRef="shares">3113000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
	<us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-08219D631D25DB1B8F749CCE55684CEF" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
	<us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-74DBFF5630A608BE9B409CCE55686FD4" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
	<us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A70437AF47E347CBBE439CCE55683893" unitRef="shares">1000</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
	<us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BF65D36F476FB421FB059CCE556858B7" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
	<us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="FD2017Q4YTD" decimals="-3" id="Fact-95F8C6ABD8580387030E9CCE5568666B" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D2C41FC08832440DDF299CCE556802D6" unitRef="shares">1638000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3A172668DD373349DF3C9CCE5568BBA8" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8964639FE6117D29A8D89CCE55688494" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:InterestCostsCapitalized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-02B4C28CFCFA220876949CCE5549709A" unitRef="usd">800000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-AE52BC71B88904009CB19CCE5549D644" unitRef="usd">-848000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-94468D5EAA0087250CB79CCE5549FB10" unitRef="usd">1500000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-A7563B7013F50C7340CB9CCE55497DEB" unitRef="usd">-1491000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-095960A80DD901B54E3F9CCE5549CFC9" unitRef="usd">1100000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-8ECA616E078BE85015C09CCE55495ED4" unitRef="usd">-1101000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-902653EAE85C1FD902379CCE5558E542" unitRef="usd">7725000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FF175CD8F722B6A2C1E19CCE55582E83" unitRef="usd">7061000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EB38EDCB715E1E01BBFB9CCE5558D2EA" unitRef="usd">18047000</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-969EDB453AB3F435B3D39CCE5549676C" unitRef="usd">7725000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-D4C026441E5175DB36DD9CCE554939B7" unitRef="usd">7061000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-48C73ACFBDD48A85DBEA9CCE554946A7" unitRef="usd">18047000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebtExcludingAmortization contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-4791740F200D9BF4247D9CCE55498E10" unitRef="usd">3856000</us-gaap:InterestExpenseDebtExcludingAmortization>
	<us-gaap:InterestExpenseDebtExcludingAmortization contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-F1D33415B16C7D68D4699CCE55492513" unitRef="usd">3852000</us-gaap:InterestExpenseDebtExcludingAmortization>
	<us-gaap:InterestExpenseDebtExcludingAmortization contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-3" id="Fact-6E7B19429223416106499CCE554969ED" unitRef="usd">7344000</us-gaap:InterestExpenseDebtExcludingAmortization>
	<us-gaap:InterestPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1DDFEB091147E4072FEB9CCE555892E8" unitRef="usd">4224000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7DAF5B5B72DE3DF57C779CCE5549944B" unitRef="usd">3852000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-975B8D946004FF1B65409CCE5549D7B7" unitRef="usd">6896000</us-gaap:InterestPaid>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-C835D5F5D779B2C39A9B9CCE55581F60" unitRef="usd">7915000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="-3" id="Fact-19279FA3C68769E507F19CCE5539BBE9" unitRef="usd">16540000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-BF01A36BF662108396C99CCE5529F578" unitRef="usd">31278000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-3" id="Fact-AE379F8EC3CEA85CF93D9CCE552952D8" unitRef="usd">41411000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-FBCF6EA49742A430866D9CCE55584BFB" unitRef="usd">11742000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q4" decimals="-3" id="Fact-EB1F730F00143ECE63E19CCE55392CDA" unitRef="usd">16500000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-3" id="Fact-5B70393CD28E5AABD7229CCE555849D1" unitRef="usd">11621000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q4" decimals="-3" id="Fact-39373A5DC256760F74659CCE55392433" unitRef="usd">8371000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q4YTD" decimals="-5" id="Fact-01441003F22F2E51B857B9EE21B83F54" unitRef="usd">20700000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2017Q2QTD_pcrx_ProductAxis_pcrx_DepoCyteMember" decimals="-5" id="Fact-224C3362956B553ABFB8D1B440C0C3E4" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B985BE3EB1B5C041900F9CCE55583212" unitRef="usd">678000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4258A797D25D928F1B6C9CCE5558F693" unitRef="usd">1323000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-46BCA42D2D6C6F67C8E39CCE55584967" unitRef="usd">4078000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-2E7BECD42D72E326A41B9CCE554971A2" unitRef="usd">172490000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-589FE37A3463AC5472D69CCE55295EAF" unitRef="usd">348888000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-6703118251E16B622C4F9CCE5549B7DD" unitRef="usd">391466000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-AF8AD50AC63D29894FCC9CCE55294454" unitRef="usd">628371000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7DC7C2E7CD26458B1A449CCE55395EF5" unitRef="usd">44838000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F395B63FEDBFC3E42F4F9CCE55494C0E" unitRef="usd">56217000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-F605F5C5A7C1E5E58507B70461426113" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-09D6F57DBAFD551C9C299CCE55494E37" unitRef="usd">108738000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-681CC0D5DB4DC5154198B7115D28A002" unitRef="usd">300000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-3B7F5158C501BA7ECDAAB7045E434926" unitRef="usd">276173000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-3" id="Fact-FE6610FFAEE84441C5589CCE55492629" unitRef="usd">324000</us-gaap:LongTermDebt>
	<us-gaap:LongTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-E1BB90CEC464F556E84E9CCE5539C0AC" unitRef="usd">0</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-E2EE5B6CEF490D337F249CCE5529F142" unitRef="usd">60047000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A28567C68E8907B179589CCE5549D5A0" unitRef="usd">19464000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BAD23588DC7F8F66E5FE9CCE5549AF4A" unitRef="usd">-21040000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-617AEEF12C02EC057FEB9CCE5558954A" unitRef="usd">18182000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C3A2003CA525971D995C9CCE5529D0D5" unitRef="usd">10699000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA5657491062A9CFF0DC9CCE5558252D" unitRef="usd">7261000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AF19F7EF37FBFC01A6179CCE5558B639" unitRef="usd">224162000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BD2A617185FD24016E649CCE5549F851" unitRef="usd">-19256000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B947E45D29B3A5A2F7169CCE554994FB" unitRef="usd">-61754000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5151371530C73B12E58E9CCE55491945" unitRef="usd">-223765000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3318D2F9D4D49B2CFAB19CCE55490EB1" unitRef="usd">28021000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-00227270281EBDA0AB0B9CCE55399D63" unitRef="usd">33453000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F98A83935C31ACCF85959CCE553992C6" unitRef="usd">17785000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F0A0D454A958DB7F71809CCE555807DB" unitRef="usd">1856000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E03D796DC9DFF2C388C69CCE5529FC42" unitRef="usd">1856000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-8C10243F28F260B13E719CCE5549D06C" unitRef="usd">-3854000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-C69ABBEC1644864E758D9CCE5549C1B2" unitRef="usd">-7958000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-2C86B79052EDC164E0309CCE5549C89F" unitRef="usd">-22164000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-A8483D513EEC67ABE6DE9CCE5549950D" unitRef="usd">-3973000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-488D7B168D199B76DFBC9CCE55498805" unitRef="usd">-37949000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-82D856DEF1DE189ECF779CCE5529E8F1" unitRef="usd">-37949000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B3B347441801AD0DC1269CCE5558A01E" unitRef="usd">-19866000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9FC062B46298026337C29CCE55583565" unitRef="usd">-19743000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-7D827CEB58DAA2FE3B1D9CCE5558571B" unitRef="usd">-7597000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-3" id="Fact-507FF531B7E80FE57FCC9CCE5558581D" unitRef="usd">4595000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-219D8136E3005C0698F89CCE5558E5B9" unitRef="usd">-42611000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A72CCBE530D73F979E76A4FCE58332FC" unitRef="usd">-42611000</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CD3E6DAAD8E8FDD3446A9CCE5558A580" unitRef="usd">-7335000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DE62AE2D0AADAB6339A09CCE5558F63E" unitRef="usd">-5820000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-600C75110172BF9F60BF9CCE5558EA40" unitRef="usd">-17534000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NumberOfReportableSegments contextRef="FD2017Q4YTD" decimals="INF" id="Fact-9E04230878FFA2BB18559CCE5539AC52" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A946F4F3157B704712C59CCE5558C0D3" unitRef="usd">239542000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD" decimals="-3" id="Fact-F76DEF9BCDEF5656346D9CCE55491770" unitRef="usd">67728000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2QTD" decimals="-3" id="Fact-9DD06892437FA6E3423F9CCE554900E1" unitRef="usd">76084000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-9166F5D378BD05CC01FC9CCE5549010B" unitRef="usd">89220000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4QTD" decimals="-3" id="Fact-C32B1ECB7E970ADF19E09CCE55498D44" unitRef="usd">75363000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E49831DB187EB54A50C29CCE5558CD3D" unitRef="usd">308395000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD" decimals="-3" id="Fact-439797CC9DADB4FBC9759CCE55583F51" unitRef="usd">83333000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2QTD" decimals="-3" id="Fact-BBDBEB610022B21B3C389CCE55585F26" unitRef="usd">86714000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-14C24606FCFC3FAFAB4F9CCE55588CD4" unitRef="usd">70907000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4QTD" decimals="-3" id="Fact-9CDB1C38C14943F19F6A9CCE5558F943" unitRef="usd">70613000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DF68C51961AB1EF217439CCE5549EA6F" unitRef="usd">311567000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-41EAAA08AFEE76D935DD9CCE55494DC3" unitRef="usd">9455000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5B2A4611DDECC2DB57E49CCE55582EEA" unitRef="usd">-32024000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B90710FBFB0F128B64399CCE555841C4" unitRef="usd">-24937000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q4" decimals="-3" id="Fact-42B474202B14AE6AF9D39CCE55295AAE" unitRef="usd">53733000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-007A4237B29103072B2A9CCE5539CF92" unitRef="usd">7886000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q4" decimals="-3" id="Fact-9F48DEDC660C190A26579CCE5549DCB9" unitRef="usd">5366000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q4" decimals="-3" id="Fact-C1B62CC462759F2AEE229CCE5549A051" unitRef="usd">5245000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q4" decimals="-3" id="Fact-EAD99856F6A606C0A30D9CCE5529640C" unitRef="usd">7570000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" decimals="-3" id="Fact-AE6F5437C5C0CA21D84C9CCE5549A652" unitRef="usd">8089000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q4" decimals="-3" id="Fact-36FCCD81B8E1A199C4AF9CCE5529D6E8" unitRef="usd">19577000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9C069A04B560B71484779CCE5549F5EE" unitRef="usd">5700000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-47A58D065ED3AA714AFE9CCE555817BC" unitRef="usd">6000000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-939DE07F31DEFA615A569CCE55581148" unitRef="usd">7500000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-437FF581D2B3A39CA7AB9CCE5549A6EB" unitRef="usd">380500000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-3C40009D89244AFAE4F99CCE5549DF8E" unitRef="usd">232300000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AD71D7DC88D978D815D89CCE5549044F" unitRef="usd">624000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BCCB248B3A7BBCE5BB1D9CCE55398CCB" unitRef="usd">825000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-2DE2BD3F29D38D5B304E9CCE55584F97" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-F3C18468A8807E2BF0AE9CCE5558781C" unitRef="usd">-424000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D96636FE463C14CE4CCC9CCE5558D3E1" unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AC5128CF3C68E38980779CCE5568C0D6" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8C78C7ABBB32C4989F0A9CCE55680F89" unitRef="usd">-424000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6141C631A832AA5D5FFC9CCE5529D8B4" unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6EF825305644427199F69CCE5558A8A3" unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DE1C8AAA044BAE3B4B799CCE55689BCF" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-DDD493982B2B6BB3228F9CCE55291840" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BF479035AF35DFD20B099CCE5568A6D1" unitRef="usd">-424000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6D7C205056B72CD54701A4FCD89081A6" unitRef="usd">-424000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F882926F13850AEC56099CCE55394824" unitRef="usd">18914000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-410668549FE954F450039CCE55397104" unitRef="usd">16498000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0D5D9FFB49177F1C59939CCE5558BA68" unitRef="usd">-165000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9159C9715A24336864BF9CCE55493A9E" unitRef="usd">-82000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-35DE25A86079A63D109F9CCE5558932A" unitRef="usd">167000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsForPostemploymentBenefits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EDD2A0430C57215AFBE6A53830345620" unitRef="usd">303000</us-gaap:PaymentsForPostemploymentBenefits>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E8BBD7E0E4CCBCD1243BA51B71D15D4F" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E4C7813C0787F5F3ABB1A51B6EC144A0" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-56BC533C661F75FEEFE9A51AEA9C3C84" unitRef="usd">11000000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="FD2015Q4YTD" decimals="-3" id="Fact-10B0F64AD6B589F98F91A5197FD3175E" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
	<us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D5A16665DD7CE3213B19A5197FEB6A4C" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
	<us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CF968CA9BB641CFE9F04A5197FBFC468" unitRef="usd">15000000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="D2017Q3SD" decimals="-5" id="Fact-0166273BEC3797594BFB53FD6F6345A9" unitRef="usd">15000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-15BFBB87D1AA535BBD219CCE55493F98" unitRef="usd">189082000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0D71742320C66843EA449CCE5539CC26" unitRef="usd">192815000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CF8E83BC08D4D7DB7BBB9CCE55587089" unitRef="usd">502752000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5C8B294716E8EE9D3BD89CCE554978D6" unitRef="usd">40295000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0F7241FEE333718AD6539CCE5529B751" unitRef="usd">24709000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B315EACE9FB258915F269CCE55396A04" unitRef="usd">19266000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-004CB1FEC429123C02089CCE55491E85" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-A0BF39A11536A0CF062C9CCE55493833" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-575A2EEAF9192345DE3D9CCE5539D20D" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-AE1F4C13C2378C65DD579CCE55491134" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-42C9079D7689602E28349CCE5539BFD3" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-1BC3C857E276619819AC9CCE55390070" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-E9F8DDB0E79B9E0A0CA39CCE55492F57" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-872841D985864D5C26AA9CCE55497D03" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-3CAC8865864EFD1AA97A9CCE553958DB" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-2849F811325A0C76B6669CCE55492203" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BBC865CDF2CAF10FFE6C9CCE5529A6B7" unitRef="usd">9277000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-CC1201516E556CFA407A9CCE5529479E" unitRef="usd">6694000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-45E28DCBC09C92EFEC20A51B6A43C43E" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-33C03C42F0CBFAACB6B7A51B66F7DC77" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-57782B46E05DD0D9C0C4A51A9AAA6E2C" unitRef="usd">345000000</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromIssuanceOfDebt contextRef="D2017Q1Mar13_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-5" id="Fact-31408C2E97250CB0D70AB6DC05104C8D" unitRef="usd">345000000</us-gaap:ProceedsFromIssuanceOfDebt>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B88BCDCD14BF64013E419CCE5539212B" unitRef="usd">217240000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ECBBC4884DAC8E2050F49CCE5558351A" unitRef="usd">171627000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-30070D4912AE858DFEBD9CCE5539BC87" unitRef="usd">321713000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7E45A9A6D89543585D079CCE5549823B" unitRef="usd">10073000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5DA7C9336239260FCF449CCE555804DC" unitRef="usd">5770000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-ACFAED7B6A81D5E98BDF9CCE554974DB" unitRef="usd">6778000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-81246F6529C0D89C19A99CCE5539297C" unitRef="usd">138526000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-E9F72103AE68BC12D7399CCE5539D5D9" unitRef="usd">5623000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-9E62D3BF0B91F31481729CCE5539DBAF" unitRef="usd">63201000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-5F4A21E3D23C6A7509D19CCE5539FC36" unitRef="usd">1606000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-135C20B9DD8ECF197B869CCE5539AB3F" unitRef="usd">33787000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-A140F8168A5F72A008A09CCE5539AC5A" unitRef="usd">34309000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-2CA458AE2550C8805EB49CCE5539BA9A" unitRef="usd">156256000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-3711B556A9FD452EC2189CCE5539446B" unitRef="usd">7086000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-C0EB3228D88C282795699CCE5539541A" unitRef="usd">73632000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-61650F0987A054A5ADD39CCE55390D1D" unitRef="usd">1603000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-1B44787190E3701D7FA49CCE5539EB7A" unitRef="usd">34933000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-6709BA493463AA4BEEFB9CCE5539573C" unitRef="usd">39002000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-C51939ADEAFA248DD5019CCE5529FDBB" unitRef="usd">101016000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-B06A4ED541F5AD7113EB9CCE5529BF8B" unitRef="usd">107046000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-6EE414E1EB33F21CBC599CCE5549A376">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pcrx_ComputerEquipmentAndSoftwareMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-9D0C5FC924C4D3EBA8F39CCE5549DD8A">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-84ADCFC83C437992A1EE9CCE5558D8A0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-CE92E9DA991C76A91D629CCE55582455">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-FA5442BEB92C9243B9949CCE55587069">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PurchaseObligation contextRef="FI2017Q4" decimals="-5" id="Fact-62C2170A5CDE1032CA859CCE5568DF2A" unitRef="usd">300000</us-gaap:PurchaseObligation>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-D7739D0AF99240DBA9A89CCE5558C57F" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-9F651BDD606C7148351F9CCE5558CB83" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2015Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-5" id="Fact-7EBCF67ED1DC214B9E139CCE55584204" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2015Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember" decimals="-5" id="Fact-E946B418A10EA659D2B49CCE55493784" unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2016Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-5" id="Fact-76FB80D231133ECE9A4D9CCE5549B5BD" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2016Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember" decimals="-5" id="Fact-FBF69EA35CB878E42E309CCE55399FE8" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2017Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-5" id="Fact-CBA8A7ADE42EDDA631A41F0BB4555D84" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2017Q4YTD_us-gaap_EnergyAxis_pcrx_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pcrx_MPMAssetManagementMember" decimals="-5" id="Fact-FCF260AEE99F4A42BFD3206E5B482FBB" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RepaymentsOfConvertibleDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1ED775D7AEE7276D57729CCE55588BBC" unitRef="usd">1467000</us-gaap:RepaymentsOfConvertibleDebt>
	<us-gaap:RepaymentsOfConvertibleDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-18E4F8D1E0385906F33E9CCE55295B26" unitRef="usd">4000</us-gaap:RepaymentsOfConvertibleDebt>
	<us-gaap:RepaymentsOfConvertibleDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FF0FEF0F808D83B926D79CCE5558468A" unitRef="usd">118193000</us-gaap:RepaymentsOfConvertibleDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" decimals="-5" id="Fact-A128B8AC66E78745765CB713E807699F" unitRef="usd">300000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7F80D088C857B7E0239A9CCE55587EA4" unitRef="usd">28662000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5171BAE2267BB264341A9CCE5558E5A6" unitRef="usd">45678000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D856ED7635DBAAF853B49CCE5558805D" unitRef="usd">57290000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedStockExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BDCCE72ED37F6D90787E9CCE5558F693" unitRef="usd">2887000</us-gaap:RestrictedStockExpense>
	<us-gaap:RestrictedStockExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-92F3869DAB9F3DC15BBB9CCE5558A32A" unitRef="usd">5117000</us-gaap:RestrictedStockExpense>
	<us-gaap:RestrictedStockExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9DCA1CEF75CC9E4197129CCE5529EC53" unitRef="usd">6698000</us-gaap:RestrictedStockExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-F78B9E8E8E5D7AD526829CCE55398157" unitRef="usd">-346238000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-68E9FF74CD4A2993AACD9CCE554939E7" unitRef="usd">-389136000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D3EE270AC177F2C11D039CCE555817BA" unitRef="usd">248997000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-3" id="Fact-EAB22B8E884AC669C43F9CCE554932D6" unitRef="usd">65474000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-1021C78B29FBF7C4AE849CCE5549B39B" unitRef="usd">69640000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-DFCBFA67D292C831E5839CCE5549463F" unitRef="usd">68355000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-3" id="Fact-A76B0A60640D9C94630D9CCE5549CFAC" unitRef="usd">72902000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C99262CE006FF08DDFE99CCE55490471" unitRef="usd">276371000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_pcrx_ProductAxis_pcrx_DepoCyteMember" decimals="-5" id="Fact-4F6469A372DA7147F2D2D1B1140E25D9" unitRef="usd">276400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD" decimals="-3" id="Fact-796089585171580A2CC49CCE555896A8" unitRef="usd">69283000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-A5ABA0AFCC433E9D8ACD9CCE5558BC10" unitRef="usd">70934000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-3" id="Fact-565954AA9450F1F061039CCE555808EF" unitRef="usd">67335000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD" decimals="-3" id="Fact-47CD67B79E5230F2E2EE9CCE555851AD" unitRef="usd">79078000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-ECD65DDCAE9A3BF98E499CCE55397CF6" unitRef="usd">286630000</us-gaap:Revenues>
	<us-gaap:RoyaltyExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-56D3DFCE5D0CF9E4C55B9CCE5558B42E" unitRef="usd">71000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2C1D533F2841080E6E9F9CCE55587891" unitRef="usd">0</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E87C32BF29C98451BD099CCE554903FB" unitRef="usd">0</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-540F89E5256D98FFF5209CCE5529555B" unitRef="usd">3084000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-238AFDD779AF2AC0463E9CCE554943D5" unitRef="usd">2872000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E33D4DDCB497CAAA480B9CCE55495680" unitRef="usd">1901000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E9B2E3622932388568069CCE5549D6E4" unitRef="usd">244487000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8E0C0FA85AA9F80F0E919CCE5539976D" unitRef="usd">270073000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-92C00431362AE9EF03579CCE55589C07" unitRef="usd">284342000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6B781AFF1B04324C7F529CCE55493D05" unitRef="usd">139043000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E7BF57982851576927C99CCE55582F59" unitRef="usd">152613000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AF5F3A5780BEF5EEA8C89CCE5549B96A" unitRef="usd">161494000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SeveranceCosts1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-29CA91266C74D73CE777D1CA7EA5FF29" unitRef="usd">303000</us-gaap:SeveranceCosts1>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-12DA245D7588D3A63DD59CCE55586BC1" unitRef="usd">33368000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B4E19FAA9CE6588F6B119CCE55397202" unitRef="usd">31248000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-923C6B8448452FD544EE9CCE55583A50" unitRef="usd">31601000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-E2B415892304F25B95019CCE5549B432" unitRef="shares">15848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-931266D9B6DDE7BE8BA19CCE5558DC2A" unitRef="shares">46939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-1316EA614347FCB223CC213E2E29639B" unitRef="shares">107061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-46F08CBE0B67CAB1C09D9CCE55588F99" unitRef="usdPerShare">79.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-F615CDB54FADF1C710AE9CCE554998F7" unitRef="usdPerShare">68.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-EDFEA6F9CCD9F1437B7F213E30600C1B" unitRef="usdPerShare">49.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-CC50D8DFF463C546DCE39CCE55585447" unitRef="shares">232046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-39E4EF753641172EDE479CCE55494A93" unitRef="shares">256631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-7FBCB9C95EB2856C0F71213E22634467" unitRef="shares">343583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-1C6CDE4955A9078D4C6B9CCE5558ADB1" unitRef="usdPerShare">78.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-8A9B1E0499555EB9855A9CCE55491BF7" unitRef="usdPerShare">40.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-6C8F87AB1CF277F8D946213E24B73A18" unitRef="usdPerShare">44.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-ECFDFD06C3F85B8F68C89CCE55496010" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-A371BD048A856F154AA39CCE55584F7C" unitRef="shares">216198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-E351EE1810FEFEDF48739CCE5558EB90" unitRef="shares">364403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-3A28975C49E5DAE3EF19213E33A3358C" unitRef="shares">499546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-B702FBA126A63CC668DA9CCE5549032D" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-4B6F5C97D5C2D54A8D0A9CCE5549CA9B" unitRef="usdPerShare">78.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C56A245C2675C1C7B8C49CCE5558D8B8" unitRef="usdPerShare">52.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E3383AEA2475FAC6DA05213E35C5A947" unitRef="usdPerShare">47.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-38670D63C769935AC76C9CCE55493C9E" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-395F3FE845E4ACD135199CCE5549453B" unitRef="shares">61487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B78F7B248BE97348DCD09CCE552962AA" unitRef="shares">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-099E5BAA3EFB76F4DE15213E28190FDB" unitRef="shares">101379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FEFC8B04937EC5085B87A4FC5B9851C1" unitRef="shares">101000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-ECF85217B7433D0D4A249CCE5549B701" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-58D7DD51EA219D404DA09CCE5558405B" unitRef="usdPerShare">78.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-306AEE033F65FA0C92F9213E2AF1DA19" unitRef="usdPerShare">53.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" decimals="3" id="Fact-FC91838709D0F7D315B49CCE5539818E" unitRef="number">0.507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-AF26B0C0843D04250FA69CCE5549451E" unitRef="number">0.529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" decimals="3" id="Fact-720AB3562586CD881AF79CCE5539A131" unitRef="number">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-E97513E01E135D13331C9CCE5549D9C4" unitRef="number">0.535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" decimals="3" id="Fact-6B2622B3B19CBF6FADBC20B5F7450DC5" unitRef="number">0.538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-68C4E9B5AD20CAE299BA9CCE554977B7" unitRef="number">0.514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-59C76F90551650B9B46D9CCE5539C623" unitRef="number">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-6D864299C64F25DD33699CCE55391712" unitRef="number">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-43F285828D503085625F9CCE5539BBA1" unitRef="number">0.0049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-11CF3AF5F77A90FFCE389CCE55395AEB" unitRef="number">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-D56D61926B16AAED12A620B99C52EF34" unitRef="number">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-CFA0710368673AE347EB20B9948188E9" unitRef="number">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-4B8690D33D12883EEF559CCE55397857" unitRef="number">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-EAAA23389E7D371802899CCE5539875E" unitRef="number">0.0248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-57743FE71A36DD9BDF9A9CCE55397BCF" unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-DF011349F7778832CBDB9CCE5539D3C1" unitRef="number">0.0140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-555A70251E7A06FAB3119CCE553941E8" unitRef="number">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-F0FACBC62A40AAFB2BF49CCE55395DB3" unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="FD2017Q4YTD" decimals="INF" id="Fact-CD6E9F3A31165709E66C9CCE554972ED" unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-CCE9C8093593ADFCAB829CCE5529AA38" unitRef="shares">12129537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member" decimals="INF" id="Fact-2F700F56594CA8F309429CCE55294CA6" unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_StockIncentivePlan2011Member" decimals="INF" id="Fact-DC74D451684485E54C559CCE5529DBFE" unitRef="shares">9931700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_TwoThousandSevenStockIncentivePlanMember" decimals="INF" id="Fact-F4CB6CD7813EC4B49CD69CCE5529DDFD" unitRef="shares">2022837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2014Q2Apr30_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member" decimals="INF" id="Fact-659EE6297E017E44F2309CCE5549709B" unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4" decimals="INF" id="Fact-D9A8F5CF0BD10A460F4B9CCE552945DE" unitRef="shares">3016477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member" decimals="INF" id="Fact-2134E20271BEC939B22D9CCE55291314" unitRef="shares">122724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_StockIncentivePlan2011Member" decimals="INF" id="Fact-A88B7C13F65D0D9A404A9CCE552920D0" unitRef="shares">2893753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4_us-gaap_PlanNameAxis_pcrx_TwoThousandSevenStockIncentivePlanMember" decimals="INF" id="Fact-810CA38A00F648724F7E9CCE5529FAD0" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-B9D39219E3C6F4F105429CCE5539936B" unitRef="shares">2882384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-771389BAAA6927BEAF059CCE5529A8E6" unitRef="usdPerShare">42.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-A0D80873E7FF95650B189CCE5529C0F3" unitRef="usd">39401000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-52126CE423BBE04814159CCE552941DE" unitRef="usd">21750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-466625F06BC8E090E95F9CCE552929A2" unitRef="usd">15865000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-821813BE72ECB12AFB369CCE5539E917" unitRef="shares">25526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-45480F4AEAECF551317F9CCE553969F7" unitRef="shares">175303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-03C42DB0DF50038592779CCE552918E4" unitRef="shares">232989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-0E04E9DCAD44190AE8F59CCE55492249" unitRef="shares">294880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-8FA9954096083633D66A9CCE55398C57" unitRef="shares">401048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-EA68E14EAC675EF892809CCE5529FD1B" unitRef="shares">555897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-D1CA7B8F42CECE0B43CE9CCE55296124" unitRef="shares">906706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-E6D0E52F4DC4A9CCD6639CCE552941ED" unitRef="shares">1656598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-09C90040C8E4C1B421C99CCE5529BB58" unitRef="shares">1072625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-676E9F044235E5FFF6B39CCE5539D7FF" unitRef="usdPerShare">25.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-0B66B26CD11F32F6160B9CCE5539812C" unitRef="usdPerShare">21.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-C7088371F5169EE303259CCE5549122B" unitRef="usdPerShare">37.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-D8D24115FC7822BB12C69CCE5539754B" unitRef="usdPerShare">25.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-A332DDDB6D9A3ACFD9C19CCE5539C9D2" unitRef="usdPerShare">10.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-64D6EC4FC0F7132FBD369CCE5549816E" unitRef="usdPerShare">19.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-57F90A997A86FCC3AFDE20B999120157" unitRef="usdPerShare">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-346D2EB99E337F31247320B9913FD7D1" unitRef="usdPerShare">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-6CB496E9F419BDBA93C79CCE5549F501" unitRef="usdPerShare">20.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-BD2E63D97A7800D6783E9CCE5529C378" unitRef="usd">248276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-035CE8A640D49EEA92869CCE553919E8" unitRef="usd">162340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0EA1785987A2EBCBA06B9CCE55391270" unitRef="usd">37581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-E9EDB4632C6AE7D3F6FA9CCE5529EA97" unitRef="usd">57021000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-3694A07747F4722480739CCE5539D1AA" unitRef="shares">4677856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-8F61F804D33C0688644A9CCE55391B99" unitRef="shares">4645722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-18CA5C882D45256B796E9CCE552942E9" unitRef="shares">5207743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F5A051BD25BAC82029C49CCE55295183" unitRef="shares">4951493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-D17D6AF1C47076E7873B9CCE5539D40B" unitRef="usdPerShare">35.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-7C8343BA93C244D41DA29CCE5539CDFA" unitRef="usdPerShare">44.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2A75B2BE278E320060FA9CCE5539710C" unitRef="usdPerShare">42.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-18DC000BF5FA8383FA489CCE5539AADC" unitRef="usdPerShare">43.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-67C930FE72AD06AD53999CCE5529613F" unitRef="usd">57021000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-77255B312FB9B2B3C2699CCE55295E4D" unitRef="shares">4951493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-7592E299ED62F29B5D269CCE55295734" unitRef="usdPerShare">43.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-2380B4669159183040819CCE5529C714" unitRef="shares">9113060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_InducementPlan2014Member" decimals="INF" id="Fact-0DD6ADFF9AE8649B6B899CCE5529B596" unitRef="shares">52276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_StockIncentivePlan2011Member" decimals="INF" id="Fact-01A3F080B49C312F84B59CCE55298F06" unitRef="shares">7037947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pcrx_TwoThousandSevenStockIncentivePlanMember" decimals="INF" id="Fact-557E228F4682FE6D0B1B9CCE5529ABA5" unitRef="shares">2022837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-EEFF352965021A6928BE9CCE5529930C" unitRef="usdPerShare">16.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-52836BB49E8983E526D59CCE5539B5CF" unitRef="usdPerShare">11.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-D61DB95A291CE4DE8C2C9CCE5539C838" unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-FC694BB97152EB9520049CCE5529FC63" unitRef="usdPerShare">81.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-916269979A5D221E7D659CCE55294698" unitRef="usdPerShare">80.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8D0676066D6B509EAB3F9CCE55393E04" unitRef="usdPerShare">74.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A5F583E69BEF919A0D0F9CCE5539D96E" unitRef="usdPerShare">64.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-9F4274F679939A798D539CCE5539EED8" unitRef="usdPerShare">70.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-6D06E5C0F7567564B06A9CCE5539FF92" unitRef="usdPerShare">48.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-92D8F35FE569D8325BB29CCE5529D6B3" unitRef="usdPerShare">75.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-76FA19E6E0DD953395589CCE5539819D" unitRef="usdPerShare">38.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2140F91E5585644F82389CCE55395261" unitRef="usdPerShare">43.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2017Q4" decimals="2" id="Fact-16F62FAC1678742A85909CCE55581979" unitRef="usdPerShare">45.65</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2017Q1Mar07_us-gaap_DebtInstrumentAxis_pcrx_ConvertibleSeniorNotesDue2022Member" decimals="2" id="Fact-F8B01555F71977C053C1B6DFE30D2475" unitRef="usdPerShare">48.65</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-AC856EE4925DBDDA22749CCE55491BE8" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-467A448A4006ABBCCA2C9CCE5549A51E" unitRef="usd">16602000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-EA8A9865E85A1FDEC8A19CCE55588229" unitRef="usd">11824000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-69EECD2A6E12375530EF213E37DECFE0" unitRef="usd">22804000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" id="Fact-67124EDE48583DC73C4E9CCE5539E8DC">P0Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-2442E2AF49AD7E3563029CCE55499349">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" id="Fact-8118A59FE93E3EF015049CCE55393775">P0Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-66AF6E158AB9FE9A0A9A9CCE5549EDF9">P5Y9M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pcrx_EmployeeStockPurchasePlanMember" id="Fact-149785B8EEC06E2D3F1820B997D2958D">P0Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9F3C1063E5C219F42AE89CCE5549320A">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-DA4F1006A6F06258F8CC9CCE55297F53" unitRef="usd">47082000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-17F452EC5654640DDB159CCE5539848B">P5Y6M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-31C57FA6BA8ED8FF3E339CCE55294246">P7Y10M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-1911213AFDB63C5DDB0F9CCE5529CDF2">P7Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-3EA957FD15B1B289927B9CCE553931DF">P7Y4M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-42F2930869AFFA7D86359CCE55294D28">P6Y10M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-79B9888195A132CCEF859CCE5529C5C8">P6Y10M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-ED84C367598AE48EDE909CCE5568AEFF" unitRef="shares">36151000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F432CDAA8B540AB66E529CCE55583F06" unitRef="shares">36848000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E3EAC1526FF30D64D9209CCE5539B388" unitRef="shares">37481000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A9216E5F0BEFB2F309ADA4F7A0806F32" unitRef="shares">40669000</us-gaap:SharesOutstanding>
	<us-gaap:ShortTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-190F9E9B8570B24A239D9CCE55295374" unitRef="usd">136653000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-B17EDC6AD1F51576FCCB9CCE55399FE6" unitRef="usd">257221000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C5538DD928E92EE49D569CCE552951A7" unitRef="shares">44000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EDA0116D0F17D6AFE53EA4FC8A041AD3" unitRef="shares">2490000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-CC5522D85BE0C6F4C59F9CCE5558C5A2" unitRef="shares">35000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E7E29873B63EEB03EE889CCE5568D8E5" unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD" decimals="INF" id="Fact-2146994E13E735F20DF09CCE55298DED" unitRef="shares">160147</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3CABCE15AC8A06DC90FBA4FC69EF4970" unitRef="shares">57000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-52F9DCC0D54FA22C19139CCE5539C9D8" unitRef="shares">618434</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2058439AF23B5DD44F2C9CCE55397E24" unitRef="shares">618000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-6C652E519D78B910D9B49CCE552999B4" unitRef="shares">518226</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-54C2FD34831CF7C95F4A9CCE5558B5C7" unitRef="shares">518000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F37089741648EDE0A7009CCE55391376" unitRef="shares">539989</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-48D5AB8A2C7DC7CC1F58A4FC4ACEBED1" unitRef="shares">540000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7F4711DFA15270259779CCE5558C701" unitRef="usd">3929000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-87C4B2F3BB53BC97AFF19CCE5558C9BC" unitRef="usd">3929000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F03CBE3A8932D08AC4EDA4FC9A1439D1" unitRef="usd">120960000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-608A598DAE229435CF2FA4FC92D51446" unitRef="usd">120957000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5C4AE728B50F295DB9DDA4FC8E9BAC19" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2FA2F568BD79F377EA7F9CCE5529E4B0" unitRef="usd">2093000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FF671C7D52A7B2AE77909CCE55292BE8" unitRef="usd">2093000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD" decimals="-3" id="Fact-279111C87DBE21CB00CC9CCE5539E609" unitRef="usd">1495000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-446E0B49F76D70E328029CCE55491411" unitRef="usd">1495000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C08CA21966B8FE1C7415A4FC7B0C8E24" unitRef="usd">1862000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EB6F081A5F8FC488B1B7A4FC70FF26F7" unitRef="usd">1862000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="FD2016Q4YTD" decimals="-3" id="Fact-06E131BFA2808799D1219CCE55299D86" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
	<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="FD2017Q4YTD" decimals="-3" id="Fact-40E9FCFAE592792CA0EBA4FC68624AF8" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4D2D95B4AD8F1E3A37269CCE553976D9" unitRef="usd">10073000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1978922AFA48CAB9320B9CCE5539D945" unitRef="usd">10072000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5B870799177E26A67CEAA4F8E36E7AA4" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-97E5D77AFBBD6CF0BE6D9CCE55589A4F" unitRef="usd">5770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A4584164C10A6FE045739CCE553949CE" unitRef="usd">5770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1EA64C60E5750C71BAACA4FC5A856E61" unitRef="usd">6778000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-25BC650F34D38947AAF2A4FC524F04BF" unitRef="usd">6777000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-CB4458017B6BB5293C09A4FC4F03721C" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-AE4F154981CDE1EA0C8E9CCE55299E63" unitRef="usd">171145000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B104BB9B836CC91142409CCE55493543" unitRef="usd">-80000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E46331EA81922D6BA4779CCE55297DAC" unitRef="usd">481334000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-14EFC3A45C9A0845F7B39CCE55398264" unitRef="usd">36000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-68CFDB144CB144EDFE0C9CCE5558C253" unitRef="usd">-310145000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-73E9E633E8B931F2E45A9CCE5549930B" unitRef="usd">218392000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-49B3AA925A79F7D662569CCE552949F6" unitRef="usd">-52000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D228478F32B6ABBB91349CCE552962CC" unitRef="usd">526696000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2DD942E9D08D582453E29CCE5529CE1A" unitRef="usd">37000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-169630919C71C13D92349CCE55299CF1" unitRef="usd">-308289000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-9968371D578C2273D6659CCE55390460" unitRef="usd">218976000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-42C5CB2E77EB4519868E9CCE5558880F" unitRef="usd">-30000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-933E5B677F3275EDA41A9CCE55492F88" unitRef="usd">565207000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-47F6D203CB7FAD368E339CCE5539B45E" unitRef="usd">37000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CB9408D9427AA05029C49CCE55294258" unitRef="usd">-346238000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-D9ED877415874DFA0FA99CCE5529D835" unitRef="usd">279483000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E98A4D7503928CE36A12A4F7B2250C9D" unitRef="usd">-454000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0FCB95E59DBF047D9824A4F7A94BBE27" unitRef="usd">669032000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-1373F93D2892CF09363DA4F7A4CE5EED" unitRef="usd">41000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DF3950C9C464FB7ED97FA4F7AE383110" unitRef="usd">-389136000</us-gaap:StockholdersEquity>
	<us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount contextRef="FI2016Q4" decimals="-3" id="Fact-FA4D903774860DA5E7DAA520F0904653" unitRef="usd">0</us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount>
	<us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount contextRef="FI2017Q4" decimals="-6" id="Fact-4D64360D8DA056906FCBA4CE3EC16C32" unitRef="usd">14000000</us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount>
	<us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount contextRef="FI2017Q4" decimals="-3" id="Fact-54D16F0312111224DA58A520F090BDB2" unitRef="usd">14146000</us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount>
	<us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-BC8259010C7F8D31E539D1C6FFCD65F0" unitRef="usd">0</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
	<us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-B273ABC6CEAA8E164A0ED1C7126F6344" unitRef="usd">0</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-6E443B699FF1EB825B749CCE554970A2" unitRef="usd">10300000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-6E204489953357B3E06B9CCE5549BA5C" unitRef="usd">6000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1477809EFBA9AD6A40A99CCE5529FC7C" unitRef="usd">66000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-186A59DBC59A7064A05E9CCE552946C4" unitRef="usd">76000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="INF" id="Fact-C6C4823D2523CC0E69719CCE5539EE12" unitRef="shares">0</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2017Q4" decimals="INF" id="Fact-3C31ABF39C04012155A09CCE5549C8A8" unitRef="shares">0</us-gaap:TreasuryStockShares>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-5" id="Fact-A5F83AF1FD9B0C411D35779C472D340C" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-5" id="Fact-5F671740CA66FC441AA7779C46513677" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-5" id="Fact-B7E04E6D5E1BACC2AA49779B68517F5F" unitRef="usd">2500000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-86BE8318196150E0D3BDC40C53DA82D8" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7DB2CC4A603932BC7D23C40D0CEF13C6" unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-51F5D037D387E1E645DB9CCE5549A921" unitRef="usd">800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2FA86B3E2A1FF00D91619CCE5549378E" unitRef="usd">16600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6364925FAFDF46760B4D9CCE554915DD" unitRef="usd">-28500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4B4F67C11028B531F2739CCE55499DA2" unitRef="usd">10746000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-132AAF66ADB4EC8E61339CCE55398B62" unitRef="usd">3482000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-D9B1D4522250F6D4EEFE9CCE55496A78" unitRef="usd">2020000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-6852922B3D01851D36D09CCE5539965E" unitRef="usd">339000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-E958E0BCB837B991829A9CCE55493BF4" unitRef="usd">4905000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BBBE007ED8078D2C6F099CCE55493BEE" unitRef="usd">12871000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-BE99C38E199C4D6A8A399CCE55394513" unitRef="usd">4118000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-540E4F4F47218B70FF9D9CCE5549E82F" unitRef="usd">2611000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-B294367EE8CA2AAD5BA49CCE55391649" unitRef="usd">694000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-CE36BF30675E5A91207B9CCE5549E3EC" unitRef="usd">5448000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B1FC53F60FC35B89A718158AE6070979" unitRef="usd">15581000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-837573280DA6C30C0D48158AE31A3A4B" unitRef="usd">4403000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-46DC83BC8D87B8558808158AE4A0B0A6" unitRef="usd">4656000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-7C43F42DF75FCC884AB9158AE05CC289" unitRef="usd">716000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-D9CE23E9D8C9C95533B8158AE1B3A1CE" unitRef="usd">5806000</us-gaap:ValuationAllowancesAndReservesAdjustments>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4" decimals="-3" id="Fact-0CB502B84BE684F7888A9CCE55397A57" unitRef="usd">3043000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-35BBF464F16DB4010A6E9CCE55394F55" unitRef="usd">588000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-7DBBDAD6D219A79FEAA09CCE5539C91D" unitRef="usd">321000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-F2F6ACD0C1EE9711B59C9CCE5539135C" unitRef="usd">1559000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-7A48AEDDDA360379FBAA9CCE55492638" unitRef="usd">575000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-3" id="Fact-795607EEFD678805FC8E9CCE5539177A" unitRef="usd">3900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-6B8631D766AC3A83436E9CCE55499023" unitRef="usd">745000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-6B8E29ECF26DF985D8AE9CCE5549EEDF" unitRef="usd">797000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-59DE41DB1CCD29377B8E9CCE55499D70" unitRef="usd">1733000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-79CC81513BCB82B282B49CCE5539A80B" unitRef="usd">625000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-3" id="Fact-A10C923DAB9B358C056D9CCE5539FA31" unitRef="usd">3800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-6BC203BCEFF0619A275D9CCE5539418C" unitRef="usd">735000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-0C83F7F02CF458615ACB9CCE55397D89" unitRef="usd">1124000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-BB652B042A442C54B1929CCE55397914" unitRef="usd">1346000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-2DD6B209FBD14E1C20C19CCE55395C81" unitRef="usd">595000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4" decimals="-3" id="Fact-728DB94E691198BC133E158AF36FDA3E" unitRef="usd">3013000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-5BAC5287554F6E1140B9158AF073F53F" unitRef="usd">839000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-45CB896853E23716769D158AF1F9AD1E" unitRef="usd">696000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-855C921D3825C0D28A9E158AED866DC3" unitRef="usd">821000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-B09A440844EC4D471FDE158AEF0C025A" unitRef="usd">657000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1BA3FA4BE3C12BADB1519CCE5539FE86" unitRef="usd">9889000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-27886120EB41AE35949D9CCE55396B0F" unitRef="usd">3325000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-A1DDFB6AF2FEAC7AD95E9CCE5549E12A" unitRef="usd">1544000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-F32F4780C621EFFEB5F39CCE5539E0BC" unitRef="usd">165000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-86C920940E0EE652FE699CCE55499D75" unitRef="usd">4855000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5F2FEB53874813ED922F9CCE55499697" unitRef="usd">12971000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-B3CE167B88BD674B62979CCE55394368" unitRef="usd">4128000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-D293746C63675DFC09CB9CCE553911FB" unitRef="usd">2284000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-56E5628CB772C279F9089CCE55396A45" unitRef="usd">1081000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-ADB7989AFF27ECF78E5B9CCE55390DCA" unitRef="usd">5478000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7BAADC60126714E81F5E158AECCB8191" unitRef="usd">16368000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_pcrx_WholesalerservicefeesMember" decimals="-3" id="Fact-89BA988C618E4F264CCE158AE9CED696" unitRef="usd">4299000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForPromotionsMember" decimals="-3" id="Fact-3EA079B43877DD7105C7158AEB45197B" unitRef="usd">5084000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForSalesReturnsMember" decimals="-3" id="Fact-82ADA980A274ACE9DCAA158AE6E109C8" unitRef="usd">1241000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-B0F3A41DF1FDAF64BA47158AE85821A9" unitRef="usd">5744000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6AFEA713B2A81B865E9D9CCE5558F5E3" unitRef="shares">41301000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2FDFB812BD17644CE0B99CCE55494186" unitRef="shares">37236000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8367FEBF7572B3A05F3A9CCE554913C2" unitRef="shares">39806000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="-3" id="Fact-54B2C32F40F8C86444269CCE5558BC13" unitRef="shares">36540000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9229D274E96A059EBE489CCE5549F048" unitRef="shares">37236000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B6B5CA1BAA5A7C5E512B9CCE5558CBAA" unitRef="shares">39806000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<pcrx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-340724548596516E313D9CCE5539F015">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock>
	<pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock contextRef="FD2017Q4YTD" id="Fact-5285AFDDC2F6FAA374B7D1C248C15C68">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a summary of the Company&amp;#8217;s costs and reserves related to the DepoCyt(e) discontinuation are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:679px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:209px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Severance and Related Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Lease Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Write-Off of Property, Plant &amp;amp; Equipment and Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Asset Retirement Obligations and Other Discontinuation Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Charges incurred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash payments made&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposal of property, plant &amp;amp;&lt;br clear="none"/&gt;   equipment and inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock>
	<pcrx:CommercialPartnersAndAgreementsTextBlock contextRef="FD2017Q4YTD" id="Fact-DF2AF016E78D17DBA8A99CCE55499CCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COMMERCIAL PARTNERS AND OTHER AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;DepoCyt(e) Discontinuation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2017, the Company&amp;#8217;s board of directors approved a decision to discontinue production of DepoCyt&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (U.S. and Canada) and DepoCyte&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process. DepoCyt(e) accounted for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s 2016 total full-year revenues of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$276.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of June 30, 2017, the Company had ceased all production of DepoCyt(e).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to the discontinuation, the Company received a fixed payment for the supply of DepoCyt(e) and double-digit royalties, net of supply price, on the sales of DepoCyt by Leadiant Bioscience, Ltd. in the U.S. and Canada, and on the sales of DepoCyte by Mundipharma International Corporation Limited, or Mundipharma, in the E.U. and other European countries. In addition, the Company also received a non-refundable upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year extension and concurrent expansion of the territories where Mundipharma can market and distribute DepoCyte.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2017, the Company recorded a non-recurring charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the discontinuation of its DepoCyt(e) manufacturing activities, including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for DepoCyt(e) related inventory, which is recorded in cost of goods sold, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the remaining lease costs less an estimate of potential sublease income for the facility where DepoCyt(e) was manufactured, the write-off of property, plant and equipment, employee severance, asset retirement obligations and other estimated exit costs. Cash payments related to the lease on the DepoCyt(e) manufacturing facility are expected to continue through the end of the lease term in August 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a summary of the Company&amp;#8217;s costs and reserves related to the DepoCyt(e) discontinuation are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:679px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:209px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Severance and Related Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Lease Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Write-Off of Property, Plant &amp;amp; Equipment and Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Asset Retirement Obligations and Other Discontinuation Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Charges incurred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash payments made&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposal of property, plant &amp;amp;&lt;br clear="none"/&gt;   equipment and inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company may be required to make additional payments or incur additional costs relating to the DepoCyt(e) discontinuation which could be material to the Company&amp;#8217;s results of operations and/or cash flows in a given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Commercial Partners&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Patheon UK Limited&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Company and Patheon UK Limited, or Patheon, entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the Technical Transfer and Service Agreement, Patheon has agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. Under these agreements, the Company will make monthly base fee payments for services rendered. The agreements will remain in full effect unless and until they expire or are terminated. Upon termination of the Technical Transfer and Services Agreement (other than termination by the Company in the event that Patheon does not meet the construction and manufacturing milestones or for a breach by Patheon), the Company will pay for the make good costs occasioned by the removal of its manufacturing equipment and for Patheon&amp;#8217;s termination costs up to a maximum amount of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Manufacturing and Supply Agreement, following the FDA approval date of the suites, the Company has agreed to purchase EXPAREL product from Patheon. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Patheon), this agreement will expire on the&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10th&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; anniversary of the FDA approval date for the initial manufacturing suite.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;DePuy Synthes Sales, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company announced the initiation of a Co-Promotion Agreement, or the Agreement, with DePuy&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp;amp; Johnson family of companies, to market and promote the use of&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;EXPAREL for orthopedic procedures in the U.S.. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine and trauma, collaborates with and supplements the Company&amp;#8217;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the five-year arrangement, DePuy Synthes is the exclusive third-party distributor during the term of the Agreement to promote and sell EXPAREL for operating room use for orthopedic and spine surgeries (including knee, hip, shoulder, sports and trauma surgeries) in the U.S.. DePuy Synthes receives a tiered commission ranging from low single-digits to double-digits on sales of EXPAREL under the Agreement, subject to conditions, limitations and adjustments. The initial term of the Agreement commenced on January 24, 2017 and ends on December 31, 2021, with the option to extend the Agreement in additional 12-month increments upon mutual agreement of the parties, subject to certain conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company and DePuy Synthes have mutual termination rights under the Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or DePuy Synthes generally may not terminate the Agreement, without cause, within three years of the effective date of the Agreement. The Company also has additional unilateral termination rights under certain circumstances. The Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. DePuy Synthes is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&amp;#8217;s policies, in connection with fulfilling their obligations under the Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Aratana Therapeutics,&amp;#160;Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;5, 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&amp;#160;Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&amp;#8217;s bupivacaine liposome injectable suspension product for animal health indications. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. In connection with its entry into the license agreement, the Company received a one-time payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In December 2013, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment under the agreement. In June 2016, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in milestone revenue for Aratana&amp;#8217;s filing of an FDA Administrative New Animal Drug Application, or ANADA, and in August 2016 recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the FDA&amp;#8217;s approval of the ANADA. The Company is eligible to receive up to an additional aggregate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double digit royalty on net sales made in the U.S.. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into a jurisdiction or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until December 2027, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to serve animal health indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NOCITA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is a registered trademark of Aratana Therapeutics, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;CrossLink BioScience,&amp;#160;LLC&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2013, the Company and CrossLink BioScience, LLC, or CrossLink, commenced a five-year arrangement for the promotion and sale of EXPAREL, pursuant to the terms of a Master Distributor Agreement (as amended, the &amp;#8220;CrossLink Agreement&amp;#8221;). On June&amp;#160;30, 2016, the Company provided notice to CrossLink electing to terminate the CrossLink Agreement effective as of September&amp;#160;30, 2016. In connection with the termination of the CrossLink Agreement, a termination fee based on a percentage of earned performance-based fees is due to CrossLink.&amp;#160;This fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is payable to CrossLink quarterly over two years beginning in the fourth quarter of 2016, and was recorded in selling, general and administrative expense in the consolidated statements of operations. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is classified in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:CommercialPartnersAndAgreementsTextBlock>
	<pcrx:LiquidityPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-13EBF92BF63A3958E0EE9CCE5558599C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management believes that the Company&amp;#8217;s existing cash and cash equivalents, short-term and long-term investments and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses, capital expenditure requirements, payment of the principal on any conversions of the Company&amp;#8217;s convertible senior notes and to service its indebtedness at least through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;28, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. See &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for further discussion of the Company&amp;#8217;s convertible senior notes and conversion elections. The Company expects to continue to incur substantial additional expenditures as it continues to commercialize EXPAREL, develops and seeks regulatory approval for its product candidates and expands its manufacturing facilities for EXPAREL and its other product candidates, including costs associated with certain technical transfer activities and the construction of two dedicated manufacturing suites in England.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:LiquidityPolicyTextBlock>
	<pcrx:MovementinValuationandQualifyingAccountsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-409B4381C7F9460456EE9CCE553914B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary of activity with respect to the Company&amp;#8217;s sales related allowances and accruals for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Returns Allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Wholesaler Service Fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Volume Rebates and Chargebacks&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,544&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:MovementinValuationandQualifyingAccountsTableTextBlock>
	<pcrx:ScheduleOfInterestExpenseTableTextBlock contextRef="FD2017Q4YTD" id="Fact-966C754C344682420FD79CCE55394F29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the total interest expense recognized in the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized interest and other (Note 5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(848&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate on convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:ScheduleOfInterestExpenseTableTextBlock>
	<pcrx:ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E7269AF635E0A9057C159CCE5549E0AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net summarized by major category, consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;138,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock>
	<pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock contextRef="FD2017Q4YTD" id="Fact-6F2609D3B285541355A19CCE554924FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table contains information about the Company&amp;#8217;s plans at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Stock Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards Reserved for Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards&lt;br clear="none"/&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards Available for Grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2007 Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2011 Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,931,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,037,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,893,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014 Inducement plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,129,537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,113,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,016,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Reserved&lt;br clear="none"/&gt;for Purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;br clear="none"/&gt;Purchased&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Available&lt;br clear="none"/&gt;for Purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2014 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-3A486DF5D95E07C8AC4B9CCE555865AE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;ACCRUED EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued royalties&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product returns, rebates and other fees &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:AssetRetirementObligationsPolicy contextRef="FD2017Q4YTD" id="Fact-F34CED2CB3254C5AEDC59CCE5539BB2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Asset Retirement Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records interest expense to accrete the ARO to full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AssetRetirementObligationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-F2894025579C33A708FA9CCE5539F8A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All highly-liquid investments with maturities of 90 days or less when purchased are considered cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-B5929E4780BBEDE17C169CCE5568927F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s leases for its research and development, warehouse and DepoCyt(e) manufacturing facility in San Diego, California all expire in August 2020, and its lease for its EXPAREL manufacturing facility in San Diego, California expires in December 2025. The Company&amp;#8217;s lease for its corporate headquarters in Parsippany, New Jersey expires in March 2028.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, aggregate annual minimum payments due under the Company&amp;#8217;s lease obligations are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Minimum Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023 through 2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total rent expense, net of amortization of unfavorable lease obligations and tenant improvements, under all operating leases for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Deferred rent at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company&amp;#8217;s research and development facility in San Diego, California included a lease incentive allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the payment of leasehold improvements, which the Company utilized completely in 2015 and 2016. The leasehold improvements were capitalized into fixed assets, net on the consolidated balance sheets and are depreciated over the lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Litigation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any litigation which it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&amp;#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. The Company is cooperating with the government&amp;#8217;s inquiry. The Company can make no assurances as to the time or resources that will need to be devoted to this inquiry or the impact, if any, of this inquiry or any proceedings on its business, financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Purchase Obligations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients. The Company was granted a deferral for the required pediatric trials in all age groups for EXPAREL in the setting of wound infiltration and plans to conduct these pediatric trials as a post-marketing requirement, which was stated in the New Drug Application approval letter for EXPAREL. The Company recently secured feedback from the FDA on a pediatric trial design in all age groups and is in the process of finalizing its clinical strategy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; purchase price for the Acquisition, the Company entered into an earn-out agreement with Skyepharma which was based on the Company reaching certain revenue milestones following the Acquisition. Pursuant to this agreement, the Company is required to pay Skyepharma milestone payments up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are for milestones not yet met. Additionally, the Company agreed to pay to Skyepharma a low single-digit percentage payment on collections of EXPAREL sales in the U.S., Japan, United Kingdom, France, Germany, Italy and Spain. Such obligations to make percentage payments will continue for the term in which such sales related to EXPAREL are covered by a valid claim in certain patent rights related to EXPAREL and other biologics products. The Company has the right to cease paying the low single-digit percentage payments in the event that Skyepharma breaches certain covenants not to compete contained in the stock purchase agreement or the last valid patent claim expires. Refer to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 6&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to an agreement with Research Development Foundation, or RDF, the Company is required to pay RDF a low single-digit royalty on the collection of revenues from its DepoFoam-based products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="FD2017Q4YTD" id="Fact-FF8D13B04E7D57C4E5799CCE5558E252">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OTHER EMPLOYEE BENEFITS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a discretionary percentage match as defined in the plan and determined by the board of directors. The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of related compensation expense for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-FC452255409EAAF768189CCE5539001E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Senior Notes Due 2022&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 13, 2017, the Company completed a private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$345.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2022, or 2022 Notes, and entered into an indenture agreement, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year, payable semiannually in arrears on April 1 and October 1 of each year. The 2022 Notes mature on April 1, 2022.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total debt composition of the 2022 Notes is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375% convertible senior notes due 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;345,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt, net of debt discount and deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The net proceeds from the issuance of the 2022 Notes were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$334.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2022 Notes were used by the Company to repurchase the majority of its then-outstanding convertible senior notes due 2019 in privately-negotiated transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders may convert the 2022 Notes at any time prior to the close of business on the business day immediately preceding October 1, 2021, only under the following circumstances:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(i) during any calendar quarter commencing after the calendar quarter ended June 30, 2017 (and only during such calendar quarter), if the last reported sale price of the Company&amp;#8217;s common stock for at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the conversion price on each applicable trading day;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ii) during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; business-day period immediately after any &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading-day period (the &amp;#8216;&amp;#8216;measurement period&amp;#8217;&amp;#8217;) in which the trading price (as defined in the 2022 Indenture) per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount of the 2022 Notes for each trading day of the measurement period was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the product of the last reported sale price of the Company&amp;#8217;s common stock and the conversion rate on each such trading day;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&amp;#8217;s assets; or&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(iv) if the Company calls the 2022 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding April 1, 2022, holders may convert their 2022 Notes at any time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&amp;#8217;s common stock or a combination of cash and shares of the Company&amp;#8217;s common stock, at the Company&amp;#8217;s option. The initial conversion rate for the 2022 Notes is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.9491&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount, which is equivalent to an initial conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$66.89&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of the Company&amp;#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the closing sale price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$48.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of the Company&amp;#8217;s common stock on the NASDAQ Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the 2022 Notes had a market price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,048&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are converted, the Company would be required to repay the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$345.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&amp;#8217;s option).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to April 1, 2020, the Company may not redeem the 2022 Notes. On or after April 1, 2020, the Company may redeem for cash, shares of the Company&amp;#8217;s common stock or a combination of cash and shares of the Company&amp;#8217;s common stock, at the Company&amp;#8217;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&amp;#8217;s common stock has been at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the conversion price then in effect for at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during any &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading-day period ending within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; trading days prior to the date on which the Company provides notice of redemption. The redemption price will equal the sum of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &amp;#8220;make whole fundamental change&amp;#8221; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &amp;#8216;&amp;#8216;make-whole fundamental change&amp;#8217;&amp;#8217; (as defined in the 2022 Indenture) occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2022 Notes are the Company&amp;#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&amp;#8217;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&amp;#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&amp;#8217;s subsidiaries.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;While the 2022 Notes are currently classified on the Company&amp;#8217;s consolidated balance sheet at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as long-term debt, the future convertibility and resulting balance sheet classification of this liability will be monitored at each quarterly reporting date and will be analyzed dependent upon market prices of the Company&amp;#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2022 Notes have the election to convert the 2022 Notes at any time during the prescribed measurement period, the 2022 Notes would then be considered a current obligation and classified as such.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under ASC 470-20, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt with Conversion and Other Options&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&amp;#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$274.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was calculated using a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.45%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; assumed borrowing rate. The equity component of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$70.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the five year term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company allocated the total transaction costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Senior Notes Due 2019&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 23, 2013, the Company completed a private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate principal amount of&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2019, or 2019 Notes. The 2019 Notes accrue interest at a fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year, payable semiannually in arrears on February 1 and August 1 of each year. The 2019 Notes mature on February 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total debt composition of the 2019 Notes is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25% convertible senior notes due 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt, net of debt discount and deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Company used part of the net proceeds from the issuance of the 2022 Notes discussed above to repurchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$117.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; aggregate principal of the 2019 Notes in privately-negotiated transactions for an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$118.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and the issuance of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. The partial repurchase of the 2019 Notes resulted in a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; loss on early debt extinguishment. In May 2017, the Company repurchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; aggregate principal of the 2019 Notes in a privately-negotiated transaction for an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and the issuance of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of principal remains outstanding on the 2019 Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders may convert their 2019 Notes prior to August 1, 2018 only if certain circumstances are met, including if during the previous calendar quarter, the sales price of the Company&amp;#8217;s common stock was greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the conversion price then applicable for at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; out of the last &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days of the quarter. During the quarter ended December&amp;#160;31, 2017, this condition for conversion was met. As a result, the 2019 Notes are classified as a current obligation and will be convertible until March&amp;#160;31, 2018. As of December&amp;#160;31, 2017, the 2019 Notes had a market price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,905&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount, compared to an estimated conversion value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,839&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount. In the event that the remaining 2019 Notes are converted, the Company would be required to repay the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of principal value in cash and settle approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the conversion premium in cash, common stock or a combination of cash and shares of its common stock at the Company&amp;#8217;s option as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the total interest expense recognized in the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized interest and other (Note 5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(848&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate on convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-38DBDD719044B5EAB6F09CCE55686B51">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible Debt Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon settlement of the convertible senior notes, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
	<us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted contextRef="FD2017Q4YTD" id="Fact-2483644B9A3415E831069CCE5539659F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update includes multiple provisions intended to simplify various aspects of accounting for share-based payment transactions including accounting for excess tax benefits and tax deficiencies, classification of excess tax benefits and tax deficiencies in the statement of cash flows and accounting for award forfeitures. The update also removes the requirement to delay recognition of an excess tax benefit until it reduces current taxes payable, instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This update became effective for the Company beginning January 1, 2017. The Company elected an accounting policy change to record forfeitures as they occur rather than estimating forfeitures during each period and recorded a charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to retained earnings as of January 1, 2017 related to the reversal of cumulative forfeiture estimates. The adoption of this standard also resulted in the recognition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. The changes have been applied prospectively in accordance with the update, and prior periods have not been adjusted. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based awards, will be classified as cash flows from operating activities in the Company&amp;#8217;s consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The standard requires entities to measure most inventory &amp;#8220;at the lower of cost and net realizable value&amp;#8221;, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of which is net realizable value). Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The standard became effective for the Company prospectively beginning January 1, 2017. The adoption of ASU 2015-11 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not Adopted as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and has subsequently issued a number of amendments to this update. The new standard, as amended, provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The standard&amp;#8217;s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 provides a five-step model that includes (1) identifying the contract with a customer, (2) identifying the performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations and (5) recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new standard will become effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective&amp;#160;method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt this standard using the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with the current revenue accounting standards. Based on its review of its current customer contracts, the implementation of ASU 2014-09 will not have a material quantitative impact on the Company&amp;#8217;s consolidated financial statements, as the timing of revenue recognition for EXPAREL product sales is not expected to significantly change. The Company will recognize existing collaborative licensing, milestone and royalty revenue earlier, subject to the variable consideration constraints, than it would have under the current standard, however, such changes are not expected to be material to the Company&amp;#8217;s consolidated financial statements. Adoption of the new standard will result in additional revenue-related disclosures in the footnotes to the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&amp;#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2016-01 changes accounting for equity investments and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income (loss). Entities have the option to measure equity investments without readily determinable fair values either at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The standard also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. ASU 2016-01 will become effective for the Company beginning January 1, 2018. The Company has elected to measure equity investments without readily determinable fair values at cost adjusted for changes in observable prices. The guidance related to equity investments without readily determinable fair values will be applied prospectively to equity investments that exist as of the date of adoption. The adoption of ASU 2016-01 may increase volatility in the Company&amp;#8217;s net income as changes in observable prices of equity investments without readily determinable fair values will be recorded in net income (loss). The Company does not expect the implementation of this standard to have a material impact on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;This update requires lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment for items such as initial direct costs. For income statement purposes, the new standard retains a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while financing leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). This update also introduces new disclosure requirements for leasing arrangements. The standard will become effective for the Company beginning January 1, 2019. Early adoption is permitted, although the Company does not expect to do so. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. For operating leases it will result in the recognition of lease liabilities and corresponding right-of-use assets upon adoption, which will have a material impact on the Company&amp;#8217;s consolidated balance sheet. The Company does not believe the adoption of this ASU will have a significant impact on its consolidated statements of operations, stockholders&amp;#8217; equity or cash flows. At adoption, this update will be applied using a modified retrospective approach. Refer to Note&amp;#160;17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for further discussion on the Company&amp;#8217;s leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity&amp;#8217;s portfolio. This ASU will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued&amp;#160;ASU&amp;#160;2016-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic&amp;#160;230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a&amp;#160;business combination.&amp;#160;ASU&amp;#160;2016-15&amp;#160;will become effective for the Company in the first quarter of fiscal year 2018. The Company does not expect any changes to its consolidated statement of cash flows upon the adoption of this standard.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q4YTD" id="Fact-9732AB2E09CD50A06FEC9CCE5549AD30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCK PLANS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s amended and restated 2011 stock incentive plan, or 2011 Plan, was adopted by its board of directors and approved by its stockholders in June 2014. The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. Since the adoption of the 2011 Plan, any remaining shares available for issuance under a 2007 stock incentive plan, or 2007 Plan, are reallocated to the 2011 Plan. In April 2014, the Company&amp;#8217;s board of directors adopted the 2014 Inducement Plan which authorized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to be granted as equity awards to new employees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the Company&amp;#8217;s board of directors adopted an amendment to the 2011 Plan. Under the amendment, an additional&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of common stock were authorized for issuance as equity awards under the 2011 Plan. The amendment to the 2011 Plan was subsequently approved by the Company&amp;#8217;s stockholders and became effective in June 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company&amp;#8217;s stock option grants have an exercise price equal to the closing price of the Company&amp;#8217;s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (generally over four years from the date of grant although the Company may occasionally grant options with different vesting terms). Since 2015, the Company has granted RSUs to employees and its board of directors. The Company uses authorized and unissued shares to satisfy its obligations under these plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2014 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Company&amp;#8217;s board of directors adopted the 2014 Employee Stock Purchase Plan, or ESPP, which was subsequently approved by the Company&amp;#8217;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&amp;#8217;s common stock at a discounted price and to help retain and motivate current employees as well as attract new talent. Under the ESPP, up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &amp;#8220;employee stock purchase plan&amp;#8221; within the meaning of Section 423 of the Internal Revenue Code. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&amp;#8217;s common stock on the purchase dates of June 30 and December 31 or the last trading day of an offering period. The per share purchase price will be equal to the lesser of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of the Company&amp;#8217;s common stock on either the offering date or the purchase date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table contains information about the Company&amp;#8217;s plans at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Stock Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards Reserved for Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards&lt;br clear="none"/&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Awards Available for Grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2007 Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2011 Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,931,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,037,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,893,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014 Inducement plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,129,537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,113,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,016,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Reserved&lt;br clear="none"/&gt;for Purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;br clear="none"/&gt;Purchased&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares Available&lt;br clear="none"/&gt;for Purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2014 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Compensation expense for stock options and RSUs granted to employees and directors is based on the estimated grant date fair value of options recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for options and RSUs granted to non-employees is based on the fair value of options, which are revalued each reporting period until vested and are recognized as expense over the requisite service period. Compensation expense for ESPP options is based on the grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized stock-based compensation expense (net of forfeitures) in its consolidated statements of operations for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation from:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Stock options (employee awards)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Stock options (consultant awards)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity and related information for the period from January&amp;#160;1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number of&lt;br clear="none"/&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted&lt;br clear="none"/&gt;Average&lt;br clear="none"/&gt;Exercise Price (Per Share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average&lt;br clear="none"/&gt;Remaining&lt;br clear="none"/&gt;Contractual&lt;br clear="none"/&gt;Term (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Aggregate&lt;br clear="none"/&gt;Intrinsic Value&lt;br clear="none"/&gt;(in Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,677,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;906,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(618,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(294,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,645,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,656,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(518,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(401,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(175,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,207,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,072,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(539,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(555,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(232,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,951,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,882,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,951,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$41.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation cost related to non-vested stock options is expected to be recognized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.7 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company&amp;#8217;s stock options have a maximum expiration date of ten years from the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average fair value of stock options granted for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.78&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.82&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68% - 2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.03% - 2.48%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.40% - 2.28%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.31 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.77 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s RSU activity and related information for the period from January&amp;#160;1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number&lt;br clear="none"/&gt;of Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted&lt;br clear="none"/&gt;Average Grant&lt;br clear="none"/&gt;Date Fair Value (Per Share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Aggregate&lt;br clear="none"/&gt;Intrinsic Value&lt;br clear="none"/&gt;(in Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;232,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,848&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;216,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;256,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;364,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;343,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(101,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(107,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested and expected to vest at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;499,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation cost related to non-vested RSUs is expected to be recognized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company&amp;#8217;s RSUs have a maximum vest date of four years from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&amp;#8217;s common stock on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair values of the ESPP share options granted are estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ESPP option fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.80 - $13.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.57 - $25.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.93 - $25.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.62% - 1.14%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.37% - 0.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.11% - 0.13%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of ESPP share options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-216A00100619169939E39CCE5529C624">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and warrants, the vesting of RSUs and the purchase of shares from the Company&amp;#8217;s employee stock purchase plan (using the treasury stock method), as well as the conversion of the excess conversion value on the Company&amp;#8217;s convertible senior notes.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-BA31CC1113BA1B137A189CCE554926D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the years ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, no potentially dilutive securities have been included in the computation of diluted net loss per share for those periods. As discussed in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has either the obligation or the option to pay cash for the aggregate principal amount due upon the conversion of its convertible senior notes. Since it is the Company&amp;#8217;s intent to settle the principal amount of its convertible senior notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&amp;#8212;basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computation of diluted securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of conversion premium on the 2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of ESPP purchase options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&amp;#8212;diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net income (loss) per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following outstanding stock options, RSUs, conversion premiums on the Company&amp;#8217;s convertible senior notes, warrants and ESPP purchase options are antidilutive in the periods presented (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion premium on the 2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average ESPP purchase options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2017Q4YTD" id="Fact-6494E718DB6C35115D35A4C3F42D0E72">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its equity investment in a minority interest of a company over which it does not exercise significant influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is evidence that changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity investments are reviewed on a regular basis for possible impairment. If an investment&amp;#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&amp;#8217;s ability to continue as a going concern and (v) any other information that the Company may be aware of related to the investment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="FD2017Q4YTD" id="Fact-85076F9BDF928602676A9CCE55586BBA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amount and fair value of the Company&amp;#8217;s convertible senior notes are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Financial Liabilities Carried at Historical Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying&lt;br clear="none"/&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375% convertible senior notes due 2022 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25% convertible senior notes due 2019 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;(1) The closing price of the Company&amp;#8217;s common stock was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$45.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; compared to a conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$66.89&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;(2) The closing price of the Company&amp;#8217;s common stock was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$45.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; compared to a conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$24.82&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share which, if converted, would result in a conversion premium of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;ten thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;ten thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-1F2BD2B7233618F91DCD9CCE55588970">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&amp;#160;1 inputs.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&amp;#160;3 inputs.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&amp;#8217;s convertible senior notes at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The carrying amount and fair value of the Company&amp;#8217;s convertible senior notes are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Financial Liabilities Carried at Historical Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying&lt;br clear="none"/&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375% convertible senior notes due 2022 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25% convertible senior notes due 2019 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;(1) The closing price of the Company&amp;#8217;s common stock was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$45.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; compared to a conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$66.89&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;(2) The closing price of the Company&amp;#8217;s common stock was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$45.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; compared to a conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$24.82&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; per share which, if converted, would result in a conversion premium of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;ten thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;ten thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt; shares of the Company&amp;#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with maturities greater than three months, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with maturities greater than one year. Net unrealized gains or losses from the Company&amp;#8217;s short-term and long-term investments are reported in other comprehensive income (loss). At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, all of the Company&amp;#8217;s short-term investments are classified as available for sale investments and are determined to be Level&amp;#160;2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, all short-term and long-term investments were rated A or better by Standard &amp;amp; Poor&amp;#8217;s.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes the Company&amp;#8217;s investments at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017 Debt Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Short-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;179,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Long-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;317,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;317,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2016 Debt Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Short-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain assets and liabilities are measured at fair value on a nonrecurring basis, including assets and liabilities acquired in a business combination, and long-lived assets, which would be recognized at fair value if deemed to be impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level&amp;#160;3 inputs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;TELA Bio, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company made a cash investment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;in convertible preferred B shares of TELA Bio Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;portfolio of products for ventral hernia repair and abdominal wall reconstruction. In conjunction with the investment in TELA Bio, the Company acquired an option to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of convertible preferred B shares of TELA Bio under the same terms and conditions as existed on the initial purchase date. The purchase option expires on September 15, 2018. If the Company does not exercise its purchase option, the Company may be required to invest up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in TELA Bio convertible preferred B shares under certain conditions. This contingent purchase obligation expires on October 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The investment in TELA Bio, the purchase option and the contingent purchase obligation were recorded at fair value based on integrated valuation pricing models. These models included both unobservable and observable market inputs including projected revenues, option purchase price, volatility and projected liquidity date. The equity investment in the TELA Bio preferred B shares was recorded at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the purchase option was recorded in prepaid expenses and other current assets at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of the contingent purchase obligation was determined to be de minimis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholesalers accounted for over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s accounts receivable: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholesalers accounted for over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s accounts receivable: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Revenues are primarily derived from major wholesalers and pharmaceutical companies which generally have significant cash resources. Allowances for doubtful accounts receivable are maintained based on historical payment patterns, aging of accounts receivable and actual write-off history. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, no allowances for doubtful accounts were deemed necessary by the Company on its accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-E6A5965C2199AD67E7919CCE5529D680">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of purchase price over fair value acquired in a business combination and is not amortized, but subject to impairment at least annually or when a triggering event occurs that could indicate a potential impairment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6126A3123C0B28ADEAC69CCE55390915">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reviews long-lived assets, including fixed assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-D1E2794EB12E8B3973DB9CCE5549F20C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) before income taxes and the related tax expense is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) before income taxes:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(39,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total income (loss) before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current taxes:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The tax provision of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is principally the result of minimum state taxes. The tax provision of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2015 is the result of the federal alternative minimum tax and state taxes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. federal statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(43.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of rate changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(130.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible senior notes refinancing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of the adoption of ASU 2016-09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s effective tax rates of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33)%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.28)%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, differed from the expected U.S. statutory tax rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This difference was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance. The Company&amp;#8217;s effective tax rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.45%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2015 was favorably impacted by the utilization of domestic net operating loss, or NOL, carryforwards for which there was a full valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the Company&amp;#8217;s deferred tax assets and liabilities at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal and state credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;134,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;120,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(120,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company&amp;#8217;s federal NOLs and federal tax credit carryforwards totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$380.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company also had state NOLs and state tax credit carryforwards of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$232.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, which are subject to change on an annual basis due to variations in the Company&amp;#8217;s annual state apportionment factors. The Company had non-U.S. tax NOLs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The existing federal NOLs will begin expiring in 2025 while the existing state NOLs begin expiring in 2024, if the Company has not used them prior to that time. The non-U.S. NOLs do not expire. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Since the Company had cumulative changes in ownership of more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within a three-year period, under Internal Revenue Code sections 382 and 383, the Company&amp;#8217;s ability to use certain net operating loss and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&amp;#8217;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&amp;#8217;s initial public offering and other financing transactions. As a result of these ownership changes, the Company estimates that approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$192.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of federal net operating losses are subject to annual limitations. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$134.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of these federal net operating losses were available. The Company estimates that an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will become available from 2018 through 2022, and the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through 2025. In addition, California and certain states have previously suspended or limited the use of net operating loss carryforwards for certain taxable years, and certain states are considering similar future measures. As a result, the Company may incur higher state income tax expense in the future. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance is appropriate. The Company had a net reduction in its valuation allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$28.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a net increase in its valuation allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the years ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. There is significant doubt regarding the Company&amp;#8217;s ability to utilize its net deferred tax assets and, therefore, the Company has recorded a full valuation allowance reducing its net deferred tax assets to zero at both &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, new legislation was signed into law reducing the corporate U.S. tax rate from 35% to 21% for tax years beginning after December 31, 2017, fully repealing the corporate alternative minimum tax and making the NOL carryforward period indefinite for NOLs generated after 2017. In accordance with ASC Topic 740, deferred tax assets and liabilities are required to be measured at the enacted tax rate expected to apply when temporary differences are to be realized or settled. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company re-measured its deferred tax balances based upon the new 21% tax rate. This resulted in a reduction of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$55.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the Company&amp;#8217;s deferred tax assets, which was offset by a change in its year-end valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Company established a deferred tax liability with an offset to additional paid-in capital resulting from the conversion feature of the 2022 Notes. The initial difference between the book value of the convertible debt, issued with a beneficial conversion feature, and its tax basis was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$70.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a temporary difference. The net effect of the deferred tax liability recorded to additional paid-in capital was zero because the Company has a full valuation allowance against its net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2017, the Company recorded a reserve of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to unrecognized tax benefits, or UTBs, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relates to tax positions taken in 2017 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relates to tax positions taken in 2016. The Company did not have any such liability at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&amp;#8217;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&amp;#8217;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Due to the Company&amp;#8217;s full valuation allowance against deferred tax assets, none of the UTBs, if recognized, would affect the effective income tax rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimates that it is not reasonably possible that within the next twelve months, any of the unrecognized tax benefits will significantly increase or decrease. The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2014 through 2017, and state tax jurisdictions for the years 2013 through 2017. However, the IRS or states may still examine and adjust a net operating loss arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&amp;#8217;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6C69A631BD7B7F11C9B69CCE55395F7E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, all deferred tax assets were fully offset by a valuation allowance because there is significant doubt regarding the Company&amp;#8217;s ability to utilize such net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-2F80B7064CCC607A13F09CCE554928E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;GOODWILL AND INTANGIBLE ASSETS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2007, the Company acquired from SkyePharma Holding, Inc., or Skyepharma, its California operating subsidiary (Pacira California), referred to herein as the Acquisition. The Company&amp;#8217;s goodwill arose in April 2012 from a contingent milestone payment to Skyepharma in connection with the Acquisition. The Acquisition was accounted for under Statement of Financial Accounting Standards 141, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting for Business Combinations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was the effective GAAP standard at the Acquisition date. In connection with the Acquisition, the Company agreed to certain earn-out payments based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL and certain other yet-to-be-developed products, as well as milestone payments for DepoBupivacaine products, including EXPAREL, as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the first commercial sale in the U.S. (met April 2012);&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the first commercial sale in a major E.U. country (United Kingdom, France, Germany, Italy and Spain);&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(iii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; when annual net sales collected reach &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (met September 2014);&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(iv)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; when annual net sales collected reach &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (met June 2016); and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(v)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; when annual net sales collected reach &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The first milestone was met in April 2012 resulting in a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment to Skyepharma. The Company recorded this payment net of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contingent consideration liability recognized at the time of the Acquisition, resulting in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded as goodwill. In September 2014, the Company recorded an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone in connection with achieving &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of annual EXPAREL net sales collected, and in June 2016, the Company recorded another &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone for achieving &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of annual EXPAREL net sales collected. For purposes of meeting future potential milestone payments, with certain exceptions, annual net sales are measured on a rolling quarterly basis. Cumulatively through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has recorded an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$31.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as goodwill for earn-out payments which are based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL. Any remaining earn-out payments will also be treated as additional costs of the Acquisition and, therefore, recorded as goodwill if and when each contingency is resolved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Acquisition was treated as a stock acquisition for tax purposes and, therefore, the acquired intangibles for book purposes are not deductible for income tax purposes. The Company also recorded goodwill related to contingent payments due under the Acquisition during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which are not deductible for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The change in the carrying value of goodwill is summarized as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Percentage payments on collections of net sales of DepoBupivacaine products  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Milestone payment triggered by collections of net sales of DepoBupivacaine products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Percentage payments on collections of net sales of DepoBupivacaine products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,460&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets acquired in the Acquisition consisted of core technology, developed technology, trademarks and trade names. There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; amortization expense for intangibles for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the years ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, amortization expense for intangibles was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-A4CD8E06BFDA2E8FA1649CCE5549F818">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INVENTORIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of inventories are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is required to perform ongoing stability testing on select lots of EXPAREL at various time intervals. In October 2016, as part of its ongoing stability testing, the Company identified that a single batch of EXPAREL, which was manufactured in early 2016, did not meet the required specification. An internal investigation tied this unexpected result to a modification in the manufacturing process that existed when this product was made, which has subsequently been corrected. The Company reserved all impacted inventory on hand and recorded a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; charge to cost of goods sold in 2016 related to this matter.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-3C0435BC4AE80AF1F32A9CCE552973DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value and is determined using the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:MajorCustomersPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-2108F57E6304D85DA60E9CCE55391E44">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Major Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s customers are national and regional wholesalers of pharmaceutical products as well as commercial, collaborative and licensing partners. The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The table below includes the percentage of revenue comprised by the Company&amp;#8217;s three largest wholesalers in each year presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Third largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from customers outside the U.S. accounted for less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s total revenue for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MajorCustomersPolicyPolicyTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="FD2017Q4YTD" id="Fact-BC73D7336669387236B29CCE553923C0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term and Long-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with initial maturities of greater than three months at the date of purchase, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with initial maturities greater than one year at the date of purchase. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company&amp;#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from net loss and are reported as a separate component of accumulated other comprehensive loss until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-CACDFE2480902B22C1049CCE55395E97">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update includes multiple provisions intended to simplify various aspects of accounting for share-based payment transactions including accounting for excess tax benefits and tax deficiencies, classification of excess tax benefits and tax deficiencies in the statement of cash flows and accounting for award forfeitures. The update also removes the requirement to delay recognition of an excess tax benefit until it reduces current taxes payable, instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This update became effective for the Company beginning January 1, 2017. The Company elected an accounting policy change to record forfeitures as they occur rather than estimating forfeitures during each period and recorded a charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to retained earnings as of January 1, 2017 related to the reversal of cumulative forfeiture estimates. The adoption of this standard also resulted in the recognition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. The changes have been applied prospectively in accordance with the update, and prior periods have not been adjusted. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based awards, will be classified as cash flows from operating activities in the Company&amp;#8217;s consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The standard requires entities to measure most inventory &amp;#8220;at the lower of cost and net realizable value&amp;#8221;, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of which is net realizable value). Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The standard became effective for the Company prospectively beginning January 1, 2017. The adoption of ASU 2015-11 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not Adopted as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and has subsequently issued a number of amendments to this update. The new standard, as amended, provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The standard&amp;#8217;s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 provides a five-step model that includes (1) identifying the contract with a customer, (2) identifying the performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations and (5) recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new standard will become effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective&amp;#160;method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt this standard using the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with the current revenue accounting standards. Based on its review of its current customer contracts, the implementation of ASU 2014-09 will not have a material quantitative impact on the Company&amp;#8217;s consolidated financial statements, as the timing of revenue recognition for EXPAREL product sales is not expected to significantly change. The Company will recognize existing collaborative licensing, milestone and royalty revenue earlier, subject to the variable consideration constraints, than it would have under the current standard, however, such changes are not expected to be material to the Company&amp;#8217;s consolidated financial statements. Adoption of the new standard will result in additional revenue-related disclosures in the footnotes to the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&amp;#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2016-01 changes accounting for equity investments and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income (loss). Entities have the option to measure equity investments without readily determinable fair values either at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The standard also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. ASU 2016-01 will become effective for the Company beginning January 1, 2018. The Company has elected to measure equity investments without readily determinable fair values at cost adjusted for changes in observable prices. The guidance related to equity investments without readily determinable fair values will be applied prospectively to equity investments that exist as of the date of adoption. The adoption of ASU 2016-01 may increase volatility in the Company&amp;#8217;s net income as changes in observable prices of equity investments without readily determinable fair values will be recorded in net income (loss). The Company does not expect the implementation of this standard to have a material impact on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;This update requires lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment for items such as initial direct costs. For income statement purposes, the new standard retains a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while financing leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). This update also introduces new disclosure requirements for leasing arrangements. The standard will become effective for the Company beginning January 1, 2019. Early adoption is permitted, although the Company does not expect to do so. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. For operating leases it will result in the recognition of lease liabilities and corresponding right-of-use assets upon adoption, which will have a material impact on the Company&amp;#8217;s consolidated balance sheet. The Company does not believe the adoption of this ASU will have a significant impact on its consolidated statements of operations, stockholders&amp;#8217; equity or cash flows. At adoption, this update will be applied using a modified retrospective approach. Refer to Note&amp;#160;17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for further discussion on the Company&amp;#8217;s leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity&amp;#8217;s portfolio. This ASU will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued&amp;#160;ASU&amp;#160;2016-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic&amp;#160;230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a&amp;#160;business combination.&amp;#160;ASU&amp;#160;2016-15&amp;#160;will become effective for the Company in the first quarter of fiscal year 2018. The Company does not expect any changes to its consolidated statement of cash flows upon the adoption of this standard.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-F5ECD8DC299A9681E7B09CCE5549F1E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pacira Pharmaceuticals,&amp;#160;Inc. and its subsidiaries (collectively, the &amp;#8220;Company&amp;#8221; or &amp;#8220;Pacira&amp;#8221;) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its proprietary DepoFoam&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Pacira is committed to driving innovation in postsurgical pain management with opioid-sparing strategies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s lead product, EXPAREL&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, was approved by the United States Food and Drug Administration, or FDA, on October&amp;#160;28, 2011 and launched commercially in April 2012. DepoFoam is also the basis for the Company&amp;#8217;s other FDA-approved product, DepoCyt(e), which the Company had manufactured for its commercial partners before discontinuing production in June 2017. The Company also sells its bupivacaine liposome injectable suspension product to a commercial partner to serve animal health indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pacira is subject to risks common to companies in similar industries and stages of development, including, but not limited to, competition from larger companies, reliance on revenue from one product, reliance on a single manufacturing site, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology and compliance with government regulations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-CBF9CA46B552B94BCC679CCE55498B3D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;FIXED ASSETS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net summarized by major category, consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;138,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company capitalized interest of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;and&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located in England in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an ARO of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, included in other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements. The increase in 2017 relates to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revision in estimated future cash flows related to the AROs, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of liabilities incurred in the current period and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accretion expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6510EE4422B4F13BA8019CCE5539080A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1 to 3&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Manufacturing and laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 to 10&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q4YTD" id="Fact-D67F7E5FC6B4EBAEDF8C9CCE553918D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Useful lives by asset category are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1 to 3&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Manufacturing and laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 to 10&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-89990FBB43CAFC49DE269CCE5558D6E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present selected quarterly financial data for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,934&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For periods where the Company reported a net loss, no potentially dilutive securities were included in the computation of diluted net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-04884CF0744660596D369CCE55490ACB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s former Chief Medical Officer, Dr. Gary Patou, is a partner of MPM Asset Management LLC, or MPM, an investor in the Company. The Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consulting expenses with MPM or Dr. Patou in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nothing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payable to MPM. The Company&amp;#8217;s agreement with MPM expired on December 31, 2015. The Company contracted with Dr. Patou directly for his services for the first six months of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana as discussed in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Commercial Partners and Other Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. MPM and its affiliates are holders of capital stock of Aratana. David Stack, the Company&amp;#8217;s Chief Executive Officer and Chairman, was a managing director at MPM from 2005 through March 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. The Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; expenses under the consulting arrangement in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and expenses of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the years ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In connection with the consulting arrangement, Dr. Pace received an option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and an option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.67&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nothing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payable to Dr. Pace for consulting services.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q4YTD" id="Fact-86C8035AF3983BF4CF799CCE55299ADB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses consist of costs associated with products and processes being developed, and include related personnel expenses, laboratory supplies, active pharmaceutical ingredients, manufacturing supplies, facilities costs, preclinical and clinical trial costs, development costs related to significant scale-ups of manufacturing capacity and other outside service fees. The Company expenses research and development costs as incurred. A significant portion of the development activities are outsourced to third parties, including contract research organizations. In such cases, the Company may be required to estimate related service fees to be accrued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-FA210146F0AC2D3E36889CCE5558BED5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s sources of revenue include (i) sales of EXPAREL in the United States, or U.S.; (ii) sales of DepoCyt(e) to its commercial partners within the U.S. and the European Union, or E.U.; (iii) sales of its bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product for use in animal health indications and (v) license fees and milestone payments. The Company recognizes revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Product Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company records revenue at the time the product is delivered to the end-user. The Company also recognizes revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and its bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with the FDA&amp;#8217;s current Good Manufacturing Practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contract terms, inventory data and other related information which may become known in the future. The Company reviews the adequacy of its provisions on a quarterly basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Returns Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company allows customers to return product that is damaged or received in error. In addition, the Company allows EXPAREL to be returned beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior to, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following product expiration. The Company estimates its sales return reserve based on its historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;terms. The Company accrues discounts to wholesalers based on contractual terms of agreements and historical experience. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Wholesaler Service Fees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s customers include major and regional wholesalers with whom the Company has contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Volume Rebates and Chargebacks&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers the Company provides to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary of activity with respect to the Company&amp;#8217;s sales related allowances and accruals for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Returns Allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Wholesaler Service Fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Volume Rebates and Chargebacks&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,544&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalty Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from royalties based on sales of its commercial partners&amp;#8217; net sales of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product to serve animal health indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Licensing and Milestone Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of a termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in the Company&amp;#8217;s consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company&amp;#8217;s performance obligations under the applicable agreements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1E144AC41D7BE3886D5A9CCE555877AA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued royalties&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product returns, rebates and other fees &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2017Q4YTD" id="Fact-54AB7093D7AD44864C269CCE5558279F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table illustrates the changes in the balances of the Company&amp;#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Net Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(Losses) From Available&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For Sale Investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-C96D00024CC19467E0AD9CCE55490214">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following outstanding stock options, RSUs, conversion premiums on the Company&amp;#8217;s convertible senior notes, warrants and ESPP purchase options are antidilutive in the periods presented (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion premium on the 2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average ESPP purchase options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-964E31E503B3227420B69CCE5558A15B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes the Company&amp;#8217;s investments at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017 Debt Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Short-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;179,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Long-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;317,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;317,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2016 Debt Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Short-term:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q4YTD" id="Fact-EA35020F76C5F6EDD3659CCE5539956A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total debt composition of the 2019 Notes is as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25% convertible senior notes due 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt, net of debt discount and deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total debt composition of the 2022 Notes is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.375% convertible senior notes due 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;345,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(61,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt, net of debt discount and deferred financing costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-8CCBE48DC5FCAAB8B2F49CCE554930C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the Company&amp;#8217;s deferred tax assets and liabilities at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal and state credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;134,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Discount on convertible senior notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;120,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(120,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C9E7D7E7A1758C57BF479CCE5549D80A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&amp;#8212;basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computation of diluted securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of conversion premium on the 2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of ESPP purchase options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding&amp;#8212;diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net income (loss) per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E7813713B59B4B90F2EE9CCE554985D6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. federal statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(43.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of rate changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(130.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible senior notes refinancing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of the adoption of ASU 2016-09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q4YTD" id="Fact-61D487B7F946DA8688D79CCE5549A5D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized stock-based compensation expense (net of forfeitures) in its consolidated statements of operations for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation from:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Stock options (employee awards)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Stock options (consultant awards)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-DBFDA009E17387C12EC99CCE555894B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, aggregate annual minimum payments due under the Company&amp;#8217;s lease obligations are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Minimum Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023 through 2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2017Q4YTD" id="Fact-1589FCECDFCEBF210C199CCE5558B22C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The change in the carrying value of goodwill is summarized as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Percentage payments on collections of net sales of DepoBupivacaine products  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Milestone payment triggered by collections of net sales of DepoBupivacaine products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Percentage payments on collections of net sales of DepoBupivacaine products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,460&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q4YTD" id="Fact-61ADFF5BE270963E48269CCE5558E732">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of inventories are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-69D41AB31802123A19C99CCE55586A5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present selected quarterly financial data for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,934&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For periods where the Company reported a net loss, no potentially dilutive securities were included in the computation of diluted net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-96164DF2F1BA12CDDFF49CCE5549B98A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity and related information for the period from January&amp;#160;1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number of&lt;br clear="none"/&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted&lt;br clear="none"/&gt;Average&lt;br clear="none"/&gt;Exercise Price (Per Share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average&lt;br clear="none"/&gt;Remaining&lt;br clear="none"/&gt;Contractual&lt;br clear="none"/&gt;Term (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Aggregate&lt;br clear="none"/&gt;Intrinsic Value&lt;br clear="none"/&gt;(in Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,677,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;906,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(618,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(294,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,645,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,656,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(518,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(401,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(175,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,207,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,072,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(539,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(555,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(232,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,951,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,882,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,951,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-AB55FDC6E73531DF71D49CCE5549BBAB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68% - 2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.03% - 2.48%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.40% - 2.28%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.31 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.77 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2017Q4YTD" id="Fact-49C088195145D073B8749CCE5539DA51">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below includes the percentage of revenue comprised by the Company&amp;#8217;s three largest wholesalers in each year presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Third largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-0C05A89B8EE4E49E067F9CCE5539536F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reportable segment and, accordingly, no segment disclosures have been presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q4YTD" id="Fact-F9DDC7A00A05A089993E9CCE5539839B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s stock-based compensation program includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&amp;#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The valuation of stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable stock options. Accordingly, the Company uses an option pricing model to derive an estimated fair value. In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of the option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes its available historic volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option exercises. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&amp;#8217;s common stock is estimated to be zero as the Company has not paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. The Company records forfeitures as they occur rather than estimating forfeitures during each period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-4AA44E5B66E642E3D8359CCE55499D82">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, inventory costs, impairments of goodwill and long-lived assets, liabilities and accruals and the valuation of deferred tax assets. The Company&amp;#8217;s critical accounting policies are those that are both most important to the Company&amp;#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management believes that the Company&amp;#8217;s existing cash and cash equivalents, short-term and long-term investments and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses, capital expenditure requirements, payment of the principal on any conversions of the Company&amp;#8217;s convertible senior notes and to service its indebtedness at least through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;28, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. See &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for further discussion of the Company&amp;#8217;s convertible senior notes and conversion elections. The Company expects to continue to incur substantial additional expenditures as it continues to commercialize EXPAREL, develops and seeks regulatory approval for its product candidates and expands its manufacturing facilities for EXPAREL and its other product candidates, including costs associated with certain technical transfer activities and the construction of two dedicated manufacturing suites in England.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s sources of revenue include (i) sales of EXPAREL in the United States, or U.S.; (ii) sales of DepoCyt(e) to its commercial partners within the U.S. and the European Union, or E.U.; (iii) sales of its bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product for use in animal health indications and (v) license fees and milestone payments. The Company recognizes revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Product Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company records revenue at the time the product is delivered to the end-user. The Company also recognizes revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and its bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with the FDA&amp;#8217;s current Good Manufacturing Practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contract terms, inventory data and other related information which may become known in the future. The Company reviews the adequacy of its provisions on a quarterly basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Returns Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company allows customers to return product that is damaged or received in error. In addition, the Company allows EXPAREL to be returned beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior to, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following product expiration. The Company estimates its sales return reserve based on its historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;terms. The Company accrues discounts to wholesalers based on contractual terms of agreements and historical experience. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Wholesaler Service Fees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s customers include major and regional wholesalers with whom the Company has contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Volume Rebates and Chargebacks&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers the Company provides to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary of activity with respect to the Company&amp;#8217;s sales related allowances and accruals for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Returns Allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Wholesaler Service Fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Volume Rebates and Chargebacks&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,544&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Payments/credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalty Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from royalties based on sales of its commercial partners&amp;#8217; net sales of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product to serve animal health indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Licensing and Milestone Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of a termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in the Company&amp;#8217;s consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company&amp;#8217;s performance obligations under the applicable agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Major Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s customers are national and regional wholesalers of pharmaceutical products as well as commercial, collaborative and licensing partners. The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The table below includes the percentage of revenue comprised by the Company&amp;#8217;s three largest wholesalers in each year presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Third largest wholesaler&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from customers outside the U.S. accounted for less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s total revenue for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses consist of costs associated with products and processes being developed, and include related personnel expenses, laboratory supplies, active pharmaceutical ingredients, manufacturing supplies, facilities costs, preclinical and clinical trial costs, development costs related to significant scale-ups of manufacturing capacity and other outside service fees. The Company expenses research and development costs as incurred. A significant portion of the development activities are outsourced to third parties, including contract research organizations. In such cases, the Company may be required to estimate related service fees to be accrued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, all deferred tax assets were fully offset by a valuation allowance because there is significant doubt regarding the Company&amp;#8217;s ability to utilize such net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s stock-based compensation program includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&amp;#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The valuation of stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable stock options. Accordingly, the Company uses an option pricing model to derive an estimated fair value. In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term of the option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes its available historic volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option exercises. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&amp;#8217;s common stock is estimated to be zero as the Company has not paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. The Company records forfeitures as they occur rather than estimating forfeitures during each period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All highly-liquid investments with maturities of 90 days or less when purchased are considered cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term and Long-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with initial maturities of greater than three months at the date of purchase, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with initial maturities greater than one year at the date of purchase. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company&amp;#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from net loss and are reported as a separate component of accumulated other comprehensive loss until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value and is determined using the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1 to 3&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Manufacturing and laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 to 10&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Asset Retirement Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records interest expense to accrete the ARO to full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of purchase price over fair value acquired in a business combination and is not amortized, but subject to impairment at least annually or when a triggering event occurs that could indicate a potential impairment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its equity investment in a minority interest of a company over which it does not exercise significant influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is evidence that changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity investments are reviewed on a regular basis for possible impairment. If an investment&amp;#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&amp;#8217;s ability to continue as a going concern and (v) any other information that the Company may be aware of related to the investment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reviews long-lived assets, including fixed assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible Debt Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon settlement of the convertible senior notes, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and warrants, the vesting of RSUs and the purchase of shares from the Company&amp;#8217;s employee stock purchase plan (using the treasury stock method), as well as the conversion of the excess conversion value on the Company&amp;#8217;s convertible senior notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reportable segment and, accordingly, no segment disclosures have been presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-B4F26F5FE983E3BC6D4F9CCE55585F03">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is authorized to issue up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,668,877&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,480,952&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;The Company is authorized to issue up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; shares of preferred stock. No preferred stock was outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table illustrates the changes in the balances of the Company&amp;#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Net Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(Losses) From Available&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For Sale Investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-8EE5EF175C85EF3B29E59CCE5549B568">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, inventory costs, impairments of goodwill and long-lived assets, liabilities and accruals and the valuation of deferred tax assets. The Company&amp;#8217;s critical accounting policies are those that are both most important to the Company&amp;#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-000592DAF7C2322DCF19BA0217EF1C08" xlink:label="Fact-000592DAF7C2322DCF19BA0217EF1C08_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-259DDEF5054DD27395EF9CCE5549CD94" xlink:label="Fact-259DDEF5054DD27395EF9CCE5549CD94_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-274B579C8B72328A77EE9CCE55394D5F" xlink:label="Fact-274B579C8B72328A77EE9CCE55394D5F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3063725544F5DB7A05E2BA0219E152DE" xlink:label="Fact-3063725544F5DB7A05E2BA0219E152DE_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-49121028CAD6B7820DA49CCE5539AA52" xlink:label="Fact-49121028CAD6B7820DA49CCE5539AA52_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C5795D8981D2A059632DBA0215F8F66B" xlink:label="Fact-C5795D8981D2A059632DBA0215F8F66B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F4A7D696D7D0145E281A9CCE5539B3D4" xlink:label="Fact-F4A7D696D7D0145E281A9CCE5539B3D4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FAD6D09C34E711293990BA02138F6249" xlink:label="Fact-FAD6D09C34E711293990BA02138F6249_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-000592DAF7C2322DCF19BA0217EF1C08_lbl" xlink:to="Footnote-B217B180A0DBBF63349FA4D7614529DC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-259DDEF5054DD27395EF9CCE5549CD94_lbl" xlink:to="Footnote-064E4620E85C34A744769CCE55685A35_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-274B579C8B72328A77EE9CCE55394D5F_lbl" xlink:to="Footnote-064E4620E85C34A744769CCE55685A35_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3063725544F5DB7A05E2BA0219E152DE_lbl" xlink:to="Footnote-B217B180A0DBBF63349FA4D7614529DC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-49121028CAD6B7820DA49CCE5539AA52_lbl" xlink:to="Footnote-064E4620E85C34A744769CCE55685A35_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C5795D8981D2A059632DBA0215F8F66B_lbl" xlink:to="Footnote-B217B180A0DBBF63349FA4D7614529DC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F4A7D696D7D0145E281A9CCE5539B3D4_lbl" xlink:to="Footnote-064E4620E85C34A744769CCE55685A35_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FAD6D09C34E711293990BA02138F6249_lbl" xlink:to="Footnote-B217B180A0DBBF63349FA4D7614529DC_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-064E4620E85C34A744769CCE55685A35_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The closing price of the Company&#8217;s common stock was $45.65 per share at December&#160;31, 2017 compared to a conversion price of $24.82 per share which, if converted, would result in a conversion premium of less than ten thousand shares of the Company&#8217;s common stock or $0.3 million of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately ten thousand shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</link:footnote>
		<link:footnote xlink:label="Footnote-B217B180A0DBBF63349FA4D7614529DC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The closing price of the Company&#8217;s common stock was $45.65 per share at December&#160;31, 2017 compared to a conversion price of $66.89 per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately 5.2 million shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>pcrx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacira.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pcrx="http://www.pacira.com/20171231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.pacira.com/role/AccruedExpenses">
        <link:definition>2107100 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.pacira.com/role/AccruedExpensesDetails">
        <link:definition>2407402 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.pacira.com/role/AccruedExpensesTables">
        <link:definition>2307301 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialPartnersAndOtherAgreements" roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements">
        <link:definition>2116100 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables">
        <link:definition>2316301 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS COMMERICAL PARTNERS AND OTHER AGREEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialPartnersAndOtherAgreementsDetails" roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails">
        <link:definition>2416402 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.pacira.com/role/CommitmentsAndContingencies">
        <link:definition>2118100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2418402 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails2" roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2">
        <link:definition>2418403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2318301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.pacira.com/role/Debt">
        <link:definition>2108100 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.pacira.com/role/DebtDetails">
        <link:definition>2408402 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails2" roleURI="http://www.pacira.com/role/DebtDetails2">
        <link:definition>2408403 - Disclosure - DEBT (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.pacira.com/role/DebtTables">
        <link:definition>2308301 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.pacira.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.pacira.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pacira.com/role/FinancialInstruments">
        <link:definition>2109100 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails">
        <link:definition>2409402 - Disclosure - FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails2">
        <link:definition>2409403 - Disclosure - FINANCIAL INSTRUMENTS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails3">
        <link:definition>2409404 - Disclosure - FINANCIAL INSTRUMENTS (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pacira.com/role/FinancialInstrumentsTables">
        <link:definition>2309301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.pacira.com/role/FixedAssets">
        <link:definition>2105100 - Disclosure - FIXED ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.pacira.com/role/FixedAssetsDetails">
        <link:definition>2405402 - Disclosure - FIXED ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.pacira.com/role/FixedAssetsTables">
        <link:definition>2305301 - Disclosure - FIXED ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2106100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsDetails" roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails">
        <link:definition>2406402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>2406403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2306301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.pacira.com/role/IncomeTaxes">
        <link:definition>2114100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.pacira.com/role/IncomeTaxesDetails">
        <link:definition>2414402 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.pacira.com/role/IncomeTaxesTables">
        <link:definition>2314301 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.pacira.com/role/Inventories">
        <link:definition>2104100 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.pacira.com/role/InventoriesDetails">
        <link:definition>2404402 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.pacira.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.pacira.com/role/NetIncomeLossPerShare">
        <link:definition>2112100 - Disclosure - NET INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareDetails" roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails">
        <link:definition>2412402 - Disclosure - NET INCOME (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareDetails2" roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails2">
        <link:definition>2412403 - Disclosure - NET INCOME (LOSS) PER SHARE (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.pacira.com/role/NetIncomeLossPerShareTables">
        <link:definition>2312301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherEmployeeBenefits" roleURI="http://www.pacira.com/role/OtherEmployeeBenefits">
        <link:definition>2115100 - Disclosure - OTHER EMPLOYEE BENEFITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherEmployeeBenefitsDetails" roleURI="http://www.pacira.com/role/OtherEmployeeBenefitsDetails">
        <link:definition>2415401 - Disclosure - OTHER EMPLOYEE BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.pacira.com/role/RecentAccountingPronouncements">
        <link:definition>2103100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" roleURI="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails">
        <link:definition>2403401 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.pacira.com/role/RelatedPartyTransactions">
        <link:definition>2117100 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.pacira.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2417401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2119100 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2419402 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2319301 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlans" roleURI="http://www.pacira.com/role/StockPlans">
        <link:definition>2111100 - Disclosure - STOCK PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansDetails" roleURI="http://www.pacira.com/role/StockPlansDetails">
        <link:definition>2411402 - Disclosure - STOCK PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansDetails2" roleURI="http://www.pacira.com/role/StockPlansDetails2">
        <link:definition>2411403 - Disclosure - STOCK PLANS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansDetails3" roleURI="http://www.pacira.com/role/StockPlansDetails3">
        <link:definition>2411404 - Disclosure - STOCK PLANS (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansTables" roleURI="http://www.pacira.com/role/StockPlansTables">
        <link:definition>2311301 - Disclosure - STOCK PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.pacira.com/role/StockholdersEquity">
        <link:definition>2110100 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.pacira.com/role/StockholdersEquityDetails">
        <link:definition>2410402 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails2" roleURI="http://www.pacira.com/role/StockholdersEquityDetails2">
        <link:definition>2410403 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.pacira.com/role/StockholdersEquityTables">
        <link:definition>2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3">
        <link:definition>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails4" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4">
        <link:definition>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pcrx_AccruedEndOfTermFeeCurrent" name="AccruedEndOfTermFeeCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_AccruedOperatingExpensesCurrent" name="AccruedOperatingExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" name="AchievementOfDevelopmentAndCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_AchievementOfMilestoneAxis" name="AchievementOfMilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_AchievementOfMilestoneDomain" name="AchievementOfMilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" name="AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation" name="AmortizationOfOtherAssetsAndUnfavorableLeaseObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" name="AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_AratanaTherapeuticsIncMember" name="AratanaTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_AvailableNetOperatingLossSubjecttoLimitation" name="AvailableNetOperatingLossSubjecttoLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct" name="BeginningPeriodPriorToProductExpirationAllowedForReturningProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" name="COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_CaliforniaOperatingSubsidiaryMember" name="CaliforniaOperatingSubsidiaryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_CollaborativeArrangementMilestonePaymentsReceived" name="CollaborativeArrangementMilestonePaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived" name="CollaborativeArrangementMilestonePaymentsToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_CollaborativeArrangementUpfrontPaymentReceived" name="CollaborativeArrangementUpfrontPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_CollaborativeLicensingAndDevelopmentRevenue" name="CollaborativeLicensingAndDevelopmentRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_CommercialPartnersAndAgreementsAbstract" name="CommercialPartnersAndAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_CommercialPartnersAndAgreementsTextBlock" name="CommercialPartnersAndAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_Compensationexpensefromemployeestockpurchaseplan" name="Compensationexpensefromemployeestockpurchaseplan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_Compensationexpensefromstockoptionsemployees" name="Compensationexpensefromstockoptionsemployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_Compensationexpensefromstockoptionsnonemployeeawards" name="Compensationexpensefromstockoptionsnonemployeeawards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition" name="ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_ContractTerminationFee" name="ContractTerminationFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_ContractTerminationFeeCurrentPortion" name="ContractTerminationFeeCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes" name="Conversionofprincipalandequitycomponentofconvertibleseniornotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ConvertibleSeniorNotesDue2022Member" name="ConvertibleSeniorNotesDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_CustomersOutsideUSMember" name="CustomersOutsideUSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_DebtConversionAndRedemptionTermsAxis" name="DebtConversionAndRedemptionTermsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_DebtConversionAndRedemptionTermsDomain" name="DebtConversionAndRedemptionTermsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtConversionConvertedInstrumentSharesIssuedValue" name="DebtConversionConvertedInstrumentSharesIssuedValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member" name="DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" name="DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" name="DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" name="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption" name="DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" name="DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" name="DebtInstrumentConversionObligationPremiumOnCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" name="DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" name="DebtInstrumentConvertibleAssumedBorrowingRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConvertibleConversionPremiumShares" name="DebtInstrumentConvertibleConversionPremiumShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentConvertibleConversionValue" name="DebtInstrumentConvertibleConversionValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" name="DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentMarketPrice" name="DebtInstrumentMarketPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" name="DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock" name="DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_DebtIssuanceCostsAmortizationperiod" name="DebtIssuanceCostsAmortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" name="DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_DebtRedemptionTermsonorafterApril12020Member" name="DebtRedemptionTermsonorafterApril12020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" name="DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_DeferredTaxAssetsStockBasedCompensation" name="DeferredTaxAssetsStockBasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_DepoCyteMember" name="DepoCyteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DiscontinuedOperationsAssetsremovedfromService" name="DiscontinuedOperationsAssetsremovedfromService" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown" name="DiscontinuedOperationsFixedAssetandInventoryWritedown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DiscontinuedOperationsPaymentsForLeaseCosts" name="DiscontinuedOperationsPaymentsForLeaseCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DiscontinuedOperationsRemainingLeaseCosts" name="DiscontinuedOperationsRemainingLeaseCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_DiscontinuedOperationsResidualLeaseCosts" name="DiscontinuedOperationsResidualLeaseCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" name="EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" name="EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EffectiveIncomeTaxRateReconciliationForeign" name="EffectiveIncomeTaxRateReconciliationForeign" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" name="EffectiveIncomeTaxRateReconciliationInterestExpensePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax" name="EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_Effectofstateblendedtaxratechanges" name="Effectofstateblendedtaxratechanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" name="EmployeeStockPurchasePlanESPPSharesinESPP" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" name="EmployeeStockPurchasePlanNumberofSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" name="EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_EmployeeStockPurchasePlanfairvalue" name="EmployeeStockPurchasePlanfairvalue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pcrx_EuropeanRightsExpansionNewDistributionPayment" name="EuropeanRightsExpansionNewDistributionPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium" name="FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ForeignPropertyPlantandEquipmentNet" name="ForeignPropertyPlantandEquipmentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward" name="FutureNOLsWhichWillBecomeAvailable2015Onward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_FutureNOLsWhichWillBecomeAvailable20182022" name="FutureNOLsWhichWillBecomeAvailable20182022" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_GoodwillRecordedforEarnOutPayments" name="GoodwillRecordedforEarnOutPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_GoodwillRecordedonMilestonePayments" name="GoodwillRecordedonMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_GrossProceedsFromIssuanceofDebt" name="GrossProceedsFromIssuanceofDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" name="IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_IncomeTaxProvision" name="IncomeTaxProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_IncomeTaxProvisionLineItems" name="IncomeTaxProvisionLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_IncomeTaxProvisionTable" name="IncomeTaxProvisionTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid" name="IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_IncreaseDecreaseInRoyaltyInterestObligation" name="IncreaseDecreaseInRoyaltyInterestObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits" name="IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_InducementPlan2014Member" name="InducementPlan2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_InitialTermofManufacturingSupplyAgreement" name="InitialTermofManufacturingSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_InvestmentsContingentPurchaseObligation" name="InvestmentsContingentPurchaseObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_LiquidityAbstract" name="LiquidityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_LongTermInvestmentsMember" name="LongTermInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_MPMAssetManagementMember" name="MPMAssetManagementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_MajorCustomerOneMember" name="MajorCustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_MajorCustomerThreeMember" name="MajorCustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_MajorCustomerTwoMember" name="MajorCustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_MaximumFairMarketValuePurchaseofESPPShares" name="MaximumFairMarketValuePurchaseofESPPShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" name="MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" name="MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" name="MovementinValuationandQualifyingAccountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_MundipharmaLtdMember" name="MundipharmaLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_NetOperatingLossSubjecttoLimitation" name="NetOperatingLossSubjecttoLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation" name="NetSalesCollectedThresholdWhichTriggersaPaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_NonUSNetOperatingLoss" name="NonUSNetOperatingLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_PatheonMember" name="PatheonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition" name="PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million" name="PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_Percentageoftotalrevenue" name="Percentageoftotalrevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned" name="PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" name="ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ProceedsfromConvertibleDebtNet" name="ProceedsfromConvertibleDebtNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ProductAxis" name="ProductAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ProductDomain" name="ProductDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ProductReturnsRebatesandOtherFees" name="ProductReturnsRebatesandOtherFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" name="RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" name="RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ScheduleOfInterestExpenseTableTextBlock" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" name="ScheduleOfSharesAvailableForIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_SecondLargestCustomerMember" name="SecondLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_SettlementPeriodConvertibleDebtConversionRequest" name="SettlementPeriodConvertibleDebtConversionRequest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest" name="SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue" name="SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue" name="Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_SkyePharmaHoldingIncMember" name="SkyePharmaHoldingIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" name="StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_StockIncentivePlan2011Member" name="StockIncentivePlan2011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_TermExtensionof2003Agreements" name="TermExtensionof2003Agreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_TotalChangeinDiscontinuedOperationsBalance" name="TotalChangeinDiscontinuedOperationsBalance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pcrx_TotalGoodwillRecordedforEarnOutPayments" name="TotalGoodwillRecordedforEarnOutPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition" name="TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" name="TwoThousandNineteenSeniorConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_TwoThousandSevenStockIncentivePlanMember" name="TwoThousandSevenStockIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pcrx_UnitedStatesStatutoryTaxRate" name="UnitedStatesStatutoryTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" name="UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" name="UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" name="UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_UponFirstCommercialSaleInMajorEUCountryMember" name="UponFirstCommercialSaleInMajorEUCountryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_UponFirstCommercialSaleInUnitedStatesMember" name="UponFirstCommercialSaleInUnitedStatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pcrx_WholesalerservicefeesMember" name="WholesalerservicefeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>pcrx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpenses" xlink:href="pcrx-20171231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesDetails" xlink:href="pcrx-20171231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesTables" xlink:href="pcrx-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Debt" xlink:href="pcrx-20171231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails" xlink:href="pcrx-20171231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails2" xlink:href="pcrx-20171231.xsd#DebtDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtTables" xlink:href="pcrx-20171231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DescriptionOfBusiness" xlink:href="pcrx-20171231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:href="pcrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstruments" xlink:href="pcrx-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssets" xlink:href="pcrx-20171231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsDetails" xlink:href="pcrx-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsTables" xlink:href="pcrx-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxes" xlink:href="pcrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesDetails" xlink:href="pcrx-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesTables" xlink:href="pcrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Inventories" xlink:href="pcrx-20171231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesDetails" xlink:href="pcrx-20171231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesTables" xlink:href="pcrx-20171231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefits" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactions" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlans" xlink:href="pcrx-20171231.xsd#StockPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails" xlink:href="pcrx-20171231.xsd#StockPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails2" xlink:href="pcrx-20171231.xsd#StockPlansDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails3" xlink:href="pcrx-20171231.xsd#StockPlansDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansTables" xlink:href="pcrx-20171231.xsd#StockPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquity" xlink:href="pcrx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityTables" xlink:href="pcrx-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedOperatingExpensesCurrent" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_d516994a-6002-4749-9ce0-9cce6da7a967" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_pcrx_AccruedOperatingExpensesCurrent_d516994a-6002-4749-9ce0-9cce6da7a967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_b332cf67-e224-8a9f-2479-d010eb13f3c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_b332cf67-e224-8a9f-2479-d010eb13f3c0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedEndOfTermFeeCurrent" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_7118dd5d-9572-5c7a-8e34-9cce6c302348" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_pcrx_AccruedEndOfTermFeeCurrent_7118dd5d-9572-5c7a-8e34-9cce6c302348" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductReturnsRebatesandOtherFees" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_5515f51e-d3c4-4eab-f84e-9cce6b850cc0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_pcrx_ProductReturnsRebatesandOtherFees_5515f51e-d3c4-4eab-f84e-9cce6b850cc0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_398178db-2a20-f509-e672-630b4bfd2e21" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_398178db-2a20-f509-e672-630b4bfd2e21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_643c6112-a783-b8ac-1bba-e0aecf28becf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_643c6112-a783-b8ac-1bba-e0aecf28becf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount" xlink:label="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_5433b2b4-e4fd-8237-bdea-cd3842acf919" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_5433b2b4-e4fd-8237-bdea-cd3842acf919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_4adbde80-36e3-b879-a631-f0caa0dbbe76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_4adbde80-36e3-b879-a631-f0caa0dbbe76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation" xlink:label="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_a91622e9-0fd3-2227-1458-9ca22ee3dc23" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_a91622e9-0fd3-2227-1458-9ca22ee3dc23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_95be95e4-0ed3-e1e8-0c63-33a490947570" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_95be95e4-0ed3-e1e8-0c63-33a490947570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_37775d39-399b-0ffb-48fe-db3396bf06a8" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_37775d39-399b-0ffb-48fe-db3396bf06a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncreaseDecreaseInRoyaltyInterestObligation" xlink:label="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_4b54eaed-3d7f-3975-8078-9cce6b27c016" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_4b54eaed-3d7f-3975-8078-9cce6b27c016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_4adbde80-36e3-b879-a631-f0caa0dbbe76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_121f9e9b-9a4d-e32c-aef0-97aedfda4465" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_121f9e9b-9a4d-e32c-aef0-97aedfda4465" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentOfContingentConsideration" xlink:label="loc_pcrx_PaymentOfContingentConsideration_b157aa8d-8a4b-7a24-6ca0-9ca22f190855" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_pcrx_PaymentOfContingentConsideration_b157aa8d-8a4b-7a24-6ca0-9ca22f190855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_698fdacf-193f-2d30-d69b-d951ce6235f5" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_698fdacf-193f-2d30-d69b-d951ce6235f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_4adbde80-36e3-b879-a631-f0caa0dbbe76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_77b56fba-9e97-b87e-83d8-9cce6d68af1e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_77b56fba-9e97-b87e-83d8-9cce6d68af1e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0c01a3fb-cfe2-13ca-1d6f-ee99ad27e1f7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0c01a3fb-cfe2-13ca-1d6f-ee99ad27e1f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_9da40861-8335-5a8e-60b4-2c6d2263d7f3" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_9da40861-8335-5a8e-60b4-2c6d2263d7f3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes" xlink:label="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_9a03e384-70c7-01e9-0e4f-9ca22e0345b1" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_9a03e384-70c7-01e9-0e4f-9ca22e0345b1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeLicensingAndDevelopmentRevenue" xlink:label="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_98988bbe-1b1b-2323-ae1a-9ca22e4f1005" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_98988bbe-1b1b-2323-ae1a-9ca22e4f1005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_a2b142e3-b3f3-b7b6-6428-5812971ab980" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_CostOfRevenue_a2b142e3-b3f3-b7b6-6428-5812971ab980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_75fb9940-bd63-976c-4153-3fd85df1949d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_75fb9940-bd63-976c-4153-3fd85df1949d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_05ca609c-5d87-898f-3376-5194cad9e4be" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_RoyaltyExpense_05ca609c-5d87-898f-3376-5194cad9e4be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DebtDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1ba9bb67-398f-5b40-d538-c6d5b7e79933" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d5d85dda-6e86-9458-9e20-bdb390e35a60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_1ba9bb67-398f-5b40-d538-c6d5b7e79933" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d5d85dda-6e86-9458-9e20-bdb390e35a60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_1ba9bb67-398f-5b40-d538-c6d5b7e79933" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_1ba9bb67-398f-5b40-d538-c6d5b7e79933" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_4f6eef66-81ac-9a00-25dc-b0ba94f4aa1a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_1ba9bb67-398f-5b40-d538-c6d5b7e79933" xlink:to="loc_us-gaap_InterestCostsCapitalized_4f6eef66-81ac-9a00-25dc-b0ba94f4aa1a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FixedAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/FixedAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_4fb73434-9f02-7c64-b46f-9cce6df5903e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_4fb73434-9f02-7c64-b46f-9cce6df5903e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c3fa658e-2108-f8f1-5239-330a908982a2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c3fa658e-2108-f8f1-5239-330a908982a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_7bbb7d3b-92ca-5cca-129e-9cce6b378fb6" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_7bbb7d3b-92ca-5cca-129e-9cce6b378fb6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Effectofstateblendedtaxratechanges" xlink:label="loc_pcrx_Effectofstateblendedtaxratechanges_dcfbc88a-df08-34d2-a16e-9cce6bd3f9d1" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_pcrx_Effectofstateblendedtaxratechanges_dcfbc88a-df08-34d2-a16e-9cce6bd3f9d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_A73329D8E4236BD7027BBA72CD818B63" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_A73329D8E4236BD7027BBA72CD818B63" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_9934354B14ECB4576AAFBA73844E8691" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_9934354B14ECB4576AAFBA73844E8691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_69a2e78a-8c8f-2eec-89b8-9cce6edf9cf5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_69a2e78a-8c8f-2eec-89b8-9cce6edf9cf5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_69a2e78a-8c8f-2eec-89b8-9cce6edf9cf5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_e56405b8-dd11-954e-a13b-53d9b95e2621" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_e56405b8-dd11-954e-a13b-53d9b95e2621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_a728b545-a47c-2414-a14c-9cce6c5f220e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_a728b545-a47c-2414-a14c-9cce6c5f220e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_211f9603-61ca-7ef7-2141-bb8ed157e3f6" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_211f9603-61ca-7ef7-2141-bb8ed157e3f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_e5aff4c4-dcfd-57b9-9f7d-cdee77a4045f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_69a2e78a-8c8f-2eec-89b8-9cce6edf9cf5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_e5aff4c4-dcfd-57b9-9f7d-cdee77a4045f" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_7b48fb0b-f861-53ae-57e7-9ca22f673115" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_7b48fb0b-f861-53ae-57e7-9ca22f673115" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_7b48fb0b-f861-53ae-57e7-9ca22f673115" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits" xlink:label="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_fe0dfd8c-3a38-79d3-e3cc-9ca22dac3848" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_fe0dfd8c-3a38-79d3-e3cc-9ca22dac3848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_9f904e4b-2e06-aacf-a7ec-13e1e7c99c9e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_9f904e4b-2e06-aacf-a7ec-13e1e7c99c9e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_002e59bf-dd40-7260-a9ce-7bf122905487" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_002e59bf-dd40-7260-a9ce-7bf122905487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_e39e5156-06d6-49b1-df8b-0301bc94cf73" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_e39e5156-06d6-49b1-df8b-0301bc94cf73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockPlansDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsemployees" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsemployees_dd5f7c45-a60a-7c1d-4fac-9ca22f048ee3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsemployees_dd5f7c45-a60a-7c1d-4fac-9ca22f048ee3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsnonemployeeawards" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_83195a86-b76c-1f9b-43ed-9ca22db46652" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_83195a86-b76c-1f9b-43ed-9ca22db46652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_cf06cdb3-6564-4960-43b4-9bba063ebf87" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:to="loc_us-gaap_RestrictedStockExpense_cf06cdb3-6564-4960-43b4-9bba063ebf87" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromemployeestockpurchaseplan" xlink:label="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_fdd5b08b-e4aa-a5e4-91ef-9ca22e8894fd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:to="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_fdd5b08b-e4aa-a5e4-91ef-9ca22e8894fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockPlansDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>pcrx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpenses" xlink:href="pcrx-20171231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesDetails" xlink:href="pcrx-20171231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesTables" xlink:href="pcrx-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Debt" xlink:href="pcrx-20171231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails" xlink:href="pcrx-20171231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails2" xlink:href="pcrx-20171231.xsd#DebtDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtTables" xlink:href="pcrx-20171231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DescriptionOfBusiness" xlink:href="pcrx-20171231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:href="pcrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstruments" xlink:href="pcrx-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssets" xlink:href="pcrx-20171231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsDetails" xlink:href="pcrx-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsTables" xlink:href="pcrx-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxes" xlink:href="pcrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesDetails" xlink:href="pcrx-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesTables" xlink:href="pcrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Inventories" xlink:href="pcrx-20171231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesDetails" xlink:href="pcrx-20171231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesTables" xlink:href="pcrx-20171231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefits" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactions" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlans" xlink:href="pcrx-20171231.xsd#StockPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails" xlink:href="pcrx-20171231.xsd#StockPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails2" xlink:href="pcrx-20171231.xsd#StockPlansDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails3" xlink:href="pcrx-20171231.xsd#StockPlansDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansTables" xlink:href="pcrx-20171231.xsd#StockPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquity" xlink:href="pcrx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityTables" xlink:href="pcrx-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductAxis" xlink:label="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductDomain" xlink:label="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:to="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E_default" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductDomain" xlink:label="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:to="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DepoCyteMember" xlink:label="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:to="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PatheonMember" xlink:label="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:to="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MundipharmaLtdMember" xlink:label="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:to="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AratanaTherapeuticsIncMember" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:to="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:to="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:to="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_893618B3B8E4FE466284BA64FDA1FDE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:to="loc_us-gaap_MaximumMember_893618B3B8E4FE466284BA64FDA1FDE8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneAxis" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneDomain" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59_default" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneDomain" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:to="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Percentageoftotalrevenue" xlink:label="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EuropeanRightsExpansionNewDistributionPayment" xlink:label="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TermExtensionof2003Agreements" xlink:label="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_A5A3BAD85892778D05B3BA64FDA339B7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_InventoryWriteDown_A5A3BAD85892778D05B3BA64FDA339B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsResidualLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationCurrent" xlink:label="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining" xlink:label="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsRemainingLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown" xlink:label="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsIncurredAssetRetirementObligationIncurred" xlink:label="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsPaymentsForLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsAssetsremovedfromService" xlink:label="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalChangeinDiscontinuedOperationsBalance" xlink:label="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFee" xlink:label="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InitialTermofManufacturingSupplyAgreement" xlink:label="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFeeCurrentPortion" xlink:label="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CaliforniaOperatingSubsidiaryMember" xlink:label="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:to="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SkyePharmaHoldingIncMember" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:to="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:to="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:to="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EB784FA535F05911B54EBA64FD87489E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:to="loc_us-gaap_MaximumMember_EB784FA535F05911B54EBA64FD87489E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition" xlink:label="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:to="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:to="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:to="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_A7E914F70130051045DBBAE840C5E1DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:to="loc_us-gaap_UnsecuredDebtMember_A7E914F70130051045DBBAE840C5E1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_062A0846B08333DBD6DBBAE840C8E9C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_062A0846B08333DBD6DBBAE840C8E9C7" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_EE62E8307BF9CF2CA40DBAE840C83875" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_EE62E8307BF9CF2CA40DBAE840C83875" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60_default" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsfromConvertibleDebtNet" xlink:label="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock" xlink:label="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentMarketPrice" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtIssuanceCostsAmortizationperiod" xlink:label="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GrossProceedsFromIssuanceofDebt" xlink:label="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DebtDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:to="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:to="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_6E745E02EEC48B21632BBA64FDF65DB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_6E745E02EEC48B21632BBA64FDF65DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_B13DAF80DB669B156C73BA64FDF6A1DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_B13DAF80DB669B156C73BA64FDF6A1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:to="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:to="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:to="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CAF12F13685EC32F4467BA64FDEDFD72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:to="loc_us-gaap_MaximumMember_CAF12F13685EC32F4467BA64FDEDFD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_1A0FF81ECE36CD34E0C1BA64FDEDF3D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_1A0FF81ECE36CD34E0C1BA64FDEDF3D3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount" xlink:label="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InvestmentsContingentPurchaseObligation" xlink:label="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LongTermInvestmentsMember" xlink:label="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:to="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B4A63D1F4E6E3E3490D4BA64FDE7A6FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B4A63D1F4E6E3E3490D4BA64FDE7A6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:to="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerOneMember" xlink:label="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerTwoMember" xlink:label="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerThreeMember" xlink:label="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NumberOfMajorCustomers" xlink:label="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/FixedAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_B7137C83FB623D11A7D3BA64FE22574A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_B7137C83FB623D11A7D3BA64FE22574A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ComputerEquipmentAndSoftwareMember" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_E667D67AB324D06D0F59BA64FE222A8D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_E667D67AB324D06D0F59BA64FE222A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_BB85A5393D4B9D8BD978BA64FE2256EB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_BB85A5393D4B9D8BD978BA64FE2256EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ForeignPropertyPlantandEquipmentNet" xlink:label="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesIncurred" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FixedAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" xlink:label="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:to="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9_default" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" xlink:label="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:to="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInUnitedStatesMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_399A3FAD94BCF0B6EC8CBA64FE184A5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_399A3FAD94BCF0B6EC8CBA64FE184A5D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million" xlink:label="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation" xlink:label="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalGoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedonMilestonePayments" xlink:label="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:to="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:to="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:to="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:to="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionLineItems" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionTable" xlink:label="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:to="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_DD4C13B28B08D9A1078AC40AF73ED4EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_DD4C13B28B08D9A1078AC40AF73ED4EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvision" xlink:label="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Effectofstateblendedtaxratechanges" xlink:label="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NonUSNetOperatingLoss" xlink:label="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AvailableNetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable20182022" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit" xlink:label="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_061447A9EFBF2BFDB034C40AF73F4142" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_061447A9EFBF2BFDB034C40AF73F4142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UnitedStatesStatutoryTaxRate" xlink:label="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_691C66868E00F454B6BBBA64FDC121D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_691C66868E00F454B6BBBA64FDC121D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D1086D6D5CFE8CB56D9EBA64FDC1810D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D1086D6D5CFE8CB56D9EBA64FDC1810D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:to="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:to="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MPMAssetManagementMember" xlink:label="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:to="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:to="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyAxis" xlink:label="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyDomain" xlink:label="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:to="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyDomain" xlink:label="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:to="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConsultingAgreementMember" xlink:label="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:to="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:to="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:to="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9DD5646476BD566806ADBA64FD96B5C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:to="loc_us-gaap_MaximumMember_9DD5646476BD566806ADBA64FD96B5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:to="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:to="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InducementPlan2014Member" xlink:label="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandSevenStockIncentivePlanMember" xlink:label="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StockIncentivePlan2011Member" xlink:label="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_930560E58F28EECAF225BA64FDD1E373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_930560E58F28EECAF225BA64FDD1E373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockPlansDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsemployees" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsnonemployeeawards" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromemployeestockpurchaseplan" xlink:label="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockPlansDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:to="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_604E92EDA1228637E14ABA62A3B7512E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_604E92EDA1228637E14ABA62A3B7512E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_25D839CD3645F7BB7D99BA62A3B76319" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_25D839CD3645F7BB7D99BA62A3B76319" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanMember" xlink:label="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:to="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:to="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:to="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_98497B6C1ECFC0FC3B23BA636E284BF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:to="loc_us-gaap_MinimumMember_98497B6C1ECFC0FC3B23BA636E284BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0426CD1940F286DA16C3BA63AB33EF0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:to="loc_us-gaap_MaximumMember_0426CD1940F286DA16C3BA63AB33EF0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12C948E272034289DE6BBA683DD8D1C6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12C948E272034289DE6BBA683DD8D1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue" xlink:label="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue" xlink:label="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:to="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:to="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:to="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LargestCustomerMember" xlink:label="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SecondLargestCustomerMember" xlink:label="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ThirdLargestCustomerMember" xlink:label="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CustomersOutsideUSMember" xlink:label="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ComputerEquipmentAndSoftwareMember" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:to="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:to="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:to="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:to="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_WholesalerservicefeesMember" xlink:label="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForPromotionsMember" xlink:label="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>pcrx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of carrying amount and fair value of the long-term debt</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of short-term investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3_label_en-US" xlink:label="lab_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="lab_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="lab_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:to="lab_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:to="lab_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:to="lab_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="arc" />
    <link:label id="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4_terseLabel_en-US" xlink:label="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Senior Convertible Notes [Member]</link:label>
    <link:label id="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4_label_en-US" xlink:label="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Senior Convertible Notes [Member]</link:label>
    <link:label id="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4_documentation_en-US" xlink:label="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the series 2019 senior convertible notes, which is a written promise to pay a note that can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:to="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="arc" />
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:to="lab_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:to="lab_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:to="lab_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect adjustment of the adoption of Accounting Standards Update 2016-09 (Note 3)</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon conversion of 2019 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon conversion of 2019 convertible senior notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible senior notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:to="lab_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:to="lab_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:to="lab_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="arc" />
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC_terseLabel_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC_label_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC_documentation_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ComputerEquipmentAndSoftwareMember" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:to="lab_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and laboratory equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C_label_en-US" xlink:label="lab_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:to="lab_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28_label_en-US" xlink:label="lab_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:to="lab_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5_label_en-US" xlink:label="lab_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:to="lab_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E_label_en-US" xlink:label="lab_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:to="lab_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:to="lab_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:to="lab_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reconciliation of income taxes at the U.S. Federal statutory rate to the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of significant components of the Company's deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:type="arc" />
    <link:label id="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6_terseLabel_en-US" xlink:label="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6_label_en-US" xlink:label="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity [Abstract]</link:label>
    <link:label id="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6_documentation_en-US" xlink:label="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LiquidityAbstract" xlink:label="loc_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:to="lab_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:to="lab_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:type="arc" />
    <link:label id="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E_terseLabel_en-US" xlink:label="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning period prior to product expiration allowed for the product to be returned</link:label>
    <link:label id="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E_label_en-US" xlink:label="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beginning Period Prior to Product Expiration Allowed for Returning Product</link:label>
    <link:label id="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E_documentation_en-US" xlink:label="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the beginning period prior to the product expiration, which the entity allows for the product to be returned.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct" xlink:label="loc_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:to="lab_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:type="arc" />
    <link:label id="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D_terseLabel_en-US" xlink:label="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period following product expiration upto which the product is allowed to be returned</link:label>
    <link:label id="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D_label_en-US" xlink:label="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period after Product Expiration upto which Product is Allowed to be Returned</link:label>
    <link:label id="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D_documentation_en-US" xlink:label="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the period following the product expiration, upto which the entity allows for the product to be returned.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned" xlink:label="loc_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:to="lab_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued returns</link:label>
    <link:label id="lab_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA_label_en-US" xlink:label="lab_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Sales Returns [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:to="lab_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18_terseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves for prompt pay discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="arc" />
    <link:label id="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109_terseLabel_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued wholesaler service fees</link:label>
    <link:label id="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109_label_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler service fees [Member]</link:label>
    <link:label id="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109_documentation_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesaler service fees [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_WholesalerservicefeesMember" xlink:label="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:to="lab_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates and chargebacks</link:label>
    <link:label id="lab_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593_label_en-US" xlink:label="lab_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Promotions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForPromotionsMember" xlink:label="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:to="lab_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Additions for Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments (Credits)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Deductions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of annual minimum payments due under the Company's lease obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842_label_en-US" xlink:label="lab_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:to="lab_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:to="lab_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="lab_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:to="lab_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:type="arc" />
    <link:label id="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative licensing and milestone revenue</link:label>
    <link:label id="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36_label_en-US" xlink:label="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Licensing and Development Revenue</link:label>
    <link:label id="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36_documentation_en-US" xlink:label="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue derived from reimbursements received in connection with feasibility studies and development work and for the licensing of technology.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeLicensingAndDevelopmentRevenue" xlink:label="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:to="lab_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:to="lab_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321_label_en-US" xlink:label="lab_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:to="lab_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:to="lab_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product discontinuation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:to="lab_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:to="lab_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:to="lab_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983_label_en-US" xlink:label="lab_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:to="lab_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861_negatedLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Royalty interest obligation</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:to="lab_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:to="lab_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:to="lab_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net income (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:to="lab_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E_label_en-US" xlink:label="lab_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:to="lab_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1_label_en-US" xlink:label="lab_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:to="lab_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:to="lab_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:to="lab_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="arc" />
    <link:label id="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7_verboseLabel_en-US" xlink:label="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:to="lab_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt-current and long-term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:to="lab_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349_label_en-US" xlink:label="lab_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:to="lab_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price of notes into common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA_verboseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Premium, Shares</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Premium, Shares</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Premium, Shares</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:to="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated conversion value</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Value</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Value</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:to="lab_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Investments, Other than Investments in Related Parties, Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount" xlink:label="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:to="lab_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="arc" />
    <link:label id="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C_terseLabel_en-US" xlink:label="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Contingent Purchase Obligation</link:label>
    <link:label id="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C_label_en-US" xlink:label="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Contingent Purchase Obligation</link:label>
    <link:label id="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C_documentation_en-US" xlink:label="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments, Contingent Purchase Obligation</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InvestmentsContingentPurchaseObligation" xlink:label="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:to="lab_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="arc" />
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E_label_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:label>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E_documentation_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsAbstract" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:to="lab_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="arc" />
    <link:label id="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1_terseLabel_en-US" xlink:label="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product [Axis]</link:label>
    <link:label id="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1_label_en-US" xlink:label="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Axis]</link:label>
    <link:label id="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1_documentation_en-US" xlink:label="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product [Axis]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductAxis" xlink:label="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:to="lab_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="arc" />
    <link:label id="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E_terseLabel_en-US" xlink:label="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product [Domain]</link:label>
    <link:label id="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E_label_en-US" xlink:label="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Domain]</link:label>
    <link:label id="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E_documentation_en-US" xlink:label="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Product [Axis]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductDomain" xlink:label="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:to="lab_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="arc" />
    <link:label id="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD_terseLabel_en-US" xlink:label="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DepoCyte [Member]</link:label>
    <link:label id="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD_label_en-US" xlink:label="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DepoCyte [Member]</link:label>
    <link:label id="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD_documentation_en-US" xlink:label="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DepoCyte [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DepoCyteMember" xlink:label="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:to="lab_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parties to Contractual Arrangement [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parties to Contractual Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="arc" />
    <link:label id="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821_verboseLabel_en-US" xlink:label="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patheon [Member]</link:label>
    <link:label id="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821_label_en-US" xlink:label="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patheon [Member]</link:label>
    <link:label id="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821_documentation_en-US" xlink:label="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Patheon U.K. Limited.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PatheonMember" xlink:label="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:to="lab_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="arc" />
    <link:label id="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34_terseLabel_en-US" xlink:label="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mundipharma Ltd [Member]</link:label>
    <link:label id="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34_label_en-US" xlink:label="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma Ltd [Member]</link:label>
    <link:label id="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34_documentation_en-US" xlink:label="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mundipharma International Corporation Limited [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MundipharmaLtdMember" xlink:label="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:to="lab_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:to="lab_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="arc" />
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8_terseLabel_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aratana</link:label>
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8_label_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aratana Therapeutics Inc [Member]</link:label>
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8_documentation_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Aratana Therapeutics, Inc.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AratanaTherapeuticsIncMember" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:to="lab_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="arc" />
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by categories of milestones achieved.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneAxis" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:to="lab_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="arc" />
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Different categories of achievement of milestones.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneDomain" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:to="lab_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="arc" />
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of development and commercial milestones</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299_label_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement of Development and Commercial Milestones [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299_documentation_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the achievement of development and commercial events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:to="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:type="arc" />
    <link:label id="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089_terseLabel_en-US" xlink:label="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total revenue</link:label>
    <link:label id="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089_label_en-US" xlink:label="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of total revenue</link:label>
    <link:label id="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089_documentation_en-US" xlink:label="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of total revenue</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Percentageoftotalrevenue" xlink:label="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:to="lab_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:to="lab_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="arc" />
    <link:label id="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17_terseLabel_en-US" xlink:label="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Rights Expansion &amp; New Distribution Payment</link:label>
    <link:label id="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17_label_en-US" xlink:label="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Rights Expansion &amp; New Distribution Payment</link:label>
    <link:label id="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17_documentation_en-US" xlink:label="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">European Rights Expansion &amp; New Distribution Payment</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EuropeanRightsExpansionNewDistributionPayment" xlink:label="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:to="lab_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="arc" />
    <link:label id="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E_terseLabel_en-US" xlink:label="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Extension of 2003 Agreements</link:label>
    <link:label id="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E_label_en-US" xlink:label="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Extension of 2003 Agreements</link:label>
    <link:label id="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E_documentation_en-US" xlink:label="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Extension of 2003 Agreements</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TermExtensionof2003Agreements" xlink:label="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:to="lab_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="arc" />
    <link:label id="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162_terseLabel_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Residual Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162_label_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Residual Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162_documentation_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Residual Lease Costs</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsResidualLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:to="lab_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Current</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationCurrent" xlink:label="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:to="lab_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Amounts of Material Contingent Liabilities Remaining</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Amounts of Material Contingent Liabilities Remaining</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining" xlink:label="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:to="lab_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:to="lab_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="arc" />
    <link:label id="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E_terseLabel_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Remaining Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E_label_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Remaining Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E_documentation_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Remaining Lease Costs</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsRemainingLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:to="lab_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="arc" />
    <link:label id="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6_terseLabel_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Fixed Asset and Inventory Writedown</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6_label_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Fixed Asset and Inventory Writedown</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6_documentation_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations - Fixed Asset and Inventory Writedown</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown" xlink:label="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:to="lab_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165_terseLabel_en-US" xlink:label="lab_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs Incurred, Asset Retirement Obligation Incurred</link:label>
    <link:label id="lab_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165_label_en-US" xlink:label="lab_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Incurred, Asset Retirement Obligation Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsIncurredAssetRetirementObligationIncurred" xlink:label="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:to="lab_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for Postemployment Benefits</link:label>
    <link:label id="lab_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69_label_en-US" xlink:label="lab_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Postemployment Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:to="lab_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="arc" />
    <link:label id="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8_negatedTerseLabel_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Payments For Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8_label_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Payments For Lease Costs</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8_documentation_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Payments For Lease Costs</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsPaymentsForLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:to="lab_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Liabilities Settled</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Liabilities Settled</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:to="lab_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="arc" />
    <link:label id="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8_negatedTerseLabel_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations Assets removed from Service</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8_label_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations Assets removed from Service</link:label>
    <link:label id="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8_documentation_en-US" xlink:label="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations Assets removed from Service</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsAssetsremovedfromService" xlink:label="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:to="lab_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="arc" />
    <link:label id="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E_negatedTerseLabel_en-US" xlink:label="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Change in Discontinued Operations Balance</link:label>
    <link:label id="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E_label_en-US" xlink:label="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Change in Discontinued Operations Balance</link:label>
    <link:label id="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E_documentation_en-US" xlink:label="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Change in Discontinued Operations Balance</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalChangeinDiscontinuedOperationsBalance" xlink:label="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:to="lab_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="arc" />
    <link:label id="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC_terseLabel_en-US" xlink:label="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Termination Fee</link:label>
    <link:label id="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC_label_en-US" xlink:label="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination Fee</link:label>
    <link:label id="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC_documentation_en-US" xlink:label="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum dollar amount it would cost the entity to terminate a contract as of a given date.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFee" xlink:label="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:to="lab_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="arc" />
    <link:label id="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B_terseLabel_en-US" xlink:label="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Term of Manufacturing Supply Agreement</link:label>
    <link:label id="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B_label_en-US" xlink:label="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Term of Manufacturing Supply Agreement</link:label>
    <link:label id="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B_documentation_en-US" xlink:label="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Term of Manufacturing Supply Agreement</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InitialTermofManufacturingSupplyAgreement" xlink:label="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:to="lab_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="arc" />
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front payment received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Payment Received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the upfront payment received under the collaborative arrangement.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:to="lab_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="arc" />
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payments Received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the milestone payment received under the collaborative arrangement.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:to="lab_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="arc" />
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments Company is entitled to receive based on terms of agreement</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payments to be Received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:to="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="arc" />
    <link:label id="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD_terseLabel_en-US" xlink:label="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Termination Fee, Current Portion</link:label>
    <link:label id="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD_label_en-US" xlink:label="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination Fee, Current Portion</link:label>
    <link:label id="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD_documentation_en-US" xlink:label="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract termination fees payable within the next twelve months.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFeeCurrentPortion" xlink:label="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:to="lab_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:type="arc" />
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC_label_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of New Accounting Pronouncements Not yet Adopted [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:to="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:to="lab_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="lab_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion and Redemption Terms [Axis]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB_label_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion and Redemption Terms [Axis]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB_documentation_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information regarding the conversion and redemption terms of the debt instruments.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:to="lab_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion and Redemption Terms [Domain]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60_label_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion and Redemption Terms [Domain]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60_documentation_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Identification of the conversion and redemption terms of the debt instruments.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="lab_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:to="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF_terseLabel_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020 [Member]</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF_label_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020 [Member]</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF_documentation_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020 [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:to="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding August 12018 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding August 12018 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt conversion terms for the period prior to the close of business on the business day immediately preceding August 1, 2018.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:to="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt:</link:label>
    <link:label id="lab_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46_label_en-US" xlink:label="lab_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="lab_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Discount on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt, net of debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:to="lab_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="arc" />
    <link:label id="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8_terseLabel_en-US" xlink:label="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt, Net</link:label>
    <link:label id="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8_label_en-US" xlink:label="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt, Net</link:label>
    <link:label id="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8_documentation_en-US" xlink:label="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt, Net</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsfromConvertibleDebtNet" xlink:label="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:to="lab_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:to="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Number of Consecutive Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Number of Consecutive Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:to="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of the conversion price that the closing sales price of the entity's common stock must exceed for at least 20 days within 30 consecutive trading days, in order for the notes to be convertible.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:to="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Obligation Number of Consecutive Business Days after Consecutive Trading Day Period</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Obligation Number of Consecutive Business Days after Consecutive Trading Day Period</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:to="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Period of Consecutive Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Period of Consecutive Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:to="lab_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal Amount Denominator for Conversion into Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal Amount Denominator for Conversion into Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the principal amount of notes used as a denominator for purposes of computing the conversion ratio of convertible debt.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock" xlink:label="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:to="lab_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of the entity's common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:to="lab_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="arc" />
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B_terseLabel_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement Period - Convertible Debt Conversion Request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B_label_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Period - Convertible Debt Conversion Request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B_documentation_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of trading days in a settlement period for convertible debt conversion requests.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:to="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Premium on Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Obligation Premium on Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:to="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:to="lab_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D_label_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentMarketPrice" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:to="lab_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Obligation Number of Trading Days Prior to Date on which Entity Provides Notice of Redemption</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Obligation Number of Trading Days Prior to Date on which Entity Provides Notice of Redemption</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of trading days prior to the date on which the entity provides notice of redemption during which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemed.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:to="lab_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:to="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4_terseLabel_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Redemption Price Due to Fundamental Change as Percentage of Principal Amount</link:label>
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4_label_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Redemption Price Due to Fundamental Change as Percentage of Principal Amount</link:label>
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4_documentation_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be repurchased in the event of a fundamental change by the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:to="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:to="lab_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Assumed Borrowing Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Assumed Borrowing Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Assumed Borrowing Rate</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:to="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75_label_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA_terseLabel_en-US" xlink:label="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Amortization period</link:label>
    <link:label id="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA_label_en-US" xlink:label="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Amortization period</link:label>
    <link:label id="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA_documentation_en-US" xlink:label="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Amortization period</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtIssuanceCostsAmortizationperiod" xlink:label="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:to="lab_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:to="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="arc" />
    <link:label id="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0_terseLabel_en-US" xlink:label="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance of Debt</link:label>
    <link:label id="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0_label_en-US" xlink:label="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance of Debt</link:label>
    <link:label id="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0_documentation_en-US" xlink:label="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GrossProceedsFromIssuanceofDebt" xlink:label="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:to="lab_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E_verboseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Value</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:to="lab_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:to="lab_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="lab_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:to="lab_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="arc" />
    <link:label id="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3_terseLabel_en-US" xlink:label="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Largest customer</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3_label_en-US" xlink:label="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3_documentation_en-US" xlink:label="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the largest customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LargestCustomerMember" xlink:label="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:to="lab_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="arc" />
    <link:label id="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939_terseLabel_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second largest customer</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939_label_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939_documentation_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second largest customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SecondLargestCustomerMember" xlink:label="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:to="lab_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="arc" />
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14_terseLabel_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third largest customer</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14_label_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14_documentation_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the third largest customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ThirdLargestCustomerMember" xlink:label="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:to="lab_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="arc" />
    <link:label id="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0_terseLabel_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers outside U.S.</link:label>
    <link:label id="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0_label_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers Outside US [Member]</link:label>
    <link:label id="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0_documentation_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to customers outside U.S.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CustomersOutsideUSMember" xlink:label="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:to="lab_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Major Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenue from customers to total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of composition of the Company's debt and financing obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:type="arc" />
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of total interest expense recognized related to the Notes</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA_label_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the amount of interest rate expenses related to convertible notes.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:to="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:to="lab_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:to="lab_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="arc" />
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C_terseLabel_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options, employees</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C_label_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options, employees</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C_documentation_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options (employee and board of director awards)</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsemployees" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:to="lab_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="arc" />
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341_terseLabel_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options, non-employee awards</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341_label_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options, non-employee awards</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341_documentation_en-US" xlink:label="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense from stock options, non-employee awards</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsnonemployeeawards" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:to="lab_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:to="lab_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="arc" />
    <link:label id="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83_terseLabel_en-US" xlink:label="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense from employee stock purchase plan</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83_label_en-US" xlink:label="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation expense from employee stock purchase plan</link:label>
    <link:label id="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83_documentation_en-US" xlink:label="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense from employee stock purchase plan</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromemployeestockpurchaseplan" xlink:label="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:to="lab_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492_totalLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:to="lab_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Savings Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:to="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:type="arc" />
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841_terseLabel_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholsesaler Service Fees and Prompt Pay Discounts</link:label>
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841_label_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Valuation and Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841_documentation_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Movement in Valuation and Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:label="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:to="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of percentage of revenue comprised by the three largest customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of useful lives by asset category</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of change in carrying value of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances at the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="lab_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="lab_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:to="lab_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:to="lab_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:to="lab_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:to="lab_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7_label_en-US" xlink:label="lab_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:to="lab_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0_label_en-US" xlink:label="lab_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:to="lab_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:to="lab_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:to="lab_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:to="lab_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:to="lab_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906_label_en-US" xlink:label="lab_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:to="lab_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:to="lab_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding at December 31, 2017 and 2016</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:to="lab_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.001 and 250,000,000 shares authorized; 40,668,877 shares issued and outstanding at December 31, 2017; 37,480,952 shares issued and outstanding at December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:to="lab_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:to="lab_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:to="lab_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:type="arc" />
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E_terseLabel_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</link:label>
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E_label_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</link:label>
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E_documentation_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:label="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:to="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="arc" />
    <link:label id="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461_terseLabel_en-US" xlink:label="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PPI-California</link:label>
    <link:label id="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461_label_en-US" xlink:label="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Operating Subsidiary [Member]</link:label>
    <link:label id="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461_documentation_en-US" xlink:label="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the California operating subsidiary, which is also referred to as PPB-California.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CaliforniaOperatingSubsidiaryMember" xlink:label="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:to="lab_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:to="lab_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="arc" />
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5_terseLabel_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SkyePharma Holding, Inc.</link:label>
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5_label_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skye Pharma Holding Inc. [Member]</link:label>
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5_documentation_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to SkyePharma Holding, Inc.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SkyePharmaHoldingIncMember" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:to="lab_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial purchase price for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="arc" />
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750_terseLabel_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments for EXPAREL agreed in connection with acquisition</link:label>
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750_label_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreed Milestone Payments for Sale of Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750_documentation_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:to="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="arc" />
    <link:label id="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53_terseLabel_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total milestone payments paid</link:label>
    <link:label id="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53_label_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53_documentation_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition" xlink:label="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:to="lab_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of fixed assets and amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:type="arc" />
    <link:label id="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC_terseLabel_en-US" xlink:label="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of unfavorable lease obligation and debt issuance costs</link:label>
    <link:label id="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC_label_en-US" xlink:label="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Other Assets and Unfavorable Lease Obligation</link:label>
    <link:label id="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC_documentation_en-US" xlink:label="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amortization of deferred financing costs and unfavorable lease obligations. Deferred financing costs are amortized over the term of the associated financing arrangement. Unfavorable lease obligations are determined based on the fair value of a lease compared to the acquired lease terms in connection with a business combination, which are amortized over the remaining lease term.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation" xlink:label="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:to="lab_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:to="lab_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:type="arc" />
    <link:label id="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828_negatedLabel_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Royalty interest obligation</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828_label_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Royalty Interest Obligation</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828_documentation_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease during the reporting period in royalty interest obligation during the reporting period. Royalty interest obligation consists of obligations relating to the assignment of royalty interests on future revenues.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncreaseDecreaseInRoyaltyInterestObligation" xlink:label="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:to="lab_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:type="arc" />
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733_negatedLabel_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733_label_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Contingent Consideration</link:label>
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733_documentation_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents earnout and milestone payment made which is associated with the acquisition of business.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentOfContingentConsideration" xlink:label="loc_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:to="lab_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses and Interest in Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:type="arc" />
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3_terseLabel_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3_label_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Shares Issued Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3_documentation_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Shares Issued Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:to="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from 2022 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of 2019 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance and financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:type="arc" />
    <link:label id="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735_negatedTerseLabel_en-US" xlink:label="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs for conversion of convertible senior notes</link:label>
    <link:label id="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735_label_en-US" xlink:label="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of principal and equity component of convertible senior notes</link:label>
    <link:label id="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735_documentation_en-US" xlink:label="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the principal amount of notes and related equity component for the conversion of the premium on convertible senior notes</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes" xlink:label="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:to="lab_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest, including royalty interest obligation</link:label>
    <link:label id="lab_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538_label_en-US" xlink:label="lab_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:to="lab_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:to="lab_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:type="arc" />
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from conversion of 2019 convertible senior notes</link:label>
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2_label_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued, Value</link:label>
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2_documentation_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued, Value</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionConvertedInstrumentSharesIssuedValue" xlink:label="loc_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:to="lab_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:type="arc" />
    <link:label id="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA_negatedTerseLabel_en-US" xlink:label="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from conversion of 2019 convertible senior notes</link:label>
    <link:label id="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA_label_en-US" xlink:label="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Market Value of Common Stock Issued for Convertible Senior Notes Premium</link:label>
    <link:label id="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA_documentation_en-US" xlink:label="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair market value of the common stock issued to settle a convertible senior notes premium at conversion.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium" xlink:label="loc_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:to="lab_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:type="arc" />
    <link:label id="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E_terseLabel_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in accrued fixed assets</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E_label_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Capital Expenditures Incurred And Not Yet Paid</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E_documentation_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Capital Expenditures Incurred And Not Yet Paid</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid" xlink:label="loc_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:to="lab_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:type="arc" />
    <link:label id="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fixed assets summarized by major category</link:label>
    <link:label id="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C_label_en-US" xlink:label="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment Components [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of property, plant and equipment.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock" xlink:label="loc_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:to="lab_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:to="lab_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="arc" />
    <link:label id="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B_terseLabel_en-US" xlink:label="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MPM</link:label>
    <link:label id="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B_label_en-US" xlink:label="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MPM Asset Management [Member]</link:label>
    <link:label id="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B_documentation_en-US" xlink:label="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PMP Asset Management ("MPM"), an investor in the Company.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MPMAssetManagementMember" xlink:label="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:to="lab_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143_verboseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Member of board of directors</link:label>
    <link:label id="lab_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143_label_en-US" xlink:label="lab_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:to="lab_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="arc" />
    <link:label id="lab_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5_terseLabel_en-US" xlink:label="lab_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5_label_en-US" xlink:label="lab_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyAxis" xlink:label="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:to="lab_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE_terseLabel_en-US" xlink:label="lab_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE_label_en-US" xlink:label="lab_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyDomain" xlink:label="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:to="lab_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="arc" />
    <link:label id="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B_terseLabel_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting agreement</link:label>
    <link:label id="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B_label_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B_documentation_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the consulting agreement entered into by the entity with a related party.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConsultingAgreementMember" xlink:label="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:to="lab_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses incurred by the entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="arc" />
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A_terseLabel_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares that can be purchased under option (in shares)</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A_label_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction Option to Purchase Shares of Common Stock Number of Shares</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A_documentation_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of shares that can be purchased by the related party on exercise of option.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:to="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="arc" />
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7_terseLabel_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of shares that can be purchased under option (in dollars per share)</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7_label_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction Option to Purchase Shares of Common Stock Exercise Price</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7_documentation_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exercise price of shares that can be purchased by the related party on exercise of option.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:to="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:to="lab_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="lab_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="arc" />
    <link:label id="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8_terseLabel_en-US" xlink:label="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8_label_en-US" xlink:label="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8_documentation_en-US" xlink:label="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InducementPlan2014Member" xlink:label="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:to="lab_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="arc" />
    <link:label id="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D_terseLabel_en-US" xlink:label="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D_label_en-US" xlink:label="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D_documentation_en-US" xlink:label="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandSevenStockIncentivePlanMember" xlink:label="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:to="lab_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="arc" />
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F_terseLabel_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F_label_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F_documentation_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information about the entity's 2011 stock incentive plan.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StockIncentivePlan2011Member" xlink:label="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:to="lab_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Reserved for Issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="arc" />
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Shares in ESPP</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Shares in ESPP</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Shares in ESPP</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:to="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="arc" />
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB_terseLabel_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Fair Market Value Purchase of ESPP Shares</link:label>
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB_label_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Fair Market Value Purchase of ESPP Shares</link:label>
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB_documentation_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Fair Market Value Purchase of ESPP Shares in a Calendar Year</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:to="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="arc" />
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan fair value</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan fair value</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of fair value of common stock eligible employees can purchase common shares at through an employee stock purchase plan.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:to="lab_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Available for Grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="arc" />
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Authorized</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Authorized</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Authorized</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:to="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="arc" />
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Available For Purchase</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Available For Purchase</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Available For Purchase</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:to="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="arc" />
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0_terseLabel_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which They are Payable [Axis]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0_label_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Axis]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0_documentation_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to milestone payments for products by the stage at which they are payable, in connection with the acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:to="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="arc" />
    <link:label id="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9_terseLabel_en-US" xlink:label="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stage at which Milestone Payments for Product are Payable in Connection with Acquisition [Domain]</link:label>
    <link:label id="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9_label_en-US" xlink:label="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stage at which Milestone Payments for Product are Payable in Connection with Acquisition [Domain]</link:label>
    <link:label id="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9_documentation_en-US" xlink:label="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stages at which milestone payments for products are payable, in connection with the acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" xlink:label="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="lab_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="arc" />
    <link:label id="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0_terseLabel_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon first commercial sale in the United States</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0_label_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon First Commercial Sale in United States [Member]</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0_documentation_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stage for milestone payments upon the first commercial sale in the United States.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInUnitedStatesMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:to="lab_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="arc" />
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8_terseLabel_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8_label_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon First Commercial Sale in Major EU Country [Member]</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8_documentation_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stage for milestone payments upon the first commercial sale in a major EU country (UK, France, Germany, Italy or Spain).</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:to="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="arc" />
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F_terseLabel_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">When annual net sales collected reach $100.0 million</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F_label_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Annual Net Sales Reaching Dollar 100.0 Million Threshold [Member]</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F_documentation_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stage for milestone payments when the annual net sales reach 100.0 million dollars.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:to="lab_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="arc" />
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148_terseLabel_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">When annual net sales collected reach $250.0 million</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148_label_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Annual Net Sales Reaching Dollar 250.0 Million Threshold [Member]</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148_documentation_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stage for milestone payments when the annual net sales reach 250.0 million dollars.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:to="lab_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="arc" />
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37_terseLabel_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">When annual net sales collected reach $500.0 million</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37_label_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Annual Net Sales Reaching Dollar 500.0 Million Threshold [Member]</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37_documentation_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stage for milestone payments when the annual net sales reach 500.0 million dollars.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:to="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="lab_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:type="arc" />
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761_terseLabel_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual net sales threshold</link:label>
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761_label_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Threshold for Determining Milestone Payments for Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761_documentation_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:to="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="arc" />
    <link:label id="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D_terseLabel_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment obligation arising in connection with the acquisition</link:label>
    <link:label id="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D_label_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Obligation Arising Due to First Commercial Sale of Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D_documentation_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the payment obligation which the reporting entity is entitled to pay to other party on completion of first commercial sale of its product in connection with the acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:to="lab_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="arc" />
    <link:label id="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42_terseLabel_en-US" xlink:label="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability recognized at the time of the acquisition</link:label>
    <link:label id="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42_label_en-US" xlink:label="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Payment Obligation Established for Sale of Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42_documentation_en-US" xlink:label="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of contingent consideration liability established for sale of product in connection with acquisition.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:to="lab_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill recorded in connection with the acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="arc" />
    <link:label id="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087_terseLabel_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Obligation Arising Due to Net Sales Collected Threshold of $100 Million</link:label>
    <link:label id="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087_label_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Obligation Arising Due to Net Sales Collected Threshold of $100 Million</link:label>
    <link:label id="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087_documentation_en-US" xlink:label="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Obligation Arising Due to Net Sales Collected Threshold of $100 Million</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million" xlink:label="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:to="lab_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="arc" />
    <link:label id="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD_terseLabel_en-US" xlink:label="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales Collected Threshold Which Triggers a Payment Obligation</link:label>
    <link:label id="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD_label_en-US" xlink:label="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Sales Collected Threshold Which Triggers a Payment Obligation</link:label>
    <link:label id="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD_documentation_en-US" xlink:label="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Sales Collected Threshold Which Triggers a Payment Obligation</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation" xlink:label="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:to="lab_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="arc" />
    <link:label id="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9_terseLabel_en-US" xlink:label="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Goodwill Recorded for Earn Out Payments</link:label>
    <link:label id="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9_label_en-US" xlink:label="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Goodwill Recorded for Earn Out Payments</link:label>
    <link:label id="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9_documentation_en-US" xlink:label="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Goodwill Recorded for Earn Out Payments - Cumulative</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalGoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:to="lab_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="lab_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:to="lab_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="arc" />
    <link:label id="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861_terseLabel_en-US" xlink:label="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage payments on collections of net sales of DepoBupivacaine products</link:label>
    <link:label id="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861_label_en-US" xlink:label="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Recorded for Earn Out Payments</link:label>
    <link:label id="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861_documentation_en-US" xlink:label="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount recorded as goodwill for earn-out payments made by the entity based on a percentage of net sales of EXPAREL collected.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:to="lab_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="arc" />
    <link:label id="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E_terseLabel_en-US" xlink:label="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment triggered by collections of net sales of DepoBupivacaine products</link:label>
    <link:label id="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E_label_en-US" xlink:label="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Recorded on Milestone Payments</link:label>
    <link:label id="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E_documentation_en-US" xlink:label="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Recorded on Milestone Payments</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedonMilestonePayments" xlink:label="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:to="lab_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:to="lab_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:to="lab_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:to="lab_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net income (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding&#8212;basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:type="arc" />
    <link:label id="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09_terseLabel_en-US" xlink:label="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of RSUs (in shares)</link:label>
    <link:label id="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09_label_en-US" xlink:label="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Restricted Stock Units</link:label>
    <link:label id="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09_documentation_en-US" xlink:label="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits" xlink:label="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:to="lab_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of conversion premium on the 2019 Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of ESPP purchase options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding&#8212;diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:type="arc" />
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:type="arc" />
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1_terseLabel_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:label>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1_label_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Partners and Agreements [Text Block]</link:label>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1_documentation_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the entire disclosure of commercial agreement and arrangement with third parties.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:to="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:to="lab_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068_label_en-US" xlink:label="lab_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:to="lab_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:to="lab_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="arc" />
    <link:label id="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34_terseLabel_en-US" xlink:label="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34_label_en-US" xlink:label="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34_documentation_en-US" xlink:label="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to product goods and services and not intended for resale, located in a foreign country or territory.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ForeignPropertyPlantandEquipmentNet" xlink:label="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:to="lab_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:to="lab_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Asset Retirement Obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Asset Retirement Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:to="lab_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Liabilities Incurred</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesIncurred" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:to="lab_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Accretion Expense</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation, Accretion Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:to="lab_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:to="lab_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:to="lab_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:to="lab_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:type="arc" />
    <link:label id="lab_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793_label_en-US" xlink:label="lab_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793_documentation_en-US" xlink:label="lab_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DocumentAndEntityInformationAbstract" xlink:label="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="lab_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550_label_en-US" xlink:label="lab_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:to="lab_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:to="lab_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763_terseLabel_en-US" xlink:label="lab_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763_label_en-US" xlink:label="lab_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:to="lab_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:to="lab_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33_label_en-US" xlink:label="lab_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:to="lab_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:to="lab_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:to="lab_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:to="lab_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F_label_en-US" xlink:label="lab_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:to="lab_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E_label_en-US" xlink:label="lab_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:to="lab_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:to="lab_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:type="arc" />
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of information about the plans</link:label>
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40_label_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Shares Available for Issuance [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of shares available for issuance which includes information about awards reserved for issuance, awards issued and awards available for grant by plan.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:label="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:to="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of recognized stock-based compensation in consolidated statements of operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Company's stock option activity and related information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average assumptions used to estimate the fair values of each option grant using the Black-Scholes option pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual minimum payments due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 through 2028</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:label id="lab_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C_label_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive from Lessor</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="loc_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:to="lab_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:to="lab_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:type="arc" />
    <link:label id="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754_terseLabel_en-US" xlink:label="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754_label_en-US" xlink:label="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754_documentation_en-US" xlink:label="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for basis of presentation and principles of consolidation.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="loc_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:to="lab_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:to="lab_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:type="arc" />
    <link:label id="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721_terseLabel_en-US" xlink:label="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721_label_en-US" xlink:label="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721_documentation_en-US" xlink:label="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LiquidityPolicyTextBlock" xlink:label="loc_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:to="lab_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Major Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligations</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligation [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="loc_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:to="lab_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Transactions</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per Share Data</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of computation of basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of potential dilutive effect of the securities excluded from the calculation of diluted loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:to="lab_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:to="lab_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="arc" />
    <link:label id="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customer one</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761_label_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer One [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerOneMember" xlink:label="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:to="lab_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="arc" />
    <link:label id="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customer two</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D_label_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer Two [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerTwoMember" xlink:label="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:to="lab_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="arc" />
    <link:label id="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customer three</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946_label_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customer Three [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerThreeMember" xlink:label="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:to="lab_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:type="arc" />
    <link:label id="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B_label_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B_documentation_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers of the reporting entity.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NumberOfMajorCustomers" xlink:label="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:to="lab_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:type="arc" />
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E_terseLabel_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued operating expenses</link:label>
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E_label_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Operating Expenses, Current</link:label>
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E_documentation_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedOperatingExpensesCurrent" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:to="lab_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:type="arc" />
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352_terseLabel_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352_label_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued End of Term Fee, Current</link:label>
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352_documentation_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for end of term fee. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedEndOfTermFeeCurrent" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:to="lab_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:type="arc" />
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22_terseLabel_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product returns, rebates and other fees</link:label>
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22_label_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Returns, Rebates and Other Fees</link:label>
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22_documentation_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Returns, Rebates and Other Fees</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductReturnsRebatesandOtherFees" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:to="lab_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8_label_en-US" xlink:label="lab_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:to="lab_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP purchase options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:to="lab_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential dilutive effect of securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER EMPLOYEE BENEFITS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing obligations:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:to="lab_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="lab_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:to="lab_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense recognized</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:to="lab_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="arc" />
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377_terseLabel_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377_label_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377_documentation_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionTable" xlink:label="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="lab_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5_label_en-US" xlink:label="lab_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:to="lab_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="arc" />
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3_terseLabel_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Provision [Line Items]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3_label_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Provision [Line Items]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3_documentation_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Income Tax Provision [Table]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionLineItems" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="lab_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="arc" />
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5_totalLabel_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income (loss) before income taxes</link:label>
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5_label_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Total</link:label>
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5_documentation_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The earnings or loss from continuing operations before income taxes for the entity as a whole, including domestic and foreign operations.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:to="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="arc" />
    <link:label id="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9_terseLabel_en-US" xlink:label="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Provision</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9_label_en-US" xlink:label="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Provision</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9_documentation_en-US" xlink:label="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Provision</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvision" xlink:label="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:to="lab_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of income taxes at U.S. Federal statutory rate to the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="arc" />
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign taxes</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign operations.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="arc" />
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest Expense, Percent</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to interest expense.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="arc" />
    <link:label id="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E_terseLabel_en-US" xlink:label="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of rate changes</link:label>
    <link:label id="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E_label_en-US" xlink:label="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of state blended tax rate changes</link:label>
    <link:label id="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E_documentation_en-US" xlink:label="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed as the result of changes in state blended tax rate changes.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Effectofstateblendedtaxratechanges" xlink:label="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:to="lab_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="arc" />
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes refinancing</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="arc" />
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of the adoption of ASU 2016-09</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Effect Of New Accounting Pronouncements</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Effect Of New Accounting Pronouncements</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant components of deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="arc" />
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938_terseLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Stock Based Compensation</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Stock Based Compensation</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:to="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="arc" />
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D_totalLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets, before valuation allowance</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross, Net of Deferred Tax Liabilities, Before Valuation Allowance</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Deferred Tax Liabilities, Before Valuation Allowance</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:to="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:to="lab_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="arc" />
    <link:label id="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2_terseLabel_en-US" xlink:label="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-US Net Operating Loss</link:label>
    <link:label id="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2_label_en-US" xlink:label="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US Net Operating Loss</link:label>
    <link:label id="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2_documentation_en-US" xlink:label="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-US Net Operating Loss - This value represents the amount of the tax loss from foreign operations.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NonUSNetOperatingLoss" xlink:label="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:to="lab_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="arc" />
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5_terseLabel_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Cumulative Percentage of Change in Ownership as Condition to Offset Taxable Income or Tax</link:label>
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5_label_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Cumulative Percentage of Change in Ownership as Condition to Offset Taxable Income or Tax</link:label>
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5_documentation_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:to="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="arc" />
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B_terseLabel_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Operating Loss, Subject to Limitation</link:label>
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B_label_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss, Subject to Limitation</link:label>
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B_documentation_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Operating Losses, Subject to Limitation</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:to="lab_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="arc" />
    <link:label id="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F_terseLabel_en-US" xlink:label="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available Net Operating Loss, Subject to Limitation</link:label>
    <link:label id="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F_label_en-US" xlink:label="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available Net Operating Loss, Subject to Limitation</link:label>
    <link:label id="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F_documentation_en-US" xlink:label="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available Net Operating Loss, Subject to Limitation</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AvailableNetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:to="lab_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="arc" />
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324_terseLabel_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2018-2022)</link:label>
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324_label_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2018-2022)</link:label>
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324_documentation_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2018-2022)</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable20182022" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:to="lab_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="arc" />
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488_terseLabel_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2015-Onward)</link:label>
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488_label_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2015-Onward)</link:label>
    <link:label id="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488_documentation_en-US" xlink:label="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future NOL's Which Will Become Available (2015-Onward)</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:to="lab_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="arc" />
    <link:label id="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8_terseLabel_en-US" xlink:label="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8_label_en-US" xlink:label="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8_documentation_en-US" xlink:label="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit" xlink:label="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:to="lab_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="arc" />
    <link:label id="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989_terseLabel_en-US" xlink:label="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States Statutory Tax Rate</link:label>
    <link:label id="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989_label_en-US" xlink:label="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Statutory Tax Rate</link:label>
    <link:label id="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989_documentation_en-US" xlink:label="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States Statutory Tax Rate</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UnitedStatesStatutoryTaxRate" xlink:label="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:to="lab_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:to="lab_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="arc" />
    <link:label id="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622_terseLabel_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term:</link:label>
    <link:label id="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622_label_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:label id="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622_documentation_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LongTermInvestmentsMember" xlink:label="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:to="lab_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed Securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:to="lab_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="arc" />
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanMember" xlink:label="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:to="lab_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="arc" />
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average remaining contractual term</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Outstanding Weighted A Average Remaining Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="arc" />
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options, Outstanding Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in dollars)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average assumptions used to estimate the fair values of each option grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="arc" />
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB_terseLabel_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB_label_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB_documentation_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:to="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="arc" />
    <link:label id="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13_terseLabel_en-US" xlink:label="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation arrangement by Share-based payment award, equity instruments others than options, vested and expected to vest, weighted average grant date fair value</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13_label_en-US" xlink:label="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation arrangement by Share-based payment award, equity instruments others than options, vested and expected to vest, weighted average grant date fair value</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13_documentation_en-US" xlink:label="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation arrangement by Share-based payment award, equity instruments others than options, vested and expected to vest, weighted average grant date fair value</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue" xlink:label="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:to="lab_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="arc" />
    <link:label id="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA_terseLabel_en-US" xlink:label="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA_label_en-US" xlink:label="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA_documentation_en-US" xlink:label="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, aggregate intrinsic value</link:label>
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue" xlink:label="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:to="lab_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>pcrx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpenses" xlink:href="pcrx-20171231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesDetails" xlink:href="pcrx-20171231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/AccruedExpensesTables" xlink:href="pcrx-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:href="pcrx-20171231.xsd#CommercialPartnersAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:href="pcrx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pcrx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="pcrx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Debt" xlink:href="pcrx-20171231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails" xlink:href="pcrx-20171231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtDetails2" xlink:href="pcrx-20171231.xsd#DebtDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DebtTables" xlink:href="pcrx-20171231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DescriptionOfBusiness" xlink:href="pcrx-20171231.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:href="pcrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstruments" xlink:href="pcrx-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:href="pcrx-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssets" xlink:href="pcrx-20171231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsDetails" xlink:href="pcrx-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/FixedAssetsTables" xlink:href="pcrx-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="pcrx-20171231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxes" xlink:href="pcrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesDetails" xlink:href="pcrx-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/IncomeTaxesTables" xlink:href="pcrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/Inventories" xlink:href="pcrx-20171231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesDetails" xlink:href="pcrx-20171231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/InventoriesTables" xlink:href="pcrx-20171231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:href="pcrx-20171231.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefits" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:href="pcrx-20171231.xsd#OtherEmployeeBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:href="pcrx-20171231.xsd#RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactions" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:href="pcrx-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:href="pcrx-20171231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlans" xlink:href="pcrx-20171231.xsd#StockPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails" xlink:href="pcrx-20171231.xsd#StockPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails2" xlink:href="pcrx-20171231.xsd#StockPlansDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansDetails3" xlink:href="pcrx-20171231.xsd#StockPlansDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockPlansTables" xlink:href="pcrx-20171231.xsd#StockPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquity" xlink:href="pcrx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:href="pcrx-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/StockholdersEquityTables" xlink:href="pcrx-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="pcrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.pacira.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_399210B42CEE61A483EFBA64FE0DFBF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_399210B42CEE61A483EFBA64FE0DFBF4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D1176DDB17CC1045145BBA64FE0DC19D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05A45EC4C33C35CCFEC7BA64FE09D1BD" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedOperatingExpensesCurrent" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_pcrx_AccruedOperatingExpensesCurrent_A8F30B37DA8A8486E8E6BA64FE0A882E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_E45E2FF0898F04D6E956BA64FE0ACDC6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AccruedEndOfTermFeeCurrent" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_pcrx_AccruedEndOfTermFeeCurrent_B6B4A39A8A7CBE638840BA64FE0A6352" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductReturnsRebatesandOtherFees" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_pcrx_ProductReturnsRebatesandOtherFees_979D269731CA743F21C2BA64FE0A7F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5F524A5466231129191FBA64FE0988BC" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_D84C29367534F80F3C4DBA64FE0A65F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E1A47DBE0D51F7CAD93BA64FE0B67C9" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_AC8B938F92CC7B51B7ABBA64FE0BEE6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreements" xlink:type="extended">
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsAbstract" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsAbstract_4626293EBD9E64DC5D60BA64FDA76059" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsAbstract_4626293EBD9E64DC5D60BA64FDA76059" xlink:to="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_F8FD4920CC69A072DFBEBA64FDA75AE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsAbstract" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsAbstract_3EF2ED544DB73E6E0D2DBA64FDA5ED2E" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:label="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsAbstract_3EF2ED544DB73E6E0D2DBA64FDA5ED2E" xlink:to="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_BEA97DDB04B633875BCFBA64FDA5AF4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CommercialPartnersAndAgreementsAbstract" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsAbstract_A6C003FF2448CC43BACFBA64FDA0517E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductAxis" xlink:label="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProductDomain" xlink:label="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ProductAxis_7ECEA096DA74CA73D221BA64FDA100E1" xlink:to="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DepoCyteMember" xlink:label="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ProductDomain_5252916B2B38C74BC7F6BA64FDA1E42E" xlink:to="loc_pcrx_DepoCyteMember_5027486E80F4700CE891BA64FDA15CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_10F371B960FC12586B7DBA64FDA1FB59" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PatheonMember" xlink:label="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:to="loc_pcrx_PatheonMember_2F56B2FD489B807DBF58BA64FDA12821" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MundipharmaLtdMember" xlink:label="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2DCC137FF1067C5AF5ABA64FDA11BF1" xlink:to="loc_pcrx_MundipharmaLtdMember_1DB6CA24F020DAB60A70BA64FDA14D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5990748274648E67D688BA64FDA17D29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AratanaTherapeuticsIncMember" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFC502743CCFD926F2DDBA64FDA1AD44" xlink:to="loc_pcrx_AratanaTherapeuticsIncMember_02BE5D6093BCBF9F1D38BA64FDA185E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3BB50C3D6C55500D8958BA64FDA16DC8" xlink:to="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_893618B3B8E4FE466284BA64FDA1FDE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_91846256B5C4A764AEB1BA64FDA1A81D" xlink:to="loc_us-gaap_MaximumMember_893618B3B8E4FE466284BA64FDA1FDE8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneAxis" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfMilestoneDomain" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_12200818287F2C081525BA64FDA12A51" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_1A5EC878EA278C7A1047BA64FDA1AA59" xlink:to="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_9F25C1A0BD1FD8F51AD6BA64FDA2D299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC33C37FC5FCD6B21704BA64FDA1E770" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Percentageoftotalrevenue" xlink:label="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_Percentageoftotalrevenue_7561CA41ADF5C1C955F8BA64FDA2C089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_Revenues_5F68EA6761C24051627CBA64FDA2B1B1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EuropeanRightsExpansionNewDistributionPayment" xlink:label="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_EuropeanRightsExpansionNewDistributionPayment_CD6811EA0078F18384A3BA64FDA2AD17" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TermExtensionof2003Agreements" xlink:label="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_TermExtensionof2003Agreements_24DA7B74B7373C180F5DBA64FDA2FA3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2DAB76BE55413DCF3BAFBA64FDA361A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_A5A3BAD85892778D05B3BA64FDA339B7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_InventoryWriteDown_A5A3BAD85892778D05B3BA64FDA339B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6653D9B5213646D5673DBA64FDA2D0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_1E219B0BDA723ECBF585BA64FDA361A2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsResidualLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsResidualLeaseCosts_662ED000F6EDA4987B48BA64FDA3B162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationCurrent" xlink:label="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_AssetRetirementObligationCurrent_CBD0242FF22D7D775941BA64FDA3D7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining" xlink:label="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining_5F5C36C75063210587AFBA64FDA3F61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_SeveranceCosts1_B599056D0011C6F0DF21BA64FDA20D31" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsRemainingLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsRemainingLeaseCosts_AAC653F943B89E6F3080BA64FDA2FE7E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown" xlink:label="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown_D61E6832948335A8D13DBA64FDA2F0A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsIncurredAssetRetirementObligationIncurred" xlink:label="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_CostsIncurredAssetRetirementObligationIncurred_B9B06253179E4A991264BA64FDA23165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_PaymentsForPostemploymentBenefits_1CC397A316DF8D517BE2BA64FDA29C69" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsPaymentsForLeaseCosts" xlink:label="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts_9DA0DE520ED7B1F32DA8BA64FDA233C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_AssetRetirementObligationLiabilitiesSettled_A0D6FC2D91BBFE75140ABA64FDA29AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8723025EADBE7CB51C6EBA64FDA2A745" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DiscontinuedOperationsAssetsremovedfromService" xlink:label="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_DiscontinuedOperationsAssetsremovedfromService_37AB350035ED8343BDF6BA64FDA39EE8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalChangeinDiscontinuedOperationsBalance" xlink:label="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_TotalChangeinDiscontinuedOperationsBalance_E5F452D59BEA86A7260ABA64FDA3604E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFee" xlink:label="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_ContractTerminationFee_BF6CC83C8F6D12CA34CDBA64FDA2CFAC" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InitialTermofManufacturingSupplyAgreement" xlink:label="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_InitialTermofManufacturingSupplyAgreement_D5DDD649D785CBC3CB53BA64FDA2248B" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementUpfrontPaymentReceived" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementUpfrontPaymentReceived_D43B4A6EE33CDF994C06BA64FDA27A2E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsReceived_BFEB9541196B3B6B1D05BA64FDA25FF2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived_23383370E4593C23113CBA64FDA26D87" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContractTerminationFeeCurrentPortion" xlink:label="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0FD34A7AEEEA8F0A51ABA64FDA2062C" xlink:to="loc_pcrx_ContractTerminationFeeCurrentPortion_3FB9BAD27538CA397990BA64FDA28ECD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3598C35FED4B8BA1212DBA64FD921741" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3598C35FED4B8BA1212DBA64FD921741" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E72C516DC783AF6F1165BA64FD9270E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F8B4434C9FF57E293B7EBA64FD8BCB14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F8B4434C9FF57E293B7EBA64FD8BCB14" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_966A3FE53CDD0F8E343CBA64FD8C531A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5316A812806EDE2A962DBA64FD8CE219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_DD47043EDBADBAD57F57BA64FD8CDED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_25AFFC925F01DBA8EBD1BA64FD8C01B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_A270BCCD818CE6CD2FDBBA64FD8C7630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E64817D65E736B643126BA64FD8C3B42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3D579811247BFE0173C0BA64FD8E9B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_EC56D2E15D2C373A9C1BBA64FD8E3AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_E1F5FD4A92658BBDE8C1BA64FD8E45F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="loc_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_IncentiveFromLessor_1360D841C7C7244FEBDCBA64FD8C761C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_F96CBD6D2A270A2C84ACBA64FD8C48F1" xlink:to="loc_us-gaap_PurchaseObligation_7DE3CF918DA2A5F517F9BA64FD8C3820" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E7D81DA23C88B99D748BA64FD867125" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E7D81DA23C88B99D748BA64FD867125" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_538EDCC011FCC0307D25BA64FD867EEE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CaliforniaOperatingSubsidiaryMember" xlink:label="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81145E8A5BD73288AB76BA64FD86BDEA" xlink:to="loc_pcrx_CaliforniaOperatingSubsidiaryMember_AC73EA8F8DCAB97A4579BA64FD866461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_7AACA54BD19E04232DD5BA64FD866966" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SkyePharmaHoldingIncMember" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_40F8E7B93A1D61488056BA64FD8679A4" xlink:to="loc_pcrx_SkyePharmaHoldingIncMember_E6D76C5D12FD800E5622BA64FD8659F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FA5A54FAF67A80049078BA64FD87F828" xlink:to="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EB784FA535F05911B54EBA64FD87489E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3845C35EB4520D76A3E6BA64FD876FC4" xlink:to="loc_us-gaap_MaximumMember_EB784FA535F05911B54EBA64FD87489E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_15E465999827D2CE5A72BA64FD861754" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2422A860A260F85A8B55BA64FD87F97D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_CE5036CF045C7843F92BBA64FD87C750" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition" xlink:label="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8E7635745DECD7C93411BA64FD8765F1" xlink:to="loc_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition_654CE82BB269C0CBAD1CBA64FD87FC53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4CA6D10B2A0883A1899BBA64FD90DEC1" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_AC28362F0D0D1D35E527BA64FD90ED33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:to="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC396ECB4F59F111909CBA64FF1F3AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_ShortTermInvestments_F652515D0A3CE013F1E7BA64FF1F8A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_AB01A8B7E559D1E176BEBA64FF1FD6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_InventoryNet_E410C9386717C0B68ADFBA64FF1F4F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B8690A4317ACDA57C3C8BA64FF1FEB56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F568639510C1180CF296BA64FF1F79B2" xlink:to="loc_us-gaap_AssetsCurrent_E518F1A4355135865C9CBA64FF1F82AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_LongTermInvestments_7080EEC2D5AD1F4A30F1BA64FF1F32E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_07D437401EA7D4264D99BA64FF1F1672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_Goodwill_D0CCFF166C4837B4533BBA64FF1F55A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount" xlink:label="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_7583B644809012BE8B43BA64FF204113" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_7583B644809012BE8B43BA64FF204113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6F7A8F6246938AB4FAA6BA64FF20CBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B24DFB3C21EFBD94F020BA64FF1F1C4A" xlink:to="loc_us-gaap_Assets_1299CCFA5E8F18A85A42BA64FF204DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4930A8933EE8D8EAAF67BA64FF1F85EC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_AccountsPayableCurrent_A90AE055E00A75EB13FABA64FF209C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_F909E2CD008FE86EF0C5BA64FF20C02C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_3C7DE0810E86551E525ABA64FF201DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7E2796545B64BF0A7F0BBA64FF2005F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_TaxesPayableCurrent_27DDB813A2CC24CF5CCBBA64FF209680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_717ADDC3D97144C390F4BA64FF20475C" xlink:to="loc_us-gaap_LiabilitiesCurrent_B4C6B04BDFDE9A565D1ABA64FF201A78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_2F49965FBA773BE8A5EABA64FF20C529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_E369519384868D291AB4BA64FF200EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_Liabilities_22E0627F9A566AC66A53BA64FF207906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_CommitmentsAndContingencies_94C42916E34D573F0412BA64FF20BDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_PreferredStockValue_AD98CC7AFF3C78C7ACAFBA64FF2084B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_CommonStockValue_48230CA7C87DADC8B541BA64FF202DBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6A3C76721F80180343B9BA64FF20C061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7BB7EED21238E8E8CABDBA64FF20CE28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C81196F2B12693D44ADBA64FF269BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E6B74649869B0D8EB1ABA64FF20E102" xlink:to="loc_us-gaap_StockholdersEquity_C34C90B9D4EA77495434BA64FF260A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1347433273A277400837BA64FF2095AA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_CADE99ADC8BB89FFD36EBA64FF26A510" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A6F9D807A995870C6A0EBA64FEFC20D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_67F85E6BE663C5A58D21BA64FEFD5C21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_67F85E6BE663C5A58D21BA64FEFD5C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D7DC67884654226E45ACBA64FEFDADE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1606E9E88F4CB3D73181BA64FEFD6660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_DC791D4E182FEB4D3E80BA64FEFDE204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DFA6A05809E00E3B998FBA64FEFD8A27" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DFA6A05809E00E3B998FBA64FEFD8A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_CommonStockSharesIssued_B0A73DD5E7FA5F2B9D5CBA64FEFDF153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_05F31144D66D90660F84BA64FEFD1CEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_05F31144D66D90660F84BA64FEFD1CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E471C1F1ED076766A892BA64FEFC30B7" xlink:to="loc_us-gaap_TreasuryStockShares_BD4678D97DF238DD5150BA64FEFD534F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0EBA50C08B630005B1B6BA64FE9A978B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:to="loc_us-gaap_NetIncomeLoss_0EBA50C08B630005B1B6BA64FE9A978B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_194BB8C53C288351AE5FBA64FE9A466B" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation" xlink:label="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation_81B2155279AFC676EA4CBA64FE9A12DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_92CB4CD0EA692715B1C1BA64FE9A5592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_836063E79B4A96D8EFF4BA64FE9A7A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A8076E06B2D989F0572BA64FE9AE5B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_416E737A9A305F00F0D1BA64FE9AB666" xlink:to="loc_us-gaap_ShareBasedCompensation_C7D034C3F169D0938B5DBA64FE9B0269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_B9B710172A05EFF47E56BA64FE9B7A0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1AB5E28B073098D05E45BA64FE9B1C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4BCCBF5EF729432A8370BA64FE9B3032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8DF632CB61A4A5182A56BA64FE9BE880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7CFE3FB83D9072923F57BA64FE9B4D72" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncreaseDecreaseInRoyaltyInterestObligation" xlink:label="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_pcrx_IncreaseDecreaseInRoyaltyInterestObligation_0D401C81F2FC62328AECBA64FE9B4828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EA653BABB4D38447C53ABA64FE9B95AB" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_49564E6012BEC9294AF1BA64FE9B13FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_F87B4C7D47A18BF13309BA64FE9AE994" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_569D42BCFD6CA45F85D8BA64FE9BF547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E647B90F1630CD6CD4E8BA64FE9B9FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_00D61EA9BF17BCC7F4B3BA64FE9B9031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_12C60E9BBE6F0A0EAFD3BA64FE9B5DC0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentOfContingentConsideration" xlink:label="loc_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_pcrx_PaymentOfContingentConsideration_F812EFDBE8F6BAC587E2BA64FE9BA733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_FFBF9BBC32161315B238BA64FE9CD9E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4B5B44093D50BCD8DBCABA64FE9BE441" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_85109D22ABC8BB1EBFECBA64FE9C38DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_FF4705AFB7A38D336FDCBA64FE9CF312" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_512DCA005D1B57CA500BBA64FE9CD9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0C0BC9C67347FE48E1A3BA64FE9CEEB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1EE1F1FC9E3898741099BA9620F3314A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_B8294391CB0A6A6477B6BA64FEA1BDD4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes" xlink:label="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes_53ED426EA6A344458BEFBA64FEA18735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B023C66A1891A4183942BA64FE9CC200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_5395402353B3EA6881A2BA64FEA1F785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_0F7287971F550CA456CFBA64FEA14EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_352E6C4326CC377E48C3BA64FEA17892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9327027F4E939C28FDFEBA64FEA1CE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:to="loc_us-gaap_InterestPaid_C3FFAF8F99B276874925BA64FEA1C538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EF0FAEFDB861468B0B43BA64FEA1A1EF" xlink:to="loc_us-gaap_IncomeTaxesPaid_810202896E97B7E9B488BA64FEA19872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D62C1CD661DF523DAE5FBA64FE9AABA8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionConvertedInstrumentSharesIssuedValue" xlink:label="loc_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:to="loc_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue_11D87B0932A4C6D0A506BA64FEA205F2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium" xlink:label="loc_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:to="loc_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium_E66BC9F2B8181183FA03BA64FEA2A8BA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid" xlink:label="loc_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6665C9A308A0FA9D8F04BA64FEA15E58" xlink:to="loc_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid_6DF4F388EB95B9573EBABA97AB8A950E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_41EDF27B4B0B134190D7BA64FECB5CBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:to="loc_us-gaap_NetIncomeLoss_41EDF27B4B0B134190D7BA64FECB5CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7DD6637DEB9A3AF7C591BA64FECC09D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_C933835E7C7197C9EAF1BA64FECC6C26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23E3BB6B0D22C2FF03FDBA64FECC1668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E75C9187FD6AAEE449B2BA64FECBD3E7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ADA5693F789BDC8564CBA64FECC0322" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_F0FE0D0F9CE9BD35B85BBA64FEE767AB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CollaborativeLicensingAndDevelopmentRevenue" xlink:label="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:to="loc_pcrx_CollaborativeLicensingAndDevelopmentRevenue_4BF380727C14B0329D56BA64FEE7EA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:to="loc_us-gaap_RoyaltyRevenue_B6F40BBF05B856145804BA64FEE7417C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8ED537109001274D593ABA64FEE79FC0" xlink:to="loc_us-gaap_Revenues_6265A46E7DDB431F79C5BA64FEE71321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="loc_us-gaap_CostOfRevenue_23F23F9CE008F34C2114BA64FEE765DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_F912EAFAE2C1521DD1BDBA64FEE84F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05ACDF379302F4E7EA93BA64FEE890B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_6CF00BE6B499F63665F2BA64FEE848D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D72409F88B127C7AE77FBA64FEE7DC4A" xlink:to="loc_us-gaap_OperatingExpenses_E6A16FA2C5B3730C9B2DBA64FEE81728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_OperatingIncomeLoss_B11592F7859D0BE7378FBA64FEE83F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_InvestmentIncomeInterest_BB10CDA579A7E0AFE337BA64FEE8B24C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_InterestExpense_26FFD66C208F7B77D41FBA64FEEDD983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8B2180162A53D9B1EB0EBA64FEEE6444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_RoyaltyExpense_7B0568C54BB34134EE2FBA64FEEE9861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1673A69A73EE11C6894FBA64FEEE847D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4DE8D4592567A71D3D99BA64FEE8871A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_D4F72CD6D147B99141D1BA64FEEE0EA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E91C1304B8B251577A9CBA64FEEEF4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_AE5A79BF2E039B2FB3B5BA64FEEE0912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_NetIncomeLoss_F9807ECF78FA8E978C52BA64FEEEA760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:to="loc_us-gaap_EarningsPerShareBasic_E58E6E78E596C2F74CB6BA64FEEE5D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EE2727E6E7AB541A2DA0BA64FEEE5A65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3405FDB6CB27EC6FE5DDBA64FEEE2042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BEE2AA740E4624C4061BA64FEE784E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F22B75A1DA79FB2D873FBA64FEEF38B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_EF28F56B072B29D4124FBA64FEEF23FE" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D891A0F0F399B6B1274BA64FEEF328B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6B3E83696B257F68EB91BA64FEBC8B03" xlink:to="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34186D528D3052B26A4EBA64FEBC8771" xlink:to="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_CommonStockMember_CBF99CFC4ED9B8D4D2DCBA64FEBC8449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3B7891253DF5860A748BBA64FEBC5682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_RetainedEarningsMember_6172C6850D7C0AFD093FBA64FEBC9956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3C20330EBF98E63A9123BA64FEBC8518" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AF8138EEB0F55651BF0FBA64FEBCE7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AC280D11DE08BB40B6DBA64FEBC5C25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_9C63262D791B8A477FF2BA64FEBC4BF4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_795CB1FBD44C8E6C83D5BA64FEBC88B6" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_3010049B8E1FEC1040ECBA64FEBD722E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5C2E35A0A28675338F7EBA64FEBCA9C3" xlink:to="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6039E5F386FAB9A7A627BA64FEBDBC3E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockholdersEquity_168ED6388B88060AEE1ABA64FEBDC33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_SharesOutstanding_C08F8676EEDD5BAC9C49BA64FEBD7F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5E283005969E92D3505BBA64FEBDBC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_BD56C2B5704982F26E2ABA64FEBD72E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E031FB36FCB0BD3943F5BA64FEBD7F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_427B7C1A61A03FE45C14BA64FEBDCE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E2D2A8A9ADB4D13CF651BA64FEBD0A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C415FBE05C8DE8FCEF61BA64FEBD6683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C239D8FB649A9C7458ACBA64FEBD5C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_033727172B5A40182480BA64FEBD3298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_55AF908D7E5D6BB4DD09BA64FEBD0B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3248C691FB2791043EAABA64FEBD94D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D28BC44CFC3F66ADBF56BA64FEBD81D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_C3B5B13ADC61BC176E82BA64FEBD86D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_NetIncomeLoss_FDE6AC254E3E7AF0AB3BBA64FEBD1695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_StockholdersEquity_C21DCC8BC5BEF6853DF6BA64FEBD174B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09990F310CEB897AEA65BA64FEBD2C69" xlink:to="loc_us-gaap_SharesOutstanding_3884EE44B2B3DDFF26FCBA64FEBD9BBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41775E7D3E7BB7FCB5AFBA64FE0770DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41775E7D3E7BB7FCB5AFBA64FE0770DB" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5496A54B18EFD9BC3F3CBA64FE073042" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7BB121997E34726D561FBAE840C5E6CD" xlink:to="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35B974D4E253EADEF748BAE840C58A62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_A7E914F70130051045DBBAE840C5E1DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_29F1AF0ED7A4A2053C0EBAE840C55F64" xlink:to="loc_us-gaap_UnsecuredDebtMember_A7E914F70130051045DBBAE840C5E1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_61652C8F358933677D82BAE840C5BEF8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_062A0846B08333DBD6DBBAE840C8E9C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_062A0846B08333DBD6DBBAE840C8E9C7" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_EE62E8307BF9CF2CA40DBAE840C83875" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75AE09359259223401ABBAE840C80ECA" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_EE62E8307BF9CF2CA40DBAE840C83875" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_3F780C40D2472079186BBAE840C820EB" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_EFB3FF519674F1EDCFB5BAE840C8BC04" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_95A20CDC021C7525B3B1BAE840C8CFCF" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0D599D2901641B1E1313BAE840C88C60" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member_8ADC62705B836A90FBFEBAE840C8FA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BFB40895F88461916474BAE840C5A148" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_EA07D188249CC0DBA1A4BAE840C8A14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0D4B54198A1D6D6C8084BAE840C80C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_775AA5FBBA832FEDA1AABAE840C861D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_65724BC089C9BF06A022BAE840C84E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_41A57A714AED74E741CCBAE840CA0C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_58D2067F24C3DFB53DCABAE840CA25CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_CF85A054A6F7D7AE0542BAE840C87E46" xlink:to="loc_us-gaap_LongTermDebt_D97781DFBA6E54CFE429BAE840CAA9C3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ProceedsfromConvertibleDebtNet" xlink:label="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_ProceedsfromConvertibleDebtNet_8B77AD2CE93BF37C534FBAE840CA48F8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_7348977E00428BBB483ABAE840CAC342" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_E53395513CE1072C8FF5BAE840CA4EE6" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_A669F837E1C12937C9F3BAE840CAD0A0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_2ED339CA606913C6A470BAE840CA8966" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_D9BA3951E619234DA737BAE840CD1244" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock" xlink:label="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock_912DEC154D5C7D47D197BAE840CD4E95" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_0E4B47079FF8E8416BFABAE840CD2D55" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_C20488C25C2D725FFC2ABAE840CD0F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_731D6EC6FD4C05250FA5BAE840CD76BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4A4140A90F7CE23A592EBAE840CDB902" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_0FD2DBBA5845372680E4BAE840CDA526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_SharePrice_4D0EE3E60B9080143F4EBAE840CD5436" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentMarketPrice" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_1A188838AF520444193FBAE840CDC78D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption_2D8063FA00BEC8F0CA8EBAE840CD119E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_4AE717BCE4DA687F4917BAE840CF2521" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_28CB073CDB6330D326C4BAE840CF70F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ConvertibleDebt_F0BEF7EB3ABB9A38AC04BAE840CF971F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_DB7AC195AF78F144B11CBAE840CF94B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9B39D49347E4EC8CEB5DBAE840CF83BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_FA1375F5EC34B79A9D30BAE840CFAB75" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtIssuanceCostsAmortizationperiod" xlink:label="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtIssuanceCostsAmortizationperiod_17A2227B8ABB94D5858EBAE840CFCCDA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_2FF3B135AEBACAFC384BBAE840CFEEAA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GrossProceedsFromIssuanceofDebt" xlink:label="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_GrossProceedsFromIssuanceofDebt_611C7858C63765F2599BBAE840CF09C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D8BB5F0FF77BF0287584BAE840CF1AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_AEA51D433389A08B9B77BAE840CF969A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8669AFFEFC98DA90B41ABAE840CFA6F5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionValue_F5FB63A317B48076A264BAE840CFBE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6E4D4102996D232DB23CBAE840D27C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_81D1440A8CF13957F290BAE840D27B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_72B8F1B24106253B1271BAE840D2B703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_RepaymentsOfDebt_EB5B1CA1DDA9749F06B1BAE840D2F92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7C531493F3C750446DA2BAE840C81E1B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B7D438A2895EA250E23EBAE840D2745B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DebtDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6F948A94CA8A078C42DBBA64FDF522B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6F948A94CA8A078C42DBBA64FDF522B7" xlink:to="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:to="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F793CA8C2B131C7E3258BA64FDF625FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_6E745E02EEC48B21632BBA64FDF65DB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A8A0B781070478A5D33ABA64FDF65C13" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_6E745E02EEC48B21632BBA64FDF65DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E24FE8FCCE4A560FC7BDBA64FDF5F6D5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D6CC5E036A7E57CD5569BA64FDF66D6E" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_A7334D02C22783A96F73BA64FDF65C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_EEAC743FE675A9035FBABA64FDF66CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_B13DAF80DB669B156C73BA64FDF6A1DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_B13DAF80DB669B156C73BA64FDF6A1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestCostsCapitalized_B2D2CD9D028EF67C82F3BA64FDF6B1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_InterestExpenseDebt_501A00BA1919EA0EA8F0BA64FDF6A5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_63F345E6C7634F417B46BA64FDF62426" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_61AB44FF2E621DEE6187BA64FDF656BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B3DA946C2C222AA0AB6ABA64FE05F5AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B3DA946C2C222AA0AB6ABA64FE05F5AE" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_7A2E720387A1F5197FD2BA64FE0587A4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B3DA946C2C222AA0AB6ABA64FE05F5AE" xlink:to="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_90641249D5BC32E987A7BA64FE0516FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6559E0B69084A0E3773ABA64FE72CEE7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B9CDB3DBFBE40CB9763EBA64FE728577" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DocumentAndEntityInformationAbstract" xlink:label="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityRegistrantName_EAC2118E3922E03571F8BA64FF35A550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityCentralIndexKey_2D24E62412F4EF5524F6BA64FF35E2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_DocumentType_76B3A586541CA3A8CC0EBA64FF35F763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_DocumentPeriodEndDate_89D6BC84573C2E3CB646BA64FF35ADE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_AmendmentFlag_C3BE7604AC5FA3FBD7F3BA64FF356F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_CurrentFiscalYearEndDate_43ECBAD7B5FF6B274E46BA64FF354870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_97D19D8C47416933E9DDBA64FF35F607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityVoluntaryFilers_8066EEF79A0E43473C64BA64FF350150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityCurrentReportingStatus_68D83BE22A91DEF2C351BA64FF35E26D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityFilerCategory_46A14D9F927B1894CB0BBA64FF35CF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityPublicFloat_FF779BCA57A3EC007A20BA64FF358E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_46EA04C72307E694298FBA64FF366E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_DocumentFiscalYearFocus_077BA629D272B79B222ABA64FF362FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DocumentAndEntityInformationAbstract_CF88F4F0B5F2D2413B23BA64FF35E793" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A2574978EA98B92DED0BBA64FF365D62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_BAE1AEFE7845FDA26074BA64FDF13DFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_BAE1AEFE7845FDA26074BA64FDF13DFD" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B62FDDF04B0144D633FBA64FDF110BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0762A6AB35B32F9FEC85BA64FDED7B80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0762A6AB35B32F9FEC85BA64FDED7B80" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97E459AA39B0C0F03581BA64FDED858F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87A46A4FE9DF6E4D6C28BA64FDEDB6D0" xlink:to="loc_us-gaap_UnsecuredDebtMember_A8C5430B927771FF0168BA64FDED0980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_C9E33209A9804CE4EA34BA64FDEDFB62" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_EFB3BDC57D45CE65F407BA64FDED2475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_DD58DA0BC89DF588B912BA64FDED1E0E" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EA6BD931AB10A0D03E24BA64FDED8FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F1E1BBF3252001FD0C9FBA64FDED61F7" xlink:to="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CAF12F13685EC32F4467BA64FDEDFD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_986CC17F3C9038CAE464BA64FDED8BD6" xlink:to="loc_us-gaap_MaximumMember_CAF12F13685EC32F4467BA64FDEDFD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_011C7DCE95E68E161F00BA64FDED88E1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_1A0FF81ECE36CD34E0C1BA64FDEDF3D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_1A0FF81ECE36CD34E0C1BA64FDEDF3D3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandNineteenSeniorConvertibleNotesMember" xlink:label="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4C056054357293D94BE1BA64FDEDEEA9" xlink:to="loc_pcrx_TwoThousandNineteenSeniorConvertibleNotesMember_CEB640CF6154750D1EF4BA64FDED3DA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2939A7B4DAA029006560BA64FDEEC3BA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FB6998B8F7B8C2F1B594BA64FDEE96F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B6DD13786052B2F8A80CBA64FDEE0FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_334B86999FD732A4ECCFBA64FDEE6461" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_737B8B73FF122D64D0FFBA64FDEEA512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_A2CF8DDF295AE17D724BBA64FDED1EAD" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3976599C338A2E28DAB1BA64FDEE4361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_SharePrice_2AFDB7CD3C4785A1FA1BBA64FDEE7349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_B0E39327147FB0C49571BA64FDEEDF55" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_50F7A3E397AE86319B4FBA64FDEE7BBA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DebtInstrumentConvertibleConversionValue" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionValue_BE5AD706191C6A4DC2C5BA64FDEE64AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0FCF7855E023A86B1F32BA64FDEE925F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CC85BA73E097334ACC27BA64FDEEAFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount" xlink:label="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_539E3A71588ADBC0A99FBA64FDEEADBF" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InvestmentsContingentPurchaseObligation" xlink:label="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_E67809A258769DD30D7CBA64FDEEA106" xlink:to="loc_pcrx_InvestmentsContingentPurchaseObligation_8301A2901E45DEFC65DCBA64FDEEF67C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88330E16306ED67C82C0BA64FDE6A385" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88330E16306ED67C82C0BA64FDE6A385" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A8134A54BD428BAD97B6BA64FDE67561" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7988E7F9D759F605803CBA64FDE74441" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LongTermInvestmentsMember" xlink:label="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ABEDEDA9A4E2A1FB6E2BA64FDE7571A" xlink:to="loc_pcrx_LongTermInvestmentsMember_30FD4A91981204505345BA64FDE73622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_3DCB0F6A4994DEE236C9BA64FDE7AA96" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_67D82C9A21C0180A7F4CBA64FDE7F7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_CommercialPaperMember_98E11DAF6FD2A2934F0FBA64FDE795E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_BEC0256AB42CC49449E9BA64FDE77C34" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_B24D5031D4F18FE82087BA64FDE7277C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_482F98EB43F041462EB7BA64FDE75BAE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B4A63D1F4E6E3E3490D4BA64FDE7A6FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57C3AAABAE7ECBB04065BA64FDE7F000" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B4A63D1F4E6E3E3490D4BA64FDE7A6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_09E8E9412F0640A3AFB5BA64FDE6F150" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_DB97550ACFFDBC2B85DFBA64FDE7F834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E5BE1616F362B00F46C7BA64FDE772F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3842CA53AD555E629D9CBA64FDE7D87D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3B6036CFBE25C752DD25BA64FDE7F027" xlink:to="loc_us-gaap_AvailableForSaleSecurities_E8B3FF7F17BCA86D576FBA64FDE77A3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_EDC51A26A80317323728BA64FDE29F6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EDC51A26A80317323728BA64FDE29F6D" xlink:to="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62F3F3DA2BE0B3CDD680BA64FDE2BCBD" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A04727E0D782B80090DABA64FDE26E8D" xlink:to="loc_us-gaap_AccountsReceivableMember_2BD8F80FE3C5DC7903D8BA64FDE2E2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3735ECF98A3D2A9E95DEBA64FDE27643" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_81507E71E68298FAE585BA64FDE2B230" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_05B89DF0C984178B4BB8BA64FDE23725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_4A54416BC77622E1870ABA64FDE269D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerOneMember" xlink:label="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerOneMember_AB3FFF8D63BBB2CB88A8BA64FDE20761" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerTwoMember" xlink:label="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerTwoMember_18C436490E8CEDDEF562BA64FDE2687D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MajorCustomerThreeMember" xlink:label="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CEE6512CAEF78F08850FBA64FDE20698" xlink:to="loc_pcrx_MajorCustomerThreeMember_33E712D8FE5E8BB7E765BA64FDE38946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B84ED3AAD42393F9D69CBA64FDE2808D" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NumberOfMajorCustomers" xlink:label="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="loc_pcrx_NumberOfMajorCustomers_A4CA04FE393CA44B81F8BA64FDE35D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_EE283AACD3EA40879DD7BA64FDE3358E" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C4350F638A5EAF715965BA64FDE3183E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F0DE5BEC7E5FF64F0DB4BA64FDF1319C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0518B58625149245F38DBA64FDF0B7CC" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3C2E63A43C697133D939BA64FDF1CF21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C97574F159B4F9667390BA64FE26396D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ED2CF22DBFB3AC3E11D1BA64FE265AA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5B725772813329F6E452BA64FE2163E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5B725772813329F6E452BA64FE2163E4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87F21407DFE97CE02E89BA64FE218AFB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_B7137C83FB623D11A7D3BA64FE22574A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_B7137C83FB623D11A7D3BA64FE22574A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_95E40B31A5FA95FAF910BA64FE22D4F9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ComputerEquipmentAndSoftwareMember" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_E667D67AB324D06D0F59BA64FE222A8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_E667D67AB324D06D0F59BA64FE222A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_BB85A5393D4B9D8BD978BA64FE2256EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_BB85A5393D4B9D8BD978BA64FE2256EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96AECEE4E38CA3F70E9CBA64FE2227E5" xlink:to="loc_us-gaap_ConstructionInProgressMember_0D9BC6AF8D9CA2F83D23BA64FE2264A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14C413CF968D9C3D8832BA64FE21F06C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_37F01BB453086E24C091BA64FE22D878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01884616AB895FF26294BA64FE224542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C04099FD314CCCC21070BA64FE222049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_Depreciation_97680FC99C2425A066FEBA64FE221068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_InterestCostsCapitalized_A479226070FCB19F7395BA64FE22A083" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ForeignPropertyPlantandEquipmentNet" xlink:label="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_pcrx_ForeignPropertyPlantandEquipmentNet_9632C8BE9B5AB7457AEBBA64FE22ED34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligation_267FD375A6718D0C08E5BA64FE235587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAssetRetirementObligations" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetRetirementObligations_BF9F4B4C21E8A91B8EFCBA64FE23235B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationLiabilitiesIncurred" xlink:label="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligationLiabilitiesIncurred_6E1B05E4DC0A3277D57DBA64FE238756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6B74DEC53F82F55223FCBA64FE22BB65" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_1B69F37256D971B2069DBA64FE2330DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7444F9EDD13FDBF755B5BA64FE25E0B7" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock" xlink:label="loc_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7444F9EDD13FDBF755B5BA64FE25E0B7" xlink:to="loc_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock_A7109D70EE0175D095C3BA64FE25F68C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4FAE6B80660A5E9C270CBA64FE1DF510" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4FAE6B80660A5E9C270CBA64FE1DF510" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C5FD2BD800B720F8B88ABA64FE1D9F49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FD97D32637F3D9AF48E9BA64FE17CFE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FD97D32637F3D9AF48E9BA64FE17CFE8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain" xlink:label="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_D85D9753BC08EC042F4DBA64FE1791C0" xlink:to="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInUnitedStatesMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponFirstCommercialSaleInUnitedStatesMember_E3A05D97630627134354BA64FE172CF0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_09A223C817BA51C166E9BA64FE1796C8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember_41C68F3AFA61D052FA15BA64FE17E06F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember_77E82D16A6C9DF727CB8BA64FE18E148" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_StageAtWhichMilestonePaymentsForProductArePayableInConnectionWithAcquisitionDomain_12E26BDC8EA5FCF2F59BBA64FE1711D9" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_E08AD0F33588614BD221BA64FE18DA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_AFF12FD09CF9E1005DC5BA64FE17DD09" xlink:to="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_399A3FAD94BCF0B6EC8CBA64FE184A5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_399A3FAD94BCF0B6EC8CBA64FE184A5D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_DC3368D0EE79A9957DBEBA64FE189761" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition_A3E14AA0C43437E0576DBA64FE18979D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition" xlink:label="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition_04598F439E614350329DBA64FE18AC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_4A7B726D9D0EC00BF912BA64FE180462" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million" xlink:label="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million_F6B4426B986B841537DBBA64FE180087" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation" xlink:label="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation_03488510629FA9FE05F9BA64FE1830CD" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TotalGoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_pcrx_TotalGoodwillRecordedforEarnOutPayments_48B7BC6A0B1E211171C3BA64FE186AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A5494F1AB0C40C4901C0BA64FE188396" xlink:to="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_us-gaap_Goodwill_069D451425917282B6F7BA64FE182703" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedforEarnOutPayments" xlink:label="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_pcrx_GoodwillRecordedforEarnOutPayments_38B1F969D6EFD4938DA6BA64FE19F861" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_GoodwillRecordedonMilestonePayments" xlink:label="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_pcrx_GoodwillRecordedonMilestonePayments_6BDB9746CD1D39675B89BA64FE19654E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_643176D1F17A9318545BBA64FE18377D" xlink:to="loc_us-gaap_Goodwill_6028B05AA9A344011AFABA64FE19AB11" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA7978BF554399E27EC9BA64FE10E77E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EE5CFB54020570AEDE70BA64FE1054B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B7C44435CBD8070FF941BA64FE1051D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_068BC7EAC1E2423831DFBA64FE10E32E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_13D346DE5EECE8766171BA64FE11E3C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42E2DAD3758CE8544E45BA64FE118364" xlink:to="loc_us-gaap_SegmentDomain_146DDFF7912D014C4B0EBA64FE111051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_778FEBA404EDBB001ECDBA64FE11C650" xlink:to="loc_us-gaap_RangeMember_CA44205A381A51BEC7E9BA64FE1159A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_B757C62316E36453CB03BA64FE101DC4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_BC5453D2448A06B3E0A8BA64FE119C29" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_A8FBD9D9F5FB5812451DBA64FE118DB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8292A864FDC9DB9016C5BA64FE1B83E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8292A864FDC9DB9016C5BA64FE1B83E6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_F63265B7C16D3B74B4D1BA64FE1B80A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C69E279F6EFADE721B28BA64FDBEAE5D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C69E279F6EFADE721B28BA64FDBEAE5D" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_F05699F802398D27459EBA64FDBEE9FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_170EA172CF5DAEBDC8F1C40AF73E98F7" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionTable" xlink:label="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_170EA172CF5DAEBDC8F1C40AF73E98F7" xlink:to="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_83B5147AB324BDDA2F48C40AF73E18F2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7B4F6F6821733BB98206C40AF73EDE08" xlink:to="loc_us-gaap_ResearchMember_466C0507F231FBEBB372C40AF73EC6C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2524CD6CFA47315554D4C40AF73E6AE7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_BB1FB1F6D57B3A8F83A6C40AF73EAA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_818FD271395481BE36D7C40AF73E16B7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_B5F17F9FD5B3E3412C2EC40AF73EF123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F915866FC010102ED34C40AF73EA297" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_DD4C13B28B08D9A1078AC40AF73ED4EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689E700E031E0BCC7739C40AF73EA84F" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_DD4C13B28B08D9A1078AC40AF73ED4EE" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvisionLineItems" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_18A241B20171EC2FC887C40AF73E7377" xlink:to="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AEFC142CBB55DCCFC24CC40AF73EC07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A88CEA11197881691065C40AF73EE94F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_844E4818F3826F2F7F13C40AF73EA9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_B40CDA929F3B5D4F448BC40AF73E453B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_F3A5CD507914BF37B7FBC40AF73E4566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_FA299963CAF6C6B7D3C2C40AF73ED7AC" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncomeTaxProvision" xlink:label="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_IncomeTaxProvision_3B1562343641F36A4E6FC40AF73F95C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B38B3912BF69553C76A2C40AF73F15F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F2CE08C8DC8EBAF275C3C40AF73F0087" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_77F019342ABF0600A602C40AF73F88A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_BF2714FD7AA8C8A74BCCC40AF73FDFBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_DBBD01606048D0B400DAC40AF73F7F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F737951C286C91AAE46CC40AF73F83A4" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent_4BAA0519F3E794C38789C40AF73F1C8A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Effectofstateblendedtaxratechanges" xlink:label="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_Effectofstateblendedtaxratechanges_A7DDA561BDF85BA873E4C40AF73F496E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_01DBB357B401AAFE2FADC40AF73F3BD5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements_C6EEAC16DA6E179398FEC40AF73F1B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_B05169431EDCD165E236C40AF73F6137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ED9FC7D1A941232B6361C40AF73F9BF0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CCA5D6982C692E60A46AC40AF73F9985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7814EAA41E0D8C7C4577C40AF73F2211" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_957EB54D7083A1BE250FC40AF73F4EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_DE9B2777ABFDCC9F5F6FC40AF73F187F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_B7B8968C1ECE569A351AC40AF73F034E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_DFF09A2BF69F9F5B9AA0C40AF73FFF55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_848DFC601652812CDAEEC40AF73F10BD" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_822358AD4FFBB9A814D9C40AF73FA938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_267AECB034CF54A734C7C40AF73FF5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_85FC1B5341DE4686C2EAC40AF73FF9AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_A3E8DE24375A43719EA4C40AF73F49C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_D026776F980E4F0BFF5EC40AF73F3433" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_A3F80F9EF4D0A6C1FFA4C40AF73F444D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_B2FA0A80929003689B29C40AF73FAC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A22DE0E8BF96CD259BD3C40AF73F8B2B" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_F1851C8C5200D480B6F6C40AF73F874C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_99F061220429A6459CD1C40AF73FA583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_5A94AD7F6BF6BC47310CC40AF73FE125" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NonUSNetOperatingLoss" xlink:label="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_NonUSNetOperatingLoss_B569CF76CF16704296ADC40AF73F25A2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_7D65B79F192E73F1BC59C40AF73F63D5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_NetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_NetOperatingLossSubjecttoLimitation_3C48A3FB11C277FC396DC40AF73F453B" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_AvailableNetOperatingLossSubjecttoLimitation" xlink:label="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_AvailableNetOperatingLossSubjecttoLimitation_6381051FB08C330C5C1AC40AF73F9D8F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable20182022" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_FutureNOLsWhichWillBecomeAvailable20182022_F1E97650D07D7E4D90C1C40AF73F5324" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward" xlink:label="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward_86BD5DFDB8E801B622C1C40AF73F5488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739907AE68D0DC3A6C88C40AF73F7BED" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit" xlink:label="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit_84FA0A7BC51E2F1BFB84C40AF73FEBA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_061447A9EFBF2BFDB034C40AF73F4142" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_061447A9EFBF2BFDB034C40AF73F4142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1F6EDB87A20F8368418BC40AF73F0D81" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_UnitedStatesStatutoryTaxRate" xlink:label="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_pcrx_UnitedStatesStatutoryTaxRate_52337CE46E0916D393AAC40AF73F6989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_A456DE08F7CCBE73D603C40C537CFC96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_7E71936C6A97628DDBD1C40AF73EF8A3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_11415FDA17B1DF0519FBC40D0C7DB91E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03E2E337AD26859BAD13BA64FDBCBBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D40CD72D4F4B5DC25D5FBA64FDBC325A" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_84E15D5301E1E6B84545BA64FDBD444C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F4C58CAC3C60F0BB8BF7BA64FE2D7CE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F4C58CAC3C60F0BB8BF7BA64FE2D7CE6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_A42825FE61B0BEB5DEF4BA64FE2DFBA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6193CFE4CAF0F05C103ABA64FE292B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_366E03088EF7018AB241BA64FE29A908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_56D8704BFD38EA0153AFBA64FE29EE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="loc_us-gaap_InventoryNet_A66FB75ED45980840AA1BA64FE2A1842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3EF9B9F563BFC7A65C95BA64FE29BCB7" xlink:to="loc_us-gaap_InventoryWriteDown_DBA50D68D2F3C195A859BA64FE2AC284" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A6C6E41A48F864E570CCBA64FE2BCAE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A6C6E41A48F864E570CCBA64FE2BCAE4" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F6FA3338A6DBCE683A2DBA64FE2BD3BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A907D6E6E71BBC8AFBC5BA64FDC8B3E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A907D6E6E71BBC8AFBC5BA64FDC8B3E2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_46DE0F1CC63C36223C43BA64FDC96EE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2000C3A084923A1C6D03BA64FDC48EE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EFD038B9EEC877A9EFFABA64FDC4C5DE" xlink:to="loc_us-gaap_NetIncomeLoss_2000C3A084923A1C6D03BA64FDC48EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1BC2CA09D81E2A81EBDEBA64FDC4724A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4892D155353383E8EC26BA64FDC4B651" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits" xlink:label="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits_DEE9968DA4844361D609BA64FDC48F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_66F88042C5A0BE6A1A4EBA64FDC46A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_17E5ACD40B71FB214246BA64FDC4C80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_02FEF4B758943592DEC6BA64FDC55651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97A066C4156B09424C6CBA64FDC55F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_6732FBA0F52C967E2C63BA64FDC5F432" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_EarningsPerShareBasic_6732FBA0F52C967E2C63BA64FDC5F432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_EBAAA0F8A2A69633A9CCBA64FDC5D3C2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_483A5CA5A5F02460D7A3BA64FDC45642" xlink:to="loc_us-gaap_EarningsPerShareDiluted_EBAAA0F8A2A69633A9CCBA64FDC5D3C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E89D1AF5562555564BE2BA64FDC0AEBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E89D1AF5562555564BE2BA64FDC0AEBC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7F469B4B29A43CB7F870BA64FDC17763" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_691C66868E00F454B6BBBA64FDC121D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_691C66868E00F454B6BBBA64FDC121D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D1086D6D5CFE8CB56D9EBA64FDC1810D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D1086D6D5CFE8CB56D9EBA64FDC1810D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_4913477DCEAF2A08108ABA64FDC1A796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_WarrantMember_19426D6941851ED02796BA64FDC194C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_BDE8D87FE81203B3FAC1BA64FDC1FCE5" xlink:to="loc_us-gaap_EmployeeStockMember_182C3AC8F46505764A93BA64FDC15D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A801841E817D94AC8932BA64FDC162C2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_421829FB24306AE1F1A1BA64FDC1246B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8EB3AAD2FB4C2CD57BD1BA64FDC11F67" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09F38E50C7C814D7E01ABA64FDC71E37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09F38E50C7C814D7E01ABA64FDC71E37" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3A8F6A8D6C9F69156760BA64FDC7FC08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09F38E50C7C814D7E01ABA64FDC71E37" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3BD72ADAFF2A7E404BBEBA64FDC72A13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefits" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7FA5E51213B2670ED654BA64FDA9076B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7FA5E51213B2670ED654BA64FDA9076B" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_BB8637263C52BFA3D2C4BA64FDAAF69B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/OtherEmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5C25532AC75B64EC907EBA64FDA82FB0" xlink:to="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_41FE83752B5E375117C6BA64FDA8028F" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_C7D9DF6E62DE8E5357B0BA64FDA82E36" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_DCD81229768794196E03BA64FE30CE98" xlink:to="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_130F61DBCD3C47FF71C7BA64FE31EFFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_5404707BF0FF2264E516BA64FE2E9098" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8B4919710A7164A86635BA64FE2E91AB" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax_E150BCAA0C1D12944148BA64FE2F584A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_701748CF465C15186A3FBA64FD98BE41" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9A583B899430F66DD887BA64FD988085" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3D3507F9976A3E90F8BBBA64FD95FDAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3D3507F9976A3E90F8BBBA64FD95FDAE" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_704E3AC208279460427DBA64FD95EDE8" xlink:to="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MPMAssetManagementMember" xlink:label="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:to="loc_pcrx_MPMAssetManagementMember_1D6DC083FD2B209C2EDEBA64FD95BC9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ABA2BDB7F30763F258B9BA64FD953931" xlink:to="loc_us-gaap_DirectorMember_04A19419029DC26F4F11BA64FD96A143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyAxis" xlink:label="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EnergyDomain" xlink:label="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EnergyAxis_EAB6EEFAE6E21AA5A5B2BA64FD9697F5" xlink:to="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ConsultingAgreementMember" xlink:label="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EnergyDomain_0F3F43DF62A45FA878E6BA64FD96FDBE" xlink:to="loc_pcrx_ConsultingAgreementMember_AF533D7DC7A00B160893BA64FD96137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3818818DE0D766B9D8D1BA64FD96877A" xlink:to="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9DD5646476BD566806ADBA64FD96B5C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_30F646B213A2F10B86B4BA64FD969D0B" xlink:to="loc_us-gaap_MaximumMember_9DD5646476BD566806ADBA64FD96B5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7250C41AD425A68EB90EBA64FD95B27C" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_C722C24F09587636DA91BA64FD966BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2069D6DEF063702B3E2EBA64FD9608D2" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_F9AFD94F3FBB9F55D573BA64FD96E22A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_77DF6DBF7EA5B465B0ACBA64FD963144" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_E2D7FDB8A7A9B262C0E2BA64FD96D2D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_76C0083EEB0044317B72BA64FD83430B" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_97CC6F67A1BA0455BE77BA64FD83C55F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:to="loc_us-gaap_Revenues_9E98587DD89D22A5A17CBA64FD806507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_E728041B9B35A3B8FF6DBA64FD806039" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:to="loc_us-gaap_CostOfRevenue_E728041B9B35A3B8FF6DBA64FD806039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:to="loc_us-gaap_OperatingExpenses_508B6FFC298724795887BA64FD80B8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0C0668B00FBF9C5BDC5DBA64FD80FBA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:to="loc_us-gaap_NetIncomeLoss_0C0668B00FBF9C5BDC5DBA64FD80FBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_35FF571EE3B2CC98DD56BA64FD80DFAD" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_97BC9C6C095FADDC4703BA64FD807DB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7B062075B7ACD6198766BA64FD8286CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7B062075B7ACD6198766BA64FD8286CC" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4FEAC1CE17DACDA5E506BA64FD82FA46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_153873A8B9664E02AB1FBA64FDD645E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_153873A8B9664E02AB1FBA64FDD645E4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EA1841B3ED7BBD5ACCDBA64FDD655F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02DBEC8FCE9D3BB05A32BA64FDD09305" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02DBEC8FCE9D3BB05A32BA64FDD09305" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5A7550B47097BB528D47BA64FDD026D3" xlink:to="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_InducementPlan2014Member" xlink:label="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_InducementPlan2014Member_B11AA05A982818C218B6BA64FDD083C8" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_TwoThousandSevenStockIncentivePlanMember" xlink:label="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_TwoThousandSevenStockIncentivePlanMember_12C4122764E918BF5DE8BA64FDD0885D" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_StockIncentivePlan2011Member" xlink:label="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_CBE0A6DE74B08CB41628BA64FDD0E731" xlink:to="loc_pcrx_StockIncentivePlan2011Member_D3F13B53F9ED6002D844BA64FDD0BB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43714375D47975BDB905BA64FDD0B8B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_930560E58F28EECAF225BA64FDD1E373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_930560E58F28EECAF225BA64FDD1E373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D271CC0B47322E569FB7BA64FDD1A5A6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_261D432E51C5991316A7BA64FDD1F511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_222A09122E7166430E42BA64FDD00820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5743BBB1BE1CEF645C56BA64FDD1967F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_62B9BEC3868C14A1C6F6BA64FDD1E93E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_B8FA9ED193F2A81C3DA4BA64FDD1A116" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_983B723C456EAAE312CABA64FDD16ECB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanfairvalue_7FE636EC5B7543FBB89EBA64FDD1A5D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6350191A3D4B57FFB367BA64FDD10642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_AB6E560B140593ABC9B5BA64FDD18A3C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_95F22087DE3A1D980B62BA64FDD1F423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8E7686AEB14E64979752BA64FDD12E2A" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_C8B9915EAA018B95D5BEBA64FDD13861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_83294912D164F1E25C7CBA64FDD1181F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5882E53D228D7D56D7FABA64FDD1663B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB563C4E63D946393F3ABA64FDD11B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8B6AD4ECB38411A2184BA64FDD19A6F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_987EC1A0EB142F91BEDDBA64FDD16DE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockPlansDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B78801089657B700C712BA64FDCB33AA" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_47C3B590F843CD51011FBA64FDCC45A3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_CostOfSalesMember_789B31D0097A8210BE98BA64FDCC50E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7C62E4B9C9FD114DD607BA64FDCCAE23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43D3ABC477EE5BE1DA3ABA64FDCC9637" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_35CF416DEF7A23996650BA64FDCC46D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90CEE383394CEB680A93BA64FDCCD990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_893B17952801659294B1BA64FDCCF979" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C4DCFCDAA64A4316E81EBA64FDCC46A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C49E431AD39752E1B4C2BA64FDCCBD86" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0F9395783975BB71FCE4BA64FDCCDAEA" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsemployees" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsemployees_D0CEB8DC9A18E99CA526BA64FDCC7C7C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromstockoptionsnonemployeeawards" xlink:label="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromstockoptionsnonemployeeawards_4F94D6BAB05271E4CDAFBA64FDCCB341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_RestrictedStockExpense_D2C79F48FF2B882C4339BA64FDCCD83E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Compensationexpensefromemployeestockpurchaseplan" xlink:label="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_pcrx_Compensationexpensefromemployeestockpurchaseplan_131815C8B401B8A7A04FBA64FDCC9C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1785F7B91AC788B83B76BA64FDCCFCC8" xlink:to="loc_us-gaap_ShareBasedCompensation_0882C7AEF1FA5500FB53BA64FDCCC492" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockPlansDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23E4AACBCC2216A0D92BBA62A3B4A50E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23E4AACBCC2216A0D92BBA62A3B4A50E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:to="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_22915340DC9022F67BFBBA62A3B664A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_604E92EDA1228637E14ABA62A3B7512E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_604E92EDA1228637E14ABA62A3B7512E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_25D839CD3645F7BB7D99BA62A3B76319" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_25D839CD3645F7BB7D99BA62A3B76319" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_EmployeeStockPurchasePlanMember" xlink:label="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B01F99E6FBD9857C54A4BA62A3B6A5E5" xlink:to="loc_pcrx_EmployeeStockPurchasePlanMember_7468E384337320256075BA62A3B70A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:to="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9FF9D49616278E8EEF08BA6301ABE320" xlink:to="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_98497B6C1ECFC0FC3B23BA636E284BF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:to="loc_us-gaap_MinimumMember_98497B6C1ECFC0FC3B23BA636E284BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0426CD1940F286DA16C3BA63AB33EF0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_060B3E13FAC7ED77CE43BA6302E75866" xlink:to="loc_us-gaap_MaximumMember_0426CD1940F286DA16C3BA63AB33EF0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2AE56808C33428CA9B07BA62A3B6545B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9180F6FBE23D2F4500C6BA62A3B89F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_AD68A11C0780E6865B96BA62A3B8D330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2E4248854D238940BDA6BA62A3B8C9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_761C9BA45FA8CB105003BA62A3B8B325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7A4DF0959DE4434F8B83BA62A3B8ADB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A3FD31865D5F755C4FFBBA62A3B730EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30EFBD72073C7FCAC5DEBA62A3B8AF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25905C5DF8746E390593BA62A3B886EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F0013C9988B7E0DE4561BA62A3B85D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_023C00E2435613F6D69CBA62A3B8AC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68E0FD49542821D597D8BA62A3B88205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_654BBC7FE6BAA98791ACBA62A3B8D120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DD04399EB8BFA02DFBF3BA62A3B9277E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F51BFCC3B2D2BB286316BA62A3B9A7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FB96E9D4CA275EA5A0ADBA62A3B82AE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AE4D9C7005C7AB65AECDBA62A3B99B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F1F49E826B14A49A0EA3BA62A3B9DDB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A152A4B3FB3D579E9B58BA62A3B96EA5" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A0070C4D0321AD9C12D6BA62A3B9C625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_093E5AB95E99313B892BBA62A3B987BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_2DDCFB1DB81903A18229BA62A3B9FB92" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_88D3FF7FB3CA2729A083BA62A3B9E15F" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3E72B675E8C97A534A61BA62A3B99437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7C9EB63D98E17733221EBA62A3B9AFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7529D46D88A3AB5D4D65BA62A3B9045E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4755CBBAB4901D8BEE21BA62A3B9D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_26102434EDB0AFBE41EEBA62A3B98917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FE2BEAFE28DA7ED9F92FBA62A3B94004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_E9AEC766F58A178F6652BA66D0483FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10B054503A11269523B9BA62A3BA46D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_012ED2C26CF9FEF61407BA62A3BAAB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_73159770DD6153F64812BA62A3B9335C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44E23DF83DDFE1050C32BA62A3BA6540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1142F8B4C1A11426A4FCBA62A3BAA260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EB96CA190FC1336AA046BA62A3BA8CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6CFF20B7FF590ECE310BA62A3BADEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_96488C09D9557C30BE46BA62A3BA93C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_A85403CE191AFB17E98CBA62A3BA0165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F50724A8A7C9CA148867BA62A3BA573D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_EDDEC2951BD900FF4D34BA62A3BAB17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_967176B57B32B85165D9BA62A3BBC141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A5AC4E11781004F04812BA62A3BB8F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9D82D4ED6429BFAD1E8DBA62A3BBB4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_A38F6CDE28287C9056F9BA62A3BABEFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9AF8E891E7E7266F66DEBA62A3BB6AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_8FBC9C1AF9049ED69EFCBA62A3BBF377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12C948E272034289DE6BBA683DD8D1C6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12C948E272034289DE6BBA683DD8D1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72FDE66399D8F13D78F7BA62A3BB2CB1" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest_1494E46BEFFB17D5B561BA62A3BB47CB" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue" xlink:label="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue_C911C595C806C34F6003BA62A3BB3E13" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue" xlink:label="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A9419722C3E7F013515BA62A3B71A5E" xlink:to="loc_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue_16F281F02C88383CD529BA62A3BB44BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09639E561EE8D3C103B0BA64FDD48645" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:label="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09639E561EE8D3C103B0BA64FDD48645" xlink:to="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_35904C3E07951CBCD5B1BA64FDD44B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09639E561EE8D3C103B0BA64FDD48645" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B448C58E5680AF0D5148BA64FDD4139E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09639E561EE8D3C103B0BA64FDD48645" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5C46CFDF6005672475D7BA64FDD45702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09639E561EE8D3C103B0BA64FDD48645" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A9BCBD7CC3EF7BE19519BA64FDD4A3F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_17D2E4D66BA6B43F95F7BA64FDDE381F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_17D2E4D66BA6B43F95F7BA64FDDE381F" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67D8704540DF62043297BA64FDDE3C7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_C6A4430801C768A64347BA64FDDA4648" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_C6A4430801C768A64347BA64FDDA4648" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A5A031DBEA1F77DB4770BA64FDDB1D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_C6A4430801C768A64347BA64FDDA4648" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0E0DB393E188FE453D33BA64FDDB8302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_C6A4430801C768A64347BA64FDDA4648" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_D9C4737F24182077B6B6BA64FDDB8BBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockholdersEquityDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_88D2CEFCA494679F9DF3BA64FDD8C1EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_88D2CEFCA494679F9DF3BA64FDD8C1EA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_428C2FB465DEED80A8B0BA64FDD8CC6E" xlink:to="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_910FCD6AEF9FDB15A72CBA64FDD8C6F1" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59B4C86FFAD5A827EBF7BA64FDD87F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3EE850D9278F6BB29DF4BA64FDD80C0E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_DE45ED24E1C5E631F60ABA64FDD88A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_60B04707A8E8F4611C04BA64FDD84718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6F9D574E1B4C3E13FD75BA64FDD89E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_51DEF0020E0E707720A7BA64FDD8C57A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EFD2121C1DB87067EB26BA64FDD85730" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_C4F179A06236DBDD5009BA64FDDC26E5" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_98C14AE85633B8DAE013BA64FDDC3F01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_749A36ED685802F0233ABA64FE6B7599" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_749A36ED685802F0233ABA64FE6B7599" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C0045CB58256C5C30CFEBA64FE6B8C12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_28EB6F3653621C8CD6ADBA64FE3FF96B" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LiquidityAbstract" xlink:label="loc_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28EB6F3653621C8CD6ADBA64FE3FF96B" xlink:to="loc_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_LiquidityAbstract_C8648DB4CEC4FE448A20BA64FE3FD2D6" xlink:to="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct" xlink:label="loc_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:to="loc_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct_81AFDD3B92F3C5D5CF36BA64FE3F489E" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned" xlink:label="loc_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_483F20283DA43B5C581FBA64FE3FC1F0" xlink:to="loc_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned_A17A9370417FA526A657BA64FE3F9F0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_926DE478839659AB7F3CBA64FE38EADD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_926DE478839659AB7F3CBA64FE38EADD" xlink:to="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C191A7102E3893408101BA64FE38DDF3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_109EA28C9932BAEDDF99BA64FE38F05D" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_9248B131A572D6170001BA64FE38492D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50DD26BC48333F6BCC62BA64FE38BD96" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98390BC47DB9A305185FBA64FE38071D" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_064BEE03C7E8BEC4309FBA64FE38138E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_2EB938CF57D445E1B8AABA64FE38D99F" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LargestCustomerMember" xlink:label="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_LargestCustomerMember_9A92C622F26CE29B4F42BA64FE38EDE3" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_SecondLargestCustomerMember" xlink:label="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_SecondLargestCustomerMember_7174D3A7ADA455908532BA64FE38D939" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ThirdLargestCustomerMember" xlink:label="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_ThirdLargestCustomerMember_7747EC69E882B576889BBA64FE38FD14" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_CustomersOutsideUSMember" xlink:label="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6511002BFBE130DEB348BA64FE381F28" xlink:to="loc_pcrx_CustomersOutsideUSMember_B22E76A6C2C735684EA2BA64FE380ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_66BC00D2DE13E82C0A5FBA64FE387A95" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6EF6364026BD1C91122BBA64FE392EDE" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_63AC79DE645AEB6F6BEBBA64FE391ABC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1E19420067AC59F0B5E8BA64FE3476CE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_ComputerEquipmentAndSoftwareMember" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_4F7B46CD4804F4B1DC5CBA64FE3476FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_DE33993238DD3B6FBD0ABA64FE34AD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3F5642BB908AC4E28D26BA64FE34624C" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_68BF472E2E98C5D2D989BA64FE346537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B505B556F5C93793A74FBA64FE34F62C" xlink:to="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:to="loc_us-gaap_MinimumMember_0B07E0685DEB5F937B95BA64FE343EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_83C4C4CDF875DF6043DCBA64FE34DA28" xlink:to="loc_us-gaap_MaximumMember_F00F5BD248F2A8045DFFBA64FE34F06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E10FE9EC76E7FA038603BA64FE3386B0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8114D8BE506394EA05D4BA64FE349445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_AAF5349102C60166068EBA64FE340AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_386B08AF8E6A2BB4A0DBBA64FE336917" xlink:to="loc_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_D896AD5E6A04AF4FC221BA64FE34FF3C" xlink:to="loc_us-gaap_NumberOfReportableSegments_150C69FF6F8F29451B68BA64FE34A566" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="loc_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_35BDD440BC881244D423BA64FE637754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_UseOfEstimates_5ACDE0BD7CE23E3410FABA64FE636223" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_LiquidityPolicyTextBlock" xlink:label="loc_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_pcrx_LiquidityPolicyTextBlock_DC8A4F4D480623889973BA64FE633721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3109637963CF0B642897BA64FE632127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_92B1FD4ED3AF45FF99D0BA64FE6349B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_CDCD58F9B03233189B9EBA64FE63868B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_61B3F683E79ECDDFF018BA64FE63364A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8794BFE979F1F9D0A3F9BA64FE633481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_AA34605C807393F0F4FDBA64FE6448F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1D6A9A7576F1060413E9BA64FE642034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_A9935BA390A771866C93BA64FE6488E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_120B919442CD85938EACBA64FE648CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="loc_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_AssetRetirementObligationsPolicy_4CB98864D2AFF0734941BA64FE64239F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_A0EEA8466336B0999E26BA64FE64B982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_7CD5BFB15EDF565B58A8BA64FE640A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11CFE5C530EBCFAC701ABA64FE648B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_DebtPolicyTextBlock_0DE488111213AE86B2AEBA64FE643C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_E61FF7D8378A2942147BBA64FE64B545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ED56D71F71C72E83A092BA64FE64E5E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0116F4B16FFBBC1739B1BA64FE5EF364" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70DEA4B399667E340A4CBA64FE649A8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5D99C0878A5B6E779C3ABA64FE3C0519" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5D99C0878A5B6E779C3ABA64FE3C0519" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0BE583B1366FCB7AA841BA64FE3C4B50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_AllowanceForSalesReturnsMember_AFFBDBF11D193923DF32BA64FE3C03EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_C37B5B5CE5EFFC8A7E92BA64FE3CEC18" xlink:type="arc" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_WholesalerservicefeesMember" xlink:label="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_pcrx_WholesalerservicefeesMember_8763E7B729B71BAE1A3ABA64FE3C3109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForPromotionsMember" xlink:label="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3CE15B8ECF8516A22EFBBA64FE3CA1BC" xlink:to="loc_us-gaap_AllowanceForPromotionsMember_43D5545AE04224E5150ABA64FE3CF593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3B06B63259F11C68511BBA64FE3C3A60" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C01C34291211F8371E6CBA64FE3CEDF3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1010BABB3ECB4DC98144BA64FE3CA9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_B8E26D526178FD0481F1BA64FE3D70D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_33A66DBE02F31F33E503BA64FE3DB9C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5A01FB6723C040367DF1BA64FE3C0040" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_60223E7B7E19EDC8A85EBA64FE3D2523" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07FB33B2D871D3700689BA64FE50D8AD" xlink:type="locator" />
    <link:loc xlink:href="pcrx-20171231.xsd#pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:label="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07FB33B2D871D3700689BA64FE50D8AD" xlink:to="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_E509B6E0C24E584C3E08BA64FE509841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07FB33B2D871D3700689BA64FE50D8AD" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48AE2122A9AF143CF505BA64FE50FBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07FB33B2D871D3700689BA64FE50D8AD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A304858E6FC6CB760782BA64FE5048B3" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>hcpvendorinsurance.jpg
<TEXT>
begin 644 hcpvendorinsurance.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" +% F0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  6V'_R91_9.,_Y]L/\ 7_AW_H+A^/\ D??%%? __$13\%/^A7^*7_@ML/\
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M4_Z%?XI?^"VP_P#DRC_B(I^"G_0K_%+_ ,%MA_\ )E']DXS_ )]L/]?^'?\
MH+A^/^1]\45\#_\ $13\%/\ H5_BE_X+;#_Y,H_XB*?@I_T*_P 4O_!;8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HKX+_X*J?"/0_@G\=OA7^T)'X?TFZCT37K?3_%/G6R.EQ
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M'>1AA@\JXYWX^E_^"HGQAU7]D#]@,'X>PP>&I+B:TT.VET^!84T>"0-N:)5
M5#A=JD8VEP1R!6]3"6<53=^=I+IJW:SUT:>ZUTUZGF8?B1.A6K8JGR.A!RFK
MW:LG+W=%S1E%7C+2^S2:9];45\_?#O\ 8.^'EA\'=#BT6P_LG6Y(K._G\264
MC)JNIRJ4E8W-RK"2X20[MR2,R$-TX%> ?\%VO!NCW&C_  =U>70+'4]4D\8V
MVGR/]FA-S>6Q5W-KO? *,W\#L$R<G')J88>,Z\:"EO+EO;T5]^YTX_-Z^$RZ
MICYTD^6/-;FW\K\O;R>NGF?H!17A_P"QS\*O"6@Z9=^,-%^'VG?#+6?$/F6%
M]HUG;0VBHEK<2K'OBAS'YH!^9D)!SU(P:]NEB6>)D=5='!5E89# ]017/5BH
MNT=?Z\KGJX.M.K252HK7[7?YJ+^32L.HK\</B#'\-?A'XW_:=TK5_A=97=K>
M>)8]$\/ZS!I]M#8>$+B57\MVF4^?:QAOG_<QL#LV]P*_02T^"#Z#_P $U+GP
MEXWU+3OB)/I_A.XDFOKF/[7!=.D+RQ2(9 2VPA"CGYOD4\&M\1AXTL.L1>Z:
MB]N\>9]7JDUO:]U8\3*L^J8W%U,)[-*4.=/WF]8S<%>\5I)Q;37-:S3UM?Z+
MHK\T_P#@CO\ "7P?\3?@KX1&M?#'3[+4-"$NOVGC1[2VCN[VXBOV58TG0F79
M&HVLLNW((P, ,?:/^"GOQ'UB;XK_  /^&,&I7NC^&/B/X@:'7KBUG,#W=O$8
MO]%\P$,JOO.[!&1@>U;5\!R8I86,KMMKLM.N[[/3?3S,L!Q*Z^4K-JM/E3C%
MI)MN\K66L8]9+756=]D?8E%?#?[6.AZ;^PM^TM\";_X6:1:^%;;QCK;>'M<T
M;28EMK'5K=O* >2%1L,J;LB7&_C!-8W_  5[^%_A_7OVFOV<;J\\/Z1=R:WX
MH&G:E/+8QNU_;AX"L$S%<O&-SX1B1\S<<FHHX559TDI:3;C>VS7E?TZ]33&9
M]4P]'$2=-.='E;7,[-2VM+E]?L]/,^_:*\HMO@AX*L_VJ8/$$/A3PY%K]IX>
M5(;]-/B6YA59/*7:X7(Q&-@(Z*-O3BOER;X3^%S_ ,%XE7_A'-#VGP5_;17[
M#%@WWG-_I6-O^N_Z:?>]ZSH4(U)*-[:2>W\J;[];'9F69UL)&+]FG>I"'Q-:
M3MK\/1O;\>A]]45\ _\ !5SPAX:L/VP_V?\ 6K[P);>+I+V]OTU.PMM-MKB[
MUR"&*-DA99BJ3;<L51VQR<<G!Z+_ ()%:%9>)_$?Q-^(7A&]@T/X=>)M3\C2
MO!$;MO\ #LL7^L::+ C@=\[O+CW* P^8X%73PJGA_;WZ/IVERI;]=6M+:6.2
M6?S6:?V;[-;I7YM;<G.Y6<4K*ZBTI-ZIVL?;E%?EO\9_!?ACPE_P6!\;QI\*
M-#\;V$OABWO)=*.EV<MI#/,\ EOI8I, D;V9F0-(2Q..68?H7X;^ G@[P5\$
M[KP+8Z+I\WA-8IT;2;F);BV5)&:0Q%&!!0%N%.<#%9UZ*IT(5KWYE>WWI]?T
MU.G*\UK8S$UJ#IJ*IR<;\S=]$T_A2UOKJVOF=[17YR?L)>*[K]B3X\?$#X1[
M?^)=XKTJV\6^#(I),))+.J1M"OMYC >N(B<5L?\ !&3X=:5I/QL_:"O9;"SN
M=:TGQ;/IT6I2PJ]TD1DEWH)2-P5F4$@'!(&>E=$L$ES-2T4>9:;ZI-;Z6;LS
M@PW$DJLJ-)TK3G.4)+F^'E3E>_+[RDE>.BT9^@=%?EIK/@'PGX:_X*S?%C3O
M^%1Z!XTTB2RTP&P;2K.2RTIKE[59KQHI""/]8[%HE9RS9.!EA]Y>//V>O!6D
M?LGZSX$70]-O_"NE:7<+;:?>1)=16Q57D3 <'#(Q!4]5P#G(S6%6@H4:=5/X
MTG_GUZ:=-3MR[-JV*J5Z?LTO92E'XGJT[+["5G9WLVUV9ZS17Y<ZQX<?]B*\
MNO@9\1M-@\7_  C\=2)J'@'4=2M!=II-X74FT;<"%;YB 1C[V1P[ ?>GQA_9
M9\ ?$SPOHZZYX6T74M.\'65RNE:7/91/I]MOB"@B J4^54 7C"Y/'3"Q5&-&
M'M;WB[V=NRUZ[IZ-?.Y65YI6QCE2]FHU(64HN6TF]->76+5I1EU7V4[GJ5%?
MGA_P1$_9N\%^-/V:M$\:7>@:<GBSPYXHO9K35H;>..\*A#'Y3R[=SQ;7/R$X
M!P1BNO\ VZM(\2_#S]I"Y^(6J_#:'XU_#6#2(;&6RM90^I^"9DW2275O%@E7
M=65O,3:X"KET !.V(P<:6(]AS?-Z=+KK;7;5HX\%Q!5K97#,YT;*5G9-RLGN
MW:%].MHO37:]ON"BO,OV-O$FA>+?V8_!U_X9U?4M=T2>P!MK[4=WVR8;CGSB
MQ),@.0Q).2"<\UZ;7+5ING-P?1V/H,-7C6HQK1LU))Z.ZU[/JO,****S-PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH X[X_? W0OVD_A!KG@GQ(D[:/K]OY$[0%5FA((99(RRL ZL 02#R.E
M;?@/P3I_PV\$Z3X?TF'R-,T6TBLK6/\ N1QJ%7/O@5K44^9J/*MMS+V%/VOM
MK>]:U^MKWMZ7/GJ[_P"">EBW[2>J_%BS^)GQ+TOQGJUL;&2XM_['>&&UXVP)
M%+I[KM4*H!8%_EY8DDGT#0/V>SX>^#NJ^$H_&OC2XN-9DGEN?$%S+:3:L6F;
M+X)M_('R_(!Y.%7&,$ CT6BM)5IR@H/9*WR[>ART,MP]&I*K233DVW[TMWN[
M7M?SWL>;^+/V7M ^)/P)M_ 'BVYU/Q7I]JL7EW^H>0M\LD3!HI0T,4<:R)@
M,J#(ZYR<L_:?_9DT[]JKX/S^!]7U_P 2:)H=]L6]&D-:K+>QH0RQNT\$NU=R
MJWR!6RO7&0?2Z*GVDF[^=_GW_!?<:RP5&4'3<=''E>]^772^_5]>K[G@OP]_
MX)Y>$/!_B?PAJNL:YXM\<S?#^U6T\,PZ]<6WV;154!0T<5M! CR84?/*';@<
M\"NX_:&_9C\+?M-:#IUIXBBO8;S1+M=0TG5-/G^SW^DW*])89,'!]0P93@9!
MP*]"HJIUZDI*3>JU^=[W];Z^IG1RS"TJ3HP@N66C3UNDK).][V225]DK(\B\
M#?L<:%X;^,4'Q U[7?$_CWQC8VAL-/U+Q!+;$Z9 ?O+#%;000J6R<OL+G)^:
MJ7Q[_8ET[]H+XQ^%/&U_XU\<:-J7@B1I]%M]+;3A;6<K "1\36DC.7"@$.S
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ML7EW^H>0M\LD3!HI0T,4<:R)@ ,J#(ZYR<]'\4?A#X=^-/PUU#PCXHTV'6-
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M6)))] M?V<Q9? J\\#Q>-/&@.H^<;K7GFM)=7G,SEY<N]NT/S!BO$0VK]W!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45YI^V/X[
M\5_"O]EOQWXI\%7GA^R\2>%]%N=8M7UO2YM2L9/L\;3/&\,5Q;N=ZHRAA*-I
M8,0X&T_.?['_ /P53?Q?\//V;M-^)RKJ'Q+_ &B="/B6S@\(>#]432]*M/)C
M?$AWWA C>:*-YGE1 &WN(EP"Z:=1RC'=6^?-S-6[Z0E]WI<J>Y%3EL[_ "MR
MWO\ ^!1^\^UZ*^;OB?\ \%%_!GP8_:U\1>!/$WBG2-,L?#'A"VU^\TXZ#K$N
MM2S7%\EK ULR6[6]W'(TD<*0VQDN&G;8$)!%:?[4_P"W1H'P8_86U[XR:=JT
M.BZ;;V>^QOO$OAG6OL]E.TODI]OLH+<W\*++\KYA5D_BVTHZP51;/3YW<?S6
M@[/G]GU_X"E^4D>_45\P>+O^"Q7[/OP\U+5].UOQGJ\.I>'=<L_#&J16_@W7
M+@6^IW</G6UN/+LVW>>@S$PRLF0%)) *Q_\ !8S]GVXL/#$\/BCQ5<MXRO=4
MTS1[6W\ ^(9KRZO-,W?;K0VZV)FCN(MK9A=%D;'RJU'FOZT3_)I^C3)3NK_U
MU_R?W/L?3U%>$_\ #S#X'R6_A6>'QY;7EIXQLHM2L+RTTZ\N;2WM993!%->3
M1PM'8(\P:)6NVA#2JT8RZE1SWQ!_X*[? GX<:5\0)[WQ)KTEQ\,;J]L/$-I%
MX4U;SK*YM+1KR2([K8+AH%,B2;O+D4$H[ $@G[J;ETO?Y.S^YM)^;2*BG)I+
MK:WSU7WI-KR1]+T5\WZ;_P %6_@S!X?\"W/B#7-9\+7WCNQL+V"SU+PSJT)T
MH7LQM[;[<[6JK9)-.&CADNO)28J3&6'-:&D_\%1?@=K7Q4N/!,/B^^7Q-:^)
M+KPA+9S^&]5@"ZM;V_VE[/S)+98S(T.7CPV)@#Y1DP:J<)1;C+I>_P FD_N;
M2?JNZ)C)2BI+9I/Y--K[TFUY)]CZ HKP?]F#_@H?X"_:K_9AUGXNZ%#XHL_!
MNB3:@)9[_P /7]M)<06DD@-Q CPJUPC(F[,(<*24)#HZCFOA_P#\%=/@SXO^
M _@GQ_J6J>(/#6F^/+&75+&VO_#.J?:+>RBV>9?3JML3#8H)(]UZ^+0;U_?$
M$$G)+F<+:JVGK>WWV=O0JS_%KYK?[CZ=HKSOXZ_M5^!OV<?#&DZMXHU._P#L
M^OS&#3(-'T:]UR]U%A$TS&&UL89IY%6)&D9E0JB*68@<U\[_  !_X*I6&K?M
M8?%;X=_$?5?#VD6VD^/=.\'^!;JQT:_A_M5KW2TOX8;N4M-%'.P9T1G,"R%,
M*NX[:(1<Y.$=U_G%6];R6A,FHQ4WM^EF[^B2=V?9E%>":M_P4X^">C-XM\WQ
M;>R#P5;7=YJ#VWAW5+E+B&SE6&\DLFCMF&H+;2,$G-F9O(8XDV8JG\._^"J'
MP4^+'B1](\/:WXNU/4TT_2-5-O'X"U]7-GJK(EA<#=9#,4I<?.,JFURY41N5
M48N32BKWM^-[??9V[V?8<_<5YZ6_2U_NNOO7<^AZ*^:/VI?^"BNB_!SXQ:S\
M)-$AU27XFIX"U+QG93S>&M0U#1[);=2(#=20*B"*1UD!8SQ*#'L\Q7D0'G?V
M+_\ @K1X"^-_[*OASQ1XW\0Z7HGCA/!>B^*O$VE6>E7\<<']I )#]BC=7>Z6
M2XW0QI TSF3$?+D D%SP<X[*WXN:_!PE?M8<HN+47N__ +5_CSQMWN?7-%>#
M?'G]NGPKX)_85\6_&?P]K]C#I&CZ9<R6^H:OH6JS6^FW<;-#MU"RMX#?PK%.
M-LZ&%9(@DF\)M.,:7_@J[\#_  SXF_X1O7_&S67B.RCT/^T /#FK)90-JZC[
M!+Y[VWEB"9SL65GV(Y5'97.VFH2<G!+5-*W6[V7J*7NQYWMJ_DK7?XH^DJ*^
M&/@M_P %8[_X@?M$_&"YU^'3?#?P:^&.OMX+AAG\(^(!XKU;62MLT'V:/R2M
MWYV^Y7[)##]HC$4,GSI.I'LGB;_@J9\"O"-SX<AO/&ER9/%VD:AKFD"V\/:G
M=?;;?3]WVY08K=@)X-K>9;MB="#F,4E%N,9K[237HUS+YN/O6WMJP>DY4WNG
M;[G9_P#DVGKL?0=%?+%Y_P %HOV=+.\2V_X2_P 37%U)XCO/"$=O:^ O$-S-
M)K%I&)9K%4CL68S!&#*H&9 #LWX.-:3_ (*Y?L]Q_#_PIXJ_X3]SX>\9PK<V
M%\N@:FT5M UV;)9[W%MFPA-R##YEX(4WC&[-"BW:W6UO.ZNK>JU7=";2W_JS
ML_QT]=#Z1HKXN_:#_P""RW@/X>?$/QAX)TF]O-'\0>"O$VA>';[5]>\%^(;K
MP_\ :+Z>$RVQN[.T>**8V\@$)ED57DE0\Q@L?<;O]O3X4V?Q-UCP>WB:=]=T
M,7*W$<6CWTMO-/;0&XN+2WN%A,%S=Q0@N]K [SJO)C&:5UR>TZ:_<DFWZ6DG
M?S']KEZ_YMI?>TTO1GL%%>)_LS?\%%/@Y^V'KUMIGP[\8?V[?7N@1>*+6*72
M;ZP^V:;+,\"W,1N88Q(HE1HW"$M&PPX4D Z-_P#MS_"W3?C9<_#V7Q-)_P )
M3:2-;20II5[):&[6W-R;%;M83;/>_9QYOV193<>7\WE[>:<HN+M)6W_#1_<]
M'V"/O?#KM^*NOO3NO+4];HKPO]FG_@I1\%OVO?$6EZ5\/O&+ZSJ&MZ/-K^GP
MSZ+J&G?;K*&Y-K-)&;J"(.8IUV2(#O0E=R@,I/@7_!1#_@LE'^SUH'QFT/X;
M:>][\0/@O%H5UJCZ]X7U.;0W74+R*)[<W$9AC640RI(A,WS[CL201R;7RRYE
M!K5_Y\K?HGH^P+5-KI^NR^=U;U['WC17AT/_  4;^$$G@75]='B>[N$T#7W\
M*WUA:Z!J5QJRZJD?FM:1Z>ENUW,_E9E'E1.#$#("4!:J7[6?[<OAWX'?LY>%
M/'^D>)_#<6E>--:T;3](UB_TS4M2TJZBO;F(<M812/$TD)=8I)-L7G-$'8 X
M(HMM)=7%?.5N7[[IKNM@Z7>FC?RC\7W6=^W4]^HKY^\$?\%2?@5\0OB,/">G
M>-WCUPZUJGATQ7^AZCI\2:CIL8EO;5IKBW2)98XCY@4N-Z!F3<JDAMK_ ,%2
M/@K<Z/X;U Z_XE@L?&&OP>&=$N+GP5KEO'JE]/$);=8FDLU#0S1G=%<#]S*
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MQBC>X2VB,JY=4!VK]27?_!4'X&6.L^*K"3QQ_I/@]=U[MT74&2\(NQ9%+%Q
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M?^TEX(\/:'KOQJB2Q\.:%X<L+2SB\)L;&VU#2=02[:^AA:^)C^U)''#(A=G
M1=LNW<C94O\ P1G\5R_'^3QU_P +>\/?/\9#\6_L7_"#S<9T\Z>VG^9_:?\
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MP_:KT_XKWOQC;4M6T/6/$=[I5OJ7AHW*VMCJNG)9QV!=;M"8[1DWQ[!&K!Y
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M:UV$'R<KCIRVM\I<Z_\ )M?-I7V1\P?LN?\ !-2V_9C^)=GXMM_&FHZSK:>
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MY4H)[)QO;JE%KW6OYE\7+TBN:YI3BYU%&^KDE?I[R^*_\MO=YNLO=L=EJ/\
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M)/YJ*B]=+S47;61R59N-/G2UM)^DO=Y5YW;EMK:-]7H?>_\ P4'_ &\?#/\
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MMMMH\(73]0"K$?+N)S#(/-8-&Z@)72?L5_L+_&+X+?M#>!/$WB^\^$5EX?\
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M_$?A5H/A==_$!/$>NZ;I]VVDR6][]GDM);07N[S08;B$LL<ZB5XF"R1JQ;Z
MMO\ @J+X6M))]-U'P=X_T[Q)9^*(_";Z3?1:;;75S,]@FH+<Q%[P1/$UH_FK
M&K_:3M9!!YBE*XC7?^"(OA+Q%\)I/"5Q\7_C;Y-UH-]X9O-02ZT1+R_T^[O?
MMLD$F-,\K E:;:5C!Q.V2Q6,Q]3<?\$K;/5&^(/]I?&GXQ:NGQ,,)UJ"]B\.
M26TACMHK7B#^R1"VZWA2,B1'"\NFR3#AIKV7*U[WO/\ \GO'75VY-'YZJ[U)
MBFYWF_=\M_ABGZ^]S26O9:*Z/3/VK/VQ=,_9+^#-MXUU;PGXSUVQG!>:VTR&
MS@DTV)8'GDENY[VXM[6V1$C8$S3KN<JB;W95/Q+^UY_P5:^*,NO^)/%GPKT#
MQY:^ O 7PZT3XDVDZ6'AVYTWQ/:WQNW9;];F^6]BMVCA6.,VGESQRQ3,Z21^
M4)/L_P".O[#'AKX[^%OA[I-SKGBK1(?AK-YNERZ?-;323*;*2R9)OM<$ZMF&
M5OWBA9E;YDD4DY\E\*?\$9?"GAWPKXA\/W7Q4^+^N>&_$?P^M/AI/I=]+HBP
MP:5:1R):F-X=-CE$\1FF<.TC!FE.]74*JW3]DISE*^CO'TL[W7KRV3T^*^EB
MJ<FH14DKM*_KSQ_#E4KM:ZQMU*5]_P %U/@WX8^,O_"OM?MO$NE^+;:U<7VF
MQ2:9J=_9ZA'9&]ETTV%E>SWSS+$K 2Q6[VK./+6X9R%/M_PE_;+TWXQ?LM/\
M7=/\&?$*W\,3:/'KNEVLVF12ZKKMJ]JEPK6UI!-)(6.\QA) C,Z$@&,I(W*:
M/_P3DLO",_B]/#WQ7^+?A[3/'<4LFM:;:76ES6]SJ,L*PR:HIGL9)8KA@BLT
M<;K:LR\P$$@]#IW["_AZU_8/C_9]N?$?B[4O"L/AH>%4U6XEM$U<6:Q^7'EH
M[=+=F2,*HW0%6"_.KY;=+<?92_FM&UMK^]S6OV=E&_V=_>N33NIP4OAUO^%O
MO5^;^\M':QYO\/?^"O\ X+^+.AS+X7\!?$KQ'XNL=1U+3[_PEI*Z1?ZK8#3Q
M;&\G:2&_>RD2/[9;#;#<R2LTNQ8VD5D'4^,O^"EW@_P)J?B&XU#PK\18_!7A
M"&X.O^,UT=#HVB7,%G]MEM+A?-^UQR+"1ES;>0)&6(R^:=E<WX5_X)*>'?A_
MXZD\7>'/BC\6/#WC274YM1;7;)]%$Q6>SLK6YM3 ^G-:&WF73[1RA@/EO$#$
M8A\M=+KO_!-;PKXCU+QW;7?B_P"(<O@KXFP,OBCP<^H6SZ1JUPUNEN]X9&MS
M>Q3.D49<0W,<;LNYHR2Q*ERVTWY=?\>FW]VU[7UY[7]T<-US[7^?+=V_[>VO
M]EQOM(\R^%O_  7A^#_QLU+2M'\(Z+XX\4^*];U>31+/1-#&EZMON192WL:M
MJ%K?2Z9&9889-BR7BN"CAU3RY"EWPU_P5XM_'?Q5CL- ^%'Q)U?PU;>#+_Q'
MJ4UK;6$NIV5]:Z@UA)IS6PO-_FQW$,\+E0Z;RC>8(5:6N>_:H_8I^)J>*_V>
M]'\,^*_C=X^M_"_C5]3U/QF^H>&(=0\'V(TJ]L8F2.6&WBN")+Q6.;2ZD>..
M7S"Y$:-W?C/_ ((]?#CQ=X973(O$GQ#T;S-$N=&O[FPU&V\[6'N-1&IR7EUY
MMNZRS&\,DA0KY$GG.LD+IM5::AI*.UVGW^!V=O\ $T]=+K1VN3/FY5%6YK1?
ME_$]Y?\ @"TZV=VDVBCX6_X+-^ ?'.DZ)_8G@7XI:WK^NW.NV4.B:;8:?>R1
M7.CJ6O('O8KQM-WX VA;M@VX<CG'7?#K_@IWX+^+1T^_\.>%_B%JW@^:RMKK
M5/%4&EPG2O#CW&GQZC'!>#SOM*M]EFB=GC@DAC,BJ\BL<5RD'_!(31]*\<0:
M_I/QF^,VB7EK>ZOJ44=H/#S0QW.J6Z6]W*%ETI\96-2JYV(1\J@?+6E^SE_P
M2>\-?LS:-_8NC?$OXK:GX6O].@TW7M U.XTI[#Q*L%LMI"]SY=A'*CK:QP0L
M;:2 2I GFB1B[-GO3;^W96[<VO-?KR[6ZWM?2Z''XO>VN_7ENN7RO:]^FZ[,
MU_V%?^"J?PJ_X*%^(O$VD^ ;V5[_ ,+V]O?RQR7^G7@N;.X+K#<JUC=7"Q[C
M&P,%P8KF/Y?,A3<N8=9_X*5:9+#J*:-\/?B'??;=)U#4O!NI/!IT>F^.6LT+
MS1V4C7BM&P +@7@MO,1&>,NHS7HW[,?[+_\ PS%X330(/'GCSQAH>GP+9:-9
M>(I[*5-#M% "6T3V]M#),JJJJ'NGGE 7'F<G/GVB?\$S?#_AG2;_ $W3OB!\
M2K32(;:^M?"VG^?ILT'@(7BLEP=-\RR9B2CNBB\:Y6)&*QA%.*G%I2C)4/Y7
M:_>SM?L]MKJ_-TL50;33J6W5_3K;NM[7L[6ZW.&_9F_:P^('PS_8*3X[?%1/
MB%XQLO$EGIVMG0?[+\/6M_X9@G1//ECEM[N.WET\%UFC\YS=1PY\TN^0O7'_
M (*H>$;76_&5I?>#?'.GQ_#[Q-<>'/$-U)-H\L6F)!IIU*347$5^\AM/LVPC
M:AGW2*GD[L@>D?#/]DG2/ /[(<'P8U+7_$GC/PU#H,GADWNN?8_[0FL&B:%8
MG-M;PPG9$0BMY6XA06+MECP7@K_@E=\,O"4VJ&ZN/%7B*'Q!X)'@?6(-5U%9
M(M7@+RO-?3B.-,WTIF</,N!@@*JUTXF5-UJCIKW?L_I?Y1L^K<[W]TQPT9JG
M359WE]JWX\OWMKHE%+J8WB+_ (*V^$O ?C?3?"GB?X;?&;PYXOUW4['3])T:
MX\/PW<NI1WK2+:W2SVMQ-:Q0NT4BD3S1R(4(>-*Y_P#9!_;H\=^+/BW\4_!_
MB?0/$?COQ#HWQ%.F0Z=H=II%C)X&T673K"XA;41)?A66-YYD,D4MQ),\4QB1
ME78G2ZM_P2MTKQ'K/A75]4^+OQBU77_!^K:=J5CJUW<:/)=/#8&9K6QD']G>
M6T"M/*S,$%Q(6!DF<JFVS\/O^"7ND?"_]HOQ/\4=%^*?Q5L_%/B_7I=;U1@=
M%\FZCDCBB-@R_P!G9:U"00!0[-*ACW)(K/(SS0<(RDYZW32^^FX_-VFI->?+
M9/4J>T=N7^[]]IJ7RORN'RYM4R_\4O\ @I7H'PB^)OC/POJ7@#XD37'@;4O#
MME?W=I#ILEM+!K=Q);6E]%_IHD-NL\9CE#(LRD@B)URPQO!W_!7CX;>++HW$
M^@?$3P]X94>($;Q%K>B+8V,<^B9-_;O$TOVM)%579=UN%;RW7<'!2MG]I#_@
MF5X0_:;^(_B7Q#JWB[XCZ$GC'3=(T[6=.T#5H;""]_LN]:\LIQ,(3=12H[R+
MF&=%*ODKO5'7@+#_ ((I>$FTFWTC6/BU\9O$WAQ-0U[4+K1]3FT,V^I'6UD7
M4(YI(M,CN"C^;*05E5T,A*L,+C)6Y?.S_))7^?-+3NO0ZG[.R?\ >5_\-FY6
M\[V2OI9?,X*X_P""P5S\#?VF/BW=_%N#6O"/@&PT3PS-X/\ #6M6^C:-J#7-
M_)J:L6O)=0-J?.6R\P-<7-NL:C8\<<BMO]E_9)_X*Y_#7]N+QU!H'PTT;QWX
M@G_L^'5+Z]&F10Z;IMO)//;LYNWF$%P$GMY8R;1YPS*WEF0(Y7"'_!%[P/=>
M.AXSU#XE?&K5OB):6FGVNE^*[KQ!;?;='^PF?[++#;I:K8O*D=Q-%NGMI=R2
M2;MS2RM)ZE\&_P!B-?A)^TGJOQ1NOB=\2O&.OZWX<M?#5];:Z=)^QSPVTDDL
M4P6VL('27S)IV(1UC_?L!& L839>S;L]E^23M?NV_BVZ6>[,JEY7DM[1]+^Z
MI6[*R;CW=W)7L>XT445@ 4444 %%%% !1110 4444 %%%% !1110 5Q_[0/Q
MHTS]G+X&^+O'VM174^D^#=(N=8NXK50TTL<$;2,J!B!N(7 R0,GD@5V%9WB[
MPEIGC_PKJ6AZW86NJ:/K%K)97UE<QB2&[@D4I)&ZGAE9200>H-*5[.V_]>OY
M,NFXJ:<]NIX!??M=_%+0K/1M$U/X1^&K'XA^,=2DM/#&G'QWYFBZE;QVC7<L
M\U\MB9X#&B%&06<G[PJ$9XR95\?\2?\ !9SQ!8:3XCGT_P"!]_(W@?PI>^*?
M$)U'Q7;6L4(T_5)-.U&UM3'%,\\D4D$Y1G2%)=J?,@;<OO:?\$W/A&/AG9>$
MVTKQ7-INDWL5_I=U-XWUR75M$EB1HX_L6HM>&\LT5))$$=O-&@261=NUV!QO
MB#_P2:^!7Q.>\_M3PWXFCCU'P_\ \(M=P:=XXU[3;>[TTS&X>"2*VO8T?S)F
M:21V4O*SN79BS9T3BJB;UC?;RY7_ .W6;\EHU\)DD^2S>NFO_;ROI_AO9]'H
MU+XCQGP[_P %0?BQI7[2/BGPAJ/PJT3Q!IFJ?%-OAYX5O=/\5K;QZ?(NAPZD
M/MZR6JR!'0M)YD(G()F39^ZB-QH>*?\ @LG<?#;X]:YX*\2_#C3XUM[6\&CW
M>C>*O[3-_>VVH6.G?9K@BT2VMM]Q?Q$;;F66.,9GA@<B.O7S_P $L_@I_P +
M$T/Q8- \3IXA\.ZO;Z]9WB>-]=5C?PVD5FEU*HO-L\K6\*1R-,',J[_,W[WW
M2:K_ ,$M?@7KNMZE?7W@NXO7U9M5:XM[CQ!J<MF!JCQRWZQVS7!AB2:6))2D
M:*HE7S%"N2Q%R+EZVC9^;Y(I._G+FD]'NOB-$T]9>6W^*3:_\!Y8_)O0X[6_
MVK?COIW[2OP1\&:Q\-/!'A2/QCJNLQ>(%3QF^HQS6MG:+(DUE*-/5I%/F[ML
MT=M(9("AVH?,;ZRKQ[2_V#OAII=GX5C;3O$NH7'@J\FO]'O]3\7:QJ.HV\LT
M1B</=W%T]Q,FP@+'+(Z)LC*JI1"OJ7A;PY;^#_#6GZ3:27\MKIMO':PO?7TU
M]<NB*%!EGG=Y97P.7D=G8Y+,22:'RVLOZ_'^ON,8J2=W_P -_7]=67Z***@T
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P-9^*&
M@Z#XPB\/7&I0_P!O3Z;/K$6FQ*TUW+:0-&DLJQ("Q :6-1@9)8  FB_]>FOY
M:@;]%?//P_\ ^"I7P;^*?P<\0>/O#]_X^U3PMX7U)=(U"ZA^&_B3S4NS,8&A
MCMS8":9HY04D\I'\IL"39D5G:[_P5T^!_AWXDZEX0GO_ (DR^)-(L1JE[96G
MPL\57;6]GO:/[4S1:<R^1YBNAESL#(RELJ0&DW)16[_RO^6OIJ%U:_1?YV_/
M3UT/I>BO&O'?_!0+X1?#;Q^OAO6/%OD7R7L.F7ES%I=[<Z9HUW-L\FVO[Z*%
MK6PFD\V,)'=2Q.YD4*"6%:7[4_[9WP]_8OT'0M3^(>HZYIMGXFU2/1-,;3?#
M6IZVUU>R_P"JM]EC;S,KR'A P&\\+D\4K.R?=V7F]-%YZK[T'EY7^7?T/4Z*
M\=_:7_;S^&G[(4?A ^/;[Q1IQ\>W8T_0H[#P=K.L27UT5#+;;+.UF:.=ER5B
MD"NVQ\*=C8]%\0_$S0O"5CH\^JZC%IB^(+R#3].2[5H9;JYF_P!7"L; /O/)
M*D94*Q. IP[-ZKO;Y]O75:;@W;?M?Y=_31ZF[17SCXJ_X*Q_ WP-\1->\,ZS
MX@\6:7>^%M;@\.:S>77@+Q!%I&E7\YC$$4^HM9"SB$OFQ%':8(ZRHRL0P)M>
M(O\ @J-\&O"OQ.\>^#KO5/&O_"0?"^Q;4_%$%O\ #[Q#<Q:3:A#()FFCL6B=
M'169&1V$@5BF[!J>9<O/TLW?R23;]$FF_)I]1\K4N1K716\V[+[WHO/0^A**
M\8@_X* ?"ZX_9"E^.ZZIXD'PMALSJ3:LWA#6%G^R @?:A9FU^UF#!W^:(2GE
MYDW; 6KC_%7_  5U^!G@KP%X/\3:EJ_CV#1O'LD4.@RK\-/$TDE_),YCMT\I
M-/,B-.P/DAU4SA6,6\ FK<9*3@UJFE;S>R]7T[B3O%36SOKZ;_=U['TO17S?
MX+_X*P_!;Q]\7K3P%87GQ)C\87MG<ZA#I5_\+O%.GSM;VQ*SS?Z1IR (CC86
M) WLJ??95/M'P:^,&B?'OX;:9XM\.?VP=$UB,RVC:IHUYH]RZ!BNXVUY%%.@
M.,J60;E(894@E<K<>9;?\.OS3^Y]@;L^5[G44444@"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO"?B?_A&M)L-8UVS%[XK;[##?>?:0*Y9E,,RML!9PH)=4(*AI-NR[<WR=O\
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M !1110 4444 %%87Q.U:TT#X:^(;Z_DFAL;+3;F>YDAN'MY$C6)F8K(A5T8
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MXE=MKM&35T5*R<M=(RY;]-VK_P"%M))]Y13M?3] Z*^(/^"/7B_6?%WAK5M
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MC<297Y3TC_@C#\1-$T#^RH?C%X4DTY-..D06]S:?$.Y2RM"@0PP"3QRWD*4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%=+X(^,WA#XF:WKVF>'/%?AOQ!J7A:Y%EK5IINIPW<^D3D;A%<I&Q:%\<[7
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M?#6E_$&RO%EUB^U&VEE\17/VFU9K>338UN(XF"QRQNR!DR03]PU/&W_!&O\
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MZS;E-XFMH/,\R:,H"VY 1@9SBORL^'G_  0P_:+\#_"OP-H;_P#"CKJ[\*>
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M))M(;2?MES?#3OM N$@\MDWVLI54,7F%2)%^=_B;_P $&?C"?AO<^$O#FO\
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M7_Q7^&MEX5O=1?1[?6;CQ/91Z?/>HS(UJD[2B-I@R,#&&W J1C@U\&_M/_\
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M?MN_!>Q\/:!J\WQ=^&$.E>*[>YN]$O7\56*V^L0VREKF6VD,NV9(E!,C(2$
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M"/Q.U?1])TBYT"W@D=3JA46D\D<\T3>42Z [ [C>/D(!(X?5_P#@L%X(T_\
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM0O3IUKX@D\7Z>FEW-T S&!+DS>4TH",2@;=A3QP:'HVGTW_ "_,2U2:V?\
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M0NQ,;\*Q/R-Z&C[//T[^NWWA]KEZ_P"6_P!QZ117A>K_ /!4#]FG0([-K_\
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M_#M/X=?]#'\?_P#P^WC?_P"6U50E[*HY[WMIZ1J1_P#<E_EYZ%6\Z:@G;?\
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M\0_V$/A+\*_ .M^)]=\6_'^RT3P[83ZGJ%Q_PO/QR_D6\,;22/M75BQPJDX
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MU\FOB2?725I;WO&SZHYZ=.U%8>^D=/-/1-KHKJZ6EDI-K>Y\#_L7_M$?"O\
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MFCX2-H'CO1].N[;??R6VI-)'I44:.-LZH&\]0K,D&]2$+!E^SO\ AVG\.O\
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M1AERCL5+>R_\.T_AU_T,?Q__ /#[>-__ );4?\.T_AU_T,?Q_P#_  ^WC?\
M^6U9Q=E3OO'?^]Z_GOOY:&DFI.;Z2V_NKFNDOE[M]VMSY)_;"_;J^,?@+XN>
M(?AYI7Q'_P"$0U;P_>Z#-;79\/6,MU?KXBUZ:VMH9EFC>)+6PL$.Z50K//Y>
M]_E=9=#P-^T?\5]-^+-UXT\/^)-$\;:/X@^/-S\/M0@7PM9S:_\ \(];12QQ
M0K<V<<)$=M=17SKY\<K&.0$RKAR_U-_P[3^'7_0Q_'__ ,/MXW_^6U'_  [3
M^'7_ $,?Q_\ _#[>-_\ Y;4X244D^GXKFA*WW1E&_:;^<U??YK:7_!\DH_\
MI4E-)6LXI;6M\M^(_P!N#XS:O^TEJ7PJ@\;67A+4_@BFEZQXPUC4++2@/%=@
M+0W=_)]B)>[,!5XH%FMXK:%'65S=<"W/T+^RO\3/B[H7['UY\7OBKJT7BC4-
M0\%VGB&U\):'H*V[Z?+'9R7$R(Z,\D\MPS*%3 $81$ =M\C[_P#P[3^'7_0Q
M_'__ ,/MXW_^6U'_  [3^'7_ $,?Q_\ _#[>-_\ Y;5#YO8RII^\^O9ZW:\G
MI9;*WFQZ.M&I+X5NMKK2WZW?6Z[:_"/Q3_;<^-_Q3_8L^*OBO1?B;]OTWQ/X
M'T6STS5- MM/33=&\7:K?);#2-'NA"6N(HHI4CN'F>61)6.R2)@4C^G/VH/#
M=W_P3C_X)YZ'IOPU\0:;X=U_PU;Z/I]SJL]KI=GJOB"PLWC26U@D>U-D;^6-
MFBMUEA*O)*$4!GW#;\:?\$9?AI\0OB+INL:SX]_:/U+0M+2.2+PK=_&7Q+<Z
M0;V*7S8=0W27C7:W,3 ;"EPJ+M!V;OFKM_\ AVG\.O\ H8_C_P#^'V\;_P#R
MVK5RCR^XK7DG;?2+O%-]=Y+_  M)W=R8JTU[3WDEZ:M)2MV^%/3:7,U96/E7
MQ5^W)\5;#]H77O#.C?$+7+ZUNOB?X*\$6T-UX;T^-]&1]/CU/6?D%OYG^D6[
M&,+(9&C82&-EP-O-_#?]JK5/ 7[17QC\8^"?&UG>J/%GC'7OB/HSV-K/8^&M
M,TG3O[/T^2]F"_:(KN2XL(&AA,T8D@FG;RFVB4?9W_#M/X=?]#'\?_\ P^WC
M?_Y;4?\ #M/X=?\ 0Q_'_P#\/MXW_P#EM4WM%I:-J2OUUC37X2AS+SD];ZN[
MJ\6^CBWYVY[_ 'J:7K%.SO8^5/BS^UW\>/A)9^#_  [XV^)$?A[6?B+X+G\4
MV\^B>&+,ZI;WMK:6R1Z'I4<Z3Q7U_=74LD\@,+^5!&RH@ \^L35_VH/VE?C7
M^U%X?^$>D?%K1O"/Q T&R\.2>+-+\/MX<C73\V\%SKLES:ZI'/J%RQ20+:OI
M\'V8-+B63<A6OL;_ (=I_#K_ *&/X_\ _A]O&_\ \MJ\=MO^" WPAD_:%C^(
M&J>/_P!HW7_L%Q+?:1H>H?%75VL=!NI%*O<VMPDJ:@DQ#299KML^:X.0<#15
M%[7FLDKW\M&W%6ZJSM)?:Y8MM/F;QY'[+EOK:WGK:[];JZ_EYGOHCY9^+/\
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MA+6T4GW:J)V]7:+BGJK6MI8QC->T4NLG*U]ER<J?^'5J3V?-=RUNC\YO!_\
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[8+P[O\ 6^1Y'R^5O_>UT6O_ +?GB3]GW]L/XT:5XZL=<\2_#7PJGAN>TOM
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M:W%=*7(]_P"OZ^[N24445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J/B70D\3^'KW3I+B]M$OH'@:>SN&M[B$,"-T<BD,CC.0PY!J]7
M)?'SPS;>-?@?XPT:\\17/A"UU;1KNREURWN1;3:0LD+(;E)20$:/=N#$C!7K
M4S;46XJ[+II.:3=E??L>#_"?_@G'H&G?#+XGVC_%+QIXI\0_$^*^T+5/&"C2
MAJ-C9F^OI6LH$CM#9HT<MY=J[- S&1Y,A=J)'V"_L:2O\*_"_P ,=1\6:]XH
M^&6F^%;KPKKEAK(L&G\16[PK#"9C!9Q,LL:# DADB7 .Z*1F$D?Q+^R+X6T[
MPI^Q7^TY\$-:\*6?AOQ/X-T/5M3O-?\ !M[/I&G^*H3>:JD%\([:59+2Z$]E
M,CHSL[Q1PYDD3Y$^F/C'XKUWPC_P1,N-7\+W=[::Q9_"JUFM[NQ)^TVR_P!G
MQ>9-$5!.](][*0"<J,5K-?Q+.Z2I^2:DJB5^W+:6ZO=MM)ID.4U7@II\S<_-
MJSI;6WYDXVL[6BDM&CJX?^":?A9O#E\;OQAX^U+QM<:E9:K:^.;J>P;Q!I<U
MC')%9>01:"UV0Q2S($DMW6032F42M([-4U__ ()7^ -4\'Z7I.GZ[XW\.O#9
M:CI>M:AI=];I>^+;+4;@W6H6]^\D#@BXG+2-) L,L9=A%)$&(/R/XZ\$>'?#
M'[9.F?"'POI6D)^S1X@\1>$AXFTBWC5M$N+V[TS7)C;RQ[3$RW<L&C/,A^69
MYD+AC.V[F/"MEX?^(Z^/-'^(DPG^''PV\)>.-4^&$M[,XCTX66OW4"WUFQ *
MSV4*6D=O,AWQ1R?(<.22H^366OQ/17^&G>6G=QTY?M1^+0JE3;47%K7DM9_S
MSDH6\HM-W7P-^ZKW/O\ \9?L8S?$J2:'4/%^OZ#;>&]4MM1\ 7.BKIZWO@DQ
M6;6CBU,ED8VCDCDD0Q7277#O\Y#(D7/^(_\ @E3\-M9\+Z7HMC?^+- TR+1Y
M/#NO0Z?>09\::;+.]S-:ZD\L,CN)+B6:5I(3#-F>4"0+(ZGA?CO!>_&+P=^R
M/X<^*MC#>^'/'5[&GC?2]0@$ECJM\- N9X;2[C92CQM=*6\MP%:2*,8/ KX\
MT/4V^(WPB^*UWX\GFN;+X7?##6-8^#=_=2/+<630Z_KEO:ZE8NRES=)!!HT2
M3+E_+E1<D3-NUG3E3J24G=Q;VU;Y8N[7=M+;[2;;9EA;5Z4'#W;J%KZ6YYKE
M7I%ZW^RUIJ?I#9?\$_O!NG?'>/QK#J/B2.PAU@>)HO":SP#0(]:%M]E&IB/R
M?/\ .\GY=GG^1N_>>5YO[RF?%_\ X)^>$OC1\6]4\4:AK?BVSL_%-M96GBKP
M]:7-O_9/BR*S=GM4NUD@>=5C+MQ;30B0,5E$B\5\??#2:>^^)6A?$'6(8X_V
M@;KXZ0^$KZ8L1?QZ*;-7DTWH&^Q#3\WGD_ZOS?WOW_FKI/BQ\7/&'[*/[;7[
M3'C7P?>Z!?6.F6O@O4=9T+7?MVH7NLI-]KMS:Z:XN0MG(Q*^6HBEC:3CRE,C
M/413Y8-OM;YQ@UZKEFE?IRV2LDS*K5C=KEZ?AS3B[>?-%OSYN9V;9[Y<?\$K
MOAYK5EK.B:YJ_C+Q'X"U&34Y]/\ !FH7EN='\.S:E%<17DEFT<"78+I=7(59
M;B5(O.;RECXQPVJ_\$4O#>L_$.P\7S_&W]H"3Q99'1UEU-]:TN3[?%I-PUQ8
M136[Z>;9A%(P^<0B1L-N<F68R<YXV_X*G^-OAGX+;XGW6F>#_$?P[U*?Q/I]
MMX:TNUN8O$FA7&BVU_.6N[@S21RK)]@99(UMH6MVGC&Z;J? M*_:&UCP%_P4
M^\41Z_J/P7^)&K_$-?AE+?VRW5W]FTZUN-2OUCNM/L;BXN<W%NTE@1)&\,6Z
M2.Y\M7D\MKPL*DJE-1=G>-N][VC\]W>^V[-\2XK#5)U?A49.W1J\5/T5VKJV
MLE>U]3ZL\??\$]8X/!FO?#6)OB1X\TCXH>-/^$XU;Q'JNIZ596_A6<7=O+<1
M1-9I;79,L2ND:+#,I&Y9)8U;YO;/VL_V3;/]K'X3:=X/D\7>+O ECIFKZ?K,
M5SX9%@MPTMC.EQ;1G[9:W,8C6>*&3"H"3$H)VEE;XX^"OQQU[]B]/&NO1:[X
M=L?@W'\;/$FD^*[C6;&]U?5+%YE3['+'>/?)MC-R(K<J\4S9EC5=H^[[O^T3
M\7_B'\*_V+?A]K7CK0/AIXQ\2ZUXJ\,Z?XFM;G39['2[%+[5K:$26]K)+<LU
MQ;/+"5WS@;XS*"-JQG'"ISIT73TO[*WDY1AR+M[JY=>UK^5*ZKS75.HO6TI*
M3UUO)INW=Z=S@/C#_P $P;WX<:4OB/P[X[_:#^(>MVWC#4?%]OH=G/X1@CGU
M'4K:2SN))VN;*U'V00RRJR1S"15D8QAG"%>J7_@DCX=\=?"_P]IGB;Q?XYTN
M]_X5OH_P^\26WAS48;*UUB'3SYL,GF&%KB)XYGF*M#-'N60APV!CSNZ_X*+?
M'"7Q5=PS^'?@[+I\_C?Q7X!M='-Q?EYYM-TBXO[6XDOC\H1VMGCEC%HQQ*"K
M?(0W.:E_P4P^)/PI^$^M7]LWP5\,>'?#7PK\$^/]+M9M!NK6TT^WU&:2VO+!
MB+]4VH("8'54$8959)-NXU03='3X6J;7E%PGRKT4.9VUMY-)&56WM')[Q4T_
M.U6"EZOVO+O;77579[CK'[#+_!+]FKXA_#C0'^)?Q:3XR:K?W%U=:YJVEP_\
M(U<7<)!NY+F-;6X\E'CB(:,7-R'"L!]YA[3XF_93\)^-/V6G^$&IP7DOA&;1
MH]$E6*Z>.Y:)%4!_-!W>9E0VXDY;DYR:^5[#]O#XY>)_AAXS^)T=Y\%=%^'W
MPU\?W&AZY#:Z9?Z_-=Z!!/;";4X;W[;9Q1-'!+)*P,$J[4+#.W:]G]O'Q'XD
M^,__  2 ^+'BGQ)K&DS0:BLNM>%YM!@O=$5-*6\1K W)^UR-.9(@DDG*12++
MM,( .8BN:FI/1-0]>7E7)_Y+)N.VTDVFK(;BG[O1S]'+F?/_ .315_5-+77L
M_C'^PA'>_"_6? HMO'_Q(U[XJ7%I_;_Q#U35=-L;O1EL9(FM9I&M1:LC0IO-
MNEE:$&0$RE/,:4^V?'O]E?PY\?O@M:^"+FXU?PW9Z1<65[HM_H4Z6U]H5U92
M)):SVS.CQAHVC7"R(Z,,JR,I(/R[XH_;P^+GP:^+&MQ>+]=^$O\ PK;X;Z_I
M<'C'Q#9>&+]!%IFJ0,UL49M29+>:VE$2SNWG*T5W%,$BP8V]4\?_ +4'C_X)
M?L9^%/%7BF;P9_PG/C36-+T>WN9-)N=,T;16U2[CAMWNK=KJ:4^2DJ[U$Z>;
M(NT-"'RM+FDER[N4;6T?,^7D[)/56>EN^@1<+7>BY7OJN77G^6GO*VS6FIS7
MA_\ X([^&O"?Q!M/$^F?%[XZVFK+X@O_ !1?R'7+&9=5U&]M#9W$[+)9-]G)
M@9U L_LX7<" #''LWH_^"67AK3/$+>)M(^('Q'\/_$'^V;K5XO%^G#1X]2B%
MS##!-:^0=/:QD@:*VMU;S+9Y&,*.TC2#?7R!^QY^T7?_  F^,OBCPS#_ ,*B
M^(6IQ?&#QG+J.K7&K3&XT?5+?PZ)XGM1=33O913>5=Q.\MR_DQAX5W("R^G^
M/_\ @I]\;=-_X17P)X7\&:5XE^+^O7MY%=6B>'H[*/3OLUC9W?V:2WO=;M8&
MDE%W\DEOJ5POEQF14EP\:%[0IRAUA!JRVC))V76T;6:MM;3WK-4K.<U:S4II
MWZN+DFWTO+??5O=\MSVOQ=_P2C\*>+_C!+XV?X@?%.SUB36;7Q &MK^P!BOH
M=+ETOSDF:S:X&^WE;*>;L1P'B6(EMTL?_!++PUIGB%O$VD?$#XC^'_B#_;-U
MJ\7B_3AH\>I1"YAA@FM?(.GM8R0-%;6ZMYEL\C&%':1I!OKQ+Q+_ ,%4OBUH
M'QW\'Z9)X<^'L&CZS,F@ZYHID>6?PWK1\.S:NT%QK7VM+/*R1JA2"WGC$)$K
MW,;,(@SQ_P#\%/OC;IO_  BO@3POX,TKQ+\7]>O;R*ZM$\/1V4>G?9K&SNS;
M26][K=K TDHN_DDM]2N%\N,R*DN'C0]Z&W3MKIIM;>-E%Z77+9=;&\N9N//U
MC=7[:[WV=W)6=GS7?2Y^@F@Z5_8>BVMF;J[O3;1+&;BZ??-.0.7<@ %CU. !
MSP .*Y;]H+X#:!^TQ\)-5\&>)DNCI>J>5)YMI-Y-S9SPRI-!<0O@[)8I8XY$
M;!PR#((XKD+C]H[QSHOP9\$:\_P1\<^*O$7B+3H[C6=%\+:SX?F_X1VY,:-)
M#)/>ZE:PS*'9T5X'D!\LDX!&>%_:H_;8^(7P?_83\??%/3?A/>^#/$?@]5DB
MT?X@ZKIZ1SP;HQ)<[])NKY"H5VPC21LS1G)12&*G!\SB^CZ/K>VC]>J]=D33
ME91DNNO_  Z_1ZD'QF_X)7Z-^T1X8TVQ\<?%;XM^)+ZRT?6- N-4N9=&2YU"
MRU*%(IHWCCTY;>)D6.,I+;PQ2Y4AW<.X:S9?\$QM,T+PCXS\-Z-\6/B[H?A;
MQU97,&HZ-:7&DFU2ZN81%<7\)DT]Y(YI!N9HP_V<O([^0&.:\_E_;N^*=M\>
MK[X,S:E\+(?&6HZ];6.B^,?[%O'T"&&XTVXU!+6:R^W"2:^5;<IL6[B#K*DP
M50/*/SW\;_VH/$-W\2=0^+T_A3PKKGB[2/@1XZL]8T+5-2NI?"VLII.OV5K-
M)% _F+Y$Z).ZJ%#2J\<<DA"AUJ-)U9>R>TE+TMR2J-?>M>S?-K8JC-SY.5O2
M4;>3E-03^[9]ERNU['V_^S#^P!9_LQ?$V_\ $T7Q,^)/C)M0\+:9X1DT[Q -
M'^Q)9Z>'%JRBTT^WD\Q?.GR2Y#>>V5.$V<IXB_X)1:+K/P#UKX6V?Q:^,.A_
M#W4'A_LS0[&XT?R?#,,=PMP+>SDETYY3$750%N7G**NV,H,U!\-?VBOBQ\=?
M'7BZU\":K\&?#7AGP3J)\)3:;K.FWMQJ5G>-IT,]M?9ANHHVA>6>%%LMD;/%
MEUN@<1UJ_L+_ +3WQ!_:7UPIK>I^"2O@S3#I'CFPT[P[=6L]KXH6YF26V@F>
M^E6.&**)&\MXY'=;B&02*'V"I\\Y<TGJTG\G[R;^]>G.EI=HPIN"I^[MM\U[
MMEZ6>G:+>R3?"?&'_@DG]J\,>.-:L?C!\>]9\1:SXEB^(*VUB?"D=S=ZQ:6/
MV6WCA\_2XX%5HHX8]LK*A,:EG&79N'_91_X(_77Q!_8'\!^&_BSXG^+WA/QO
MIOA&Q\,26AU#0+F;PG!;S6\T]K8O#;7%NT%Q/9V\A>9IYMB1IOC ,8R/@!\0
M]6^"_P 8)_#7AWPQX,\2V>K_ !D\>_8=0\4:I<W.H:7J-OI+SP""9TE>-' F
MBDFW.T<3&-8V#?+5LO\ @JW\>=5^ \7C5++X.VW]J?!:X^+MK:?V;J-Q]C-E
M,BW%@[?:T\_STD79,!%]G;.Y+@5.'FW3C*'VXTY_X;4I-6]*<9)]XQ27Q6>M
MG5G*%KN,Y0]7[112?DY--=%*3N]+KZPT[]@K0O!'C^\\3P>(OB!KFE#5#XL/
M@DW.G_V1>:ZHW'4$!@CE2XDD'F>7]I2U\YC)Y2M\PY'P;_P3RT+XK>$O'VL>
M(-)\4_#C7OB+XJM?&-BEKJMO+K'@VYM4C:W:)T-Q:)*+C[5</&GG6[/>3 ^:
M'8MX9K_[9OQ+\5?'?2;?0S\,?AFE]\:['P]KUW;:;-J+Z_IA\*+JT,MY.)[4
M^9Y06,Y!"!(QN=(R)?TBI\DZ<4WIM;RTIS35MG\"75*"2M:P35FD]>9<W>Z;
MG'6^^O,_/F;=[L\"O/V"DF^(&C>,H/BO\5+#QQ9Z>FD:QX@MI-(6Y\5V"2F5
M+6\B-@;9$5F<JUI#;R)YDA5U+$GWN&/R8E0%B% 4%F+$X]2>33J*SN[<O3^O
MPZVVU?=AN^9[_P!+\DEZ)+H@HHHI %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5'>6D6H6DD$\4<\$R&.2.10R2*1@@@\$$=JDHHWT8'E_
M@O\ 8E^#WP[^$VN> ]%^%W@*P\$^)KF:[U?04T*V.G:I)+(9',\!0I(-QX#
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M-42.-%:21@D:!I';+GLZ*.9W;[_YW_%ZON[7V0-)I)]/\K?@M%V6VYXA<_\
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MR2GJM+.?*FUV;6G;GBDU_BBJC>ZC>%[ZW^W?#/\ P5MT?XK?$V'PS\-O@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_LO6-+U_QO8>'/$-SK5CJ.GO;6-R;A4N[%9(8TND=[:0+.KF$A2RF3&*]?\
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M23Q_JF@2Q:KXAUFR_M)9=5NHV:YN9H(I81*OFR/B-)(UVJJJ54"OFN7_ ()
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M'9O6_@DMEET_F2(#[6L08RQA<EU!^7/"O_!$+Q9J/PE3P%X\^+O@SQ3X1M?
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M+:JYG,1\P1[/FKC?%G_!6#X*/\.AJ-A\1[7PT^L^&7\2Z-JOB'PEJR:>UO\
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ME6ZQQCR]D*HK1$QL&0E2[KVW-;W>:+MO[JE%M=-TFM6[W,Y1;H\J?O<LE?\
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MBI>JBO[NOF[K[M+I/H[/E>STZ2MWT\E9[K3[5GOM=75[KY=_9K^/?CW]G/\
MX)V^.?VG_']AXJ\9Z]+I$VL7GA?3_'DFK:;/#;RR;KN!+Z"W33F";A)!;!HS
M';JRH\KE3V'BW_@JOXO^'WQ<L_ &K_!.27Q9JVL:%:6(TSQ;!/IR6&L?:EM+
MNXGE@ADCD5[*X26"*&;:5!620,#77_'S_@GU%H/_  31^(_P)^"=G#:?\);H
ME[I&F0>+?%VJWEI8&[3RY'^TW'VVX1$5F=8D786R/DWLXO>!_P#@F#\,9/!'
MA1O$?AS5X?%&C:A8>([B>R\?Z]<M%JMM$4B"WCW$4\]M!OD6&&55A1'(6&,,
M5K:/)?R3A]UUS6^2:6ME=+W=+*I?V7N_&^?7SLN1O3O>^SZMNUI<=XF_X*A^
M*O!OA>/Q7<?""+6_!5Q?ZIX;@NM!\6Q3ZE+KFG+=B>#[-<V]M$MH\UE<QQ7)
MN [81GMX@_'*>*?^"TNH_#7P5H%]XI^$LUCJ_P 1/#ND^(? FG:7K%WK;ZRM
M\\41@NEM-/>X@EADF0LMM!>%HSN0,V8Q[?\ %O\ 8)\(R67CKQ+X+\,63?$#
MQ%97\EC!J?B+4;;04U.ZMI('O?LJ^?;6UPZR,LEU#:&9E9P2VX@\?^RU_P $
MK/ O@C]D?0_!?Q"\*V.H>)I=!TS2M=N+3Q5JVI)!+8!?).FW<[17%C&DJ>=&
MEJMN(I&)4!AN.4-;N73D_'GYDGY>[K9:67+>\B:U^9*GL^;\''EOZQ;5NK3=
MTK(\WT__ (*]_%#X@Z!XFLM"_9SUGPMXI\.>"+_QA,WCK5Y] T^2.UN6MW^S
MQR6)U"2-MADB,]E;&08#"+)(Z;P!_P %"OBUX>\$>&+?QM\._AZ-=\3_  ^L
M_$GARY@\=W6SQ7J<DEI UB5_LA%MG+W<+$@R8\Y B. [1^S>%O\ @G?\*O"7
MQ!NO%,6F^*M1UW4/#K^%+VXUCQIK>K"_TU\[H9X[J[D28G/^LD5I/]KBL_3_
M -C>QMOB!\--*C\+^&;/X=?!64:GX3N)M6N]5UJ6]:SGM"L@N(\Q)&D[,)#<
MSO*VW(CV99T^6[YNO^=3;M92IM=W%IZ6"2DY<RV5]/E3M_Y,II]HRNM4>K>/
M/'UW\./@WJ_B;4-/LWOM$T>74KFQBU.*&W:6*$R-$MW<^3&J;@5$LOEJ!\S!
M!G'QQ\-/^"R7B7XAZII/A^/X-0R>*M5\=GP(6L_%A;0[:X?1UU:"<W5S96]R
M\4D)<;HK-U_<NRM(K1>9]46'[->CZE\(O%W@GQ3<:CXO\/\ C6:_.HVNI:A>
M7*_9KO(>UC>>>69(@K'"K*%0L1&(D"1IYG/_ ,$E/@=<>)=.UG^Q_',>K:5J
M4.LP7D/Q'\213M?16:64=U(ZWX,LPM4$/F2%F*%P2=[94;<[<MFE9+H[IR_"
M\?Q-ER*'*]US:]]+1_'WG]VO3YI_;7_X*5>.OCC_ ,$]?B')\.M%O? WC30?
MAW+XN\3WUEXMCMKOPD/M%[;QQV4ILY/MCO-IUR&.+4^3\R2)*54>Z?\ !1?Q
MC\38/A#\)="\!VMA>+X]\1V.B:U-/XVO_"UY)%);R.(HKVSM+BXA\PHVZ>)D
MDCV+M#;SMUW_ ."-W[.UQX-M_#]SX)U>_P!(AL[G39(+WQCK=W]NM+B5IY+:
MZ:2\9KJ 3,TR13ETBE9I(U1R6KT/XJ_L-_#7XQ^&O NC:II.LZ=I/PTGBN/#
M5EX>\2ZGX>@TMX4$<)5+"X@#^6@VH'#! S!<!FRY\DHJ-K>_&3_PJ5VONLDG
MOK=]YYI<METC-+_%**2?_@2;OTOHM#Y!\,?MQ^._&G['=IX0_L[7/"M]JOP_
M\;&'QC#XV76==TS4_#EVUE("\NFPI/YOR2+<E4;[P,08!SZ-_P $V/'/BSQ#
M^TKXYL]?\:>*?$^GR?#+P#K5I9ZK>":#3)[JUU!;DP@*.96@61W<O([$[G("
M*OH>N_\ !)#]GWQ--=27_@2>YEN)=7FBD?Q%JF_3&U;G4?L3?:<V0G.XL+;R
MP#)*0!YC[NN_9Y_8,^&G[+/CK4/$G@RP\46NL:II%GH-S+J7C'6=8CDLK,;;
M6+RKVZFC7R@6"L%##>_/SMG2G4BG4E+>:7G9IU'U_P 45?1VCKKOE6A=05/:
M/-Y:.5.WW*#^;['GNF_\%#O$$O@G7/'EW\,HXOA<'FL_#VMP>)X9+[4[U-13
M38K>ZLWB06GGW#_NW2:X 1291"V$/-/_ ,%*/B3H'[2V@?"77_@[X5T[Q=K%
MU<V,LEMX^FNM/27^RKO4;&2&4Z8CR03"RGAE9XXI('3(BF4@GV"Q_P"">GPB
ML#XQB7PM<RZ7X]>YEUG19];U"?1));@LUQ-#ISSFTM9I&9F>6WBC=F9F+$DF
MJH_X)O\ PA;P]H>GRZ'X@NW\.ZPNO66I77B[6+C6/M8@>W!EU"2Z:[GC\B1X
M3#+*\1B8QE"GRUC]FSWM;Y]_5=.CT3BM6])7Z=W^6FE]+O?5VZ-GB7PH_P""
MN'C'XQZ7.^D? ;4S=Z=\/=,^(5[$/$:W0GM[S[0GV:R2VMIKFYE26WD0 P1E
M_+<A?]6):WQ6_P""SEYX$MO#ECX>^%5]\2/%>H65WJFIZ5X.N-5U];6VM9TM
MID@>QTJ>3[29RZ)%?16*9C/FRP,0M>P_!K_@E)\!?V>M8U"\\%>";GPZ-4T>
M+0;JTM/$6J"PDLXYC.B?9#<F .)B\GF",2%Y96+9E<MJ-_P3?^$>W0Y(](\3
MVVJ>'[JXO+;6K;QIK<&MS/<%#.MSJ*78N[J.3RHMT5Q+)&PB0%2%7&EX>T32
M]W6Z^<K+Y+EUWT:ZW*J\MW[/RM?_  J]_-ROUTNNUGI_'+]I;6_!EUX.T#P3
MX3LO$OCOQW:W.H:9I&OZO)X?MHK:VCB>X:XG6VN9(W7SXD$:P.2[@-L4,P^8
MM0^,GQ"_;U_:N^%&CV":U\/_ (?W_A+4?$=X=(\?76D:YIFJ6.I6]I,)(;>S
M>WO5AFWP"":9K::.:21E#1QJWUU\;OV5? _[0OAW1=-\2Z9?A/#<XN-(N](U
MB]T34-*<(8R;>\LIH;B$-&2C!) &4E6!!Q6)H/["7PS\*_&KPY\0-+TK7=,\
M2>$](.A:4+/Q1JL&G6UB>6@-@ER+.168*[;X6+.B.Q+HK I.,:RJ2V3;_P#)
M9*/W2<7\KIWT,*L9RI<D79M*[\^:+?WQ37SLTT<CXO\ VZ=7T#XC^/1I_@.+
M5/AQ\);E['QGXB;Q EOJ&FS)IL>HO)!8-#MN+=(9HE9S<1R;W(2)U4M7G'Q4
M_P""K'C'X#V=N/%GP1=[W7AI-[H$>A>,+>]@N=/U"_@L%ENI)H+<V\\4UU;"
M2&);A?WZE)7579/H#7?V*_AOXC^,]_X^N=$OAXAUB&.#55@UN_M]-UL1ILB:
M]T^.9;.[=$PJO/"[*%4 C:,</J/_  2B^!NJ_#F7PI-X=\3G1)+RTO(XT\<:
M\DUE]DD\VU@MIUO!-;VL,N)([6%T@1U5EC#*I$4K*4?:;>[?_P!NMZZ-::*\
M;_:6\^5OW?ZVM\_B3=[;.RLXOCY_^"F/B;1M.QK'PQTK2+W3?$NK^'-:N)_%
M4@T6QDL_)^S[-0-B(_,NA<1%$NEM4 68>:615DX7X#_\%._C-XV\=V_A2]^$
M/AG5]7\7^,/%VB>'=0M_&@M=(M(]$FEB,5XQLC<H6,8 >*"?<'WD*?W2^WV/
M_!+'X+6%MKL7]C^,;F+Q/?RZEJZW?C_Q!=#4I)2AG27S+UM\$WE1B6 _N91&
M@=&"@#4T'_@F[\'O"WQRTWXC:9X=UG3O%>D:C?:M:2VOBG5H;.&XO26NV^QK
M<BU*RLS,R&(H6=FVY8DE.UH\^_+9^MHZKYIVVLM-=2)W<&H[\UU_A]_3[G%/
MTOO8\)T7_@L;K5GX5\(ZOXD^%.GZ;;>*[;7[55T[Q<;YX-8TO78=&%F/,LH
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M=:/X3N/B%+\/'UB^\20&^6<Z.-5MKM;.*.1&@EBX(-PKQ[XR58EUCN?M*_\
M!3+Q#\!_BM\5-#L?A--K&B_!KP[IOC#Q#JUYXEALGO-(NC="6:PMXX9VFEB^
MR2XBG:WWF-_F4>69.O3_ ()7_!>+X@_\)1'I/C:+6#XJ_P"$VW1_$+Q$EO\
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M88U+/(['@* "2:3T7,]MRDFY<BW[=33HKPWXY?\ !1GX4_LZ?$/0O"OB>_\
M&7]N^)M*DUO2[?2/ FO:VMY9QX\V59+*SFCQ&&4R L#&'0N%#*32^('_  5
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M\I\\EKO9*IIUL.G.4)WD[N+2^<>1._JZ=[;)WMIH\#]H[]EC4? O_!)'P_\
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M&M9U7XJ^'= T#P#X:U.[\=VD>M0ZGKFK1S*^IK+-%$(3*$@\KR[Z\BSYSO\
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MVESJWQ.\3ZSHMYJ$D#)Y5U;W>HRV\D\D>[RS/$P+1+M82+'7TI5U:SJI2?\
M>^]R<FODY67]VQE3I\GNWZ+\$HW^=KO?6ZZ!1116)J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<I\=?A?\ \+N^"OBWP;_;&J>'_P#A*M'N])_M339/
M+O-/\^%HO.A;M(F[<I]0*ZNFS3);PM)(RHB LS,<!0.I)J*L(S@X3V:L_0NG
M.4)J<-T[H^9?^"2'_!.#_AUA^Q_9_"G_ (3[5_B)]FU*ZU'^T;VU^QQP^<P/
MDP6_F2^3$,;MOF-EWD;C=@?3E<S\+/C1X/\ CGX>EU?P3XL\->,=*@N)+.2]
MT/4X-0MXYXSAXC)"S*'4\%<Y'<5TU;U:DYRYI[Z?EI^!C3A&"Y8]W]]]?Q/R
MS_X+L_'KX?\ B+]IO]G_ ,*WWB;0&/PN\9KXD\8VUE\7- \':UI-K)82)'&A
MN-8L+Z*=UN(I5,>T&(Y#\A6^/IK;X9_%2\_::T:P^+/PV\$VWB/QQX<\?_#_
M %/QQ\=O#^O)K$NC)&C6=_<KK5]? SD2%'E#A$V$E2HCK]FOVMOVV;3]G#QU
MX!\!:)H3^,_BE\4[FZMO#'A\7RV,,BVT)FN+J[N2DAM[6)0NZ18I6RZA8W)Q
M6MIW[5$/@#5[#1_B\/!_POUG51:V^F-<>+()M.\07LOFF2UT^:=+::X>(1KN
M#01N?,!"8P3G0O37/#O>_P#>O!JW?EE"-MU>Z=]4.O%3:4^RT_N^^G?MS*<K
M[:6:MHSX^^.7_!:CX7_'+]C_ .)&DQZS\-='U[4_#E[HL&D7/QA\$R76I75Q
M#Y"O:NFKFW^S*9&=GN)8)=L?RPLS!:\4_8#_ &N?V;_^"=W_  3OT7QU:ZE\
M+M?_ &AO#?A*Q\.ZKHNI_'+0M1U748K=HQ+#873:I>06]G_K)H[:%HU.W'DH
MS 5^G6E?MM_!G7K/PK/8?%SX87L/CNZDL?#4D'BFQD3Q%<1N(WALR)2+B17(
M4K%N(8X(S7FO[%O_  4R\*?M/^#O$,_B>X\(?#SQ-X<US7]+GT.?Q3#=326F
MD736]QJ*F2.!_LX(#,QC"QAAN:K@W"53E5FTF_2%[_\ I;YEV=]+7+EK&$9Z
MI2T7=RVO_P""]'W6]]#Y!_X+,?\ !0KX2?M ?#3X/:;\._B+\)O'%UH'Q%T/
MQIJHL?BKX0LQI]KI]PLLL3&]U6WWS.&(01[DRC;G3Y2?EOP?\8O .@?MECXC
M:1XC^#_A>.Z_:%G\:_;(_BUX'2YM/#UWHWV2X<K%K!X:ZQ++"I+2!58J[  ?
ML=JG_!2W]G'0[2WGO?C_ /!.S@N[:.\@DG\<Z7&D\$A98Y5)G 9&*L PX)4X
M/%=J_P"TW\-X_B;9^"F^(/@A?&6HV7]IVF@G7;7^T[JTVE_M$=MO\UHMH+;P
MI7 )S2I/V=[=6W^--M?^48I];<W>XIR=2FH/^6WRM-)_^57;SY?G^8G_  3S
M_;4^#O['/P=US6-5\5? C7?CM)>QZ3XE\0K\;O#=K;?$>!M3=QJV5OG'F16]
MQ(Y^U017&(E@0LFS'KGQ@_X*Z? _]K/]AOX[>&]>\7?!+2_$$T&N^%](\.7?
MQ3\,WJ^)XO*9+.]BEENX[=8YP\;[967RV5E+$KD_:_PL_:R^%GQSU:"P\$_$
MOX?^,;ZZM'U"&VT/Q%::A+-;)*87G589&)C656C+@8#@J3D8K@_VY_VV9OV1
MH?".G:3X>TOQ+XK\<W-W;Z/9:MK;:)8W+6MJ]U)$;L6]QBX>.,K#%Y9,K\91
M0S+EB8JI2=*KM)..FF]EI;3I+2UDV]-%;2C)TZO/#XE+F?RN[._3;?6R6N]_
MR"_9>T'X%0ZAH1^)'CCX"6YO/@#HG@*74K+XJ>#6U/PWJ]E/+%>*LK7DJDS6
MTB[2BS0S1JT,^U6*'[+^%_[6_P"S=XB_X)D7GPK\1?%[]G;P.^JQ7MI_PC_A
M?XB>&M*:SM);UY(_W4=W<6$<QB8/+;H\MHSF2,9B;:/T+\/^+=6\5?">RURV
MT";3M<U'2DOHM$U>X%M);7#Q!Q:W$D:RB,JYV.RJ^W!(#8P?@S5/^"VOQ$T+
M]F*Q^)=_\#_!5A!9_$>7X;>*],G^)=Q]H\)7JWL=FDLI71B)8R[%V\L96,Q,
M-^]O+ZZ\IUZLZ$DN:3U]95'L]K<U3E\DXW[OGHN-.G"O'96:?^&FMU_AIWVW
M3MU1\2?'S5_A%XS\!^!=1TKQ#^RG#<Q_#GQWX&O/#VB^/O!^F'3O[19IM(DN
M(FU(VJ .&:2.UFFCAGG8Q 1DE:GC'4_AWX[\'VCS?$OX 0^(-<^#7A/X?:3>
MR_%CPH;OX>:_IDLLCZO)(NHDK'#N!C>R>:9FXV*I+#]G]>_:PTGX1:MXJO/B
MGK'PW^&W@O3-3M]+T37=4\8)!_;$KP))(LJ7,$$<#JSA%5)I]^&)V$;:X76?
M^"EOA?X>?MC>._AOXYE\)>!_"/@WPCI/BV/QKJWBF*VL;M+^YEMDAD6:...%
MO,B(5O/</O3 !.!G"H^=./5W7R52?R=JLG_-M:S14XIQOM;]94H];WLZ<%U6
M_->[/RL_;UU?X-^,O@E^T-X;\%^,_P!GOQUK?Q(TV&>'Q!J?Q,\&C6-1U4ZG
M!,OEWTNH1226L444D@6\19+4LL5L\L1VQT?VS/BAX'^*/B/Q/K)\9_ SQ_K5
MUXS\$^)= U)/BSX-CNM)T+3X[7[=H(-UJD921)X9I2B,;:5I=XDW<#]IO'G[
M:WPG^'GA_P 57U]\1/!+/X+T,>(]7M(M>M&N;.P9-T5P\?F92.3@([85RR@$
MYKYY_P"";'_!8JT_X*"^*=<AE\/?#_PMH>FZ#'XBMK[3_BIH_B"[>VD\ML76
MGP;+JQ>)9-LWGQJD<BE%>08<JE*2?+'>%I:]+/F7E]AKNTFMF[E2W)>6TKKN
MVY**?F]T]=$WS;V:_+_P=XH^'^M?L&3_  JO]0_9PL$U#Q3X\U6SM=6^+WA&
M2+PXE]!)+HTD5M!JDMF#YSQQ&3;++:F)C$J!Q.OK'[)_Q-^ .H?'OQIXB^,'
MB#X)Z@E]\)_"%B+S4/BOX0NSKWB32K:476\1ZLS23LTD40FN $=8I%9Q&PW_
M *6?$;_@HUHVB_&_X :'X,@\+?$3P5\=]5U+2(/%6C>*$FBT^:TM);G=&D4,
ML5RC>2Z,1/&48#AN<5-%_P""END>+/\ @I%IGP%T"U\)>)M,U'PWJ&LR^)-&
M\5I>S:9>6,\4-QI]U9I 5BD!F0\W!8<Y1>,BBY+V26LE;S_=PDF_)J+O?JU'
M?1.I.WORV3OY/VE12MYWE&UNBYO4_'_]B^P\*:)X>_9VT;XC?'[X=^%_#?@3
M0+FS^P^'?BO\/Y+KP=K<>M7%['?F:XFNBMO<6\D<32Z<XNE"&-E,;L*^\_V(
M?VMOV;/V>/VH?BGJB?%[]G72-"\5A+]_$-]\0_#<VMZQ>RW,T\D3W=O>&6\M
M8EE"QM>PQSPD-&KS1;67[ZU/]HKX?Z)\1;SP?>>.O!UIXMT_3FUBZT2;6K9-
M1MK)02UT]N7\Q80 <R%=O'6OGG]D#_@JO9?M;_"7XJ_$S3?"-O\ \*M^'XO6
MTO6M'\1VVM7NO?8VN!<12642A[2;;!'+&A:198KN!P^2RK4L0WS5>B4Y/TE+
M5_?HO2VNHO8W?(EK)P27FE[J2]-_O\S\WO%'Q?\ AMJ?[6/B[QVGBG]G>TTK
MQ9H7Q!\/Z_:V'Q?\+W4GBI+ORSHTEU)=:EYMRLH5MJ7#A+4L(UB@B4$^3_"S
MQ)I/@;X9RZ!I7Q"^"GAZVU#X3^"M&\1V9^,?A 0>)]0TC4M^IZ=(8M6;=)<V
M),$<L@\IH_W3O&G3]M/V8OVV'^./PSMO&FMV'@K1O!=[I4VMQ>)M$\9Q:UHD
M%NK1[8[BY:"W\FX".S2(5,:;"%EDPVWJ!^W9\$&\.Z)K ^,GPJ.D^)HKN;1[
MW_A++#[/JL=H"UT]O)YNV580"9"A(C .[%3!2HQC#^5+?^[[2UUZSDVGH[+2
MRU?M/;MU%KS-OKU]F]'OHH15T[V;UOJOSU_X);_M=_ /]G;Q=^T]_;_C_P"
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M #5=!\%_$[P^W@[Q+J?B?QV]UX1^*_B*\GN[W2O[+::RNM1\/RRSL$/FA93
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MMGP_'#P+!X=TC1_V=?B)X^M[+X;:;IUK#;6VEMI>G2C4M9T>)4 M4DO$VK+
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M#\>S^)8?A#XGT_0)+;4;T:/9:ZTED]K%>1QR_8ERAF($X,<KPQGYWBCV]O\
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MW:-A+# 6)8Q[AL$2<\4Y0<MK)O[FE^;UVM9FC5O/6*MUU4G^4=]=6CT;2/\
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MM=MV\=N?,SMQ,ZQ\_,P&36=:4HTY2@KM)ETXJ4U%[,Y+]E_]KC3?VK;*\O\
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M7I\0/ ^D:[%8:OI4>L6<5XMEJMF]G?6@D0-Y<\+_ #1R+G#(W*D$5KU^=/\
MP49^"=O\6/\ @HG!HX^&.H_%NY\3?!_4;6'2I-;@BM-(NEU2T6VU%8;VX2"$
MPNX9IK=3<+A61)&50/*[S_@F%\7O$7P^^,ECJO@_Q;J'B*?Q3X?OK?6[_6]%
MU2Z\::3#8VEOK%OIPU">\@M?M5Q!-+]GO8(H)8W@CD 4%8L(?O(^U2LG>WRJ
M.F_6UN9^6UVG:MI.GOR__(1FOOYK+IHV[*U_UJK.\3:W<Z#8PRVND:CK4DMU
M!;M#9/ CPI)(J/.QFDC7RXU8NX5BY5#L1VPI_([XA_\ !,+QIH]FVCZ-\#_C
M/X]\,R?"/Q%X?TV#Q7XK\*N=&UB]OH;K3HEL8+^WT^U%I)'*R-:0[(E^S;'8
MQ*L6OJ'[(7Q=L?C1:7VG_LT_$J/0[N_^'VN:BL'BWPY%!>ZAIAG&M3WT7]L#
M[;++#/''OF60RO;AB1LC<ZPIQE**YMW'?SFXZ^2C'F?DU9ZW(K3Y*<IQ3=E+
M3KI&+5O5RLO.,K[6/UKJ*]M%O[.6!S($F0QL8Y&C< C!VLI#*?0@@CL:_%?]
MH;_@EQ\:H?@!:^%? W[.;RZAX>LO'7A2*^TGQKI?A^:73M2UN/4-)>T,5RAD
MM(E)W6UP\&!YZF,@JLWJ&O\ [''Q%T;XF^*/$?A3]EOQGI;I\4O"/C#PYY>N
M>&(YK&VMX[<:Y-%_Q-BL,UR()EE8$/<_:$\PL-Y10I0J.,6]).SOT3DHW?\
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MC@," RL 0>H(!%6Z** "BBB@ HHHH *Y7Q_\%_#_ ,4=?T+4=<AU&\?P[/\
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MS^TU\?WUGXC^,]*\&:%IGBSP)X6L[AIKK41!+--:OH4%S$%MX[AQ'(J."$+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^L];)]'JO1[,TZM=4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_BUIN@PZ%K?AGPQ?^(Y-*EL89XI=/N(+&*:XA0N_GI*8Q#F9PS*P&>_M/\
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MFN712[[5:0JFXA0 :Z:#0[*VUB?4([.UCO[J-(9[E8E$TR)N**SXR0NYL G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9;X^<(T:58[?@Y$.&)C:J.57VO57]'S*2M]SZ6MI?5J\1_=P<4_BT[M;7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>item5colorcharta02.jpg
<TEXT>
begin 644 item5colorcharta02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" *S!.$# 2(  A$! Q$!_\0
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M4\>_^ >B_P#ROKO:* ."_P"%0^(/^BJ>/?\ P#T7_P"5]'_"H?$'_15/'O\
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MJ>/?_ /1?_E?1_PJ'Q!_T53Q[_X!Z+_\KZ[VB@#@O^%0^(/^BJ>/?_ /1?\
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MHO\ \KZ[VB@#@O\ A4/B#_HJGCW_ , ]%_\ E?1_PJ'Q!_T53Q[_ . >B_\
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M4\>_^ >B_P#ROKO:* ."_P"%0^(/^BJ>/?\ P#T7_P"5]'_"H?$'_15/'O\
MX!Z+_P#*^N]HH X+_A4/B#_HJGCW_P  ]%_^5]'_  J'Q!_T53Q[_P" >B__
M "OKO:* ."_X5#X@_P"BJ>/?_ /1?_E?1_PJ'Q!_T53Q[_X!Z+_\KZ[VB@#@
MO^%0^(/^BJ>/?_ /1?\ Y7T?\*A\0?\ 15/'O_@'HO\ \KZ[VB@#@O\ A4/B
M#_HJGCW_ , ]%_\ E?1_PJ'Q!_T53Q[_ . >B_\ ROKO:* ."_X5#X@_Z*IX
M]_\  /1?_E?1_P *A\0?]%4\>_\ @'HO_P KZ[VB@#@O^%0^(/\ HJGCW_P#
MT7_Y7T?\*A\0?]%4\>_^ >B__*^N]HH X+_A4/B#_HJGCW_P#T7_ .5]'_"H
M?$'_ $53Q[_X!Z+_ /*^N]HH X+_ (5#X@_Z*IX]_P# /1?_ )7T?\*A\0?]
M%4\>_P#@'HO_ ,KZ[VB@#@O^%0^(/^BJ>/?_  #T7_Y7T?\ "H?$'_15/'O_
M (!Z+_\ *^N]HH X+_A4/B#_ **IX]_\ ]%_^5]'_"H?$'_15/'O_@'HO_RO
MKO:* ."_X5#X@_Z*IX]_\ ]%_P#E?1_PJ'Q!_P!%4\>_^ >B_P#ROKO:* ."
M_P"%0^(/^BJ>/?\ P#T7_P"5]'_"H?$'_15/'O\ X!Z+_P#*^N]HH X+_A4/
MB#_HJGCW_P  ]%_^5]'_  J'Q!_T53Q[_P" >B__ "OKO:* ."_X5#X@_P"B
MJ>/?_ /1?_E?1_PJ'Q!_T53Q[_X!Z+_\KZ[VB@#@O^%0^(/^BJ>/?_ /1?\
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MHO\ \KZ[VB@#@O\ A4/B#_HJGCW_ , ]%_\ E?1_PJ'Q!_T53Q[_ . >B_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**3YO:FA<T /HIH;+4=/FH =13=NZG \4 <'\7_^2A?"O_L:)_\ TRZI7>5P
M?Q?_ .2A?"O_ +&B?_TRZI7>4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !134Z
MT(M  E.-0M*L0^9E7\<5X'^T/_P4U^"'[+\UQ;>*/'^C)JUJ61],L&.H7RN/
MX&BA#&,DC&9-HSU-;8?"UJ\N2C%R?9*Y<*<I.T4?0&,GI3J_*GXL_P#!S?H=
ME+<0^!_AGJNI+TAN];U*.SQ_M&&)9=P]O,4GU[5\O_%G_@X&_:$^(S2)I.I>
M'?!5NQVA=)TM)9 I]7N3*=WNH7VQ7UF#X"S>O:\%!?WG^BNSOIY77GTL?OD7
M51RRBJ>I:_9Z3$KW5W;VL;-M#R2*BDX)QDD<X!/X5_,[XU_X*#_''XB,W]K?
M%GQ])')PT,.M3VT3# ',<;*AZ=Q[]Z\IUWQ)J/BJ_P#M6J7]YJ%TW6:ZG:20
M_P# FYKZ##^%V(?\:LEZ)O\ -H[(Y'+[4C^IO4_C=X-T:X:&\\5^'+691N*3
M:E"C >N"V<5C6/[6/POU*Z6&V^(W@6XF?.V.+7K5V;&3P!)['\J_EQHKN7A;
M'K7?_@/_  33^Q%_,?U5:9\9_".N3&*S\4>'KN55W%8-1AD8#UP&/J/SKH+3
M4H;VW66*>&6.095D<,I'J#7\FM:7AKQEJ_@ZY\[2=5U+2I>I>SN9(&'!'5&!
MZ$_F:SJ>%LK>Y7^^/_!)_L/M+\#^L 2*?[M+G/2OYC/!O_!0'XX^ [B-M-^+
M?Q!A6/[L4FN7$T /7_5R,R?F*]X^&7_!P%^T7X "KJ6L>'O%\:* %UC2(U./
M]ZV,)S[L3^->/B/#3,H?PY1E\VOTM^)SRR:JOA:9^_0+"@EOI7Y+_!W_ (.<
M(S/#;^/?AC+''@>;>:#J(D/OMMYE7Z\S9KZ\^!__  6>_9X^.$<,5OX\L_#N
MH3 9L_$*-IK1D] 99/W))]%D:OF,=PSF>$UJT7;NM5^%SCJ8&M#='U<%Q169
MH?B.Q\4:7#?:;?6NH6=TN^&XMY5ECD4]"K+D,*T4->%)-.S1RN+6XZBFY8FG
M4$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )7T?\*A\0?]%4\>_P#@'HO_ ,KZ .]HK@O^%0^(/^BJ>/?_  #T7_Y7T?\
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M'HO_ ,KZ .]HK@O^%0^(/^BJ>/?_  #T7_Y7T?\ "H?$'_15/'O_ (!Z+_\
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M3Q[_ . >B_\ ROH [VBN"_X5#X@_Z*IX]_\  /1?_E?1_P *A\0?]%4\>_\
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MG_@)HO\ \KZ5?A#X@ _Y*IX^_P# /1?_ )7UPF)WU%<%_P *A\0?]%4\>_\
M@'HO_P KZ/\ A4/B#_HJGCW_ , ]%_\ E?0!WM%<%_PJ'Q!_T53Q[_X!Z+_\
MKZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\ 15/'O_@'HO\ \KZ/^%0^
M(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/
M?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\ *^C_ (5#X@_Z*IX]_P#
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M[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7T =[17!?\
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M%_PJ'Q!_T53Q[_X!Z+_\KZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\
M15/'O_@'HO\ \KZ/^%0^(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@
M'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\
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ME3Z** .#^+__ "4+X5_]C1/_ .F75*[RN#^+_P#R4+X5_P#8T3_^F75*[R@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .#^+__ "4+X5_]C1/_ .F75*[RN#^+
M_P#R4+X5_P#8T3_^F75*[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***;_RTH =FF\$T[H*Y_P"('C_1_A3X0U+Q#X@U
M*UTG1=(@:YO+RY?RXK>-1DDD_P#ZR3@9)Q2C%R:45JQI-NR+7BCQ3I_@K0;S
M5M6O+73=-T^)KBYN;F58H8(U&6=F)PJ@ DDU^(?_  5K_P""RNH_M77M_P"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,\(#SEN:;_P58_X*G:U^WAX^;0]#FNM+^&.BW!.G6)RCZJZDK]KN!W/4HG\
M/]XL:^1-*TRYUW4K>RL[>XNKN[D2&""%#)+,[':JHH!)8G   .2<#J*_;.#>
M#HX."Q^/2YK72>T5_G^1]+E^7JFO:5=_R$T^PN-5OX;6UAFN+JXD6*&&%&DD
ME=L!551RS$G  Y)('>OVC_X)!_\ !&.'X"0:?\3/BKIT-SXX;%QI&C2XDA\/
MCJLLG9KGH0!Q'[ORNG_P2#_X(XVO[,UC8?$GXE6<5Y\1+B/SK'37 DA\.JPX
M/<-<XZL"0F2J\Y8_HH!E>M>#QEQJ\2W@L"[0VE)=?)>7Y^AS9AF3E^[I/3JQ
MRKM7\*<.E X%%?F)X84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 UQ4<@\U<=NAJ:BC8#\ZO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HQS110!Y]^T;^S?X0_:K^%]_X0\;:1!J^CWPR
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MO*A65I1W_P _0^5J4G3ERR)**:KXIU<YF%%%% !1110 4444 %%%% !1110
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MPK_[&B?_ -,NJ5WE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'\XO[0'P&\3?LR?%S6O!/BZP:QUO0YS%(H;,=PG5)8VXW1NI#*V.A&>:]/\
M^"<7[>NN?L"_'NW\16GG7WAO5-MKXBTI#M%]; \.@.!YT>24)(ZE2=KFOT_B
MWAVGF^$6,PMG-*Z:^TNU_P CV\PPJKP]I'?IZ']*'0>]/)Q7,_"_XG:)\9?A
M]I/BCP[J,.JZ'KMLEU974)^66-AD>X(Y!!P5((."#725^"2@XRY9;H^6DFG9
MCJ***1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_ /1?\ Y7UWM% '!?\ "H?$'_15/'O_ (!Z+_\ *^C_ (5#X@_Z*IX]_P#
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M% '!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7UWM% '!?\
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M3Q[_ . >B_\ ROKO:* ."_X5#X@_Z*IX]_\  /1?_E?1_P *A\0?]%4\>_\
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M )7T?\*A\0?]%4\>_P#@'HO_ ,KZ[VB@#@O^%0^(/^BJ>/?_  #T7_Y7T?\
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M_P"5]=[10!P7_"H?$'_15/'O_@'HO_ROH_X5#X@_Z*IX]_\  /1?_E?7>T4
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MB@ HHHH **** .#^+_\ R4+X5_\ 8T3_ /IEU2N\K@_B_P#\E"^%?_8T3_\
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MV?,WON+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 <'\7_ /DH7PK_ .QHG_\
M3+JE=Y7!_%__ )*%\*_^QHG_ /3+JE=Y0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%-^Y0 H.:\B_;+_ &P_"7[$OP6OO&7BNZVQQ9AL;&-P+C4[D@E((AZG!)/1
M5!8\ U>_:K_:H\(_L>_!_4O&GC*_6ST^R79! I#7&H3D$I!"F<L[8/'0 %B0
MJDC^>7]NC]N3Q=^WA\9IO%7B:3[+86VZ#1]'BDS;Z3;YR$7^\[8!>0CYF'90
MJK]=PIPK4S2LISTI1W??R1Z. P+K2YI?"MS(_;#_ &O?%W[:WQHU#QGXMNOW
MTV8K"R1C]GTFV!)2",>@');JS$D\FL[]F#]F+Q9^US\8M-\$^#=/:\U34&W2
MRMD6^GP X>>9\'9&N>3W)4*"S 5G_ +X"^*OVF?BKI/@OP;IDFJ:YJ\FV-!E
M8X4'WI9'.0D:#EF/0<=2 ?Z%_P#@G=_P3X\+_L _!Z/1]+6/4/$FI*LNNZTT
M>V749@#A5[I"F2$3MR3EF8G]2XBXAPV1X183"I<]K*/9=W_6I[F+Q4,-#DAO
MT-G]A7]A_P *_L(_!6U\*^'8?M-]-MFU?59(PMQJESC!D;^Z@R0B X5?5BS-
M[@B_+0IPM*#Q7X'B,1.M5=6J[R>K9\I4FYRYI;@,&EHHK,D**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK@_B_P#\E"^%?_8T3_\ IEU2N\H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T9P* $)R*
M\V_:>_:@\(_LD?"#4?&GC/4EL=)T\;8XU&ZXOIR"4@A3.7D?' Z  L2%!83_
M +27[1OA7]E3X2:MXV\9:DNGZ-I29X^::[E/W(8DR-TC'@+T[D@ D?SV?\%
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M\2Y)/+,;*@_A>L7W7^:ZG@8["NA4Y>G0DHI =PI:\$XPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIC<=^E"
M<=J 'T5'3D&&I70#J*;MW4X=*8'!_%__ )*%\*_^QHG_ /3+JE=Y7!_%_P#Y
M*%\*_P#L:)__ $RZI7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4'FBFM@T  &%KA/V@_V@O"O[
M,'PJU3QGXQU./2]#TF,L[GF29S]R*->KR.<!5'))],D7_C'\7_#WP$^'&K>+
MO%6J6^CZ#HD)GNKF8G:BCHH Y9F)"JJ@LS$  DXK^?'_ (*7?\%(O$?_  4"
M^*YN)/M6E>!]&D9-"T4OPHZ?:9AG:UPX/)&0B_(/XF;Z?ACAFMFU>RTIKXI?
MHO,[L%@Y5Y7?P]3+_P""AW_!0[Q9_P % /BRVJ:HTFF^&-+D==$T19,Q6,9.
M-[GH\SC&Y^G0#"@"O%_AO\.-<^+OCK2?#/AG3;K6->UJ=;:RL[=0TEPYSQUP
MJ\9))  !).!D0^ _ >L?$[QGIOA[P]IMUK&MZO<+:V=E;(7EN)&/  Q^.3@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBC+R3.S;515&268X &"23CDU^V7_  2K_P""-$W[-?AG3_'WBS7=7T7XG:A
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M%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\ 15/'O_@'HO\ \KZ/^%0^(/\
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MW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\
MY7T =[17!?\ "H?$'_15/'O_ (!Z+_\ *^C_ (5#X@_Z*IX]_P# /1?_ )7T
M =[17!?\*A\0?]%4\>_^ >B__*^C_A4/B#_HJGCW_P  ]%_^5] '>T5P7_"H
M?$'_ $53Q[_X!Z+_ /*^C_A4/B#_ **IX]_\ ]%_^5] '>T5P7_"H?$'_15/
M'O\ X!Z+_P#*^C_A4/B#_HJGCW_P#T7_ .5] '>T5P7_  J'Q!_T53Q[_P"
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MR\^&/P\U!X_A_IDVS4]1@?'_  D<R-T4CK;(PX[2,-W0)7YY(C2.JJ-S,0
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MX"_X+*_\%6H?V1?"4_P_\#WT<WQ*UR#$UQ&P8>';=QCS6[>>P_U:'[HP[<;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
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M /R4+X5_]C1/_P"F75*[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P G^9CFF"Y9>UAMU/IX'-%-0X%.K\V/%"BBB@ HHHH **** "BBB@ HHHH
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MAEEF<\DLQ)))SDDDDU?^'OP]UOXJ^---\.^&]+O-:UK5)EM[2SM(S)-,Y/0
M#IP22>% )/ )K]/_ -E7_@VOOK[[/J7Q@\7)9Q_*QT7P\0\I[XDN9%VJ?X2J
M1L#G(?I7Z1?LW_L5_##]DO2?LO@'P;I&@R,FR6\$9FOK@=<27$A:5AD [2Q
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MP,:%/VE3XCJOV1/V3?%7[:/QNTWP1X3M=US=?O;R\D0_9]+M@5$EQ+CHJY
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MT&%_N,D37$R_\"<[/S2LCX,_\%$/B7H7Q/T^XUG7)M=TR[N(XKNTG@B565F
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M>78#D7M:BUZ%SPYX>OO%NOV6EZ79W.H:CJ4Z6MK:V\9DFN97.U411DLS$@
M$DGUP:_?;_@D3_P2[L?V%_AO_;WB*&UO/B;XCMU_M*X&)%TN$X86<+<C .#(
MRGYW Y*JM>4_\$3O^"4'_#/^BV?Q8^(FG[?'&J0;M&TVXC^;0H'',CJ>EQ(I
MQ@\QJ=N=S,!^DR<_E7B<<<7?6IO!81_NUN_YGV]/S.;,LP<W[.F].H ]/UIU
M%%?FYXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2?5:CV.!7Y>?\%X_^"8!^(NBW?QL\!Z<6\0:7"#XFL+=,MJ-L@P+M0.3+&H
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M_3+JE=Y7!_%__DH7PK_[&B?_ -,NJ5WE !1110 4444 %%%% !1110 4444
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MU"^\,W39(@<FZM<_1CO&?9R!Z5\Q?%C_ ()T?$[X8F26/1TUZSC)_?Z9)YS
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MAO\ @<8V?FE>F>*?^"@7PA_:I^&6H>"_B?X8U"VT?68?*NTDC%U!&>SHZ?O
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M%9>Y_P"%0^(/^BJ>/?\ P#T7_P"5]+\7_P#DH7PK_P"QHG_],NJ5WE '!?\
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MR_ NK+FE\)R_Q1^*'B#XT?$'5O%7BC5+C6O$&MW!NKR\G8;Y7.!CH JC  4
M*JJ . *]T_X)E_\ !.K7/^"@'QD6QW76E^"=%99=?U>-<-$A^[;P[@09Y.<9
M!"C+$' 5N#_8R_9 \5?ML_''3?!?A>':TQ\[4-0D0M#I5JI >>0^V<*N069E
M4'G(_HP_98_9A\+_ +(?P7TGP3X1LQ:Z9IJ?O)FPT][.V/,GE;^*1SSGH!A0
M JJ!^A<7\3T\KPZP6#MSM67]U=_\CULPQBH1]G#?\C-^''[+<OPC\#:7X;\-
M^/\ QEH^B:-;K:6=G;V6C"."-1@ 9L"3ZDDDL2222:Z _"'Q!M_Y*IX]_P#
M/1?_ )7UWBFG5^$RJ2G)SD[MZGRTI-N[."_X5#X@_P"BJ>/?_ /1?_E?1_PJ
M'Q!_T53Q[_X!Z+_\KZ[VB@1P7_"H?$'_ $53Q[_X!Z+_ /*^C_A4/B#_ **I
MX]_\ ]%_^5]=[10!P7_"H?$'_15/'O\ X!Z+_P#*^C_A4/B#_HJGCW_P#T7_
M .5]=[10!P7_  J'Q!_T53Q[_P" >B__ "OH_P"%0^(/^BJ>/?\ P#T7_P"5
M]=[10!P7_"H?$'_15/'O_@'HO_ROH_X5#X@_Z*IX]_\  /1?_E?7>T4 <%_P
MJ'Q!_P!%4\>_^ >B_P#ROH_X5#X@_P"BJ>/?_ /1?_E?7>T4 <%_PJ'Q!_T5
M3Q[_ . >B_\ ROH_X5#X@_Z*IX]_\ ]%_P#E?7>T4 <%_P *A\0?]%4\>_\
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M[_X!Z+_\KZ[VB@#@O^%0^(/^BJ>/?_ /1?\ Y7T?\*A\0?\ 15/'O_@'HO\
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ME2H+#\]R-IYSGOFO0H5,GSN*J<L:BCW6J^^S1_56.PD<WP#@I.G*2W35XO\
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M?;9V=U=,#C$,;/\ R%>E>._VE/@?\#%=;K5/#]Q>1#'V>PC&H7 /H2F[8?\
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M% '!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7UWM% '!?\
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MV/O^"*_P9_9--OJ4VDGQQXHA*N-5UZ-)E@<=##;X\J/!P0V&<?WZ^P%^[1C
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MV-X3M_\ 5F^G_P!R#'_H1%>+B/%'A2C\6/I?*2?Y,ZX\/YE/:A+_ ,!9ZT*
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M047[$.AC_6:IJS?[KQK_ .R&KMM^QEX5@VF234IL#G=.!GW.%%;1\$?$BO\
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M0QDC!FDP0H.0H#,00N&_H#)<IPG#V =>NU>UY2\^R_0^LP]&&#I<T_O/4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVK:]KMP+:SMH^,L>2S'HJJH+,QX55)R #7[QPCPS3RG#_7<9;VC5VW]E=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 44W[]"?>H =132#G\:.J
M4 .HIOETX'B@#@_B_P#\E"^%?_8T3_\ IEU2N\K@_B__ ,E"^%?_ &-$_P#Z
M9=4KO* "BBB@ HHHH **** "BBH9G$89BVU5ZGTH H^)/$=EX1T"\U34KNWT
M_3]/A>YNKFXE$<5O&@+.[L3A54 DDG  K\"?^"NG_!4.^_;H^)+>'_#=Q<6O
MPS\.W!^P0G,;:Q.,J;R5>#C&1&K?=4Y.&9@OJ'_!;#_@K"W[0VOW7PI^'>H_
M\4+I<^W6M2MY,+K]PA_U2,.MO&<'/ D< C*JI;\YE7)7CGV')_SP,5^S<"\(
M>Q2Q^-C[S^%/HN_K^1]%E^"C2A[:MZHM^'O#]]XKUZRTO2[.XU#4M1G2VM;6
M",R37$KG:J*H&2S$@ 8))/KS7[X?\$B/^"75G^PS\./^$B\26]O=_$WQ) HO
MYP1(NDP'#"TB;IUP9&'WF& 2%4GY'_X)5_!WX8_L1Z+%\3_B5?0ZM\2KZ$G2
M-#M(OM4F@PL#EG(_=I=.#@AF!C7Y>&+@?0WQ5_X*\:]K"R6_A'P_;:3%R%N;
M]_.F([$(I"J?J7%>EQ%@\[SRI]1RVDU27Q2E[J?HW:Z]+W]#\MXV\;.%\I<J
M-7%1E);QC[SNNFETOFT??UQJ$-C'NED6-1U)8# KQWXK?M\?#3X31R1W'B"W
MU*^CR!:Z>?M,A8<%25^53_OLM?FE\3/VB/&WQ?D?_A(_$NIZA#)]ZW,@BM_^
M_2 )_P".YKC%0RL%568GA0 3D^GUIY?X.T</'VV<8A16[2T7_@3_ ,C^:\^^
MDSB:\W0X?PM[[2EJ_E%?YL^ROBK_ ,%>M6U420>$?#L%A'G"W6HR>9(1_P!<
MD(52/=V'M7S;\3OVEO'GQ@,G_"0>)]3O87X:V63R;<CWBCVJ<>I!/O5+PU\$
M_$7BC:T>GR6L+?\ +6Z/E+^ .6/X#'O7H/AK]E>TMMLFK:A-<MU,5N/+3_OH
MY)_ "OE.)/&SPBX#C*-7$0J58_9A^\G==+ZI/YI'FY;P)XO<?24G"<*4NLOW
M<+>FEUYV9XF!O^7;N.<8'<_2NJ\+?!3Q%XK=6CL6M86_Y;77[M,>P()/X U]
M">&_ &B^$@O]GZ;;V[J,>8%W2?BQRWZUNV5A-J<ZQV\,UQ(>B1H68_@!7\J\
M;?M"LPQ#>&X,RVRV4ZEV_E&.B^]G[SP;]!O"4[5^*L:Y/=QAHO\ P)W?X'F'
M@K]EWP_IH6;7[K4M5D(!-O:.MI$I[@N5=W!]@A]Q7KW@S7-/^&,:_P#")^&_
M#GA^9<A;N*T^T7>#US-,9&_ $"MK0/@'XN\3*K6^AWD<;'[TX$.!Z_.0?RKM
MM _8N\07Y4WU]86*GL@:9A_(?K7\[YQXG>.7&LFI5*T82Z17LXV[)V7YL_I/
MASPK\,^%DOJF'IN:^U+WY?C>WX'F^O?$SQ#XD)^VZUJ4RL.4,Q6,_P# %('Z
M5AU],:!^Q1HMFRMJ&I7]ZR_>5 L*-^A;\FKM-#_9U\'^']ODZ):R,O1ILS'/
MK\Y->-AOH]\<9O-5LWQ"BWNY3E)_A=?B?:5..LFPD>3!TFUY)17^?X'QS8:7
M=:I.([6WN+B3LD49=C^ !KK- ^ 'B[Q"JM;Z)=1JW5I\0@?@Y!_(5]D6&BVF
MG6PCAMX847HJ1A5'X5;4!/05^@9/]$_+H6EF6+E/RBDOSN>'BO$S%2TP])1]
M6W^5CY<T#]B_Q%?LOVV^L+%?]C=,P_#"C]:[+1/V(])MMK:AJU]=MQN$:K"I
M/_CQ_6O<AS2=NE?J64^ /!N!L_JW/)=9-O\ #;\#YW%<;9O7T]KRKR27X[_B
M<!H?[,G@W1-K+I$=PR_Q7#M)G\"<?I77:/X3TW0H/+L[&UMD4<+%$J@#Z"M0
M'--)Y_\ KU^DY;PGDV 7+@\-"'I%+]#Y_$9AB:[O6J2EZML8(]@^Z/P%/'/]
MVG45[T:<8JT4<8FP4F,?-3J*T ;]X?\ UZ F13J* $V_+BEHHH **** "BBB
M@ HQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6CP".UM;>!%Z+'&%'Y"N1_X5#X@;_FJGCS_P#T7_ .5]!^$'B'_HJGCS_P
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M%_PJ'Q!_T53Q[_X!Z+_\KZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\
M15/'O_@'HO\ \KZ/^%0^(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@
M'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\
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M3Q[_ . >B_\ ROH_X5#X@_Z*IX]_\ ]%_P#E?0!WM%<%_P *A\0?]%4\>_\
M@'HO_P KZ/\ A4/B#_HJGCW_ , ]%_\ E?0!WM%<%_PJ'Q!_T53Q[_X!Z+_\
MKZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\ 15/'O_@'HO\ \KZ/^%0^
M(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/
M?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\ *^C_ (5#X@_Z*IX]_P#
M/1?_ )7T =[17!?\*A\0?]%4\>_^ >B__*^C_A4/B#_HJGCW_P  ]%_^5] '
M>T5P7_"H?$'_ $53Q[_X!Z+_ /*^C_A4/B#_ **IX]_\ ]%_^5] '>T5P7_"
MH?$'_15/'O\ X!Z+_P#*^C_A4/B#_HJGCW_P#T7_ .5] '>T5P7_  J'Q!_T
M53Q[_P" >B__ "OH_P"%0^(/^BJ>/?\ P#T7_P"5] '>T5P7_"H?$'_15/'O
M_@'HO_ROH_X5#X@_Z*IX]_\  /1?_E?0!WM%<%_PJ'Q!_P!%4\>_^ >B_P#R
MOH_X5#X@_P"BJ>/?_ /1?_E?0!WM%<%_PJ'Q!_T53Q[_ . >B_\ ROH_X5#X
M@_Z*IX]_\ ]%_P#E?0!WM%<%_P *A\0?]%4\>_\ @'HO_P KZ/\ A4/B#_HJ
MGCW_ , ]%_\ E?0!WM%<%_PJ'Q!_T53Q[_X!Z+_\KZ/^%0^(/^BJ>/?_  #T
M7_Y7T =[17!?\*A\0?\ 15/'O_@'HO\ \KZ/^%0^(/\ HJGCW_P#T7_Y7T =
M[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7T =[17!?\
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M%_PJ'Q!_T53Q[_X!Z+_\KZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\
M15/'O_@'HO\ \KZ/^%0^(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@
M'HO_ ,KZ/^%0^(/^BJ>/?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\
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M3Q[_ . >B_\ ROH_X5#X@_Z*IX]_\ ]%_P#E?0!WM%<%_P *A\0?]%4\>_\
M@'HO_P KZ/\ A4/B#_HJGCW_ , ]%_\ E?0!WM%<%_PJ'Q!_T53Q[_X!Z+_\
MKZ/^%0^(/^BJ>/?_  #T7_Y7T =[17!?\*A\0?\ 15/'O_@'HO\ \KZ/^%0^
M(/\ HJGCW_P#T7_Y7T =[17!?\*A\0?]%4\>_P#@'HO_ ,KZ/^%0^(/^BJ>/
M?_ /1?\ Y7T =[17!?\ "H?$'_15/'O_ (!Z+_\ *^C_ (5#X@_Z*IX]_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#@_B__P E"^%?_8T3_P#IEU2N\K@_B_\ \E"^
M%?\ V-$__IEU2N\H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X/XO_\ )0OA7_V-$_\ Z9=4KO*X/XO_ /)0OA7_ -C1/_Z9
M=4KO* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .#^+__ "4+X5_]C1/_ .F75*[RN#^+_P#R4+X5_P#8T3_^F75*[R@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\.S>,&^)GB2
M/5K?PVG@U8+(^'YK2XG;4Y92)?MBW4;((D12(?*,;L6#2;@NU=W244 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\7_
M /DH7PK_ .QHG_\ 3+JE=Y7!_%__ )*%\*_^QHG_ /3+JE=Y0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW\>J6-O=0MYD-P@EC8?Q*PR#^1J@.+^+W_)0OA7_ -C1/_Z9=4KO*X/XO_\
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ML(-1C2.[BAG0.BRK&[H' (R%=AGN>M+5WMTM^.WY!>PX?"'Q !_R53Q]_P"
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M .5]=R9/F_V><F@S$=J8'#?\*A\0?]%4\>_^ >B__*^C_A4/B#_HJGCW_P
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MZ36;#*@W5E_:%M +R%=Z%GM_,51(A) 926'2YV'_  J'Q /^:J>/?_ 31?\
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M#X@_Z*IX]_\  /1?_E?1_P *A\0?]%4\>_\ @'HO_P KZ[VB@#@O^%0^(/\
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M(/\ HJGCW_P#T7_Y7T?\*A\0?]%4\>_^ >B__*^NY\^@39':@#AO^%0^(/\
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M )7T?\*A\0?]%4\>_P#@'HO_ ,KZ[GS" V>V:!-S_.F!PW_"H?$'_15/'O\
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M .5]=R)23T_^M1YC9_3%,#A3\(/$!'_)5/'O_@'HO_ROH'P@\0 ?\E4\>_\
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M//<Z!XWL]3AN?$%N]RI2\$CWD,]O-%<*</#) T("H(TC$<823QG^P5H/Q4^
M%QX%\;>+OB!XSOI-477K7Q9?ZE#;Z_I.IQL&MKVR>UAAM[22W*IL2"!(B%;S
M(Y/-F\P>OWZ^:O?\M C=67D_D^GJ?/GP3_:H^)6G_&#QWX=L]>^,_C[P!'\/
M;[Q'8^+?B#\*[GPG>:#K%M(D8LA*VE:=:7,4L<OFHGV=I%,$NYV4A5\B\/\
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MLLS1I'$BI&B1QPP1Q0Q(H6.-!G/J..M.5M+=E]_4:'449HH&%%%&: "BBC-
M!367"TZB@#F?BT,?#3Q!_P!@ZX_]%M7PK^R7X6\.^,_^#:?PSIOBNWL[KPY<
M?!N4WXND5H4C6QD?>=Q !0J&#;EVE00RD C[^\2:%%XFT*\T^=I(X;Z%X)#'
MC<%92IQD$9Y]#7RE\.?^"/\ X=\&?!7PU\*]:^+?QD\<?"#PO;164'@C69]%
MMM+OK>$$1074MAIMK>7$*G#-%)<-'+M E61<J<>5M3CM>UGZ7_X ]I1EVO\
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MWD!#^3;:;96ELTA.#YLT,DB@;5959U;IOV:/@!HW[*W[/O@WX;^'[K4[S0_
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M^0^BF[?>BJ&.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!%S2\4=*JZIJUMHFGS75W<0VMK;HTDLTKA(XE R69CP !
MR2>!25]@6NB+5%>07'[?OP+M+F2&;XR?"N*6)BCH_BNQ5D8=01YO!]J;_P /
M!?@+_P!%H^%/_A66'_QVNGZI7_D?W,T]C/LSV&BO'O\ AX+\!?\ HM'PI_\
M"LL/_CM'_#P7X"_]%H^%/_A66'_QVE]5K_R/[F'LI]F>PYIN5']WY?TKR#_A
MX'\"0O\ R6GX3_\ A6V'_P =KNU^)FEZMX"O/$>BWECKFGP6DEW#/97*S0W(
M16.$D7(.2I'&>:RJ4JE-7G%I>@.G):M'2_+[4#&>U?"7P6_X*Y^,O$7PC^"O
MQ-^('P?\/^$_A=\<+RPTS3-6T'QK-KM_HEWJ#!;-;^UETRT2.&20^6TL,TVQ
MV3*X)9?NA9L=><^E39K\C'F5[$V::"O^S4;2XK@-?^(OC;3OVA/#?AS3_  U
M/P'J6G7=SJWB_P#MR"'^Q;J/;Y%K]B8&6?S@6/F(0J;?F'-)/6Q3/1>]'6HQ
M-SZTWSL^^,_A3 ER">U)E<?PUX7_ ,% OVO+[]BO]G]?&6F>&;/Q?J<VNZ3H
M-KIEUJK:7!)+?W\%DKO<+!.R*C3ASB)CA2,9KD_!'[>'BJS^/7B#X3_$KP#H
M_@GQ];^$IO&>@S:-XAE\0:%KMC"Z0S 7,EI92QW$4TD8>%H,%'5E=LD+/,K7
M]?P5V'6W];V/J$[6].*7O7C?[ W[0&M?M3?L3?"OXD>(K73;/7/''A>PUN_@
MT^*2*UAFG@21UB21W=8PQ(&YV..I->P"7)/TY]JJ5XOE?H3&5]B2@&HEN,B@
M3@G'X5)1+149N5'=?6@2Y].*=[;@245#YV?RH\["Y_&D!-WH&*B%PI_X#C/M
M2"X .>F>E4(F-)P/2N)\#?M#>$/B5\5/''@G1=7^V>)OAS)90^(K/[+-%_9[
M7EN+BV'F.@CDWQ$-^[9@.AP>*I?L]?$;QM\1O".H7GCWP!_PK?5K75[RSMM.
M.N6^KB[LHY"+>]\V$!4\^,!_*/S)]T\\U/-_F/8]$!&:;\I_NTP2X_Q->/?\
M%!/V@]9_94_8B^*WQ)\.6NEWFO>!?#%]K=A!J$3RVDLT$+2(LJQNCE"RX.UU
M..XHE*RNRHQNTEU/9,+_ +-..*YOX7^++CQK\.- UBZ6!+K5=/M[N58E*QAY
M(U9@H)) R3@$D@=2:W_.P:IZ.QG&2:NB7(H%>)_M1_M<G]G#XH?!GPW_ ,(_
M_;'_  MSQ:WA;[0;[[/_ &3BPNKSS]OEOYW_ !Z[-F4^_G=Q@^SK-G%3S(IZ
M.S[7)3141FW '\O>E:7'X4P\R2BDR?2EI@%%%-8D#M0 [I1T-027*QKN=E4=
M.:9_:4':9/SKDJX[#TY<M2:3\VE^92BVKI%JBJ_]J0?\]%_,4?VI!_ST7\Q4
M?VI@_P#G['_P)![.78L"CO55M2A_Y[)^=*FI0L/]8GYT?VEA+V52/WH?LY;V
M)\J?[M *]?E]<UXO^W=^VYX8_P""?G[-VI?%#Q9H_BCQ!H^EWEG8G3_#MK%=
M:E<S7-PEO$L4<LL2N?,D7(W@XS@$\5E^-_\ @HG\/?!_[*'A'XT6[ZIXB\$^
M-KK1K72Y=)CBEF=M4NH;6!F#R(JA))U\P;MR;7&"PQ79&2DDXZINWS>QE*5M
MSWW*Y[4F5/\ =KP[]N_]O+PG_P $^_@]#XR\6:3XH\01WE[]BM-*\.VT%SJ=
M[(L,MQ(8XYI8D81P032-\X.V,X#-@&_\=/VWO _P"^!GA_QYJ%Q?:UI_C.YL
MM/\ "UAI$ GO_%%[>J&L[2T1V1#),.09'CC5<L[HBLP.9?H5V\SV/(]J"5]J
M\O\ A9^T7=>//#GB&]U[X=?$'X=7WAL"6XTSQ';V32W$10NLD%Q97-S9S [6
M!5)RZ,!YBH&3=X+X,_X+->&-<^"'A7XK:_\ "/XT>"/@_P"+(HKF'QQJUIH]
MWI>FP3*QBGO(=/U*YO;:%F54,KVXC1I$\QHU)8.^M@W5S[*XSVH)4>E>9_M.
M?M/^'?V5O@'JWQ$UR'4-6TG31;)#9Z2D4UYJDUQ/';V\%LLCI&\DLLL:H&=5
M);D@9-6?V:OVD/#O[4_[/?A;XE>'?M=OH/BS3TU&"*_5(KJRSD/#.JLR)-$R
MNCA68!D8!B.:7,M?(%J>AY'MQ2XKY8N/^"I>C7WA?4/&7A_X4_&+QC\)M+N&
M2?X@:)IVGS:/);QL$N+RWMGO4U2[M8FWDRVUE*)%B=X?-3#-]#_#;XF:)\7_
M (?Z-XJ\,ZG:ZUX=\164.HZ;?VS[H;NWE4/'(I]&4@\\U72_]:A?6QOEE7N*
M/E]O6O!_B9^W?I/A7XTZE\-_!O@OQU\7O'/A^TAO]?TKPDNGH/#D,W_'O]KN
MM1N[2U26499(%F:<H/,\ORR'/I/P<^*C?%SP/#K$GASQ1X3NO-DM;K2/$-A]
MCOK*:)RCH=K/%*NX$K-!)+#(N&CD=2&*6NP'845")<#GIQ2F0$]?>F!+QBCK
M41ESW]J57R>J^O%'4"2@8J,2\TGG;3TJ;@2 C/:ES7GOB7X]GPU^T!X<\ MX
M/\=7H\1:==ZB?$EII/F>'M*^S[?W%W=[\132;OW:;3NVMR,5TG@'XE^'_BSX
M.LO$7A;7='\2^']25GM-3TJ]CO+.Z"L58I+&S(P#*P)!."".HIWNK@;U%1^?
M@ ],^O%24P#%%%% "<>U+3&&&_D*@EU*&U0-)(BCJ"30KMV1,ZD8+FD[+OT+
M5%4!X@L\\W$?_?5+_;]E_P _$?YUI[*?9G-]>PW_ #\C]Z+U%4?^$ALO^?B/
M_OJC_A(;+_GXC_[ZH]E/LQ_7L-_S\C]Z+W:FX4_W:IQZU:2-A)HV8^]> _\
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M!NR;[?KH>V=Z,U$9<'WI!)_C5 34"HO-R<=\4>;ENE'6P$O6B@'-% !1110
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MACFAF4I(C@,KJ1@@@]0?0UXF?<:8C-,/]6JPC%7OI>YC7S:=6#@XI;'YE?\
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M"C%<8)%?&UG*4FUL_P V>127+9L^*=(\.Z/^V=_P4,^%OA'XW:7I/CKPG;?
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M\1QSW"%+J635[>YCU"9KA2/.,MPWG%4,F\HI6(JW+Y))^=E;_@EV?O-=7?\
M$^'/VE/C5X]_9]^!/[?OPU\.^/O&EYHOP;\+:5KG@[7KS7+N\\0>')=3M9[B
M>Q;4WD:ZF\IHA+$TTC3)'<*A8HL>.T^*GPC\5?#W]KS]F'POI_QH^-?V3XY6
M.N6GC^:X\5SS'7!:6$-\K6L39@TB1W5HS)ID=JR13.(C&^R5/K^T_P""?7PE
MM/V<_%7PI_X11IO!7CMKF3Q+#<:K>SZAK\MP1YT]WJ#S&\GF<*H,LDQDVHBA
M@JJ!U7B/]FOP7XM^(7@/Q5J&C&XU[X9K=KX;NC=S+_9PNH!;S_(KA)-T0"_O
M0^,9&&YJ^OW?@-Z[>?XVM_F?GW\4_B-XV^ G[+7_  4*\%Z-X^\<W%G\(;#[
M9X-U74M?N[[7-"%[X?AOVC349I7NG6*=W,3R2-(@.-V N.G^/>C^)/V/="_9
MM^)?AOXL?$KQGXO\=?$'0/#?B7^V_$]S?Z5XQL=5++<>5I2R#3[1HEQ/$]C;
M1LJ0-G<&D8^Y_M__ +%,/CS]CO\ :8L_AOX8^U?$KXV^&IK:[0ZAL_MF]CT\
M6=JN9Y!!#B-$3(,:G&6.<M6]\!_^";'PG^#NO^$_$UCX5O8==\)VTBZ/977B
M#4;[1_#,L\86<Z;ITMQ)8V#,-RYM88L([*#M8@K5[=.7\-_O"5N56ZW_ $/D
MWX+:=X@_:J_X)@^*OVFO$GQ6^*'A?XJ7EGKWB>QFTSQGJ&GZ#X+DTZYNEMK#
M^R$G33YX+<6BI,M[!(\Q,WFL2V$N_%_X@?&'XN_"3X)_'+Q9X7^*'BKX3:A\
M*(=:\6>&/A9XQNO"?B'0]:FMH[R34!%'>V;ZA"(U\E+7[0S1L698I2:^J/%?
M_!+;X(^-/$NM7]]X5U4V/B751K>M>'K?Q3J]KX7UJ\W(SS76BQ72Z;<-(\2/
M*9;9O.<%Y-[$L=[X_?L"?#/]I?6KC4/%&G^)H[O4-*&B:@V@^+]8\.KJUB#(
M5MKQ=.NH%NHE\Z;:DX<()I0H4.V5S7?-Z?*P?U^7^1\S>(OBS%^T7^VS^S;H
M^@_$3QUK?PO^)/P?\0ZK)=6>M7FA3:\O_$H-O?2_8S;/#<[)7(>-(GC,KA1'
MDBOGG]D?QKJW[!__  ;2+\7?AS>^*#X\U#1%M;>34-?O=7L],EFUQ[);FUL+
MVX>RMS$)VE*QI''(T8\TL,M7Z?:9^R5\/-$^(G@OQ5I_A>QTW6/AWH=QX:\-
MFR=[6VTC39_(\RVCMHV6#9BVA !0E!'A2H)SC?"C]@WX7?!CPOXI\/Z%X=O/
M^$5\9"X34_#>HZW?ZIX?,=Q)+)/%!IMU/+:6L4C3REH[>*-&W8*D "JE\#C'
MK_F_T8J>DKR\OR/F3]F[X??%[X<?M3_"UO"W@3]IG0_ <T%YI_Q$N?BC\1]*
M\3VE^@LW:TO88UUN_FM[K[8BJRVD<,3+.VY<(FS[]S@5XO\  W]@/X:_L\:_
MI>I>';/Q9<W&@VILM'37_&>M>(K?0XBGED64&H7<\5I^Z_=9@6-O+)3)0E:]
MIJFTUH 4445(QK'*U^:O_!4[4O%Q^.AAU*34$\+-;1?V8JEA:N<?O#QA3('S
MG/S!=O8K7Z5?>-5KC3([P?OHXY/J :^@X7SY91C5C)4E4LFK2\_U/A^/^$*G
M$>5O+X5Y47=.\?+H]M#\.BJ]?\*,^Y_/_P"O7[A?\(]9X_X]X_R%'_".V?\
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M^J75S<&XN#/I?V[[%+'+*S,\+PF-LD%2#BJJ*\W)=K(BFK4U!]&F_35'R_\
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M&J7^DZ@NFZIKL27>AJR275LD<EN97VN[V9@DW)M1D4D'Z.^,_P"P'\-/CO\
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MS110 8HVT44 %%%% !BC'-%% !1110 4444 &VDVBBB@!0N*,9HHH *,444
M%%%% !1110  8HQ110 4444 %%%% !BDV@444 +1110 4 8HHH **** #%&*
M** $V\4;1110 N*3:*** %Q2;1110 NW-&VBB@ Q1C%%% !1110 4444  7%
M &*** "BBB@ HHHH .E&,T44 %%%%  !BC%%%  !B@C-%% !BC%%%  5W48S
M110 8HHHH ,48S110 4444 &.:,8HHH ",T444 &VD"@=J**  H#2@8HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>itemsremoved.jpg
<TEXT>
begin 644 itemsremoved.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ,J G(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8^'?$MKXNTB2YU"]BU2TL%L+:=KB^N)W6&W3Y(8HWD:-47A50 5Z[0 4444
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MPM[+PI(+F_FU&\%G:RK]HC8QK+:(NIF4*K%42YBMF)'FK+C;7NG[1UYH5A\
M_&,OB?4#I7AY=(N1J-V+.*]:& QL'*P2QRI,V"0(VC<.2%V-G! /)?\ @EUK
M.F:_^SA=76D7$5U9RZU.1+$-0:-CY<.=DEYDRK_MPN\)_@=OFKZ/KP;_ ()W
MI\+[+X$RVGPHOO$5]X?AO5FN#K3W@N(Y[BTMKI0L5P%%O&8)H&$,,<<*;B%1
M3N%>\T >-?ML^$/'/Q(^%\7AOP7+X7MX]7N(AJ[ZOK]UH[S6D<T4DMM');V\
MKXGB66%V4QLBR94D]-/]C?X;>(?A)\!=/T+Q+>Z==WEI>7K6L5AJ,^I6VG63
MW4KVEI'<SHDTRPP-''OD7<=G? K@O^"IGP]\(^*OV4=2UGQ/X7C\37?A6[LM
M0TB--"M=7N1<K>V[)"L5P50Q3.B1S+YD8>(L-PX-2?\ !*O4M'UK]B[0K[0;
M)]-T^_U+5;L6JVEG:VL$DFH7#R+:QVCR0+:[V;R@DLGR%=SLVZ@#0\+_ +>'
MAOXC_M5/\-=!FN!<:+J5WH^JO>:7,J7=U';/,%M9MP7"&&X5V=-I:%@IZ$^]
MU\(? SXK:1??\%8/$VAV^F>"HO$?VW4HM3\367A^9;O7+98<VNF-<_8UC6>V
M\J0NQN6,@@< ':1%]WT 9OC"\U'3_"NH3Z1%IT^J16[O:1ZA<M;6LD@'RB65
M4=D3/5@C$#L>E?,W[$7[/'Q)^&'QMUOQ%XOUOPO=1:YIUR=6&E>*+W5Y=:OW
MO1);W,D4]O#%;""U!@40@!@W*C"X^A_C#X-/Q$^%/B/0@D<IU?3I[0))#;RJ
MY=" I2XBEA(.<8DB=/56'%?)?_!-[P]HO@K]HWQMHD-EHFBZWIVGO#-I[V>B
M:;K#0+=;%G>TM-'L+@0/M!60R2PG<,9)#4 ?;%<-^T9X,N_'?PDU*SL;W4+"
MXBVW0DLM7GTJ4B,[RHN(71DR 1RP4Y^8XS7<UR?QJ\?:1\/?A_=W&LR:DEO?
M*UC$NGZ5+JEU))(C86.WCBE:1L G!1EXY&,T >"_\$LOB6WQ/^'GB>\;7+O7
M&BOH8W:34M4U.*W?ROF2.ZNY)89@"#EK2:2/(Y;=7U-7S;^P%X<^&OPBT_4_
M"W@RS^(^E:CJ!_M*ZMO%>C:AI0F"!8]]K;R0PV=O&-R@Q6<<:9()3)S7TE0!
MX-_P4L^(/@CP-^QIXV@\>R3/I.NZ=-IT-C;W$4-UJ<[(62&(R!D+?+N(977:
MK;D<94\]_P $GO .D_#W]EV2TTK5M)U[=JK+<ZCINMP:M#=O!:VUJA\R"VMH
MU*P6\*;%B_@#%F+&M;_@I?\ $[PO\._V;+B'Q=XS\?\ P[TK6KN*V_X2+PE:
MM)>6+HPE5#((I!$LGEE,D#=NV@Y-=E^R5_PCT_@#5+KP[XS\5>/(;W6)YKO4
M]?D9KD7&R-&B5/*A6.-55,+'&JY)/+,Q(!ZE7C_[<_BE_"/[.^H3VUOJMYJ-
MU?6-C8VNEZI=Z7>7EQ-=11QPQ7%JCRQEV8+G 3GYV1-S#V"OG+_@I[=_#GP!
M^S3J/Q!^(GPWT[XE6G@K;+;65V(U2W,LL2M(TLGR0HI",SD'&P8YQ0!T?_!/
MC4]2U7]E30WUC6=4UK58K[5(+MM2DN);RPE34;E&L999P)96M2/LYE8#S/(W
MCAA7M5>2_L/^)/"7BO\ 9JT2[\">&;'PEX2^TW\.FZ?8[#:-&E[.AN(63Y6C
MG8-,K#[PESSG->M4 %%%% !7Q)_P53\$?$;Q#XHT.XT4%M!.C:O9V]QHWAG5
M=1U-9I8(0=+N&L[D?Z-?LH4R&)!#]F!\U6*FOMNOC_\ X*J_&_QS\)M9^%UG
MX(\?:#X+GUB[U%KVWU/5;'2EU.&.&--PN;R-XML)F\PQJRRL0K*'6-T(!]2^
M ;#[!\.-%M9-.32C#IL$36"XVV>(E!A&&887[O#'IU/6OE__ ()CIXO\/ZYX
MJ\.:G/XNU7PAH6FZ=#HNH:Q!JEO%$P>Y1[2)-1M8)G\N-("95\Q")%!8%>?I
M>W\.2^+?A'%I.LW[:A/J.DK:WU[I]R]F;EWA"R2PRQ%7BW$EE9""N01C%?(_
M_!)/Q/X/UO7->TKPOILD-]X+\,:-X=UN>_\ &S^([RUO+=[M7LX0UY<[+*,@
MF.11$LC-)A3M(0 3_@IC?Z;>?M$> =+\92^"7\&36&(K;4KOPY;WK7DM]#&V
M?[7MIV:!D"+BV\MR_!+$IM^A/VM/"6BZ7^Q1X^T(1W6C>'K;PG=V(31[+S7L
M+5;9D A@5XPP1!Q'N52JX) S7@'[;VNZK\9OVE='\&#1/B+;>#]-@B&IW T#
MQ#=:-X@N/M<3BT\NR:&-T6,;VG9Y(R,H0 C@_3_[3E]XCTS]G7QQ=>$-8TGP
M]XHM=#O)]+U/5&C6RT^X2%F2:8R H(U(RQ?Y0 <\4 >$?\$L-!GM?#OCG4[+
M4V'AO4]:22UTC_A"HO#5M:O]BM-ES:10W4R"UGMOL\H7".'DD+A7)4?6%?('
M_!,SX^_&G]H3Q-XIU7QW?>#]6\%6D$=CIM[H6H:=>Q2W4;?>#V<TN)7B8/,K
MG8K-%Y6%+5]?T %%%% !7QO_ ,%9S#I>H_"J]%QX<M[NYU6[TU5F:.WUB\$M
ML=D5I<G3K]HX_,"&4>6BMF(%\[4?[(KXR_X*^:-;>.$^%'ABXMRSZKK5Y=1W
M%D;>+5;9K6T:<&WFN;RSMT0LJ^8KS;G 7:C89D /IOPCX^LA\"="\0K?+/97
M>D6EQ!=_/=+-YL<?EOE41G#%U.0B9SG:O0?*_P#P2B\*Z/K^N^(O$>K^&M-A
M^(5A;6\.I:G'I&D6L:SSF1KH6K6EA:S"%Y$SB=Y7(5,MNW,WUQX!TJ'3_A/H
MMC' EO;P:3! D*1QQK&@A50H6%FC4 <8C9E'\)(P:^:/^"7NJ^,+2[\5^'-8
MO/%FM>&/#NGZ9!HNI:NE_'&I_P!)1[5!?6-I,[1QQP,T@\U6$J L&!! ,K_@
MJ%^T3\7/@+\1/!@^&?B?PU!'J^FWD-SX?O(8YKNYE,UO&MZJ^6SA(4E?:=RQ
M^:T0D#*2*^F_V=_^$Q_X4=X6_P"%@"%?&G]G1?VN(C&<3XYW>7^[WXQN\OY-
MV[;\N*^<_P!N?2-2D_:3\(W2P:OI[#2[F.TUW2M$\5W(C@,]F7L;B71+R(!G
MD!E7[0A0JAQ]U]WU_0 5\S>,/V;?&?B/]NW3/'*Z3\*!X=T2_BN+:\GTX/K]
MU#+8B"X5I=@*O%) C1MN;>L@7]V(3YGTS7YFZAXK\$_$3_@LW9^*]!\6:!K=
ME>ZSIV@SV%CJMO/J]QJ%OIDTL5S %!(TV%?.BF4MO$YFP '(< _3*BBB@ HH
MHH I>(=630]%N+J2WNKM(5RT-M 9Y9!TPJ#ENO2OE?\ X)DZ=XQ\//K^D^+K
M+Q4EUIEM# ;[4+K5DL+YQ+,"UK975K!;6B8V_N[;<JKM'"A2?K6OS;_X(]:K
M\,/"7[37BZWT&\TJT\0^/-#@U2WLXO$%GJ5V4CGG6:"^:.V@D;45>-YI$)F$
M8E?;(0<L ?0W[;'[/O@_X]?M _# :Y\1=*\!^(=$\^YT58_*_MJ_)DB\Q+7[
M2[VI4A55PUI-)AOD:/DGZ>SFOAS_ (*W:-XF\5^)?"UE8_#_ $;XB^%K2V-W
MJ^F:YJ$\NE;O. BDFL(KB$$*ZH#<W DAB$FXJH1VK[2\)>%-/\"^&+#1M)MD
MLM,TN!+6TMT)*P1(,*@R2<   ?2@#1HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^!O\
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MAOGV[2#FO0JQ?B1J=MHOP[UZ\O9HK>SM-.N)IY9;EK5(HUB8LS2J"T8 !)<
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MFO5/V>G\SX!>!V T90WA^P(&D2M+IX_T:/\ X]W;YFA_N$\E=I- '85\F?\
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M?_@CH\OASXB^/_# \'ZYX?M-%LK4P7.KZ38VNI31O++)&+V2WL;>1IV1U?\
M>RSD_.=Q8,S '>?MQ_\ !/34?VB?CYIOC7PYI?PV:^_L/^S;^\\1V<EY*Y@N
M%N+>'R2KPR0R-N20D*Z)NV[F93']>5^;'_!3CX7>&Q^TXNK:SX7^&OA8^(K1
M-*FUS7=0TM+G4H?.M7_M"T$K(T-]"ZI"LLOFC;M&W!P?TGH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /F3]K3]J/Q7\!/VA-(MM*U?1)/"[Z-;W.O65[HUS<?V%&]]
MY*ZB]Q"04C?+1;"'P8]^U55VKV/]I>[\.V/[/OC*;Q=I5YK?A>+2+AM5L;2-
MGGN+8(?,";65@P7)#!E*XW!AC(^-?^"C7Q=\-:U^UEX2TVUU3P;?ZUH7V:SL
M[1KRP82:FU_"[6>LB659$LA#LEC '^N^89=41_I;_@H-K=YX>_9<\176F^#K
M;QGJ:6TRV5O>36D5A93-!*BW%TUS<VZ>0-Q5L2;CY@&,$L !/V%-6\!ZQ\,]
M8D^'W@[6_!FD1ZHL,D&IVYBDU#;96JP7:9DD+1RV@M6!8A^OF*LF\5[;7@G_
M  3R\+KX%^$.M:(^G2Z/?Z;KLJWMA-IVF:?/;2/;V\@\R'3[JYB4LCHX+.'(
M925 VEO>Z /%O^"@^C?V[^RCX@A?3C?P1W6GW-Q*OVLOI,,5];RR:BJVDL5P
M[6BH;D)%(C,8-H/."W]A_4-2U']D_39KNVO+\E[_ .P3W4]X9=>M/M$OV:[(
MOII;B$7$6R01RR-Y8D X4 #@O^"J?QCTOP9\+]!\(ZA=^#[.7QCJ$,UJ_B/7
M(M.M7EL[VSEBC>.6-H[J)YGA26)F3,;L=P&67O/^">V@KH'[+>D!;C0+AKV_
MU&_E_L+4(;S2HI9[V:5X[1H?W:0*SD+&I.P#:69@20#YJ_89U/3-=_;9O]=U
M/2?#&@:WJ5YJNEZ99Z+K'AVZAM8;:.-#:NMO&U^US&L9\UO/,6X=-NU1^@-?
M*W[-'Q'\))^UUXP\*^'/A=\/O TFGZGJ-O->PQ2VNNZHZF.26Y\I+!8##,[[
M@WVQBP )7=E5^J: "OSX_P"">O@;4?A!^VKKES??#WQAI%OXJM=4M$D7PSJ=
MOI7AN5+]=D274TCI<)=6]O%(UP0BYMX54*9&6OT'K\_OV(?VA?V<O#W[4AL_
M!2_$1/'?BF]U/1+C^VX@XM8?M;2Q1NP8DVWFV\Z6W+E,SE]AE9W /T!KE?CK
MJZ>'_@CXQOY(=.N([+0[VX:+4('GM)0EN[%9HT!=XSC#*H+$9 Y-=57,?&K4
M'TGX-^+;J*Z^PR6VBWDJ7)LQ>?9RL#D/Y!R)=N,[,?-C'>@#YR_X)&:-';_!
M;4-4\[5KN[UM-/N99]1N=,N9-OV1/+BBDM+V[<6\:G;%'.ZF-<!5QDGSK]NW
M2=)^+G_!0OP%9Z1XQU7^T] TF&#7M,L+NP5+&UFU#Y'B>YU&V\JZ:6+Y_+AN
M7VP0Y0'RQ)U7_!%VTOO^%,:S=WGC+P#XJ^T?8U"^&=0MK_RR%E=;BYDAMX-D
MTL4D ,3)E/()X+E1Q?[;&BKX _;A:];5+&VT*^M-"U6^M++PSHZZC8/)JAM?
MM%K<7"M/=7$T@59 BAHHU7!9FC6@#ZA_;_BMO^&-OB'<7$6L2?8=%N+B)])B
MA>]@=4.)(_.#1+@$[F<%0A?<"N0>,_X)4_%BW^,W[,#:U9F":RFU,M!=6UE8
MVMM="2TM9V\K['&D,@C:5H6?&?,@D!/RUV?[??A35?&'[(WC2WT37?%/A[4K
M:S%[#=>'9#'J,GDNLIAC98)V'F!=AVQ,<,>V:Q?^"=NMZCXC^#>M7VKVWC*P
MU2Y\0W+7-EXIU"*\U.R;RH (W^SPQV<8VA65+/S(,,&$KN\F #WROE;_ (*P
M^.3X.^#OAJVGUOP!X:TWQ%XAL=)N=1\1ZM-ITKA[F%S:6TD=G<F,SI'(CS_)
MY( <$XROU37@_P#P4>B?3/V5O$&O6W]O&^\/B&[MX]+U06,CD7$+'+/>V2#[
MOW_M"2(-WEDL=C &W^PIJNEZQ^RYX<DT5[2738WO((I;34KC4K:7R[N9&:*Y
MGA@DGC+*2LGEA6&-I9<,?7:\;_X)_?$!OBG^R%X-U]GC=M1@F<LFI:IJ0)%Q
M*O\ K]347;]/^6F0.B,R!&/LE 'QM_P6(UV[T+PW\(YK#6?"6DWMKXTBOH$U
MZYL]/2Z,-O*\BQ7MY$\-NXA\X]4=OX&RI5OIC]G?0Y_#'[/_ (&TVYOM+U2Y
MT_P]86TM[IBHME=NEM&K2P!%5!$Q!*A5"[2, #BOF7_@L=<S6OA#X8_V7XV\
M0^#/$\WB8VNCR:=:27-O+-+;R1+)=(MS;H8HG>-\2M)&3C=#*,X]6_X)M>"=
M7\#_ +&G@Q=9\2W'BN76+7^V;6\F$H9+6Z_?P1XE=Y!B-URI8[22H.U5H ]U
MKYY_;SMM+LF\'ZSK/Q/OOAC8:7-=!KJ?0HM3T.5G$122]:>)[>V:)D!BFE:,
M@O(%8[F%?0U?$O\ P6@\0:GX<\(>!I],E\"F5;B]86OB&W749+Q@L.!!82RI
M!/L4O([RAO+$8"E3)\P!]B^'M;LO$?@VUOK/4K76K&YM1)'?6LR-%>+M_P!8
MCH=N&ZY!QS7Q5_P1A^%FB^';7Q7XMT?0DT"W\7:?IL]O:1Z?J4<=M#^_<1B\
MN;2"*_RSL_GPM,I,C%&$3Q@_8WPJT&V\*_"W1+.#3](TV**QC>2UTBW$5FDC
M+OD\E%5?E+LQ'R@G.<9-?,G_  2R^-?PB^)T7B*R^%7@_P 2^$;>PMHC<6^H
MZNU]##$MU=V\,:I]JG6W;$+/Y8"$)(H(RI50#/\ VN?V?-0^/OQ_-[>?&/X5
MZ$-*\BPT6QN;*X?5_#L@N(IVN;:0:E&L-^X#1^<L()C=%(905?Z-_:RTQ];_
M &9O'=E'::]?S7FAW<,=MHLWDZA,S1, ('VMA\]#M;_=;[I^+_\ @HS\%+0_
MM+6_B;7-$\%^&M)U2.TL-0UA+6]O)[^R2^@D69YH]#N(M.NA/M42M<'*!.5V
MJZ?5W[=_[..@_M,_LWZ]H^MQ:[YNGVMQ?:;<:+/<1W]K<_9I8MT0AFA:7,<L
MB&)I%5PY!QU !P?_  2J\6^,_'WP>\8:W\0=-UBP\6ZAXJE_M!KTLD=P\5G:
M0'R(FM;;RD0Q&)@(V#20R.)'#\?4%?.G_!-6Z\3W7PB\2GQ+/J=Y&OB.9=)N
MM2NKF2\N;3[-;'=)'<:A?O#B8SJJ>> 557\M-_/T70 4444 %?+/_!4O]G/Q
M]^T7X(\#VW@C2M \00Z)X@2]U?2M1%FC7EOM*?))=0RHJ@,^Y5"LV5Y(#(_U
M-7Q!_P %BOAW8Z7X6T;QA9:;\)[?5[B;[!?:GXN^QFXN($4NEK:)=W$$#R%3
M.^&D'W.H!+  ^N_AQH6K>%?A%H.F:Q/::GKNFZ/;VM]-;QBW@N[E(561D55
M1&<$@!0 ", 8Q7S+_P $IM!NM.T[Q7=ZOX:L_#7B2\AL!JMM'IRQO;3*)RUM
M]I.IWTEQ'$S.%W>2!N9@F9&"_1WPL\\? /PY_:(TMKG_ (1^V^U#29@+(O\
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MQK'A&^MO#^J6NB:S-'MM+ZYL?ML5L^1\S0^9'O&,\;UZ]:^9O^"=W[2?Q/\
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M7$,9DC9K=&5I2&4$*#R<<'H?1JYWXO7:V'PF\43OJ5[HR0Z1=R-J%G"9KBQ
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M8>'_  9.G@+X<>+_ (?ZII^EV&E:M;^(8+UY[3R%<)8K<W+,)/)9I,K&<?O
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M5UKMCXF_M*[UC6+S2["Z_LXQ7$K?Z7]B@E13"L-L\!=54,F4D3R@#[ZHHHH
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M>/\ ^"6/Q T+XE?L_P"M:EX8\->'/!?AYO$,RZ=X?TC2&TP:/ ;6U=(YD-O
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MO-0NKUX[-;62T/V<7<RP2/#)^\BDDA$;NCX96=@0#P/1* /EC_@J$-8O=!\
M66B:EJKW<VL7,S^'M/>^BD\011V,[/F2SNK655@'[[!FVL4"['<H![]\#M<M
M/$WP5\'ZEI]U%?6&H:)97-M<Q-,R7$3P(R.IG)F(92"/,)?GYB3FOG__ (*B
M^ V\=^!_#MB^B>//$JW^H&&SM?#T=DBV=TMO<%7GN)K2X>WAE5RDDO$81"&S
MN,<OT#\$9?/^#'A%QI]]I(?1;-A8WMO';W-EF!/W4L<2I&DB_=9415!! 4
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M* "BDS7!?M%_&RY^ /P_D\1IX;N_$&GV6Z349(M3L=/CTV!4+-/))=S1)L&
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M6I>'_P#A%]+L]=N'T#39;^WU&[MM/,4(3[3<PHHFE,HF(9MS!#&A9M@-7O\
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MZU\#[VWU'X*^$+BTUZ?Q5:SZ)920ZW.I676$,"%;I@>0THPY'JU '4U\R_\
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M@[5_ 'P0T?2M=M(['5+9I_.@26SE";IG8?-:6MI >"#\D"=>=QRQ /0:***
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MV#VTS%Y#,RLMM)!"V4;:]?:_C73]#;X$:M:^*$2T\-'09HM65)7VPVGV=A,
MZ'=@1[OF4YXR.: /E3_@BA\4M5^*WPJ\5W>I3Z3,]K<VUO<?9M:;4)3=!93(
MY4WUX(H7B^S/'AQNW2$;EVL>U_;2_:A\;?!'X_>#M%T:_P!(T[3M:2T_LZTN
M[-95\3W;WPAN[62X:519K#;-'*LA7YWDQEBOEO:_X)O^)_AOXPT'7=1\">(O
M'?B2ZN[/33=S^*K4VMU!:1I-;V<*Q+#"BA!!.A.SS2R'S&8X-><_MJ>)X/ 7
M_!13PA?3:SI=@-2\+V4#PQ:EIL%\8H=6<O).EY97)^S@SJ$,+P.6,PW-@-$
M?6OQT\+W?C?X->)]'L;A;.[U/39[6.X;4KK31;ET*[_M-JR3P[<YWQ,KC'#
M\UY[^P'^SG:?LO? 4^&K+Q/I/BZ-]3N+YK_3].@M$W2;,H[1L[SR+M&9YY))
MY."[L<5J_MU6\5U^Q]\1%GT2_P#$<(T6=WTRSN&@DO0HR4+JCD(<?/B-R4W
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MOXBM]9UJWNK/4Y8-(@U.^A;3+/;)=III:')_Y9,SL[0>5T4+2^)V^'7_  \
M2'6_A1JH\>3+8RZ/XKMHS)%J<21/F23:ZE5MF9HR75@/,4@_,0 #Z<HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^!_CK??$KP?\
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M7>K746;9;\Q&UBAM[&[*EC,Q:5S;\F/RY=R%H_J#]N&."7]CWXEBZ_LGR/\
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M1CRVR,*JK\O  X'S1_P2F\;:EXMO?$OV_5-:;?HNDW0M]4NM5N7\0/(UWO\
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M6%8Q.9 !$-G'!/6@#VRBBB@"GX@LKG4]!O;:RO7TV\N+>2*"[2)96M9&4A9
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MC-J#>&DL=>\+Z5J>FZ8]U#+&;AKB\9!&A+QEH3OWF$,H78QK[<_9YUN/Q-\
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M^H_LX>/H-*T6U\1ZI-X=OTLM)N8FEAU*<VTGEP.BLI8.V%(#*3G[R]1\P?\
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MX?\ A?P[X0T$:I<0G3M%DC>W68!&9SL1 &8,K?=S@J<G(KW6@ HHHH ****
M"BBB@#\_O^"@WP^\4>(OVN?#NI7>B^%_%5MIT<#>&EA\.ZF\U[*UVB7&E7TU
MOJD5OY:P.\RR7D(@_?%0I(=7^Q/VE=<M=,^#>LVDWCK3?AS=ZS;OI]AKM[<1
M0"TN'1MI0R,H+X#$8.X8)'(KY[_;^^()^%GQH\%KI_[.GA?XG?VG<PM<:_J.
MG[Y;*>68)'' R6<Y,_[E3F1HD!:#+@$LOLO[>/@C2_'_ .R!\0['5O#MSXH@
M_L*[DCL+55^TRR")MIB+1R;7YZ^6YQGY'^Z0#G/^"<O@74_ 'P3U6TU+XJ0?
M%TRZY-);ZO#KDVL"WA6&&-83/-+(X<^69FCW;8VN&5<J Q]_KY0_X(_:_)XU
M_9QUOQ%/I]Q:77B/7EU&YN##'!;7T[:;8+(UO%';6Z1QQNK0'$?S26\CEBSD
M+]1ZKX@L-"ELTO;VTLWU&X%I:+/,L9N9BK,(T!/S.51SM'.%)[&@#SG]LN/0
M)/V?-4_X2GPMK_C#P^MYI[WVGZ(MRU_$BWL!%U$+8B?-NP$Y\H[ML+8K8_9U
MC\-W'P:TP>%[7Q%!X>F$IMXO$"7_ -M96D;<7%_FX*L22N_@J5V_+BN&_P""
MA@COOV<KNPN+*6Z@O-0T[R]PLY+.>Z74+8VUI=175S;I-!<3;(7C,BAD=P67
M(SJ_L,_#^Y^&O[.6F:=>V$FD7<M[?WTVG>7:Q6^GM/=RS&"VBMKBYAAMD+XC
MC69RJ!03NR  ?/'[.7@Y)_\ @IAXDU.T^)UP8=,N-3L9/!L]C<V!MQ'\J)#
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MNB?$V?Q*_B"348Y]6^)]IJEC]NAMY8%N'LEUF9G*P[D0?9V9!L^5=@*^@_\
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ML;K6$A7S%M93Y<9D0E2=D;NK 2\?>Y /M"BBB@ HHHH **** "BBB@ HHHH
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M5E;/EWC7P]HC?\%=-'U:VC\&0ZHJ066HW6MPR7-S*382/!!8-;QI%;W>!O\
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MF,(!^AE%(#N&1T-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^:7Q&\7^)?B9_P4J\+S:OX6U&PT>[\365K*FCZCXK2PUF'3=3G6PNK
MZ(>'3:K-!,DD@7[?% XV%Y)(BCG[N_:G\/7OBK]G?Q?8Z??^&=,NI-.D=;GQ
M%;1W&DH$P["Z6167R652KL5;:&+8)&*_/W]IWXJ_#SX]?\%8O RP$V]YX+\4
MZ3I=[JL?@W-]%<VNHF*.--1DU6+-K+>R"T=8].G92)F)",LJ_9'_  4A\8Z-
MX7_9;U.UU^%)M,\07,.F-_Q.K;2YTD8F2)H#<!EGF\R)-L 1VD/&QAD4 '_!
M/[X5:7X!^$MWJ-AK?P[\7'7;UY8M?\(Z3865M=VX Q 6LXTCD6*8W"IU94*J
MS.X=V]YKP3_@G78ZH_P.U+6M>\/>+O#FO>*=>NM7U&/Q(]B+Z]E=8T%P8;(^
M5;HZ1IMB(60!<R#>Q)][H **** "BBB@ HHHH ^&OVG/AUK7[6O[:&F7=O\
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MH:C%KEG?7Z:E9VT<4TTD,:B5$DA;8DQ"AAG_ )ZC?WG_  4*T+Q'XIL="L_
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M/QM_P@W[/T.MQ6>J>)1::3!((M!<75S=J40&2!KF0;P =^Z5\E022QZ_)_\
MP1JBU*Q'BB'5O$_CG7&O-(T[6='7Q%:S6[76E7ESJ%Q;WI$M[<L\TC/(CD;
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M^<(]_FLS,2^=Q+$D\UWM% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV:K^SS^R?JGBO1->N?#^IZ=?V7E30Z:E^;@-.@>$H[HH#)N.XNH^4#/.#?\
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MG212I)C=0#[4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT2PTVY70=(MK[P'H.NV.C:;XQUWQ)'%#.;I1-%_:.(K2W/E[$@A#,!&=SD!
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M^S'X5TGQ9_P40\:^);3PU'I1T;6-7TP26FD:W/:7,Z,-]V]^TO\ 9OVEVGN
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MNENLTDLQ']I?VDLX=8E5O+^S@?*5\QE^Y:_.3X!?%NW_ &C_ -NM;F[\2Z'
MMOXK2_U3PK_9.JV4S:O;Z9Y-O<GS[7*31VAB1HS.L):,G:Q + 'U'_P4GU>/
MP]^R1K&HL\=K<6&JZ/<65]-=+;6^E7:ZG:FWO)V:*8&"&79)(OE2;D1AMYR,
MG_@E]\4M ^(_[.5S%I>J0:KK.F:_J@\07$5TMPEW?RWUQ++=QE8H0L%PS&:)
M1$F(Y%&#C<>E_P""A?Q3\8_!?]D#QCXD\ SZ=;>*]/AA%C+>Q))&A>>.-L+(
MZ1E]K$+YCJFX@L<#!V/V4?'WB_Q[^SQ8>(_&%G VMZ@]W=P6MG);M(;4SR&U
MC9HY7@\[R?+#;9"N[J0<X /D[]FSX6^!?A9_P57U;2O \G@#0)X)-:O=6T;^
MT=!N=3F-R(9-UI!;VBW]L/,)=Q-/MVG&#E0OZ!5\8?LX^-OA9XQ_;*AUFS^%
M'CSP3XSU>_US3/MVJ:K8R:?-J=HQ>_!M[?4)_P#2!Y\H$HBQM>4!L$9^SZ "
MDSFEKX>_X)(V.E7?B?Q3K%J-5L[^]TVWBEL]4UN]O-32!+B<6Z7D4NGVT*RP
M1;85,4DW"MEG+-+( ?<-%%% !7PIK7PRT+P5_P %4-(G?0;[2KZS$,>B:S>S
M:[K%SJT5YYLUY%%<'5$@M+=9453 UM-&2H..0J?==?FQ\5?$?@#XK_\ !5?P
MWXATSPY/JFI:5XETS29+M1>+=:A*$(,\9>S:*&WLY+=3(%GC,A#@MMDV3 'Z
M3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?MP
MZEJ>D?LD^/KC1_$FE^$=1CTF3RM6U&0QV]KD@-N80S$%E+(I6&1MSKM1C@'U
M6O#?^"CVM:OX:_8Y\6ZEH[^$8FT\6]S>/XFTU]0TU+1+B-IFDB0@_*@+;S\J
M;=Q("Y !G?\ !,[QEH?C/]F2*3P[>1W6EV>I3VT21ZI>Z@ML,(XC#7=E92HN
MUU8)Y 4!P59@V:^=?$WPT\4_#O\ X*[>$[^'1O'?B6RN9Q ^O:CJ,!@FCD@9
MW<6T&G"'$"2-$DT\R3[(9XTD(_=O[W_P2W;3_P#AGS5QIMK8Z?;CQ+>%;*TT
M.;2H[1"D+1*%FFFDE5H6B='9\K'(D02,1"-?&?'7PQ\&ZM_P6=BOM6?Q7IWB
M2ZATVYL[2&TM+FTUQ;:WWQ7 N,BXMXH9%D1HL,&;<RL!+(* /:O^"A.K:-=:
M=X5\.^-GUK1/AUK4T]QJGB721="YT:]MF@ELX_,A1Q"LW^D R2KM_=A05D>,
MUU7[ ND6NB_LI>';?3M!D\,Z/]IU&32M.:":V\FP?4+E[5EAF59($>!HG6%E
M!B5U3 VUE?MM?LB^(_VI7\+S>'?'O_"$77ADW4L3O8W-X@N9/),-VBP7EL!/
M!Y3A#)YB8GD!3FO4?AQXGDE^'*7VM>)?#6N7%EYXU'5=)A^QZ<&B=P^$:>8Q
M^6%VL&E;!1LD=  ?&G[$'P:\7_#C]O3QCINH^"?%D7ACPYJ6NS:/K>N:IK-_
M;I:WTT4ZO;S75W);3332>8S^5$KHK!6(*,TON_\ P4(^&D/Q#^&7AZ:]\6>"
MO"NFZ#KB7UW_ ,)?),-%U)6M[B!()EBN;<LPDFCE3=(0'A4[20".6^#_ .UA
MJ_[2/[6L6CV5O;:=X9\,MJJQWND^+K*[77$22-89I+158O:R0O&RRJZO'-YJ
M8VJ7;K?VWO@5XF^.FG^&/^$=T^VDOO"FJ#6+&[.NP:>\4S6US:R*4N-,OX77
MRISUCSEL@KM^8 ZW]C_PMXB\$_LX>%-)\3>+=(\>7VGZ?#!#X@TY9?+U>W6-
M1%.S2S3,[NH#,_F$,3FO2ZPOAAI-_H'PWT&QU3;_ &E9Z?!#=;9HYAYJQJ'P
M\<,*-R#RL,2GLB#Y1NT ?#?[<,^K^*/VLM*TB?PUXW\1VFA1V.I::D_AJTO?
M#EW-)=IB-'NKA+=;F Q^89VC:2,2+MP0N?<O^"BO@O3?''[*?B6#4;WQ#HYM
M;6:ZM=7T>>>*71ID@E*W+^3/ Q1>009 ,LO(.&'S/_P5$\&^&?B1^UIX4M/%
MW@F3[1I]G8-X9U[4/&>@Z58ZE,;UA<VL<-\S7"%%EC9I[:,S[O*" %48_9O[
M4OB;4?!G[-_CG5M(MM4O-3T[0[NXMH=-95NW=8F(\LM'( W?_5N>.%8X! /-
M?^":_AK4M!^"^NW.H0:O8)K7B"6_M-/O9;V=-/A-M;1A+>:[GFEFA9HWE#Y1
M=TKJJ +N9OAG]E;QMIW[5=Y\0;O6/#$-IJFH"YU"WTR[U^T:^CC@-O;F6V&H
MFPDF6)8E9VMB&\L' (4K2_X);:9HVC? [Q);Z#I6EP6/_"4W4SZSI<UY+9>*
MII(+>274(C=$R#+L87 )3S+9]G' R?B)^U!\0;G_ (*$Z7\+8_!.JQ^%+2>P
MU*SUFS:\B34(FMYOM;SSK']E\J,NH%NS[V: M_%&* /JRBBB@ HHHH ****
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M&H^+[#639W=KI2V%SJ4,#VUEYKP:>DR(D9"!C*H.Q-[$D[K?_!+#QUH?C_\
M9EDN_#VGZ-IVGKJTA":3HL>DV;F6WM[C*11W5RI*B949O,^_&Z[1MYX'Q6C7
M7_!5 :;J^M^.;:=[BPU;PU8Z=XMTQ-.:);%H[QYK%[I+LHYC*&/[/*N%>2/#
M22,H!Z/_ ,%2_C-J'[/W['6M>+=,UG6=!O-)OK%UNM-@AE;:;A ZR>;)'&L9
M4MDM(HSM&'SL;8_X)^0:3K7[)NF26<UUK-CJ%]JL;WNI+#+<:LB7]Q LLTD9
M*W.Z*.-1.23*BH[<L0(?^"CNH:G8_LP7:Z5JJZ?-=ZOIMM-;!YTGUN![N)9=
M/@:"WN9A-<(6C4QPNPW?PC+#I_V,-;AU_P#9E\+3P/*R)%-;,DVH7-_+;/%<
M2Q/ \MS!;S[XF1HV22%#&R%,?+D@'S!^Q%X9\4VW_!0[XER13W,_@"PU/5H=
M,OK70YH-/DVR0P-IJ,;6*&(6CQ,F8Y9/,=)3R6<CT?\ X*HZ3;:Q\+_#MQJZ
M6\&B>'M;AU&:351H\VBW[O!<VZV]U#J6HV43[3(LJY<D2+$5!(.WS']DR6=/
M^"K?Q%CMX_A!%9N=7DG_ +"L+6'4V?[5$I$EP&\^>Z&$>Y7:41IE#,K*$/I/
M_!631++Q9\,_ FBSZ8U[>ZUXG-M8W5O87^IWVE2K87DWVFWLK)EEN)%$6.3L
MC#>8P8)M(![[^SX]O)\!_!C6BV"6C:)9M"MC';QVH0PIM\I;>6:%4QC:(I9$
M QM=AACV%<5^S?X5M_ W[/O@G1K2&2VMM+T.SM8HI+2>T>-4A10##.S2Q'C[
MDA++T)R*[6@#X8_X*(>,/$?PQ_;:^'>H^&?#7C::\\0:&=);4]$OYH8=2DCO
M/.ATZ4):S1H"Q;,DKIQ< #@2$?2_[;&EOK?[(GQ)M(] N/%$D_AV]1-)MWN4
MFOV\IL1H;4&XWD]/)_>9QM(;!KY9_P""GGA'5_$?[7GP[CLOAOK/C&SU#1FM
M_M%HU]+;B^CNO-M/-%NICLVA(E*74S* ;HLIW0Y7Z^_:7^(*_"G]G[QEXD:[
MO['^Q=(N+L7%B;<7,15"08OM"O#OSC =64G *GI0!Y)_P3D\?ZCJ7ACQ7X8U
MC_A.;Z\T#5MUKK7B#1]?L5URUDMX&$\0U;?)&%E,T1A$SX,)DX$@KSSQ'%#K
MG_!4.XTJ2UU73],MM;T[69;>[O+Q+?6]2CTCRXKZW$>FNFV*$K"T;7\2,\;L
MT>=OF>G?\$^/C+\2_C'X3UV7X@S>')9-'O?L"PP:=?:9K6G2^6DOD:A;W$4:
M>:8989!)"%C82 JN"#7DVO?"R[U?_@KK>ZY=:SX]TVQ#:7Y%DN@7ES8ZAY-D
M[QM#J"2_9[:V#M<))%)#N:3S2'_>#: ?<-%%% !1110 4444 %%%% !1110
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MZGX+D^RZW).GA[Q)H']M6VNW"PX@/D+8WDI6*0C/E+"Q\Y1Y\><-]P5\>?\
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M2LEBGWP-PMI<7!63(V1$-E0#[2HIL:>7&%R3@8R>IIU !1110 4444 %%%%
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M0\.ZG<:[]I>XU&QN[2^U<O8VC/+,MU<7$SF*0O:K(TI#QVB%0HP*T_%_P1^
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MOX4L];NO#K:=9W<\UU:W#Z,NHK-+;2K9R0MJJM;K#YB2><%_>,BG 90Z-F?
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M?J86>T$RJL*R*TFQBS212QO%)$8PNYRWD[7_  3R^/\ X0^+G@?Q)HGAO1/
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MO$6KK=V</D6MO;SWB64EY;_;&MTN98K<S+"C.OFMMW(/E;[I;_P3ZB\1Z%\
M(_#_ (E\$ZOX)N?#U_>6MI%?0V<1O[1KF5[>?9:W$\:R-"T9E *J)2^U0N .
M5_X*BJ/!7[+X\9S^,/%GA^X\%W=G<2C1=8U'36UR)KF 3VC+8AW+S(K(C^4_
ME%RP &2.U_8 U:ZUC]E_27O=:N]=NH=2U6WDGN[VZOI[?9J5RHM7N;I4FG:
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MV6_"\=SH-IX7P+HV^D6]C/9#3K<W<Q@ADCFCCD\Y8C&)7*#S)-[@LK!CQ_\
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MO]JC3?"_A7Q)\4?!^M>'M&M-0EN_"WA35-;;5/M-VT:6JQ,/[*V_)EYKA6*
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M:R%[.+6#S%@@$CQP>6CR>4A=U8G))8@'N-%%% !1110 4444 %%%% !1110
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M/ YUGX,6NLVZ^(3=Z;J%K9O+ITVK2Q6%K<W,*7%W+9:=+'+=B%!O";EQM)W
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M?#_C6QO@ODMXDL[]($6R86T,3"VW0%XDDF-L)M\@GE?;MR:_0NO@2[\?:/\
M$7_@J1;)HNJ>#=0TF+Q'!<3V'_"4Y?4KZ'3'M3=+9A\K>6GDR1L&78\?D;5+
MJ\D8![C_ ,%5;C3[3]B7Q%+JT%_<Z='J6CO<1VUM:7*,HU2U/^D1WDL5J]KG
M'G">1(_*\S<P%<]_P2:_:L\)?M&?!75M)\(64$&G>"[T6ZW%GH=MHMG>+<%Y
M0T=I;NZ0.&\Q7C)R<+)R)!76_P#!4&_FT_\ 8=\;-;^,;GP#+*EK NNQ37%N
M+(R74*#S)K<B:")BVUY8SN16)&>A?_P37N9=3_93TV_O9KR;6+_4M1EU1+NU
MD@GL[D7DRO:D2_O"(2/*4MSMC'"@!0 >*_ ?Q)I-S_P4\UZVM_&SW^HC4-:C
MN2D.H^??,%39H]WY@^RQ+:*DDL 0EY(QO"HKLTO7?\%5/#/AWXR^$_"W@K4[
M?Q-KDDVJF:6P\.1VVIW%D_V2YEMKBYTR7/VN O;L-O'\1S@,1P'P&^-&MZA_
MP5J\2^%)]3\</IZ7&JR6\5S;VMO87%L% .^$2&9Q'/$8X[PHH\N*WBX,I:37
M_P""N?A7P#'KG@+Q'K6@>";G6[&]:UU#5+[3]'NM7M-.DM+WRE@74Y8K:1&N
M 01(7*JTK(H;+  ^LO@'X3M? 7P+\&:'8C55LM&T*RL;<:G'Y=ZL<=NB*)U_
MAEPHW#LV17R3_P $CAI'A_7M;TRRM[1VU+0K76K'4VT'3[;5-9L9+JY1+C4+
MJVE>1[HNK[H[CYP<MDL9 GOWB_Q%H_AS]@:?5)/%6J^!="L_!*7 \0Z196SW
MFBP"S4BY@@@2: NBX98XDDC) "!ABO ?^"/WC2V\8>(OB)-9:Y%K]K<FUNUU
M&>ZM+74]79_,W75YI<,6^TD)&-\T[/)S^ZBV_, ?<=%%% !7P=IGQ(^+.K_\
M%!]*L]>UI]#\.76K!;GPQY]K;B^6+S%M;M5;5FN$7RP"T<4'ES,%=X_E(/WC
M7YO>,/VJ/#OQ\_X**^&M.U&P>.'PUXRM[&+3#J6GK?2W<%W>V5O<I&FGF[Q'
M+;O/-$]\BK;S6[@.)'BH ^G_ /@I+=:LGP$TRVTO1GU/[9XGTB.>XA\5Q^&[
MC256\C=+F*YDX,BR*@$>#NW$$,,@]-^PQXMG\=_LO>&]7GU>WUT7[74D%]#K
MXU[SX/M4HBW7@1%ED"!0VU0JL&49"Y/G/_!5N\U:W_9_@A&DZ)J?A+4;^UL=
M<DU6]M[>UTXRWELEO=2^?:SIY,;DL[DH$7+?-P!V_P#P3V\2?\)?^RIHFI.M
MD;BYO]4-S/9&![:^F74;E9+F*2"*&*5)F4R+*D8#APW.<D ]KHHHH **** "
MBBB@ HHHH **** "BBB@ HHKRS]N77=0\+_L4_%_4](N]4L-5T[P5K-U9W6F
MR+'>VTR6,S))"SD*LJL 5). 0* /4LYI:_.;_@@GK]IXBL?%%S#XF\*>(KJ;
M1-(FN?[*^/=_\2;B-V64EI[6Y1?[.9FW<+G<0R_\LQ7Z,T %%%% !1110 5\
MOZ=_P4AFA_:3_P"%;ZY\.-4T&[3Q%;>');R;Q!IDNV6ZMGNK>5;=)C.\;Q(,
ME4.TM@_<<K]05\2>,_B/'9?\%9#9:MXCL[MK$:7::9;P:C=V<FC0W,#!K66-
M-,>&X::X*R;6O5PLT&X(-@< ^VZ;#"EO$J1JJ(@PJJ,!1["G44 1QVD4,K.L
M<:NQ)9@H!8G&<G\!^0ITD:S1LCJ&5AAE(R"/0TZB@!%4(H & . !VI:** "B
MBB@ J*"RAMIII(XHXY+A@\K*@!E8*%!8]SM '/8 =JEHH Q/B'\1=%^$_A"Z
MU_Q%J$6E:/8[/M-W*#Y< =U0%B <+N89)X'4D $U/X,\5Z+XU\-VVI>']1TS
M5=(N5W6]UI\Z3V\H_P!ET)4_@:\9_P""AWBGQ#I_P,.A^%_#WC;6M5\17=M
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MZG!J6E1WEK(EW;3Q":&2%@ZSH1E2I'!!&,$=<U\:_P#!)+XK_#GXDWOCS_A
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MU2QO-4\-V,O]I);75BFIR12SQ0W&L7L5N!,V/+^S6LGS9"A044 ^I?%'Q_\
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MX&[/'#=!^POX+\3^ OV:M%L?&2ZK#XEDN+R[OK>_D1VM'FNI91%&4FF'DJ&
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M&M UO]L:]U6^B_::6ZUSQ)!?1V&HRO;>&;::UC,43HBLI-KF/> 2RL<9!'%
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MP'H_[-_@F'6Y)+35;#Q9#IJ1:C,TPD^U7L16U*[(!*09/.W$^>I"Y7S/>_V
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MM8U.RETCQ1-X=FT[3[>&%M1?[1'<0&0E##M@W'>5S\H0L/IZOE#_ (*3^!M
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M-\7EAI%E8KN\I2\K'T/_ (*\Z3JOB+]FS0M-T>^TT7EYXKT\_P!BW=G/=?\
M"4)%YDSV"I!:7<IRL9E;9 ?D@<,RJ6- 'JW[.'C+PU+^QYX2U[P+I,&B^%?^
M$;AO-)TZ_O4C2RMQ"&6.:X5I5&T</(&D&0S;FZGYG_X)?^*?!WB_XX:C+X;\
M5^&O$]A:>'+E?#,6D^*(]7;2])DU+S'CF2.PMV0O,5*FYEDEPI"AL22-]7_L
MPZ;J.D_LZ>"K;6;^;5-2AT:V2YN9[&6R>5O+&<PRQQR)CIAXT;CE5.0/F/\
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M-K)+Y@OOL\;*8NIQYN/M?]M^6/7/V6/$=M:PZ7J4VI6JR64=]9WUY87+1$7
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M:^NYKC_A'KW0#?01I/'I\<R!_M2#_F'J8SL_=FXGX;>:[C]K']F+P_\ M=?
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MZ;;VL%JMWX=_M1K9(H[R.2&-_M,6VWG%WNEB"_.]O"V[*"OI"N.^-'QT\-?
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M^'FEZ!_:.AV=O8:M'J5S;:WX=AU_3-4C2*5/(GM)716 :1)%8,"KPH17K-%
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M12S&)@A606S%8I$(\Q/,)25U< ^S:*** "BBB@ HHHH **** "BBB@ HHHH
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M(HQ*D:1)$LD)DB=8E(EE;>U>>?'_ .-+>$?^"A6D16%[XVT_3/#^MV-KJO\
M9<&M:K97\DVG22KIHLH=.-HDL@ECF+_;"RA=Q7+;" >X?\%+=4?0_P!B[Q?>
M_;+'3K2S>QGU&\NIXHEM;);ZW-U(AEFAC,JP"0HK2H&?:N3G!P_^"87AK4M$
M_9EE:_U2TGTFZU74!IME;VEG:MIT"W<ZDS&U=P;J0_O)MTCNLK.&;=D#H?\
M@H[=>"+?]C[Q/'\1+3Q)>^%KV:QL9E\/A?[3CGGO8(;>2 L0H99Y(FR>  <@
MC@\__P $U?C9\*?B;\(]2\.?"N]\0:OHWA></<:CK47[_66NVDE-WNP-P>59
MU(*1D-$P"!-A8 \:^$GCSQUX1_X*'S1+#XZ\2>%[S5[S2OL<6OM?:7I>F^1
M+*^BCDU1WD9FR9C);80%V14X:3[WKXQ\#?LZ_%[X:?MSR^+['POX<NO"EYKE
MY#=W0U:R@(T>6**.U6"U6R#PR0%27(FW2A<,S;@(_LZ@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^0_\ @J!\4H+#P7<V&B>(=1TKQ!H\9BN6TG7-
M8L+VPDN[:X>VG%OIUG<->B)+2YN&C;:J1VTC,P4DU]>5\<_M_?$JU^!?QCM_
M$&I_!_X4^)AK?A75-+MO$FOZ_+I]U<P1Q*\NCL1ITXWW/G,L,0D+2XFPHY#
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M38I3C! 7[3\+WMWJ/@C3KB\L#I-_/8Q23V2.KFRE,8+1 _=.ULKGH<5\D_\
M!)R*XO(O$.I2ZOJ+27>EZ:+_ $^\@U>.ZN[X&X,VJ7BW\:B*]GW*DL5NTD:^
M0O[QQLP >7_\%@8/"\_[5WP_TW7/#\^IS>+?#\FEEY[2QG-\D5XMTEEIIN()
M72^D>/#,G\+0#825>/\ 1+1]'M/#VDVUA86MO8V-E$L%O;6\0BB@C4 *B*H
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MFZSJFGSJJ1Z'I6E6&F2:EYU[H>G0M<M;V=W"FFV:">/S'#2&2Y=FW R84,X
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M++S([B_<S6VF7NF_;0][.XN)+>\_TB.64,'D$A8[W8AF!#$ ]FHHHH ****
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M?#.B2Z3:S-(0S22)+<7$DD['EY7E)<XZ8KSKP1^P7>^$/VPM6^*9?X/LFKM
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M%>O^*[&[U07FFR:SJ%QJ%Y9PFUMXY$>>>1W<O<1SSD#:B&X*(BJH%>6?%?\
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M=&^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:0FHWJ7 C OBZ6\E@+.5HQ%B:>9]\>8D*_<-% !1110 4444 %%%% !1110
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M75K;#3PV4<5I&VFNK$I+:,;9G5&4&-YY'0JYW5]&T44 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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;*CW4;J )**CW4;J )**CW4;J )**CW44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>paciralogoa05.jpg
<TEXT>
begin 644 paciralogoa05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0#017AI9@  34T *@    @ " $Q  (
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M# P,# P,# S_P  1" '!!' # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M16Z-_/VKLJDH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV$[6Z_*V",'BNIKYZ<)0ERS5FNC.1IIV84445(@HHHH **** "BBB@ HHHH
M**** "L?X@>/]&^%7@?5O$OB+4+?2=#T*TDOK^\F)\NWAC4L['&2< = "2>
M"2!6Q7YD_P#!RU^U]_PK?]GW0?A'I-TJ:MX^G%_JR*?FCTVW<%5/IYMP%P1U
M%O(#P:]+)\NECL93PL?M/5]ENW]QMAZ+JU%!=3Z^^!O_  4V^!/[2GQ'L_"/
M@CXB:7KWB34$DDMK&.VN8GF6-#(^TR1JIPBLV,YP#Z5[Q7\G/[._QKU3]G#X
MZ>$_'FC?\A+PIJD&HQ(6VK.$<%XF/]UUW(?9C7]5'PN^)&E?&'X;:#XLT.X6
MZT;Q)I\&I64H_CBE0.N?0X;D=CD5[G%G#<<KG!T6Y0DGJ[737HETV^9U8[!J
M@UR[,WJ***^1//"BBB@ HHHH **** "BBO//CE^T?H?P3L6CF87VLR+NAL(G
MPWLSGG8ON>3V!YP =EXJ\6Z;X(T2;4M6O(;&S@&6DD;'/8 =2Q[ 9)KY:^-_
M[8FH^.3-IOAWSM*TELHT^=MS=#ZC[BGT')[GDBO+_B?\7]<^+^NF\UBZ+JF?
M(MD^6&W![*O]3DGN:P8>E:<ME<ELLQ'-6X>E4X>E7K9&D9552S-P !R352))
M8?O5?TRQFU.ZCM[>&2XGF(5(XU+,Y] !R:],^$_[)&N>,O+O-8+:)IS88*ZY
MN91[)_#GU;GV-?1GP_\ A3H7PSLO*TFQCBD88DN'^>:7ZL><>PP/:I<BN4\/
M^&O[(6J:P([GQ!-_9=N<'[/'A[AA[_PK^I]A7NW@KX<:+\/K/R=*L8K<D8>4
MC=+)_O,>3].GM6Y14.390445YW^T#^UI\-?V5M"&H?$+QIH/A6%UWQ17EP/M
M-R,X_=0+F67H?N*W0U=.E.I)0IIMOHE=CC%MV1Z)17Y>_M#_ /!SU\/_  E)
M/9_#7P1KWC"X0E%O]5E72[(^CH@$DKK[,L9KXK^-G_!PK^TA\6O.ATO7-!\!
MV4N5,6@:6GF%>W[VX,L@;_:1EY]!Q7U6"X(S7$*\HJ"_O.WX*[^]'?3RRO/=
M6]3^A:N+\<?M)?#KX9-(/$GC[P7X>,)(<:GKEM:;,=<^8XQ7\O/Q0_:K^)WQ
MK>3_ (2[XA>-/$JR J8]1UFXN(@IZJ$9RH4^@ %<#7TE#PWZUJ_R4?U;_0[(
MY-_-+\#^GK7_ /@JC^SEX;G\NX^,_P /Y&W%<VNJI=KD>\6X8]^A[5S5Q_P6
MH_9>M;B2-OB[HA:-BI*65XZDCCAA"01[@X-?S545Z$?#G _:JS_#_)FW]CTN
MLG^!_2I#_P %J?V79YEC7XNZ*&<A06L;U5Y]28<#ZGBNBT;_ (*M?LX:[,T<
M'QF\!QLI S<:BMLO/O)M'^%?S$T42\.<#]FI/\/\D']CTN[_  /ZN?!W[5_P
MM^(CJOA_XE> -<9SA1I_B&TNBW;C9(>]=^K!U#*<J>01WK^0>NN^''[0'CSX
M.RJ_A'QKXL\+M'G:=)U>XLL9.3_JW7J>OK7!6\-UO1K_ 'Q_5/\ 0QEDW\LO
MP/ZRJ*_G.^#7_!>?]ICX/R1))XVM_%]C#C_1?$6G170;ZS($G/\ W\K[#^ W
M_!TCIMUY-M\3OAC>6;<"34/#-ZLZM]+:?:5 _P"NS'GIQS\]C.!<THZP2FO[
MK_1V_"YR5,KKQVU]#];J*^=_V<O^"K?P!_:DEM[7PQ\1M%AU:X "Z7JY.F7A
M<X^14G"B5N?^61<=>>*^B*^5Q&%K4)<E>#B^S37YG!.G*#M)6"BBBN<D****
M "BBOQD_;)_X+O?'/]DS]M?XC^"]-3P3X@\/^'=;EMK*'5=)</%!]Y4WPRQD
ME0P&YLD[03WSZV4Y+B,RJ2IX:UXJ^KMI>QT8?#SK-Q@?LW17XM^'O^#IKQI;
M6VW5OA+X7O9L##6FK3VJYYS\K)(?3OQ@]<\3ZK_P=/>*YK7;8_"#P];SY^_/
MKDTRX_W1$A].]>O_ *CYQ>WLU_X%'_,Z/[,Q';\4?L[17X-^(/\ @Y$_:$^(
MVLVVG:/8_#WPJ+Z9+>.6UTF:XDC+D+N)GF=3@G/W!T'![_O)7F9QD.*RU0^M
M6]^]K.^UM_O,,1A9T;<_4****\4Y@HHHH ***_&G_@I3_P %H_CY^R'^WE\0
M/ ?A_4/#O_"/Z#=6C6-M>Z3%,T<4MG;SX+J0Q#>:3R<C.,C%>MD^35\RJNCA
M[72OJ[:72[/N=&'P\ZTN6!^RU%?@YHW_  <W?M :<NVX\._"O4 7R6ETJ]1@
M/0;+M1^)!KK-*_X.D/B=#YGV[X:^!+C.-GD3W<.WKG.YWSV],>_;W)<!YLMH
MI_\ ;R_6QTO*\0NB^\_;>BOQFLO^#J#Q-':HMS\'="FF'WGCU^6-3]%,+$?F
M:E_XBH_$'_1&='_\*.3_ .1ZQ_U)SC_GU_Y-'_,G^S,1_+^*/V4HK\9;_P#X
M.H/$\EHRVOP=T&&?C:\NO2R(.><J(5)XSW']*Y?Q%_P=%?%RY#?V3\/?AS8]
M-OVL7MUCUSMFCSG\,>]5'@;-WO32_P"WE^C8UE>([?BC]PJ*_ 36_P#@Y*_:
M.U5LVZ^ --^8MBVT1VX/\/[R9^!^?N:YZ_\ ^#A;]J"\NVDC\6:#:HV,11>'
MK0HO&.-R,W/7DGK75'P_S1[N"^;_ ,C3^R:_E]Y_0Y17\\=A_P '"W[4%G=K
M))XLT&Z1<YBE\/6@1N,<[45N.O!'2NL\,?\ !RU^T-H3I]LT_P"'&M*N0WVK
M1YXRV3ZPW"8(Z#C'J#1/P_S2.S@_1O\ 5(3RFOY?>?OA17XV_#S_ (.GM=M7
M5/%GPATF^5N&FTG6Y+0K[B.2*7/TWCKU]?I?X)?\''?[/?Q.GM[7Q"WBOP!=
M285WU73OM%H&/826S2-MZ#<Z(!WP.:\O%<)9M05Y46U_=M+\$V_P,)Y?7CO'
M[M3[WNK6*^MWAFCCFAD&&1U#*P]"#Q7E?Q$_92TGQ&)+C19/[(NFY\O&ZW<_
M3JOX<>U==\)?CEX-^/7AL:QX)\5:!XKTWC=<:5?1W21DYPK["=C<'Y6P1@\<
M5U5?/2C*$N62LUT9QRC;1GQ7X_\ ACKGP[NS'JEC)#&QPDZ_-#)]&''X'!]J
MY>3H:^]K_3[?5;.2WNH8;BWF&UXY4#(X]"#P:\9^*/['MCK(DN_#<RZ?<'YC
M:2DM Y_V3U3]1]*:EI8GE/F2?J:A%Q):S+)$[1R1D,KJ=K*1T(-;?C7P5JO@
M35&L]6L9[*?G:'7Y9 #U5NC#W!-8,W2J>Q)[M\%?VS9](:/3?%S275KPL>HH
MNZ6/M^\ ^\/]H?-[-7TEI.KVNO:=#>65Q#=6MPNZ.6)PZ./8BOSLGZFNL^$O
MQWUWX-:GYFGS?:+"1LSV,S$PR^I']UO]H?CD<5+CV*4C[OHKC?A#\<]"^,VE
M^;ILWE7L2YN+*4@30^^/XE_VAQ]#Q795F4%%%% !1110 4444 %%%% !1110
M V2188V9F55499B< #U-?.?@[_@KE^SCX_\ 'FF>&='^*FB7VM:Q?1Z;96Z6
MUT!<7$CB-$5S$$^9B #NP<CFN+_X+A_M?_\ #)W["6OQZ?>+;^*/'N?#FE;6
M_>1K*I^TS#N-D&\!A]UY(O45_.?I^H3Z3J$%U:S26]U:R++#+&Q5XG4Y5@1R
M"" 0:^[X8X1AF6&GB*\G%7M&UM;;MW3TOIIV9ZF!R]5H.<G;L?UY45XW_P $
M_OVHH?VR/V0?!'C]9(6U#5K!8M5CC  AOXOW5RNT?='F*S*/[K*>]>R5\5B*
M,Z-65&HK.+:?JM#S91<9.+W04445B2%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5_-G_P6]TV32?\ @J9\6HI55&:\LI@
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M7#?WGD<EF/N36?5G1]'O/$6K6NGZ?:W-]?7LJP6]M;Q-+-/(QPJ(J@EF)(
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M'NAEEV[LJ-0@+9'I@$GVK^IBOR7Q(E^_HKR?YH\#./CBO(****_-3Q@HHHH
M**** "OR;_X+J?\ !';3]6\-ZQ\;OA7I$=GJFGK)?>+=%M$Q'?1#YI+^%.BR
M(,M*J@!UR_#AO,_62FR1K-&RLJLK##*1D$>AKU,IS:OE^(6(H/U71KL_ZTW-
ML/B)49\\3^0FBOJK_@LA^Q7;_L2?MKZWH^CVJVOA#Q-&->T&-%PEM!*S![<>
MT4JR(HR3L\LGDU\JU_0^#Q5/$T(8BE\,DFCZ^G44XJ<=F%?KY_P;4_MW7-U<
M:M\!?$5XTL,<4NL>%6D;_5 '==6@]CN\Y1VQ-Z@5^0=>E?L=_'6X_9F_:F\
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MB/V7OV*--^$$=OK.OK!JOB7 =!C=;Z>?]@'[SC^^>G;'4^\T45YK=R0HHHH
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MG]IM_+HODK(^,K5'4J.;ZA1117"9!1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_&O\ X.H_^1_^#/\
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M?L#1117\]GR04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOKZZF.%AB12S'U)XP .22  20*V+R]ATZSFN+B6.WM[=#)++(P5(U R68G@
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M .#J/_D?_@S_ -@_5?\ T9:U^RE?C7_P=1_\C_\ !G_L'ZK_ .C+6OK."?\
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M^[5?-?\ P26_9&_X8R_8;\(^&KNU%KXBU:/^W=>!7#_;;A58HW'WHHQ%"?\
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MZ,IQU^H.""!^NE<'^T!^SQH'[17@UM+UB+RKB+Y[._B4>?9OZJ>ZGNIX(]"
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MOGQ#\220W'Q"\?\ AGPM:MAFMM(@EU2ZQW5BWE1JW7E6D XZ]*\%_P""./\
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M\H_VBOV<?$?[+?C];>Z:9[,R>=I>K0 HDX!RI!'W)%P,KG((R,C!/VI^PO\
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M (-S?^4EFE_]B_J7_H"U_057XGX@?\C1?X%^;/FLV_C_ "04445\.>8%%%%
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MD_8 _8A'CF6U\<>,+,-HD9\S2]/F7_C_ &!XFD!_Y9#'"G[YY/RCYL#]A_\
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MB"-<DXZHXQ^.<?C7]-5?R[_\$S]1BTO_ (*%_!229BJ-XTTN$$#/S/=1HO\
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M^,LR^J99/E?O3]U?/?\ "YZ>8UO9T7;=Z'W51117X*?*A1110 4444 %%%%
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M^%L9]\5_5-7Y'XD1_P!IHR_NO\SY_./CB_(****_-SQPHHHH **** "BBB@
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M$E6YVLV"!\LU^WX3&4<525;#R4HOJOZW\CZ:G4C./-!W1]F_\$E?^"M6N_\
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ML8=SM50=M?.?Q'^)7B#XO^-=0\1^*-8U'7]=U20RW5]?3M--,WNS=@,  <
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MYE;=LRT?4[3^5?U65^8^(TH3EAY0:>DMO^W3Q<X:;@UY_H%%%%?F9XH4444
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M0HHHK\S/%"BBB@ HHHH **** "BBB@ HHHH **** "OBO_@OC^S/_P -"_\
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MK X(/J*^P/V2O^"XWQ[_ &4[>UTW_A((O'7ANWPBZ9XE5KLQ(.,1W 83)@<
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M9M]OU1\/T5ZY:_L!?'B^MHYH?@G\7)H9 &1T\'Z@RN#W!$.#3_\ AWQ\?/\
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ*KZ1#<6VDVL=Y,MS=1Q(LTRIM$K@ ,P Z9.3CMFK%2,**** "BBB@ HHHH
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MJM*A,0HHHK,H**** "OR9_:S_P"3F?'7_8:N?_1AK]9J_)G]K/\ Y.9\=?\
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MRG:AP0017HOPA^/OA3X[P:A-X5U)M4@TUTCN)/LLT"JS D >8JD\#M[5P_\
MP[O^#O\ T)__ )5;W_X]7<_"'X!^$_@/:7UOX4TMM+AU%TDN$^U33AV4$ _O
M';'!/3&>*- U.QHHHJ1A7P1_P5&^ VH:-\2(_'EI;R3:3K$,4%]*BY^RW$:B
M-=_HKH$ /JI'<9^]ZKZII5KKFG36=[;6]Y:7*&.:">,21RJ>JLIR"#Z&JC*S
M ^._^"=O[8?ASPY\.8_!/BK5+719M+ED?3[J\D$=O-"[%RAD;A65V;[Q ((
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M]E&>D,.H90?BZLWZUZ#\'_V2? /P-OA>:!H,,>I %1>W,C7%PH/!VLY.S/\
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M@3X?:)\,?#L>D^'],M-)T^(EA#;IM!8]6)ZLQP,DDDX%;%2,^4?VUOV]M>^
M_P 3X_"_AG3]+DDM;>.XO+F^C>3<SY(1%5EP N"6R<DXXQD^V?LO?' _M"_!
MK3?$LEFMA=3L\%S"A)C65&VL4)YVG@C/(SC)QDY_QV_8[\$_M#ZU:ZEKUI=Q
MZE:QB'[39S^3)-&#D*_!# 9.#C(SUQ7<_#_P!I/PN\'V.@Z'9I8Z7IZ;(8E)
M.,DDDD\EB222>2235:6%J;-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JFOZ.GB'0KW3Y))H8[Z"2W:2%@LD8=2I*D@@,,
MY!(/-6Z* .9^#_PFTCX(_#[3_#>BQLEG8KS(^#)<2'EI'( RS'D]N@&  *Z:
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>premises.jpg
<TEXT>
begin 644 premises.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ,G G@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH H^)O$MAX,\.7^KZK=PV&F:7
M;R7=W<S-MCMXD4L[L>P !)^E0^"O&NE?$;PEI^NZ'?V^IZ/JL"W-G=P-NCN(
MV&593Z&N._:[./V6/B)_V+M]_P"B'K,_88.?V0_A]_V"(OZT >L4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8\G"JH_"@1QO_!1S]H3PWK_[ WQCLK=?$OGW?@_4H8_-\,:G$FYK=P,LUN%
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MA?';_P -CK?_ ,CUT7P;\;?"7PWXG_LKP@++3-3\1.$V+87%NU^T4;N%WR(
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MU\4?A?J>AV-U;V-Y>")H9YXC+%&\<J2KN4,I*DH <$'GK0!X]XUNM6TWPO\
M$+0[_7]4U^WT/Q)X>%E/J A\^)99["1EW11Q@C>21D9&>M>I6['_ (::O!DX
M_P"$8MSC/?[7-7&ZK\$_$6K>&?&G]K>(O"\7B#Q/J.GZC"\-I*EG:_8S;LBN
MC2[V#>0<D,N W'2LL2?$NV_:*N]^L_#>.Y_X1JW8L]C=A3&;N4#C[1_>/7W
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MJ,>K2/+=V+079O)6>+R=X*!59 ,YR,')SF@.A^@XZ4M>;_\ #)/@#_H"3_\
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MAZ^L[Z6_D87GV?R(6M-1C"1QPQ^8SRP91=S'* 9_64?LE> 2?^0)/_X-+O\
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M_P#A6ZM_\DT 5_#_ (J_:BFUFT75?!/P,M]/:0"ZDM/%^IS31IW*(VGHK-Z
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M .%;JW_R30(@\->*_P!J"76[1=8\$? ^#32_^E267B[4IKA$P<F-'T]%9NF
MSJ/<5PGPZ^'W[3WPI\6>)M5T_P .?!75CXNGAU&X6]\3:A:&RF,>Z:%%CL9
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M13^"GP7T6ZU.7]FO6I+FS26XFU1?&U]9SPP@!BBBUV (H0' !)([G%9^H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%VJ:3KEWKGC+4'N+*YMA#]FB$T<]DH?>ZN3YD@8A5.%!/7B@#TW]FSX<^/\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\W?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"2*/\ AU_\#O\ H3;C_P '^I__ "17H_\ PTGX _Z''P]_X&I_C1_PTGX
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M.XJP)R2<YR30/H5O^&,H_P#HJ7QG_P#"J?\ ^(H_X8RC_P"BH_&?_P *I_\
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MY?E;!L\LEB9"J^R#]K?X8X_Y'OPQ_P"!Z?XT <[_ ,,91_\ 14?C/_X53_\
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M%KPW\*/VH_A\/$>LV6CGQ+I>H:'I?VE]OVV]FN].\J!/]ML' ]J .E_X9C\
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M*X=!1]4TO7+FW>[M[#5]+N=-GNXDVAWB6=$\P+N7=LR5R,@9JOK7_)T/AO\
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M.>)M&UW4=)\'^+H;I+M+V>TFDA:"9U$:RNZQ[FC*JES&-ZA74B,#0\0\6?\
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M.FU"%M/@'E'Q'<Q30WLC#;ME9[=L#++DDU]L_P#!/G5+34X/B_\ 8X1 EO\
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M$\OC&QUS0M1M;H:@^D:=#;6XN[NZC38EO&^VXB$:N!*;G"]6"]1K/@[XB?\
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M<Q[=WHL\_P"T?8Z'KWB+RM?B\.Q/X(\9Q ,U[FXE807&,1M(R!1)%D)=(I=
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M?AGI6D>&X]<D1]*TN?5?$$DLSQYB-S<^4MO"$^;9ER[\[5 W?:5<?\5OV?O
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MX&Z=J.E>%;JY3PRLGFW^O:=9S,&N;C ,<[B0 =B1@]JE^+_B/_A,_P#@I?\
MLN:O!_8\>DWGC/74L;;3=4M[^.V\OPS()-Q@)1&9CG;G)&">U<]_P1(^(=[X
M/_X)L_#&WO\ XA> /#EI)HT,NG6.N67VNX2([@S*1<Q;4:4284KU#'/S5Z)^
MT;K;^)?V]?V*[[_A(_"_BB"X\4^)S!>Z#:^1;;1H4@*D>=+N<-G)W#'3'% ^
MI]ZT444""BDS2T %> _M,_$;Q+\./VGOA._AS3-%U--:^TZ1JPU"\:W:VLIK
MO3Q)+;A5;S9UV@B/@$!B2 ,U[]7COQD^$7A[XN_M-> D\0:='?GP]I=_K>FN
M69)+*\AO--,<R,I!# %E/8J[*<@D4 >P@Y%<UXQ^+^@> M52RU2YNH;B2(3*
ML=A<3@J21]Z-&7J#QG-=*.!2T <'_P -*^#O^?\ O_\ P47G_P :H_X:5\'?
M\_\ ?_\ @HO/_C5=Y10!P?\ PTMX._Y_[_\ \%%Y_P#&J\Z_X);3K=?L*^"9
M8SF.634G4D$9!U*Z(X/(_&OH&O ?^"7IS^P[X._Z[ZG_ .G.[H T/^"D\YM?
M^"?_ ,9)0-QB\(:E(%_O8MW./TJS_P $\_%\OQ!_8D^&>O3V9T^;6]#AOY+4
MDDVS2Y<QY(!.TMCH.E'_  4.2UE_88^+"W_VG[ WAB]6Z^S'$WE&)@_EG^_M
MSCWQ65_P2[\-ZGX,_P"">'P>TC6HVAUC2_#%I:7T;NKLD\:[9 67Y2=P.2.#
MVH'T.E_;JNOL/[$?QBF+^6(? ^M2%]Y3;BPG.=PY'U'(K\Z_V3OV,M9^(WP>
M\)>'=)TZ'X9>,?"GPXTBRUD:=JT+WWQ(L2;6>.[BDDM]BI\D@CG;<8YL1S*
M 1^B7[=DJ_\ #$7QB&]1N\#ZT ?-$7/]GS_Q'A?J>G6O@?\ 9Z_X*(^$?C#\
M-?AOX"ETKXKGQ[H6D6DG@3Q=:^%7AO%F6T02V[F410W *KM=%/EW4(SM1U!
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M*4*"K)P?AGXF^(?V:+#XGV-K\,]2U?X%:]XNUC7-29M!G>#P7'^ZF$D*6O\
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MN?2]"M- T6'3].MK?3[*UB$-O!;1+%';H!@*BJ % '0 8K\S/^"BO[!4_P
MO@%\/]1G^+/Q7\5+:_%KPW*]CJ.IK+977VK6[+B2%B%.QEWAMPP[$C'((!^F
M6K>'['7OL_VZRM+S[),MS!Y\*R>1*OW9%R#M89.".15RBOC#X&:%XQ^-OC:>
MWD^(OB;3;=HKR<JEU<2/OCEMN<^>% /VEAM50%"*!WR >BZ3H5CXY_;Y\2:?
MK<7VFR\/V=MKNDVDT8:WFOC#!"]SSP9;>/RPN?N_;&8<X(Z#]O3X.^&_BO\
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M>0V&!V=15O\ 83_9@\#^%_V/_A]I<_ACPWJ\NEZ1'9M>W6C6OG7?EDIYCX3
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M*R@ S-+)DDI7OGB?Q5IG@G0;G5-8U"STO3;-0T]U=S+##$"0!N9B ,D@#U)
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M _8S^'&A0OX FCT71(;!75;M%?RLID+V'R\"@70]4_;$-H/V1_BE]O$#6/\
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MP4(^$/BZY_8:^+4/_"PO$NK&?PK?PK9?V9IH^UEH641@B!3\Q./O#KU%8O\
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MG6-*UZ3XA"\ATV>4++)9W$.]8XW1F7<F42Y"MPC+L'M?_!*WX)Z%J/Q%\?\
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M]\1:KXE_X*(_L7S:OX?N?#DZ>*/$R);SW4-PTJ_V#(=X:)F4#)(P3GBO$_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SO%W_ "*FI_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH].DU+4]/@TNZTF21Q%%<[D81-;O+A2K*'3SD.X[6%=%K7[2'P\'[3GAM_\
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MF670YYX;>><QVD<!:,&41@EOWL3(75D4,3]\_P#!1?X_^ ]>_8"^-=E9>/\
MPA]LN_ ^L0P&+Q!;HX=K*55VLK%@<D= 37YHV_[8$/Q5L?!OB+3--\?>$_%&
MF^&M(L]8LM$^(UE8:5XHMXK41?;HU:$LT[1*T:3-R%B\MU"X:@%L>J:%X*;Q
MA_P49^#DNK>)[[2$\>V=_P"(?#?B^'5A<37U]8[;6TBE;9&K[HXD60#:FH)(
M"5$F\GZ,_:D_9&US]J;Q3JMY9>)_$'@WXC:7#93>(?!FESVEMI/CBVMG<1WD
M4LL+LSL'VQ2REEB>-(I5  8?$?P)^.WP[\3_ !]^%NNZ_P"&/%,'P5\%>&-9
MT"^AU75$UZXTN:Y=%DS]B0,A5P'9,8A,?F0XXK[R\#_M1>!?&5IH&A:O\4=+
MG!EFE^'WQ"FNXX+Y)$+(UCJ,<FPBX 0J?,"QWL:YXE% ,\5F_P"":OP[U3X)
MIJ^@>+_B%<>")BUCXD-PL0UCP=-%(S31R6J1*T4,;-^\ABV-;L/.CW([UC:U
M_P $F/%W@[QGH.CM\<+[5=.U6W">%?%6L69F>:\D)D,<DT#JN]T^58F_<S1A
M=N)%.?IFY^.VB-XTOO%OASQ1X#T?XK:1%'#XE\/G7[>+2?'UF@Q'+#*SX60#
M(AN#\T1S!/E,%?AG]IG]NO6+/XL^-M+\*Z=<^*OV:+_2X'C\,PB>V71[XH9;
MV.1K<K.JB8E7@CE B*AHUVDF@$>%?'N?7OV;?'FHK-\2A+X]CO6M[NSMU6"R
M\5V,#2PM>VKF$H_ERQ&+S268%'0J,<?6W[$'@:XUK]GC1_'GA[QCH'Q+^&>C
MKJVB^(-!O['RD\/&Y:&>619+>)+F*)) V]6BD>%B)HP(P0/"M8_:#^&O[1VL
MZ?H/Q)UCPM\.]5\"Z*FE>$_&6C^'[G5=2TI3<%UTRY@B80I-%&B%6)9)DGR0
M6E(KGOV4=8U#]EK1O%(^#GQ=N6&C:OHFCVOAR^AM_#=KXZO-0=Q-<M<?(ZQ0
M,%V2E%V(XAD^Z#04?J?\//&D_P 0-+T/2_$MWJ6BZ[:7CVOA+Q9<-%-=VMYC
M<=,O7C)CF9XA&58-Y5] T;J5EQB?Q_9ZU/)XL\1^'[.TT/XIZ;I#Q^+?#+7!
MCT[QE9K"RQW,,A& X'$-SMRN#!,, &/X4\ _M(_%_P"'7P=\8SZ+X=^ _B7X
M=>+9%N-2TS7/&Q%[I=UA8IE:/S_.MDC*Q[D7/D%-\8V]-KQ?^UE^U%JVA>'?
M#FM:9^SH^K2K=6_A[Q<GQ!AEN8E9/EAEE\S9(TT6U2L@VS!-Q/F**"2#_@DA
MHNB^%?ACX6U"\CU7Q+\-=5\':O;^(+*;3[.+_A%Y9-3MKB>0R08N'CB=DRCD
MR6P/F*0N0GN7[?/[;MQ^Q9=:%I6M:#XH\;7UM:KJ7@KQQH$;75]LFD*+9W,:
MQLMP6"(KX8+<(48!)0I'E_\ P3X^$(_8R\+0ZUIGC;X6R_$_PGI5Y!XA\*QZ
MLL:>,([NZ%V$2_EN3"S1!4AM[A(HP-OE3 *!L^?/#W@C^S_#DWB&T\-74_PW
MUC4WN]3TJU^,J:?J'AIY)#YTL$2R QNK%%> QKY'E%U:0;7 /J?IA\ _C)J7
MQ^AU3QKX<TC3M"^(NCRK:>(O#D6H>;IWB^T5$,<\4[1IEPK%8IL?(R/!,<+\
ME'3M0\,6'C[5;B#3[K4OA1J_AU8M8TRXC>*Y\&3"]G,O[KB2*&.3)= =ULRJ
M\?[O.SX^^&,/B7X5?%+X>SR7?@C0]:^T26VG>*XO&.FWLCPSW;3.M\Z2+'*5
M@E;Y!M6Z6./ $D2UZI\7/^"GW@GX.?MD>99Q7^H?$Z7PU GB'0/"]F-5TWQ!
M;1W,BK,UVN%7",##*3E=S13*/X0#YO\ VTO#&D^*_P!I_P 8V&L?'GXL^!-6
MT#59+/P]KGA[PK?:I]H6>"W?RS-!+%&9762 L0/+N-G.948+].?\$R?B/?>-
M6\97/A>74_\ A9'@Z*QL_$WAK7(+C3?^$K@59MLT2WA:<#8Z""YE.?E\B7 4
M&/CM:\7_  \_:(^&DE_]HNV^$5UXEOKY-%C\;?\ "+ZIX6NI7$,PN;':'6&)
M_,.TEC 7\V$^6X\OK?@I\2?!;_$O7/ 6L>--&\':]X$L])C^'GC.+7;?4A%"
MMM*([:XGW*MP[J&26%L)/&JD%90"@-G7?'/]J3X?_L6^ AJ%YINL:_\  CQ:
MMX]_H$%L$O\ P'?0.#*((7=)%C\ULFW3Y[:1-\1",%7J/A)\6;#]K3PEX=F^
MWZWX?UBV2WO_ (=>/+N.!KFXCNK:.XBMKM8I61WEA*^; Y47"+N 25 4_.GX
M\?&S4_CM\</$7C.)OB-X?\:M>VDVM>%+'6],%I=V"JL!N]/2^_=2%Q&'1&*S
M%H3"X5,%NG^"/[1>G_L^:WI]W8Q>+?$GP1NS<_;_  ]-J=I')IEY(P1Y[J"V
M!: 1R R[B"T4D>Z)EC&T K&;X>^*UU\/?^"QNL>(]??0=*\::/\ $S79]<TB
M?Q,+?2WLT\(:>GG;Y,(J28D,4DBKM8HDK (2.E\)_'3XM>!?A[X\U*P^(/@/
MQC\#XK*74['PO#J^EPW'@JZ>>$))?$VXDMM/BN2V]8BKVI="F%4D>0?&+Q[X
M<3_@HCKVGWGBB34]/OOBQ?Q6WB^UO+&5EBNO#>CVT,[J7$5RB,4\U64+.BR;
M"LOW?;_AQ^S!I/V+XB>#M/\ V@;33/']IH]I'XMT.]M='_LKQ)8O&T(>RERE
MM+YA@\Z-I8\H3'%. #\H,Z?X-_$NQUK_ (* _LN6,_A6)=?U35M;U.W^(=KX
MGT?6YO&EE'I%Q!)%?7D#.TLZ3'_51,$Q$"JH 47];J_GI_X)^_%R;P[_ ,%%
M_P!E&/6[:^\+_#G0QKUOH-UKFM:1>'=<0WLSF1(-HL2S-DQG!1B0GR2X'[P#
M]I3X=8_Y'[P5_P"#RV_^+H)9X+XRG^)$'_!1KQH?AWI_@6]E;P'HGV\^)+VZ
MMM@%[J7E^5Y$4F[.7W;L8PN,Y-=R-3_::'_,#^!'_@\U7_Y$KCO"O[1/@#2_
M^"A'C[4+GQQX1@L+GP/H<,-S)J]NL,SI>:D717+[690Z$@'(#+GJ*]OMOVGO
MAK>0++%\0O \L3C*NFNVI5AZ@[Z!'A/[1WPB_:1_:-^$&J^$+NS^!NF0:J$#
M7,>JZI.8MK!LA#;*">..>#@]J\<_8D_X)Q?M%?L5:\]]!KGP>\8S-YP$^HSZ
MA;W962*WC$;S1VYWQJ+?<%VCYY78GH!]N?\ #2OPY_Z'_P %?^#RU_\ BZ/^
M&E?AS_T/_@K_ ,'EK_\ %T >??VI^TW_ - /X$_^#S5?_D2OF;_@JN_QQUCX
M!^"[7QCH_P +DT6;XG^#@W]@ZE?W-\7_ +<M"@1);=$(R!G+=,XK[:_X:5^'
M/_0_^"O_  >6O_Q=?)G_  66^/G@?6OV6O"JZ?XM\'ZI/!\3?!\[0IJ-M= 1
MKK=J79DW'Y57<22, #/:@$?57Q2_Y*Y\,O\ L*7O_INN:[^O%?'WQY\#:W\9
MOAA!9^,_"EW,VKW<:QP:M;R,S-87"J  Y.2Q  [D@5[50!YX_P#R=?'_ -BD
M_P#Z6+7H=>>/_P G7Q_]BD__ *6+7H= '%_M#3^-+?X+^(7^'EMI%YXR%J?[
M,@U-B+:5]PW X_BV;]@)"E]H8A237YM_L::K^T%XF_X(PZC?2R?"2U\)2Z1K
M?V2.[T>XM=4:U6XN5/FQVDBVZS!E895 &P"R@DY_4'QYXVTSX=^$KS6-7O8]
M.L+10'G<%L,[!$55'+NSLJJ@!+,RJ 20*^$OV,?B3HGQ _X(<:Y#I&ZVFT70
M]:L[^PELS9S6,WGW+D/&2?O[MX8$AM_7J #Z'TM^ROX ^(FGZU)XE\<ZAX*E
MCO\ P]I^G6EOX=M;J$%8C+('F,\C98"8@;<=6SVKVZL;X=?\D^T+_L'6_P#Z
M+6MF@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9WB[_D5-3_Z])?\ T UHUG>+O^14U/\ Z])?_0#0!^5'
M_!*34IK/_@F?\)=0%H+_ %33=-TZTT[2KKP8VHZ?J-E+<XN)YKF.TEF)0RS'
M]W(-@M\;/F;/K'Q3L[6T_;J_8X-O?V]_+-XR\427/V;PT= MH'.@28CBMV17
M*!<?.[2,>?GXVCGO^"*'@W4M;_X)M_".\UOPEX[\5Z0OAZ*/1(]*UR"TTZVB
MWR^:3 ;N!FF,S2Y>16^4(%(&170?&/0]>\/?\%'/V4;?5+/Q+I^B_P#":>(7
MT&UU[48M0O;: ^&W\Y/-269C&)0VP22,XRP^Z% !]3]$:_.;]@#X9^#_ !UX
M(\;:9XXTG3?".H67B#QA!#K$][-HNN:I:7/B'4I6*R*8V>Q5&*X9G4L6.%&"
MWZ,FOS8_9Q\2WOBCX1M%^XUO6)_&/BBWTGPY::O(]].+77+ZU65;>6UN1"NR
M% \[RI%D$G;G% '=?\$[-2U?Q7_P4A^.FNZG#J4XO/ _A.UCU:>/=;ZOY%QK
M$?GP3".-)8G&UT(4-LD0G.=Q^J_CS\)=0^(EOI]_HMQIT>L:2)X/LNIQO)I^
MJVEQ&([BTN%7Y@C@(0Z@E6C4[67<K?._[$'C7Q=>?\%!_C!X9\6V\-G>:+X(
M\*7\ML-2;4I8+BZ;4?-1KG9$DNT0Q@%84 PWWA@U]E4"/"_A[^SIJ\*:!HUW
MIFC>%O!/AR^&KC2[35[K6+S5[Y6+HT]S<*K>2CE7"G>S-'&-RJI1NMUK1K,_
MM/\ AH?9+7_D5]6/^J7_ )^]-]J]'KQ3XX?&G1?@S^U'\-AK7VX#Q58WWA^R
M:VM7G"W4]WIWE^85^XA*XWG@$CUH ]A_L6S_ .?2V_[]+_A7CWQ=_8OM/'OQ
M@@\>^&O%GB+X>^*3IRZ1?W&C);M!J]HKF2-+B&:-T9XV9MD@PRAF&<'CVNB@
M#PK_ (9.\;?]%R\;_P#@LTW_ .,4?\,G>-O^BY>-_P#P6:;_ /&*]UHH'=GA
M7_#)OC;/_)<O&_\ X+--_P#C%6/V ?%^I?%S]DGPIK_B>>+6-<NS>Q7-[);Q
MHUQY5[/"K$*  =D:]!VKVVO ?^"7PQ^P[X._Z[ZG_P"G.[H M_\ !1O1K4?L
M%?%\+;0*3X3U 96)<C,##(XKYXC_ &M-'_82_9;^$O@SPY_P@&M:W;:&D</A
M[7M;&GZK?VZ2^5$T!$;;BP24D[,9C/ YQ]'?\%(IA;?L"?&*1ONQ>$M1=N.P
M@8FJ/['7@_P7\;?V7/AUXLN/#NB:RU[I$=U87FH:9%)<QPO(TT8!=2R8)#8S
MP?>@#S[XH_'.T_:@_P""3GQ9\66]IH]A?R^#M=M+F+2[V*YCLYX[252%FD1%
M!(*L-X& PS7Y>_#W]CKQ/^V9\#/V>O$_]E6%K=?V"?#?@WQ9J5W;6\=ZULLD
M,-I*Z;G6[2ZCG=!D1W4"[0$?<I_7W_@H-X,T?P7_ ,$X?CI:Z1I&FZ;:-X)U
MRZ>VL[&)(I)6LY69VC "L6(R<]>]?E&WC:^\._\ !-OP9\,]'.K:I\']<^&=
MCJU\]M=A]0\.>(C.NH27-N_DF2%4EB96B!VH)6==@ R#1[]\+M/^(7[/W[1G
M@#X->#/#6E?#_P ?+X3OM0\56UO/$Z>+X8[AY+<6LSKY*NL*R1PW;1%HI/W4
MB^6M?5O@GPQX$T+X#R0:/H,NJ_!"\CDT_P 0^&M0MW.I^![E"6G9T.9@%E.^
M9-Q>)_W\3%#Q\(?L^_\ !.^;XMZ=\/==\<_&[QUX:U7QQ;R_\(-XAM[Q+HO-
MRKZ9),Y5VN D)*[LI<)NY\S>&]>_X(Y>']=C^!6I>-_#?B76=:^,M[J,NJ>(
M] U^Y>.U\7:8FVVB6"1R5ROD-Y-RH BE9[>0>7C #[GTQK&HZ7X-U_0?!/CK
MQ9IL-Y,3>?#CX@O-;_:;G*%A:W?17F,:D$G]U>1*3\LJD59L&O/%/B^Y\8>"
M[708/BII=NB>(M M[E#I'Q L8B42:WF/RAU.Y8;@_-$V8)_EP5_*[]KOX[1?
MM&>.-3L-/U7X:VWPN\537>E+I6[5H;[0+."Y\Z8R!+*46OEN^9%BE9%D??"-
MIQ7U/_P3T_:KL_&OC'1/A)XL\=>&I_$$D+:OX*\:Z7IEQ8W<^HS!9C:N)(8X
M)%>WVY  2Z4 _P"L8;0+'5:?\ /AWXD^+WQ%\7^&-'TFW^&&JV]JGBW0[CPW
M!<W/A/4)#<-=7,EN_P \+(R(LR(/,APDJ$Q@;>:_:=_90OOA_P#M _LW:;'>
M:9J:1^,3?>%?$^EZ/I5E<:F(=-N)X[2ZF<JLDC21H?[MPARNV5>?:/'7C/QM
M\)?VE]:\7:;HME;>/+JQL(-8\.QZ@RV?C*VMEE62:"/RV<LJR1^3=XS&V+>?
M"[2/DC]NSXE:1^TU=?#7P7X8\5ZM\'O"=WK=_K&IW30FXOOAI-%9SFY5[=GA
M:"%MTGF1%L0%'>,[0% !]A>&OB-XT\;>,E\:>$/A7)I/Q%AACC\4:#)K%A'I
MWB^SB9HO/B)DSYB$.L%SC(*F&;Y2I3R[X8_MZ^&?&]C%I^F?!?QA=?![X@QZ
M@LFGZA<:2H\-W%MB6[*B*[>6WA0-YKQ,JM 0)(OD.%^.?VP_V=_CC^Q#XJ\+
MV][^U;\8/%=N^FG4O#6I^&].29YFG65I85#760TOE$@AO+E!3)#X%<1^RI_P
M3R^-VLWNK^)_!7Q8^*V@>-=+L(;Z&/2M.CN?M[W,<33I&Z786*3R2J;V'#@1
M2>7M)H"R/U.\5?$O7O#$GAK0/$GA+5#JTZW-Y\/_ !G#JFERSW")'&QM+EC+
MLEDD1@I'W+J--V4E4&NP\-7FH>,K]?'_ (0T*TTCXF#3+2[\3^$976.R\8V+
M19AEAE8!?.525AN>Q!@FP #'^(FK?$'5M1CM_#"_M2?'6]\*F2_T>YAN?# C
MCT_+@R(%^U-$D99,L!("C",ID#(^G/''[$G[0'P@\=20^,OVK/CYI'ASPVJP
M^"_%^D>&TU"RU*VDM59XU=;\&!RJ%1&V5E"+M)< 4 ?I-I$WA*/X<7>HV&EK
MK7P9UQY8-<T6>T:.]\#70<F?,7$D,,<@)DB&'MG'F1_N\[/E?]H+]C7P?\>?
MV[?[%\7W]Q)K,^FZ-:>$?'MI*Z,T!@U.>&VO6CD6*X=I$3Y6PMR@;;MDR:]\
M^'O@;XL:-IOB/4E\1Z#+\<]/MA#KNF66C?V?8>)[ 1^7;7*K-/(DUTNUFBNB
MR G_ $:=5508_P \OCM\'OC[XS^*&HQ67B=M:^%OB:X2.33K70;*R>U6S-R/
M(N+9I1-910EKHSPAE\LDD*$Z D>L6/P#\%_$2+Q/X9\(^#K7X;>/O"NE7]]K
M1@\274EA\1(8UEVW.@W%P9#(NZ/<;AU/D9,#+(,2Q^]_L@_#WX??#AOB+/H'
MAV&Z^#>JVVC:=JFDFUE6?PE+':M))*8W_>I$D\TC2#/F6[ 2*?+'R?+/Q!^&
M'[6GQU^&O@NP\1ZO#/X:NK,2^"M:@TK1X)40VP41BXBF5HY7ASL7.)E4%<NM
M<?\ "']K']J/_A8&LWGAF]U'1_'&J>$U\2ZK!>^&]-6TUW2+&*)$NHV>X\II
M$M]JHVU7(D59.BX!GZ#_ +0_["_P_P#VA?$>A6OQ#L[.[\66D"P_#KXEJI>=
M0"98[2XV,L;S-N;(X6YC+%"D@^72^"7PTT_X?>-O$%_X/\(Z?X3^,.EVUNOB
M_P )?:VDL?&%C&'2"YLI9F(5#N?R9AC:Y:&< _,GQI\)?^"@OQM\/_"GQ!X5
MUSX<:#XQLK1+G4=9\/-I5Q:7_A:RCG=5N#:1R'[/ &CW863]S(K-&=H"K]D^
M%O"/Q'\4CPWIWQ1U[PCI.OV\7G_#OQSX<6XN9#<,H/V:[DE*)+YL0"O 5"72
MKN5A(@V C\QM;^'7@WQ5_P %,+[3[BVU+0_@W<?%[7%O+'1=,EM-1\.S)X7T
MZ:2X)Y:*&&X"%U$?[DQ.ZG9T^K-5_;3_ &=CXGU7X:Q>-_%=I\2M/U.ZG\,_
M$'2]"N+_ %>_NF413M<'RS'=#RXHUD&#;SP")D\LA=GS))K7Q(?_ (*Q:_J.
MA1^';3X]Z3\2/$5R^AQ:C)=Z;<PQ^$;)$DBB=D!$L:R%&<(VX^6S#:,:&E_&
M:S\$>!_'LA\$V'B72=>2^$ N_@JR?\(1>F99"S(H%R8P!.LD,>T0.ZS(%0[%
M"CW'Q1H^BQ?\%G_V1-/OO#B:#XOT'P]J&E:G;R:>]_;ZG%#83I:WT-SM5&5T
M3Y+AAYBC=$ZJPP/T/UG]KSX*^'-<GTR_\?\ @"TU&UF:VFM9=2MUECE7(*%2
M<[AM;C_9/I7YE?"OXI>,OB?_ ,%)/V$K_P"(MU'K.O7_ (?U^[L=4O=%GT>]
MO;;R;J-&EM8W9(9@JIRQ:*97$BE3A*['XN_&OX#Z-^UE)>^%?#E[XDOM4M99
MGOH=4OK#4(6FEN8)RC.I A\N1MH1"VV<DE ,4"/T$_:6D\<0^ DE^'=AHD\,
MR;KZ\1?.U*TMV'S36%N5\FXG"\HLDB*2!P_"-U?P<\.^%K7X4>'$\,16UQX=
M&G0'3IO+R9H"@*.20"68'))&<DYYKPB]^&?A7QO^WCXIT7Q*IGTC0O >A'3+
M2?4YH8;8M=:BKLBB11N*QQ@M@DA5YKW_ ,#6OA7X:^#].T#0[C3+#2-)@6VM
M+9;L,(8U& H+,2?Q)H)-S^Q;/_GTMO\ OTO^%>=?'G]IOX6?LP1VC^/_ !#H
M?A:.^5GADO(B$8*0I)8*0.6 Y(SVKOO^$NTK_H)Z?_X$I_C7PA^VS^S3\3/V
MO/BE?:?XM\)? [QK\,[.>2/28[G7;RVOVMFPRF:-76-I4D"D#)4C)!4F@#[.
M^$/Q/\%_'KPBNO>$;S3];TAW$:745N51R420$;U!(*2(P8<$,"":^;O^"TEI
M:Z;^RKX2D%E8NO\ PM'P:KK);AU8'7+0= 5SU!ZCI^%<3\,O"_[4?P'\!:=X
M=\":=^S[I>GV8D62/4O$6H7OFA85CM@K,2T:QQ0PPA 67 #9&"A[#_@L'?1>
M*/V4?!-B+VTGOY?B9X,:1+61),NNMVC-M!8<9![]Z /H/XGZ7:Q_%WX9[;:W
M!_M6\.1&/^@=<^U>C5QWQ4\ ZOXLU3PYJ6B:EIVGZAX=O);E1?6;W,,ZR6\L
M#*0DD; CS,@Y[8QSD5?[+^)G_0<\"_\ @BNO_DN@"N__ "=?'_V*3_\ I8M>
MAUP7@WX<^(X/BE+XG\1:OHMY(-*_LN"WT[3I;95!F\UG9GFDR>   !WZ]N]H
M R_&GA33?'/A74-(UBP@U33-0@>&YM)EW).A'*D?R/8X(KX3_8O^'^G?#O\
MX(/7EKI]H(#<>']<N;B1@/-N)&NKH[I&#N78#";BQ/R<XZ#[9^,FB^(?$7PR
MUBR\*ZG;Z/X@G@Q9W<ZDHC @E20"4W*&3> Q0L&"L5VGX-_8$\ >)_A__P $
M*_$47B2XG1+_ $K7+S3=,G8RRZ1;O/<$1&9E5I S;I 2.D@P2,4 ?H!\.O\
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M6?VCOAM%I^NR:&V@P7&N3*+6.XCU.*WOM-+VL@<9"N&)#*0RNJ'G&#V?A?\
M: 2^\3:9H_B'P[K?A&^US<NF-?/;SVM_(JEVA2>WEDC$P16;RV()".5W!6(E
MUDY_:@\-_P#8K:M_Z5Z;0!WHX%<SXR^#?AKX@ZHE[K&EQWMU'&(5D:61<("2
M!A6 ZD_G73UPOQC_ &FOA]^SY+I\?C;QCX?\,3:L7%E#?WB12W>P9<QIG<P7
M(R0,#(SUH 9_PS#X$_Z%^#_O_-_\71_PS#X$_P"A?@_[_P W_P 77'_\/(/@
M5_T5'PG_ .!7_P!:C_AY!\"O^BH^$_\ P*_^M0!V'_#,7@0?\R_!_P!_YO\
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M_)+X7M_CE;^(H_%?BBS27PO-<_\ "++';Z[>6D1NM[2NTGEP(7$'SDER-N<
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M_!/[]F&]\/\ [%7PSTZ[\;>/+.ZTW08+.:"UUA6@B>,;"J%HR2H*\$GI7?\
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M[YKEVU7?)+*W5Y'D9G9CU9B:_1$\B@#XO^)WQ@_9U\7W?B'P=XM^.7B#4?\
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M>_\ @9>?_&JS/AWXDNO&7B;X7:Q?%&OM5\$W=Y<,B[5,DATMVP.PRQP*]6H
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MU>DT >'_ /!2Z+S_ /@GQ\:(^?WG@W4T&!D\VSC@=_I7A?\ P3-\%>$/@?\
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M];2 ".YMG"(KQ2"(H28T?=$ZNO0M\0?\%3OVW?A7^R1/X%\(_L]?"_X2>/\
MQ3K/BJ70M0TR&*XLIM&OK7Y8%ADM6B,<HF$B95A@I[4!N?<&B?\ !)_X+/;V
MU[K?A(:IXE>*-M1U/^U+M);VX$91Y3MD4<[GX   =L 9Q7Y*_P#!?C1[7PUX
M=&EV-C;WUKIGBBVM;;2Y?.N%:./2K9$5DC E; 48(D)RN2  <^L_ K_@L9^V
M%IWPSD>?P+\++C3M.U"6V^T>)KK5!J5I"4,D8F" R,B-F(R2#S J&23*@R'Y
M4_;U?]I7]LW5K6#6O"G@?3K/7)FURRO=$U.[L[4W<.CQW,]M#>3R!'D6V",%
M1 9MQV.ZF@:33/UR_9%L= L?^"?7P\,H'C/X-ZYX3TVW\06&7FN?"5VMM#YL
M\07]XL"R@NZC#VS@2QX3(3=M[.ZT3]I+2O#'BKQ2TNI2:!#_ ,*Z\?J!))>E
MIYF6UO&&(FG9 H*EMEZBEE"2(=N9^Q?J&K/^S#\.-<\$:;#IOQ"TWP1HDVM>
M%KR=(K;QIIPLX4AN8I1\JS&-=L4Y^ZP\F<8"LC],OO!FH>)=9FMM*N=9^#.N
M>'EM]>T2>%XKSP'<)>R^:%MU42Q)%-EI$#;[5U62+]WG8$GHEW;:_'\0-1\4
M>%].MM*^*FEPQCQ7X3:X$=CXWLE^2.YAD;@2X4B"X.",>1/@ &/D/B!>6MQ^
MS+XFNO UHFL?#37K>:WNM"O;0)<> ]05QO'V=U)BBCE!,D;#-K(HE0>5D)U!
M%]HFMZ!X1\6Z_*]\TGF?#CXC)M<W[LA*V-Z5PCW!C W*2([R-=R[95(6>YMM
M>B^(&H^)_"^G6VE_%72X8AXK\)M<".Q\;V2_)'<P2-P)0%(@N#@@CR)\  Q@
MCY\^&?@G]HB+XS>'[+XF^*[)=.FU.-_A_P"+8+?39BD7V2826]_+&@::XF/V
M?"*RI<1QR'<'5<>WZ+K7B*Y^(VK:SH^E6VA_&30H(CXP\'"XV:;X[L%_=Q7U
MG*^!OPI$-P>4(^S7& %>.71M8\+0?"V[O]/LGUOX(:VTD&N:'/;M'=^ [E6S
M-^X \R.*.7F2(8>U<>9'^[^Y:\8>#IM2N_#OA[Q#XBN;?6;>8S_#?XDP!)9S
M,Z$_8[H@"-W>,!61L1WD8R-LJ_* 0Z+K/A:/X77-]86KZW\$];>2'6=&FA:.
M[\"7*M^]!A_UD44<HS)%P]JZ[T_=_P"KL>-O!4^K7OA_0M=\07%IKUI*9_AU
M\18%225Y'3/V.ZQA)&>, /&V([N-=R[94^7.T;6?$5S\1M6UG1M*M=#^,FA0
M1'QAX.$^W3?'5B/W<5]9ROA=^U2L-P>5(-M<8 1X[.C:UX6C^%EU?6-NVM?!
M+6VDAUG2)HGBN_ ERKDS Q?ZV**.49DB&'M77>G[L?NP#X1^&.L#6_\ @LAX
M/'B.2QTCXB6_QE\0?VKHUMJ=S<6LL \&VJ0W<"* I5G63:\BJ55O+<[E2OU/
M^+/QH'P^U72-#TK2I_$GBWQ!YC:?I4$HA'DQ[?-N9Y2"L-O'N0%R"2SHBJS,
M!7YC?#V*XT;_ (*U^"M-OFFUF.#XV>(I-/\ $=SJ$5L]^C^"[$B A!F>18Q&
MV,!)1^\SN4BOTF\#-N_:@\>B]V_;!I6E&P#=?L1^TYV^WV@3;L?[&>U V?G-
M^TK_ ,$[M3_X*M_\%/?B1IGB_P ;WGPUU7X3^#_#MM&_A2&.\BU!;Y[^<[WN
MDW IM"_*JANI Z5)_P 0L6E_]''?%+_P6:?_ /$5]\_"S]E:Y^'/[:_Q9^+#
M:S#=6OQ+TC0M.CTX6Y62P?3ENE9C)N(<2"=2!@$;3UR*]GH"[/R?_P"(6+2_
M^CCOBE_X+-/_ /B*/^(6+2_^CCOBE_X+-/\ _B*_4'XB_%/PU\(="75/%6OZ
M1X<TUY1 MUJ5VEM"7()"[G(&<*Q_ U5^&WQN\'?&2.X?PGXHT'Q(EH%,S:;?
M1W(C#%@I)0G@E6'U4CM0%V?F1_Q"Q:7_ -''?%+_ ,%FG_\ Q%>$_MQ_\$4H
M_P#@GQ??!+Q;IGQ5\<?$&?6?BYX9T:32]2TZU2,H;IIO,#0J'RABZ?=Y)/05
M^ZU? ?\ P<%79L?A!^SY)Y<$W_%]?"JE)HQ(C R3CE3P:!IL^M/BMHJV'Q#\
M"W8N+R0WWBE"T4L[/%#MTN_7]VAX3/4XZGFNX\6?\BKJ?_7I+_Z :Y/XR_\
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MNKR:XG$YFDE^R8+(QEV_+G]Z>?E7 ,_7;_A(?B/_ -"GX._\*BX_^0:^$_\
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M** "BBB@ HHHH _/?]N'XA^)_P!GO]HCXK^,_AGXA^)UU<66B:5JGCRP\/\
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M</VO/B3J_P -/VF/@Y)H^LZ+I,FMW<FCW4.H(&;5+>:\L!);0$D!9BH+J?\
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M$OAM? VN+8>-[:#""5";7]U,JX,%Q( 0"(9OE(9*/Q%_8!_9S^)OA?PAXO\
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M"J/PM\5_B!J'AOQ5X[DL=1\-7\6F#2Y%N;#4+J5E6&TCE0^="K@+(%!R N.
M!I8^RJ***!!7@'_!1'35U/X<?#Y69E$/Q-\*SC'<IJL# 'VR!7OYKX^^//B'
MXM_'/X.^%O$47ACP$NA6?C#1M9BM4U^Y34)HH-4B"(2]KY2NWRYRQ R<9XR
M>D?M_>%?B#XU\"^#=.^%OBO2?!7C:?Q0AL-7U+3A?VUMBQO2X:$@AMR!E''&
M>HZCL=2^%?B*/P1<+>_$;Q7-=BQ87#Q6VF(DC^6=Q5?LA(!.<#/ KC)_BYK7
MCOXM>&=$UWPS%X>O_#_B.UE?R-534(I//TW5"$+*B;)%$88J1]V6,_Q5[;XG
M_P"1;U#_ *]I/_030!\??LGZ=\9?B%^SEX1U/3K'X._V>]@MM;FYTV99GC@+
M0JS@;AN(CR<$C)/TKY6_X+A?#3Q)X[^'G@?P!\7/A=X9U3PUXSUN*QTOQUX2
ML5,O@O4V/[LR>8595E4%>08Y!E3\P2OK/]AGX;_%C6?V5/"-SH/Q-T;1=(FA
MF:UL9?"R73VR?:)?E,IF7?SGG ZUY9_P4W\7?M*_ S3_  ?873^'?B5\)O&6
MJV^D>*=2M-*^P7WAQVF4PRM&OF PLP4>;D;' !QN4T%'U-H7["_PM\5?#W3(
M[WPS(Z7%G;R,%U:]78X565E(FRK*P!5AR" 0<BOG[_@BI\,/#7B;]G.VUK4?
M#VBW^K:I:Q7MU=W-E'+++-'J6IPH^6!VE8X(0 N -@( .:^V? X=OA]HX1@K
MG3H=K$=#Y:X-?+7_  1XU;3M=^ <%YI%K!9:7/IT1MK>&R^QI"!J6JJP$7G3
M;<R*[?ZUL[L\9V@%T/K^BBB@04444 %%%% !1110!B>/M6L/"/AB^\17MH+E
M?#MI<:@"L:M,BI$Q?RR>C%01U&<X/%5/@O\ %"S^-WP>\*>,].@NK73_ !=H
M]GK=K#<A1/#%<P),BR!20'"N <$C(.":\-_:A_X*4Z5^SCX]US05^'?CKQI;
M>&(]+AUW4-'2T^S:?=ZM/]GTRT*SSQO(T\NT,R*R0K)&SD!N/1/V5/VC_P#A
MH#0?$5I?^$]2\">*/ NK?V#KOA^\N+>Y.GS_ &:"ZB\N:!FBEB>WN8'5E(QN
M*E05(H ]4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.\
M7?\ (J:G_P!>DO\ Z :T:SO%W_(J:G_UZ2_^@&@#\WO^"'WB2X^$_P#P30\$
M>)M)O?"=W9P^%[6X\1Q:I%=6UUIK*95@2.YABE\]60!A;A"Z-)D9\T"M3XER
M6^J_\%'_ -ES6&G@&NZSXZ\0SZUI\.ESZ:NF3KX8VHIAG592SQ;',K@>9D8
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M,G'_  B^K'&>/^/O3* $_P"&G? P_P"8X/\ P$G_ /B*/^&GO W_ $'1_P"
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MK'<V]AX9N;:6Y:,LJJRI""Q4[P!V^:OI#_AA3X+_ /1*?A]_X(;;_P"(I?\
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M4$%X\+",<QC(_P!@9Z5X3\8_BU#\.?VH_'.D:9\#/"7Q:O96M;JY?4=-\_\
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M@_0?3W[?'P./[2'[('CKP6FA67B6?6]/V0:;=^7Y=U*DB2(/WA" AD!!8@9
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MWU&6>26.-)+N03$&V6,H3'L.'X,L>"VZ@+GSW_P3*_8.\1^$OVN?AWXLU/\
M9WTWX<Z!X-T*]$.OS7^F7=Q=R30I%;X-L=[R[7FS*P)*MRPQS^JE?.$VFW_[
M/'[8'PI\%>&=>U:'P-XNL->GN/#]P8I[2Q-I%:&!;5V3SH8E,KXB$A0 @*J@
M 5]'T""O-?B9^V)\,/@UXU3PYXH\;:'HFNRJKQV-S,5GE##*[5QEB1S@<]*]
M*KP_XY?\$Z/A+^T9\7;+QWXL\/7E]XKTV)8K/4(=6N[5[0 8^012*%)&,D#)
MP,]* /6_!7C;2OB+X9MM8T6\CU#3;S=Y4\8(#%79&&" 00RLI!&0016K6-X"
M\"V'PW\+0:1IOVHVL#RR[KJYDN9I9)9'ED=Y)"7=FD=F))ZFMF@#\Z/^#AZ_
M;3-%_98G3<&7XY:&H*[<C='<+D;E9<C.>5/2OT6 P*_.O_@X7MH;S3/V58YR
MHB;XY:&3NN%MP6$5R5!D96"Y8 9*GK7Z*T#Z!1110(\&_P""GQQ^P'\4><?\
M29N?3]XE?#'[2GP?M/'?[.?[*UMX'^&?B:U\7RZMIL<#W%[)H=OJ>[P]>F15
MO(Y&>&3"[T<#Y2F2" 5/W-_P4_\ ^3 OBEGI_8S=/^NB5XW%>^)I_!W[%":K
MIN@VNFC7=-\F:TU*6XG<_P#"+ZEMW1M B@$9)PYP<#GK0.^A\1^!_$6EZA\1
MO&GAZ"PU>\OK.2*Z,FD>-+BX2SO8Y&+)+:$[(XHA(Q61R!M2)U\O=E:O[=O[
M*WQ,^%4G@#Q;)-XCL=8M/%ME-/!?>.)7^R%[TVD)9(YB5:0&-ED@A^42[C\R
M5^KFB_\ !//X.>&]=OM3T_P3:6-_JCN]Y-;WEU&;LN<N),2@.&P 0<@@8QCB
MOSC_ .#B/X)V?PD\36?Q/OM4T4WOC;Q/H<&AVYTQ_MB7.GVT[O$]VC+(D#H&
M8JCC)&W;N8.H.]SVGXS_ !&\>> I?C[X>>[&A2^'OAG'>Q2:)XVU77DM[Z6[
M=6_>WJ(8+A(O+.V,?=G0L>5%=AN^#^K:Q>_\*T^*/C;6_%_P^\8:/8ZM82>)
M+^06;?V[#83QRQ2X#H66>,XRIVGDBOFCX=?M,:M^T)\(?CW%J%AX)TVT\.?#
M@I:Q>&]/N;2-FFO]TKS&>61I)69 2^<DY+$DU1_8IL=0T;]N7]IVVO&*0R>.
M;"Y@@:,JT8?Q\[;SD='4H1C&=ISG:M 'UI^TIXGO;_4_'?B3Q'\0[?PKI.B:
M1K,%J9[.SCM86MM4M4M(GDE4EC+.(EP6!9G"KC(IGCO_ ()^>)?!WPS\0:WX
MT_:,N/L$"WFNZKK^J^$=/BN;"1C#*UZ)D*^2]L+6$1.H'E)"!SS7D/\ P4UU
M#PCXQ^!GQ4\&Z_XHG\-W%Y<WN)+?0;O6;A)X_$-A?01_9;=?,82K;XWCA5;>
M>!7RW\8O^#AKXQ?M3?"?6?AIXC_9RN_!^A?$C3I?#^HZY%'JE^^@VUV#;RW9
M@6U4R&)7:3R\J6V8XS0!^F7[-G@^?]L7_@F^+&[\6KKTWB35=4GC\106XLX]
M=2'7+AX;@QQ8"17,<,9?RL?),Q0K\I'S#^QE^R9X3US_ ()%:Y\2]9\.>&K?
MQ-J.GZS?V,6BVKV%GH8@GG@2.!$8+C]SN/RJI+'Y1DY^J/V"M%MOV-_^"9_A
MK2+>]E\86?@2VN["#4+6W^SKJJI>S(MP%8MY41R&9B2$0,Q) KQ']A'XCQ>/
MO^"%WB&"*R6V_L+2M=L&GMX62RO2+FY<RP,7?<#O^;YN'W# &  1]]?#G_DG
MVA?]@ZW_ /1:ULUC?#K_ ))]H7_8.M__ $6M;- @HHHH **** "BBB@#X5_X
M*D:)KGA+Q_X6^)DGB_Q%X5'@O5H[?PV\/BWPQX>M2]S9S+='S=3LY7D#A51[
M9V8/M2157RLUVW_!(J6WUWX5^/\ Q&=>O?%&L^*_%\NI:MJEYXLT?Q)-<3_9
M+6)5\_2X88(TCBBB1(2F41%YP17*_P#!3O3_ !Y\/_C5\,_BO'XW^'O@SP=\
M/=0F$&J:[X,O]9@T9[RTEM[B349H;V)+:T<&-5N/+'DO@/((Y'KVC_@G]\=_
M$W[1'PBU#Q#K^H:)KUE)J31Z+KNB^&[O0M-UVS\J)A<VT5U<32S0EV<+/E$E
M"Y0,FUW /=J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
MO%W_ "*FI_\ 7I+_ .@&M&L[Q=_R*FI_]>DO_H!H _+;_@F9X1MM6_X);_!.
MZT;QWXGM_$S>"C;7'A6.XU:YTBXC-S=!)9(M/S+:RG<?WH!# #=')Q7HGCG3
MM T3]K;]A73M UBXUC^R]<UZQU!IK^ZNFMKJ+PV5>/;<GS81@*PC*IPP.T9K
MF?\ @B]X^T+P=_P3F^$EGIGQ/O?"_B"?PQ;WNL:-'HG]J(-TT\<%S@1%XRZ0
MA?O[&\GA0P8GLOC;%I-W_P %$/V1M6L->U+Q-?ZOXQ\1OJ>H7MD;,O+'X<:-
M$2+RXPJ*@&, \LQ+$T#ZGZ%5^='_  3WUSP[JWP:UZP\1^)]5T;R?BUXHT:R
MM8+NS\HO/K-_<"8QSQ,4^\ZE@3G:/>OT6'%?G)_P3^OI= ^#NO2ZA\.(/%UE
M>_%?Q0(;^[MM.D2&Q&LWZS)$T\T;^8)U<[<$?.Q&<T >E_L@V46G_P#!7#]H
MB*#5[K78E\">#-M]<3)-)<?O-7Y+H IQTX':OJ3XK?%NU^%UMIT7V&_UG6=<
MN?L>EZ78JIGO9-I=CEF5$C1%+O([!54=R54_+/['(M5_X*T_M"_8M$D\.6W_
M  @?@PKILD$<#6G[S5\J4C)0>ORDCFOH#]HOPW>R:GH^NQZ1/X@TBSLM0TG6
M;"SC9[\VEY'&&FMU5E+LC0J&12'*.Y3+*%8$+X*_:/FU+7])L?$.@1Z+;^(Y
M&@TC5;+58=4TR]N%#,;8S1[3',0CE0R[6V, Y;"G4UDY_:@\-_\ 8K:M_P"E
M>FUXMX%^'5[XW^'.B?#[3[WQ#J-K9^((M9UGQ1)H4OAS[-%#,)XH+<%$>2?*
M0Q%U!P@D+OOPK=)K/[-]D/VG?#G_ !5?Q%W-X7U3+?\ "3W7 %WIW ^;C[QS
MZX'I0!]!U\,?\%6/CSX_:\/P]^&OC&_\,^+]16WM-%T32+#SM<\87T^Y]L4I
M=1:6,$,;-<79&V/>3NR@CD^H?^&;;/\ Z&[XC?\ A377_P 57QO^U#\!]7M/
MVP?$ \)>(/%'@26'PGITGBWXP:MKQ*^$M 2XNY7L;4S$J]U-(CMAQY4*_O7W
M-Y:$&C&^!-I\1_V:O&NH^$O!6K_ ?3/^$:LSJ?Q9\8-H%Z]CX;E$'F^3<:E/
M>^;?79^\4?R_*B_>2>7OC1[(_;__ &@?^%5-XQ.H>"?L7C#4O[)^%6BGP9>1
M^(?B7)L)$Z63WBFRM6(+B69OEMQYT@C4JK<=JWP[\(6/POT6_GTSXF?\*CU"
M^\OX7?"R+6+HZ_\ %O63,+I=7O5F;?';^://'V@X"EKFY(S'$)+7X->+]:^,
M&JZ=;_$/5;[]H)=.8^/_ (B+K4LGA[X':#(PN?[)M#(0DUV4&Y1( SD&XN-L
M2QQ$ U? W[7WQU\ _%?6?!EQXP^$L/B"RU>?5OB->+X6U*;1/ T1M(92&O!.
M!+,^1Y<)5#Y:O*[1J%#>V_ K]NK2?V@O@-\#_%_B#5[";5M2\033W,^EZ9=?
M8IU2WU*))8?E?*.H1AAF^]UKYRN_A;\/+?X*)<>9\3XOV=[^]>#PUX2@U>ZG
M\2_'[7)Y!)]L>-B)6M9)5,B[BOGJ&FF*6J*K>E_L=?"#4KG]AWX!WUG=>*;/
M6[SQ#=QR:/\ \)=/:6EBV-5WPK+$CJ-FTKE$PV.,!J /L:#]J[P%=:A/:1ZW
M(]U:JC30KIUT9(@^=I9?+R VUL$]=IQTKB?@#^T_X&\-_!/23>ZT]NBRS(9'
MT^Z";GNI HR8\9)8 >I(%<'X/^$'C>;X^^-H0-6+PZ?I)8?\++U 8!^UX^;[
M'ENAX(&/?-<]X>^$_BV;]G71)[R?7;>Q?6+19KB'XA7TLL2G5T4LL1M55F';
MYQZYH ]HUWX]>%KKX^^&M22\OVL+30M4MIIAI-YLCDDGL"BD^5@%A'(0.^PU
MP?[9FA^"_P!H?X0WFDZ'XV\5^!+H"2:>;PSI=Q;7.K1^6^ZTD<0[O+<L?ND-
MNP0?7V;_ (9MM/\ H;OB-_X4UU_\51_PS;9_]#=\1O\ PIKK_P"*H$?)OP]N
M_#?[$_[*$ITG6_B1XZUW7[K3'D.I>&+[Q%J/APR+#!.]O;QVQ<I#'YCK%MVA
M\Y^5F%>,?L[?'/X/^!_^"UOA-O#D?C3PKIM[\(M4L=GB[0M5TR^U?46U6WN'
M,$%W$COF*.5R($$2A&P%"X'Z,_\ #-MG_P!#=\1O_"FNO_BJ^/O'?[,.F7__
M  77^'PN]9\57?V7X-ZO>6%Y+K4SWUC.NJVL+&.4_,BM%<.I"GG<V:!GTM^T
M%\;O#WCGX4WVE:-<:A?:I>SVB6\$6E7>Z1A=0GC,6.@)R>!CFG?\.Z/@\GC?
M5O$D7A-K77=<>5K^^M]4O(9KD2[_ #%8K*/D(DD&W[N'88P<5U/_  S;9_\
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MJUU-LC A\N&)W9F,0 5CDA1SG![O6OV"8KWQ7J6K:9\6_C7X=?5FCDNX-/\
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M?L-_M+Z=$8I6$\NFI(@=8V9%*QAF^=PJ9 .-V3P#3O$'_!:;XIZ;K=W;Z?\
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M_$_XU:K\0OA['>?!W0?FU.\1(3XNB87&[3;M64GR^!L+'\,=ZY/Q=\9_$/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 54UK7;+PWI<]]J-Y:V%E;+OFN+F58HH5]69B ![DU;KR7X_VN
MG:M\5_AU8ZYY1TN>XO7LDO(?,L)-76.,V0F7@,P7[2T:DC+H"OSJA !VO@;X
MR>$_B;//%X>\2:+K4UJ TT5G>)+)$IX#,H.0#V)&#6-K7_)T/AO_ +%;5O\
MTKTVO&K^X\?7/PU^%NL>,--\-V?QODUZ&VTV&U8PF6S)/VN.X9/,(0V@DEE5
M-T:N(\?,J&NEUK4OBF/VF?#F=(^'WF?\(QJNT#6+SI]JT[))^S?[N!CUYZ4
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M'O7EFL_L2?'35?"VA> 4\ >"(/A6+J36/&MD_P 0;B76_B;J+D,6U2^^P M
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MGP-X2TSQEJQ^#NMI+8WVN?V/''"=7T_,@E\F;<P8*-FWD,3D8Y^I?[2^*_\
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MMBNY_9C\ Z)\2?V'_A/IGB'2--US3CX1T64VE_;)<0LZ6<#(Q1P02K $''!
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M4\$>QKLG\!:')#Y;:+I+1E&B*FSCP4;JN,=#@9'M7BWQ1U#XH'XI_#/S-(\
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ME>/?#]QI6MZ=9:KIMVH6:VNX5EBD .1E6!'!P0>Q&16E7SE^WW\=]:^%NH^
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MM.CU+4M0U'5;/[7<I+))''!:K,_EY_=2%Y&5PH* +E]RI_PH?]G[_HB&F_\
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M@J"\R] >%<]J]?TC_@I-\$]:U.&TC\=V$4D[;5>XMI[>)3C/S2.@11QU8@4
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MOZ!H&@:!;+9V.FV.GS0V]C"@X14$>% '^-;)_;_^#X4'_A-[#!. ?LUQR?\
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M>8T<%C>&24DA54$RA5RS*"[D(H)9F502/ Y?$GQ)O?V!_B!X8U;_ (0.SN_
M&B3Z%K]K:"YN?*D6T24B&X#[')BE0\J"K$JRC'((]DUWX!^!%T3X3,/!7A'-
MQJMLLI_L>W_> Z;='GY.>0#SZ5Z9_P ,Y_#W_H1/!O\ X)+;_P"(KR+6[?XI
M?V-\*<W?P]V_VG;>1_HE[P?[.NL;OWGIG\<5Z3]F^+G_ #^?#G_P#O?_ ([0
M!QWA7]G[P&\?Q1SX(\('R-8E6/.C6W[L?V;9G ^3CDD_B:U_V?\ ]GKP!=?
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MFG*+J8NRXA4@!MN6^884T >VU\'?MFQ/>_MO>(;7PMI?A[P]XWO/!>G1:O\
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M4T#2V&/%&H9)-QJ/4^=D].!VY]37LU<9HG_)P?B7_L7])_\ 2C4J (9OV?\
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M:FGP7Z9S9W&Z.-XG)5E5@&4L C;&95;IM:4_\-/^&SCC_A%M6&?^WO3: .\
MP*^4?^"HO[-OC[XZ0?#+4/AUI'ASQ'K.AZW=V=QI_B1A_8UG;7UA/;OJD@P6
M\^U.PQ%%9OWSK@!BR_5]>1?MB?M&ZC^S[X!TV/PSHT/B7Q[XPU&/0_"VCS2M
M%#>7CJS;YG4$I!%&KR.W]U,9&<T <I_P3F_X)^V7[ /P5TCPXGB[Q1XOU6#2
M+33M1O-0OYWM)Y( _P"]@MI)'6V!WXV(=N$7 '.?HBOS<\?ZE\6?B-\7[_PW
MI7[17B2P7P%(+[XJ>-[&"QT_PGX+@1!*^E6J20M]IOV3[S-(%MHVWR@NR1F!
MO$/CR&Q;QA)\4_V@CH'C(C2OA9X(6YT^+Q5X[N@/,;4)M]EBQLMGS?O4'E0
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M^8=Z .T&D_%7_H8/A]_X3]Y_\FUQ'[.6E?$]O@WI/V?7? *Q;[G ?0;MB/\
M2)<\_;!_*O>:X+]F7_DB>C_[]S_Z4RT 1?V3\5?^@_\ #[_PG[S_ .3*/[)^
M*O\ T'_A]_X3]Y_\F5Z%10!Y[_9/Q5_Z#_P^_P#"?O/_ ),H_LGXJ_\ 0?\
MA]_X3]Y_\F5Z%10!Y[_9/Q5_Z#_P^_\ "?O/_DRC^R?BK_T'_A]_X3]Y_P#)
ME>A44 >>_P!D_%7_ *#_ ,/O_"?O/_DRC^R?BK_T'_A]_P"$_>?_ "97H5%
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M6=G C4+&?W<>0#]MT <+_P *#L?^AA\=?^%)>?\ Q=<%\6_V:_'>L>*/#_\
MPA/C[4="T:U,\^L_VEJ=_?7.HGRRL-O&!*JPH7.]Y<EAL"A2&./=Z* /#OV>
M_P!F#QAX6^&=O:?$OXE>(?&/BSSYI)]2TN]NM*M3&SDQ1K )6QL3"EBQ+$$\
M9P.W_P"%!V/_ $,/CK_PI+S_ .+KNJ* .$?X#:?&A8^(O'( &23XEN^/_'Z\
M*B\1_#^+XVR:XWC7XACPM=Z3!IL.OG5-5_L62Y%U+\HOL?9R""N'\S8<@!LG
MGW?]IC0[SQ+^S_XOL+&TN-0N+K2YH_LEOGS;Q"OSPICJSIN4#N6Q7AN@?%/P
MU9^(-=\6W.KV)^$U]HTEF+5];^W0ZPCQPI;6-KI.U6M98U6YB> 1B1VE53O.
M1& >X#X!V)'_ ",/CK_PI+S_ .+I?^%!V/\ T,/CK_PI+S_XNK7[/NBZMX<^
M!OA&PUWS1K%II-M%=K+)YDD<@C4%&;^)EZ$]R":["@#Q?XT?LX^*-8\');>
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MXS7.O>$+;1!:W6G6$-Y87=_J7RDWGG?:G$48^=1"JD'*G<#D5Z__ ,*#L?\
MH8?'7_A2WG_Q==U10!PO_"@['_H8?'7_ (4EY_\ %UY/^TQX8\,:5I \.1^)
M?B3J?B%KK3K]M,TK5=3U"[BMDOH6:9XX-[1IM23#-MR4;:217TBW2ODSXEV\
MPU'QQX;TT7&F?$6]\4QZRETVJ_V<UQ8,(Q!<AS-")X8XD> HIE\IT.8SN&X
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M!C:[\.] \4:E'>:EH>CZC>0@+'/=64<TB '( 9E)&"2:V:** "BBB@ HHHH
M*S/$G@K1_&<42:QI.FZJD!+1K>6J3B,D8)4,#@X]*TZ* (-/TZ#2;.*VM88K
M:W@01Q11($2)0,!54<  =A4]%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840053600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 20, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacira Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001396814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,711,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840470736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 54,126<span></span>
</td>
<td class="nump">$ 35,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">257,221<span></span>
</td>
<td class="nump">136,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">31,658<span></span>
</td>
<td class="nump">29,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">41,411<span></span>
</td>
<td class="nump">31,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="nump">9,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">391,110<span></span>
</td>
<td class="nump">243,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">60,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">107,046<span></span>
</td>
<td class="nump">101,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">55,197<span></span>
</td>
<td class="nump">46,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount', window );">Equity investments</a></td>
<td class="nump">14,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">628,371<span></span>
</td>
<td class="nump">391,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,658<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">41,057<span></span>
</td>
<td class="nump">36,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">56,217<span></span>
</td>
<td class="nump">44,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">276,173<span></span>
</td>
<td class="nump">108,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">16,498<span></span>
</td>
<td class="nump">18,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">348,888<span></span>
</td>
<td class="nump">172,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001; 5,000,000 shares authorized, none issued and outstanding at December 31, 2017 and 2016</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 and 250,000,000 shares authorized; 40,668,877 shares issued and outstanding at December 31, 2017; 37,480,952 shares issued and outstanding at December 31, 2016</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">669,032<span></span>
</td>
<td class="nump">565,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(389,136)<span></span>
</td>
<td class="num">(346,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">279,483<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 628,371<span></span>
</td>
<td class="nump">$ 391,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the carrying (reported) amount of the entity's investments as of the balance sheet date. This amount may represent the individual investment's or group of similar investments' original cost, fair value, or such other amount at which the investment is shown in the entity's balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SX 210.12-15)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611379-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840601632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">40,668,877<span></span>
</td>
<td class="nump">37,480,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">40,668,877<span></span>
</td>
<td class="nump">37,480,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839873808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product sales</a></td>
<td class="nump">$ 284,342<span></span>
</td>
<td class="nump">$ 270,073<span></span>
</td>
<td class="nump">$ 244,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeLicensingAndDevelopmentRevenue', window );">Collaborative licensing and milestone revenue</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">286,630<span></span>
</td>
<td class="nump">276,371<span></span>
</td>
<td class="nump">248,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">87,915<span></span>
</td>
<td class="nump">110,104<span></span>
</td>
<td class="nump">71,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">57,290<span></span>
</td>
<td class="nump">45,678<span></span>
</td>
<td class="nump">28,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">161,494<span></span>
</td>
<td class="nump">152,613<span></span>
</td>
<td class="nump">139,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Product discontinuation</a></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">311,567<span></span>
</td>
<td class="nump">308,395<span></span>
</td>
<td class="nump">239,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(24,937)<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
<td class="nump">9,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,047)<span></span>
</td>
<td class="num">(7,061)<span></span>
</td>
<td class="num">(7,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(3,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty interest obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">167<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(17,534)<span></span>
</td>
<td class="num">(5,820)<span></span>
</td>
<td class="num">(7,335)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(42,471)<span></span>
</td>
<td class="num">(37,844)<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (42,611)<span></span>
</td>
<td class="num">$ (37,949)<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">39,806<span></span>
</td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">36,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">39,806<span></span>
</td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">41,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeLicensingAndDevelopmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue derived from reimbursements received in connection with feasibility studies and development work and for the licensing of technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeLicensingAndDevelopmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827095648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (42,611)<span></span>
</td>
<td class="num">$ (37,949)<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments</a></td>
<td class="num">(424)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(424)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (43,035)<span></span>
</td>
<td class="num">$ (37,927)<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842324000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Two Thousand Nineteen Senior Convertible Notes [Member]</div></th>
<th class="th"><div>Convertible Senior Notes Due 2022 [Member]</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Two Thousand Nineteen Senior Convertible Notes [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Convertible Senior Notes Due 2022 [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2014</a></td>
<td class="nump">$ 171,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 481,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (310,145)<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">10,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">33,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of 2019 convertible senior notes</a></td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of 2019 convertible senior notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible senior notes, net of issuance costs</a></td>
<td class="num">(4,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2015</a></td>
<td class="nump">218,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">526,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(308,289)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,848,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">5,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">31,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible senior notes, net of issuance costs</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(37,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2016</a></td>
<td class="nump">218,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">565,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346,238)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment of the adoption of Accounting Standards Update 2016-09 (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="nump">160,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 31,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of 2019 convertible senior notes</a></td>
<td class="nump">120,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">120,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of 2019 convertible senior notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible senior notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,328)<span></span>
</td>
<td class="nump">$ 68,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,328)<span></span>
</td>
<td class="nump">$ 68,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments</a></td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(42,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2017</a></td>
<td class="nump">$ 279,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 669,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (389,136)<span></span>
</td>
<td class="num">$ (454)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839988208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (42,611)<span></span>
</td>
<td class="num">$ (37,949)<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangibles</a></td>
<td class="nump">13,833<span></span>
</td>
<td class="nump">12,919<span></span>
</td>
<td class="nump">11,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation', window );">Amortization of unfavorable lease obligation and debt issuance costs</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">10,423<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">3,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">31,601<span></span>
</td>
<td class="nump">31,248<span></span>
</td>
<td class="nump">33,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(1,721)<span></span>
</td>
<td class="num">(4,082)<span></span>
</td>
<td class="num">(3,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(10,133)<span></span>
</td>
<td class="nump">30,367<span></span>
</td>
<td class="num">(32,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,476<span></span>
</td>
<td class="num">(3,377)<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and income taxes payable</a></td>
<td class="nump">9,359<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">8,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncreaseDecreaseInRoyaltyInterestObligation', window );">Royalty interest obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(3,555)<span></span>
</td>
<td class="num">(1,339)<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">17,785<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
<td class="nump">28,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(19,266)<span></span>
</td>
<td class="num">(24,709)<span></span>
</td>
<td class="num">(40,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(502,752)<span></span>
</td>
<td class="num">(192,815)<span></span>
</td>
<td class="num">(189,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">321,713<span></span>
</td>
<td class="nump">171,627<span></span>
</td>
<td class="nump">217,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(8,460)<span></span>
</td>
<td class="num">(15,857)<span></span>
</td>
<td class="num">(7,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates', window );">Equity investments</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(223,765)<span></span>
</td>
<td class="num">(61,754)<span></span>
</td>
<td class="num">(19,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
<td class="nump">10,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan', window );">Proceeds from shares issued under employee stock purchase plan</a></td>
<td class="nump">1,862<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from 2022 convertible senior notes</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2019 convertible senior notes</a></td>
<td class="num">(118,193)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance and financing costs</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes', window );">Costs for conversion of convertible senior notes</a></td>
<td class="num">(285)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">224,162<span></span>
</td>
<td class="nump">7,261<span></span>
</td>
<td class="nump">10,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">18,182<span></span>
</td>
<td class="num">(21,040)<span></span>
</td>
<td class="nump">19,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">35,944<span></span>
</td>
<td class="nump">56,984<span></span>
</td>
<td class="nump">37,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">54,126<span></span>
</td>
<td class="nump">35,944<span></span>
</td>
<td class="nump">56,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest, including royalty interest obligation</a></td>
<td class="nump">6,896<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes, net of refunds</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue', window );">Issuance of common stock from conversion of 2019 convertible senior notes</a></td>
<td class="nump">120,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium', window );">Issuance of common stock from conversion of 2019 convertible senior notes</a></td>
<td class="num">(126,328)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid', window );">Net increase (decrease) in accrued fixed assets</a></td>
<td class="nump">$ 2,189<span></span>
</td>
<td class="num">$ (789)<span></span>
</td>
<td class="nump">$ 1,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amortization of deferred financing costs and unfavorable lease obligations. Deferred financing costs are amortized over the term of the associated financing arrangement. Unfavorable lease obligations are determined based on the fair value of a lease compared to the acquired lease terms in connection with a business combination, which are amortized over the remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AmortizationOfOtherAssetsAndUnfavorableLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the principal amount of notes and related equity component for the conversion of the premium on convertible senior notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Conversionofprincipalandequitycomponentofconvertibleseniornotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionConvertedInstrumentSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Shares Issued, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionConvertedInstrumentSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair market value of the common stock issued to settle a convertible senior notes premium at conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FairMarketValueofCommonStockIssuedforConvertibleSeniorNotesPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capital Expenditures Incurred And Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncreaseDecreaseInCapitalExpendituresIncurredAndNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncreaseDecreaseInRoyaltyInterestObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease during the reporting period in royalty interest obligation during the reporting period. Royalty interest obligation consists of obligations relating to the assignment of royalty interests on future revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncreaseDecreaseInRoyaltyInterestObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents earnout and milestone payment made which is associated with the acquisition of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Shares Issued Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831131024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira Pharmaceuticals,&#160;Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its proprietary DepoFoam</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Pacira is committed to driving innovation in postsurgical pain management with opioid-sparing strategies.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s lead product, EXPAREL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, was approved by the United States Food and Drug Administration, or FDA, on October&#160;28, 2011 and launched commercially in April 2012. DepoFoam is also the basis for the Company&#8217;s other FDA-approved product, DepoCyt(e), which the Company had manufactured for its commercial partners before discontinuing production in June 2017. The Company also sells its bupivacaine liposome injectable suspension product to a commercial partner to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pacira is subject to risks common to companies in similar industries and stages of development, including, but not limited to, competition from larger companies, reliance on revenue from one product, reliance on a single manufacturing site, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology and compliance with government regulations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819402064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, inventory costs, impairments of goodwill and long-lived assets, liabilities and accruals and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management believes that the Company&#8217;s existing cash and cash equivalents, short-term and long-term investments and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses, capital expenditure requirements, payment of the principal on any conversions of the Company&#8217;s convertible senior notes and to service its indebtedness at least through </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2019</font><font style="font-family:inherit;font-size:10pt;">. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. See </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">,</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of the Company&#8217;s convertible senior notes and conversion elections. The Company expects to continue to incur substantial additional expenditures as it continues to commercialize EXPAREL, develops and seeks regulatory approval for its product candidates and expands its manufacturing facilities for EXPAREL and its other product candidates, including costs associated with certain technical transfer activities and the construction of two dedicated manufacturing suites in England.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the United States, or U.S.; (ii) sales of DepoCyt(e) to its commercial partners within the U.S. and the European Union, or E.U.; (iii) sales of its bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product for use in animal health indications and (v) license fees and milestone payments. The Company recognizes revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company records revenue at the time the product is delivered to the end-user. The Company also recognizes revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and its bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contract terms, inventory data and other related information which may become known in the future. The Company reviews the adequacy of its provisions on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Returns Allowances</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows customers to return product that is damaged or received in error. In addition, the Company allows EXPAREL to be returned beginning </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months</font><font style="font-family:inherit;font-size:10pt;"> prior to, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">twelve months</font><font style="font-family:inherit;font-size:10pt;"> following product expiration. The Company estimates its sales return reserve based on its historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terms. The Company accrues discounts to wholesalers based on contractual terms of agreements and historical experience. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wholesaler Service Fees</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers include major and regional wholesalers with whom the Company has contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volume Rebates and Chargebacks</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers the Company provides to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Returns Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prompt Payment Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wholesaler Service Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Volume Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from royalties based on sales of its commercial partners&#8217; net sales of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Licensing and Milestone Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of a termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in the Company&#8217;s consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company&#8217;s performance obligations under the applicable agreements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Major Customers</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers are national and regional wholesalers of pharmaceutical products as well as commercial, collaborative and licensing partners. The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The table below includes the percentage of revenue comprised by the Company&#8217;s three largest wholesalers in each year presented:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest wholesaler</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from customers outside the U.S. accounted for less than </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s total revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs associated with products and processes being developed, and include related personnel expenses, laboratory supplies, active pharmaceutical ingredients, manufacturing supplies, facilities costs, preclinical and clinical trial costs, development costs related to significant scale-ups of manufacturing capacity and other outside service fees. The Company expenses research and development costs as incurred. A significant portion of the development activities are outsourced to third parties, including contract research organizations. In such cases, the Company may be required to estimate related service fees to be accrued.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, all deferred tax assets were fully offset by a valuation allowance because there is significant doubt regarding the Company&#8217;s ability to utilize such net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s stock-based compensation program includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation of stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable stock options. Accordingly, the Company uses an option pricing model to derive an estimated fair value. In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected term of the option</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected dividends</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes its available historic volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option exercises. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. The Company records forfeitures as they occur rather than estimating forfeitures during each period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments with maturities of 90 days or less when purchased are considered cash equivalents.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term and Long-Term Investments</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with initial maturities of greater than three months at the date of purchase, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with initial maturities greater than one year at the date of purchase. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from net loss and are reported as a separate component of accumulated other comprehensive loss until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 to 3&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 to 10&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Retirement Obligations</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records interest expense to accrete the ARO to full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over fair value acquired in a business combination and is not amortized, but subject to impairment at least annually or when a triggering event occurs that could indicate a potential impairment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Investments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its equity investment in a minority interest of a company over which it does not exercise significant influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is evidence that changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investments are reviewed on a regular basis for possible impairment. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern and (v) any other information that the Company may be aware of related to the investment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reviews long-lived assets, including fixed assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Debt Transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon settlement of the convertible senior notes, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Per Share Data</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and warrants, the vesting of RSUs and the purchase of shares from the Company&#8217;s employee stock purchase plan (using the treasury stock method), as well as the conversion of the excess conversion value on the Company&#8217;s convertible senior notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment and, accordingly, no segment disclosures have been presented.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831085376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">. This update includes multiple provisions intended to simplify various aspects of accounting for share-based payment transactions including accounting for excess tax benefits and tax deficiencies, classification of excess tax benefits and tax deficiencies in the statement of cash flows and accounting for award forfeitures. The update also removes the requirement to delay recognition of an excess tax benefit until it reduces current taxes payable, instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This update became effective for the Company beginning January 1, 2017. The Company elected an accounting policy change to record forfeitures as they occur rather than estimating forfeitures during each period and recorded a charge of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to retained earnings as of January 1, 2017 related to the reversal of cumulative forfeiture estimates. The adoption of this standard also resulted in the recognition of </font><font style="font-family:inherit;font-size:10pt;">$29.3 million</font><font style="font-family:inherit;font-size:10pt;"> of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. The changes have been applied prospectively in accordance with the update, and prior periods have not been adjusted. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based awards, will be classified as cash flows from operating activities in the Company&#8217;s consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. The standard requires entities to measure most inventory &#8220;at the lower of cost and net realizable value&#8221;, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of which is net realizable value). Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The standard became effective for the Company prospectively beginning January 1, 2017. The adoption of ASU 2015-11 did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not Adopted as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2017</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, and has subsequently issued a number of amendments to this update. The new standard, as amended, provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The standard&#8217;s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 provides a five-step model that includes (1) identifying the contract with a customer, (2) identifying the performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations and (5) recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard will become effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective&#160;method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt this standard using the modified retrospective method.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with the current revenue accounting standards. Based on its review of its current customer contracts, the implementation of ASU 2014-09 will not have a material quantitative impact on the Company&#8217;s consolidated financial statements, as the timing of revenue recognition for EXPAREL product sales is not expected to significantly change. The Company will recognize existing collaborative licensing, milestone and royalty revenue earlier, subject to the variable consideration constraints, than it would have under the current standard, however, such changes are not expected to be material to the Company&#8217;s consolidated financial statements. Adoption of the new standard will result in additional revenue-related disclosures in the footnotes to the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-01 changes accounting for equity investments and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income (loss). Entities have the option to measure equity investments without readily determinable fair values either at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The standard also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. ASU 2016-01 will become effective for the Company beginning January 1, 2018. The Company has elected to measure equity investments without readily determinable fair values at cost adjusted for changes in observable prices. The guidance related to equity investments without readily determinable fair values will be applied prospectively to equity investments that exist as of the date of adoption. The adoption of ASU 2016-01 may increase volatility in the Company&#8217;s net income as changes in observable prices of equity investments without readily determinable fair values will be recorded in net income (loss). The Company does not expect the implementation of this standard to have a material impact on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">.&#160;This update requires lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment for items such as initial direct costs. For income statement purposes, the new standard retains a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while financing leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). This update also introduces new disclosure requirements for leasing arrangements. The standard will become effective for the Company beginning January 1, 2019. Early adoption is permitted, although the Company does not expect to do so. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. For operating leases it will result in the recognition of lease liabilities and corresponding right-of-use assets upon adoption, which will have a material impact on the Company&#8217;s consolidated balance sheet. The Company does not believe the adoption of this ASU will have a significant impact on its consolidated statements of operations, stockholders&#8217; equity or cash flows. At adoption, this update will be applied using a modified retrospective approach. Refer to Note&#160;17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on the Company&#8217;s leases.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity&#8217;s portfolio. This ASU will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued&#160;ASU&#160;2016-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic&#160;230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a&#160;business combination.&#160;ASU&#160;2016-15&#160;will become effective for the Company in the first quarter of fiscal year 2018. The Company does not expect any changes to its consolidated statement of cash flows upon the adoption of this standard.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819402064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVENTORIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of inventories are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to perform ongoing stability testing on select lots of EXPAREL at various time intervals. In October 2016, as part of its ongoing stability testing, the Company identified that a single batch of EXPAREL, which was manufactured in early 2016, did not meet the required specification. An internal investigation tied this unexpected result to a modification in the manufacturing process that existed when this product was made, which has subsequently been corrected. The Company reserved all impacted inventory on hand and recorded a </font><font style="font-family:inherit;font-size:10pt;">$20.7 million</font><font style="font-family:inherit;font-size:10pt;"> charge to cost of goods sold in 2016 related to this matter.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831192000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FIXED ASSETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net summarized by major category, consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,256</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,526</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$13.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company capitalized interest of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located in England in the amount of </font><font style="font-family:inherit;font-size:10pt;">$59.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$33.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had an ARO of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, included in other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements. The increase in 2017 relates to a </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> revision in estimated future cash flows related to the AROs, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of liabilities incurred in the current period and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of accretion expense.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819415248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GOODWILL AND INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2007, the Company acquired from SkyePharma Holding, Inc., or Skyepharma, its California operating subsidiary (Pacira California), referred to herein as the Acquisition. The Company&#8217;s goodwill arose in April 2012 from a contingent milestone payment to Skyepharma in connection with the Acquisition. The Acquisition was accounted for under Statement of Financial Accounting Standards 141, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Business Combinations</font><font style="font-family:inherit;font-size:10pt;">, which was the effective GAAP standard at the Acquisition date. In connection with the Acquisition, the Company agreed to certain earn-out payments based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL and certain other yet-to-be-developed products, as well as milestone payments for DepoBupivacaine products, including EXPAREL, as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the first commercial sale in the U.S. (met April 2012);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the first commercial sale in a major E.U. country (United Kingdom, France, Germany, Italy and Spain);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> (met September 2014);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> (met June 2016); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;"> when annual net sales collected reach </font><font style="font-family:inherit;font-size:10pt;">$500.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first milestone was met in April 2012 resulting in a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment to Skyepharma. The Company recorded this payment net of a </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> contingent consideration liability recognized at the time of the Acquisition, resulting in </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> recorded as goodwill. In September 2014, the Company recorded an </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone in connection with achieving </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> of annual EXPAREL net sales collected, and in June 2016, the Company recorded another </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone for achieving </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> of annual EXPAREL net sales collected. For purposes of meeting future potential milestone payments, with certain exceptions, annual net sales are measured on a rolling quarterly basis. Cumulatively through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;"> as goodwill for earn-out payments which are based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL. Any remaining earn-out payments will also be treated as additional costs of the Acquisition and, therefore, recorded as goodwill if and when each contingency is resolved. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Acquisition was treated as a stock acquisition for tax purposes and, therefore, the acquired intangibles for book purposes are not deductible for income tax purposes. The Company also recorded goodwill related to contingent payments due under the Acquisition during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, which are not deductible for income tax purposes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the carrying value of goodwill is summarized as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Milestone payment triggered by collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,737</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets acquired in the Acquisition consisted of core technology, developed technology, trademarks and trade names. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> amortization expense for intangibles for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. For the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, amortization expense for intangibles was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831026176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalties</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product returns, rebates and other fees </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831086640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes Due 2022</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2017, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$345.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.375%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2022, or 2022 Notes, and entered into an indenture agreement, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">2.375%</font><font style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on April 1 and October 1 of each year. The 2022 Notes mature on April 1, 2022.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2022 Notes is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net proceeds from the issuance of the 2022 Notes were </font><font style="font-family:inherit;font-size:10pt;">$334.0 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2022 Notes were used by the Company to repurchase the majority of its then-outstanding convertible senior notes due 2019 in privately-negotiated transactions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders may convert the 2022 Notes at any time prior to the close of business on the business day immediately preceding October 1, 2021, only under the following circumstances:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) during any calendar quarter commencing after the calendar quarter ended June 30, 2017 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> business-day period immediately after any </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading-day period (the &#8216;&#8216;measurement period&#8217;&#8217;) in which the trading price (as defined in the 2022 Indenture) per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the 2022 Notes for each trading day of the measurement period was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&#8217;s assets; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv) if the Company calls the 2022 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding April 1, 2022, holders may convert their 2022 Notes at any time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2022 Notes is </font><font style="font-family:inherit;font-size:10pt;">14.9491</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount, which is equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$66.89</font><font style="font-family:inherit;font-size:10pt;"> per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately </font><font style="font-family:inherit;font-size:10pt;">37.5%</font><font style="font-family:inherit;font-size:10pt;"> to the closing sale price of </font><font style="font-family:inherit;font-size:10pt;">$48.65</font><font style="font-family:inherit;font-size:10pt;"> per share of the Company&#8217;s common stock on the NASDAQ Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the 2022 Notes had a market price of </font><font style="font-family:inherit;font-size:10pt;">$1,048</font><font style="font-family:inherit;font-size:10pt;"> per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are converted, the Company would be required to repay the </font><font style="font-family:inherit;font-size:10pt;">$345.0 million</font><font style="font-family:inherit;font-size:10pt;"> in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to April 1, 2020, the Company may not redeem the 2022 Notes. On or after April 1, 2020, the Company may redeem for cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&#8217;s common stock has been at least </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading-day period ending within </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> trading days prior to the date on which the Company provides notice of redemption. The redemption price will equal the sum of (i) </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &#8220;make whole fundamental change&#8221; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2022 Indenture) occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2022 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the 2022 Notes are currently classified on the Company&#8217;s consolidated balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> as long-term debt, the future convertibility and resulting balance sheet classification of this liability will be monitored at each quarterly reporting date and will be analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2022 Notes have the election to convert the 2022 Notes at any time during the prescribed measurement period, the 2022 Notes would then be considered a current obligation and classified as such.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under ASC 470-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options</font><font style="font-family:inherit;font-size:10pt;">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of </font><font style="font-family:inherit;font-size:10pt;">$274.1 million</font><font style="font-family:inherit;font-size:10pt;"> was calculated using a </font><font style="font-family:inherit;font-size:10pt;">7.45%</font><font style="font-family:inherit;font-size:10pt;"> assumed borrowing rate. The equity component of </font><font style="font-family:inherit;font-size:10pt;">$70.9 million</font><font style="font-family:inherit;font-size:10pt;">, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the five year term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allocated the total transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes Due 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 23, 2013, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2019, or 2019 Notes. The 2019 Notes accrue interest at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on February 1 and August 1 of each year. The 2019 Notes mature on February 1, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2019 Notes is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company used part of the net proceeds from the issuance of the 2022 Notes discussed above to repurchase </font><font style="font-family:inherit;font-size:10pt;">$117.7 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal of the 2019 Notes in privately-negotiated transactions for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$118.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. The partial repurchase of the 2019 Notes resulted in a </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> loss on early debt extinguishment. In May 2017, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal of the 2019 Notes in a privately-negotiated transaction for an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">10 thousand</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of principal remains outstanding on the 2019 Notes.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders may convert their 2019 Notes prior to August 1, 2018 only if certain circumstances are met, including if during the previous calendar quarter, the sales price of the Company&#8217;s common stock was greater than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price then applicable for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> out of the last </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days of the quarter. During the quarter ended December&#160;31, 2017, this condition for conversion was met. As a result, the 2019 Notes are classified as a current obligation and will be convertible until March&#160;31, 2018. As of December&#160;31, 2017, the 2019 Notes had a market price of </font><font style="font-family:inherit;font-size:10pt;">$1,905</font><font style="font-family:inherit;font-size:10pt;"> per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount, compared to an estimated conversion value of </font><font style="font-family:inherit;font-size:10pt;">$1,839</font><font style="font-family:inherit;font-size:10pt;"> per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount. In the event that the remaining 2019 Notes are converted, the Company would be required to repay the </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of principal value in cash and settle approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of the conversion premium in cash, common stock or a combination of cash and shares of its common stock at the Company&#8217;s option as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the total interest expense recognized in the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized interest and other (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,725</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective interest rate on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819380064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1: </font><font style="font-family:inherit;font-size:10pt;">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2: </font><font style="font-family:inherit;font-size:10pt;">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3: </font><font style="font-family:inherit;font-size:10pt;">Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div></td></tr></table><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&#8217;s convertible senior notes at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The carrying amount and fair value of the Company&#8217;s convertible senior notes are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Liabilities Carried at Historical Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying<br clear="none"/>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(1) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;"> per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;"> compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$66.89</font><font style="font-family:inherit;font-size:8.5pt;"> per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">5.2 million</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(2) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;"> per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;"> compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$24.82</font><font style="font-family:inherit;font-size:8.5pt;"> per share which, if converted, would result in a conversion premium of less than </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock or </font><font style="font-family:inherit;font-size:8.5pt;">$0.3 million</font><font style="font-family:inherit;font-size:8.5pt;"> of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with maturities greater than three months, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with maturities greater than one year. Net unrealized gains or losses from the Company&#8217;s short-term and long-term investments are reported in other comprehensive income (loss). At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s short-term investments are classified as available for sale investments and are determined to be Level&#160;2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, all short-term and long-term investments were rated A or better by Standard &amp; Poor&#8217;s.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the Company&#8217;s investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br clear="none"/>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Long-term:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,430</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br clear="none"/>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain assets and liabilities are measured at fair value on a nonrecurring basis, including assets and liabilities acquired in a business combination, and long-lived assets, which would be recognized at fair value if deemed to be impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level&#160;3 inputs. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">TELA Bio, Inc.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company made a cash investment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in convertible preferred B shares of TELA Bio Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;portfolio of products for ventral hernia repair and abdominal wall reconstruction. In conjunction with the investment in TELA Bio, the Company acquired an option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of convertible preferred B shares of TELA Bio under the same terms and conditions as existed on the initial purchase date. The purchase option expires on September 15, 2018. If the Company does not exercise its purchase option, the Company may be required to invest up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in TELA Bio convertible preferred B shares under certain conditions. This contingent purchase obligation expires on October 31, 2018.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in TELA Bio, the purchase option and the contingent purchase obligation were recorded at fair value based on integrated valuation pricing models. These models included both unobservable and observable market inputs including projected revenues, option purchase price, volatility and projected liquidity date. The equity investment in the TELA Bio preferred B shares was recorded at </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the purchase option was recorded in prepaid expenses and other current assets at </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the contingent purchase obligation was determined to be de minimis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> wholesalers accounted for over </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s accounts receivable: </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;">, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> wholesalers accounted for over </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s accounts receivable: </font><font style="font-family:inherit;font-size:10pt;">36%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">29%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">, respectively. Revenues are primarily derived from major wholesalers and pharmaceutical companies which generally have significant cash resources. Allowances for doubtful accounts receivable are maintained based on historical payment patterns, aging of accounts receivable and actual write-off history. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, no allowances for doubtful accounts were deemed necessary by the Company on its accounts receivable.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831131024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">250,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, of which </font><font style="font-family:inherit;font-size:10pt;">40,668,877</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">37,480,952</font><font style="font-family:inherit;font-size:10pt;"> were outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,000,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of preferred stock. No preferred stock was outstanding at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> or </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2016</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Unrealized Gains</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Losses) From Available</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For Sale Investments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820222096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK PLANS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK PLANS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Incentive Plans</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s amended and restated 2011 stock incentive plan, or 2011 Plan, was adopted by its board of directors and approved by its stockholders in June 2014. The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. Since the adoption of the 2011 Plan, any remaining shares available for issuance under a 2007 stock incentive plan, or 2007 Plan, are reallocated to the 2011 Plan. In April 2014, the Company&#8217;s board of directors adopted the 2014 Inducement Plan which authorized </font><font style="font-family:inherit;font-size:10pt;">175,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to be granted as equity awards to new employees.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company&#8217;s board of directors adopted an amendment to the 2011 Plan. Under the amendment, an additional&#160;</font><font style="font-family:inherit;font-size:10pt;">4,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were authorized for issuance as equity awards under the 2011 Plan. The amendment to the 2011 Plan was subsequently approved by the Company&#8217;s stockholders and became effective in June 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s stock option grants have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (generally over four years from the date of grant although the Company may occasionally grant options with different vesting terms). Since 2015, the Company has granted RSUs to employees and its board of directors. The Company uses authorized and unissued shares to satisfy its obligations under these plans.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company&#8217;s board of directors adopted the 2014 Employee Stock Purchase Plan, or ESPP, which was subsequently approved by the Company&#8217;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&#8217;s common stock at a discounted price and to help retain and motivate current employees as well as attract new talent. Under the ESPP, up to </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Internal Revenue Code. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $</font><font style="font-family:inherit;font-size:10pt;">25,000</font><font style="font-family:inherit;font-size:10pt;">. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&#8217;s common stock on the purchase dates of June 30 and December 31 or the last trading day of an offering period. The per share purchase price will be equal to the lesser of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value of the Company&#8217;s common stock on either the offering date or the purchase date.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table contains information about the Company&#8217;s plans at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Reserved for Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards<br clear="none"/>Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Available for Grant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2007 Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2011 Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,931,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,037,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893,753</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014 Inducement plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,129,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,113,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,016,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Reserved<br clear="none"/>for Purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares<br clear="none"/>Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Available<br clear="none"/>for Purchase</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014 ESPP</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation expense for stock options and RSUs granted to employees and directors is based on the estimated grant date fair value of options recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for options and RSUs granted to non-employees is based on the fair value of options, which are revalued each reporting period until vested and are recognized as expense over the requisite service period. Compensation expense for ESPP options is based on the grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized stock-based compensation expense (net of forfeitures) in its consolidated statements of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation from:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (employee awards)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (consultant awards)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">785</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock option activity and related information for the period from January&#160;1, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of<br clear="none"/>Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price (Per Share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average<br clear="none"/>Remaining<br clear="none"/>Contractual<br clear="none"/>Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate<br clear="none"/>Intrinsic Value<br clear="none"/>(in Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,677,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">906,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,880</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,645,722</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,656,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518,226</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175,303</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,072,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(232,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,882,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$41.6 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock options is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.7 years</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s stock options have a maximum expiration date of ten years from the date of grant. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average fair value of stock options granted for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$20.78</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$19.13</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$37.82</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68% - 2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03% - 2.48%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40% - 2.28%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.9%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.31 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s RSU activity and related information for the period from January&#160;1, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number<br clear="none"/>of Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted<br clear="none"/>Average Grant<br clear="none"/>Date Fair Value (Per Share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate<br clear="none"/>Intrinsic Value<br clear="none"/>(in Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,046</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(101,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested and expected to vest at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested RSUs is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.9 years</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s RSUs have a maximum vest date of four years from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&#8217;s common stock on the date of grant.</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the ESPP share options granted are estimated using the Black-Scholes model with the following weighted average assumptions:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP option fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.80 - $13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.57 - $25.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21.93 - $25.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62% - 1.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37% - 0.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11% - 0.13%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of ESPP share options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831141440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, no potentially dilutive securities have been included in the computation of diluted net loss per share for those periods. As discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">, the Company has either the obligation or the option to pay cash for the aggregate principal amount due upon the conversion of its convertible senior notes. Since it is the Company&#8217;s intent to settle the principal amount of its convertible senior notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computation of diluted securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of RSUs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of conversion premium on the 2019 Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ESPP purchase options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding stock options, RSUs, conversion premiums on the Company&#8217;s convertible senior notes, warrants and ESPP purchase options are antidilutive in the periods presented (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of RSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion premium on the 2019 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average ESPP purchase options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6600154160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes and the related tax expense is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,898</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax provision of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is principally the result of minimum state taxes. The tax provision of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2015 is the result of the federal alternative minimum tax and state taxes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. federal statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes refinancing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of the adoption of ASU 2016-09</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s effective tax rates of </font><font style="font-family:inherit;font-size:10pt;">(0.33)%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">(0.28)%</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, differed from the expected U.S. statutory tax rate of </font><font style="font-family:inherit;font-size:10pt;">35.0%</font><font style="font-family:inherit;font-size:10pt;">. This difference was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance. The Company&#8217;s effective tax rate of </font><font style="font-family:inherit;font-size:10pt;">12.45%</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2015 was favorably impacted by the utilization of domestic net operating loss, or NOL, carryforwards for which there was a full valuation allowance.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,939</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,230</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,753</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s federal NOLs and federal tax credit carryforwards totaled </font><font style="font-family:inherit;font-size:10pt;">$380.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company also had state NOLs and state tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$232.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which are subject to change on an annual basis due to variations in the Company&#8217;s annual state apportionment factors. The Company had non-U.S. tax NOLs of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The existing federal NOLs will begin expiring in 2025 while the existing state NOLs begin expiring in 2024, if the Company has not used them prior to that time. The non-U.S. NOLs do not expire. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the Company had cumulative changes in ownership of more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> within a three-year period, under Internal Revenue Code sections 382 and 383, the Company&#8217;s ability to use certain net operating loss and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&#8217;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&#8217;s initial public offering and other financing transactions. As a result of these ownership changes, the Company estimates that approximately </font><font style="font-family:inherit;font-size:10pt;">$192.4 million</font><font style="font-family:inherit;font-size:10pt;"> of federal net operating losses are subject to annual limitations. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$134.8 million</font><font style="font-family:inherit;font-size:10pt;"> of these federal net operating losses were available. The Company estimates that an additional </font><font style="font-family:inherit;font-size:10pt;">$10.3 million</font><font style="font-family:inherit;font-size:10pt;"> will become available from 2018 through 2022, and the remaining </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> through 2025. In addition, California and certain states have previously suspended or limited the use of net operating loss carryforwards for certain taxable years, and certain states are considering similar future measures. As a result, the Company may incur higher state income tax expense in the future. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance is appropriate. The Company had a net reduction in its valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$28.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and a net increase in its valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> during the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. There is significant doubt regarding the Company&#8217;s ability to utilize its net deferred tax assets and, therefore, the Company has recorded a full valuation allowance reducing its net deferred tax assets to zero at both </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, new legislation was signed into law reducing the corporate U.S. tax rate from 35% to 21% for tax years beginning after December 31, 2017, fully repealing the corporate alternative minimum tax and making the NOL carryforward period indefinite for NOLs generated after 2017. In accordance with ASC Topic 740, deferred tax assets and liabilities are required to be measured at the enacted tax rate expected to apply when temporary differences are to be realized or settled. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company re-measured its deferred tax balances based upon the new 21% tax rate. This resulted in a reduction of </font><font style="font-family:inherit;font-size:10pt;">$55.7 million</font><font style="font-family:inherit;font-size:10pt;"> in the Company&#8217;s deferred tax assets, which was offset by a change in its year-end valuation allowance.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company established a deferred tax liability with an offset to additional paid-in capital resulting from the conversion feature of the 2022 Notes. The initial difference between the book value of the convertible debt, issued with a beneficial conversion feature, and its tax basis was </font><font style="font-family:inherit;font-size:10pt;">$70.9 million</font><font style="font-family:inherit;font-size:10pt;">, a temporary difference. The net effect of the deferred tax liability recorded to additional paid-in capital was zero because the Company has a full valuation allowance against its net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Company recorded a reserve of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to unrecognized tax benefits, or UTBs, of which </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> relates to tax positions taken in 2017 and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> relates to tax positions taken in 2016. The Company did not have any such liability at December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&#8217;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&#8217;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Due to the Company&#8217;s full valuation allowance against deferred tax assets, none of the UTBs, if recognized, would affect the effective income tax rate. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates that it is not reasonably possible that within the next twelve months, any of the unrecognized tax benefits will significantly increase or decrease. The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2014 through 2017, and state tax jurisdictions for the years 2013 through 2017. However, the IRS or states may still examine and adjust a net operating loss arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&#8217;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819460096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">OTHER EMPLOYEE BENEFITS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER EMPLOYEE BENEFITS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a discretionary percentage match as defined in the plan and determined by the board of directors. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> of related compensation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819469984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CommercialPartnersAndAgreementsAbstract', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CommercialPartnersAndAgreementsTextBlock', window );">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DepoCyt(e) Discontinuation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, the Company&#8217;s board of directors approved a decision to discontinue production of DepoCyt</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (U.S. and Canada) and DepoCyte</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (E.U.) due to persistent technical issues specific to the DepoCyt(e) manufacturing process. DepoCyt(e) accounted for </font><font style="font-family:inherit;font-size:10pt;">2.6%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s 2016 total full-year revenues of </font><font style="font-family:inherit;font-size:10pt;">$276.4 million</font><font style="font-family:inherit;font-size:10pt;">. As of June 30, 2017, the Company had ceased all production of DepoCyt(e).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the discontinuation, the Company received a fixed payment for the supply of DepoCyt(e) and double-digit royalties, net of supply price, on the sales of DepoCyt by Leadiant Bioscience, Ltd. in the U.S. and Canada, and on the sales of DepoCyte by Mundipharma International Corporation Limited, or Mundipharma, in the E.U. and other European countries. In addition, the Company also received a non-refundable upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with a </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> year extension and concurrent expansion of the territories where Mundipharma can market and distribute DepoCyte.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Company recorded a non-recurring charge of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> related to the discontinuation of its DepoCyt(e) manufacturing activities, including </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for DepoCyt(e) related inventory, which is recorded in cost of goods sold, and </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the remaining lease costs less an estimate of potential sublease income for the facility where DepoCyt(e) was manufactured, the write-off of property, plant and equipment, employee severance, asset retirement obligations and other estimated exit costs. Cash payments related to the lease on the DepoCyt(e) manufacturing facility are expected to continue through the end of the lease term in August 2020.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a summary of the Company&#8217;s costs and reserves related to the DepoCyt(e) discontinuation are as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:209px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Severance and Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Write-Off of Property, Plant &amp; Equipment and Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Retirement Obligations and Other Discontinuation Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges incurred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments made</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposal of property, plant &amp;<br clear="none"/>   equipment and inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may be required to make additional payments or incur additional costs relating to the DepoCyt(e) discontinuation which could be material to the Company&#8217;s results of operations and/or cash flows in a given period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial Partners</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patheon UK Limited</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company and Patheon UK Limited, or Patheon, entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the Technical Transfer and Service Agreement, Patheon has agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. Under these agreements, the Company will make monthly base fee payments for services rendered. The agreements will remain in full effect unless and until they expire or are terminated. Upon termination of the Technical Transfer and Services Agreement (other than termination by the Company in the event that Patheon does not meet the construction and manufacturing milestones or for a breach by Patheon), the Company will pay for the make good costs occasioned by the removal of its manufacturing equipment and for Patheon&#8217;s termination costs up to a maximum amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Manufacturing and Supply Agreement, following the FDA approval date of the suites, the Company has agreed to purchase EXPAREL product from Patheon. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Patheon), this agreement will expire on the&#160;</font><font style="font-family:inherit;font-size:10pt;">10th</font><font style="font-family:inherit;font-size:10pt;"> anniversary of the FDA approval date for the initial manufacturing suite.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DePuy Synthes Sales, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company announced the initiation of a Co-Promotion Agreement, or the Agreement, with DePuy</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies, to market and promote the use of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXPAREL for orthopedic procedures in the U.S.. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine and trauma, collaborates with and supplements the Company&#8217;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the five-year arrangement, DePuy Synthes is the exclusive third-party distributor during the term of the Agreement to promote and sell EXPAREL for operating room use for orthopedic and spine surgeries (including knee, hip, shoulder, sports and trauma surgeries) in the U.S.. DePuy Synthes receives a tiered commission ranging from low single-digits to double-digits on sales of EXPAREL under the Agreement, subject to conditions, limitations and adjustments. The initial term of the Agreement commenced on January 24, 2017 and ends on December 31, 2021, with the option to extend the Agreement in additional 12-month increments upon mutual agreement of the parties, subject to certain conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and DePuy Synthes have mutual termination rights under the Agreement, subject to certain terms, conditions and advance notice requirements, provided that the Company or DePuy Synthes generally may not terminate the Agreement, without cause, within three years of the effective date of the Agreement. The Company also has additional unilateral termination rights under certain circumstances. The Agreement contains customary representations, warranties, covenants and confidentiality provisions, as well as mutual indemnification obligations. DePuy Synthes is also subject to certain obligations and restrictions, including required compliance with certain laws and regulations and the Company&#8217;s policies, in connection with fulfilling their obligations under the Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aratana Therapeutics,&#160;Inc. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;5, 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&#160;Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&#8217;s bupivacaine liposome injectable suspension product for animal health indications. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. In connection with its entry into the license agreement, the Company received a one-time payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. In December 2013, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment under the agreement. In June 2016, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone revenue for Aratana&#8217;s filing of an FDA Administrative New Animal Drug Application, or ANADA, and in August 2016 recorded </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to the FDA&#8217;s approval of the ANADA. The Company is eligible to receive up to an additional aggregate </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double digit royalty on net sales made in the U.S.. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into a jurisdiction or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until December 2027, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOCITA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> is a registered trademark of Aratana Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CrossLink BioScience,&#160;LLC</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company and CrossLink BioScience, LLC, or CrossLink, commenced a five-year arrangement for the promotion and sale of EXPAREL, pursuant to the terms of a Master Distributor Agreement (as amended, the &#8220;CrossLink Agreement&#8221;). On June&#160;30, 2016, the Company provided notice to CrossLink electing to terminate the CrossLink Agreement effective as of September&#160;30, 2016. In connection with the termination of the CrossLink Agreement, a termination fee based on a percentage of earned performance-based fees is due to CrossLink.&#160;This fee of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> is payable to CrossLink quarterly over two years beginning in the fourth quarter of 2016, and was recorded in selling, general and administrative expense in the consolidated statements of operations. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> is classified in accrued expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CommercialPartnersAndAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CommercialPartnersAndAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CommercialPartnersAndAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the entire disclosure of commercial agreement and arrangement with third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CommercialPartnersAndAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831137632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s former Chief Medical Officer, Dr. Gary Patou, is a partner of MPM Asset Management LLC, or MPM, an investor in the Company. The Company incurred </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> consulting expenses with MPM or Dr. Patou in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> there was </font><font style="font-family:inherit;font-size:10pt;">nothing</font><font style="font-family:inherit;font-size:10pt;"> payable to MPM. The Company&#8217;s agreement with MPM expired on December 31, 2015. The Company contracted with Dr. Patou directly for his services for the first six months of 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana as discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 15</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Partners and Other Agreements</font><font style="font-family:inherit;font-size:10pt;">. MPM and its affiliates are holders of capital stock of Aratana. David Stack, the Company&#8217;s Chief Executive Officer and Chairman, was a managing director at MPM from 2005 through March 2017.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> expenses under the consulting arrangement in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and expenses of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. In connection with the consulting arrangement, Dr. Pace received an option to purchase </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$11.02</font><font style="font-family:inherit;font-size:10pt;"> per share and an option to purchase </font><font style="font-family:inherit;font-size:10pt;">70,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.67</font><font style="font-family:inherit;font-size:10pt;"> per share. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">nothing</font><font style="font-family:inherit;font-size:10pt;"> payable to Dr. Pace for consulting services.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819469984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s leases for its research and development, warehouse and DepoCyt(e) manufacturing facility in San Diego, California all expire in August 2020, and its lease for its EXPAREL manufacturing facility in San Diego, California expires in December 2025. The Company&#8217;s lease for its corporate headquarters in Parsippany, New Jersey expires in March 2028.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, aggregate annual minimum payments due under the Company&#8217;s lease obligations are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Minimum Payments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,089</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023 through 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total rent expense, net of amortization of unfavorable lease obligations and tenant improvements, under all operating leases for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Deferred rent at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company&#8217;s research and development facility in San Diego, California included a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the payment of leasehold improvements, which the Company utilized completely in 2015 and 2016. The leasehold improvements were capitalized into fixed assets, net on the consolidated balance sheets and are depreciated over the lease term.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any litigation which it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. The Company is cooperating with the government&#8217;s inquiry. The Company can make no assurances as to the time or resources that will need to be devoted to this inquiry or the impact, if any, of this inquiry or any proceedings on its business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Obligations </font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients. The Company was granted a deferral for the required pediatric trials in all age groups for EXPAREL in the setting of wound infiltration and plans to conduct these pediatric trials as a post-marketing requirement, which was stated in the New Drug Application approval letter for EXPAREL. The Company recently secured feedback from the FDA on a pediatric trial design in all age groups and is in the process of finalizing its clinical strategy.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the initial </font><font style="font-family:inherit;font-size:10pt;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;"> purchase price for the Acquisition, the Company entered into an earn-out agreement with Skyepharma which was based on the Company reaching certain revenue milestones following the Acquisition. Pursuant to this agreement, the Company is required to pay Skyepharma milestone payments up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$62.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;"> are for milestones not yet met. Additionally, the Company agreed to pay to Skyepharma a low single-digit percentage payment on collections of EXPAREL sales in the U.S., Japan, United Kingdom, France, Germany, Italy and Spain. Such obligations to make percentage payments will continue for the term in which such sales related to EXPAREL are covered by a valid claim in certain patent rights related to EXPAREL and other biologics products. The Company has the right to cease paying the low single-digit percentage payments in the event that Skyepharma breaches certain covenants not to compete contained in the stock purchase agreement or the last valid patent claim expires. Refer to </font><font style="font-family:inherit;font-size:10pt;">Note 6</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font><font style="font-family:inherit;font-size:10pt;">, for further discussion.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to an agreement with Research Development Foundation, or RDF, the Company is required to pay RDF a low single-digit royalty on the collection of revenues from its DepoFoam-based products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831137632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present selected quarterly financial data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,866</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,743</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,597</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,973</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods where the Company reported a net loss, no potentially dilutive securities were included in the computation of diluted net loss per share.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827309952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, inventory costs, impairments of goodwill and long-lived assets, liabilities and accruals and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management believes that the Company&#8217;s existing cash and cash equivalents, short-term and long-term investments and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses, capital expenditure requirements, payment of the principal on any conversions of the Company&#8217;s convertible senior notes and to service its indebtedness at least through </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2019</font><font style="font-family:inherit;font-size:10pt;">. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. See </font><font style="font-family:inherit;font-size:10pt;">Note 8</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">,</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of the Company&#8217;s convertible senior notes and conversion elections. The Company expects to continue to incur substantial additional expenditures as it continues to commercialize EXPAREL, develops and seeks regulatory approval for its product candidates and expands its manufacturing facilities for EXPAREL and its other product candidates, including costs associated with certain technical transfer activities and the construction of two dedicated manufacturing suites in England.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the United States, or U.S.; (ii) sales of DepoCyt(e) to its commercial partners within the U.S. and the European Union, or E.U.; (iii) sales of its bupivacaine liposome injectable suspension product for use in animal health indications in the U.S.; (iv) royalties based on sales by commercial partners of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product for use in animal health indications and (v) license fees and milestone payments. The Company recognizes revenue when there is persuasive evidence that an arrangement exists, title has passed, collection is reasonably assured and the price is fixed or determinable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company records revenue at the time the product is delivered to the end-user. The Company also recognizes revenue from products manufactured and supplied to commercial partners upon shipment, such as DepoCyt(e) and its bupivacaine liposome injectable suspension product for use in animal health indications. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees and volume rebates and chargebacks. The calculation of some of these items requires management to make estimates based on sales data, contract terms, inventory data and other related information which may become known in the future. The Company reviews the adequacy of its provisions on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Returns Allowances</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows customers to return product that is damaged or received in error. In addition, the Company allows EXPAREL to be returned beginning </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months</font><font style="font-family:inherit;font-size:10pt;"> prior to, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">twelve months</font><font style="font-family:inherit;font-size:10pt;"> following product expiration. The Company estimates its sales return reserve based on its historical return rates and related product return data. The returns reserve is recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prompt payment reserve is based upon discounts offered to wholesalers as an incentive to meet certain payment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terms. The Company accrues discounts to wholesalers based on contractual terms of agreements and historical experience. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wholesaler Service Fees</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers include major and regional wholesalers with whom the Company has contracted a fee for service based on a percentage of gross product sales. This fee for service is recorded as a reduction to gross product sales and an increase to accrued expenses at the time of sale, and is recorded based on the contracted percentage.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volume Rebates and Chargebacks</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volume rebates and chargeback reserves are based upon contracted discounts and promotional offers the Company provides to certain end-users. Volume rebates are recorded at the time of sale as a reduction to gross product sales and an increase in accrued expenses. Chargeback reserves are recorded at the time of sale as a reduction to gross product sales and a reduction to accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Returns Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prompt Payment Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wholesaler Service Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Volume Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from royalties based on sales of its commercial partners&#8217; net sales of DepoCyt(e) and sales of its bupivacaine liposome injectable suspension product to serve animal health indications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collection is reasonably assured. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Licensing and Milestone Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the up-front license fee is recognized accordingly on a prospective basis. Upon notification of a termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are recognized over the remaining contractual term. If the termination is immediate and no additional services are to be performed, the deferred revenue is generally recognized in full. All such recognized revenues are included in collaborative licensing and milestone revenue in the Company&#8217;s consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company&#8217;s performance obligations under the applicable agreements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Concentration of Major Customers</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Major Customers</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s customers are national and regional wholesalers of pharmaceutical products as well as commercial, collaborative and licensing partners. The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The table below includes the percentage of revenue comprised by the Company&#8217;s three largest wholesalers in each year presented:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest wholesaler</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from customers outside the U.S. accounted for less than </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s total revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs associated with products and processes being developed, and include related personnel expenses, laboratory supplies, active pharmaceutical ingredients, manufacturing supplies, facilities costs, preclinical and clinical trial costs, development costs related to significant scale-ups of manufacturing capacity and other outside service fees. The Company expenses research and development costs as incurred. A significant portion of the development activities are outsourced to third parties, including contract research organizations. In such cases, the Company may be required to estimate related service fees to be accrued.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, all deferred tax assets were fully offset by a valuation allowance because there is significant doubt regarding the Company&#8217;s ability to utilize such net deferred tax assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s stock-based compensation program includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation of stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable stock options. Accordingly, the Company uses an option pricing model to derive an estimated fair value. In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected term of the option</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Expected dividends</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-6px;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes its available historic volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option exercises. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. The Company records forfeitures as they occur rather than estimating forfeitures during each period.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments with maturities of 90 days or less when purchased are considered cash equivalents.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term and Long-Term Investments</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with initial maturities of greater than three months at the date of purchase, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with initial maturities greater than one year at the date of purchase. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from net loss and are reported as a separate component of accumulated other comprehensive loss until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 to 3&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 to 10&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Asset Retirement Obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Retirement Obligations</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records interest expense to accrete the ARO to full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over fair value acquired in a business combination and is not amortized, but subject to impairment at least annually or when a triggering event occurs that could indicate a potential impairment.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Investments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its equity investment in a minority interest of a company over which it does not exercise significant influence using the cost method. Under the cost method, an investment is carried at cost until it is sold or there is evidence that changes in the business environment or other facts and circumstances suggest it may be other than temporarily impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investments are reviewed on a regular basis for possible impairment. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether a decline in value has occurred include, but are not limited to: (i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) a significant adverse change in the regulatory, economic or technological environment of the investee; (iii) a sale of the same or similar investment for an amount less than the carrying amount of that investment; (iv) factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern and (v) any other information that the Company may be aware of related to the investment.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reviews long-lived assets, including fixed assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Debt Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Debt Transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This is done in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon settlement of the convertible senior notes, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the reacquisition of the equity component and is recognized as a reduction of additional paid-in capital.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Per Share Data</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options and warrants, the vesting of RSUs and the purchase of shares from the Company&#8217;s employee stock purchase plan (using the treasury stock method), as well as the conversion of the excess conversion value on the Company&#8217;s convertible senior notes.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment and, accordingly, no segment disclosures have been presented.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">. This update includes multiple provisions intended to simplify various aspects of accounting for share-based payment transactions including accounting for excess tax benefits and tax deficiencies, classification of excess tax benefits and tax deficiencies in the statement of cash flows and accounting for award forfeitures. The update also removes the requirement to delay recognition of an excess tax benefit until it reduces current taxes payable, instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This update became effective for the Company beginning January 1, 2017. The Company elected an accounting policy change to record forfeitures as they occur rather than estimating forfeitures during each period and recorded a charge of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to retained earnings as of January 1, 2017 related to the reversal of cumulative forfeiture estimates. The adoption of this standard also resulted in the recognition of </font><font style="font-family:inherit;font-size:10pt;">$29.3 million</font><font style="font-family:inherit;font-size:10pt;"> of previously unrecognized excess tax benefits in deferred tax assets, fully offset by a valuation allowance. The changes have been applied prospectively in accordance with the update, and prior periods have not been adjusted. All tax-related cash flows resulting from stock-based compensation, including the excess tax benefits related to the settlement of stock-based awards, will be classified as cash flows from operating activities in the Company&#8217;s consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. The standard requires entities to measure most inventory &#8220;at the lower of cost and net realizable value&#8221;, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures, one of which is net realizable value). Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The standard became effective for the Company prospectively beginning January 1, 2017. The adoption of ASU 2015-11 did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not Adopted as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2017</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, and has subsequently issued a number of amendments to this update. The new standard, as amended, provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The standard&#8217;s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 provides a five-step model that includes (1) identifying the contract with a customer, (2) identifying the performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations and (5) recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard will become effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective&#160;method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt this standard using the modified retrospective method.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with the current revenue accounting standards. Based on its review of its current customer contracts, the implementation of ASU 2014-09 will not have a material quantitative impact on the Company&#8217;s consolidated financial statements, as the timing of revenue recognition for EXPAREL product sales is not expected to significantly change. The Company will recognize existing collaborative licensing, milestone and royalty revenue earlier, subject to the variable consideration constraints, than it would have under the current standard, however, such changes are not expected to be material to the Company&#8217;s consolidated financial statements. Adoption of the new standard will result in additional revenue-related disclosures in the footnotes to the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-01 changes accounting for equity investments and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income (loss). Entities have the option to measure equity investments without readily determinable fair values either at fair value or at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The standard also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value. ASU 2016-01 will become effective for the Company beginning January 1, 2018. The Company has elected to measure equity investments without readily determinable fair values at cost adjusted for changes in observable prices. The guidance related to equity investments without readily determinable fair values will be applied prospectively to equity investments that exist as of the date of adoption. The adoption of ASU 2016-01 may increase volatility in the Company&#8217;s net income as changes in observable prices of equity investments without readily determinable fair values will be recorded in net income (loss). The Company does not expect the implementation of this standard to have a material impact on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">.&#160;This update requires lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. The lease liability will be equal to the present value of lease payments and the right-of-use asset will be based on the lease liability, subject to adjustment for items such as initial direct costs. For income statement purposes, the new standard retains a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. For lessees, operating leases will result in straight-line expense (similar to current accounting by lessees for operating leases under ASC 840) while financing leases will result in a front-loaded expense pattern (similar to current accounting by lessees for capital leases under ASC 840). This update also introduces new disclosure requirements for leasing arrangements. The standard will become effective for the Company beginning January 1, 2019. Early adoption is permitted, although the Company does not expect to do so. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. For operating leases it will result in the recognition of lease liabilities and corresponding right-of-use assets upon adoption, which will have a material impact on the Company&#8217;s consolidated balance sheet. The Company does not believe the adoption of this ASU will have a significant impact on its consolidated statements of operations, stockholders&#8217; equity or cash flows. At adoption, this update will be applied using a modified retrospective approach. Refer to Note&#160;17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on the Company&#8217;s leases.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity&#8217;s portfolio. This ASU will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company is currently evaluating the impact of ASU 2016-13 on its consolidated financial statements.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued&#160;ASU&#160;2016-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic&#160;230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">, which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a&#160;business combination.&#160;ASU&#160;2016-15&#160;will become effective for the Company in the first quarter of fiscal year 2018. The Company does not expect any changes to its consolidated statement of cash flows upon the adoption of this standard.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6327-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826933504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock', window );">Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholsesaler Service Fees and Prompt Pay Discounts</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Returns Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prompt Payment Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wholesaler Service Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Volume Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Payments/credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of percentage of revenue comprised by the three largest customers</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below includes the percentage of revenue comprised by the Company&#8217;s three largest wholesalers in each year presented:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second largest wholesaler</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third largest wholesaler</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of useful lives by asset category</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful lives by asset category are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 to 3&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 to 10&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Movement in Valuation and Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MovementinValuationandQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827135104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of components of inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of inventories are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831032336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock', window );">Schedule of fixed assets summarized by major category</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net summarized by major category, consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,256</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,526</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfPropertyPlantAndEquipmentComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6601257824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of change in carrying value of goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the carrying value of goodwill is summarized as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Milestone payment triggered by collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,737</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Percentage payments on collections of net sales of DepoBupivacaine products</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6666657696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalties</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product returns, rebates and other fees </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819376128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of composition of the Company's debt and financing obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2019 Notes is as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total debt composition of the 2022 Notes is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt, net of debt discount and deferred financing costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of total interest expense recognized related to the Notes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the total interest expense recognized in the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized interest and other (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,725</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective interest rate on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of interest rate expenses related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715809024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of carrying amount and fair value of the long-term debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount and fair value of the Company&#8217;s convertible senior notes are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Liabilities Carried at Historical Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying<br clear="none"/>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.375% convertible senior notes due 2022 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25% convertible senior notes due 2019 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(1) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;"> per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;"> compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$66.89</font><font style="font-family:inherit;font-size:8.5pt;"> per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">5.2 million</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">(2) The closing price of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:8.5pt;">$45.65</font><font style="font-family:inherit;font-size:8.5pt;"> per share at </font><font style="font-family:inherit;font-size:8.5pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8.5pt;"> compared to a conversion price of </font><font style="font-family:inherit;font-size:8.5pt;">$24.82</font><font style="font-family:inherit;font-size:8.5pt;"> per share which, if converted, would result in a conversion premium of less than </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock or </font><font style="font-family:inherit;font-size:8.5pt;">$0.3 million</font><font style="font-family:inherit;font-size:8.5pt;"> of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately </font><font style="font-family:inherit;font-size:8.5pt;">ten thousand</font><font style="font-family:inherit;font-size:8.5pt;"> shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of short-term investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the Company&#8217;s investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br clear="none"/>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Long-term:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,430</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016 Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value<br clear="none"/>(Level&#160;2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Short-term:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6601257824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Unrealized Gains</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Losses) From Available</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For Sale Investments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819351104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock', window );">Schedule of information about the plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table contains information about the Company&#8217;s plans at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Reserved for Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards<br clear="none"/>Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Awards Available for Grant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2007 Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2011 Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,931,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,037,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893,753</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014 Inducement plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,129,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,113,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,016,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Reserved<br clear="none"/>for Purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares<br clear="none"/>Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Available<br clear="none"/>for Purchase</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014 ESPP</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of recognized stock-based compensation in consolidated statements of operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized stock-based compensation expense (net of forfeitures) in its consolidated statements of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation from:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (employee awards)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options (consultant awards)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">785</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the Company's stock option activity and related information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock option activity and related information for the period from January&#160;1, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of<br clear="none"/>Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price (Per Share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average<br clear="none"/>Remaining<br clear="none"/>Contractual<br clear="none"/>Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate<br clear="none"/>Intrinsic Value<br clear="none"/>(in Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,677,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">906,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,880</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,645,722</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,656,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518,226</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175,303</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,072,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(232,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,882,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,951,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.91</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions used to estimate the fair values of each option grant using the Black-Scholes option pricing model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68% - 2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03% - 2.48%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40% - 2.28%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.9%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.31 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76 years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares available for issuance which includes information about awards reserved for issuance, awards issued and awards available for grant by plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6696866032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computation of diluted securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of RSUs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of conversion premium on the 2019 Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ESPP purchase options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.02</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential dilutive effect of the securities excluded from the calculation of diluted loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding stock options, RSUs, conversion premiums on the Company&#8217;s convertible senior notes, warrants and ESPP purchase options are antidilutive in the periods presented (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of RSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion premium on the 2019 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average ESPP purchase options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826839232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes at the U.S. Federal statutory rate to the provision for income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. federal statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes refinancing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of the adoption of ASU 2016-09</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the Company's deferred tax assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,939</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount on convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,230</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,753</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831110080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS COMMERICAL PARTNERS AND OTHER AGREEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CommercialPartnersAndAgreementsAbstract', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock', window );">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a summary of the Company&#8217;s costs and reserves related to the DepoCyt(e) discontinuation are as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:209px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Severance and Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Write-Off of Property, Plant &amp; Equipment and Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Retirement Obligations and Other Discontinuation Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges incurred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments made</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposal of property, plant &amp;<br clear="none"/>   equipment and inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CommercialPartnersAndAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CommercialPartnersAndAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6600501024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of annual minimum payments due under the Company's lease obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, aggregate annual minimum payments due under the Company&#8217;s lease obligations are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Minimum Payments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,089</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023 through 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831040816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present selected quarterly financial data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,866</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,743</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,597</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,<br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,<br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,973</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods where the Company reported a net loss, no potentially dilutive securities were included in the computation of diluted net loss per share.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831005040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct', window );">Beginning period prior to product expiration allowed for the product to be returned</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned', window );">Period following product expiration upto which the product is allowed to be returned</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the beginning period prior to the product expiration, which the entity allows for the product to be returned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BeginningPeriodPriorToProductExpirationAllowedForReturningProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period following the product expiration, upto which the entity allows for the product to be returned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PeriodAfterProductExpirationUptoWhichProductIsAllowedToBeReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840758320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals</a></td>
<td class="nump">15,581<span></span>
</td>
<td class="nump">12,871<span></span>
</td>
<td class="nump">10,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments (Credits)</a></td>
<td class="num">(16,368)<span></span>
</td>
<td class="num">(12,971)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember', window );">Accrued returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments (Credits)</a></td>
<td class="num">(1,241)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Reserves for prompt pay discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals</a></td>
<td class="nump">5,806<span></span>
</td>
<td class="nump">5,448<span></span>
</td>
<td class="nump">4,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments (Credits)</a></td>
<td class="num">(5,744)<span></span>
</td>
<td class="num">(5,478)<span></span>
</td>
<td class="num">(4,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember', window );">Accrued wholesaler service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals</a></td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">4,118<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments (Credits)</a></td>
<td class="num">(4,299)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="num">(3,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForPromotionsMember', window );">Accrued rebates and chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals</a></td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments (Credits)</a></td>
<td class="num">(5,084)<span></span>
</td>
<td class="num">(2,284)<span></span>
</td>
<td class="num">(1,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForPromotionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForPromotionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840196496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - Net revenue - Customer concentration<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Largest customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Second largest customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Third largest customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Customers outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Major Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_CustomersOutsideUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_CustomersOutsideUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841017440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing and laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing and laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820222096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting Pronouncements (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative Effect on Retained Earnings, Net of Tax</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax', window );">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax</a></td>
<td class="nump">$ 29.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842329568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 11,742<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">11,621<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,915<span></span>
</td>
<td class="nump">16,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">31,278<span></span>
</td>
<td class="nump">$ 41,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827357040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 156,256<span></span>
</td>
<td class="nump">$ 138,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(49,210)<span></span>
</td>
<td class="num">(37,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">107,046<span></span>
</td>
<td class="nump">101,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ForeignPropertyPlantandEquipmentNet', window );">Foreign Property, Plant and Equipment, Net</a></td>
<td class="nump">59,800<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset Retirement Obligation</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetRetirementObligations', window );">Increase (Decrease) in Asset Retirement Obligations</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationLiabilitiesIncurred', window );">Asset Retirement Obligation, Liabilities Incurred</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAccretionExpense', window );">Asset Retirement Obligation, Accretion Expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">39,002<span></span>
</td>
<td class="nump">34,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">34,933<span></span>
</td>
<td class="nump">33,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">7,086<span></span>
</td>
<td class="nump">5,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 73,632<span></span>
</td>
<td class="nump">$ 63,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ForeignPropertyPlantandEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to product goods and services and not intended for resale, located in a foreign country or territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ForeignPropertyPlantandEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetRetirementObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the carrying amount of asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetRetirementObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841839168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition', window );">Payment obligation arising in connection with the acquisition</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition', window );">Contingent consideration liability recognized at the time of the acquisition</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded in connection with the acquisition</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TotalGoodwillRecordedforEarnOutPayments', window );">Total Goodwill Recorded for Earn Out Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,737,000<span></span>
</td>
<td class="nump">$ 30,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_GoodwillRecordedforEarnOutPayments', window );">Percentage payments on collections of net sales of DepoBupivacaine products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,460,000<span></span>
</td>
<td class="nump">7,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_GoodwillRecordedonMilestonePayments', window );">Milestone payment triggered by collections of net sales of DepoBupivacaine products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,197,000<span></span>
</td>
<td class="nump">$ 46,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInUnitedStatesMember', window );">Upon first commercial sale in the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember', window );">Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember', window );">When annual net sales collected reach $100.0 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition', window );">Annual net sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million', window );">Payment Obligation Arising Due to Net Sales Collected Threshold of $100 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation', window );">Net Sales Collected Threshold Which Triggers a Payment Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember', window );">When annual net sales collected reach $250.0 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition', window );">Annual net sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation', window );">Net Sales Collected Threshold Which Triggers a Payment Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember', window );">When annual net sales collected reach $500.0 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition', window );">Annual net sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of contingent consideration liability established for sale of product in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_GoodwillRecordedforEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount recorded as goodwill for earn-out payments made by the entity based on a percentage of net sales of EXPAREL collected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_GoodwillRecordedforEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_GoodwillRecordedonMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill Recorded on Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_GoodwillRecordedonMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Collected Threshold Which Triggers a Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NetSalesCollectedThresholdWhichTriggersaPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment obligation which the reporting entity is entitled to pay to other party on completion of first commercial sale of its product in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Obligation Arising Due to Net Sales Collected Threshold of $100 Million</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentObligationArisingDuetoNetSalesCollectedThresholdof100Million</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TotalGoodwillRecordedforEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Goodwill Recorded for Earn Out Payments - Cumulative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TotalGoodwillRecordedforEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar100.0MillionThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar250.0MillionThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819381648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828232272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 12,295<span></span>
</td>
<td class="nump">$ 11,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedOperatingExpensesCurrent', window );">Accrued operating expenses</a></td>
<td class="nump">20,646<span></span>
</td>
<td class="nump">16,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">4,091<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedEndOfTermFeeCurrent', window );">Accrued interest</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProductReturnsRebatesandOtherFees', window );">Product returns, rebates and other fees</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 41,057<span></span>
</td>
<td class="nump">$ 36,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedEndOfTermFeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for end of term fee. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedEndOfTermFeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedOperatingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedOperatingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProductReturnsRebatesandOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Returns, Rebates and Other Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProductReturnsRebatesandOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845962784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 13, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 23, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 07, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 02, 2012 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest', window );">Settlement Period - Convertible Debt Conversion Request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption', window );">Debt Instrument Conversion Obligation Number of Trading Days Prior to Date on which Entity Provides Notice of Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionValue', window );">Debt Instrument, Convertible, Conversion Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="nump">14.9491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock', window );">Debt Instrument, Conversion Obligation Premium on Common Stock</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Debt Redemption Price Due to Fundamental Change as Percentage of Principal Amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt</a></td>
<td class="nump">$ 274,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate', window );">Debt Instrument, Convertible, Assumed Borrowing Rate</a></td>
<td class="nump">7.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt Instrument, Convertible, Carrying Amount of Equity Component</a></td>
<td class="nump">$ 70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt Related Commitment Fees and Debt Issuance Costs</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtIssuanceCostsAmortizationperiod', window );">Debt Issuance Costs, Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault', window );">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 [Member] | Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays', window );">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays', window );">Debt Instrument, Conversion Obligation Number of Consecutive Trading Days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice', window );">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod', window );">Debt Instrument Conversion Obligation Number of Consecutive Business Days after Consecutive Trading Day Period</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays', window );">Debt Instrument, Conversion Obligation Period of Consecutive Trading Days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock', window );">Debt Instrument, Principal Amount Denominator for Conversion into Common Stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum', window );">Debt Instrument, Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentMarketPrice', window );">Debt Instrument, Market Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 [Member] | Debt Redemption Terms on or after April 1, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays', window );">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays', window );">Debt Instrument, Conversion Obligation Number of Consecutive Trading Days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice', window );">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption', window );">Debt Instrument Conversion Obligation Number of Trading Days Prior to Date on which Entity Provides Notice of Redemption</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice', window );">Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember', window );">Two Thousand Nineteen Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,381,000<span></span>
</td>
<td class="nump">$ 612,000<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock', window );">Debt Instrument, Principal Amount Denominator for Conversion into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_GrossProceedsFromIssuanceofDebt', window );">Gross Proceeds From Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument, Repurchased Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt Instrument, Repurchase Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember', window );">Two Thousand Nineteen Senior Convertible Notes [Member] | Debt Conversion Terms Business Day Immediately Preceding August 12018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock', window );">Debt Instrument, Principal Amount Denominator for Conversion into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentMarketPrice', window );">Debt Instrument, Market Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionValue', window );">Debt Instrument, Convertible, Conversion Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,482,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,345,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,173,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProceedsfromConvertibleDebtNet', window );">Proceeds from Convertible Debt, Net</a></td>
<td class="nump">$ 334,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Two Thousand Nineteen Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">118,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(1,276,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="num">(8,517,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,000<span></span>
</td>
<td class="nump">$ 108,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the conversion price that the closing sales price of the entity's common stock must exceed for at least 20 days within 30 consecutive trading days, in order for the notes to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days prior to the date on which the entity provides notice of redemption during which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationNumberofTradingDaysPriortoDateonwhichEntityProvidesNoticeofRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of the entity's common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Assumed Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleAssumedBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleConversionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleConversionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Market Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the principal amount of notes used as a denominator for purposes of computing the conversion ratio of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtIssuanceCostsAmortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtIssuanceCostsAmortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be repurchased in the event of a fundamental change by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_GrossProceedsFromIssuanceofDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_GrossProceedsFromIssuanceofDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProceedsfromConvertibleDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Convertible Debt, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProceedsfromConvertibleDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days in a settlement period for convertible debt conversion requests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SettlementPeriodConvertibleDebtConversionRequest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsonorafterApril12020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsonorafterApril12020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingAugust12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841388752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest Expense, Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 10,423<span></span>
</td>
<td class="nump">$ 4,088<span></span>
</td>
<td class="nump">$ 4,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest Expense, Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">7,344<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">10,423<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="num">(1,101)<span></span>
</td>
<td class="num">(1,491)<span></span>
</td>
<td class="num">(848)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense recognized</a></td>
<td class="nump">$ 18,047<span></span>
</td>
<td class="nump">$ 7,061<span></span>
</td>
<td class="nump">$ 7,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">7.77%<span></span>
</td>
<td class="nump">7.22%<span></span>
</td>
<td class="nump">7.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844430704">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 07, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares', window );">Debt Instrument, Convertible, Conversion Premium, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionValue', window );">Estimated conversion value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount', window );">Equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_InvestmentsContingentPurchaseObligation', window );">Investments, Contingent Purchase Obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember', window );">Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares', window );">Debt Instrument, Convertible, Conversion Premium, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares', window );">Debt Instrument, Convertible, Conversion Premium, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Convertible Senior Notes Due 2022 [Member] | Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Convertible Senior Notes Due 2022 [Member] | Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Convertible Senior Notes Due 2022 [Member] | Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Notes | Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Notes | Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Notes | Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Carrying Value | Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Carrying Value | Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt-current and long-term</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The closing price of the Company&#8217;s common stock was $45.65 per share at December&#160;31, 2017 compared to a conversion price of $66.89 per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately 5.2 million shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The closing price of the Company&#8217;s common stock was $45.65 per share at December&#160;31, 2017 compared to a conversion price of $24.82 per share which, if converted, would result in a conversion premium of less than ten thousand shares of the Company&#8217;s common stock or $0.3 million of cash. The maximum conversion premium that can be due on the 2019 Notes is approximately ten thousand shares of the Company&#8217;s common stock, which assumes no increases in the conversion rate for certain corporate events.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Premium, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleConversionPremiumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleConversionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleConversionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_InvestmentsContingentPurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Contingent Purchase Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_InvestmentsContingentPurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the carrying (reported) amount of the entity's investments as of the balance sheet date. This amount may represent the individual investment's or group of similar investments' original cost, fair value, or such other amount at which the investment is shown in the entity's balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SX 210.12-15)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611379-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TwoThousandNineteenSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828341248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 317,722<span></span>
</td>
<td class="nump">$ 136,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">317,268<span></span>
</td>
<td class="nump">136,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">257,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">257,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">28,338<span></span>
</td>
<td class="nump">9,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Asset-backed Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">28,301<span></span>
</td>
<td class="nump">9,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">48,999<span></span>
</td>
<td class="nump">39,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">48,976<span></span>
</td>
<td class="nump">39,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">180,119<span></span>
</td>
<td class="nump">88,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term: | Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">179,944<span></span>
</td>
<td class="nump">$ 88,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">60,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">60,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term: | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">23,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term: | Asset-backed Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">23,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term: | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">36,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember', window );">Long-term: | Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 36,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829006848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details 3) - customer<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NumberOfMajorCustomers', window );">Number of major customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Credit risk | Major customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Credit risk | Major customer two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Credit risk | Major customer three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_MajorCustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_MajorCustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_MajorCustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_MajorCustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=pcrx_MajorCustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=pcrx_MajorCustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820417264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">40,668,877<span></span>
</td>
<td class="nump">37,480,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829085328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balances at the beginning of the period</a></td>
<td class="num">$ (30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balances at the end of the period</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balances at the beginning of the period</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="num">(424)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balances at the end of the period</a></td>
<td class="num">$ (454)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838209296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Awards Reserved for Issuance (in shares)</a></td>
<td class="nump">12,129,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP', window );">Employee Stock Purchase Plan (ESPP), Shares in ESPP</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MaximumFairMarketValuePurchaseofESPPShares', window );">Maximum Fair Market Value Purchase of ESPP Shares</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanfairvalue', window );">Employee Stock Purchase Plan fair value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Awards Issued (in shares)</a></td>
<td class="nump">9,113,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available for Grant (in shares)</a></td>
<td class="nump">3,016,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized', window );">Employee Stock Purchase Plan, Number of Shares Authorized</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="nump">160,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase', window );">Employee Stock Purchase Plan, Number of Shares Available For Purchase</a></td>
<td class="nump">339,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="nump">$ 41,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 7 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 20.78<span></span>
</td>
<td class="nump">$ 19.13<span></span>
</td>
<td class="nump">$ 37.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 10 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member', window );">Inducement Plan 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Awards Reserved for Issuance (in shares)</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Awards Issued (in shares)</a></td>
<td class="nump">52,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available for Grant (in shares)</a></td>
<td class="nump">122,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_TwoThousandSevenStockIncentivePlanMember', window );">Two Thousand Seven Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Awards Reserved for Issuance (in shares)</a></td>
<td class="nump">2,022,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Awards Issued (in shares)</a></td>
<td class="nump">2,022,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available for Grant (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member', window );">Stock Incentive Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Awards Reserved for Issuance (in shares)</a></td>
<td class="nump">9,931,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Awards Issued (in shares)</a></td>
<td class="nump">7,037,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available for Grant (in shares)</a></td>
<td class="nump">2,893,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan (ESPP), Shares in ESPP</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanESPPSharesinESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Number of Shares Available For Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanfairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fair value of common stock eligible employees can purchase common shares at through an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanfairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MaximumFairMarketValuePurchaseofESPPShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Fair Market Value Purchase of ESPP Shares in a Calendar Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MaximumFairMarketValuePurchaseofESPPShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_TwoThousandSevenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_TwoThousandSevenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826645152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 31,601<span></span>
</td>
<td class="nump">$ 31,248<span></span>
</td>
<td class="nump">$ 33,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Compensationexpensefromstockoptionsemployees', window );">Compensation expense from stock options, employees</a></td>
<td class="nump">24,056<span></span>
</td>
<td class="nump">24,505<span></span>
</td>
<td class="nump">27,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Compensationexpensefromstockoptionsnonemployeeawards', window );">Compensation expense from stock options, non-employee awards</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="nump">6,698<span></span>
</td>
<td class="nump">5,117<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Compensationexpensefromemployeestockpurchaseplan', window );">Compensation expense from employee stock purchase plan</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">31,601<span></span>
</td>
<td class="nump">31,248<span></span>
</td>
<td class="nump">33,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
<td class="nump">6,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,341<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">5,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 22,793<span></span>
</td>
<td class="nump">$ 21,513<span></span>
</td>
<td class="nump">$ 22,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Compensationexpensefromemployeestockpurchaseplan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense from employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Compensationexpensefromemployeestockpurchaseplan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Compensationexpensefromstockoptionsemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense from stock options (employee and board of director awards)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Compensationexpensefromstockoptionsemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Compensationexpensefromstockoptionsnonemployeeawards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense from stock options, non-employee awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Compensationexpensefromstockoptionsnonemployeeawards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845538192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue', window );">Share-based Compensation arrangement by Share-based payment award, equity instruments others than options, vested and expected to vest, weighted average grant date fair value</a></td>
<td class="nump">$ 47.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue', window );">share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">$ 22,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">5,207,743<span></span>
</td>
<td class="nump">4,645,722<span></span>
</td>
<td class="nump">4,677,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,072,625<span></span>
</td>
<td class="nump">1,656,598<span></span>
</td>
<td class="nump">906,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(539,989)<span></span>
</td>
<td class="num">(518,226)<span></span>
</td>
<td class="num">(618,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(555,897)<span></span>
</td>
<td class="num">(401,048)<span></span>
</td>
<td class="num">(294,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(232,989)<span></span>
</td>
<td class="num">(175,303)<span></span>
</td>
<td class="num">(25,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">4,951,493<span></span>
</td>
<td class="nump">5,207,743<span></span>
</td>
<td class="nump">4,645,722<span></span>
</td>
<td class="nump">4,677,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">2,882,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">4,951,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 42.16<span></span>
</td>
<td class="nump">$ 44.03<span></span>
</td>
<td class="nump">$ 35.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">43.93<span></span>
</td>
<td class="nump">38.20<span></span>
</td>
<td class="nump">75.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">12.55<span></span>
</td>
<td class="nump">11.13<span></span>
</td>
<td class="nump">16.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">48.66<span></span>
</td>
<td class="nump">70.27<span></span>
</td>
<td class="nump">64.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">74.65<span></span>
</td>
<td class="nump">80.91<span></span>
</td>
<td class="nump">81.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">43.51<span></span>
</td>
<td class="nump">$ 42.16<span></span>
</td>
<td class="nump">$ 44.03<span></span>
</td>
<td class="nump">$ 35.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">42.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 43.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward', window );"><strong>Weighted Average remaining contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">6 years 10 months 27 days<span></span>
</td>
<td class="text">7 years 4 months 22 days<span></span>
</td>
<td class="text">7 years 3 months 22 days<span></span>
</td>
<td class="text">7 years 10 months 11 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 6 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end of the period</a></td>
<td class="text">6 years 10 months 27 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the beginning of the period (in dollars)</a></td>
<td class="nump">$ 37,581<span></span>
</td>
<td class="nump">$ 162,340<span></span>
</td>
<td class="nump">$ 248,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised (in dollars)</a></td>
<td class="nump">15,865<span></span>
</td>
<td class="nump">21,750<span></span>
</td>
<td class="nump">39,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the end of the period (in dollars)</a></td>
<td class="nump">57,021<span></span>
</td>
<td class="nump">$ 37,581<span></span>
</td>
<td class="nump">$ 162,340<span></span>
</td>
<td class="nump">$ 248,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period (in dollars)</a></td>
<td class="nump">47,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">$ 57,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions used to estimate the fair values of each option grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (as a percent)</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (as a percent)</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">51.40%<span></span>
</td>
<td class="nump">53.50%<span></span>
</td>
<td class="nump">52.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 9 months 6 days<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 20.78<span></span>
</td>
<td class="nump">$ 19.13<span></span>
</td>
<td class="nump">$ 37.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">364,403<span></span>
</td>
<td class="nump">216,198<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">343,583<span></span>
</td>
<td class="nump">256,631<span></span>
</td>
<td class="nump">232,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(101,379)<span></span>
</td>
<td class="num">(61,487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(107,061)<span></span>
</td>
<td class="num">(46,939)<span></span>
</td>
<td class="num">(15,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">499,546<span></span>
</td>
<td class="nump">364,403<span></span>
</td>
<td class="nump">216,198<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 52.85<span></span>
</td>
<td class="nump">$ 78.59<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">44.23<span></span>
</td>
<td class="nump">40.21<span></span>
</td>
<td class="nump">78.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">53.76<span></span>
</td>
<td class="nump">78.33<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">49.98<span></span>
</td>
<td class="nump">68.84<span></span>
</td>
<td class="nump">79.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 47.32<span></span>
</td>
<td class="nump">$ 52.85<span></span>
</td>
<td class="nump">$ 78.59<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 22,804<span></span>
</td>
<td class="nump">$ 11,824<span></span>
</td>
<td class="nump">$ 16,602<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest', window );">Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest</a></td>
<td class="nump">499,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcrx_EmployeeStockPurchasePlanMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions used to estimate the fair values of each option grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">53.80%<span></span>
</td>
<td class="nump">63.40%<span></span>
</td>
<td class="nump">50.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcrx_EmployeeStockPurchasePlanMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 10.57<span></span>
</td>
<td class="nump">$ 21.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcrx_EmployeeStockPurchasePlanMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="nump">$ 25.28<span></span>
</td>
<td class="nump">$ 25.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">0.49%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardRestrictedStockUnitsVestedandExpectedtoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation arrangement by Share-based payment award, equity instruments others than options, vested and expected to vest, weighted average grant date fair value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SharebasedCompensationarrangementbySharebasedpaymentawardequityinstrumentsothersthanoptionsvestedandexpectedtovestweightedaveragegrantdatefairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedandexpectedtovestaggregateintrinsicvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829513856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,595<span></span>
</td>
<td class="num">$ (7,597)<span></span>
</td>
<td class="num">$ (19,743)<span></span>
</td>
<td class="num">$ (19,866)<span></span>
</td>
<td class="num">$ (3,973)<span></span>
</td>
<td class="num">$ (22,164)<span></span>
</td>
<td class="num">$ (7,958)<span></span>
</td>
<td class="num">$ (3,854)<span></span>
</td>
<td class="num">$ (42,611)<span></span>
</td>
<td class="num">$ (37,949)<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding&#8212;basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,806<span></span>
</td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">36,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits', window );">Dilutive effect of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect of conversion premium on the 2019 Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Dilutive effect of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements', window );">Dilutive effect of ESPP purchase options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding&#8212;diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,806<span></span>
</td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">41,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845563440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE (Details 2) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">6,060<span></span>
</td>
<td class="nump">6,816<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">4,482<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP purchase options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive effect of securities (in shares)</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841556016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 13, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (39,898)<span></span>
</td>
<td class="num">$ (36,339)<span></span>
</td>
<td class="nump">$ 3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(2,573)<span></span>
</td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(1,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal', window );">Total income (loss) before income taxes</a></td>
<td class="num">(42,471)<span></span>
</td>
<td class="num">(37,844)<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvision', window );">Income Tax Provision</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income taxes at U.S. Federal statutory rate to the provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">2.26%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationForeign', window );">Foreign taxes</a></td>
<td class="num">(1.28%)<span></span>
</td>
<td class="num">(0.81%)<span></span>
</td>
<td class="nump">12.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="num">(43.96%)<span></span>
</td>
<td class="nump">10.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.21%)<span></span>
</td>
<td class="num">(0.54%)<span></span>
</td>
<td class="nump">7.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">4.96%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="num">(30.63%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent', window );">Interest expense</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="num">(37.57%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Effectofstateblendedtaxratechanges', window );">Effect of rate changes</a></td>
<td class="num">(130.88%)<span></span>
</td>
<td class="num">(4.65%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing', window );">Convertible senior notes refinancing</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements', window );">Effect of the adoption of ASU 2016-09</a></td>
<td class="nump">68.89%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="num">(2.04%)<span></span>
</td>
<td class="nump">15.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.33%)<span></span>
</td>
<td class="num">(0.28%)<span></span>
</td>
<td class="nump">12.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 95,067<span></span>
</td>
<td class="nump">$ 96,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state credits</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="nump">13,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">2,593<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">4,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">3,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsStockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">16,925<span></span>
</td>
<td class="nump">21,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">134,908<span></span>
</td>
<td class="nump">151,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Discount on convertible senior notes</a></td>
<td class="num">(14,678)<span></span>
</td>
<td class="num">(3,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance', window );">Net deferred tax assets, before valuation allowance</a></td>
<td class="nump">120,230<span></span>
</td>
<td class="nump">148,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(120,230)<span></span>
</td>
<td class="num">(148,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NonUSNetOperatingLoss', window );">Non-US Net Operating Loss</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax', window );">Minimum Cumulative Percentage of Change in Ownership as Condition to Offset Taxable Income or Tax</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance for deferred tax assets</a></td>
<td class="num">$ (28,500)<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit', window );">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)</a></td>
<td class="nump">55,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_UnitedStatesStatutoryTaxRate', window );">United States Statutory Tax Rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt Instrument, Convertible, Carrying Amount of Equity Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">380,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NetOperatingLossSubjecttoLimitation', window );">Net Operating Loss, Subject to Limitation</a></td>
<td class="nump">192,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AvailableNetOperatingLossSubjecttoLimitation', window );">Available Net Operating Loss, Subject to Limitation</a></td>
<td class="nump">134,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FutureNOLsWhichWillBecomeAvailable20182022', window );">Future NOL's Which Will Become Available (2018-2022)</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward', window );">Future NOL's Which Will Become Available (2015-Onward)</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">232,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AvailableNetOperatingLossSubjecttoLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available Net Operating Loss, Subject to Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AvailableNetOperatingLossSubjecttoLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net of Deferred Tax Liabilities, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Effect Of New Accounting Pronouncements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationEffectOfNewAccountingPronouncements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationInterestExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Effectofstateblendedtaxratechanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed as the result of changes in state blended tax rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Effectofstateblendedtaxratechanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future NOL's Which Will Become Available (2015-Onward)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FutureNOLsWhichWillBecomeAvailable2015Onward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FutureNOLsWhichWillBecomeAvailable20182022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future NOL's Which Will Become Available (2018-2022)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FutureNOLsWhichWillBecomeAvailable20182022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The earnings or loss from continuing operations before income taxes for the entity as a whole, including domestic and foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncomeTaxProvisionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Tax Provision [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncomeTaxProvisionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NetOperatingLossSubjecttoLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Losses, Subject to Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NetOperatingLossSubjecttoLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NonUSNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-US Net Operating Loss - This value represents the amount of the tax loss from foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NonUSNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_UnitedStatesStatutoryTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>United States Statutory Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_UnitedStatesStatutoryTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831084160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense recognized</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844295376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 05, 2012</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,078,000<span></span>
</td>
<td class="nump">$ 67,335,000<span></span>
</td>
<td class="nump">$ 70,934,000<span></span>
</td>
<td class="nump">$ 69,283,000<span></span>
</td>
<td class="nump">$ 72,902,000<span></span>
</td>
<td class="nump">$ 68,355,000<span></span>
</td>
<td class="nump">$ 69,640,000<span></span>
</td>
<td class="nump">$ 65,474,000<span></span>
</td>
<td class="nump">$ 286,630,000<span></span>
</td>
<td class="nump">$ 276,371,000<span></span>
</td>
<td class="nump">$ 248,997,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,868,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Supplemental Unemployment Benefits, Severance Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DiscontinuedOperationsResidualLeaseCosts', window );">Discontinued Operations - Residual Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationCurrent', window );">Asset Retirement Obligation, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining', window );">Discontinued Operation, Amounts of Material Contingent Liabilities Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DiscontinuedOperationsRemainingLeaseCosts', window );">Discontinued Operations - Remaining Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown', window );">Discontinued Operations - Fixed Asset and Inventory Writedown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsIncurredAssetRetirementObligationIncurred', window );">Costs Incurred, Asset Retirement Obligation Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPostemploymentBenefits', window );">Payments for Postemployment Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts', window );">Discontinued Operations, Payments For Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(744,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationLiabilitiesSettled', window );">Asset Retirement Obligation, Liabilities Settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Disposal Group, Including Discontinued Operation, Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,467,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DiscontinuedOperationsAssetsremovedfromService', window );">Discontinued Operations Assets removed from Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,470,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TotalChangeinDiscontinuedOperationsBalance', window );">Total Change in Discontinued Operations Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,470,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContractTerminationFee', window );">Contract Termination Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContractTerminationFeeCurrentPortion', window );">Contract Termination Fee, Current Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember', window );">Aratana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementUpfrontPaymentReceived', window );">Up-front payment received</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember', window );">Aratana | Maximum | Achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived', window );">Milestone payments Company is entitled to receive based on terms of agreement</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=pcrx_PatheonMember', window );">Patheon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContractTerminationFee', window );">Contract Termination Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_InitialTermofManufacturingSupplyAgreement', window );">Initial Term of Manufacturing Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10th<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=pcrx_MundipharmaLtdMember', window );">Mundipharma Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EuropeanRightsExpansionNewDistributionPayment', window );">European Rights Expansion &amp; New Distribution Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TermExtensionof2003Agreements', window );">Term Extension of 2003 Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProductAxis=pcrx_DepoCyteMember', window );">DepoCyte [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Percentageoftotalrevenue', window );">Percentage of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payment received under the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment received under the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContractTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum dollar amount it would cost the entity to terminate a contract as of a given date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContractTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContractTerminationFeeCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract termination fees payable within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContractTerminationFeeCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DiscontinuedOperationsAssetsremovedfromService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations Assets removed from Service</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DiscontinuedOperationsAssetsremovedfromService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations - Fixed Asset and Inventory Writedown</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DiscontinuedOperationsFixedAssetandInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DiscontinuedOperationsPaymentsForLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations, Payments For Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DiscontinuedOperationsPaymentsForLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DiscontinuedOperationsRemainingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations - Remaining Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DiscontinuedOperationsRemainingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DiscontinuedOperationsResidualLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations - Residual Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DiscontinuedOperationsResidualLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EuropeanRightsExpansionNewDistributionPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>European Rights Expansion &amp; New Distribution Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EuropeanRightsExpansionNewDistributionPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_InitialTermofManufacturingSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Term of Manufacturing Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_InitialTermofManufacturingSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Percentageoftotalrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Percentageoftotalrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TermExtensionof2003Agreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Extension of 2003 Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TermExtensionof2003Agreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TotalChangeinDiscontinuedOperationsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Change in Discontinued Operations Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TotalChangeinDiscontinuedOperationsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationLiabilitiesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations settled, or otherwise disposed of, during the period. This may include asset retirement obligations transferred to third parties associated with the sale of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationLiabilitiesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsIncurredAssetRetirementObligationIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations (ARO) costs incurred (whether capitalized or charged to expense) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsIncurredAssetRetirementObligationIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts of material contingent liabilities, for example, but not limited to, product or environmental liabilities or litigation, that remain with the entity despite the disposal of the disposal group that is classified as a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14453-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5333-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.Z.5.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7384-122677<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14472-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14394-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913245&amp;loc=d3e12021-110248<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=pcrx_PatheonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=pcrx_PatheonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=pcrx_MundipharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=pcrx_MundipharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProductAxis=pcrx_DepoCyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProductAxis=pcrx_DepoCyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841428448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2012</div></th>
<th class="th"><div>Apr. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcrx_MPMAssetManagementMember', window );">MPM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcrx_MPMAssetManagementMember', window );">MPM | Consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses incurred by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Member of board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Member of board of directors | Consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares', window );">Number of shares that can be purchased under option (in shares)</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice', window );">Exercise price of shares that can be purchased under option (in dollars per share)</a></td>
<td class="nump">$ 16.67<span></span>
</td>
<td class="nump">$ 11.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Member of board of directors | Consulting agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses incurred by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price of shares that can be purchased by the related party on exercise of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares that can be purchased by the related party on exercise of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcrx_MPMAssetManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcrx_MPMAssetManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnergyAxis=pcrx_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnergyAxis=pcrx_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830199552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Annual minimum payments due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 7,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">8,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">7,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">5,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2023 through 2028</a></td>
<td class="nump">19,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">53,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Leasehold Improvements, Gross</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase Obligation</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e40010-112707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827937184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 21, 2007</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pcrx_SkyePharmaHoldingIncMember', window );">SkyePharma Holding, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition', window );">Total milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=pcrx_SkyePharmaHoldingIncMember', window );">SkyePharma Holding, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_CaliforniaOperatingSubsidiaryMember', window );">PPI-California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Initial purchase price for acquisition</a></td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pcrx_SkyePharmaHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pcrx_SkyePharmaHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_CaliforniaOperatingSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_CaliforniaOperatingSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830149456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 67,335<span></span>
</td>
<td class="nump">$ 70,934<span></span>
</td>
<td class="nump">$ 69,283<span></span>
</td>
<td class="nump">$ 72,902<span></span>
</td>
<td class="nump">$ 68,355<span></span>
</td>
<td class="nump">$ 69,640<span></span>
</td>
<td class="nump">$ 65,474<span></span>
</td>
<td class="nump">$ 286,630<span></span>
</td>
<td class="nump">$ 276,371<span></span>
</td>
<td class="nump">$ 248,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">21,295<span></span>
</td>
<td class="nump">18,228<span></span>
</td>
<td class="nump">23,811<span></span>
</td>
<td class="nump">24,581<span></span>
</td>
<td class="nump">23,621<span></span>
</td>
<td class="nump">43,152<span></span>
</td>
<td class="nump">23,053<span></span>
</td>
<td class="nump">20,278<span></span>
</td>
<td class="nump">87,915<span></span>
</td>
<td class="nump">110,104<span></span>
</td>
<td class="nump">71,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">70,613<span></span>
</td>
<td class="nump">70,907<span></span>
</td>
<td class="nump">86,714<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="nump">75,363<span></span>
</td>
<td class="nump">89,220<span></span>
</td>
<td class="nump">76,084<span></span>
</td>
<td class="nump">67,728<span></span>
</td>
<td class="nump">311,567<span></span>
</td>
<td class="nump">308,395<span></span>
</td>
<td class="nump">239,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,595<span></span>
</td>
<td class="num">$ (7,597)<span></span>
</td>
<td class="num">$ (19,743)<span></span>
</td>
<td class="num">$ (19,866)<span></span>
</td>
<td class="num">$ (3,973)<span></span>
</td>
<td class="num">$ (22,164)<span></span>
</td>
<td class="num">$ (7,958)<span></span>
</td>
<td class="num">$ (3,854)<span></span>
</td>
<td class="num">$ (42,611)<span></span>
</td>
<td class="num">$ (37,949)<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net income (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL(^6+=S_]CX(J@:^'47Z@M02P,$%     @ U'A<3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M"C5,Y9@-'7R8"-J-EQ.:;LCB'U!+ P04    " #4>%Q,7^>1[HH%  ";'0
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M/>12+_8K0GXE)Z"D369!Q,&KR@1 ;X(<,B7BXDA(K6,)^Q;EH#8EYK&$S83
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M_H/-AH3*A>,7?S;CF(V&PV[Z06S^QOE?4$L#!!0    ( -1X7$S;\A!6M0$
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MP]E.8S89'OOY!['E&Y<_ 5!+ P04    " #4>%Q,/8^9?+0!  #2 P  &0
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M.8+",:<[^N9XE$WK@H,562\:^ GN5W\RWF*+2B4U=%9B1PS4.;W;'8YIP$?
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M>S-^@KF>-Y3,Q7^!*R@,#THP1VF4BRLI!^>-GEE0BA9/TRZ[N(_339K,L&T
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MT&(+2RTU&"^M(0Z:@M[O3N=#C$\!7R6,?G4FL9*KM4_1^% 7-(N"0$$5(H/
M[08/H%0D0AG?9TZZI(S ]?F%_5VJ'6NY"@\/5GV3=>@*>J2DAD8,*CS:\3W,
M];RB9"[^(]Q 87A4@CDJJWQ:237X8/7,@E*T>)YV:=(^3C?[XPS;!O 9P!?
M,>5A4Z*D_*T(HLR='8F;>M^+^,2[$\?>5-&96I'N4+Q'[ZWD/,O9+1+-,><I
MAJ]B=DL$0_8E!=]*<>9_P?DV?+^I<)_@^]\4_B/_89/@D @._RUQ*^9/E6S5
M4PVN3=/D264'DR9YY5T&]IZG-_D5/DW[)^%::3RYVH OF_K?6!L I61W.$(=
M?K#%4-"$>'R#9S>-V60$V\\_B"W?N/P)4$L#!!0    ( -1X7$QED?Z7M $
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U3VX[3,!#]%<L?
ML&[=%%95$FF["($$4K4(>':326*M+\%VFN7O&3O9$"#BQ?:,YYPY,Q[GHW7/
MO@,(Y$4KXPO:A="?&/-5!UKX.]N#P9O&.BT"FJYEOG<@Z@32BO'=[@W30AI:
MYLEW<65NAZ"D@8LC?M!:N)]G4'8LZ)Z^.IYDVX7H8&7>BQ:^0/C:7QQ:;&&I
MI0;CI37$05/0A_WIG,7X%/!-PNA79Q(KN5K['(V/=4%W41 HJ$)D$+C=X!&4
MBD0HX\?,29>4$;@^O[*_3[5C+5?AX=&J[[(.74'O*:FA$8,*3W;\ ',]1TKF
MXC_!#12&1R68H[+*IY54@P]6SRPH18N7:9<F[>-T<^0S;!O 9P!? /<I#YL2
M)>7O1!!E[NQ(W-3[7L0GWI\X]J:*SM2*=(?B/7IO)>>'G-TBT1QSGF+X*F:_
M1#!D7U+PK11G_@^<;\,/FPH/"7[X0V&V39!M$F2)(/MOB5LQQ[^2L%5/-;@V
M39,GE1U,FN25=QG8A_2(['?X-.V?A6NE\>1J [YLZG]C;0"4LKO#$>KP@RV&
M@B;$XUL\NVG,)B/8?OY!;/G&Y2]02P,$%     @ U'A<3..L9PVU 0  T@,
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M>(MG.X[9:'C333^(S=\X_P!02P,$%     @ U'A<3(C]!OVV @  >PL  !D
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M_&"SH:#RX?@)SW8<L]'PIIM^$)N_<?X74$L#!!0    ( -1X7$R!@]$GMP$
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MP19#0NW"\8,_FVG,)L-A/_\@MGSCXB]02P,$%     @ U'A<3,).8D3' 0
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M>S[ADBNE++A4DCN72^.F>#8X5-9O=VZOQ[<\&E9UTYB2^5^1_P502P,$%
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MH<T@N.M:":'!E!+<F5-MS'NT! PJ;;>)V<MI*J= BWY^<,CRZN4?4$L#!!0
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MZ_DMSX%5PS*F9/VOJ/X 4$L#!!0    ( -1X7$RPQ034LP$  -(#   9
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M?>?V>G[+<V#5L(PI6?\KRC]02P,$%     @ U'A<3)Y?FULL!   410  !D
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M-; $4<;,]%K,&*5XH*!&:-I0*)AF#@6QII(Y-/N=!/3=9R$?J*<1(I6BJ0=
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M<,@U/#3E>3S \VZGB*L?4$L#!!0    ( -1X7$Q;MSD9? (  *X)   9
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M_60P."NS)7HOAG$W&(IWXR0/IK^3XA]02P,$%     @ U'A<3$^G$0=K P
M_@X  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULE5=M;YLP$/XKB.\K
M]IG7*HG4))HV:9.J3MT^T\1)4 %GX"3=OY\QE%+[7#6*%+!Y[N[Q@^_PS2ZB
M>6X/G$OOI2KK=NX?I#S>!D&[.? J;V_$D=?JR4XT52[5L-D'[;'A^58;564
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MU*N/,L%DAQXFT*0YC!J\T.#WBFJM(-$L01I@IL!>"FS]9.&/-XD_ /$&(#9
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M<=\;1O^7>E.9AK<]T1R[,JN[_][N4C=E/GC17<F3G_TS+;KG=?#_;D8;P&
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MA;',V>R5#TH0<F):^R#,^81>#NKE@%YG$Y?<U\N=R[CR,2EW#X./X<G$4<A
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M?-7J'J!0%'BN4@\@%F*EO!\ S(T"Q>P1H!P'8:4&GZ ;B'RE?)90EZ&O>,4
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M0"Y1YJQ1S,%(131.J0**_P=C0:>%P4B0\SGO] 6@U0] 4\;8!8P#C(DS1J#
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M2SE?&R)42#0ZV!XL$&SB:FOEHL(*O5@"E _:VL-B\;= C8DO0RU86F1<<)<
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MG-3D(M0PEV,VM.IA(FAGKB'!>!=:_P=02P,$%     @ U'A<3&^,N/#Y 0
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M\QX>D)2BJ<.M4*U=,2KCM4ND79P;?+V%>5$4!$@TQ>LB>8!Q#V;C7]# F&+
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M(9:[RHP0O5&[' Z(6I*]91^W53J24_'G?4[*SBS88YY'E6[@$&+CQV^F\\+
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M,I&;JU^OKUY?79Q??XS.+R[>?;K^>'7]:_3^W9NKBZO+!H<S2OI[X&T8>G&
M81W?3_22;BC,-N"1S#3A@&1;41)"IHJ79&FU\[7CJ)7GJ/<)'/!;M*=N42TK
MF6X!WR_*E5D[]M$!18%?TBTY,/QLMWX46=Y"V="  9<+3@O1L5_/S]_'HK$U
M>L*WR_U&;H79*#6+W*1+.(\NNN#RZY(T50J* YE;B>7-Y073B4251WC_\;[
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MQ30<,T: &+N1A)2@DY:;:!>CEGCOD.3;NZ^4#J>Z X$PE7V'/V]AJM$#1@S
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M$ANCBAG@..,!8Q=6NMXPVG;#.$7(>^HKD+$9;.Y;^5(LTZG6'N%K@JEXC<'
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M_;S%A)@"[5#B$=P3\EOQ%'N=0QD%0]$A=(Q@HI*7[XR4-UF^9$,A)@P*)H/
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M!*1CHR@&S$PL+6*[)$^)\"<_LG^ &@L#TK)<:&2OYRUHEE2Q1Y@X>0$[X*W
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MKQ%CR;#K1)!1";CB(#O9A)0/@)-Y4.&5<C3-SJW98FZ3;\OGI6 JR/R_?.B
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M_QO@GT,LX-(6PV9[*%I X_]TLIL9EI'T+=Q;X7]T:ZW->+:QP</?)_G=I1W
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M?*OAJ#CB<^5J/REC>FS'/A+#M_K1D/A6"*HY5B00R( A*H2J$[WP J[92R1
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M%566Q 5L,I37N7G0L%QUXP2.?] 9LTS_JNVO&26]0I'1TPS1*W6%LDD"!1.
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M674YU[57.MG#+X@=X9]1TWA"+2<ZLX5=H261C6WB>C6E$_0(\VM?*&/RD=#
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MP#1Q5;]K-(N^5]S:@DF\M>.$#!_1KM=*C@"J?\%N<857VUSYZ!#0K:[15E]
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MVSKSR!I6DDF%M*E*0Q=82_[@W(%;V8*M=#@54I6Y70;WN:RV=QR[E06DC-6
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MV=MV^"[)@W.;]_EL^J_BU7]02P$"% ,4    " #4>%Q,'R// \     3 @
M"P              @ $     7W)E;',O+G)E;'-02P$"% ,4    " #4>%Q,
M9O,+8((   "Q    $               @ 'I    9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( -1X7$SI69.6[P   "L"   1              "  9D!
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -1X7$R97)PC$ 8  )PG
M   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ U'A<3$PE @J8 @  G D  !@              ( !^ @  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -1X7$QE^_X(*P0  -X3
M   8              "  <8+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"% ,4    " #4>%Q,C!*YT% "   Z"   &               @ $G$
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ U'A<3)$UR?N#
M!   3Q4  !@              ( !K1(  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( -1X7$S6#ZOV3@(  "T'   8              "
M 687  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #4>%Q,
M7^>1[HH%  ";'0  &               @ 'J&0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ U'A<3*'!$.KJ!0  "!\  !@
M     ( !JA\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M -1X7$RO4^BFL0$  -(#   8              "  <HE  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #4>%Q,SEM:(K4!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " #4>%Q,/8^9?+0!  #2 P  &0
M    @ %(,0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M -1X7$SJGFR?M $  -(#   9              "  3,S  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ U'A<3,^O%">U 0  T@,  !D
M             ( !'C4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #4>%Q,C>L6RK0!  #2 P  &0              @ $*-P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -1X7$S;='N%M0$
M -(#   9              "  ?4X  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ U'A<3$$1\&2U 0  T@,  !D              ( !
MX3H  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #4>%Q,
M;ZE= ;0!  #2 P  &0              @ '-/   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( -1X7$Q[)B_KM0$  -(#   9
M      "  ;@^  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ U'A<3'_O+DJT 0  T@,  !D              ( !I$   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #4>%Q,+2WA!+,!  #2 P
M&0              @ &/0@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( -1X7$QED?Z7M $  -(#   9              "  7E$  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ U'A<3..L9PVU
M 0  T@,  !D              ( !9$8  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #4>%Q,B/T&_;8"  !["P  &0
M@ %02   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -1X
M7$QH$%3/T $  )P$   9              "  3U+  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ U'A<3*JLO 2X 0  T@,  !D
M         ( !1$T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #4>%Q,75F[:[@!  #2 P  &0              @ $S3P  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -1X7$SF)8@*MP$  -(#
M   9              "  2)1  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ U'A<3(&#T2>W 0  T@,  !D              ( !$%,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #4>%Q,PDYB
M1,<!   W!   &0              @ '^5   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( -1X7$S+V5ALQ $  #<$   9
M  "  ?Q6  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MU'A<3,&;SN*W 0  T@,  !D              ( !]U@  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #4>%Q,:PN$?]L!   !!0  &0
M            @ 'E6@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( -1X7$RZ9RLFPP$  #<$   9              "  ?=<  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ U'A<3'0<AB3" 0
M-P0  !D              ( !\5X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #4>%Q,L,4$U+,!  #2 P  &0              @ 'J
M8   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -1X7$PI
M\M0_M0$  -(#   9              "  =1B  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ U'A<3*!!=MBV 0  T@,  !D
M     ( !P&0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M" #4>%Q,7$?M&,0!   W!   &0              @ &M9@  >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -1X7$R>7YM;+ 0  %$4   9
M              "  :AH  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!
M A0#%     @ U'A<3%NW.1E\ @  K@D  !D              ( !"VT  'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #4>%Q,2#V55TP"
M  !N"   &0              @ &^;P  >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;%!+ 0(4 Q0    ( -1X7$Q2"=V7K $  , #   9              "
M 4%R  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ U'A<
M3/V M+@V @  6@8  !D              ( !)'0  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #4>%Q,3Z<1!VL#  #^#@  &0
M        @ &1=@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( -1X7$SU<>$:A ,  ( 0   9              "  3-Z  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ U'A<3.JRV,?L 0  V 0
M !D              ( ![GT  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #4>%Q,TMSUZ3 "  "/!@  &0              @ $1@
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -1X7$R 7H5!
M, 8  ($D   9              "  7B"  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ U'A<3#<G8<[" @  0PH  !D
M ( !WX@  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #4
M>%Q,C0\>I2L$  #T%0  &0              @ '8BP  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -1X7$S%><?JN 0  '\:   9
M          "  3J0  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#
M%     @ U'A<3.?XI]!$ @  C <  !D              ( !*94  'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #4>%Q,:/HX,N4!  #]
M!   &0              @ &DEP  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;%!+ 0(4 Q0    ( -1X7$QT_U5320(  '0'   9              "  <"9
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ U'A<3 O$
M_$K* P  BA$  !D              ( !0)P  'AL+W=O<FMS:&5E=',O<VAE
M970U."YX;6Q02P$"% ,4    " #4>%Q,&VK/<@H#   $#   &0
M    @ %!H   >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M -1X7$RLI2]/70<  ,0I   9              "  8*C  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ U'A<3#Z!Y]!S P  *P\  !D
M             ( !%JL  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #4>%Q,Q#6P2KT"  #@"@  &0              @ ' K@  >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( -1X7$R<:8GS-@8
M /XC   9              "  ;2Q  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ U'A<3"8H*);M 0  V@0  !D              ( !
M(;@  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #4>%Q,
M$$R8G"H%   U'   &0              @ %%N@  >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( -1X7$Q#YHB[QP(  .$*   9
M      "  ::_  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ U'A<3.9JF5"C @  %PD  !D              ( !I,(  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #4>%Q,;XRX\/D!  "_!0
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #4>%Q,,92(3M<$  "'+   #P
M            @ %7A $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ U'A<
M3%'],)-$ @  A"D  !H              ( !6XD! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ U'A<3 4-5&,! @  LR@  !,
M         ( !UXL! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X 3@!4
)%0  "8X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>274</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RecentAccountingPronouncements</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FixedAssets</Role>
      <ShortName>FIXED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FinancialInstruments</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - STOCK PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockPlans</Role>
      <ShortName>STOCK PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NetIncomeLossPerShare</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - OTHER EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OtherEmployeeBenefits</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommercialPartnersAndOtherAgreements</Role>
      <ShortName>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FixedAssetsTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FixedAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/Debt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FinancialInstrumentsTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - STOCK PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockPlansTables</Role>
      <ShortName>STOCK PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockPlans</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS COMMERICAL PARTNERS AND OTHER AGREEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables</Role>
      <ShortName>COMMERCIAL PARTNERS AND OTHER AGREEMENTS COMMERICAL PARTNERS AND OTHER AGREEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RecentAccountingPronouncementsRecentAccountingPronouncementsDetails</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/InventoriesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - FIXED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FixedAssetsDetails</Role>
      <ShortName>FIXED ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FixedAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/AccruedExpensesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DebtTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - DEBT (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DebtDetails2</Role>
      <ShortName>DEBT (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DebtTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - FINANCIAL INSTRUMENTS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FINANCIAL INSTRUMENTS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockholdersEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockholdersEquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - STOCK PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockPlansDetails</Role>
      <ShortName>STOCK PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockPlansTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - STOCK PLANS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockPlansDetails2</Role>
      <ShortName>STOCK PLANS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockPlansTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - STOCK PLANS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/StockPlansDetails3</Role>
      <ShortName>STOCK PLANS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/StockPlansTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - NET INCOME (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NetIncomeLossPerShareDetails</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - NET INCOME (LOSS) PER SHARE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NetIncomeLossPerShareDetails2</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2415401 - Disclosure - OTHER EMPLOYEE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/OtherEmployeeBenefitsDetails</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/OtherEmployeeBenefits</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsDetails</Role>
      <ShortName>COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/CommercialPartnersAndOtherAgreementsCommericalPartnersAndOtherAgreementsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/RelatedPartyTransactions</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="pcrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pcrx-20171231.xml</File>
    <File>pcrx-20171231.xsd</File>
    <File>pcrx-20171231_cal.xml</File>
    <File>pcrx-20171231_def.xml</File>
    <File>pcrx-20171231_lab.xml</File>
    <File>pcrx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001396814-18-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001396814-18-000009-xbrl.zip
M4$L#!!0    ( -1X7$P4J 2 FQ$" ((@(  1    <&-R>"TR,#$W,3(S,2YX
M;6SL?6EW&EF6X.>97Y'CS^/,MR]YNG/.6ZM=[2UM9^74ISD80A*=*% %8%O]
MZ^>^ ((EV 422%%]NNPR 7'W[=UW[[_]GQ^WO9^^9<6@V\___17^&;WZ*<O;
M_4XWO_[W5W]\?FT^NS=O7OV?W_[GO_VOUZ__K_WT]B??;X]NLWSXDRNRUC#K
M_/2].[SYZ<].-OCKIZNB?_O3G_WBK^ZWUNO7XR_=_1J)H XQ8Q1%7 EM;! "
M(:*BM(2$^+]__/JUU>HH3HC,VHKQ3J:$$)2W)<4"76DLRA_[\;7H=7]-__T3
M0)T/?FWW1_FPN/_W5S?#X=VOO_R2/OIYD+5_ONY_^V7RX2\$8?D:X=<4OYI^
M;504@.2Z[TT^7?'%3M9=_1WX(#W.%A_/?K1O5C^?/EGQ^]W\6S88KO[*^+/T
M);KTI4&?$2RK;WW__OWG\IO]XAH>1_27R1/3+_2Z^5\;GDX??VT-LNGC>:O;
M'JR&J?QH!1YY/\]'MZO?T1D6OPSO[[)?X*'7\%16=-O5][9_:?$+=^WBQ\(W
M[EKM;M'ZN=V_+<'"9 94D5VMQ5K\ I].'QQTVZO1A0_2K^)%9 ?#NV+-\_#)
MBB^,!J^O6ZV[ZCM7K<'7$I#)!RL("I\4_5XV6/F=\I/57THT6_VE\I-57QH6
MV?5:.NE?X//IH^F#SI)"5/0<?[CPZ'#EHWS\Z'#^T>XF8<X'PU;>KL3S1TV<
MO]/R::RU_J7\M'ITT%GU(/PL_N7_OGO[N7V3W;9F#W>W/_RZ@N:W__D__BV]
MZ]=!^<&G[.JG\MV_WI1REP3U]50B?P9 7DT^3GSX]U>#[NU=#U#Z)?W,V,RU
M^_DP^S'\J0LP1Y^^^CO[YQ>?7C1]!(QP=WB?_F'Z+]U.^K>K;E;\5,*1+: P
ME4OWYC]?_88 $:J%PNS??EG^<OF.7Y9?,GG''2A@OS/_5B!!,?3@"WZ;RA/"
MTZ_//IO[0I9W9H]C N(W>UMG^O#TGZKW3?]A0IDUI'I3DHJ<(YW&PC*<4$F\
MIJCZR<DG!Z.=L%:_X\\WK2(;?!@-T\\E'W[F9%"O$0&U.!H92NZ+W]F9HRT6
MA?XX:,NS1UL>&VT_YO8EF$6QGUD4QS:+B53\,DC%]R,5/P6IQL[V_TTBLO_W
M>0@_F9*>\*\1X.+ZMW?]'/[GP/SH#JJGX)]O^_GG8;_]U[OL]FM6/!JI*SIF
MUPG*\I_&_]:!-_^XZW7;W>$8II\Z77ADG.Y- /]U(WJO?IL^5L/OWWY9^8HQ
M1+_40+K4D&*%0/CLZ_ -V*^B3(5+*4@A'H@ I&G%L/NUEWW.\FZ_>-\?9@,_
MR@@BY+*$HH[BJ]\2CK_N@.,+$@QQB*4PG4YW"-1N]3ZVNITWN6O==8>MWF4)
MR(Y68R.NCR0HY^!]#W(IIMT>W8YZJ<[V87B3%>FQ(KM)K/B6O<G;_=OL>0K-
MKGB_$$OS9AR^G6/L-A?@\U/D-8!V8UW/S;J>DND'>]4F_GZ>WG-2W6BLP!E;
M@:/7=B:5O#V9_BD;MKIYU@FM(N_FUX-GR>W52#X*FT]2N=R?S4U8_&1A\2F%
M85:D;#S_67C^<RC%'B00C?-_W ++4PO*88EB8S8N)B$\S HT8<)95,\NTSHT
MTG,.0>9):HJLJ2:<7T QQW1V"A>RXQ'NE^_]+S?]T:"5=]Y#ECW,LGQ\S#EW
M[EF>>%X6[]<>Y^Z)[PLY<#GNF?]+-#:GZA]X-O;NK.3]L#I<DT!=1%WML)"G
MJ:5?6)!S8"W].3B;\[;TIZZ9GR:R?8ER]!A1\K,1Z[,*8 [OQ6S*/&=1)+S,
M+I,F2+JPOI*#[43#Z9=@ ?9/DYH<^&*2HP.:")O@X S.@$[27+B_,#2:?A',
M/;A=H/'P+Z$1X("SW\8)G($3>(PSX1=4Z6I*2Z<7E,:A/'?1.*RSK)&+R^P9
M._/KMR?QD$NU,M?/VP!5T4I.X5-W\)>]MUG>OKEM%7\MR/CG5B\;?,J^9?DH
M^UN_WQF\SX9+YTHK?NO+_5VVF'.-!D.(,XK:LTN_]:[U7_UB^O!@=N;U.0.,
M.F];Q74V&$X_ORQ]VT;RF<JMI_F1SJ,V<&PNC=S,LB.!4F?XY*1N \=?2!US
M1;QR:6K[Y:9;-%K[@K1V/<-?2"3Y#'QMHZ\O1U\;_]JH:J.JC:I>@%?E9ZVJ
MC=*=G=(]HP.O\Y?_)A5\3JKS+%+!<U#:"T\%&Z5ME/;E)847[FD;?7TY^OK2
M_>N%UV^:8\V7IK!/?ZQY#K6<\PZ+&]4[.]5K(LS&;36Z\Y+=5A-M-F[KXE3O
MF85M2_+_L>C#CPSO/_9:^=#DG=1(?)?P7"&[<53DW>&HR."YV/V1_G9A_=([
M8#N3F?7HOA!Q6;ZB]8]6;U0JCNGU^M_3KN4!D.93-LB*;]F@$I<RO/CS)JW"
M!MTOTJ?==G:579JP[(;NQ+ENP/=TTO+(5[(:_I\9_\_*6APN,+.[..4'$<+7
MUN#&=P?M_B@?/D^AF5W-68_S"Q&<Y5EYC9DY,S/SF/,P&Y-QIB;CU -A^.%"
M4#T%)($(_[:?OOI,K<#T^4TX/XH0/,9JD<88G*DQ./>JW@,,R*1>!=G^2S(A
M=:Q?2/"YXB2SL3J78'7.X0CP,,%I$I<GJ8\\M< L#[IKI.7,I.4Q5R@W/N9,
M?<PC[]1M M5+"52?.LLY8HVDD9Q+KY,\+&-I9.')K,A3!Z&'NZ F#GV2K.5"
MW4XC+4^0M9Q\/V]S+G/^YS(G7V77!!MG'&R<^JC^@ )68PV>T!J<6R&K$8(G
M$()SLP1--?,)JIF/L=NE,09G:@S.*J4\;K]&(S@OIE?CB.EHDXE<>DKZ@+.0
M)OYX@OCC),6I(Z6CC36X]$#T> =B33SQH@[#SGL<P-8I'M4_?1@-!R!/?WR^
M+*E]07,$]@!E[0B/=>Q^(0G ,QB[TRALH[ OJ]1SWG/B&H5M%/:,%/8,0^)=
M)@2--:5_>S<:9D7U #S\N7\U_-XJLB5E^]3*KQ?5]%TW[]Z.;B]+MW8:)S06
MJZVT.9)@5Y2=:=0":5]0I/B 25?O6NV;;IX5]_//;9?AUH]G*L,SL[F6+B>4
MWWFR-O)[8CO\;&7XZ>UP(\>/9(>?;2SQM';XY<418_'%G_W?S7M\CBOG'T:L
MA<>//\AK'TV'=&\P+$;ME.V]R>&;UT4VN+ CF+U4>!/"CW(.=Y*NP$/9O\&@
M/4ON'VC SYOYLM']"]']D[>%'S%9>582<(0DY'G9@$8(GE8(SL(23)]M!LQ?
M? !X: S0!("/&P">E=Z_S5J#[*;?Z[RYO2OZW[+TV'-6_ WXOCS-;XS^Q4?^
MA[*^T?O'U?N3,;^,XM]U>]E@V,^SCZW[$K-Q9W$'\MPW.:2\>58FO']VAS>F
M#60:=-/_M/>?AZWKS S_O.FV;[[<9/>F2+_0^MJ;RQ#^N.OG)L]'K=[[;#AI
M5"D]Z+7O]WJM@B/T,P( >O"+7VY I1*5+T.2RFS@-+2;I!H/(%XCEEO%,G:+
MP1"RN=NL:'=;O43?-_D?8..S#OS$\%*<V>.(X8[$:L3N0=80-];P<&NX@7@7
M*9;I#)/\3LQ=@?"P#W]0=/8GF>0U8GN<9):/4W3LDTSR])I,>*/)!VOR!N(]
M4IJ-Q)Q8/B,'TXCE!8OE2>(>]CM]>K%LXIX+CGO X>MC6LLW5=QSG@'/'.I+
M\<NQBO%G$+\T&GG!&GG9\<O*4D-Y[RO\X=+PD^*^$<0ME9E5Y+K<&&7^>-)G
M7X%PJ0NK[+V8:T7)OV7%L L$^ISEW7[QOC_,!GZ4$43(4N?YVWY^/<R*V_1;
MM;.-/W*0C5&1==*GER%HTV.*.FVJGI6MQ-DD'7N L(JTLW.4%;1]'N>FC50V
M4OGDMG)RZ>$=!""3G"XA-*9RHD<Y5JB3W=XE#_,%R#%W6W[QR?)#.QIT\VPP
M\*W[-^!=.MW6,.O=?RRR-OP]O_[0'O:!)!B8A9<D^0':<.Y"70KN+F2=R/@Q
MZ'HD)3B5'CY,'Y8OPM#7F.Y:/EYZ_%BWAL8*U)CVQK1?KBB_:7Q!XPLNS1<L
MQ$8+^G#D$L8I=<&,KD>#(; ,JQU5X<OW_I>;_FC0RCOOX9>'69:/:3_'C)(-
MC5JL(?&IM6)/#KW([&'IPW[>+UI7X)G-7='M)0N&&L^P205VI=^S]@#G%$(=
M.QLX=Z%M)&//8(*\-,]^H7[RN(=A;YHBP7G8D\LL$IPPQTF227_'?V_E9+MD
M-J;IZ4T338-\R!&3W''(0O_YQ9]CX\P#9Q[IHW8*STC5J,JYJLHY"<PL&[@$
MU:+[48H>?=T7D*K1JW/5J^48Y(A5I%ETC&23-#]UTKS,:"2/6BZ<!)MDV&]B
MSK-6^ 7W,(XZR:[N82E(/99[:*3E;*5ET6H<O;>_J:F>JWLXQ7EKH^67H.6G
MO%#?-)Z<P_%BTWCR-+I032*_A+(!WZ]LP$^]<ZQQ&F?F-,YNYQ5O!.9R!.:I
MMQJ>*"9]N2>X1Q2S9W":^T0W'QMI;:1U;VD]]HW(R="&=ZU[1,XQTET<V@".
MB!Q748]]&32VNL4_6KU19N^KO_X'H-TJVC?W;[-O66]Q%N_TF3?YW6@X*!]8
M3HA?G+X_7G_1;MR:FR6\GEW/VNJ<?(CQL7UDHX:7ZG8;E7S^*ODN:PV 9.EW
M;6O0'2PNIVH5Q7TWO_Z4W?6+8=8QMVD82O5MWQVT>_WT]48_GU@_5[%Q;N?6
M?GQLE/5,E?50_TD;_;Q4_TD;E7PVV>2+5\/+RB8;U7L^JM=<%+LHU7L95]<N
M2_6:3/%B];#)#L]>*9\P.WSQOO%RL\/&3QZ@DBN:Y(#1;8"J:*76ST_=P5_V
MWF9Y^^:V5?RU(/ZFW4[&<? I:V?=;VF4])+RK/BEF@XY(&)W6'MRZ9?*^=-N
M-!CV;[-BKL-WX=_3:/0+6Q.^C=8SB5M'[".)^P96S3G'3;PZ$B!U3D\,TSI6
MOY#FQ,DMIS/OA3CV_9[)M?K&/C7VJ;%/QQUG<%S[=+)1QY]:^?6B1KYK_>C>
MCFXO2Y'.( >N*#E3F 52/IZ@/NFLM>?D43[DC3]Y$?ZD8O3+\";/*RW]WF^4
M]"4H:<7HEY&23B:>7<1-5(SVLV;HZ-;LN80<C35KK-FS#3F6E/29Y)[GD_@]
M.8.?2TS9)'XOQ H_=N)W'L<<LQ:!V,U;>=I#NZJ.F,YHT_29-_FW;#!,GUW8
MO(4UV$T$82UZEWG4O"MKIY]_OND7PY7X+]K*I+Z##U>IPFKR3OC7")#\G$[G
MN\-NMMB990:#;&A;[;^RSNR)9R(RTP?6D^V8AFL[T><L^GJJ/Q-)/G[?4:,<
M!RG'V;41->IZANIZ4$SQHO7J^'%*(\&7X7!.I!2N7]SU(;/*;#^_7+6X''=S
MGHJZ40J>B:H^?B#W/'3K\@*G1IHW2/,+E[L+8O'18HN+8?GCN/&7* (OI8[[
M$@+!"Y+?IXBY;F^S(KWS8PN@OS#QO<18:P6]GXGT/HMJ\F4KQ.78\T9%S\C!
M-,6RIC1U05)\3H[F8L3XI;B&1HZ;JFVC'8WKN725;4[UGX&RGF>,^"S[#$13
M2&L*:8\AO<=>&70.TOL<O,+ER?!3V^'32W)S)GOF9[+/T9@]CXST\LS9T^=_
M%V30&F]_"7;V>2ML$W]<A+H^#W_6*&SC85^0REYR-:A1U:8^M>$0Y/,0+%""
M<4P!P/2NGR>*+X\>&=V.>O!HYWTV_",OLE:O^]]99\:AO[6Z^=O^X,(<V4;L
M%\:![(7^91;>5PP?:J3CHJ3CK$8=)4O#&TMSJ;(T9VGXJ>/$1C0N532.'I^L
M&)#62,=%2<=9C?):$=.8[ZVB4YN+%V[O>OW[+/L\[+?_^G"7IJU=EIPLH#63
MB[5XO9 HQ(^CD$8 GDH ^'X"P$\]S*_A_N6FJ(F7['=B[@J**M9][+7R]ZW;
M;-9H^2;OC-JESTR?I>]<%B_G,9JT':Y#Z5'8R%XC=M2%6KOIY"<(7(IN&R*:
M4GK_R+O#P:?/?UP6+]?HY4;<+E(W5T7NC:UM8NU&L1]#L<\NYEX2A#=YNW^;
M5;GLVWZ['&B]=,XV&'ZX^MSJ7=IQ^ ;DYL^0EK![0<+ &V$X#V%XZF3L0,OP
M.>OUNOGUW[(\*UH]DW=,Y[:;=P?E6/QO6?AQ!UQXEH*R%^8OR**(1H@N6XC.
M,%C=18@@O,M2ZPP0T:?6F/Y=69H?4_ 9BLX.^+X@JW- '-,(S%,)S#G$.@<(
M3..FSLE-G8,0'1#K-%;GJ:S..<0U!PA,DVX_1V%8/F>I'Y5]^=[_<M,?#5KI
M"L*W+"^+EF_*E7-@<M/SER4.*X[.=D7Q<D]=EO*8YD#T^6<CVS6[X?EST-RZ
ML8)OX8OGY":T&@UN>/\,-;F)M!XATCH[#6=-Y^&3=!ZR4UQ9X0TSGX29)[]_
MU##SPF\,L:;O\.GZ#ME^?I:=PL]NU^:FZ?#BM'JG>SL-7U_<"5@C"$\A".=P
MF+$] F^DX.(B\>TY<L/4B\J5MYKLLB"V$+9^'!7MF];@ NM@2VPM"V%;4'LA
M!GMK"+>+&,QL0"N_7K0*[[IY]W9T^Z+%98\W5P2<V9X%"KZ@>/+!4OE"I>V9
MB<'&RXJ-&#R&&#SU&<W)?53K1^.C'N:CYBG8&*<F<CH/J7R"R.D<;.5)I;*Q
ME1=H*\]!*A]<;&BD\IE)Y3G4/DXJE8T'OT /?HY2"2ATNKU1ZM";C;\//]J]
M42?KQ*)_FR:.CH;EK9H/5Z%5Y-W\>O Q*S[?M(K,WJ_^@?6-%Q<FLJ<CSYH&
MCA<GD,LAY2,(Y/,X3WH,T3R'@^=SB#"7:T2/(*1_MHJBE0\;H:P)Y0)E7E!)
MZ E<=R.$YR2$+]1=-T)X3D+X0MUQD\2<:Q)S#J[Y"02R26(N*8EYH4)Z^7=N
M'MUVOL ='4\45S8N_5Q=^CG$F$]=*&^LY9E:RW/(PI_ E;M^_BTKAMVOO2PM
M3;[4W?6/(J);:-6X]<:*/K6(/K45?:$NOK&BEV9%S\'=/X$5;03UT@3UA5K4
MI@YZ2770I[:FRV,7Q_.CO[1^F-'PI@]4NU\0KC?PU2)O]3ZE>78CH&SQK=O.
MWGSZ?%GBM1K+F61L0?-TLG'*L8S'977U'/R *[).=^A:17%_U2]25^O*Z?N-
MC.S?J;N6NO5A_R](-LOY]B;OI/'VO;^#<1]TP(Y7*=N+E\TM]&ED\^EDLQ&Q
M,V;U.+<DOT/(7EY(^5CT.Z/V<'9#Q6=W?7<_O)"=,>6-DCD<)G=,%I%XO&R,
M[96-(3&W8_W!@6[B+/V=^:P-\3;\-\4S)W%_EWVX,JES[+J<IC]CMRE:(%&M
M+S=9T;K+()EH#T O+H/YE95>A=Y$$C;A]TAR09,.[RX7],@)T'A:*OD\R]'?
M9JU!-D>NQ2MJ[T9YIWL'.>9MZ^VP<UF2L ZSB3"L0NV1A(#M9QS*QX]L'/81
M@H^MX4UV:0Y]"_<7<'H9;)^OT#7N_EG5M5+,3L;NGD]<>?NF"YEZPNO#U;MN
M+QL,^_F<3B]\/K<T#T)<U[^]S8IVM]6KOC?8[Y[\<X\UQL'$6@I/HXU#2'RD
M7/4A]_ O.MB:2Y=(&6KQHZ5+?J9D;-@?Z]HS%_3SY?."]1USFNUJ?9<$X_BG
M"DTX=7G%D'%P1!J-/@N-%JD>LD\\=?SRB?B=-L)P+L*@]A,&=:H6G"9O>GY-
M*TO=52'/BNO[&7-=/Q^,>L-N?FVNBZQ4CP.SH4]9#Z#M? 0<[[^ K@U:Y0G"
MP-[/?[+P0[Y;9.UAO[@,R:J:2RL23F1K+0TO*]W9G8$S.!8Y^$+4:CD@WD/R
MQV7GC^_,8) -WX'GN9X3ETM1@'T$95R,7H/P18;2JUH!&ZO:6-5+MZI/7.0=
MUY^(N2L0'O;A#XH>HEZ-VIQ*;2Y%GLE^YU'DA.=1CR+'SR*T.&MQ?J)8YIRL
M])%2RD:J&ZD^HXQN''M0,[HN8X_1]5Q#61-[7*98/W7LL4]-EQR[ION "L5E
MB^0Y2\BI:Q*\<<O/R'Z=@UM^ZAD;;\8I5&/&SM2,B?,T8TUI]:GM7%-:/3L[
M.A\.NOXHW7>]2^1YW[J=Z][Z_-=]]K&\-? ??:!+?GUQW1ZK<)N(_7KD+C/H
M.P9;G]MRL*.S_Y',WME*&;AD)'_'[]+%7X)>C_^<E4?L:-#-L\' M/\UZ@ZZ
MR?[.^>I6KWO5+_)NZP.\M)4<SN?1UT&WTVT5]Y<E5VOPG#K4[8@^CJM!\C6B
MKPG:T=5,'C_^G)S?O_A'X^SAI72,GKJ4+G['ET&J/4\=0*J.3RIZ(:22^Y%*
MG^#8D5P(J?8YH3UV&_3<@("S)]437[B?D.HB%%#NIX#R% HH+\,#ROT\X(GZ
MDR_" ^Y]0OEP#SC*NV,ZC0:=Z2R\>3IUNM\ MWD TC?>CVY3!-J?SUZZO]YF
MK<&HR'[K#OJ,8/GK'Y_]]+W3C^8#T?H/S;W!9WG_MINO?<>$0@G<P;:7+/W6
M]*,*M?EG5U-FGB([8;GE)\=PK_K5S7AM^=F5<(Z&17;]Z_XPYJ/EU&D1QCOX
MZ]X_VAX-AOW;U3];)CG3!_8GZ3BM6?O#D\^W_VXGZ_YJX-%.>CSV6M<_393F
M4W:UT)OR:FQ?6NTA^$T3B;$*"Q((19YZC;1S@7.N8A#HU6]7K=X R%7[\>D;
MW:@HTC]U!^U6[Y]9JPAC;=[AY4XK@C$B*$JEF<!4&#9]N;<>S-[KJ4W=]*8I
M)+[?'MU6#WPL+4B$?QOL  ICCB/I:#!">".\0CI.07%2NE>_Q7^.H5C[EM5@
M)#AW!2(BJ86W FPTI5:):+"> A&H!'JD;ZT"HWK+,A!C^'9G2?1&8Z:T]9(Y
M29"CSE1T\,R\6O!T:]^T#$:Z9+;#VXU#0DC+M8V"(>^=BV'Z=HPL>?4;>.3_
M7'QO^NGIZT+IMAS\:]'JO<D[V8__S.YW>&]P1%E*O:<V2AV#8\Y56(-B+#K.
MM6]: J-_>]O/RW&KI7,:?!@-4[4IU=868$J%2O4[KCWTZJ=.UN[>@O[!,^_C
M'+P:2VHB@*,4XY0@;V1%)Z$L>_53L@GECT\--D,28XGD O@;(%S"9:QZG[*[
M?E&6;X:MX4XB+2AVFDN%I298*^FUFX,4X5>__3.YBVUO6H0F=GM9X4#,KOO%
M+NQ%.#(7HA3>44&C95Y5=D:[".Q]VRJNLY],NYWUDE?/.C^5[Y@';.&EB_!\
M''WM==NQUV\-%Z$9EZ#)/"-?JSG N XZ>AE05)PA[AEEE;9%K=4<'TM?CC6:
M_&<>LKG7+\+U*;ON#H9I2V2J]>Y *$NU$R8XBRB*3E"N)*WT(!K^ZK>/K7:W
M:/TT+A2WRRNA@-;__NE-WOYY'J;%5R^"]8]^;Y1#A#@FZ2Y2I(S#.@@GK8W1
MBT"0Q5.X6$B.XGU__NU+;UA\_9]9K_>?>?][_AD\:3_/.F\&@Q'$SMO! &L,
M(L0CXI03%Z4D453"+'6H"?.:5R5X)E-"VL4H2T;SP]67K+B-63:1_[H<B=_9
M@AS1.< DXIPD$TFI4%[CX,)$RXAF6-7E2"!>"M$6* X"5&X E%H>G,0^(LR#
M-MH'BJ> 1NIJ@!(@]2& 5G7F\.,NRP?9X""R4B0)1]81*S@-$@>C[11:RK6K
MDY5350-W'2R'P[R)PIP%X#AA01$ML46&!SJ%F5"*ZA063!P <SH9[U0#;#ZV
M[I,O'L1^\;G5RSY<3:X8O\E=/\^S\N#YS^[P9NY\8"5:D\ZI%3^[_0?M/?B*
MZ\P,_[SIMF^^W&3WIDB_T/K:FSOK^^.NGYL\'[5Z[[-A@G7P*6NU;P!5W^_U
M6@5&Z&<$ /3@%[_<@$^\Z?>FL^_F:<[G:$Z$\P8K0<"Q",Z]]K2R"XI'LTQS
M-;7A1R+E\^<*J.'>7(F:*$4ED0B4-6I$O"13KE@M;,.5AW*%'Z K3G%G(?#S
M$E(L:00S8N*JF#;(XV6N0'3;L*7.EM@M!L/9)+$$\9O\7>N_^D7XHSSDKTZ0
MUQHMAA&V%GPP@\@A0'CN?)5L.D*7&<$:/NS*A[1=(RW:@&1AL,U(!2M]0#P@
M8G3$WG!399[1BAH7,+HT-CQ*^\U:\D(F[RV(LY40ND%.XZ2;6AN-,%DFKSB=
MM;E-^>Q_3Y:X?!C>9$79NSPP>>>/_*KUK5\DZ2I';7V ?.ZZ52?IK/]S;?@'
M0D09%\)RQ(@1T46.I@@+C6OFE2D\A^Y!,!X=1;$%1>*Y@%0Y<$*M%]HK57D0
M\/&U")=)?78HRLTH$HC=+2$R" \I)XF:3H-XX*)3LF85"%/'PW'!XU=^'83>
M9Z# M]VT?N@PNWJF<<R.,?]2#2X@&@@3(A),J)'&,575*AVNB>'4<E=<.AV9
M7S K=TP4%EGI+=8X2L+ 2S@'O(1(J*H/$L9J.3-O6'DVV<4B*QF7+F+A E6>
M"?#^")&IY?0A^F56\J?0RF^M;B_1 EY3%5K>]@>#SZ.O_P5?'?;?=F^[PQ6N
MX\@;S-9%391B8962EA$=C3.(2#8EHG)2U$P;96J!B'L@6%'%9M?=/%%W?)#T
M$?ZK^-*?D#7\N.L6Y?.FU^M_SQ)#/F7#4;D*;_+,+N<\1(!3M2HEH,03S3R:
MA Y"42'TJ]\^BG<3)!X,3X692^+\M9^>_S8_1K4F1I^R=@:/=!8P.<$VC[4I
M88C&<FL\<803I;R,:LKW@%&M8L+GF;XWED>DSS%FMZXE"HE,0T3-%(F"$G#Y
M2E06Q?%U?OXLJ/+P(:;KJ,*,#L$X'K#WAEJ0',NK,@X/=1/QV%3YTK?92LH\
MMW'Y:SGD)>.*\,@I)$B>$:S0]"" >Q;6U'?V9M$\H;>RZ8^[JP)X,?GN6LD]
M]J3U=32R5$OA; "*,!ZCE]J+*8T\(;7 ;S<I7HWD:MJ\!8><#])5P[PS)UH3
MC[UW^D]B#)93@-/%: 3U*%9%/6]M'2%&Q!J$-D-V'&RV9/K(,,=I\(9K%BB/
M@HOJV-<@63M7H4^+S9:DGEMEJ"/&6,=!NJP#R:M.B1BKG7U2)1^*S&TZO"O#
ME&Q\C@>">9O=WO7Z]UG2XO9?=Z.B?=,:9'>]UO[%)@U^$2L;D:,<VR@\,*"*
M$Z6*M1,63N8QV@^Z(Z*U1>R(PSQP0V-0V&(7I<-Q&B5Z36M*)!4_"[2VR!^+
MU%J*4P^)8(@ZT*FJU<]A5W/90J'3H55^H7]77DBN?F1O 43<:XA9D=*<!V^%
M47C2/T,UD[96[222B.TBN!*V(R&T3?121&F$Q5Q3*:W&7%;V&RQZK>. ,(ZV
M"]\I$=HB=($XL&(J8N8L9.8<:U9Y6,1(+1\G#'%Q>H1R^&3RO5;:Y+J_Z#%D
M(/Z-$M@4F7%6!6$J(^%X'3$JY%YXU4 \,GY;)%$28JGCU@7!)+A=RZ8]#8 ?
MJ5L+Q?!9H;=%+@VX*J0<B9)C"1)'+9)312/8\WIKS_&XEZ=R2%8%B+,2?!@,
M6_ _!C=E/>&@8[<WU9S8U.JS)NP-2'!*?/!*@:$!RR(\KHX7I*\=+Y"EL/?(
M""R0I@  OY2%MO(78Y:M+(&MQ<U =BXBA$XD8H*-1WS:P)QJ&*&FEQ(OXU:'
MX!  #]H'M+:L:8C21$B9DFX#X2+1V$W-J&6VIHU$EEC]_""\)CU?']-ITII*
MY/HV#X9=L!+"#:5,ZB+5HA(Q"*[J +/M;%B$9Q[X;UF1[J/WK^Z*;M[NWK4@
M NED(&##^S;H*NAB/NQ?M<L'A]VOD,%F>;=?Y/WA(4&'=M&K=$T"LD?P:0*"
M>0/QKTR]7U36JF1S2#T$SM/AN\43" A_#>21T5CA'&&*XC&^$$0BH6N%A+/'
M=XMKH!Q)1!6CQ!G%M(T<.<#7!!<IIZQN'1?#_^,@[;.OP]EOC?\VS#IO\L&P
M**\]C!OVRW[BSC]:O0-J!903'E,G+J %[H#$H*,%=$-  4QF+7NCFLP=I.\/
MX%%QVQ9'2R.UI9I;#>E;,-S&"6Z8(N)KN?:98+5%,@784>(92"7SEF,*OD!/
ML.+!XGIUAR MT-%X-GMN]B,SWS]WF<3U^JDZ41ZA?2RZ[>Q=-T\53S/XF!5M
M^'[K&@*#V8^4S]2*@..Q*IA.URS-PV[RSJ>L Q%6>G/R$H/YA4SS3Y8?3L>3
M^-;]F]O;K--M#;/>_<<B:V>IW^A#>]@']POD(GBI*KN(]\*<M:GZ?B[5]WU2
M7S_*X#?(-F\N+8F.H. ,AJR.:Q$4M<+[U #IB)[GX_0N(_Z9SC'QM)RX5*8O
M?0@FN&A=#;,"@N%N+S$7/09S@V1>&B=YU"I*R#$P**D(X$."ETJ)9\7<]R4&
M_:LO12LI$NC7X!GJ\4QQN2':>>E,Y,I[5E;507$9PR%X@5_]]I$@?TQ>KB#P
M97'P<95RYBJ%=$A)@UE02F(N),0"(J3+Q@PB'G)NG!I_N]360=8>I2K_G+ /
M3"+9W&>SEXR[$YZSTC$EC(F4.JDX<#0 .X,U07I(B#G5'EC)=^?D PG],):^
M$#.)90#]\SP0 2&JU]0$G<RD9 HB=\N 8W0/Y=M,R//DR!.9/49I(-(*B032
MA#LLO$MFCT;)E?%/3/D%XU@V5 W[:5I /_^>&@4GMYF+?IIN,@ \P;CVKV:4
M? X,XM0):F(DQG##@E-2"&LBMEPQ324]Q)@]D*Q/RL;IZ*S%/CT=D;0J.!$H
M@_A96H:=E9A81SGDN?X@,7X\,HU=Q4NT_-0JAS175B 3+1*I4QI\M<8@Z!IK
MLI]X;Z;C/@PILMONZ/;#?!Q7.S:IV'#D]'"A8\*HB!46E""A'3+$L)3Y1VNI
M043+%<DA^IE*OCO)5F"Z!Z$FY"WCVL4T<G*,\^'J;6LPF<Z1=>8'B$ \//Y:
MZHJ;_O(GD+])N]LS%/MU)8#((0**6&*D4%11VZC )_L@("S2 ;N57-9J9R:?
MD$L;9:4DAQD,X)\ZME\4_>\ Q:?EP4+^A+JTU.SO#?/(0J!IG8/,P%-C(-HA
M%'/KT<HZ&OH92;9)G=;BN)TR\Y664@O'Y=23$N?!-R0AE0(9M5:H=, A#0K*
M$Q.05>"$J9BW2--10IR@I:+R/N0X#AW7E,L7Y4,9+@75:78,** 40;EJJ!?6
M"]TT4]SP.6%V"'.7+)&RDFB0%H*U]RHR^.N4 G)QP-!C4V#%$<BV0V6K&<5$
M*LV-TM8QQJF'L)!A"*6)IO43JSWE=/N1Q\XXG-ZIF='U:##$:7;8CC[MR_?^
MEYO^:-#*.^_AEX=9EH_-RAQNI86I2Q5:&%K%3/38$>V#3!/[C*/ !:H9Y)J.
MU3HLL*+Z2#PH1RRVBOOP+76>]Z]\=M4:]88S#]@'#S@[=)T,LVFE:Z]WK6ZG
MO ^5#89@0>'?)A?2TC6TR>\\D1O3"&'/M=6$$BY]X ;4%MR8IQI21(96G1BL
M)NB)Z;.&+4"BO[)A_3SG!>B"2G<'@O:$1L&4LYY)F1+5*+7%E-5Z0;!&JX./
M.1J>+95/'T;/DQ8;ZB0CR"$P.%PJA5,#2D!$<B4PJ;6=8,161]#;2;L804_T
MP]RF@14Q2<3MW6@XN4T_(^=S/;\D*D2$-.0IT@8(!;'B-I40-484!:IVMD:'
M4W4=FQ9_9&XX<ISJ;2(S6+'^NCQ_HBS;#?H#[,,B.;GWB(&?Y 99%X+P//7K
M^<A"8-K%E0->5I/S(.Q/3LKG9MT7N2=(ZG]FABMJD &-8!&E6,=ZGRX0U^;'
M--Q[\N(+Q9$RAHGR.@JI*!<>)[\!<6I0D-%>+,O>/.N:&7<J:H0IL=IK[C75
MZ4*/3\,L.1&N'DF=DFV#P:B5MR$K&0P'\]-T[K8<MA^YAP$[[K@,V%M#$0G1
M QU,3*,9@A&\//C^YSP--H.]@.*2QP40OO3C*.^T$L"MGKLI*PZ##3[\B9(E
MC##7/ATL8.N,0='XU%Z%G8A8$[TM/'DXWG-DO,J*(NND\1OE>*6_%?W!X'TV
M+/.NZ4=ONZVOW5YWV,T&-KOJ%UE*<&>3(Q*_]AM*BP*@SHRG0 2%&&>15,.L
M<:BWGV.FY/P0W:.!_1B$V#3I%BO%&1.6*!H,BR+2Z5TYJG' =4* >%'TJ(0H
M38MM#<H:?'5E:#]^\^BI8D$80:@FV!HYG;1 M3#UX;($*[T)R]4P/1R'3:QB
M(G)!B?,\8NO39!X5JWN:C.OZ;2M-^ -PZ [:Y26EV23C?CX8?[7(;OO?LDZZ
MKS69A[/_1>[(+ 77!-$@EVF,-?@NCYU1D7(53:T,29B<9\A>P&W!*79_9)WR
MNQ#JOLE3V:=?W/]9I/F3_>_[WQ%6 5!AVO* L8A2$"-EB1H.WE!>OU"[ VI;
M8-R"X=R(I?(F5>G<]N^<-PP)<!;@/0+'PE"!B.%441(09[Q63)",;4-K)6!;
MD/F4W;;*"5(/0,5P@J-Q&EF%I4<*>\9*%D&$JYA8<7D/JVVXK(!K*R:#;F?4
MZJU#9)M5"VF_BS)@ TBPFO* **14Z:ZPMY;7[P5O@W\9FB. O\F@Q33YP(/N
M4XR8I)A Z)K QR1MNV#UZZ-$;A6H#4B$JZMT<_);5@W\2B>2GS+XE38XITF+
MZJJH"D" X!>>RE=L ZI?$&(+H]0@&@>,!(B81AY)2AAX'^)Y&J0:S.K3U1F6
M1P'ZU"2HWR.:)X%3)A+B6$CMWL9 3HGXF 3*>.[PLR!!W=[,DX!;",K3:B9-
M/8< "B,[D0+EP=^MNLX )!"</QD)QL]\N'J??3?M=@K9QS/9<OAKN[R"N].=
MSWDB&"2Y--:#HN.@THU;JH (-"T'<M[88\C!#F"?G@R;U4%%1158.TC(.9AI
M&@.S8S)0$"/*GPT9-JL$%H($R#6-4U8Z SD(%1,RT+1+;249A%+Z"<D 44K6
MO=YIQ,\\J@1BC2 CJ+/C7FE!@_?58AFRQ@!"HD7W0'4"VG'0V2S D3@#K!-<
MZ* QC=Y-!Q81+;GU*]!YG218X:?"9[,D:@Y< .,D,340=?BT_*M:4!/5*DE,
M^&"B3HS/]"1YLCYF4D[96_I4B,2'Z RRD"C&Z'PU]0#4;I6]>5VV2\H]T%L-
MZDFPW2R<Z?*G)2Q8JR"(A&@R^BI)3M>S5UM7+O?QM(^([&;)E1(<"21AS 1J
MTG*X@.*4M9"DK6Z11!!F/RZR95O3U^5"0_C1S@8#^,*J&NAG_W?S'J_M85(Q
M&D^,\RR 4"M)' 36:0M<0"A /EI+W_1"%],1@%XB0/]JD!950.R5=[+.L/4C
M[;]KEW70O>.D&+$Q2(.KHT9S'KTT%5=5%#NF#)L@>A#P6_3/:H&9)YYAI0.$
M.:FW8S*RA(*_6&-,F>"/ _UFA0HJRFB"##:D18):&E>-0EMSI_PU_IDBI0Z
M?C+9J"S#?9Q,??O8:^7A\\>/XT[ ;OGWK4GU8FT?&68#]Y1+IT$_"&!3<8!
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MQ\QR:R69G?J@U=/+=@9X(O*_3H:6#29GBRZUM"]/"=I6J#-@  S#!HPO8Q2
MU+/Q3S&XFJ1+CL?W?S8#<0B8FX(,&H.P%#(1;91W$%]K7/5G*NOK=^F8X.I
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MG"T/F6^V$"8JC,NS7Z8]#R;08&E)5I:NC-K:;9/7<V,^&\(^DNQ[*:RE"./
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MVE J:BUAH*!UA9@/P2]?2DCTA2OLBZ['D#5RN-G%PF:=;;F%@#:GK)JT<A@
MCI''D,5_OIG-+?UM;16O;ZO['^Z:[>:4OP*F1#),88%,BV*[<IKR0-L/9ZI;
MR=U&UNELC( .Y2"+TT5)@Y9#U9(X'&^ ]Z[?TPWH8#/+NP0;8_!5UBDGHT)@
MJU# 8U@,I?"MTS10,[1R,ZPYD(WZ'E^AWYYF'[[6#?CS\]ZDAY]^_?'J<79_
M?743YQ_YR.YJQ9O]//MT=7T[N)=^5[00ZS9)S3%#!7FMRR3!8 )60H6IPMKM
M*CM-0.SYF=]9;=<8 \3D$N9(B<B+5)D'A:0=]I@Q>A.KZ!(B^ M_KM:.ROW=
M)_[ Y[N'JYN??AW\:)AQ&O=UB_DQF^M%-DYY2-$* TX&HU/F(+*P1]<%3!>;
MC(GB>-(O*I41<R:\]@4#B"RSEYS@4-9SJ1B";$)GE;\3J3Q#_#Z_F+^[O_OP
M]'[E"9VMV5W\\CBP3&G=_T:5,185146S32IJ8Q,$Y86U&K K6[Q1'1C,-RW!
MW?BT%5,:38SH-)+D[#.*JE<H;<Y0.MO+6:JQWYEP#E>OM1JF,!E4I(PE!!&-
MS\;,$7XU!E:S+@?12M&+"K""#GY%>GW^ICU_S\&!;Y)H#-MOKP!R$<EXG%\\
MJ!@QJL\RM=KGWAU+_H9<YA_]R_W=TV?^*3=/<V22H6]K3R=?"UN'1W#2LTNW
MG-P%;T7RJ%3RFL,TAYSV^0Y7HI8.-J5P++%K/#_-?KG[VF_X[NJ^^O^O+1 <
M#(YTYJR $[?O__++_=7M W/(O_<A?%G]F[6>I'3-X>?CW< NF/5^2NF,$HJ(
M;Q%:S!DE0!$E2PJ<DO0I\*:N[,?>)!*AXR3RO(GNW8_STMR/5[=7S_6>7C!B
M57U0!R"6 5D#29)GQEO;+<F=??.O7R3C2K(J"RD#WR5IV9\+CGY\IL7C.2?X
M$'<&08?+8@$-O<#TJB/:[_<)9]>6:9:<E2_"1A6-JIM+?*NTA;Q9.%S"AXFW
M8F7@;)"4(VCM@\RUQ:M\_ZRSBHI&"%YX2;)!)4>9M]'Z!MX*G)[8WJZN$>L5
MN0A4L<XM)1M4:J4_K2CL(I9.);9V:%_?/#T.ERPWUV6LDIT<9S9Y7F[--3[P
MUK?K'*+9J@]OQ%L0(V0OJ3J1@<VU&FL,L _/;'K8-%?Q"]*)EM6L382&-096
M!^+/R\#F^HU5!GS%,N, S5GOP9%Q 1I(*[L<L8,![2[%P.::CK6=[2%%4R@I
M96((R0J+8E'98@>ZBP&XT GT*V/63D [SZF&R61]BJASD&TQ"Z;->L_Z"8S9
MF<D8V'4'9-T/RYE2TH%*"E#(M)7M9*7=P8"ZD KU*VA6&:@8J-[Y CI7[ 81
M^ ZW]Y\D=JK0Q1C8=0?02VO9]AMOG 63A<-V L[KK2HTV1782O?N<,#FZ&.*
MW@1O=+!%9XWM833EK6BB' ZH[72?0N_ND*!PBJ*D  [(90GD6./;JB+^%QP9
M$IQ"\.ZPP*283%VR0=F&^H\JV% W@+:[I]UAP1#!\R3T^O=EYET! )[KK$_\
MO2TI&X#A[)5$K3T8H?59.BEC+!PW2@RA>2@A5PM62X@"0+4:,.Y-W%0L]7JT
MRE(R=?N1DVB%)O"1CZ5M;N2<;PA"AVV-$&A?DJ=>U=8 7BI^A"F1"HJZSC,$
MWUZ8P.BAQ=9SGJ0\#T_UH??V_?7-\U./7^PMJ9 43[61>>W#^^CD!F(+:D,R
M0I'91S3)I>5J/!^W &?(49T\B.JS"Z'7XG4AU,$H$XM'F0OI(#PM9@W0.>&&
M\8Z^-2'T:K^A"2J6D(5@_MD=:)3HEML;G1W>V_O"0HB_U?::'VX/[MH:-]=:
M9IF\$)X34"]!U)&Z-IU6<!CH"83$PP1R  <7%<YNPV_J!)PHR4;V .P ZI!&
M>X8G,60U:I0LG?D^I+/;A6C! 19J+<C6+0Z>M&R-Z":MO>ZO@!$I/>H5+R:<
MO][=?IC5=Y,ZK_JUZKR(I>=S[?4KST3</>RU 6L->:\.V9M@-<?[%*T+=77[
MHMA0G!^6#^&!RG,8$Y<6T<@%<U1G=Z6V,7JTBG1LU0 78<L%8^.MOB<9[;YF
M1EG+88L0RH/,.26QZ,!B(R2RVB(C6"M8O;B,YD,F_L/_^_3P.-#!.GZ9^/)0
MW9]HHY;&NJ1", LI8,G#EPGT>+BZF\SIV=Q](:+WWA5;PS.HV^S!PG))O(]#
M;-;#1G'@A3@_G[N5.G!F&,EE'1UY0R:DY7$J)X:4NMI&)R[+YMJ^N_:YV<':
MRWX@*Z>#R8$-/QJ5=4,&5I:&LJUJYNC *[R-W/.QO5N;P7H1I$[:EIA<!2W"
M!OL4K=Z"(HIXX"E?GNW=RIV+==IH11ETC,X#K2AWR5M.&P]U_%.QW<:8#E=K
M%4IA(PO!>.%,#  MJT[@AQ$^Z[Z$PQA=$C@E:[M55X-AWF+P&MCP%O1^N0VO
MR$A;#+%=1<!].=YVZZ? "!J22\ZB*KI"_/K6 2_UMHA"'9K6;.'MT^>;NR^S
MV=?W[)6.SJ/@/W1%X162V)02UO%%2&EQV7SNL7, -O?1CQ)T(O4[QZ5K2Y%3
M0B=3L7&+ M],!7]GWZ^.FTOKCZ+^;[/[WZ_?;PGO_EHQ?!XJ:/M\GO&7N\?:
M@;L>_OWU[O$?LZU#(YL]%?,?U.']_,R_Y/[Z/?^B^=*HOS.C#S__[>\CK3;\
MDZ-!$!*T\P)S"KG5;ZR7O<3<9K/-V81P$4D_PV:7N_NO7ZJ?@VT68.0$&I%5
M_C_-UZ(OI+^"XFP%IV8Y<M(51!1$HJV@!H/A3W]^A_^@'U&G"TAXD/EO3NPC
MBK_,_$"8NGG5>Z.B"E%;T50=0:6YZ$'\2-^WZ%>T<WCP\7@MWPJ/B(YR=$;Q
M"82DV?LW]/O@H!N_4;")V7418:Q*?]%R^]/M<\?E_'Q^^O6Y4G;P&(,'3$G7
M67DI4PHNV<7+*3J73.=4WZP/P.XDY@2J1\8,R!*';#K;#-F5B(BIQ6S&]3 Z
M;Z1U%Z%[I,DV\K5FKYXRH(9"P2MCEN_4V$L;86-,ZB#"'^HG9_S9_._:;?MT
M_?!;38Y_^K7B[FW!(]W>)NV,D>25#G62M4@H90XJ[9W2,??3E&_DYC3N*$G'
MT[^/JB<*)46.OCR+NHXG!;',85(/'O]F _3EW.2/Z(YERI4UF<-:"X0RLH%Z
M)M]81=3KCJS(%\<S<'?WX5_7-S>]'=:[P %T5I()C%:2LQRQ&]\@$#,K3(\F
M9^V&DGS]O?O1LA,F0Z&@6("35FE$]CK[EB]46) !F Q))]"R$\NB).VMJH4>
M):-)9%.;^:U(<#WN%[C]:?'O_[^GZPJGN6VO3%4O_&_TG^\%/-[Q_]2&["WW
MW'ED,1G!'@&3M<0Q8;-1)?># '83,'@75:O4<S[)FL>)99V*^*_9P\/='OA(
M>LUWI90X7&4J0=?5T/6!?]$(K+''@]STW0,4;!"X,K<QU.VP,=,R>TC\AX?'
M_?JO-])#OC81E) *?7"%H^QFG)SLK:N<H^>N\W(LL6?C><2+X[S2H@/&&.L<
M:0BA=:;8*#N4J#?2R V(J]?(]8@=UPX*)C8(B0.N$J,G99<O8;F;LW\CG77V
ME7#-7N/^ZN[^P_7MU?V7'QYGGQ[J4$*%<[B[N>%O72R9.5C_R6>.A= :$M8E
M;TJ$!CI93#]<C<]8#2?)9%]F7DQF(_='<\+N4N$P.(#V[+Q\E&VV@$HWN,81
M@=U8!OD]2FWD_CF.GEQ=G*,%AX$%(2E82,T'[/S;&X6*X!N1&F?ML^N/AZ-I
M</:G/)O?;$($6X05NJ$ <[;2FV(PZN3[]Y78<[$\-JI>.\)2B)Q+\K\B'SVV
M"1%+/=[)&]!"OW*6QU0_53Q9SH^UJO.=(2*U+J=2!EA&O;$_>4J6ZX3L<_-!
MF-W.?KT^W&D85LW@(A];J!L)G5;4NJB][(<QT0Q9OXZ.HT@=T[;::ALXQL/H
MI)_CURW1=<K 'HY!79N&U#$MB2G6/-G9XCD>39%UI TMK&_S^SH)/&0)]B-U
M]O#NZGH_8+"U:-D)&< X Y J+(M0OK6>J^1[K"*W19K/O_\@TD8.VB7.?$7B
ME)-3=6E026Q/;D7W=PPWQNQ/(6WD8$V1VH6B(G!P'8D*@&F@M^LM)PNLH0-(
MNY]=/<S2[/E_?[CU[^?K<OB37Z[^>3-; "RNO5L=7L(16 )2'08RJHX;)+G<
MXRI[P#[KC-EDX0@ZS\'IB!J9I+(7%&M],U@;%'C9T.T==O/4!-TE?"6,CI5$
MC8V40T43*RJ)NCNTE7)#,%W@[UB'+\;IS[/WL^O?ZP\YW$1%1=EAU(EM?;$A
MR=!0:%.!/J%7=E^^EE2=SL68&K(.%@7&*B=<$!PUE%9B@=S#/BFQL:_F,ER,
MEMVU"1D3L<%#A!B<:(4&C-@# 1)V ?^I7-0"_<^SQ^OG/>H__?/F^N/^\SSK
MA?B8;.W+UX4#"F2?DFS%8J2(7AJ.+,:V.QY"W&ZF%LL'CC'EI(L!$L#9E<RD
M2)6EG^1CZD",)<I1U5JAYP3"Q[)N@^Q_+$3E.9O6(9?<FN$E]&7E-U)(T_GX
MLU ^5GFR+&]*3CFV3-[$'$PK0CO=KS,#L?GZ= +A\P;-)<#_"4% "%B4%)C!
MQE"7?OA%BZ5F5Q*Z-P8E^U+IOL1-QM.(4A7-:E4DI%)D[9Z,SBSW$<!0_CU0
M";TX4Z,O5EYP@*E]3)!$\):6FY XE>ARGC>2C_ \3+V[GWWFD'4#_9LC@^>^
MX>/>SG5RQK/A1<H*LN!PW[;[Y'/NG".;KS$[L ^=Y^!T1#V#K#EAR9C9"OLZ
M8ZU4FQUSN8M&I:37RND8T)PW :TCCGE4YI#,!=L"GL2WL]=916,IQNFL+ON(
MXM7#;X<KJC*B1"R.O,T6?+2YQ:).X8!UT6+,NJR3=!KY(]J77*%@+,;D)6).
MJC:T+H XY,Z=S.>E>RSLS,DALAKEH JY9)UL$,4Y[03#/)CN&K?->XH^W=W.
M>Y >_.,SQG:-37^YBU<W-U^;B5CQ_O>JXK@?8?( 8A9(A)FO SDI<_"+)@23
MUG +'N94_.G/ [?C.&+/QO.8^LWC#>U!%7;-1D&,9<$SVWP:X/F5,SRBMV"@
M)&!>/:?:VF&Q"[WE]&(=.^FE&9XO(7V8MT#5!I:_U;6BQT65KD)P**TP6I+@
MV,MI6#!=XAIHVX)I"3 0'A]/\UG9'ZM/6P27#$>@J-DT!5M(M>ZBF,L49_XR
MC(_A7JH4ZC(6*;P1-F36 ]$L6IE&V:=CO.Z)>OQ2^XC?/=V__XT]@_]X/QM:
M%;)/[R<))<D719FCF!A"5G+!.M]X.<#Z0%GD%)+/S/]85%N,3M(P_X8#6H02
MA%[PKVV8PK"_(/-CKSRZV&A\2,RJD):$7-3$6._-VOK45\'\LK'ZW=67^8[J
MK5MR]GE(P*B@1&&M1*4$1_;8FBD%)C.D^D9V73@GDGUN(8SHO_1 :&K)4)*4
M'-"5!<"=J4M)[ 0J\*+LCY4GG%%&NI(- "5TWJ86YECEIK#\![#_W/XQ7U >
MKSY?\X\]:F62P* BVE@J^@\*2\:U(1X2KDOU-G>X;"/D%&*G7C*_W:%E71?"
M</1B75THZ6)8=G@;U=64WUBU>:6GY'YD#Y!3BN^>SMX+/B?4(H;6@%+")L+G
MP%:H<U![N;,BCKD""9"%.2=.XV-[PJ>4^VY\4&XS^IB2_9%'%^&T,Z(BHR<G
M(&B59:OU\67K%]QLSB*>@]J+'5;%@S05OY(X0K::+W9L[^XZ;Z+IUL,"<?QA
M;86P'TOA!!HMLV<*(V>P_']E0]O,G-EU;^;UT@T1.0!+/TK;6(&_ .F8.*U"
M#,9CA-RZ#C'WVY))F&$!'D/;B"/,0=J<V/J SI!9NT-IX-\)<]\78D77M+(O
M<;LF=RZFSL[4^IO2T@=92SM!IH8@;LATA?LQ1=F<G=F+YPO;VZ0B7P^E(&O6
MQ-J?M!R9DZ[?<C&F@$?Q?&&SI2P[%A]+2*EN+66N\Q+^P/A^?^288N_!=/[W
MU\T7^VRWNYPDR $I45"(5%O 4%$[?9O[6$-:O5FWW8_3::1SX;M1(''^ SJ
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MUIH<#4IM"X6<WM7N<,Y\?K_^,/L0OOS]8?;AA]LAG(;#NP71<BH:39T=8)<
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M)'N0RH?P9?5OUGY0NKZ?O7^\NQ]Y<Z0<8C&4.6]C(Z*"R[!<&HT#C84;MN,
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MNKN=G\L(P% @6RB@LB$[DLJFF%I_MT$_U.VR,1K\QSJ.<SYN",>)4_">$Z=
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M'DHG4:*S4W2O74:\*U#,E[<-@MU?KFMSDU+@A,^VZ$79"%&Y(?$Z9>V$MGB
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MG==KE=F(DX["1H_@C FV9+X-"G0UDA3JWE;LWT&LP5?,YT5T(P=3A 6OB^7
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M>LM@<H[:*7U6FCPN5FF"-3"P'#P,K-NJ95N#":6+.AL,)VJ+6;://%\878[
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M!N#-%P#E>0(PBASED32]KE_A>AXH:=K2/DZZ:3*N75O_U0T-[NDAC@UU8,(
M?M(B#\.K#4"(E)!;$B%)NNJ7_I^:;5T;$EP7[L+,4QYY+;%^[A0W=$5N8X>T
M='W)PUZ*  ]AN!L(8.VN3X;)77JU;N>JVZW,.P?.+TD [,89=JO%>Y,8@)@D
M8$BY"'[ O[PJ!^57O!"D;AUNFJ2A>,$LTBL_N DRL"LW;I@%))6EB&1X-;]O
MG00>D27$7WR8&S+VX<^2YAOI%^+Z 9Y3&05QZ@4DPNM_R?QK*6 W;:&53/_>
M\T""3_P5S.)@O723E2M]Q-Y>$9TX\/(X3M9QPAK _1*L A!,&%M2OT,N7HL
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M/FP'<JM1U?/CJU,4RLXS#X>GV+-!:<K@D-VDG3%Q]H3'WF];CWR \<C[34$
M00!!@%=%@ LI17)V._?E<$7W^-8NT[?"W:"6U5=N4(W1UCJ"PH(#!0>>RH&_
M4&=1<)S@N*?BN+_3N,QG%I?Y4L9EOC0+6DG31MFJCR>4K1),*ICT5"8=TN#?
MURKX]WDK^/>9!O^V4D,$C@H6?3(6_8Y;^(?24M1..*EV0F>9\9TF()\+X43G
MVKY/G)T[!^!]XD3$&9Z($'@C\$;@C< ;@3<";P3>"+P1>"/P1N#-V7. P!N!
M-P)O!-Y<"MY<2$Y,K_V.Z>F*%+/5\6"*?P3OO-SRUAWV-#Z7=>Y;-0L-_(+E
M09,5U1$2(21"2$0I$1WV/Q 2(23BXB7",CO+-A#R(.3AXN7!E VCL]XE+T4B
M1![7/9YXX\SURO7;]8Y$H^K:?6\[]-)?>9OJ"Y+ R]5@+TCR;*.[_AU"\H3D
M"<D3FSQB4UF(V#F(V%M#ZZY8ME!N0O*$Y!TJ>:IL6-VU>WW=LB=2&SY,@G0=
MIVZXJX!>>5![GW4A256!/7IB-CCA"/?+C6[V8(B>"]OT;6\*Y2;D0LB%D(M7
M)1=O.TV8>!TFG!"85RPP0I$(N1!R(13)L\4"SB@X]TS5<[H+18G^GOV=W1+]
M/?O8%!1=/GN-/;]BTT0@I4#*YT)*5=;L[C*7!$8*C!08>0Z\*C!26),"*052
M"J042/F$9X#USDX\"H04""D0\BQX52!DE_ZVJ7:73"TP\L!-GI]H5\]=US_9
MP&I$>TS?T[,8[Y;XJ673U>8<>FW(^[W6*7WE;J0Y-J?^9QXDK('MROV#2#A,
M;./BAM4QXCAAE;WJ/[)>N+3]+4SK@/ZWK*6W%^>ACR_&=M$)MKKF=^[JMYN0
M- \SVD48$V^KSC,_P8@\/.F\H+UT@TARI9O@ED027!;$_NE-GG<M4QU)U0[7
MA'W$R]\'&;"!Q[YI-3D!TJQ(XB&QOKA)%I'D_O8ZYSL_^J0O+JPW,,1O_RO]
M$JR"[(%R<0^"0%_2\C&2ANLD"'$7UY#K3$I3N=O3D%%0^->R1'O?T,;UP.&N
M]"T#_B4W@0</N?J2Q'[N4;$8WB2$L ;LKO2=>,L(E9;T/7&C=$$2^JIO)+D-
M/%)=2[]UI5\;O=+IE?EZ'6YJ%])6Z6'H@O;")O,!Z[=>:Q2/PC7]OR_#K]-?
MKJ7?@)2LT3QV3D^+7MB'#DLNB;)T04[Q:PHL.3XV0W3Q\%\<1/G$K'PBT.,6
MT(6PWE* '6F6<"*E[$VI%,$3V3/7"5EC2^T \.';'?  TGP:W81X<]DV?A$G
M]TR8DN,NEN"1,!;L.MGL/I_FL*QIC2PI8;.BL-ADB;L@#!F"KH"7EK (<VPJ
MN""DPE$<33F5A.!3B7\M(2Q7CV5/2L@*Z03_O\CA(Q@@Q,N D"%)&7UR@-80
M1["1R(]U@/-*:(]Q7+D@PMG P-=Q5'Z!A#QH0=,:_[R-:8^O;.DV'S3?-&;/
M^8K<4IY;NEG)"7Z,RQ9GTHJ0C%[46%E\;9/H()<DS4#A4KV#)'.E>4)<4![P
M4O[8=SN(#V2NK3<LQ$T<^UQ/Q1ZH"W@?+#$?.1 XOF7'.@):*:,^AN:AC44E
MU@WU5*<'>TV^EJBPK]P?P2I?2>X*#,D,WG&/TW62>Z%=VTBH$%[=R0-/5YB]
M0O"!ONJSC6\/7CZ,RS(P50BV"S6=X([99"BYZW5"6=)'I.:/8A#4Y/8FN*[S
MQ%LBU!2@MF;*15HD\:K@6\0P"AU@SH8!CKE$"10(L)UP)""FB.?P:L;(V1)>
M(FW@GO0D(( 'N96AMUN(@[3"/B;'!9S1)W4L.*J2+3MY$*QJ! 9GDKK)IEBK
M]B(6<!1$H-C<<)=Z.5?)Z]%?Z]+KW6-C3LB7?"-]VT2HM*5O;H@R]#'R'DGM
M<_+:CQELWW;RS\#7* B8[[AM*4>@ CV$JE(."DO$Y:;P*MZVA+G8U+ZY"[*E
M1%?U+%=P!Z?1633X4 83)<D*M/@Y7D8I3+L\1%I^P]Z'UWF4B@%5 .B?)W\0
M9I*L*=4(?5">(F2?)5D*E80X&"?9$KQXL+1Q], 18(NGA;[X[?K;]7636M(B
M(*$/=AI8^BGP +#-+1(B71-TA8-_(83"[;_'X&'!976S$J^">>(_\%JP[O"U
M\ 6E'7@<^<J5ZWY1RO@+?TU14W-+?%]<@HTL(RZH_#FUO^'.0I4S+4?M1@RN
MD,C;U%T.F+?')(!/?1G#6 &ZX,W)#;7)J5Y@+MYJGH<NGA>FOQ+XE_54!3<B
MP[A+*@"M3ZMN 2QWA?8/>%;@*-UP,&KR:< 8A?SPPCR%&]"H2?PKE/4-1L&R
M))CGL(:2S]1^82X60-!PU@O!IJQ(P!IJB! +@L$SDAAL.Q3\+<FBMR'K<WY!
M;_IM$,'(*'_^ ?ZS+"V#-4C&$B-Q)"EEI!*-ZMYW]\DGB!Q!D00<!Z\=0QT
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MH_6"N>@UK22J%50B8/-0H*<,C6R.*+S3D7O<5NH9N/[C)$[37X+H#VD4Q-]
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M!5*,$8BO,0CW7E5ROMJ6?M,ZT5#2\SRU[*\T[$EA?TY"C 6DK2VV1JB$_ "
M0-"AAU)HM!C_0(_J%O0EW:Q+EW&27='M9[P@C)'^^ EKPO.MZNI6=K"%X1!"
M"]U'+]P2%BXH/.LT7RQP1X>I8!(QM*QI00SD8O(U.J58N!X51I5*4$@0F 0N
M2T2AW\#J8++\UH9C%9QEED$0><$:0T1H'&Q0'# GDOKB]T3'V649#1NE) K
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M2Z_-T5GNAV#2%\2DG9^:$DPJF+1K)FU'GY_^4-O%GVD;PW>)ZV7YCI#(<X+
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MW,J0$&[^$N9:5*Y>2,7:K6P^]D58V7N%.SMW0XIFZ9* @%71\)#-IID34^7
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M$W($Q"; NST]$;(D]WI/M]MKR;-G'DM@440W"+!1@&3.KS^950 (WB2**I
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M]4# :PFM!,IBWBC;)1%#D+(P\8<,!#/QTS)>:U (9C:OBF-F7%AK*:LY<A"
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M=G_ZXW6"FVE@I_OZ2!LFQIB<JF'473X)_MY,LM#_)"'66E0@)]E9$O#A'PD
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M<5K&;PXRX%RP&?@9#?9KB'0L<W(O'_E\=%]$S)( ?M,ON0?6TF5'0XF,J$I
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M]*IS%277YB>Q-D^?JK"=L326\N9L/A%E8#5M8V<=JK*2FT(9A *$ H0"&UG
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M!_C)GX'5>8=2OJ ;8Z5:7&5+:5V.UH&F2@14P5_!QXP1. !W8"3J C3GE0V
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M5MWN\ B'C\ER2$9D$\TT,DN>F\N-!':-'X70S,DG81+$,F52>!K2"P0'N1Z
MS??X'2Q)[*62E!X3X3[<, TCM1S3))J&*&IX SX3"V-S7. UC\>'> %<H4>9
MW=M@-V +>2,PY( 2^  P%8+Y\->)Q;! @$UC!MDF);+CD$!Z4%A#%!;)SA2:
MA8F$H<IW[U?>41"6!1=E60[P<U&:@C":<']5=G+94/8H<X7OI]?\_*;Y1GT&
M^]K-/J^9W:T'Z,&^B$?V+9SP%<?OT1O&8_@3A#DUZ\%D]_E4BO?9'Q^6S?3Y
MH(HAY=S4[R^X "\/2NLA]5IOG_<EUKI"Z91>>?MK[Z_U[?M]_6EO4JB/CQH&
M[D)_^(J82C[^WINGB??<_MFK=QJ?)I\KL,Y;@1"#W>@WV$B^HLFU@_M?3S;L
M[T;%?DE,V#H $ZZ2=OM@U:%Y=JT=10%FXL/]\^'6=<0I:7<[US3US%8=!A/\
MNT=R'BR(;PH8*\1[-49,XCB39J-=>ZC[LA*9U ')\RPB>4B[IBI$^IMI(M0A
M[7/0L9I=8V9M5982[WOQABZ9[P>E3U5XYS1AH&O9YCI%5&4I7PL#)7I/];<I
M/@GPE[FO-H5P;U[LT.PK'[VS3XOV!?9K&><LK&;;7+;G)KI4A4O*UL3D+Y)T
M%:6K9?6<\AO)'HMTD6^,8<!I)%POS;D!9<8GF#+R[Y=V3-]:VFHG5([5&9!M
M2"YB:?JGAA+1-7?0_5@D@KRE)XA[X;I1PGV=^Q<)*:*'%W4L.4%;SK%Z;7-G
M6(_=E"-'B1RE%]"I;75[#@D7^4DO3Y>(Q(,(DI=4:3A>0]"V^FV;#$%RC<@U
MRL[264V'@@7D&FU/W)LX=/]D=UR*H3I3)0)96NSM> PXNVL-G/*[_%2%2<@]
MJH&R.A[I<L"P,UB/]MBEB_RC^,/G -PBK$] 9B#<U^D8BRY498')+:J.IJF=
M/ RLODV! G*+RNLIL+V5=K#ZQGOWD5K&NDWM3+2JL!,Y4#50:Z<CFN;,PY.7
MS-K717@]"6_#F/OK2BV1[:G48-L:-(WEG%=ET<D?JX[BJI],=&QK8,X\/!:9
MH'H16]:+*)3O.\:B$95#HLH0J[803AQ'12->AG>>=+$N*@L#K$2LYHQ%+J4(
MO##"4L,E93 ?MOA="?T];,RV+*G#QV;ZU+*'UCNRWJL7=JJ?Q+4LN[]UD302
MN%-P#6HLGD<3];6=IN6T**^&')]C%2]3941+D+UVW^IURC]05X_N4X>(DQU7
M..Q7(>7[=>U**+ZL?#ZSJNXT;,SJ25!]U5H-1<:LACH-D:F[6U9VV=O7)06\
M("Y@J@MJK>TJ8\4SGZ7MLRQ<^TZS>1LQQYR_N#-5:\%]Y&Y7=8.6D)*0DI"R
M.MQG,/YQ=*VXD>]-TOK"7(?MDAM\6AN[F([28L]??O]5ES#+OD"K6M=]7FIQ
M&V-*KJGNV']K]9N-#H/K_'6% 79YI+EFIG^SFXV6T;$MML9>:+G,N"]#-N99
MS>U\0?3'C<MAB@/_YK0<P[,UN!+=1K/$A;#2GLW8<U8F=W^H1L8A<\<\N!=,
M58^%_P4)B,4=E]@&/!%XP0./='E9F37;7B=BZ9UZ'?E4]2T.@PE $AMQ-PXC
MN<@(R . C^>J.3JNNV(%8^O<:0P,KW(]FAQK(HL?GE2]<A: [Q'HP>[$/:RB
M^#'U(D^W3W>:3@=9 ZR#N'AO04+7WM2VF+?0.!K65*H6[HE4/=_%!%O'8\/R
M4'> C[U)VH$]7WGU^&&H;E//APM>K2P7%6/!!BE54=YX@2N6Z#%D;C))?*X:
MRVM)4U(4/@8BDF-OBAR/'>^10($9#NLT#?6:?_3B,8R5P]@B(<Y5R_DI7!X.
M+0:&HXC89VP6& !_?=-%U6#F0\RP<S5<M/J.0L=6O[59-^M$Y!DR"? -<\&>
MY?#6U6[TZE$;E#60<23A#@ 2U<DZ[7Z.O ?0DC(^\[V)%XMA@]TD@(/S-<@6
MYA&;V<=@X-\+#+G=S=2@O<"+L1D[=_]*/.FIW:(G.J9+50](B4BSA\V]'P6\
M'?XM<,+JJP%C)4X4.\,C:B=^G+T$BPKYXKG79J.<@IGON4@/H605B1;B6=RL
MK3Q\%T<\D%PO4H-=K+Q2KAGAP@(R 1 Q 7B06K ![Z/PA_K&GYDR2P9.HVT6
MPV%V&2"NLI=:A 7-F*HTQ34\(U8]U(!E:A%:[4;?^")H%GMR*90H\@?N^2C/
MBZ;#,O,!1 'NXP+!TRIJ$V<8I& IGQ<;1>$$5[V/&!LF]V-4K(ZEI!;E+1(3
M $.D2S4MS.*P.PW0!_E26.P2%"] =.!QC=PIL"NS0H)N!!R<1N+!"Q,)H"$3
ML%1!J0P1M%.@5B1 I0 \LT8?+"H!^"-_1Z8&4&5):]WK4=1=D&AOJ&%2PAM]
MT&^C)$[@IXG@$OY=1,=%")SP&:J9)&)CL$  7[6]E&H>5#M@SXA BLQJUH\V
M8-X<+A: Z^NZ833$1 EE'["+FTMV&TY!Y?3:S14E :O@R3'2>UVJA5JS-3M<
M2JXMI)L''_Y(AO?H1UAJT=!01(/IW/?^!&5SCG;3.7X9">"W?^=H 73/;M2K
MK2OTP>M!5?V162BH$?2*ZW7#E[I^,E1:DO\XG_J@!+0Q#)P'5C JPCM<>%@H
M;YBD(80_$E#?0R_3J$ FP<'"B(1R@^#VS&PJD@?GJK .OU2S\<9A.-2@AA-?
M1YG,E-&SA=^0MX<"S+ )L(M$BYP/_TADK"<.6@R?M([VX. IM3U%[TZL.F=<
MB1R\/E'3RE9CW:/,>>=]TV&25/:4[:KAI0[J6S=R40L _ AKK5&D=/K;W4:W
MJL&1IFE#9)@HY,_80Z;\D2TMPQ4U\J:U'<\/2TT8TFKQS=>'F!2*1 I;)#C=
MWLAS.3P3]QX02NY!46<D?\X5C#W$-\7RP?H\"*2&0M1(@!X1UDHH(A*HJA C
M >0!-M>)CL(W%=-XXD4PGG^+*,08$.C><7T@I%KLVZBWY9,# ZZ1!<SRR'RP
M"*2O>>J1:Z8'UO$"X!B?/\ZY2_OQ$9@#:"/F,4_U2?D K<Y;9#/'?JN,(OQ1
M@Y(*O2D3A(] RR_"DQX),O<,C0VT"59>QGT5HU%Q![ 1O$DRT;P-_#'A?V8W
M?/G]UP6#.C59T-(1(PPN:&M-Q>ON18"&.$J6&A,.0QO_3QN'&X2X>!I=F6J1
M^"OQU'4AVCJI,3Y$^5,1RH"[<?H4-44TM/4W(=HT0(S'L0#%+R9(@VC&AAZ&
M0P2,2[] /S>WH6!>,);8Q]!03;>[8#+G.9U6C,<[[G,U>6T$)]-0FT7(P\AR
M&241OSV9NCN*D97SDYF YJ+SG4:O%#MOG599PW795@C*;!HY!*.>9WLAJ:F%
M G@.1L$ZQ;$[ECT5DW8&YF'K-QZYXQ0IUGMGJ""'ZZI#S+04\R /KX;%4,N4
M>T,8.<#&U,,"1IIMU+8#0IJ&(3QX+9%T(\&5HY7&,#'.P;[@(6SM>F3QR[FH
M@HC&CT+HA;T+PS_5.HAY6'1^IGLH[M!?E#*!&>@QP]T! )>+SUP=A8X)X")K
M\<#M+F0&,^S=:QK>?;(P"+\&S=+-%%@9 5^Y><AXPVKF!M'3ZXB$4/;.G7 Y
MAE^6#:LG["E^S[U QD^94_LT YKFY6E5D@IV9MH:S:!';-HACH3/4U69!#AR
M,-/_G:D))3((CZ 1O]]^Q#]&*50:<C!-A_3U=)2)CC.8AGJ#!N7Z3Q'H;1B[
M9S);HF$?8 ;=Q?C,T!NJ0)@*HN(7$C>TYH(.AE*%W=C%N8!;F/@\\C<'Q,)1
M$:TR()%2A[A <1?#;]HK]#!@# :/!+RTTHB85*"42>@H9?%Y7!"-(2^ [R<:
MU%1L$KS:<*I>U&!7.A]BDYVQ*7G%2B/Y^KV/"XZI7+:O7F3$J"@1D' *:C30
MVE.I/% -H+K#Q-=<DN[MZ:W<HD)(W77M/0<A^BWP$= [Q(U>(+:RR-563 $I
MT#I:#7(KKZ5^D;9G5_593;=V93#S+UM.#:3 D7,:6NGJ<*VUE5.C_D0GK4!<
M;9/76%\^L6T'8N+)E#^Y!-&^\Y&3I506G;HD34#0GLH/H-.C\-&+A1>-%?O/
M,AIO5&4Z8%X(1OFS>4A52;C^>Q&3/-RMAT55EQ=WA!.4[C0O0'GQ*QD0-R#E
MGBN4"OW\[<9:$ R)C-LN;)JA*;&8_K:PE;!Z<VOAY@;[K_ 17AQIC('W*5]6
M;W'A!A60'*8O?G#<'=!XH; P#2XO)UBD20C*? =O"+X$<BJ)3B4$5@$SNO3:
MI3&ZU$W4E^&RZ4U+N4*X!1HO"%EA'W#D^>J)<QD08+ ',M_\F2*2JH71.2@+
M:U*D@!;()!Z'D0HM/&UW9G___:=$GM]S/GW_68WAEO_ 2E) "G ;;F'^'_W0
M_?,?__D??U^Y[FOH>^XLOP;=#A2N;V+T\YM/5[A>_]/^U^W5&^8-X0ONQN?=
MR^[@HMNR/U[U/O8^V?;EX&-W<'EYW>FT!IU/O>LW_U@2\:+<W7H36.4OH+6^
MA1.^^0S%JQ'"$"#HCWCY>W0S/%=_\ZB'<Q?ZP\S&5FL/!'VF0%>U(X9%/$DR
MJT;IAX68UXQ-!+"HMG)<5;%,B2!P\5P(T$F^VCIXE@-AAAX9\@ZSS4YEJ@"^
MB+^2-"@6QY%WEZA<>!4=TPF@A;!9T1E/,XFR=$^5Y*E,'A6FG. <5!0M3R7<
M-%R=Y>!%A4V$S"%_R93SP%>BX&LY/BC7! BUM5W,%2OL%*H4/>WVP-*@ [PQ
MDEA\\ITF_H-*'BO&%/^Y:CZD=Q=B,"IDF1NM^#QE&(I-.Q**G12M5P>AXYIU
M"F96<+O"PM5:OPF/%K&.NA>CA^NLQ$((Q>B^F'+X=@JP/*'HEA38HI*+>7"/
MIMF%>L<:G;B%OG,^]9L?>\UN^_+RLMOL7=BM3TVM[]H#IW_=.[B^:QM6=RO*
M[9???[_ZW\^__LHNOERQSU]N+[[\\OGCK]?LXN;F^O:FQNJN$&EN+L7'5.(L
MLJBR*V_^G(FO8PY>-ABO/H[0 BO:;2B+&7^<JA\MY:T7<LCFMBK8E=(;>HB2
M9U^YZT6\<-T[W)'.1")D*'9HGFKU>S%/X=ULC-Z'X5!Y#3P*==[%Q33R?,0Z
M)S>-0Z6F4?$!90#&T=^;\IE2A?#:^3SP?K@ZT!E'.CB]=BB%+U20(#4&4C6N
M;=V;7-T"K'_*M?#%W&Z *X*ARH>SVP8"/ZLVFSX3MFBH?$2]"WH+R7GG!3I7
MUA &SS=J%KWD7RXNOJ+YH6:;[0P6:3A4OO/G9ZF_Q*OWD="<DR4,@CT0G(=)
MG"UO(6+$<9/4A>_X?9ZC*#FP WZX$M/P8S+U'KC+T?F:1B'&>20>F_25NBXF
MFUW_OZ\7WZY_74A5U&G;,Q&#")_?B?,T&@7OSIYE%?/+5QA1NX^;QK'F[>IQ
MHQ"5US-EP:N-17C?BT]A:MO7!6*F@_WY3?.-^BRGW,T^;Z&7V*8AK2MP\N@-
MX_%[I[W-^?G%\[_;7_RR&BNP1"\YYKNR_$NS7S@:CRO_NB([WNN+,<$$7W20
M^;D9ONX<O=TTG9*=[^Z/O$C&>'QD BBEO#7NYWZ.BEZ=@>]9T&[OGI:0;0Y0
MDQ350HJ.3HS:^Y<BSB;\#U"PUXWO#:;L(31(OP?JY,+_A=4:AA.+?8K0#[38
M+P*,P6 &MB[843.EYV^FH)!)YDY&YHY.Z/JFA4[%P-)C=W-C.C>8,;)E+A6A
M:5SS*G5Z(Z9QGB?:)O$^%?%^(.FND'0[G7*D^[^30*B$G'<J9$W"?1+"?72R
MW7+J+-P=XZK[F2V3+02YVA&QV]R1F4<),:8Z42<,BP'N>1*W<G%,V5JFV6UM
MK'TYL3#+=L8S#=D-*NUE9&QFQN6HL+.0G4_7>XJ+:=SI#G\:]\;".EDJU$)H
M>V$US<S8N%E0S(;,]EY4X'[1DMZ4<UW9><TE;<T6$("A)Q[,%78HP9M!*=%X
MGFU.K,'U]"!%,#>,-JZ3WLZH_&+AGHGIU2G!&MUJ=1KL$Z;R)M$TE'I7:B*$
MWK;3B4#SS.'5W2-+<VJ^#_;#!7G$G3UK5<\O9.&HG;$(QH O^BOA42PPO5OE
M%#7895X&"=-PTF1&(S39ZWF[Q0/&)92@:=D-Q_!9_,+>-G+YZL[FO$!@B7N<
M#7:A@"&K;+-F&&KW'2M%WF$]+J&/FLHBC=U0ZARSY6W?Y4/AZ[2+JI(1I"E7
MRB[-M:ZKDG]!;8;^ \K/DW9A]6V^Y:2"(C&9KE16+&N6'3W.$6/=$?L\G</+
M<X+T3K,ZHS>_-<W7'>KC#:K:T4)28W[IF@JA^:KE2U8XMU0PD7*6P5J5.D=B
M)0]@?9F'.B!.)9/BYABQY>K67(3F9X+5J=,LS34_BSH'%<QXGTQXI"WS/)."
MG:E[PT3"<LIWJXD5!1JLQ"V*T\//12(%>%3)7R7)//1C*KBT1!L=/AH,&OUF
MI]GM.TX7UJO?>9L5#T?TYU,IWF=_K!QZ7A^=RB,BG;6=?+8/+ND!]MMO7QK>
M6KC?/NSMK;V^OB8MX>K5.(+H,Q]NZP!=G)^AY1KZ%8 *C5X1%2@QV(V @XW)
MP)>9,L$# ELW'J2669M9]*,N=+)R 'IMO2MJHU-]-*QWGQ)S77*.O@E.JVGU
M^^6WUJX%V^!]U-[7%'JM^>OK/*251Q#"((M:995AMPMU/1TB(F-Q)V/QZ+K#
M]JQ^9S4HM".G5$;(#H%3%3*_#@=@OZT>.BNVK=@%R,@\KA"^&27B08&O;X%E
M53IO549JR7(KT85?W<(@4ZN2IM;V7M:^X:C=M7HM8X88>9,UL *.PLTDZZQ"
MD'A,UEF[2]8966<FK#-C6I6@Z"4[I6N:NY=KLAW%?LJV)*S]ODJG8]D#TP;O
M9KK5@HT,ZH'%0T#%Z_<VL->DT/7++PN6Y8CF!1SGZ:,KN9KJQ(O$-$\PA5W5
M%EFXXP",B?N9Q>;UCXK?QA$?B@F/_DSK2>)'%O!)FE<:"7.-'8+0R&.P;",(
MU[_UN9YB >WEC-I:%M3^M%"SF)JJ[51Y<AL.,=>PI&FZJ8')MG]F&_$N-:Q[
M&O+7E,I\M@SF8M7,!T#5,)KM5B[SHGUYU;]N=C]^NKIPKON?+NQN.RN7^:EO
M]X^_7.;G+_^\_G+[^[?/UW6NC7F;=G$'?9Y61O92QL@J&!]_MKC=;)K+#^\;
MR0_O=0Z;X-VL=7IZK29_VI&;]=CZNAAI[P#IW)5*WEYK1Y],)+&_&SG[)7%C
M-0X7F-KV+)]Y*5Q[S(=<:L6'6R=UT#[T9J[]QA\9=GB)/.X;VRLV>EZC*I2J
MQ)&,RNP.V%VK0^EY+X'ZNJ!-Y70D0<V)0XUM]=H.0<VI>(BO)^'_AM&?YUYP
M/HU"[(JVBSU^=.>(^E:K9YL2HJHL=-EJF;3O$4L$Z)6N0R)!SO+6M/WD!;KE
M)I9N*D6M'$^",#J(;7(0R4&LD(HZ'NGJ68,]U*4Y%N%ZO4MDUUYWK3MF=!O&
MW#?&191<3LGEVY*L;5MMVYCM3<GEY,P2@!& [1' 6K;E]/H$8*=Y.F8AZ;=9
M0M)O5M-<E91/C[W$(5;4'X71A(7!?>AA0_LX:^T2"ZG:,X0!DP(/B3,_U!G#
M>8/PF#WPR L3J;N^>)BB\<!]J5JF_.[&8=HPI:NZ>4]YI/K=>.KH^8;7+78V
M\) >WLA3G7/@=9Q)N,;'G@"Q.RZ,I=B<?<*#9,3=.$E/]L 2^;-T&$-@<JP5
MCKTGU)MR6F B/KS)5><<L"^ G@X6^,<,:1C<O3X"$7M9'Y\DP.,0:4LI;&Z#
M!.5L$@[S!V4GB^9CPEFGNPAZ3N*'/F:D.@#H_D#ZH'TZF:'()H=]'F1R)V'(
M0!9L8R$$'E2*HK3#QF++(0F+@=6_L1XX?*?&F25[SW!9QW@T O^;-R8PU62D
MV>@9[D4TYM&]T"7W99P5.Y>(6VJ1<7F+A?D5(2<\AB5\^<&*S2<EUIZH^ K8
MZ<Y><IJB==ELMSH?+]L7U_WFQ2?[4\NYT*<IG$&O=75U\-,4MD$(TA_Q\O<>
M>(>>N^F Q?P@PLXP>O@#%H599&<(D5M'"X%>-A; MGB(2G5P1AD<PH61=Y>D
MS;**252Z04@8_8F,GF('0NSBN0V TGC>A@ML9,!>=711QAF Z/XG>/T$>T3+
MHL!D;[.8S^^P[Q"\$ZWML>!#B\$76!LD$K!^_U:',W33 =5Q2;*A@)LGL!A#
MEB!"S[M5 YVM]"_LJW*FC>R^XS0_?/K\Z??\H_WA'7: &X=+, ;ZR0,\!?O&
M1TQ[\,2C5!IDCF0P^%1/ *K= 2# 8"PF@0+GD_!!Z108OFKY].A)[,T!1%=S
M*!Q]T<VC!.HC'Q=*(FZ&CUA@0)]_E%Z<<%TH!59!TU-U84CA"/^>CPEH@FHF
MUP^QZA^#./N A?%VAJ0EJ"G"T6_8 ?PRD<#W(I+ZPI<CDV,W^Y\ZO>MNJ]F^
MZG>N+KK-:XU,K8%]W6Z?)#)=A@'FGZ;=[V"Q%:U93FQ3<+5R!+I$0S"3/+OW
M 8 JFXENIL+3SD;:-KC7'Q['(%D(5Y$R G6;0U<DROF8UZ %&^518,\D66A4
M;ZE"0X@KJMN6>C"06P0*+- P#."QBY(O\;17;FMFW;DX&T;A]%R.O2F^\S[B
MD[39CA9)Y=7H::1(J:PU?7-Q"F?S9E 7,$I/ADGDBH\"K(R _1?@7#R&H433
M4*^ZQ2YY!%?#5/6/%@"PVU S^<W]O_ >X(RK*+G/QO_.8@#F# <ZR8[:(49D
MQIV";*R6.?30?/,UC@7 +=X0&YIQUU48#4B68),;T!FAG"*;(E9-[K!Q&2(-
MF"?W O[5"=(R[8&7/V88@AF>D58?J[L3 &QS7: &M=!7"V!6!(D^)PB$T74\
MXPVL [05H&[0.@,@+%+82QM:J5/C4[1'883#U5.$KQ"6+0#F9 \F#LP<3'SE
MX;I^G4\&TN#I5./!3C7V:W:JT?@QO'^AWKA>J=FQORU:.M?XHE0(.D]6\7.-
MQD+^E=N%(R;=G4FIDC7Q817X<.OD,\HGWLRUOZ[XX<8VE$T2L"8[\OOKTS?G
MI&/) 'E;2<8[,GUSH-SD@PIE^><V=Q)*DCN2N]/5E*UJ"N5Q:<K:1[1>3ZL;
MX8:X=UB:F5MOW6CL=!RI0(IH'+FP.,9RK4E82%B.75@&)"REFVH5\KC*).+M
MV(O*-.&.,^[A&-NGH;A'7:2P7@J.Y([DKBKL0W)7>[DS=Q3VM.6N)E'#FLE<
M74[VFQ?,P?Z*;%#,GP25!'578O;-6:XDJ"2H)*BE:51S12U)4*DFS':C_98>
M\AQ%X:1P_C=,8ND-A3KN^;UQT\C.H0I=KL!/RY8$9@J%V*NKMLMC#/7Q-30:
M@UU\#0TH/7J\]O@N%FS,3_R.UO1+-C*$DCL]4R/GDIL-;U%<8K$61?2G4.!Z
M(]P$AN2)]*8M2E!\O.RUKGJM5K?;';3Z/:?5_>AD)2B<UF7S)$M0W(S#*#Z_
M%=%$\=:O(8Q%??JLBE.I$@/55#1ZY%@?)BVDI<LA%&KC<.Q??8YA.JS#E3.,
MKAD!-V+-&5V$P(W$T(N9RR-5M$IX#\ACTBH\F=U'?"@*M2?8E$^%KF?CIO4<
M!+L+@Z%DCUZ,17'@;7#9A,?9B[&Z5"3PU5K7Z1H'$YC<6&8%=H;X&*R#D43N
MF$NARSW,]2.H?P6C#;U6I<[_19-;F%DVRDVS6BS)D9?YT54C^'0:A=/(PWM<
M'V8Q+WN6EGDK3CA]@ZH45WA#6F1$8#TA>)#4Y2ZR-^FG894TK"1QQWTLR,/D
M&,NWX5@7QK>@V H<,=7(@TW2&3S3FR23C))_)5Q5GW.!.%C^2(UFPG^H:U*B
MS9CO3731NI5)806]*'Q BPEUYU177<MIX')5L<.")_R5>$-\EJJYAH649!BH
M8A)12O)(P-NP\MP#]U1YHG-XXKFJ#U7@"2P;,B_7%K,1]R)=BPD8D&.M#G@S
M7!WAQ"<*AIDF+98N:K#O@:[A!!>. 5P TM@]]P+-0GX(G*CFR9\=A/BAZH<,
MM0&)Q:'P;CT]-49@1E6/2F+5/C'E:IYYZW'%]ZZ;3!)=@4J59](51\08Z\(\
M"/U L#T]GV6#;K!OV?!7AHVO3:N:J))PJGX?IAC EZ$J3Y@6; J4!Z->JXIF
MY?590@"*M,93-@]P?+R'A;)66:' O#AARO*Z>I5B@XQ[LUN*-:(*9,3:=2]7
MQ)LT:U'_@OZ[T'8[#.%K% ;PIZOGN6MAJ,N+RZM/UTZ[WQPTG8^.<VDWVYE6
M[EP/>@?7RFW#2GE%!7^[OKS^<LLN+B]___[E]O.77]C7;[]_@;\OKW^#'VYV
M5K^EF1*IH^?J:I$7PW */+_S,(O$S@OI5*GPZVL&7ZH)]#E@(+>@P'014H2!
M3Z#; F6>S 65W<0 .Z#;)?L8PC^J;MVGBYN/8-](F0 *K;WV^Q2Q3%U\<?-=
M>57=\^; >B)&9X:S4.T"5"OXRW6O\^$F1D0I_LC.;L,I(&;/[K][SSY/4&6*
M7(%>3Z9^. ,#ZV8,B'O^46FQKWRF=/=\QD:\(+07L'*K(MF\!A9HH=B;^D(K
M<YE6^8NU PQ#E!Z,$>L+9O5NN7*E9*K%LC51=0+5)+0JGJ:3B",.E'"SZH%9
MW;&E.T&C*NN1_V!W(A CM#50#>$70_CH>@(X!JW=56-KVWLS)9CK/6VER#'#
M2'&J]A:'Q1_1VH2_1L+#FKII+;&4A-R7(6CG"2RH+!;4U?,.X>4^GRF+Y1Y-
M43U:,#Q7!YQJ>@^K3 X3++N8F3%PD<#RP3-4>VCKRU@5I81+EZH9IS46X57_
MGI?"S"Q.L/]B7PT,:ZK=_8$EC>$>7?-K;B3-"S]J&WV8V02+O',G7 [/%:.1
M]JGSV$EF+-^)>R]0)L!_\R#AT8RE$8]%FUJ55L;!!D7"IR8K6,B!KGJK;;[B
M,J!E!>^;L1#,J C-R'%FU6.U8C!>TQ7,;QCJZL/*E-9U-9>K_Z95=H%81J3M
M;\U&RVP98$6)F*M*HZ :D+R*$##B)2HO%@,6*L05@2&K&%Z;G>FJI?3)J)8Q
M.$=UF3*LJB8L4\3->!XK/FM+4S]_@<7-T,\9F"8@>EY81A5 #$R")"B(RSH,
M@<D!?(A(R1?\H%Q50*!1@O58P]$(/J)CRM?)CZ:CYF')QOQ!Z(K5X#?Z6$0;
MP'8>D<)7H0!$0R5ZRGN-<YS1Y5G!UT0G2[%N^D"LLJH?.OPCD:H*]H7OXUC/
M,P8HP)M>-"47Z+5(U%0I5KL%?6450!K'L(XR2^PU!Q<%-84'*_P$DCW",B)
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M)-]:<SZ,AO)O[%6\\2YL/V>)7-XX)#$?O[ -%KSSI02.E#W2;IH)W1:6>A&
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MUKI=7>O\'"C(6L"J@XG-Q\KO?(0B4ODZ'ML6]U5EZ#>4?S+_1?G&0B]2%3L
M\,R T5RX!]C^]V^_*_T@ *;_G;GLD4]A[,KGSP-5 23"'U6%N8"8)QZ$\$,"
MG608#24W)L17Y/N H!4:[S-;UY/R&(1+$#D+YQB49SN<B(G#C) ^@C3IW%XX
M\Q6.M<[E3"2M(3FWE Q-51"W<B:(0?-L9K"@4I[Z#]#0"ESE@!22-TQ90S/D
M#@T E*U\4,32I^5##Q^JE*>LK5AZVD6%(:W6 -KG02K8",&,6V@!.""@^F%U
M4%RRQ0V%^?7, ED"/9R %)8SMAE[$7V=0@_E^((>6M"-[-'GL4K+9#[(2ANU
M%%A]>7SB6K86%1I:6CX85'"QN'NN*D;P!"L$8Q-%QP14:L#])]"W029+QK8?
MP+3L'\K4$]TS0#+CTKQN2Y;; /F4HQC,15<7;'-1C%E8U[ H3'GV?&?T;(^X
MX@!A0#FIRH@#)KV96 [D=]S5Y3[:Q_;_8C-\:;GZ/@O!*%& !4=@"4=@I@CK
M70H/?0&?09$F=0Y]3/P5+_]HAT 0*W[P(".1\BVVV0)!NJ\(3J6?DFLU47B?
M630$/O#Q=@BO 0O2L<$M@8\@!R9@7./;@8\M-L,QPN/1'X$?DG5J*$/V9(^4
MNQ!<\@7F6,!D;*A>_P#W3/AIB:DJ7CR8,!L<)5<5<H<I4[1)T7:+$0?@8J$8
MY=CWIL"$S1:\!IS_1\"V: ""$KGB&.O/?-MY&V YPW8)-CF3WP+8L3GQ8*TV
MFN]P"5:8*IGYGEFV$1#<3_SV^<1]<)83GZ4FYKO#@P FPB1).?F&/&HXS@!J
M"3/EK>8%A5HR<Z9\MFI# ;0#-[M<1'MB\&[F<#4Q0"R.6.4@.D?HFWLS<3/(
MA%D$$I %7-8TU69S-7MF+]J+,%JL.Y),+J$Z&-H!P/VHX6#8(/=@;M)<6$UK
MK"G+MY^YF88"!1<52/1.Y8G>;K0E2<9Y_)6\N ,LTXJX<9EL0_V2$X"I9[5K
M$'Z'D/IB)#[@:$CVW=%P[JY<QPKZFP>&^<L6$?AN>]!M&JW^C='K&E<WYN"F
MTXLC\'JOUQ^>/@(O?I!DMZZZ+N*7U:!\0EJ!DAQQE>MMZLN4VVQ?F%O>S\U,
M.V1I.Z[L:7D!^E=!X%GH7R71A9GOC2(KC/T[^ (\C_<]<.'^Q(_D(S7VS^*M
M++ #!).CJ S0CG"R]ZF*PQX\\,L\\ .":#9S;/R1B<"8,@.Q.@6P16(_%1X'
M#L3(1D=219<K&L-UD2_@E]T*OX$_*+;3Q 14&"2W8"W$(X0_GWX)?718DZOR
MU(AGGHX:4!_8CZX-[A]#DL.M_#*:"96U. KP..'MX8MXC2=\7R\* XPN)/)!
M&7.0$0L.349Z?]/BI N1;5V IED8$NXV)MN#:)<M!#"0DC$YT"[ X7A@"L33
M A'IC\0NBR!=O%QB(EX<4IJ/R?,?F9O$/P)A$081_&PQL8AY_V_*7H ;X,[_
M1B* !>_A06A/@9892?/4P O@>F99?@13VUE^OBD(%^6FZ-MT"TXDD \G$U^S
MR[[E35_7FIK9OFGV!_K0N#;:W6XL-5O=J^MAZTREIB"LDJ-LA>7DICAMC!V!
M_*0#6";C+NP/2@"20?SQ^O]]Z]]>?TZ=_>] $"X"3B&B!2R'[XV[QL]P3_ZF
M(9]Y@Y?P@G] 2&!L:QYY3+="XTW!]+'P$"$L\,MUY(/@!9,97N:YXB77C>_Q
M2_)OP><^1#/[B5D,"*\X]LP+O"E.Y#_@X D[)X@"Q ^*E$3<"W,G"O J>".
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MM/JZV0MYX." B)IE#@N"K*8:'=3 ^^0E]96%$R0&/\@$6$[JF\(4X]IM"9;
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M@=!0>320EJ"HG0PC;.WI.&EF_1LIJ?7TCW1I<?2]Z5<6=J/(1$EUWYDB4U[
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M2!:%7OI#K-#$+Y0@O>'V:F<X5VKRE4](I01I2I N$S]2@G35$U,I09H2I,O
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MNM8<:%D"[Y6N#PI/X%T"GDC;7,GC7,CRU25G^=Y/N&)-F/O(%9'>"M^8[[_
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M3-L;V[6#"1^)$AJ%J)7Z)&JA@VB2@T@.8HE45'W0U5%[1Z@/4!=P'>X25;^
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M1,P1P=R'!LDV!BJD7G]B/Z)][Z:I,",U4U3I\_ MJ5P-Q'.G'JRP>/C2<[*
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MP0GA2=VN=:H3PF>2Y[@+J?9/* _8W!V=P+7MUD5U 9L1."-P1N">Z+NK-XS
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M;X,!I:7O$XAP")-'[PI]?5"6?@Z[>.B*LC X"RSH(QM9- !#ZR99_W?I8<D
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MRK*+MTDT-_GK2/KY BCR[05>HE_^]G]02P,$%     @ U'A<3+/, -W')0
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MM]&&V&AM6_^G'R_7&SP>3S^5",2.8NV(F1I@(:E2W2DE2\GJRR@+@A-$V(J
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M]ZA"VSN@#@@0LS4DH&E"I-*&6*\<48%Z"]Q$JTZJ0[?#]7AW;EB__"DZS+P
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MN4+L_C!EKL;BKB5U]G62 *G"EMX(R+6BT$#&=C4.RT^3F?8GK+U'9;P,\O0
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M1 4,%+[]199(9]C]:#F/ \]0EL)>>1N=$)YHF7!-//-,(,@QUEH*!%@U7NO
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M0[> Z6(D^*T(&_US2+!ID"CLA'6(8$Y5^!>43CT(93#MX].B'> /3((V,%V
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M4HXR 83!F"!AE-2;@\D21T8)';)Z=NQ24HTI$Z^4U%E@CSJ:L=W!'T(24DQ
MV&D"A#SCVNL* $8&]2U>*@-^4PH</>P[#\=_G9@T=_MJ +V4CGEMI:#<4+))
M0[=!-LP1]"4=]C5FR1!')^V _1=U___VKJS'C1Q)O^_/F/>9X7TL=@;@V6C
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M3!;KYOY(Y[4_4]./%/":RDY2[V\=0&O4'.L!FH)W2#L5_R^LXLY*+Y$O,2(
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MQE-N":$.:J%4989+V;S?W_E9@C$MA]:<&0KO7V=WV6_7S\BMW1 .C@F,0@@
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M:=&?5VDYHSOC:%R&WHRTH5#9L<3TA;;R4.3-9.Q#^G"3EBM$&P@104Z,PRC
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M.8'1P[:M4&A=>':PNC-VYO6N1+$^0"_ZO,#<+N6+"+/CU!<Z#DQC9U^>O7D
M]F\>7(!3Y2NV,-)9"3HS^YV;!X9._52"7H^=B46+Z2S+"%K+H>/%FP]+ ::L
MQ-1>A5%1!%>W1]=B]'=KK5P7DM (L!^[V(LB!V-C.-I@1([8 HU6))H#&,/-
M#C6Q;5"'MXR!W2/]<3W 9[]O[D<[O!BMNRNMN1]-72U*@??&UZ2F=9SRVA0Z
M<MSQ-3^]!8N8[/"1+5FK4N?$9<20B6P5J%VI9EA)#>MM4#:-0<@+31)9?F@:
MCAW#80]NZ&!#V=;7\5!^%/W75.92X$L%U:YIW:B^Z/7#A -.NF5+8.K\N.B
MH-Q8D8*8:HY5UL6>O=A[!)#=6[["5A AQT$$V<3S((Z(Z_70 A/[JFM?HP'I
M/B71[K-9#V]5-V'B]0AP ?*T^4#6QY1U48GNU9W&B^K*79,Z4%M)Z\63Y,^B
M!+-D>86KM[@?69Q2YMIEQ(II398H,BGFFS=NG'IYZ[>\3)-M]O=T\V_%EMV'
M\6N2Y>^+JKK*][$,EEE%?W48!3^F%/IU\GV%[,B-3!MBY)D1,GTO#JP!KH=-
ML?7RV6!J7U"G2,!NL +<4?S@IRVUX,^ YJL9[0-=SQ&+)//YE2^Z_! .%8LX
MIQ^/!#\Q"_Y\ ?;6@<X\\&OC\/>]P_=&@L[*Y[.:CVV:06V=-B;I\MB9.#5[
M)UE&[)J?AF)A@U<LQM&O;_$Q*"N"8P\BRW5B._8A,6!D#U=\F%XHM/@A]LV:
M9RM,&+).;YH (A8Q!%GBDWE]!(EI,^/F2(L7<=_C$3MG=%".Q66(ER3V0D4_
M&GUA++),C!#-N]TH)E[@VI@,.;?I.U%WN6.<;P2JY6)-B(R)8S3<@^/-RV(7
M>=DI+W'+& 9C#'C[LE,Q+N0O.[6#P(ECQXFLR,:8$(O=%M#7+J,("X\'X18F
M' Y<:SH+O,*3E\*%# QY_&]>X2G&!'>I?7^37+'-UBREO:GJ,EG7M$$O,@)(
M AJ?K"ARH(&[P&3;7FAREU[E6]!84#VXGK%#!7[O<4U\X_]I@LY5/<>SNHPA
MH\*0YQ5*5=QPQY;U?;K9;=.KVT]E086Z?F*[QFN8-V<X'UG%ZYJEYJO8-$@<
MQHC.!7T"#8K&L/OF&3*AS0JJ&M6]K[K#R>H\/=*+YHQ&#=@;J@-:\'N#5_"U
M;77<<VXNF(-V,7$;Q[*>)("3M7.Y@6KBEZ%_ZLUZGDGHX8U7&T\V&CU=TR^"
MW[-J9<9FZ%#R/!\B-R1&Y,9!U[+C>TCHB3D5[6E6Q+/C\P(PF#09H4 %I5 )
MU7PJ.#7+"@60CV M*LC!VAD!5,GY,K1/J46%OAZJ2/%8N[AX2+)\91/7<V@"
M&M)D%#FQ%6#+ZUOV+ <I43R!]I:@>"U459HG0O9(S=/$LP;->XOB:55OSYN,
MZDFPOG#5D[&(5_6DV>)\4O[A<4=U86B.-OVEN*V_)67:O5?L$#]R/(2=P'"(
M$YD8N6BOM81+\52UI5GM>H0@'29=;#16'4BAI\['\WI>W.:@5$S8!C;C(S9[
M?'(OR(^G5>@!^4GIE7L__GV1WX%M]C7=7(!-^EBFZZQ934ZJ*F6[3N\3RCNE
M>U>UM_"QIXG8BYCM<6DF+'6:-UN%F7=V=;;-_I[T[Q9E^6U1/K1_K)XJ]A;Q
MSZ.?H7^+U%>"BFIW+.(1>G76%'HZK5CZ3'9EGM6[,J4-DNP[^ZGJ&L2Q;8>A
M;=D!QG;D$7:O7=\@Q#X6R9I'-*,Y?%S=WK+[!FY[@,V &D*)6'H\ADR^K'@B
M'L5B!CGBKH?U=JC0DO^>9NA,VJN UF5DNRH,*91W.3%)^I"L[[,\+9\.,^JN
M12^(B.-;L16' 7*QA<,@'+)IUQ8Z9C2F'<VB]"')=[?)NFZW[[)118$7)>M:
M3[+B-(I6/G6:BE$Q>1I0/5^:F46?SG!T1J!4,+L,A5)B2:&^WXEIU&=VG7!3
MU8S8.W^NZQ$7A;8?VM!W2/_]Q+.$:HO\WZI9?QH@4JLB L3P:8H>3L04A(L.
M+6HQ6']&&\096H822. NQO8-B5'>Z4A@(X?^'R:![V+B&8Z-A^D7AI;0Y7XB
MWSO-2)=:#1"B1V"T:V!&:KS/4K\_8."M,2_(TX)&O2CRU\:]E/7<<Y LSQYV
M#UT;1F3XL>$%+HXCEU"!B4*W;\..8Z%S/V+?K'N>T8(1G$B(<<,Y==!&B^!D
MH<4QU^3@D(5STP$IMI8A )+8GZ?\(QC@+T1\/VB#& 9Q(VPY ;%@8#A4;?8I
MAN$);9L2^V;MQ8;O$B(@Q@UO_4 7+:(5@^]SBL A"V=K C)L+40$Y+"_F/?+
M,S!Z?]'[+$\OV=K:*C!-!P=1[!J>'3HQ-%SL] V'CN.*W5>AH$&1D2%U\P3)
MOJ<; )O%2D4[B 3HY!.3B7D44Y@W-HTSB*#!N)3=0P-I,IN'Q!E?ADJI-(AW
MZY L5Z/U[+<JO=UMWV>WZ0I"XM(V3,-"GF%Z'LVLXKYE Q)+R7Y)@?8T)T M
M$K"E4!2)F0B7(]5,$XT*Y>P"= 2_/T?PM'*V9TU&SR0X7[B@R5C$JVC2;'$?
M"$SO6#N?T\>B9.<0A_.'. @]B-W8@X8#B4.099E#1DALH;49Z48TBU>'"PS
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M,3+%KMH>TY#VK81=6L#&V2/U]V,-'I,GL.E0"LK6.$[Y1&LR.L4DJX/5$,F
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M"-MN%+A1WY3GPTCH;(E, YJ5@A6X'LN"W>T!V#,6HL<]I#CC4PWM=(DI1_]
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M3)<3QNRE=8Q<'SLNBCV7.(;?([ <7VB[@<IV-2M>!Q4D-3@U2*4FB$JIY]/
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M,NV?&$RKCVE]=8N2ZK[[S69E$$3\P'5CP[)AX$4FL?N[;^+0<H6N3E?:L.:
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M32+LI 1;\F,5\%VR/2J'R3RO)<\I7^%R$CK%=+2!=$C<!6"H9GE$ZQ0]9ZJ
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MR>@2E;@&%CC$1:>>:YE9^S@.!6;ODW&IL3#Z&O'L/=[UV.KH.7).3>N5$+J
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M?B*+K4"'6N3V;(5>X(A/4S,O=SOY#\&VR,7E\[ N>8NY(O8Y[S3GIN94'-)
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MOHX_O__?@%Q^A!_1)7P/,+R&X*??/L+?\"7]S)_%3F:KXER!B.JA6ZUV_LY
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MCRM"AB,9?C2AF3@XM4K9FP&H'># $#!8 CI3@'D!F#7@]]8>>7'5Y4WA\+8
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M@%@U6\SG/?D6__3^U[S,ZVR+VX>;QZ(L&IH8^ISW$ :)=;PX=2T_06D ;0<
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M7MZ<@EV)!?>)Y.U]RQYS.AL/((RAYT:)!9#IVHZ=).-LW >^SY<Y(-" [OR
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M!"GIULZ_4IU>KB*KD5\I;RQ::^4L8Q-6!>RQJBAIGE0_P?^%]B( ,:RZ?L$
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MN'^AZ[.#:FVO4I.%Z_KH=Q.;FBW*0WSR-R[KSHP>_4'1-N*FCX[_C;T)LZT
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M^@Q3\RH1FW3S*Q:<9'D6BQL?<,$:.&1H7&#DD#+G5.B0YXE[L>Z;=AB9'H0
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M\V2@H@4 Z2G$>7E95U@,FZ%),P'DH=HT3$ ,[31T$ML9FB2'$UQ' 3(-Z9X
M'V C%\B>>G2<._Q25#)NZ4_%(N_T]C6! ["9I.D42Z?VZ%60NPQQ4F/*VUUX
M=?RPRA-NY"FOVY=+W-U:<F[Z/[OBB:CBEZ+,S]O\D;RJ$[@)BCTG#>W4\VS;
M2>.AX2CR/1Z14M"<9JE*S_\+)0:\OD8GUN-:!M7GW)P86@J)7<8 4VE0I:T3
M*AILO]95TZR<(#6M*'(]QPQ]9+NQ":QQ A(&7+,!R:8T#S+Z8@E?\)?ECBW\
M3T@;WP1@ '9F4&A=(M0 [LR@\!8B5Q2+B%3Q<;QPF>(TAE6B1#CB2$7LT@#R
M34(V]=;=40+^>IN3+\A6SF-5M\4_Z/>/8ER95ABZON7#*,0+J=3V;> .\%S/
MM5=E?D]:89.RR6 QC5[0C=Y#"SBV%_",/=N;8VP.[.&3P^E\Q2:<RW*2:+KI
MZ)A#&\Z,T8KN2.' CC/CC3"?O5;FR?-1E3CA=*[JM'Y>ALQ/;_;['-<Y>)>>
MV7[+VU5LNB8 :>)8;HS_Q[;,8-Q8LTT7\-Q2D6J(:U;+?R4E+;[3]^Z;G#Q*
M4.83C_Y3U(A,QW@87<8H56,*ZU2,GQ_FYUL.1O@*!'YHIC$ L>W:'KF"DJ*A
M"<OTN5:%7!^L>0UXB&5XLI+SA14NFMCF,=H8XIN+)"P30SV/EQRT?$(UA'A:
MADJ(07_[1HBX_>RE O"HRIN6OC<29T\%#DC%/_+-"KH!L&T?2TT:1Q9( P<,
M5UAL:(8.7P4 P49TGQCMH1A%CY'WXKXH?6Q*,0ES?*HQ0.K>13(.0$U]2?YC
M:D[HB32;R] 6>3/>W517P@M3 F=:U7EQ_WKMD+V9\ #?L>,P0B#R8!2X7@#_
M7WO?VMS(C6SY?7]%?5M/A-I;[\?]L!%X>GNWW>I0RS-[P['!H*B2Q&N*I:DB
MU=;\^@7J1>I!"D !5: \$3-V6U(+)T^")Q- (D%@-RS!02A<NZEC,--'00W$
METO\EWNO7X\D^H9(/JY0D_ KIU3V4BM1I#DVQ8JM?._YY5AG?L,^ 0<W'\_X
M?^WM<<WW]A)X >?#W5.U7/#RS7IUZVRK72?@=5'>L^\PA;S>-AU;KGB_7K[7
MN2EXJ4?]Y=NBN&Y*<JN\?%PNVLO<ZV)3Q_<U;RU\4Y2\;_!\E9\YM9(W@\SY
M-^KI4M_S+9^8CCO,FG+)I/YI:)&H@!??B%O:)X %I:%:S2D,?5 DCS3X=+W(
M>4DR'^C\:K6\;3[9?IRP97L2@3CQ4NPB-R5=_ RB*$UDDFCU40Q'L!J8LT/F
M[*!)'C>H\RAX?C *A9(' @KLF=G7/T3.L8WZP83:D5%KL./E5KHF9J1:_LVK
M'.?-OS^O#R*H9I!F-(0A\CV2@LR#*>D+3P(& DIW]],UL&&EZK Z/W5H_\9#
M_Y&/H&3QJ%XOB&X13.0 V6T#?=R;:[HGR./1/08#[K!#)<V8]E;7/#/\#<[G
MOBSG5\M5W92;P=R697X]BXD'W8B$&+D@\),$1PGN(*1))/6*O=:!I\OZSIP]
MO$X'6%,NJ.2#@>FA:?JU98R2S(^;1[[!HDIJ.<09=NBH&=-$$]#A_ W64;!@
MVMZT"JA/9&<>C#,:)'X4XRSQH._&63]^X&*I]P3TC3JE@O9@':)R:JV1^H':
M:91UC<(I3OBXJOF2/Q7)5/:!Y7JI;I>H6 YD3KRR+;_)N1+7#X)]FY?GY?<-
MWYG^^WRUS;_E9=UI909BFN'434"616GBHABX;0D 1;Z+I;KR:QK2L$;V*)NG
M^,YXTP;GD2.L6RQ?%ZO5O*R<A[QLVBU+]MW7Q;N81DY N9Q [MC^WK#-,/)C
MD :E4\-T&,ZFA=38A8<BY!TM0=3*OAW2J-NH5V6)!CA3$\6F5?;GJMJR?!4G
M&,4)KS&.0M^/21B!=MU/,<!$J$! PS!CBU_W2FJ-;HC2R9&IHF[&>!RH:.V+
M()^/4SB"@NT3)*Q:2JS:J%1JAAQ5IP'<#%&D_>;]7NS&)"-I2D,$ YP$7NIU
MH\9Q[ Z5)9FQ)M*FO2<QA@N4%+?J*F6*5CU2=2[ Z&AZ)?9TB"Z2[54N)6L$
MY$N=)?%60?531$?S.8R2S,,A\5*?$ACB@*1N-S+Q7:GT2L=XAK6L?2S,R I3
M"]UBTC8VTW+RUKW(9MW"4H"V(U*GDW0[Y$ZK1:]Z#^EF2T'VGB6*T 5)@'%$
M$@HBZL,,1WVB2+U(ZIJ+ZABCRMN -:0RA]+Z98R^(9K5@#J;9.UX@!LQ85)B
MTSHQ4K/BL  -8$54="YY!<NV?-H;;P9QR!:F.$LP]8.4#<E[I+<C14%(901'
MY?<;%IL.4B,WSGSC+(IJT\F.G-XHT2>F-::9D].9GK1G2C.NPKS!R!%U&<*?
M'<HRR()"WVR2N#J'VZLYO#_ >K/</'U>W_!K,?5!9??T'*)\P4A=R&0,^Z$7
MP+:#(PV8NF7O!6-] YG[N'3PFHM<-4!G#Z'$92X]C$K<YAJ=6;7K7)\^.5^+
M=?XS^Z?S[#<X^9]+?NN77Z+:W"TK)U_5)^8_.Y\^#;PB)4+-&XJDGU8++DGI
MM:<P-0'%M.LZ7\Z:L2[RVR4?8KWY.K_/9P0@W_-2$F2^3]P@2CR:=L. *!+:
M+E?^Y8;SH%:6=J <CDI,FM0).Z[MHW E)^62-!W)?*I\\?-M\?@_F)$\Z0GY
M'[C*A'NYSB$"WI"5P5Q-JR+#X1>:YHRL1B F3N5\]7E]G?_Y?_*G&1<@$C,1
M\FE(>)?<D,:]%K&OR8F$[&\?1R5:5$X-RV&X9'5"FC11H3#)EY)2B%.E32M>
M<'!4+%3YLD4ME/&_DHMA3(CH19?*7+*_,4MB&( HC:/00R  *4)M"1+[]32)
MA?9QI7^I877HUSD<C+@DR/'ROA(8HT1QU7>4#0V?^GU[#WS8E2B9_C.N!KL8
M.!7D/]'?\G)9L/7)-9YO\EF:X1BB-(R2 /DD0# .>^4 F/BR'VVYWS[69[Q!
MY3!8#L<E_W&7)$W\<V^.+T4!$*5*HQ8\X^ =45#CRQYU4,3_ADP,84)$+P ;
MY)H/1%?SVQD*($EB-P0HHB"@$">TW[6(:2"< LC]5L/ZT(-Q.!IQ59"DYGTU
M,,>*G H($J+AL__,X@.?>356IO^L*^(NALX'\<\VXC=3V6]?5HOYZC_S>=G)
M2!@0! %.8$39"L)/0K*3D3!-A'<-E0<P7:[1X'(:8 Y'II 5J-/WOA2,PIR<
M*BB1ID$C#E%Q0"X&,S>]<@PWH= XDV1W%_^1KU;_9UW\6'_/YU6QSJ_K^H]R
MEB78RW"*PB3TXBP(2(9QOY:)7:%&;<-'&6>WD:/[] >'YW3XFIJF4G;;49E-
MT>W',8A4VH94X%#;?N0!4H[N2PXE<GK=T63'JWU*/<R(*]#?B]5VO9F73W2Y
M8A_A6>K&,2$TR8!+PB!D:Z,X[,9Q/=E#4-G?/H[B]*B<!I:LSDAS)JHO)NE2
MTA5AIK2IR0L*CJJ(*EVVJ(<R_E>J,8P)B=/0)D&ZR!]XJ^3U+2^8WU:S.,4I
M6W'Y/L@\3*B/@LC;':;$6/)05&V0D<Y&V\R^1^<T\*2/2!69%#XI-4^BVH&I
M+'_ZSDW?9.3X\>DP$FW1F:%FO#Y,U<&+N.K4HH;8.NRV*)]F80R\$&<T\Q/H
MI5F(H N[41 5JUA7_=WC:$R-R>E R2J+)%NB@F*.*"4=$>1(FWH\,_^H:*@1
M98M6**)_)1%#6!!7AF_;J]5R05?%?#.C-$DRB$"4@( @UTV [W9CI"0F<KH@
M\YO'484&D5-#DM4$*9Y$%<$414IZ(,2.-C78,_VH%JA09(L2*&%_I0/J#$BL
M2E[>HMMO6Q#&!+@A2OS 34B<A7Z6TG90MD:2W4H=--1(*Y0W;HD*=>TPPJ[P
M>F4L8M56+:J<ZEN]'.'G^!I&![&V:)(>8UZO9_1Q)%-7MCMGHNPKU<Q-$O:+
M_0S[B0^94OIL)=6-Y%,HU'9XR.\?J[9L_U2T1B9?729-W?LZ- 9K<N*C0)C&
M&K,7/+Q39:;*VO3*,MB"-RK-AK$AKR%-95LS%O"C),R2E( LA9F/">[76G&$
M8^GZ5/D11M:1MOYRD))($2BK)::X&Z8F0K1IUY,]+H04184[VS1%R8:#JJ+.
MB/CC78]LM*)\PFS 55%MR_PR_W,#F75_S$#HIWY$2>Q!%Q(884*;HR7B8Y87
M235C&S20897Y_/7OY.OE^<5G\EWVT:TA[!W7EM&)DY.8'I:SP^7\SI$Y-;3_
M-_836H=9>D-\M))K1U<1/::\>A)+&S]"?4:^+^[RZ^TJ/[]I%F?@<;YDWUSE
MM"AY=<R<47')_WN'(H@RMF0+V.HLBSP$$8Y@<Q*%<1C"4*B*Q=38AG6K0\S?
M)%[NFBDX\ZMBNZG?+GY@/R^8*!GC_[C,V4"]G/+ML]YN#_5XZ^XD'6(FA_77
M1$1Q'%=(M(N9V"5JS6,8H.V*+9RO=R&).:GM.SA_YJ1EYZ0?=\O%'?OX+%;;
M:]Z=\-7G:/YC7EY7_.'NO'QL7_'N_O99]]VFJ6'SMGCSE>?#W=8=)JZ>ZD_D
MT">]Y7WS1@@T[64+>MF8M*X8Y[,BE\WO@)#[AU7QE.??F\?H:UQP7N77J+CG
MSPDU77=6M7O8G\YO+O)%<;M>_BN_;A8=J*@VU0XO#,,412F)XM0%U,61%Z8=
M7B_(A$Y<IT<Y8CPN>Z1-/\)/5]PN9[%G&'^$EDWCJE@MK^MFQ!7O2<M5K^*_
M@3\FK_(2\(230&Q%<QK^5T\*.JN<UJPF2V@GP+YE9\[.-OX7=]9U.S:U?3)Y
MA)'%E3&''5F933])[%C66<!#8=O'5S4HO@VP/@L\?ZB5%BPVR\?EYNE%M(Y0
M&".*:>RZ49SX81+AI ,6):[0/ON(<$8,<WR1R='/UT__O6H[[Q8/3?;<@J^3
MXC)?U2%N*=LL<TPORH8O*QPH&:<.AJ(:MM/BYH^2MMZS)_BHTBT498S[TK9P
M8M[@@W%C)*Z'!(AO\Z>Z5RE?R^\#XP]&-&&-K>ONFZ^]  DRB"!.$%O=T002
MCRWPL@XD"*C44UPC0QLQ</S(E[=W/"+,']DRYS9WYCO4SI;+TZ9P\FJS9,$B
MK\/,S7S9/H]3+X_R^>*N"S7-[LJVXG=,^(_"U9RMN-AP#&C5_=!#N5SP'[@O
MKO/5\.!C<H:H!R)+)L? '=4V0+7&.+4UKR)4;Y*S9Y.5X4K=*9*A:P3OVQO&
MQC!>(*2-Y@/1\';>[".M;[_D#%]%MYMMF?^Z7"_OM_<MV IO\[X%-\UBAB+&
M/O 3%_@H#=L'+/F5])1*/?6M>VS# 0JLU]OYRKEO #H/+4+G>BO8_\88YV(1
M84JZY22_1^HT4,^<!JS3HNVTOW(8WK-G59&_SMD/UBN3SHZ1)5Z2Y2,:;LI?
M=HBT,>N*<6:]$9EM[]/.LCAFDDZB &'LTI0$8="#B (/&%!9T:$-BRS[5*5&
MU%286JUB:H)5HUKZE:?&ES_RU2/[B6*]N1OYN2<Y7H>KIZR#3DH\I8U3TTXU
M#C5+Y^?UY8^"IP#5C(T5@]3S4S<FF/@@BWW<X2"^EQE03XG1S0MH9D1 90C6
MJJ&&N#4DHV=<1_GA/0-=IZ1V"NB.U.$:JN"@DY)1%?O4E%292?UBRN9DWB#!
M.$S<,"!L>/Z_**%1TB'!!$=FY%1\?.."ZKNF!%6"9-V2:H9?XZ+*8=LMJSVQ
M6H15WDVG)JT*%BJ+JRJ;VN65LH]$ \2/ *4H\R/J>@Q)2B#V.B"N!TULJ,H,
M;UY</4/B*D&Q9FTUPZYI:>6HK5;6GE8=PBKOHQ/3504#5655E4O]JKI\;.6=
M;]Y"A'#JL6PY1MBG&'9 DCB0*K,P,+QY5?5-J:HXQ;I5U0B[QE65H;9;53M:
MM:BJM(].357E#516544N-:OJY5U>YO,;ID(S$H>IE^ X(DD0PS@,/#_N< 0P
ME"ITUC^Z>4T-G,U=66QO[QSV'V9.J638UJJOAH@V*J\[S%9JZP[><&E5<,])
M*:N*?6K"JLRD9EV=!3A*LM3S_#"!E+"9%B"W'9UD,$AGFV(S7VE5TW?'E-+0
M'I[PY_N2_Q4CNOD^FUK54BN1!L_SK=3%X6HH3/])::"X56K*)\F:HMY=L-'(
MG_S>1OXUW\P(BF+L$R_"/@J2 &3(ZW)7$@ BU,I2STB&\T..QLD;.(,D3I9
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M*][(<(>S(A1SOI7%]7;!WU?<ENOJ(K]B\[1B\_2<39J2#5W-LB3#?IPE@8=
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MVU6_2F]Q()+ST,!89&@ZG$XX,D6 0D0RZ@N=0>FR>^NGFK'!DBSRD)_&*/,
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M*_+>"OZE'^TIT[PY9;KEITS7+,F\8<GH8WW*A#+/0U$6H=2-41#2F$V3SLR
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M'XSDH,> ;[XY]#T\TS2IGA")@1(28^>$%4Z5_J^5&CP,IG:S1QG=2+\.9]]
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MEA _C_-OU=.Y6B[N\F+RW]FX,<]>5TP8+U\',.T8PX8J*L)N8".MI0;%\&N
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MJ^NQR_"[S1^#!AO@TLX'$B^X)H9;PA44VD.,@:P0=%)>6)KE=LB4#T 3?:U
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M^S232LD_Y+-1^/'I7LYLO&6'6T8=G>;S99$U6-9BFTX88]244=F$"BJ05GA
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MOG5O5D_1WO3QN&1]35I*' \,@8)[RY1RCI"PO5Q3Q&B+7:/0&)V=&IV0]XQ
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M1A89*\,T+)QGW CD:PDU=#&^Q:./-+_7J:DE<,]H3AUG.244P#*^B((22J>
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M'PFBNUCN26"9DD$S(ANS[9!16_1LK,C4[2++KE\3I +3FXO6(T&%??HL?>:
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MKPP-3%LM.6'&0ALU):>Z?)<!2D9)RL.P(XY'MHZ/=-*.\21A  D-J%)284(
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M '2FS&N#AM&4$OT1IA?VH%":DK97>!Q]Z^_1IX)1A$0'0F$!%87:Q<.[C*M
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MM-$"W^L@J3%]>PL^1X;%[[H['G]^\L% &#.  N[C4>BUTQI'?;W;C8D>SAM
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MG.< "J41@>6^E00I-Z.C-/DZ!%=K5.X=77XZGRZCX?JO/+\^'5W[1P?*K."
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MN,Z_S0LU(#T6C@+#C8#$<@=@:;5SZ/" W<H>-5!][=9>S:]W][!-.N*>,F/
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M:H&;J"U^[#'9QKK48"2$ADIJ!& &$\\BBDLN80=3'B2&)[_%^-8D[IQ8WX*
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M/*D*;ZP][KH#33-T-F1&7^ \M'2=W>2+['-V-9LLE].;Z3:UI@Y0$V8-#&A
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MSUG3!JM?5%ZT0-?^ZG>>+5;_TMG\ZB[*]M]'$F6/#0VF>&*60X#B#B4F0$
MRQU;ZY,ZXHT/2:EL/X:B-.H.AZ=RT4=S9(\-#1!(IY P4F*DE8N;E++<L0<T
MQ08Y!SPU!L!19"71N;=\_LDL6^X,LW_E^75QWW<T37;_H*C>B= 00T5Y=$LA
M!^"!?$0FY1J<!9J:,OUYV+4M"@]XXGV-"SC]L"M'!0JL15'-1]< 8Q]_, R5
M^]16ID0)1^@;=7_.-23L8  JUGOZZ?8P*LAH8H*X36ZU5!A0*!YH!SB\>%74
M@.-';>ZFU.T-1>OE*K\O[J>?K?SHF79D9 ",:.< -MP)[0S!0%;[A=%UN7 T
M->'\<S2U2N&^$/7'Y#_S1;GT8U6.+S\<D-,2"^,IMX10![50JK(GI4QY]&V$
M9?(M'V/)].P+)1\F]]G'FR?+/7IV[1T3&(40 *2]CO0"UFF\ZQ.Y:5Z$4K+1
M1ZAK4IB<=T/2QG<-[R>+VVRY*K]\[ZFS_\-!*HGB^8P\8L8AJ8DGU6'MK+NP
M^$X+',M;)FECYG_)KO(B._@$"!P8$CCDQ&+%E56$4@D$Q>A!"'"M[*WS<8!:
M!D)[A&T,AZ]WT\5I:-@_(G!.N#-,.B&0IIP)(7452+ PI1'8",V(EL'0&ET;
M8Z$ZWHI^4=/K[,\OAY&P[_-!(^0X4\P@PS%E@CA581<X>V%M85O&04M4'2PD
M\KY&#?G^08$YSS C #%M8?&Z#D(EUB6*YV"?V/F1+;[EY^6,M$;9P?#S*5L4
MOYC<9O 4!#T:%AA6AA?O;Q*JBN1%IEVU4ZBTZ=,Z'01##9A^#$?-Z3NVC)1G
MQ^499Z1@P300Q8OK+!X%FBA@2SY@)F&M)[R[KKGZM,B_9XO5K^))I)6:;]ZT
M_E[T33F6HU)WBN @\$XZPYGC7H%(%(!+*A0$NBQ?M TX[*V@:I72_?4.W;/H
M6K=[-48'Z* DD5>,*T.E!YJZTHXC/'KKEX6P]N'PHI]HVR0?'&JU[@%KC [8
M4T:B\$:'7QGBD+"H3#<F#)%>39?NH=8J$NJBK#&UFSO6^?WW=:1FM82XG"_Y
MS>J?2*0C+O;1D8%XK@DSE@A /-'0&FH>Z./?"F*:<#7ODM)]Z21?U"NLUHLL
M+MA/?Q8_'>\AN']0L%%[%YE 1289CL:]MJ"\UB#*\@M+]^\"3ZT3N;]KY$BM
M>;;X]9@01[%T8%1@0GO"D4-."D,MLE+(BG04U_)0SB<BW"68VJ-R;[65Q5O
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ML_M#\8]ODV7VO_[;_P=02P$"% ,4    " #4>%Q,%*@$@)L1 @""("  $0
M            @ $     <&-R>"TR,#$W,3(S,2YX;6Q02P$"% ,4    " #4
M>%Q,3A'>2VD9   T%0$ $0              @ '*$0( <&-R>"TR,#$W,3(S
M,2YX<V102P$"% ,4    " #4>%Q,L\P W<<E  "'E $ %0
M@ %B*P( <&-R>"TR,#$W,3(S,5]C86PN>&UL4$L! A0#%     @ U'A<3(5P
MH$;T9P  D" % !4              ( !7%$" '!C<G@M,C Q-S$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( -1X7$S"3$>5R1H! &;W#@ 5              "
M 8.Y @!P8W)X+3(P,3<Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #4>%Q,V1Z5
M O.>  !5\P< %0              @ %_U , <&-R>"TR,#$W,3(S,5]P<F4N
9>&UL4$L%!@     &  8 B@$  *5S!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
